<SEC-DOCUMENT>0001213900-15-008486.txt : 20151112
<SEC-HEADER>0001213900-15-008486.hdr.sgml : 20151112
<ACCEPTANCE-DATETIME>20151112160830
ACCESSION NUMBER:		0001213900-15-008486
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		11
CONFORMED PERIOD OF REPORT:	20150930
FILED AS OF DATE:		20151112
DATE AS OF CHANGE:		20151112

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUCELL CORP /DE/
		CENTRAL INDEX KEY:			0000811641
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				010382980
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12934
		FILM NUMBER:		151224872

	BUSINESS ADDRESS:	
		STREET 1:		56 EVERGREEN DR
		CITY:			PORTLAND
		STATE:			ME
		ZIP:			04103
		BUSINESS PHONE:		2078782770

	MAIL ADDRESS:	
		STREET 1:		56 EVERGREEN DRIVE
		CITY:			PORTLAND
		STATE:			ME
		ZIP:			04103
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>f10q0915_immucellcorp.htm
<DESCRIPTION>QUARTERLY REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-right: 0pt; margin-top: 0pt; margin-bottom: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Washington,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 14pt Times New Roman, Times, Serif"><B>FORM
10-Q</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#9746;<FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>SECURITIES
EXCHANGE ACT OF 1934</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>For
the quarterly period ended September 30, 2015</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><U>001-12934</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(Commission
file number)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 16pt Times New Roman, Times, Serif"><B><U>ImmuCell
Corporation</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(Exact
name of registrant as specified in its charter)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 49%; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Delaware</B></FONT></TD>
    <TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="width: 49%; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>01-0382980</B></FONT></TD>
    </TR>
<TR STYLE="vertical-align: top; text-align: left; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(State of Incorporation)&#9;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(I.R.S. Employer<BR>

    Identification No.)</B></FONT></TD>
    </TR>
<TR STYLE="vertical-align: top; text-align: left; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><B>56 Evergreen Drive, Portland, ME</B></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><B>&nbsp;</B></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><B>04103</B></TD></TR>
<TR STYLE="vertical-align: top; text-align: left; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><B>(Address of principal executive office)</B></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><B>&nbsp;</B></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><B>(Zip Code)</B></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.5in; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B><U>(207)
878-2770</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(Registrant's
telephone number) </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days. Yes&nbsp;&#9746;&nbsp;&nbsp;&nbsp;No&nbsp;&#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Indicate
by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every
Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12
months (or for such shorter period that the registrant was required to submit and post such files). Yes
&#9746;&nbsp;&nbsp;&nbsp;No &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller
reporting company. See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer&rdquo; and &ldquo;smaller
reporting company&rdquo; in Rule 12b-2 of the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 24%; text-align: left">Large
accelerated filer&nbsp;&nbsp;&nbsp;&nbsp;&#9744;</TD>
    <TD STYLE="width: 24%; text-align: left">Accelerated filer&nbsp;&nbsp;&nbsp;&nbsp;&#9744;</TD>
    <TD STYLE="width: 24%; text-align: left">Non-accelerated filer&nbsp;&nbsp;&nbsp;&nbsp;&#9744;</TD>
    <TD STYLE="width: 23%; text-align: left">Smaller reporting company&nbsp;&nbsp;&nbsp;&nbsp;&#9746;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
Yes &#9744;&nbsp;&nbsp;&nbsp;No &#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The number
of shares of the Registrant&rsquo;s common stock outstanding at November 9, 2015 was 3,055,034.</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0pt; margin-bottom: 0pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: center"><B>ImmuCell Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>TABLE
OF CONTENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>September
30, 2015</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>PART
I: FINANCIAL INFORMATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt; line-height: 115%; font-family: Calibri,sans-serif; text-indent: 0pt; width: 8%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">ITEM
    1.&nbsp;</FONT></TD>
    <TD STYLE="padding: 0pt; line-height: 115%; font-family: Calibri,sans-serif; text-indent: 0pt; width: 85%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Financial
    Statements</FONT></TD>
    <TD STYLE="padding: 0pt; line-height: 115%; font-family: Calibri,sans-serif; text-align: center; width: 7%"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0pt; line-height: 115%; font-family: Calibri,sans-serif; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0pt; line-height: 115%; font-family: Calibri,sans-serif; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0pt; line-height: 115%; font-family: Calibri,sans-serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt; line-height: 115%; font-family: Calibri,sans-serif; text-indent: 0pt"></TD>
    <TD STYLE="padding: 0pt; line-height: 115%; font-family: Calibri,sans-serif; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Balance
    Sheets as of September 30, 2015 and December 31, 2014 </FONT></TD>
    <TD STYLE="padding: 0pt; line-height: 115%; font-family: Calibri,sans-serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0pt; line-height: 115%; font-family: Calibri,sans-serif; text-indent: 0pt"></TD>
    <TD STYLE="padding: 0pt; line-height: 115%; font-family: Calibri,sans-serif; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Statements
    of Operations for the three-month and nine-month periods ended September 30, 2015 and 2014</FONT></TD>
    <TD STYLE="padding: 0pt; line-height: 115%; font-family: Calibri,sans-serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt; line-height: 115%; font-family: Calibri,sans-serif; text-indent: 0pt"></TD>
    <TD STYLE="padding: 0pt; line-height: 115%; font-family: Calibri,sans-serif; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Statements
    of Comprehensive Income (Loss) for the three-month and nine-month periods ended September 30, 2015 and 2014 </FONT></TD>
    <TD STYLE="padding: 0pt; line-height: 115%; font-family: Calibri,sans-serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0pt; line-height: 115%; font-family: Calibri,sans-serif; text-indent: 0pt"></TD>
    <TD STYLE="padding: 0pt; line-height: 115%; font-family: Calibri,sans-serif; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Statements
    of Stockholders&rsquo; Equity for the nine-month periods ended September 30, 2015 and 2014</FONT></TD>
    <TD STYLE="padding: 0pt; line-height: 115%; font-family: Calibri,sans-serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">5</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt; line-height: 115%; font-family: Calibri,sans-serif; text-indent: 0pt"></TD>
    <TD STYLE="padding: 0pt; line-height: 115%; font-family: Calibri,sans-serif; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Statements
    of Cash Flows for the nine-month periods ended September 30, 2015 and 2014</FONT></TD>
    <TD STYLE="padding: 0pt; line-height: 115%; font-family: Calibri,sans-serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">6</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0pt; line-height: 115%; font-family: Calibri,sans-serif; text-indent: 0pt"></TD>
    <TD STYLE="padding: 0pt; line-height: 115%; font-family: Calibri,sans-serif; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Notes
    to Unaudited Financial Statements </FONT></TD>
    <TD STYLE="padding: 0pt; line-height: 115%; font-family: Calibri,sans-serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">7-15</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt; line-height: 115%; font-family: Calibri,sans-serif; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0pt; line-height: 115%; font-family: Calibri,sans-serif; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0pt; line-height: 115%; font-family: Calibri,sans-serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0pt; line-height: 115%; font-family: Calibri,sans-serif; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">ITEM
    2.&nbsp;</FONT></TD>
    <TD STYLE="padding: 0pt; line-height: 115%; font-family: Calibri,sans-serif; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Management&rsquo;s
    Discussion and Analysis of Financial Condition and Results of Operations&nbsp; </FONT></TD>
    <TD STYLE="padding: 0pt; line-height: 115%; font-family: Calibri,sans-serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">16-24</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt; line-height: 115%; font-family: Calibri,sans-serif; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0pt; line-height: 115%; font-family: Calibri,sans-serif; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0pt; line-height: 115%; font-family: Calibri,sans-serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0pt; line-height: 115%; font-family: Calibri,sans-serif; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">ITEM
    3.&nbsp;</FONT></TD>
    <TD STYLE="padding: 0pt; line-height: 115%; font-family: Calibri,sans-serif; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Quantitative
    and Qualitative Disclosures about Market Risk&nbsp;</FONT></TD>
    <TD STYLE="padding: 0pt; line-height: 115%; font-family: Calibri,sans-serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">25</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt; line-height: 115%; font-family: Calibri,sans-serif; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0pt; line-height: 115%; font-family: Calibri,sans-serif; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0pt; line-height: 115%; font-family: Calibri,sans-serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0pt; line-height: 115%; font-family: Calibri,sans-serif; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">ITEM
    4.&nbsp;</FONT></TD>
    <TD STYLE="padding: 0pt; line-height: 115%; font-family: Calibri,sans-serif; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Controls
    and Procedures&nbsp;</FONT></TD>
    <TD STYLE="padding: 0pt; line-height: 115%; font-family: Calibri,sans-serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">25</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt; line-height: 115%; font-family: Calibri,sans-serif; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0pt; line-height: 115%; font-family: Calibri,sans-serif; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0pt; line-height: 115%; font-family: Calibri,sans-serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2" STYLE="padding: 0pt; line-height: 115%; font-family: Calibri,sans-serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>PART
    II: OTHER INFORMATION</B></FONT></TD>
    <TD STYLE="padding: 0pt; line-height: 115%; font-family: Calibri,sans-serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt; line-height: 115%; font-family: Calibri,sans-serif; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0pt; line-height: 115%; font-family: Calibri,sans-serif; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0pt; line-height: 115%; font-family: Calibri,sans-serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD COLSPAN="2" STYLE="padding: 0pt; line-height: 115%; font-family: Calibri,sans-serif; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">ITEMS
    1 THROUGH  6</FONT></TD>
    <TD STYLE="padding: 0pt; line-height: 115%; font-family: Calibri,sans-serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">26-32</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 0pt; line-height: 115%; font-family: Calibri,sans-serif; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0pt; line-height: 115%; font-family: Calibri,sans-serif; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0pt; line-height: 115%; font-family: Calibri,sans-serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 0pt; line-height: 115%; font-family: Calibri,sans-serif; text-indent: 0pt"></TD>
    <TD STYLE="padding: 0pt; line-height: 115%; font-family: Calibri,sans-serif; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Signature</FONT></TD>
    <TD STYLE="padding: 0pt; line-height: 115%; font-family: Calibri,sans-serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">33</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->&nbsp;-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 27pt">&nbsp;<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: center"><B>ImmuCell Corporation</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>PART
1. FINANCIAL INFORMATION</B></FONT> <BR>
<FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>ITEM 1. FINANCIAL STATEMENTS</B></FONT> <BR>
<FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>BALANCE SHEETS</B></FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>



<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(Unaudited)
    As of September&nbsp;30,<BR>
    2015</B></FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>As
    of December 31,<BR>
    2014</B></FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>ASSETS</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>CURRENT
    ASSETS:</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 76%; text-align: left; text-indent: 0pt; padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Cash
    and cash equivalents</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2,469,087</FONT></TD><TD STYLE="width: 1%; text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">850,028</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; text-indent: 0pt; padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Short-term
    investments</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3,720,000</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2,489,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; text-indent: 0pt; padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Accounts
    receivable, net</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">789,214</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1,005,292</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-indent: 0pt; padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Inventory</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">864,444</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">945,755</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; text-indent: 0pt; padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Prepaid
    expenses and other assets</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">275,559</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">148,399</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; text-indent: 0pt; padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Current
    portion of deferred tax asset</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">69,011</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">30,463</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; text-indent: 0pt; padding-left: 20pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Total
    current assets</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">8,187,315</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">5,468,937</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-indent: 0pt; padding-left: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0pt; padding-left: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>PROPERTY,
    PLANT AND EQUIPMENT, net</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4,955,614</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3,837,647</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-indent: 0pt; padding-left: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0pt; padding-left: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>LONG-TERM
    INVESTMENTS</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">487,000</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">496,000</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-indent: 0pt; padding-left: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0pt; padding-left: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>LONG-TERM
    PORTION OF DEFERRED TAX ASSET</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">543,602</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1,230,340</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-indent: 0pt; padding-left: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0pt; padding-left: 0pt; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>OTHER
    ASSETS, net</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">49,615</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">18,930</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-indent: 0pt; padding-left: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0pt; padding-left: 0pt; padding-bottom: 4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>TOTAL
    ASSETS</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">14,223,146</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">11,051,854</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-indent: 0pt; padding-left: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>LIABILITIES
    AND STOCKHOLDERS&rsquo; EQUITY</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0pt; padding-left: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>CURRENT
    LIABILITIES:</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; text-indent: 0pt; padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Accounts
    payable and accrued expenses</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">545,927</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">851,677</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; text-indent: 0pt; padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Current
    portion of bank debt</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">133,959</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">150,382</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; text-indent: 0pt; padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Deferred
    revenue</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">0</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">6,690</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; text-indent: 0pt; padding-left: 20pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Total
    current liabilities </FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">679,886</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1,008,749</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; text-indent: 0pt; padding-left: 20pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0pt; padding-left: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>LONG-TERM
    LIABILITIES:</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; text-indent: 0pt; padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Long-term
    portion of bank debt</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3,126,004</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">745,920</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; text-indent: 0pt; padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Interest
    rate swaps</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">118,773</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">38,817</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; text-indent: 0pt; padding-left: 20pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Total
    long-term liabilities </FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3,244,777</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">784,737</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-indent: 0pt; padding-left: 0pt; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0pt; padding-left: 0pt; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>TOTAL
    LIABILITIES</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3,924,663</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1,793,486</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-indent: 0pt; padding-left: 0pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0pt; padding-left: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>STOCKHOLDERS&rsquo;
    EQUITY:</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-indent: -10pt; padding-left: 20pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Common
    stock, $0.10 par value per share, 8,000,000 shares authorized, 3,261,148 shares issued as of September 30, 2015 and December
    31, 2014</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">326,115</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">326,115</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-indent: 0pt; padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Capital
    in excess of par value</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10,144,794</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10,042,305</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; text-indent: 0pt; padding-left: 10pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Accumulated
    surplus (deficit)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">349,865</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(574,567</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-indent: -10pt; padding-left: 20pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Treasury
    stock, at cost, 206,114 and 234,114 shares as of September 30, 2015 and December 31, 2014, respectively</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(450,901</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(512,154</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; text-indent: 0pt; padding-left: 10pt; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Accumulated
    other comprehensive loss</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(71,390</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(23,331</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; text-indent: 0pt; padding-left: 20pt; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Total
    stockholders&rsquo; equity </FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10,298,483</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">9,258,368</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; text-indent: 0pt; padding-left: 20pt; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0pt; padding-left: 0pt; padding-bottom: 4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>TOTAL
    LIABILITIES AND STOCKHOLDERS&rsquo; EQUITY</B></FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">14,223,146</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 4pt double"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">11,051,854</FONT></TD><TD STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>



<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><I>The accompanying
notes are an integral part of these financial statements.</I></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: center"><B>ImmuCell Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(Unaudited)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>STATEMENTS
OF OPERATIONS </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0pt; text-indent: 0pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>For the Three-Month </B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Periods Ended <BR>
September 30,</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0pt; text-indent: 0pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>For the Nine-Month </B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Periods Ended <BR>
September 30,</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0pt; text-indent: 0pt">2015</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0pt; text-indent: 0pt">2014</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0pt; text-indent: 0pt">2015</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0pt; text-indent: 0pt">2014</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: left; padding-left: 0pt; text-indent: 0pt">Product sales</TD><TD STYLE="width: 1%; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; padding-left: 0pt; text-indent: 0pt">$</TD><TD STYLE="width: 9%; text-align: right; padding-left: 0pt; text-indent: 0pt">2,472,428</TD><TD STYLE="width: 1%; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="width: 1%; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; padding-left: 0pt; text-indent: 0pt">$</TD><TD STYLE="width: 9%; text-align: right; padding-left: 0pt; text-indent: 0pt">1,770,129</TD><TD STYLE="width: 1%; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="width: 1%; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; padding-left: 0pt; text-indent: 0pt">$</TD><TD STYLE="width: 9%; text-align: right; padding-left: 0pt; text-indent: 0pt">7,534,281</TD><TD STYLE="width: 1%; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="width: 1%; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; padding-left: 0pt; text-indent: 0pt">$</TD><TD STYLE="width: 9%; text-align: right; padding-left: 0pt; text-indent: 0pt">5,391,599</TD><TD STYLE="width: 1%; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">Costs of goods sold</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; padding-left: 0pt; text-indent: 0pt">860,526</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; padding-left: 0pt; text-indent: 0pt">692,233</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; padding-left: 0pt; text-indent: 0pt">2,940,881</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; padding-left: 0pt; text-indent: 0pt">2,285,285</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt; text-indent: 0pt">Gross margin</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">1,611,902</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">1,077,896</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">4,593,400</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">3,106,314</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">Sales and marketing expenses</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">381,740</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">373,595</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">1,086,928</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">921,588</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">Administrative expenses</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">301,566</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">302,216</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">941,417</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">873,866</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">Product development expenses</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; padding-left: 0pt; text-indent: 0pt">301,746</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; padding-left: 0pt; text-indent: 0pt">361,232</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; padding-left: 0pt; text-indent: 0pt">904,170</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; padding-left: 0pt; text-indent: 0pt">1,716,114</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt; text-indent: 0pt">Operating expenses</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; padding-left: 0pt; text-indent: 0pt">985,052</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; padding-left: 0pt; text-indent: 0pt">1,037,043</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; padding-left: 0pt; text-indent: 0pt">2,932,515</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; padding-left: 0pt; text-indent: 0pt">3,511,568</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 0pt; text-indent: 0pt">NET OPERATING INCOME (LOSS)</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">626,850</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">40,853</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">1,660,885</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">(405,254</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">Other expenses, net</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; padding-left: 0pt; text-indent: 0pt">15,111</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; padding-left: 0pt; text-indent: 0pt">11,246</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; padding-left: 0pt; text-indent: 0pt">27,059</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; padding-left: 0pt; text-indent: 0pt">38,633</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 0pt; text-indent: 0pt">INCOME (LOSS) BEFORE INCOME TAXES</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">611,739</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">29,607</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">1,633,826</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">(443,887</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">Income tax expense (benefit)</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; padding-left: 0pt; text-indent: 0pt">260,447</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; padding-left: 0pt; text-indent: 0pt">19,277</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; padding-left: 0pt; text-indent: 0pt">709,394</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; padding-left: 0pt; text-indent: 0pt">(146,101</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt; text-indent: 0pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">NET INCOME (LOSS)</TD><TD STYLE="padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; padding-left: 0pt; text-indent: 0pt">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; padding-left: 0pt; text-indent: 0pt">351,292</TD><TD STYLE="padding-bottom: 4pt; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; padding-left: 0pt; text-indent: 0pt">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; padding-left: 0pt; text-indent: 0pt">10,330</TD><TD STYLE="padding-bottom: 4pt; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; padding-left: 0pt; text-indent: 0pt">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; padding-left: 0pt; text-indent: 0pt">924,432</TD><TD STYLE="padding-bottom: 4pt; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; padding-left: 0pt; text-indent: 0pt">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; padding-left: 0pt; text-indent: 0pt">(297,786</TD><TD STYLE="padding-bottom: 4pt; text-align: left; padding-left: 0pt; text-indent: 0pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0pt; text-indent: 0pt">Weighted average common shares outstanding:</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: 0pt">Basic</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">3,052,175</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">3,027,034</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">3,038,111</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">3,026,990</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: 0pt">Diluted</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">3,188,349</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">3,105,832</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">3,162,620</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">3,026,990</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; padding-left: 0pt; text-indent: 0pt">NET INCOME (LOSS) PER SHARE:</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; text-indent: 0pt">Basic</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">$</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">0.12</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">$</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">0.00</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">$</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">0.30</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">$</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">(0.10</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; text-indent: 0pt">Diluted</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">$</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">0.11</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">$</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">0.00</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">$</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">0.29</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">$</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">(0.10</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>The
accompanying notes are an integral part of these financial statements.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: -0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: -0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: -0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>ImmuCell Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(Unaudited)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>STATEMENTS
OF COMPREHENSIVE INCOME (LOSS)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 63pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0pt; text-indent: 0pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>For the Three-Month </B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Periods Ended <BR>
September 30,</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0pt; text-indent: 0pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>For the Nine-Month </B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Periods Ended <BR>
September 30,</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0pt; text-indent: 0pt">2015</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0pt; text-indent: 0pt">2014</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0pt; text-indent: 0pt">2015</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0pt; text-indent: 0pt">2014</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: left; text-indent: 0pt; padding-left: 0pt">Net income (loss)</TD><TD STYLE="width: 1%; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; padding-left: 0pt; text-indent: 0pt">$</TD><TD STYLE="width: 9%; text-align: right; padding-left: 0pt; text-indent: 0pt">351,292</TD><TD STYLE="width: 1%; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="width: 1%; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; padding-left: 0pt; text-indent: 0pt">$</TD><TD STYLE="width: 9%; text-align: right; padding-left: 0pt; text-indent: 0pt">10,330</TD><TD STYLE="width: 1%; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="width: 1%; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; padding-left: 0pt; text-indent: 0pt">$</TD><TD STYLE="width: 9%; text-align: right; padding-left: 0pt; text-indent: 0pt">924,432</TD><TD STYLE="width: 1%; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="width: 1%; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; padding-left: 0pt; text-indent: 0pt">$</TD><TD STYLE="width: 9%; text-align: right; padding-left: 0pt; text-indent: 0pt">(297,786</TD><TD STYLE="width: 1%; text-align: left; padding-left: 0pt; text-indent: 0pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; text-indent: 0pt; padding-left: 0pt">Other comprehensive (loss) income:</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: 0pt; padding-left: 10pt">Interest rate swaps, before taxes</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">(81,767</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">)</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">8,347</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">(79,956</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">)</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">322</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; text-indent: 0pt; padding-left: 10pt">Income tax applicable to interest rate swaps</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; padding-left: 0pt; text-indent: 0pt">32,620</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; padding-left: 0pt; text-indent: 0pt">(3,330</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt; text-indent: 0pt">)</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; padding-left: 0pt; text-indent: 0pt">31,897</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; padding-left: 0pt; text-indent: 0pt">(129</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt; text-indent: 0pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt; text-indent: 0pt">Other comprehensive (loss) income,
    net of taxes</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; padding-left: 0pt; text-indent: 0pt">(49,147</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt; text-indent: 0pt">)</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; padding-left: 0pt; text-indent: 0pt">5,017</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; padding-left: 0pt; text-indent: 0pt">(48,059</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt; text-indent: 0pt">)</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; padding-left: 0pt; text-indent: 0pt">193</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; text-indent: 0pt; padding-left: 0pt">Total comprehensive income (loss)</TD><TD STYLE="padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; padding-left: 0pt; text-indent: 0pt">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; padding-left: 0pt; text-indent: 0pt">302,145</TD><TD STYLE="padding-bottom: 4pt; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; padding-left: 0pt; text-indent: 0pt">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; padding-left: 0pt; text-indent: 0pt">15,347</TD><TD STYLE="padding-bottom: 4pt; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; padding-left: 0pt; text-indent: 0pt">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; padding-left: 0pt; text-indent: 0pt">876,373</TD><TD STYLE="padding-bottom: 4pt; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; padding-left: 0pt; text-indent: 0pt">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; padding-left: 0pt; text-indent: 0pt">(297,593</TD><TD STYLE="padding-bottom: 4pt; text-align: left; padding-left: 0pt; text-indent: 0pt">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 63pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>The
accompanying notes are an integral part of these financial statements.</I></FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: -0.5in"></P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>ImmuCell Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(Unaudited)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>STATEMENTS
OF STOCKHOLDERS&rsquo; EQUITY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Calibri,sans-serif; padding-left: 10pt; text-indent: -10pt; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman,serif; padding-left: 0pt; text-indent: 0pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman,serif; padding-left: 0pt; text-align: center; border-bottom: Black 1.5pt solid">Common Stock <BR>
$0.10 Par Value</TD><TD STYLE="font: bold 10pt Times New Roman,serif; padding-left: 0pt; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman,serif; padding-left: 0pt; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman,serif; text-align: center; padding-left: 0pt; padding-bottom: 1.5pt">Capital in <B>Excess</B>
    of</TD><TD STYLE="font: bold 10pt Times New Roman,serif; padding-left: 0pt; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman,serif; padding-left: 0pt; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman,serif; text-align: center; padding-left: 0pt; padding-bottom: 1.5pt">Accumulated (Deficit) </TD><TD STYLE="font: bold 10pt Times New Roman,serif; padding-left: 0pt; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman,serif; padding-left: 0pt; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman,serif; padding-left: 0pt; text-align: center; border-bottom: Black 1.5pt solid">Treasury Stock</TD><TD STYLE="font: bold 10pt Times New Roman,serif; padding-left: 0pt; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman,serif; padding-left: 0pt; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman,serif; text-align: center; padding-left: 0pt; padding-bottom: 1.5pt">Accumulated Other <B><BR>
Comprehensive</B></TD><TD STYLE="font: bold 10pt Times New Roman,serif; padding-left: 0pt; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman,serif; padding-left: 0pt; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman,serif; text-align: center; padding-left: 0pt; padding-bottom: 1.5pt">Total Stockholders&rsquo;</TD><TD STYLE="font: bold 10pt Times New Roman,serif; padding-left: 0pt; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Calibri,sans-serif; padding-left: 10pt; text-align: center; padding-bottom: 1.5pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman,serif; padding-left: 0pt; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman,serif; text-align: center; padding-left: 0pt; border-bottom: Black 1.5pt solid">Shares</TD><TD STYLE="font: bold 10pt Times New Roman,serif; padding-left: 0pt; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman,serif; padding-left: 0pt; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman,serif; text-align: center; padding-left: 0pt; border-bottom: Black 1.5pt solid">Amount</TD><TD STYLE="font: bold 10pt Times New Roman,serif; padding-left: 0pt; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0pt; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; padding-left: 0pt; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt/normal Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center"></P> <P STYLE="font: 10pt/115% Calibri,sans-serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman,serif"><B>Par Value</B></FONT>&nbsp;</P></TD><TD STYLE="font-size: 10pt; padding-left: 0pt; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman,serif; padding-left: 0pt; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman,serif; text-align: center; padding-left: 0pt; border-bottom: Black 1.5pt solid"> Surplus</TD><TD STYLE="font: bold 10pt Times New Roman,serif; padding-left: 0pt; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman,serif; padding-left: 0pt; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman,serif; text-align: center; padding-left: 0pt; border-bottom: Black 1.5pt solid">Shares</TD><TD STYLE="font: bold 10pt Times New Roman,serif; padding-left: 0pt; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman,serif; padding-left: 0pt; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman,serif; text-align: center; padding-left: 0pt; border-bottom: Black 1.5pt solid">Amount</TD><TD STYLE="font: bold 10pt Times New Roman,serif; padding-left: 0pt; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-left: 0pt; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt; padding-left: 0pt; text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt/normal Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center"></P> <P STYLE="font: 10pt/115% Calibri,sans-serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman,serif"><B>(Loss)</B></FONT></P></TD><TD STYLE="font-size: 10pt; padding-left: 0pt; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font: bold 10pt Times New Roman,serif; padding-left: 0pt; text-align: center; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman,serif; text-align: center; padding-left: 0pt; border-bottom: Black 1.5pt solid">Equity</TD><TD STYLE="font: bold 10pt Times New Roman,serif; padding-left: 0pt; text-indent: 0pt; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Calibri,sans-serif; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Calibri,sans-serif; text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Calibri,sans-serif; text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Calibri,sans-serif; text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Calibri,sans-serif; text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Calibri,sans-serif; text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Calibri,sans-serif; text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Calibri,sans-serif; text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Calibri,sans-serif; text-align: center; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman,serif; padding-left: 10pt; text-indent: -10pt">Balance as of December&nbsp;31,
    2014</TD><TD STYLE="width: 1%; font: 10pt Times New Roman,serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="width: 6%; font: 10pt Times New Roman,serif; text-align: right; padding-left: 0pt; text-indent: 0pt">3,261,148</TD><TD STYLE="width: 1%; font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman,serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">$</TD><TD STYLE="width: 6%; font: 10pt Times New Roman,serif; text-align: right; padding-left: 0pt; text-indent: 0pt">326,115</TD><TD STYLE="width: 1%; font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman,serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">$</TD><TD STYLE="width: 6%; font: 10pt Times New Roman,serif; text-align: right; padding-left: 0pt; text-indent: 0pt">10,042,305</TD><TD STYLE="width: 1%; font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman,serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">$</TD><TD STYLE="width: 6%; font: 10pt Times New Roman,serif; text-align: right; padding-left: 0pt; text-indent: 0pt">(574,567</TD><TD STYLE="width: 1%; font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">)</TD><TD STYLE="width: 1%; font: 10pt Times New Roman,serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="width: 6%; font: 10pt Times New Roman,serif; text-align: right; padding-left: 0pt; text-indent: 0pt">234,114</TD><TD STYLE="width: 1%; font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="width: 1%; font: 10pt Times New Roman,serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">$</TD><TD STYLE="width: 6%; font: 10pt Times New Roman,serif; text-align: right; padding-left: 0pt; text-indent: 0pt">(512,154</TD><TD STYLE="width: 1%; font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">)</TD><TD STYLE="width: 1%; font: 10pt Times New Roman,serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">$</TD><TD STYLE="width: 6%; font: 10pt Times New Roman,serif; text-align: right; padding-left: 0pt; text-indent: 0pt">(23,331</TD><TD STYLE="width: 1%; font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">)</TD><TD STYLE="width: 1%; font: 10pt Times New Roman,serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">$</TD><TD STYLE="width: 6%; font: 10pt Times New Roman,serif; text-align: right; padding-left: 0pt; text-indent: 0pt">9,258,368</TD><TD STYLE="width: 1%; font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Calibri,sans-serif; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Calibri,sans-serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Calibri,sans-serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Calibri,sans-serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Calibri,sans-serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Calibri,sans-serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Calibri,sans-serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Calibri,sans-serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Calibri,sans-serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman,serif; text-align: left; padding-left: 10pt; text-indent: -10pt">Net income</TD><TD STYLE="font: 10pt Times New Roman,serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman,serif; text-align: right; padding-left: 0pt; text-indent: 0pt">0</TD><TD STYLE="font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman,serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman,serif; text-align: right; padding-left: 0pt; text-indent: 0pt">0</TD><TD STYLE="font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman,serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman,serif; text-align: right; padding-left: 0pt; text-indent: 0pt">0</TD><TD STYLE="font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman,serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman,serif; text-align: right; padding-left: 0pt; text-indent: 0pt">924,432</TD><TD STYLE="font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman,serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman,serif; text-align: right; padding-left: 0pt; text-indent: 0pt">0</TD><TD STYLE="font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman,serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman,serif; text-align: right; padding-left: 0pt; text-indent: 0pt">0</TD><TD STYLE="font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman,serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman,serif; text-align: right; padding-left: 0pt; text-indent: 0pt">0</TD><TD STYLE="font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman,serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman,serif; text-align: right; padding-left: 0pt; text-indent: 0pt">924,432</TD><TD STYLE="font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Calibri,sans-serif; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Calibri,sans-serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Calibri,sans-serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Calibri,sans-serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Calibri,sans-serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Calibri,sans-serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Calibri,sans-serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Calibri,sans-serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Calibri,sans-serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman,serif; text-align: left; padding-left: 10pt; text-indent: -10pt">Other comprehensive (loss), net of taxes</TD><TD STYLE="font: 10pt Times New Roman,serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman,serif; text-align: right; padding-left: 0pt; text-indent: 0pt">0</TD><TD STYLE="font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman,serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman,serif; text-align: right; padding-left: 0pt; text-indent: 0pt">0</TD><TD STYLE="font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman,serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman,serif; text-align: right; padding-left: 0pt; text-indent: 0pt">0</TD><TD STYLE="font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman,serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman,serif; text-align: right; padding-left: 0pt; text-indent: 0pt">0</TD><TD STYLE="font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman,serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman,serif; text-align: right; padding-left: 0pt; text-indent: 0pt">0</TD><TD STYLE="font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman,serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman,serif; text-align: right; padding-left: 0pt; text-indent: 0pt">0</TD><TD STYLE="font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman,serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman,serif; text-align: right; padding-left: 0pt; text-indent: 0pt">(48,059</TD><TD STYLE="font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">)</TD><TD STYLE="font: 10pt Times New Roman,serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman,serif; text-align: right; padding-left: 0pt; text-indent: 0pt">(48,059</TD><TD STYLE="font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Calibri,sans-serif; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Calibri,sans-serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Calibri,sans-serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Calibri,sans-serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Calibri,sans-serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Calibri,sans-serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Calibri,sans-serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Calibri,sans-serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Calibri,sans-serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman,serif; padding-left: 10pt; text-indent: -10pt">Exercise of stock options</TD><TD STYLE="font: 10pt Times New Roman,serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman,serif; text-align: right; padding-left: 0pt; text-indent: 0pt">0</TD><TD STYLE="font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman,serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman,serif; text-align: right; padding-left: 0pt; text-indent: 0pt">0</TD><TD STYLE="font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman,serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman,serif; text-align: right; padding-left: 0pt; text-indent: 0pt">58,957</TD><TD STYLE="font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman,serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman,serif; text-align: right; padding-left: 0pt; text-indent: 0pt">0</TD><TD STYLE="font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman,serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman,serif; text-align: right; padding-left: 0pt; text-indent: 0pt">(28,000</TD><TD STYLE="font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">)</TD><TD STYLE="font: 10pt Times New Roman,serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman,serif; text-align: right; padding-left: 0pt; text-indent: 0pt">61,253</TD><TD STYLE="font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman,serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman,serif; text-align: right; padding-left: 0pt; text-indent: 0pt">0</TD><TD STYLE="font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman,serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman,serif; text-align: right; padding-left: 0pt; text-indent: 0pt">120,210</TD><TD STYLE="font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Calibri,sans-serif; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Calibri,sans-serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Calibri,sans-serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Calibri,sans-serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Calibri,sans-serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Calibri,sans-serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Calibri,sans-serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Calibri,sans-serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Calibri,sans-serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman,serif; text-align: left; padding-left: 10pt; text-indent: -10pt">Tax benefits related to stock options</TD><TD STYLE="font: 10pt Times New Roman,serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman,serif; text-align: right; padding-left: 0pt; text-indent: 0pt">0</TD><TD STYLE="font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman,serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman,serif; text-align: right; padding-left: 0pt; text-indent: 0pt">0</TD><TD STYLE="font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman,serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman,serif; text-align: right; padding-left: 0pt; text-indent: 0pt">25,707</TD><TD STYLE="font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman,serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman,serif; text-align: right; padding-left: 0pt; text-indent: 0pt">0</TD><TD STYLE="font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman,serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman,serif; text-align: right; padding-left: 0pt; text-indent: 0pt">0</TD><TD STYLE="font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman,serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman,serif; text-align: right; padding-left: 0pt; text-indent: 0pt">0</TD><TD STYLE="font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman,serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman,serif; text-align: right; padding-left: 0pt; text-indent: 0pt">0</TD><TD STYLE="font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman,serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman,serif; text-align: right; padding-left: 0pt; text-indent: 0pt">25,707</TD><TD STYLE="font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Calibri,sans-serif; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Calibri,sans-serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Calibri,sans-serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Calibri,sans-serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Calibri,sans-serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Calibri,sans-serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Calibri,sans-serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Calibri,sans-serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Calibri,sans-serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman,serif; text-align: left; padding-bottom: 1.5pt; padding-left: 10pt; text-indent: -10pt">Stock-based compensation</TD><TD STYLE="font: 10pt Times New Roman,serif; padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman,serif; text-align: right; padding-left: 0pt; text-indent: 0pt">0</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman,serif; padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman,serif; text-align: right; padding-left: 0pt; text-indent: 0pt">0</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman,serif; padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman,serif; text-align: right; padding-left: 0pt; text-indent: 0pt">17,825</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman,serif; padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman,serif; text-align: right; padding-left: 0pt; text-indent: 0pt">0</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman,serif; padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman,serif; text-align: right; padding-left: 0pt; text-indent: 0pt">0</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman,serif; padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman,serif; text-align: right; padding-left: 0pt; text-indent: 0pt">0</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman,serif; padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman,serif; text-align: right; padding-left: 0pt; text-indent: 0pt">0</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman,serif; padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman,serif; text-align: right; padding-left: 0pt; text-indent: 0pt">17,825</TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Calibri,sans-serif; padding-left: 10pt; text-indent: -10pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Calibri,sans-serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Calibri,sans-serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Calibri,sans-serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Calibri,sans-serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Calibri,sans-serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Calibri,sans-serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Calibri,sans-serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="font: 10pt Calibri,sans-serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Calibri,sans-serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman,serif; padding-bottom: 4pt; padding-left: 10pt; text-indent: -10pt">Balance as of
    September&nbsp;30, 2015</TD><TD STYLE="font: 10pt Times New Roman,serif; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman,serif; text-align: right; padding-left: 0pt; text-indent: 0pt">3,261,148</TD><TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman,serif; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">$</TD><TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman,serif; text-align: right; padding-left: 0pt; text-indent: 0pt">326,115</TD><TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman,serif; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">$</TD><TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman,serif; text-align: right; padding-left: 0pt; text-indent: 0pt">10,144,794</TD><TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman,serif; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">$</TD><TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman,serif; text-align: right; padding-left: 0pt; text-indent: 0pt">349,865</TD><TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman,serif; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman,serif; text-align: right; padding-left: 0pt; text-indent: 0pt">206,114</TD><TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman,serif; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">$</TD><TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman,serif; text-align: right; padding-left: 0pt; text-indent: 0pt">(450,901</TD><TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">)</TD><TD STYLE="font: 10pt Times New Roman,serif; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">$</TD><TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman,serif; text-align: right; padding-left: 0pt; text-indent: 0pt">(71,390</TD><TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">)</TD><TD STYLE="font: 10pt Times New Roman,serif; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">$</TD><TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman,serif; text-align: right; padding-left: 0pt; text-indent: 0pt">10,298,483</TD><TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman,serif; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Common
    Stock <BR>
$0.10 Par Value</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Capital
    in Excess of</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Accumulated</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="6" STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Treasury
    Stock</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Accumulated
    Other <BR> Comprehensive</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Total
    Stockholders&rsquo;</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Shares</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Amount</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Par
    Value</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><B>Deficit</B></TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Shares</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Amount</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(Loss)</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Equity</B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: bold 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-indent: -10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: -10pt; padding-left: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Balance
    as of December&nbsp;31, 2013</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 6%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3,261,148</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 6%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">326,115</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 6%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10,011,339</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 6%; font: 10pt Times New Roman, Times, Serif; text-align: right">(<FONT STYLE="font: 10pt Times New Roman, Times, Serif">407,408</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 6%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">235,114</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 6%; font: 10pt Times New Roman, Times, Serif; text-align: right">(<FONT STYLE="font: 10pt Times New Roman, Times, Serif">514,341</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 6%; font: 10pt Times New Roman, Times, Serif; text-align: right">(<FONT STYLE="font: 10pt Times New Roman, Times, Serif">19,836</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 6%; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">9,395,869</FONT></TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: -10pt; padding-left: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Net
    (loss)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">0</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">0</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">0</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(297,786</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">0</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">0</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">0</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(297,786</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: -10pt; padding-left: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: -10pt; padding-left: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Other
    comprehensive income, net of taxes</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">0</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">0</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">0</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">0</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">0</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">0</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">193</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">193</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: -10pt; padding-left: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: -10pt; padding-left: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Exercise
    of stock options</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">0</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">0</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">962</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">0</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">(1,000</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2,188</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">0</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3,150</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: -10pt; padding-left: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt; text-indent: -10pt; padding-left: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Stock-based
    compensation</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">0</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">0</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">22,265</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">0</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">0</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">0</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">0</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">22,265</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: -10pt; padding-left: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt; text-indent: -10pt; padding-left: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Balance
    as of September&nbsp;30, 2014</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3,261,148</FONT></TD><TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">326,115</FONT></TD><TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">10,034,566</FONT></TD><TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(<FONT STYLE="font: 10pt Times New Roman, Times, Serif">705,194</FONT></TD><TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">234,114</FONT></TD><TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(<FONT STYLE="font: 10pt Times New Roman, Times, Serif">512,153</FONT></TD><TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">(<FONT STYLE="font: 10pt Times New Roman, Times, Serif">19,643</FONT></TD><TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 4pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 4pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">9,123,691</FONT></TD><TD STYLE="padding-bottom: 4pt; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><I>The accompanying notes are an integral
part of these financial statements.</I></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;<FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 10pt"></FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>ImmuCell Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(Unaudited)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>STATEMENTS
OF CASH FLOWS </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-family: Calibri,sans-serif; padding-left: 0pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; padding-left: 0pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0pt"><P STYLE="margin-top: 0; margin-bottom: 0">For the Nine-Month</P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0">Periods Ended<BR> September 30,</P></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; padding-left: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-family: Calibri,sans-serif; padding-left: 0pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; padding-left: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0pt">2015</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; padding-left: 0pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; padding-left: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0pt">2014</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; padding-left: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; padding-left: 0pt">CASH FLOWS FROM OPERATING ACTIVITIES:</TD><TD STYLE="font-family: Calibri,sans-serif; padding-left: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-family: Calibri,sans-serif; text-align: right; padding-left: 0pt">&nbsp;</TD><TD STYLE="font-family: Calibri,sans-serif; padding-left: 0pt">&nbsp;</TD><TD STYLE="font-family: Calibri,sans-serif; padding-left: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-family: Calibri,sans-serif; text-align: right; padding-left: 0pt">&nbsp;</TD><TD STYLE="font-family: Calibri,sans-serif; padding-left: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; padding-left: 10pt">Net income (loss)</TD><TD STYLE="width: 1%; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; padding-left: 0pt">$</TD><TD STYLE="width: 9%; text-align: right; padding-left: 0pt">924,432</TD><TD STYLE="width: 1%; text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="width: 1%; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; padding-left: 0pt">$</TD><TD STYLE="width: 9%; text-align: right; padding-left: 0pt">(297,786</TD><TD STYLE="width: 1%; text-align: left; padding-left: 0pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Adjustments to reconcile net income (loss) to net cash provided by operating activities:</TD><TD STYLE="font-family: Calibri,sans-serif; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="font-family: Calibri,sans-serif; text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="font-family: Calibri,sans-serif; text-align: right; padding-left: 0pt">&nbsp;</TD><TD STYLE="font-family: Calibri,sans-serif; text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="font-family: Calibri,sans-serif; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="font-family: Calibri,sans-serif; text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="font-family: Calibri,sans-serif; text-align: right; padding-left: 0pt">&nbsp;</TD><TD STYLE="font-family: Calibri,sans-serif; text-align: left; padding-left: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt">Depreciation</TD><TD STYLE="padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt">378,475</TD><TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt">330,796</TD><TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt">Amortization</TD><TD STYLE="padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt">2,074</TD><TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt">2,158</TD><TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 20pt">Deferred income taxes</TD><TD STYLE="padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt">680,087</TD><TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt">(146,401</TD><TD STYLE="text-align: left; padding-left: 0pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 20pt">Stock-based compensation</TD><TD STYLE="padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt">17,825</TD><TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt">22,265</TD><TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 20pt">(Gain) loss on disposal of fixed assets</TD><TD STYLE="padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt">(3,984</TD><TD STYLE="text-align: left; padding-left: 0pt">)</TD><TD STYLE="padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt">4,519</TD><TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Changes in:</TD><TD STYLE="font-family: Calibri,sans-serif; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="font-family: Calibri,sans-serif; text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="font-family: Calibri,sans-serif; text-align: right; padding-left: 0pt">&nbsp;</TD><TD STYLE="font-family: Calibri,sans-serif; text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="font-family: Calibri,sans-serif; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="font-family: Calibri,sans-serif; text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="font-family: Calibri,sans-serif; text-align: right; padding-left: 0pt">&nbsp;</TD><TD STYLE="font-family: Calibri,sans-serif; text-align: left; padding-left: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 20pt">Receivables</TD><TD STYLE="padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt">216,078</TD><TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt">67,846</TD><TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 20pt">Inventory</TD><TD STYLE="padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt">81,311</TD><TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt">167,062</TD><TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 20pt">Prepaid expenses and other assets</TD><TD STYLE="padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt">(127,160</TD><TD STYLE="text-align: left; padding-left: 0pt">)</TD><TD STYLE="padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt">(185,676</TD><TD STYLE="text-align: left; padding-left: 0pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 20pt">Accounts payable and accrued expenses</TD><TD STYLE="padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt">(92,332</TD><TD STYLE="text-align: left; padding-left: 0pt">)</TD><TD STYLE="padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt">78,992</TD><TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">Deferred revenue</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; padding-left: 0pt">(6,690</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt">)</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; padding-left: 0pt">6,690</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Net cash provided by operating activities</TD><TD STYLE="padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt">2,070,116</TD><TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt">50,465</TD><TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-family: Calibri,sans-serif; padding-left: 0pt">&nbsp;</TD><TD STYLE="font-family: Calibri,sans-serif; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="font-family: Calibri,sans-serif; text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="font-family: Calibri,sans-serif; text-align: right; padding-left: 0pt">&nbsp;</TD><TD STYLE="font-family: Calibri,sans-serif; text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="font-family: Calibri,sans-serif; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="font-family: Calibri,sans-serif; text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="font-family: Calibri,sans-serif; text-align: right; padding-left: 0pt">&nbsp;</TD><TD STYLE="font-family: Calibri,sans-serif; text-align: left; padding-left: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 0pt">CASH FLOWS FROM INVESTING ACTIVITIES:</TD><TD STYLE="font-family: Calibri,sans-serif; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="font-family: Calibri,sans-serif; text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="font-family: Calibri,sans-serif; text-align: right; padding-left: 0pt">&nbsp;</TD><TD STYLE="font-family: Calibri,sans-serif; text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="font-family: Calibri,sans-serif; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="font-family: Calibri,sans-serif; text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="font-family: Calibri,sans-serif; text-align: right; padding-left: 0pt">&nbsp;</TD><TD STYLE="font-family: Calibri,sans-serif; text-align: left; padding-left: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Purchase of property, plant and equipment</TD><TD STYLE="padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt">(1,772,091</TD><TD STYLE="text-align: left; padding-left: 0pt">)</TD><TD STYLE="padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt">(520,142</TD><TD STYLE="text-align: left; padding-left: 0pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt">Maturities of investments</TD><TD STYLE="padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt">2,489,000</TD><TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt">2,489,000</TD><TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt">Purchases of investments</TD><TD STYLE="padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt">(3,711,000</TD><TD STYLE="text-align: left; padding-left: 0pt">)</TD><TD STYLE="padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt">(2,985,000</TD><TD STYLE="text-align: left; padding-left: 0pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Proceeds from sale of fixed assets</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; padding-left: 0pt">66,215</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; padding-left: 0pt">0</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Net cash (used for) investing activities</TD><TD STYLE="padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt">(2,927,876</TD><TD STYLE="text-align: left; padding-left: 0pt">)</TD><TD STYLE="padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt">(1,016,142</TD><TD STYLE="text-align: left; padding-left: 0pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Calibri,sans-serif; padding-left: 0pt">&nbsp;</TD><TD STYLE="font-family: Calibri,sans-serif; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="font-family: Calibri,sans-serif; text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="font-family: Calibri,sans-serif; text-align: right; padding-left: 0pt">&nbsp;</TD><TD STYLE="font-family: Calibri,sans-serif; text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="font-family: Calibri,sans-serif; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="font-family: Calibri,sans-serif; text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="font-family: Calibri,sans-serif; text-align: right; padding-left: 0pt">&nbsp;</TD><TD STYLE="font-family: Calibri,sans-serif; text-align: left; padding-left: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 0pt">CASH FLOWS FROM FINANCING ACTIVITIES:</TD><TD STYLE="font-family: Calibri,sans-serif; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="font-family: Calibri,sans-serif; text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="font-family: Calibri,sans-serif; text-align: right; padding-left: 0pt">&nbsp;</TD><TD STYLE="font-family: Calibri,sans-serif; text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="font-family: Calibri,sans-serif; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="font-family: Calibri,sans-serif; text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="font-family: Calibri,sans-serif; text-align: right; padding-left: 0pt">&nbsp;</TD><TD STYLE="font-family: Calibri,sans-serif; text-align: left; padding-left: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Proceeds from debt issuance</TD><TD STYLE="padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt">2,500,000</TD><TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt">0</TD><TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Debt principal repayments</TD><TD STYLE="padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt">(136,339</TD><TD STYLE="text-align: left; padding-left: 0pt">)</TD><TD STYLE="padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt">(141,647</TD><TD STYLE="text-align: left; padding-left: 0pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 10pt">Debt issuance costs</TD><TD STYLE="padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt">(32,759</TD><TD STYLE="text-align: left; padding-left: 0pt">)</TD><TD STYLE="padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt">0</TD><TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 10pt">Proceeds from exercise of stock options</TD><TD STYLE="padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt">120,210</TD><TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt">3,150</TD><TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Tax benefits related to stock options</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; padding-left: 0pt">25,707</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; padding-left: 0pt">0</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Net cash provided by (used for) financing activities</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; padding-left: 0pt">2,476,819</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; padding-left: 0pt">(138,497</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Calibri,sans-serif; padding-left: 0pt">&nbsp;</TD><TD STYLE="font-family: Calibri,sans-serif; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="font-family: Calibri,sans-serif; text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="font-family: Calibri,sans-serif; text-align: right; padding-left: 0pt">&nbsp;</TD><TD STYLE="font-family: Calibri,sans-serif; text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="font-family: Calibri,sans-serif; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="font-family: Calibri,sans-serif; text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="font-family: Calibri,sans-serif; text-align: right; padding-left: 0pt">&nbsp;</TD><TD STYLE="font-family: Calibri,sans-serif; text-align: left; padding-left: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 0pt">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</TD><TD STYLE="padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt">1,619,059</TD><TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt">(1,104,174</TD><TD STYLE="text-align: left; padding-left: 0pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Calibri,sans-serif; padding-left: 0pt">&nbsp;</TD><TD STYLE="font-family: Calibri,sans-serif; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="font-family: Calibri,sans-serif; text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="font-family: Calibri,sans-serif; text-align: right; padding-left: 0pt">&nbsp;</TD><TD STYLE="font-family: Calibri,sans-serif; text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="font-family: Calibri,sans-serif; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="font-family: Calibri,sans-serif; text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="font-family: Calibri,sans-serif; text-align: right; padding-left: 0pt">&nbsp;</TD><TD STYLE="font-family: Calibri,sans-serif; text-align: left; padding-left: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 1.5pt; padding-left: 0pt">BEGINNING CASH AND CASH EQUIVALENTS</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; padding-left: 0pt">850,028</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; padding-left: 0pt">2,270,385</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Calibri,sans-serif; padding-left: 0pt">&nbsp;</TD><TD STYLE="font-family: Calibri,sans-serif; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="font-family: Calibri,sans-serif; text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="font-family: Calibri,sans-serif; text-align: right; padding-left: 0pt">&nbsp;</TD><TD STYLE="font-family: Calibri,sans-serif; text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="font-family: Calibri,sans-serif; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="font-family: Calibri,sans-serif; text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="font-family: Calibri,sans-serif; text-align: right; padding-left: 0pt">&nbsp;</TD><TD STYLE="font-family: Calibri,sans-serif; text-align: left; padding-left: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 4pt; padding-left: 0pt">ENDING CASH AND CASH EQUIVALENTS</TD><TD STYLE="padding-bottom: 4pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; padding-left: 0pt">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; padding-left: 0pt">2,469,087</TD><TD STYLE="padding-bottom: 4pt; text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; padding-left: 0pt">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; padding-left: 0pt">1,166,211</TD><TD STYLE="padding-bottom: 4pt; text-align: left; padding-left: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Calibri,sans-serif; padding-left: 0pt">&nbsp;</TD><TD STYLE="font-family: Calibri,sans-serif; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="font-family: Calibri,sans-serif; text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="font-family: Calibri,sans-serif; text-align: right; padding-left: 0pt">&nbsp;</TD><TD STYLE="font-family: Calibri,sans-serif; text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="font-family: Calibri,sans-serif; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="font-family: Calibri,sans-serif; text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="font-family: Calibri,sans-serif; text-align: right; padding-left: 0pt">&nbsp;</TD><TD STYLE="font-family: Calibri,sans-serif; text-align: left; padding-left: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 0pt">INCOME TAXES PAID</TD><TD STYLE="padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt">$</TD><TD STYLE="text-align: right; padding-left: 0pt">3,600</TD><TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt">$</TD><TD STYLE="text-align: right; padding-left: 0pt">1,752</TD><TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Calibri,sans-serif; padding-left: 0pt">&nbsp;</TD><TD STYLE="font-family: Calibri,sans-serif; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="font-family: Calibri,sans-serif; text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="font-family: Calibri,sans-serif; text-align: right; padding-left: 0pt">&nbsp;</TD><TD STYLE="font-family: Calibri,sans-serif; text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="font-family: Calibri,sans-serif; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="font-family: Calibri,sans-serif; text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="font-family: Calibri,sans-serif; text-align: right; padding-left: 0pt">&nbsp;</TD><TD STYLE="font-family: Calibri,sans-serif; text-align: left; padding-left: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 0pt">INTEREST EXPENSE PAID</TD><TD STYLE="padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt">$</TD><TD STYLE="text-align: right; padding-left: 0pt">38,324</TD><TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt">$</TD><TD STYLE="text-align: right; padding-left: 0pt">44,771</TD><TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-family: Calibri,sans-serif; padding-left: 0pt">&nbsp;</TD><TD STYLE="font-family: Calibri,sans-serif; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="font-family: Calibri,sans-serif; text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="font-family: Calibri,sans-serif; text-align: right; padding-left: 0pt">&nbsp;</TD><TD STYLE="font-family: Calibri,sans-serif; text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="font-family: Calibri,sans-serif; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="font-family: Calibri,sans-serif; text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="font-family: Calibri,sans-serif; text-align: right; padding-left: 0pt">&nbsp;</TD><TD STYLE="font-family: Calibri,sans-serif; text-align: left; padding-left: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-left: 0pt">NON-CASH ACTIVITIES:</TD><TD STYLE="font-family: Calibri,sans-serif; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="font-family: Calibri,sans-serif; text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="font-family: Calibri,sans-serif; text-align: right; padding-left: 0pt">&nbsp;</TD><TD STYLE="font-family: Calibri,sans-serif; text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="font-family: Calibri,sans-serif; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="font-family: Calibri,sans-serif; text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="font-family: Calibri,sans-serif; text-align: right; padding-left: 0pt">&nbsp;</TD><TD STYLE="font-family: Calibri,sans-serif; text-align: left; padding-left: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0pt">Change in capital expenditures included in accounts payable and accrued
    expenses</TD><TD STYLE="padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt">$</TD><TD STYLE="text-align: right; padding-left: 0pt">(213,418</TD><TD STYLE="text-align: left; padding-left: 0pt">)</TD><TD STYLE="padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt">$</TD><TD STYLE="text-align: right; padding-left: 0pt">84,031</TD><TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0pt">Net change in fair value of interest rate swaps</TD><TD STYLE="padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt">$</TD><TD STYLE="text-align: right; padding-left: 0pt">48,059</TD><TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt">$</TD><TD STYLE="text-align: right; padding-left: 0pt">(193</TD><TD STYLE="text-align: left; padding-left: 0pt">)</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>The
accompanying notes are an integral part of these financial statements.</I></FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman,serif; margin: 0; text-align: center"><B>ImmuCell Corporation</B><BR>
<B>Notes to Unaudited Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center"><B></B>&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0pt; text-indent: 0pt; width: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>1.</B></FONT></TD>
    <TD STYLE="padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>BUSINESS OPERATIONS</B></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">ImmuCell
Corporation (the Company) is a growing animal health company whose purpose is to create scientifically-proven and practical products
that result in a measurable economic impact on animal health and productivity in the dairy and beef industries. The Company was
originally incorporated in Maine in 1982 and reincorporated in Delaware in 1987, in conjunction with its initial public offering
of common stock. We market products that provide immediate immunity to newborn dairy and beef cattle. We are developing product
line extensions of our existing products and are in the late stages of developing a new product that addresses mastitis, the most
significant cause of economic loss to the dairy industry. The Company is subject to certain risks associated with its stage of
development including dependence on key individuals, competition from other larger companies, the successful sale of existing
products and the development and acquisition of additional commercially viable products with appropriate regulatory approvals,
where applicable. These and other risks to our company are further detailed under <B>PART II: OTHER INFORMATION, ITEM 1A &ndash;
RISK FACTORS</B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0pt; text-indent: 0pt; width: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>2.</B></FONT></TD>
    <TD STYLE="padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</B></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt; width: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(a)</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Basis of presentation</B></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
have prepared the accompanying unaudited financial statements reflecting all adjustments, all of which are of a normal recurring
nature, that are, in our opinion, necessary in order to ensure that the financial statements are not misleading. We follow accounting
standards set by the Financial Accounting Standards Board (FASB). The FASB sets generally accepted accounting principles (GAAP)
that we follow to ensure we consistently report our financial condition, results of operations, earnings per share and cash flows.
References to GAAP in these footnotes are to the FASB<I> Accounting Standards Codification</I>&trade; (Codification). Certain
prior year accounts have been reclassified to conform with the 2015 financial statement presentation. Certain information and
footnote disclosures normally included in the annual financial statements have been condensed or omitted. Accordingly, we believe
that although the disclosures are adequate to ensure that the information presented is not misleading, these financial statements
should be read in conjunction with the financial statements for the year ended December 31, 2014 and the notes thereto, contained
in our Annual Report on Form 10-K as filed with the Securities and Exchange Commission (SEC).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0pt; text-indent: 0pt; width: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(b)</B></FONT></TD>
    <TD STYLE="padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Cash, Cash Equivalents, Short-Term Investments and Long-Term Investments</B></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
consider all highly liquid investment instruments that mature within three months of their purchase dates to be cash equivalents.
Cash equivalents are principally invested in securities backed by the U.S. government. Certain cash balances in excess of Federal
Deposit Insurance Corporation (FDIC) limits of $250,000 per financial institution per depositor are maintained in money market
accounts at financial institutions that are secured, in part, by the Securities Investor Protection Corporation. Amounts in excess
of these FDIC limits per bank that are not invested in securities backed by the U.S. government aggregated $1,968,787 and $566,637
as of September 30, 2015 and December 31, 2014, respectively. Short-term investments are classified as held to maturity and are
comprised principally of certificates of deposit that mature in more than three months from their purchase dates and not more
than twelve months from the balance sheet date. Long-term investments are classified as held to maturity and are comprised principally
of certificates of deposit that mature in more than twelve months from the balance sheet date. Short-term and long-term investments
are held at different financial institutions that are insured by the FDIC, within the FDIC limits per financial institution. See
Note 3.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt; width: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(c)</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Inventory</B></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Inventory
includes raw materials, work-in-process and finished goods and is recorded at the lower of cost, on the first-in, first-out method,
or market (net realizable value). Work-in-process and finished goods inventories include materials, labor and manufacturing overhead.
See Note 4.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0pt; text-indent: 0pt; width: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(d) </B></FONT></TD>
    <TD STYLE="padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Trade Receivables</B></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Trade
receivables are carried at the original invoice amount less an estimate made for doubtful collection. Management determines the
allowance for doubtful accounts on a monthly basis by identifying troubled accounts and by using historical experience applied
to an aging of accounts. Trade receivables are written off when deemed uncollectible. Recoveries of trade receivables previously
written off are recorded as income when received. A trade receivable is considered to be past due if any portion of the receivable
balance is outstanding for more than 30 days. Interest is charged on past due trade receivables. See Note 5.</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&nbsp;-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>ImmuCell Corporation<BR>
Notes to Unaudited Financial Statements (continued)</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0pt; text-indent: 0pt; width: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(e)</B></FONT></TD>
    <TD STYLE="padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Property, Plant and Equipment</B></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
depreciate property, plant and equipment on the straight-line method by charges to operations in amounts estimated to expense
the cost of the assets from the date they are first put into service to the end of the estimated useful lives of the assets. The
cost of our building (which was acquired in 1993) and the 2001 and 2007 additions thereto are being depreciated through 2023.
We are depreciating the building addition that was completed during the first quarter of 2015 over twenty-five years. Related
building improvements are depreciated over ten year periods. Large and durable fixed assets are depreciated over their useful
lives that are generally estimated to be five to ten years. Other fixed assets and computer equipment are depreciated over their
useful lives that are generally estimated to be five and three years, respectively. See Note 7.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0pt; text-indent: 0pt; width: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(f)</B></FONT></TD>
    <TD STYLE="padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Intangible Assets</B></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
amortize intangible assets on the straight-line method by charges to operations in amounts estimated to expense the cost of the
assets from the date they are first put into service to the end of the estimated useful lives of the assets. In connection with
certain credit facilities entered into during the third quarters of 2010 and 2015, we incurred debt issue costs of $26,489 and
$32,759, respectively, which costs are being amortized to other expenses, net over the terms of the credit facilities. See Notes
6 and 9.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
continually assess the realizability of these assets in accordance with the impairment provisions of Codification Topic 360, <I>Accounting
for the Impairment or Disposal of Long-Lived Assets</I>. If an impairment review is triggered, we evaluate the carrying value
of long-lived assets by determining if impairment exists based on estimated undiscounted future cash flows over the remaining
useful life of the assets and comparing that value to the carrying value of the assets. If the carrying value of the asset is
greater than the estimated future cash flows, the asset is written down to its estimated fair value. The cash flow estimates that
are used contain our best estimates, using appropriate and customary assumptions and projections at the time. We also review the
estimated useful life of intangible assets at the end of each reporting period, making any necessary adjustments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0pt; text-indent: 0pt; width: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(g)</B></FONT></TD>
    <TD STYLE="padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Disclosure of Fair Value of Financial Instruments and Concentration
of Risk</B></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Financial
instruments consist mainly of cash, cash equivalents, short-term investments, long-term investments, accounts receivable, accounts
payable, bank debt and interest rate swaps. Financial instruments that potentially subject the Company to concentrations of credit
risk are principally cash, cash equivalents, short-term investments, long-term investments and accounts receivable. We make short-term
and long-term investments in financial instruments that are insured by the FDIC. We account for fair value measurements in accordance
with Codification Topic 820, <I>Fair Value Measurements and Disclosures</I>, which defines fair value, establishes a framework
for measuring fair value and requires additional disclosures about fair value measurements. The estimated fair value of cash,
cash equivalents, short-term investments, long-term investments, accounts receivable and accounts payable approximate their carrying
value due to their short maturities. The estimated fair value of bank debt approximates its carrying value because the interest
rates are variable. Interest rate swaps are carried at fair value. See Note 9.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Concentration
of credit risk with respect to accounts receivable is principally limited to certain customers to whom we make substantial sales.
To reduce risk, we routinely assess the financial strength of our customers and, as a consequence, believe that our accounts receivable
credit risk exposure is limited. We maintain an allowance for potential credit losses, but historically we have not experienced
significant credit losses related to an individual customer or groups of customers in any particular industry or geographic area.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
believe that supplies and raw materials for the production of our products are available from more than one vendor or farm. Our
policy is to maintain more than one source of supply for the components used in our products. However, there is a risk that we
could have difficulty in efficiently acquiring essential supplies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0pt; text-indent: 0pt; width: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(h)</B></FONT></TD>
    <TD STYLE="padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Interest Rate Swap Agreements</B></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">All
derivatives are recognized on the balance sheet at their fair value. We entered into interest rate swap agreements in 2010 and
2015. On the dates the agreements were entered into, we designated the derivatives as hedges of the variability of cash flows
to be paid related to our long-term debt. The agreements have been determined to be highly effective in hedging the variability
of identified cash flows, so changes in the fair market value of the interest rate swap agreements are recorded as comprehensive
income (loss), until earnings are affected by the variability of cash flows (e.g. when periodic settlements on a variable-rate
asset or liability are recorded in earnings). We formally documented the relationship between the interest rate swap agreements
and the related hedged items. We also formally assess, both at the interest rate swap agreements&rsquo; inception and on an ongoing
basis, whether the agreements are highly effective in offsetting changes in cash flow of hedged items. See Note 9.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&nbsp;-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>ImmuCell Corporation<BR>
Notes to Unaudited Financial Statements (continued)</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-left: 0pt; text-indent: 0pt; width: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(i)</B></FONT></TD>
    <TD STYLE="padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Revenue Recognition</B></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
recognize revenue in accordance with Staff Accounting Bulletin (SAB) No. 104, &ldquo;Revenue Recognition&rdquo;. SAB No. 104 requires
that four criteria are met before revenue is recognized. These include i) persuasive evidence that an arrangement exists, ii)
delivery has occurred or services have been rendered, iii) the seller&rsquo;s price is fixed and determinable and iv) collectability
is reasonably assured. We recognize revenue at the time of shipment (including to distributors) for substantially all products,
as title and risk of loss pass to the customer on delivery to the common carrier after concluding that collectability is reasonably
assured. We recognize service revenue at the time the service is performed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(j)</B></FONT></TD>
    <TD STYLE="padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Expense Recognition</B></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Advertising
costs are expensed when incurred, which is generally during the month in which the advertisement is published. Advertising expenses
amounted to $27,545 and $15,844 during the three-month periods ended September 30, 2015 and 2014, respectively, and $72,539 and
$42,915 during the nine-month periods ended September 30, 2015 and 2014, respectively. All product development expenses are expensed
as incurred, as are all related patent costs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(k)</B></FONT></TD>
    <TD STYLE="padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Income Taxes</B></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
account for income taxes in accordance with Codification Topic 740, <I>Income Taxes</I>,<I> </I>which requires that we recognize
a current tax liability or asset for current taxes payable or refundable and a deferred tax liability or asset for the estimated
future tax effects of temporary differences and carryforwards to the extent they are realizable. We believe it is more likely
than not that the deferred tax assets will be realized through future taxable income and future tax effects of temporary differences
between book income and taxable income. Accordingly, we have not established a valuation allowance for the deferred tax assets.
Codification Topic 740-10 clarifies the accounting for income taxes by prescribing a minimum recognition threshold that a tax
position must meet before being recognized in the financial statements. In the ordinary course of business, there are transactions
and calculations where the ultimate tax outcome is uncertain. In addition, we are subject to periodic audits and examinations
by the Internal Revenue Service and other taxing authorities. We have evaluated the positions taken on our filed tax returns.
We have concluded that no uncertain tax positions exist as of September 30, 2015. Although we believe that our estimates are reasonable,
actual results could differ from these estimates. See Note 11.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(l)</B></FONT></TD>
    <TD STYLE="padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Stock-Based Compensation</B></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
account for stock-based compensation in accordance with Codification Topic 718, <I>Compensation-Stock Compensation</I>, which
generally requires us to recognize non-cash compensation expense for stock-based payments using the fair-value-based method. The
fair value of each stock option grant has been estimated on the date of grant using the Black-Scholes option pricing model. Accordingly,
we recorded compensation expense pertaining to stock-based compensation of $6,342 and $4,974 during the three-month periods ended
September 30, 2015 and 2014, respectively, and $17,825 and $22,265 during the nine-month periods ended September 30, 2015 and
2014, respectively, which resulted in a decrease to income before income taxes of less than $0.01 per share during each of the
periods reported. Codification Topic 718 requires us to reflect gross tax savings resulting from tax deductions in excess of expense
reflected in our financial statements as a financing cash flow.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(m)</B></FONT></TD>
    <TD STYLE="padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Net Income (Loss) Per Common Share</B></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Net
Income (Loss) per common share has been computed in accordance with Codification Topic 260-10, <I>Earnings Per Share.</I> The
basic Net Income per share has been computed by dividing Net Income by the weighted average number of common shares outstanding
during this period. Diluted Net Income per share has been computed by dividing Net Income by the weighted average number of shares
outstanding during the period plus all outstanding stock options with an exercise price that is less than the average market price
of the common stock during the period less the number of shares that could have been repurchased at this average market price
with the proceeds from the hypothetical stock option exercises.<I> </I>The Net (Loss) per common share in 2014 has been computed
by dividing the Net (Loss) by the weighted average number of common shares outstanding during the period, without giving consideration
to outstanding stock options because the impact would be anti-dilutive.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&nbsp;-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>ImmuCell Corporation<BR>
Notes to Unaudited Financial Statements (continued)</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Three-Month
                                                                                 Period&nbsp;</B></FONT><BR> <FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Ended September 30,</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Nine-Month
                                                                                 Period </B></FONT><BR> <FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Ended September 30,</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2015</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2014</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2015</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2014</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; padding-left: 0.7pt">Weighted average number of shares outstanding</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">3,052,175</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">3,027,034</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">3,038,111</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">3,026,990</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0.7pt">Effect of dilutive stock options</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">136,174</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">78,798</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">124,509</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">0</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt; padding-left: 0.7pt">Diluted number of shares outstanding</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">3,188,349</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">3,105,832</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">3,162,620</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">3,026,990</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.7pt">Stock options outstanding as of September 30th not included in the
    calculation because the effect would be anti-dilutive</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">0</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">85,000</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">3,000</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">251,000</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(n)</B></FONT></TD>
    <TD STYLE="padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Use of Estimates</B></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses during the period. Actual amounts could differ from those estimates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(o)</B></FONT></TD>
    <TD STYLE="padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>New Accounting Pronouncement </B></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">In
May 2014, the FASB issued Accounting Standards Update No. 2014-09, <I>Revenue from Contracts with Customers </I>(ASU 2014-09),
which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods
or services to customers. ASU 2014-09 will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective.
ASU 2014-09 was initially effective for the Company on January 1, 2017. Early application was not permitted. In July 2015, the
FASB approved a one-year deferral in the effective date to January 1, 2018, with the option of applying the standard on the original
effective date. ASU 2014-09 permits the use of either the retrospective or cumulative effect transition method. We have evaluated
the effect that ASU 2014-09 would have on our financial statements and related disclosures. We expect that ASU 2014-09 will have
no significant effect on our ongoing financial reporting, but we continue to evaluate this pending accounting standard.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>3. </B></FONT></TD>
    <TD STYLE="padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>CASH, CASH EQUIVALENTS, SHORT-TERM INVESTMENTS AND LONG-TERM INVESTMENTS</B></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Cash,
cash equivalents, short-term investments and long-term investments consisted of the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>As of</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>September&nbsp;30, 2015</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>As of</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>December&nbsp;31, 2014</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Increase</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(Decrease)</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left; padding-left: 0pt">Cash and cash equivalents</TD><TD STYLE="width: 1%; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; padding-left: 0pt">$</TD><TD STYLE="width: 9%; text-align: right; padding-left: 0pt">2,469,087</TD><TD STYLE="width: 1%; text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="width: 1%; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; padding-left: 0pt">$</TD><TD STYLE="width: 9%; text-align: right; padding-left: 0pt">850,028</TD><TD STYLE="width: 1%; text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="width: 1%; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; padding-left: 0pt">$</TD><TD STYLE="width: 9%; text-align: right; padding-left: 0pt">1,619,059</TD><TD STYLE="width: 1%; text-align: left; padding-left: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt">Short-term investments</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; padding-left: 0pt">3,720,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; padding-left: 0pt">2,489,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; padding-left: 0pt">1,231,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0pt">&nbsp;&nbsp;&nbsp;Subtotal</TD><TD STYLE="padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt">6,189,087</TD><TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt">3,339,028</TD><TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt">2,850,059</TD><TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt">Long-term investments</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; padding-left: 0pt">487,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; padding-left: 0pt">496,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; padding-left: 0pt">(9,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt; padding-left: 0pt">&nbsp;&nbsp;&nbsp;Total</TD><TD STYLE="padding-bottom: 4pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; padding-left: 0pt">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; padding-left: 0pt">6,676,087</TD><TD STYLE="padding-bottom: 4pt; text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; padding-left: 0pt">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; padding-left: 0pt">3,835,028</TD><TD STYLE="padding-bottom: 4pt; text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; padding-left: 0pt">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; padding-left: 0pt">2,841,059</TD><TD STYLE="padding-bottom: 4pt; text-align: left; padding-left: 0pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>4. </B></FONT></TD>
    <TD><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>INVENTORY</B></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Inventory
consisted of the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0pt; text-indent: 0pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>As of</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>September&nbsp;30, 2015</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0pt; text-indent: 0pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>As of</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>December&nbsp;31, 2014</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0pt; text-indent: 0pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Increase</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(Decrease)</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: justify; padding-left: 0pt; text-indent: 0pt">Raw materials</TD><TD STYLE="width: 1%; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; padding-left: 0pt; text-indent: 0pt">$</TD><TD STYLE="width: 9%; text-align: right; padding-left: 0pt; text-indent: 0pt">337,538</TD><TD STYLE="width: 1%; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="width: 1%; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; padding-left: 0pt; text-indent: 0pt">$</TD><TD STYLE="width: 9%; text-align: right; padding-left: 0pt; text-indent: 0pt">306,444</TD><TD STYLE="width: 1%; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="width: 1%; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; padding-left: 0pt; text-indent: 0pt">$</TD><TD STYLE="width: 9%; text-align: right; padding-left: 0pt; text-indent: 0pt">31,094</TD><TD STYLE="width: 1%; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt">Work-in-process</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">468,059</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">355,745</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">112,314</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">Finished goods</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; padding-left: 0pt; text-indent: 0pt">58,847</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; padding-left: 0pt; text-indent: 0pt">283,566</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; padding-left: 0pt; text-indent: 0pt">(224,719</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt; text-indent: 0pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt; padding-left: 10pt; text-indent: 0pt">Total</TD><TD STYLE="padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; padding-left: 0pt; text-indent: 0pt">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; padding-left: 0pt; text-indent: 0pt">864,444</TD><TD STYLE="padding-bottom: 4pt; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; padding-left: 0pt; text-indent: 0pt">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; padding-left: 0pt; text-indent: 0pt">945,755</TD><TD STYLE="padding-bottom: 4pt; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; padding-left: 0pt; text-indent: 0pt">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; padding-left: 0pt; text-indent: 0pt">(81,311</TD><TD STYLE="padding-bottom: 4pt; text-align: left; padding-left: 0pt; text-indent: 0pt">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&nbsp;-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>ImmuCell Corporation<BR>
Notes to Unaudited Financial Statements (continued)</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT>&nbsp;</P>




<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>5. </B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>ACCOUNTS RECEIVABLE</B></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Accounts
receivable consisted of the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0pt; text-indent: 0pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>As of</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>September&nbsp;30, 2015</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0pt; text-indent: 0pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>As of</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>December&nbsp;31, 2014</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0pt; text-indent: 0pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(Decrease)</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Increase</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left; padding-left: 0pt; text-indent: 0pt">Trade accounts receivable, gross</TD><TD STYLE="width: 1%; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; padding-left: 0pt; text-indent: 0pt">$</TD><TD STYLE="width: 9%; text-align: right; padding-left: 0pt; text-indent: 0pt">783,547</TD><TD STYLE="width: 1%; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="width: 1%; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; padding-left: 0pt; text-indent: 0pt">$</TD><TD STYLE="width: 9%; text-align: right; padding-left: 0pt; text-indent: 0pt">1,004,990</TD><TD STYLE="width: 1%; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="width: 1%; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; padding-left: 0pt; text-indent: 0pt">$</TD><TD STYLE="width: 9%; text-align: right; padding-left: 0pt; text-indent: 0pt">(221,443</TD><TD STYLE="width: 1%; text-align: left; padding-left: 0pt; text-indent: 0pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">Accumulated allowance for bad debt and product returns</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; padding-left: 0pt; text-indent: 0pt">(16,958</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt; text-indent: 0pt">)</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; padding-left: 0pt; text-indent: 0pt">(16,194</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt; text-indent: 0pt">)</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; padding-left: 0pt; text-indent: 0pt">(764</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt; text-indent: 0pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Trade accounts receivable, net</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">766,589</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">988,796</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">(222,207</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">Other receivables</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; padding-left: 0pt; text-indent: 0pt">22,625</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; padding-left: 0pt; text-indent: 0pt">16,496</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; padding-left: 0pt; text-indent: 0pt">6,129</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable, net</TD><TD STYLE="padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; padding-left: 0pt; text-indent: 0pt">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; padding-left: 0pt; text-indent: 0pt">789,214</TD><TD STYLE="padding-bottom: 4pt; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; padding-left: 0pt; text-indent: 0pt">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; padding-left: 0pt; text-indent: 0pt">1,005,292</TD><TD STYLE="padding-bottom: 4pt; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; padding-left: 0pt; text-indent: 0pt">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; padding-left: 0pt; text-indent: 0pt">(216,078</TD><TD STYLE="padding-bottom: 4pt; text-align: left; padding-left: 0pt; text-indent: 0pt">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>6. </B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>PREPAID EXPENSES AND OTHER ASSETS</B></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Prepaid
expenses and other assets consisted of the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0pt; text-indent: 0pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>As of</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>September&nbsp;30, 2015</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0pt; text-indent: 0pt">As of<BR> December&nbsp;31, 2014</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0pt; text-indent: 0pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Increase</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(Decrease)</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left; padding-left: 0pt; text-indent: 0pt">Prepaid expenses and other assets</TD><TD STYLE="width: 1%; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; padding-left: 0pt; text-indent: 0pt">$</TD><TD STYLE="width: 9%; text-align: right; padding-left: 0pt; text-indent: 0pt">234,628</TD><TD STYLE="width: 1%; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="width: 1%; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; padding-left: 0pt; text-indent: 0pt">$</TD><TD STYLE="width: 9%; text-align: right; padding-left: 0pt; text-indent: 0pt">133,119</TD><TD STYLE="width: 1%; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="width: 1%; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; padding-left: 0pt; text-indent: 0pt">$</TD><TD STYLE="width: 9%; text-align: right; padding-left: 0pt; text-indent: 0pt">101,509</TD><TD STYLE="width: 1%; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">Security deposits</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; padding-left: 0pt; text-indent: 0pt">40,931</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; padding-left: 0pt; text-indent: 0pt">15,280</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; padding-left: 0pt; text-indent: 0pt">25,651</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Current subtotal</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; padding-left: 0pt; text-indent: 0pt">275,559</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; padding-left: 0pt; text-indent: 0pt">148,399</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; padding-left: 0pt; text-indent: 0pt">127,160</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">Debt issue costs</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">59,248</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">26,489</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">32,759</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">Accumulated amortization of debt issue costs</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">(18,553</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">)</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">(16,479</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">)</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">(2,074</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">Security deposits</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; padding-left: 0pt; text-indent: 0pt">8,920</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; padding-left: 0pt; text-indent: 0pt">8,920</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; padding-left: 0pt; text-indent: 0pt">0</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Long-term subtotal</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; padding-left: 0pt; text-indent: 0pt">49,615</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; padding-left: 0pt; text-indent: 0pt">18,930</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; padding-left: 0pt; text-indent: 0pt">30,685</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total</TD><TD STYLE="padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; padding-left: 0pt; text-indent: 0pt">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; padding-left: 0pt; text-indent: 0pt">325,174</TD><TD STYLE="padding-bottom: 4pt; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; padding-left: 0pt; text-indent: 0pt">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; padding-left: 0pt; text-indent: 0pt">167,329</TD><TD STYLE="padding-bottom: 4pt; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; padding-left: 0pt; text-indent: 0pt">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; padding-left: 0pt; text-indent: 0pt">157,845</TD><TD STYLE="padding-bottom: 4pt; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>7. </B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>PROPERTY, PLANT AND EQUIPMENT</B></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Property,
plant and equipment consisted of the following, at cost:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0pt; text-indent: 0pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>As of</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>September&nbsp;30, 2015</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0pt; text-indent: 0pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>As of</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>December&nbsp;31, 2014</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0pt; text-indent: 0pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Increase</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(Decrease)</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left; padding-left: 0pt; text-indent: 0pt">Laboratory and manufacturing equipment</TD><TD STYLE="width: 1%; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; padding-left: 0pt; text-indent: 0pt">$</TD><TD STYLE="width: 9%; text-align: right; padding-left: 0pt; text-indent: 0pt">3,602,690</TD><TD STYLE="width: 1%; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="width: 1%; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; padding-left: 0pt; text-indent: 0pt">$</TD><TD STYLE="width: 9%; text-align: right; padding-left: 0pt; text-indent: 0pt">3,522,465</TD><TD STYLE="width: 1%; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="width: 1%; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; padding-left: 0pt; text-indent: 0pt">$</TD><TD STYLE="width: 9%; text-align: right; padding-left: 0pt; text-indent: 0pt">80,225</TD><TD STYLE="width: 1%; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt">Building and improvements</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">4,579,852</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">2,969,891</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">1,609,961</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">Office furniture and equipment</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">569,567</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">470,607</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">98,960</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Construction in progress<SUP>(1)</SUP></FONT></TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">738,282</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">1,270,672</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">(532,390</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">Land</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; padding-left: 0pt; text-indent: 0pt">72,807</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; padding-left: 0pt; text-indent: 0pt">50,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; padding-left: 0pt; text-indent: 0pt">22,807</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Property, plant and equipment, gross</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">9,563,198</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">8,283,635</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">1,279,563</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">Accumulated depreciation</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; padding-left: 0pt; text-indent: 0pt">(4,607,584</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt; text-indent: 0pt">)</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; padding-left: 0pt; text-indent: 0pt">(4,445,988</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt; text-indent: 0pt">)</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; padding-left: 0pt; text-indent: 0pt">(161,596</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt; text-indent: 0pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Property, plant and equipment, net</TD><TD STYLE="padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; padding-left: 0pt; text-indent: 0pt">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; padding-left: 0pt; text-indent: 0pt">4,955,614</TD><TD STYLE="padding-bottom: 4pt; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; padding-left: 0pt; text-indent: 0pt">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; padding-left: 0pt; text-indent: 0pt">3,837,647</TD><TD STYLE="padding-bottom: 4pt; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; padding-left: 0pt; text-indent: 0pt">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; padding-left: 0pt; text-indent: 0pt">1,117,967</TD><TD STYLE="padding-bottom: 4pt; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><SUP>&nbsp;</SUP></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><SUP>(1)</SUP>As
of December 31, 2014, construction in progress consisted of a building addition that was completed during the first quarter of
2015. As of September 30, 2015, construction in progress consisted principally of partial payments towards new manufacturing equipment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->&nbsp;-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>ImmuCell Corporation<BR>
Notes to Unaudited Financial Statements (continued)</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>




<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>8.</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>ACCOUNTS PAYABLE AND ACCRUED EXPENSES</B></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Accounts
payable and accrued expenses consisted of the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0pt; text-indent: 0pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>As of</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>September&nbsp;30, 2015</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0pt; text-indent: 0pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>As of</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>December&nbsp;31, 2014</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0pt; text-indent: 0pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(Decrease)</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Increase</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: left; padding-left: 0pt; text-indent: 0pt">Accounts payable &ndash; capital</TD><TD STYLE="width: 1%; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; padding-left: 0pt; text-indent: 0pt">$</TD><TD STYLE="width: 9%; text-align: right; padding-left: 0pt; text-indent: 0pt">37,965</TD><TD STYLE="width: 1%; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="width: 1%; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; padding-left: 0pt; text-indent: 0pt">$</TD><TD STYLE="width: 9%; text-align: right; padding-left: 0pt; text-indent: 0pt">251,383</TD><TD STYLE="width: 1%; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="width: 1%; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; padding-left: 0pt; text-indent: 0pt">$</TD><TD STYLE="width: 9%; text-align: right; padding-left: 0pt; text-indent: 0pt">(213,418</TD><TD STYLE="width: 1%; text-align: left; padding-left: 0pt; text-indent: 0pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">Accounts payable &ndash; trade</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">178,542</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">204,810</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">(26,268</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">Accrued payroll</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">134,466</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">145,176</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">(10,710</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">Accrued clinical studies</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">68,428</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">131,945</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">(63,517</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">Accrued professional fees</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">55,462</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">42,250</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">13,212</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">Accrued other</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; padding-left: 0pt; text-indent: 0pt">71,064</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; padding-left: 0pt; text-indent: 0pt">76,113</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; padding-left: 0pt; text-indent: 0pt">(5,049</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt; text-indent: 0pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;&nbsp;&nbsp;Total</TD><TD STYLE="padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; padding-left: 0pt; text-indent: 0pt">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; padding-left: 0pt; text-indent: 0pt">545,927</TD><TD STYLE="padding-bottom: 4pt; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; padding-left: 0pt; text-indent: 0pt">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; padding-left: 0pt; text-indent: 0pt">851,677</TD><TD STYLE="padding-bottom: 4pt; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; padding-left: 0pt; text-indent: 0pt">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; padding-left: 0pt; text-indent: 0pt">(305,750</TD><TD STYLE="padding-bottom: 4pt; text-align: left; padding-left: 0pt; text-indent: 0pt">)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; padding-right: 0pt; padding-left: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>9.</B></FONT></TD>
    <TD STYLE="padding-right: 0pt; padding-left: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>BANK DEBT</B></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
have in place certain credit facilities with TD Bank, N.A. (a wholly owned subsidiary of TD Financial Group, which is a multinational
bank with approximately $944 billion in assets and over 22 million clients worldwide) which are secured by substantially all of
our assets. Proceeds from the $1,000,000 mortgage note were received during the third quarter of 2010. Based on a 15-year amortization
schedule, a balloon principal payment of approximately $451,885 will be due during the third quarter of 2020. Proceeds from the
$2,500,000 mortgage note were received during the third quarter of 2015. Based on a 20-year amortization schedule, a balloon principal
payment of approximately $1,550,007 will be due during the third quarter of 2025. We hedged our interest rate exposure on these
mortgage notes with interest rate swap agreements that effectively converted floating interest rates based on the one-month LIBOR
plus a bank profit margin to the fixed rates of 6.04% and 4.38%, respectively. As of September 30, 2015, the variable rates on
these two mortgage notes were 3.46% and 2.45%, respectively. All derivatives are recognized on the balance sheet at their fair
value. At the time of the closings and thereafter, the agreements were determined to be highly effective in hedging the variability
of the identified cash flows and have been designated as cash flow hedges of the variability in the hedged interest payments.
Changes in the fair value of the interest rate swap agreements are recorded in other comprehensive income (loss), net of taxes.
The original notional amounts of the interest rate swap agreements of $1,000,000 and $2,500,000 amortize in accordance with the
amortization of the mortgage notes. The notional amount of the interest rate swaps was $3,259,963 as of September 30, 2015. Payments
required by the interest rate swaps totaled $5,112 and $5,538 during the three-month periods ended September 30, 2015 and 2014,
and $15,549 and $16,726 during the nine-month periods ended September 30, 2015 and 2014, respectively. As the result of our decision
to hedge this interest rate risk, we recorded other comprehensive (loss) income, net of taxes, in the amount of ($49,147) and
$5,017 during the three-month periods ended September 30, 2015 and 2014, and ($48,059) and $193 during the nine-month periods
ended September 30, 2015 and 2014, respectively, which reflects the change in the fair value of the interest rate swap assets
(liabilities), net of taxes. The fair values of the interest rate swaps have been determined using observable market-based inputs
or unobservable inputs that are corroborated by market data. Accordingly, the interest rate swaps are classified as level 2 within
the fair value hierarchy provided in Codification Topic 820, <I>Fair Value Measurements and Disclosures</I>. Proceeds from a $600,000
note bearing interest at 4.25% were received during the first quarter of 2011. This note was repaid during the third quarter of
2015. The $500,000 line of credit is available as needed and has been extended through May 31, 2016 and is renewable annually
thereafter. The line of credit was unused as of September 30, 2015 and December 31, 2014. Interest on any borrowings against the
line of credit would be variable at the higher of 4.25% per annum or the one-month LIBOR plus 3.5% per annum. These credit facilities
are subject to certain financial covenants. We are in compliance with all applicable covenants as of September 30, 2015. Principal
payments due under debt outstanding as of September 30, 2015 are reflected in the following table by the year that payments are
due:</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->&nbsp;-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>ImmuCell Corporation<BR>
Notes to Unaudited Financial Statements (continued)</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0pt">Period</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; padding-left: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0pt">$1,000,000 Mortgage Note</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; padding-left: 0pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; padding-left: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0pt">$2,500,000 Mortgage Note</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; padding-left: 0pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; padding-left: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0pt">Total</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; padding-left: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%; text-align: justify; padding-left: 0pt">Three months ending December 31, 2015</TD><TD STYLE="width: 1%; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; padding-left: 0pt">$</TD><TD STYLE="width: 9%; text-align: right; padding-left: 0pt">14,043</TD><TD STYLE="width: 1%; text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="width: 1%; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; padding-left: 0pt">$</TD><TD STYLE="width: 9%; text-align: right; padding-left: 0pt">19,371</TD><TD STYLE="width: 1%; text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="width: 1%; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; padding-left: 0pt">$</TD><TD STYLE="width: 9%; text-align: right; padding-left: 0pt">33,414</TD><TD STYLE="width: 1%; text-align: left; padding-left: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0pt">Year ending December 31, 2016</TD><TD STYLE="padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt">57,384</TD><TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt">78,456</TD><TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt">135,840</TD><TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0pt">Year ending December 31, 2017</TD><TD STYLE="padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt">61,056</TD><TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt">82,308</TD><TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt">143,364</TD><TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0pt">Year ending December 31, 2018</TD><TD STYLE="padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt">64,876</TD><TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt">86,097</TD><TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt">150,973</TD><TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0pt">Year ending December 31, 2019</TD><TD STYLE="padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt">68,908</TD><TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt">89,997</TD><TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt">158,905</TD><TD STYLE="text-align: left; padding-left: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-bottom: 1.5pt; padding-left: 0pt">After December 31, 2019</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; padding-left: 0pt">493,696</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; padding-left: 0pt">2,143,771</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; padding-left: 0pt">2,637,467</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-bottom: 4pt; padding-left: 10pt">Total</TD><TD STYLE="padding-bottom: 4pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; padding-left: 0pt">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; padding-left: 0pt">759,963</TD><TD STYLE="padding-bottom: 4pt; text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; padding-left: 0pt">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; padding-left: 0pt">2,500,000</TD><TD STYLE="padding-bottom: 4pt; text-align: left; padding-left: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; padding-left: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; padding-left: 0pt">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; padding-left: 0pt">3,259,963</TD><TD STYLE="padding-bottom: 4pt; text-align: left; padding-left: 0pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.5in; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>10.</B></FONT></TD>
    <TD STYLE="text-align: justify; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>OTHER EXPENSES, NET</B></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Other
expenses, net, consisted of the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; padding-left: 0; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0; text-indent: 0pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Three-Month
                                                                                                                    Periods&nbsp;</B></FONT><BR> <FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Ended September 30,</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0; text-indent: 0pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Nine-Month
                                                                                                                    Periods </B></FONT><BR> <FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Ended September 30,</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0; text-indent: 0pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0pt">2015</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; padding-left: 0; text-indent: 0pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0pt">2014</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; padding-left: 0; text-indent: 0pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0pt">2015</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; padding-left: 0; text-indent: 0pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; padding-left: 0; text-indent: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0; text-indent: 0pt">2014</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; padding-left: 0; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: left; padding-left: 0; text-indent: 0pt">Interest income</TD><TD STYLE="width: 1%; padding-left: 0; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; padding-left: 0; text-indent: 0pt">$</TD><TD STYLE="width: 9%; text-align: right; padding-left: 0; text-indent: 0pt">(4,461</TD><TD STYLE="width: 1%; text-align: left; padding-left: 0; text-indent: 0pt">)</TD><TD STYLE="width: 1%; padding-left: 0; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; padding-left: 0; text-indent: 0pt">$</TD><TD STYLE="width: 9%; text-align: right; padding-left: 0; text-indent: 0pt">(3,912</TD><TD STYLE="width: 1%; text-align: left; padding-left: 0; text-indent: 0pt">)</TD><TD STYLE="width: 1%; padding-left: 0; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; padding-left: 0; text-indent: 0pt">$</TD><TD STYLE="width: 9%; text-align: right; padding-left: 0; text-indent: 0pt">(10,634</TD><TD STYLE="width: 1%; text-align: left; padding-left: 0; text-indent: 0pt">)</TD><TD STYLE="width: 1%; padding-left: 0; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; padding-left: 0; text-indent: 0pt">$</TD><TD STYLE="width: 9%; text-align: right; padding-left: 0; text-indent: 0pt">(11,607</TD><TD STYLE="width: 1%; text-align: left; padding-left: 0; text-indent: 0pt">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0pt">Interest expense</TD><TD STYLE="padding-left: 0; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0; text-indent: 0pt">15,084</TD><TD STYLE="text-align: left; padding-left: 0; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0; text-indent: 0pt">14,514</TD><TD STYLE="text-align: left; padding-left: 0; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0; text-indent: 0pt">41,039</TD><TD STYLE="text-align: left; padding-left: 0; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-left: 0; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0; text-indent: 0pt">44,148</TD><TD STYLE="text-align: left; padding-left: 0; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; padding-left: 0; text-indent: 0pt">Other</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; padding-left: 0; text-indent: 0pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; padding-left: 0; text-indent: 0pt">4,488</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 0; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; padding-left: 0; text-indent: 0pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; padding-left: 0; text-indent: 0pt">644</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 0; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; padding-left: 0; text-indent: 0pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; padding-left: 0; text-indent: 0pt">(3,346</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 0; text-indent: 0pt">)</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; padding-left: 0; text-indent: 0pt">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; padding-left: 0; text-indent: 0pt">6,092</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 0; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt; padding-left: 10pt; text-indent: 0pt">Other expenses, net</TD><TD STYLE="padding-bottom: 4pt; padding-left: 0; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; padding-left: 0; text-indent: 0pt">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; padding-left: 0; text-indent: 0pt">15,111</TD><TD STYLE="padding-bottom: 4pt; text-align: left; padding-left: 0; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; padding-left: 0; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; padding-left: 0; text-indent: 0pt">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; padding-left: 0; text-indent: 0pt">11,246</TD><TD STYLE="padding-bottom: 4pt; text-align: left; padding-left: 0; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; padding-left: 0; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; padding-left: 0; text-indent: 0pt">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; padding-left: 0; text-indent: 0pt">27,059</TD><TD STYLE="padding-bottom: 4pt; text-align: left; padding-left: 0; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt; padding-left: 0; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left; padding-left: 0; text-indent: 0pt">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right; padding-left: 0; text-indent: 0pt">38,633</TD><TD STYLE="padding-bottom: 4pt; text-align: left; padding-left: 0; text-indent: 0pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; padding-left: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>11.</B></FONT></TD>
    <TD STYLE="padding-left: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>INCOME TAXES</B></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our
income tax expense (benefit) aggregated $260,447 and $19,277 (amounting to 43% and 65% of our income (loss) before income taxes)
for the three-month periods ended September 30, 2015 and 2014, respectively, and $709,394 and ($146,101) (amounting to 43% and
33% of our income (loss) before income taxes) for the nine-month periods ended September 30, 2015 and 2014, respectively. As of
December 31, 2014, we have state net operating loss carryforwards of approximately $1,920,000 that expire in 2028 through 2031,
if not utilized before then, and federal net operating loss carryforwards of approximately $1,750,000 that expire in 2029 through
2034, if not utilized before then. Additionally, we have general business tax credit carryforwards of approximately $220,000 that
expire in 2027 through 2034, if not utilized before then, which effectively protects approximately $549,000 in taxable income
(assuming a 40% tax rate) from taxes, which can be utilized only after all net operating loss carryforwards are utilized. The
$965,000 licensing payment that we made during the fourth quarter of 2004 was treated as an intangible asset and is being amortized
over 15 years, for tax return purposes only. Approximately $1,112,000 of our investment to produce the Drug Substance (our Active
Pharmaceutical Ingredient, Nisin) for <B>Mast Out<SUP>&reg;</SUP></B> was expensed as incurred for our books. Included in this
amount is approximately $820,000 that was capitalized and is being depreciated over statutory periods for tax return purposes
only.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Deferred
tax assets are recognized only when it is probable that sufficient taxable income will be available in future periods against
which deductible temporary differences and credits may be utilized. However, the amount of the deferred tax asset could be reduced
if projected income is not achieved due to various factors, such as unfavorable business conditions. If projected income is not
expected to be achieved, we would decrease the deferred tax asset to the amount that we believe can be realized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Net
operating loss carryforwards, credits, and other tax attributes are subject to review and possible adjustment by the Internal
Revenue Service. Section 382 of the Internal Revenue Code contains provisions that could place annual limitations on the future
utilization of net operating loss carryforwards and credits in the event of a change in ownership of the Company, as defined.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
Company files income tax returns in the U.S. federal jurisdiction and several state jurisdictions. With few exceptions, the Company
is no longer subject to income tax examinations by tax authorities for years before 2011. We currently have no tax examinations
in progress. We also have not paid additional taxes, interest or penalties as a result of tax examinations nor do we have any
unrecognized tax benefits for any of the periods in the accompanying financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->&nbsp;-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>ImmuCell Corporation<BR>
Notes to Unaudited Financial Statements (continued)</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>




<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>12.</B></FONT></TD>
    <TD STYLE="padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>COMMITMENTS AND CONTINGENT LIABILITIES</B></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our
bylaws, as amended, in effect provide that the Company will indemnify its officers and directors to the maximum extent permitted
by Delaware law. In addition, we make similar indemnity undertakings to each director through a separate indemnification agreement
with that director. The maximum payment that we may be required to make under such provisions is theoretically unlimited and is
impossible to determine. We maintain directors&rsquo; and officers&rsquo; liability insurance, which may provide reimbursement
to the Company for payments made to, or on behalf of, officers and directors pursuant to the indemnification provisions. Our indemnification
obligations were grandfathered under the provisions of Codification Topic 460<I>, Guarantees</I>. Accordingly, we have recorded
no liability for such obligations as of September 30, 2015. Since our incorporation, we have had no occasion to make any indemnification
payment to any of our officers or directors for any reason.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">As
of September 30, 2015, we had committed approximately $728,000 to capital expenditures, $576,000 to the production of inventory
and an additional $261,000 to other obligations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
enter into agreements with third parties in the ordinary course of business under which we are obligated to indemnify such third
parties from and against various risks and losses. The precise terms of such indemnities vary with the nature of the agreement.
In many cases, we limit the maximum amount of our indemnification obligations, but in some cases those obligations may be theoretically
unlimited. We have not incurred material expenses in discharging any of these indemnification obligations, and based on our analysis
of the nature of the risks involved, we believe that the fair value of the liabilities potentially arising under these agreements
is minimal. Accordingly, we have recorded no liabilities for such obligations as of September 30, 2015.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
development, manufacturing and marketing of animal health care products entails an inherent risk that liability claims will be
asserted against us. We feel that we have reasonable levels of liability insurance to support our operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>13.</B></FONT></TD>
    <TD STYLE="padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>COMMON STOCK RIGHTS PLAN</B></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">During
the second quarter of 2015, we amended our Common Stock Rights Plan by removing a provision that prevented a new group of directors
elected following the emergence of an Acquiring Person (an owner of more than 20% of our stock) from controlling the Rights Plan
by maintaining exclusive authority over the Rights Plan with pre-existing directors. We did this because such provisions have
come to be viewed with disfavor by Delaware courts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>14.</B></FONT></TD>
    <TD STYLE="padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>SEGMENT AND SIGNIFICANT CUSTOMER INFORMATION</B></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
principally operate in the business segment described in Note 1. Pursuant to Codification Topic 280, <I>Segment Reporting</I>,
we operate in one reportable business segment, that being the development, acquisition, manufacture and sale of products that
improve the health and productivity of cows for the dairy and beef industries. Almost all of our internally funded product development
expenses are in support of such products. The significant accounting policies of this segment are described in Note 2.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Our
primary customers for the majority of our product sales (85% and 84% for the three-month periods ended September 30, 2015 and
2014, and 83% and 82% for the nine-month periods ended September 30, 2015 and 2014, respectively) are in the U.S. dairy and beef
industries. Product sales to international customers, who are also in the dairy and beef industries, aggregated 6% and 11% of
our total product sales for the three-month periods ended September 30, 2015 and 2014, respectively, and 13% for both of the nine-month
periods ended September 30, 2015 and 2014. Sales to significant customers that amounted to 10% or more of total product sales
are detailed in the following table:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-family: Calibri,sans-serif; padding-left: 0pt; padding-bottom: 1.5pt; padding-right: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-left: 0pt; padding-bottom: 1.5pt; padding-right: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; padding-left: 0pt; text-align: center; border-bottom: Black 1.5pt solid; padding-right: 0pt; text-indent: 0pt">Three-Month
    Periods <BR> Ended September 30,</TD><TD STYLE="font-weight: bold; padding-left: 0pt; padding-bottom: 1.5pt; padding-right: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-left: 0pt; padding-bottom: 1.5pt; padding-right: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; padding-left: 0pt; text-align: center; border-bottom: Black 1.5pt solid; padding-right: 0pt; text-indent: 0pt">Nine-Month
    Periods <BR> Ended September 30,</TD><TD STYLE="font-weight: bold; padding-left: 0pt; padding-bottom: 1.5pt; padding-right: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-family: Calibri,sans-serif; padding-left: 0pt; padding-bottom: 1.5pt; padding-right: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-left: 0pt; padding-bottom: 1.5pt; padding-right: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; padding-left: 0pt; text-align: center; border-bottom: Black 1.5pt solid; padding-right: 0pt; text-indent: 0pt">2015</TD><TD STYLE="font-weight: bold; padding-left: 0pt; padding-bottom: 1.5pt; padding-right: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-left: 0pt; padding-bottom: 1.5pt; padding-right: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; padding-left: 0pt; text-align: center; border-bottom: Black 1.5pt solid; padding-right: 0pt; text-indent: 0pt">2014</TD><TD STYLE="font-weight: bold; padding-left: 0pt; padding-bottom: 1.5pt; padding-right: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-left: 0pt; padding-bottom: 1.5pt; padding-right: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; padding-left: 0pt; text-align: center; border-bottom: Black 1.5pt solid; padding-right: 0pt; text-indent: 0pt">2015</TD><TD STYLE="font-weight: bold; padding-left: 0pt; padding-bottom: 1.5pt; padding-right: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-left: 0pt; padding-bottom: 1.5pt; padding-right: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; padding-left: 0pt; text-align: center; border-bottom: Black 1.5pt solid; padding-right: 0pt; text-indent: 0pt">2014</TD><TD STYLE="font-weight: bold; padding-left: 0pt; padding-bottom: 1.5pt; padding-right: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: left; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman,serif">Animal Health International, Inc.<SUP>(1)</SUP></FONT></TD><TD STYLE="width: 1%; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="width: 9%; text-align: right; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt">39</TD><TD STYLE="width: 1%; text-align: left; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt">%</TD><TD STYLE="width: 1%; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="width: 9%; text-align: right; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt">34</TD><TD STYLE="width: 1%; text-align: left; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt">%</TD><TD STYLE="width: 1%; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="width: 9%; text-align: right; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt">41</TD><TD STYLE="width: 1%; text-align: left; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt">%</TD><TD STYLE="width: 1%; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="width: 9%; text-align: right; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt">37</TD><TD STYLE="width: 1%; text-align: left; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman,serif">MWI Animal Health<SUP>(2)</SUP></FONT></TD><TD STYLE="padding-left: 0pt; padding-right: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt">22</TD><TD STYLE="text-align: left; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt">%</TD><TD STYLE="padding-left: 0pt; padding-right: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt">23</TD><TD STYLE="text-align: left; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt">%</TD><TD STYLE="padding-left: 0pt; padding-right: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt">21</TD><TD STYLE="text-align: left; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt">%</TD><TD STYLE="padding-left: 0pt; padding-right: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt">22</TD><TD STYLE="text-align: left; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt">%</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.05in"></P>

<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->&nbsp;-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.05in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.05in"></P>

<P STYLE="font: 10pt Times New Roman,serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>ImmuCell Corporation<BR>
Notes to Unaudited Financial Statements (continued)</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.05in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Accounts
receivable due from significant customers amounted to the percentages of total trade accounts receivable as detailed in the following
table:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0pt; text-indent: 0pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>As of</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>September&nbsp;30, 2015</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; padding-left: 0pt; text-indent: 0pt">As of<BR> December&nbsp;31, 2014</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Animal Health International, Inc.<SUP>(1)</SUP></FONT></TD><TD STYLE="width: 1%; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="width: 9%; text-align: right; padding-left: 0pt; text-indent: 0pt">37</TD><TD STYLE="width: 1%; text-align: left; padding-left: 0pt; text-indent: 0pt">%</TD><TD STYLE="width: 1%; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="width: 9%; text-align: right; padding-left: 0pt; text-indent: 0pt">45</TD><TD STYLE="width: 1%; text-align: left; padding-left: 0pt; text-indent: 0pt">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">MWI Animal Health<SUP>(2)</SUP></FONT></TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">25</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">%</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">26</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">TCS Biosciences, Ltd.</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt">13</TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">%</TD><TD STYLE="padding-left: 0pt; text-indent: 0pt">&nbsp;</TD>
    <TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD><TD STYLE="text-align: right; padding-left: 0pt; text-indent: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">*</FONT></TD><TD STYLE="text-align: left; padding-left: 0pt; text-indent: 0pt">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><SUP>(1)</SUP>During
June 2015, Patterson Companies, Inc. (NASDAQ: PDCO) acquired Animal Health International, Inc.</FONT><FONT STYLE="font-size: 10pt"><BR>
<FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP>(2)</SUP>During March 2015, AmerisourceBergen Corporation (NYSE:
ABC) acquired MWI Animal Health.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">*Amount
is less than 10%.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; padding-left: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>15. </B></FONT></TD>
    <TD STYLE="padding-left: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>RELATED PARTY TRANSACTIONS</B></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Dr. David S. Tomsche (Chair of our Board of
Directors) is a controlling owner of Leedstone Inc. (formerly Stearns Veterinary Outlet, Inc.), a domestic distributor of ImmuCell
products (<B>First Defense<SUP>&reg;</SUP></B>, <B>Wipe Out<SUP>&reg;</SUP></B> <B>Dairy Wipes</B>,<B> </B>and<B> CMT</B>) and
of J-t Enterprises of Melrose, Inc., an exporter. His affiliated companies purchased $452,207 and $283,287 of products from ImmuCell
during the nine-month periods ended September 30, 2015 and 2014, respectively, on terms consistent with those offered to other
distributors of similar status. We made marketing-related payments of $3,222 and $6,355 to these affiliate companies during the
nine-month periods ended September 30, 2015 and 2014, respectively. Our accounts receivable (subject to standard and customary
payment terms) due from these affiliated companies aggregated $12,864 and $18,796 as of September 30, 2015 and December 31, 2014,
respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; padding-left: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>16.</B></FONT></TD>
    <TD STYLE="padding-left: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>EMPLOYEE BENEFITS</B></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
have a 401(k) savings plan (the Plan) in which all employees completing one month of service with the Company are eligible to
participate. Participants may contribute up to the maximum amount allowed by the Internal Revenue Service. Since August 2012 we
have matched 100% of the first 3% of each employee&rsquo;s salary that is contributed to the Plan and 50% of the next 2% of each
employee&rsquo;s salary that is contributed to the Plan. Under this matching plan, we paid $17,102 and $17,117 into the plan for
the three-month periods ended September 30, 2015 and 2014, respectively, and $54,157 and $47,920 for the nine-month periods ended
September 30, 2015 and 2014, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; padding-left: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>17.</B></FONT></TD>
    <TD STYLE="padding-left: 0pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>SUBSEQUENT EVENTS</B></FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">We
have adopted the disclosure provisions of Codification Topic 855-10-50-1, <I>Subsequent Events</I>, which provides guidance to
establish general standards of accounting for and disclosures of events that occur after the balance sheet date but before financial
statements are issued. Codification Topic 855-10-50-1 requires additional disclosures only, and therefore did not have an impact
on our financial condition, results of operations, earnings per share or cash flows. Entities are required to disclose the date
through which subsequent events were evaluated as well as the rationale for why that date was selected. Public entities must evaluate
subsequent events through the date that financial statements are issued. Accordingly, we have evaluated subsequent events through
the time of filing on November 12, 2015, the date we have issued this Quarterly Report on Form 10-Q. This disclosure should alert
all users of financial statements that an entity has not evaluated subsequent events after that date in the set of financial statements
being presented.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">During
the fourth quarter of 2015, we entered into a revised agreement with Plas-Pak Inc. of Norwich, Connecticut covering the supply
of plastic syringes used to deliver <B>Mast Out<SUP>&reg;</SUP></B>, effective through the year ending December 31, 2020. On
October 28, 2015, we filed a registration statement on Form S-3 with the SEC for the potential issuance of up to $10,000,000 in
equity (subject to certain limitations). We filed Pre-Effective Amendment No. 1 on November 5, 2015, and our registration statement
became effective on November 10, 2015. During the fourth quarter of 2015, our Board of Directors voted to exercise an option to
acquire land nearby to our existing Portland facility for a potential site for a <B>Mast Out<SUP>&reg;</SUP></B> production
facility for $238,000 (less the $23,800 option payment that was paid during the third quarter of 2015).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->&nbsp;-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><B>ImmuCell Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>ITEM 2 - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Financial Condition</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Bookman Old Style, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
aim to capitalize on the significant growth in sales of <B>First Defense</B></FONT><B><FONT STYLE="font-family: Symbol"><SUP>&#210;</SUP></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">
and to revolutionize the mastitis treatment paradigm. Our strategy is focused on developing and selling products that improve animal
health and productivity in the dairy and beef industries. These product opportunities are generally less expensive to develop than
the human health product opportunities that we had worked on during the 1990&rsquo;s. We have funded most of our product development
expenses principally from our gross margin on product sales. Our cumulative investment of approximately $21,653,000 during the
16.75 year period that began January 1, 1999 (the year we elected to change our strategic focus from human to animal health products)
and ended September 30, 2015 was offset, in part, by $4,130,000 in licensing revenue, technology sales and grant income. Having
largely completed the significant clinical studies for <B>Mast Out</B></FONT><B><FONT STYLE="font-family: Symbol"><SUP>&#210;</SUP></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">,
we reduced product development expenses during 2012, as anticipated, and were profitable during 2012 and 2013. These product development
expenses increased again, as we invested in a small-scale Nisin production facility, resulting in a net loss during the first half
of 2014, which was large enough to result in a net loss for the year ended December 31, 2014. After completing this investment,
we returned to profitable results during the second half of 2014 and have continued to be profitable during the first nine months
of 2015.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We had approximately $6,676,000 in available
cash, cash equivalents, short-term investments and long-term investments as of September 30, 2015. The table below summarizes the
changes in selected, key balance sheet items (in thousands, except for percentages):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 8pt; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-size: 9pt; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 9pt"><P STYLE="font: 9pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><B>As of September&nbsp;30,</B></P></TD><TD STYLE="font-size: 9pt; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 9pt; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 9pt; text-align: center"><P STYLE="font: 9pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><B>As of</B></P> <P STYLE="font: 9pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><B>December&nbsp;31,</B></P></TD><TD STYLE="font-size: 9pt; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 9pt; font-weight: bold; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-size: 9pt; font-weight: bold; border-bottom: Black 1.5pt solid; text-align: center">Increase</TD><TD STYLE="font-size: 9pt; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 8pt; font-weight: bold; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 9pt; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 9pt; border-bottom: Black 1.5pt solid; text-align: center"><B>2015</B></TD><TD STYLE="font-size: 9pt; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 9pt; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 9pt; border-bottom: Black 1.5pt solid; text-align: center"><B>2014</B></TD><TD STYLE="font-size: 9pt; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 9pt; font-weight: bold; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 9pt; font-weight: bold; border-bottom: Black 1.5pt solid; text-align: center">$</TD><TD STYLE="font-size: 9pt; font-weight: bold; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD><TD STYLE="font-size: 9pt; font-weight: bold; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-size: 9pt; font-weight: bold; border-bottom: Black 1.5pt solid; text-align: center">%</TD><TD STYLE="font-size: 9pt; font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; width: 52%; padding-left: 10pt; text-indent: -10pt">Cash, cash equivalents, short-term investments and long-term investments</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">6,676</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">3,835</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">2,841</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">74</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Net working capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,507</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,460</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,047</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">68</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">Total assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14,223</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,052</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,171</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">29</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Stockholders&rsquo; equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">10,298</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">9,258</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,040</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11</TD><TD STYLE="text-align: left">%</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Net cash provided by operating activities amounted
to $2,070,000 during the nine-month period ended September 30, 2015 compared to net cash provided by operating activities of $50,000
during the nine-month period ended September 30, 2014. Net cash provided by operating activities amounted to $2,322,000 during
the twelve-month period ended September 30, 2015 compared to net cash provided by operating activities of $134,000 during the twelve-month
period ended September 30, 2014. Capital investments of $1,772,000 during the nine-month period ended September 30, 2015 compared
to capital investments of $520,000 during the nine-month period ended September 30, 2014. Together with gross margin earned from
ongoing product sales, we believe that we have sufficient capital resources to meet our working capital requirements and to finance
our ongoing business operations during at least the next twelve months, but we do not currently have sufficient capital to fund
the contemplated investment in a commercial-scale production facility for <B>Mast Out<SUP>&reg;</SUP></B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">During the third quarters of 2010 and 2015,
we agreed to terms of certain credit facilities with TD Bank, N.A., which are secured by substantially all of our assets including
our building which was independently appraised at $4,180,000 in connection with the 2015 financing. As of September 30, 2015, our
outstanding bank debt balance was approximately $3,260,000. We have a $500,000 line of credit that is available as needed. We chose
debt financing at this time in order to take advantage of what we believe to be historically low interest rates, which may trend
higher in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Bookman Old Style, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
October 28, 2015, we filed a registration statement on Form S-3 with the SEC for the potential issuance of up to $10,000,000 in
equity (subject to certain limitations). This registration statement became effective on November 10, 2015. This would allow us
to raise equity at a time that we may determine the market conditions are favorable. Under this form of registration statement,
we are limited to raising gross proceeds of no more than one-third of the market capitalization of our common stock (as determined
by the high price within the preceding 60 days leading up to a sale of securities) held by non-affiliates (non-insiders) of the
Company. This limit was approximately $4,760,000, based on the closing price of $6.53 per share as of November 3, 2015. While we
may use the net proceeds from any sale of securities to fund our growth plans and other general corporate purposes, we anticipate
that a primary use of the net proceeds would be to fund a significant portion of the cost of building and equipping a pharmaceutical
facility to produce the Drug Substance (the Active Pharmaceutical Ingredient, which is our pharmaceutical-grade Nisin) for <B>Mast&nbsp;Out</B></FONT><B><FONT STYLE="font-family: Symbol"><SUP>&#210;</SUP></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->&nbsp;-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><B>ImmuCell Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Bookman Old Style, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">During
the third quarter of 2013, our Board of Directors approved the aggregate investment of approximately $3,000,000 in two projects.
The first investment involved acquiring processing equipment and modifying a portion of our facility to produce the Drug Substance
at small-scale as part of the <B>Mast Out</B></FONT><B><FONT STYLE="font-family: Symbol"><SUP>&#210;</SUP></FONT><SUP><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT></SUP></B><FONT STYLE="font-family: Times New Roman, Times, Serif">product development initiative. These expenses were not
capitalized because this plant is not expected to support commercial sales. This project was substantially completed during the
third quarter of 2014. This specifically targeted increase in product development expenses resulted in a net loss during the first
six months of 2014. The purpose of this investment is discussed in greater detail under <B>&ldquo;Product Development Expenses&rdquo;</B>
below. The second investment involved acquiring manufacturing equipment and constructing a two-story addition to our facility,
providing us with approximately 7,100 square feet of cold storage, production and warehouse space to increase our commercial production
capacity for <B>First Defense</B></FONT><B><FONT STYLE="font-family: Symbol"><SUP>&#210;</SUP></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">
and other products. Additionally, this investment allows us to better integrate the production of the Drug Substance at small-scale
into our operations. This project was initiated at the end of the third quarter of 2014 and was substantially completed during
the first quarter of 2015. These expenses have been capitalized as they support the commercial sale of our existing products. The
following table details the spending on these two projects: </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Expenses</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Capital Expenditures</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Total Expenses and Capital Expenditures</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 64%">Three-month period ended December 31, 2013</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">110,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">21,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">131,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD>Year ended December 31, 2014</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">973,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,492,000</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,465,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt">Nine-month period ended &nbsp;September 30, 2015</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">9,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">414,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">423,000</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 4pt">Total investment</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,092,000</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,927,000</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">3,019,000</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Separately,
as of October 1, 2015, we had additional authorization from our Board of Directors to spend up to approximately $1,095,000 on
new manufacturing equipment and other routine and necessary capital expenditures. This investment is in addition to the $1,145,000
that we invested in related capital expenditures during the first nine months of 2015. Most of this 2015 investment is intended
to pay for the acquisition of <B>First&nbsp;Defense</B></FONT><B><FONT STYLE="font-family: Symbol"><SUP>&#210;</SUP></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">
production equipment necessary to increase our liquid processing capacity by approximately 50% and our freeze-drying capacity
by approximately 100%. We completed the investment to increase our liquid processing capacity during the fourth quarter of 2015,
and the investment to increase our freeze-drying capacity is proceeding on schedule and is expected to be completed before the
end of the first quarter of 2016. These investments, together with the 7,100 square foot facility addition, described above, are
necessary to increase our manufacturing capacity to fill our current backlog of <B>First Defense</B></FONT><B><FONT STYLE="font-family: Symbol"><SUP>&#210;
</SUP></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">orders and to meet the increased sales demand that we
are experiencing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Results of Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><I>Product Sales</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Bookman Old Style, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
total product sales during the three-month period ended September 30, 2015 increased by 40%, or $702,000, to $2,472,000 from $1,770,000
during the three-month period ended September 30, 2014. Our total product sales during the nine-month period ended September 30,
2015 increased by 40%, or $2,143,000 to $7,534,000 from $5,392,000 during the nine-month period ended September 30, 2014. Our total
product sales during the twelve-month period ended September 30, 2015 increased by 40%, or $2,789,000, to $9,740,000 from $6,951,000
during the twelve-month period ended September 30, 2014. This sales growth has exceeded our current production capacity and created
a backlog of orders for <B>First&nbsp;Defense</B></FONT><B><FONT STYLE="font-family: Symbol"><SUP>&#210;</SUP></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">
aggregating approximately $1,554,000 as of September 30, 2015. This backlog of orders has persisted since the first quarter of
2015. We believe that some of our customers may now be increasing their orders in an attempt to secure increased inventory levels.
This could explain why the amount of the order backlog has not been reduced materially, despite our increasing inventory production
levels. During the three-month period ended September 30, 2015, domestic product sales increased by 45%, or $667,000, and international
sales increased by 13%, or $36,000, in comparison to the three-month period ended September 30, 2014. During the nine-month period
ended September 30, 2015, domestic product sales increased by 41%, or $1,836,000, and international sales increased by 35%, or
$307,000, in comparison to the nine-month period ended September 30, 2014. The growth in international sales is primarily being
experienced in Canada. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->&nbsp;-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><B>ImmuCell Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Bookman Old Style, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Growth
in sales of our lead product, <B>First Defense</B></FONT><B><FONT STYLE="font-family: Symbol"><SUP>&#210;</SUP></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">
and related product line extensions, is driving the increase in our total product sales. <B>First Defense</B></FONT><B><FONT STYLE="font-family: Symbol"><SUP>&#210;</SUP></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">
and related product line extensions continue to benefit from wide acceptance by dairy and beef producers as an effective tool to
prevent bovine enteritis (scours) in newborn calves. We believe that our increased investment in sales and marketing personnel
is helping us introduce <B>First Defense</B></FONT><B><FONT STYLE="font-family: Symbol"><SUP>&#210;</SUP></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">
and related product line extensions to new customers. We launched a new communications campaign at the end of 2010 that continues
to emphasize how the unique ability of <B>First Defense</B></FONT><B><FONT STYLE="font-family: Symbol"><SUP>&#210;</SUP></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">
to provide <B>Immediate Immunity<SUP>TM</SUP></B> generates a dependable return on investment for dairy and beef producers. Preventing
newborn calves from becoming sick immediately after birth helps them to reach their genetic potential and reduces the reliance
on antibiotic treatments. By our estimation, calf scours can cost the calf industry approximately $740 million per year (approximately
$328 million to the dairy industry and $412 million to the beef industry). Our market research suggests that we captured approximately
38% of the market segment comprised of the four leading USDA-approved scours preventative products during the twelve-month period
ended September 30, 2015. In light of the challenging market conditions faced by our customers (i.e. lower milk prices, deteriorated
milk-to-feed price ratio, etc.), there can be no assurance that this level of growth and contribution to profitability can be sustained.
We generally held our product selling prices without increase during the seven-year period ended December 31, 2007. During the
first quarter of 2008, we implemented a modest increase to the selling price of <B>First Defense<SUP>&reg;</SUP></B>. We did not
implement another price increase until the third quarter of 2014. We implemented a price increase for the tube delivery format
of our <B>First Defense Technology&trade; </B>in a gel solution (as described below) during the second quarter of 2015. This pricing
strategy recognizes that while selling a premium-priced product, we must be very efficient with our manufacturing costs to maintain
a healthy gross margin. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Bookman Old Style, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Competition
for resources that dairy producers allocate to their calf enterprises has been increased by the many new products that have been
introduced to the market. Our sales are normally seasonal, with higher sales expected during the first quarter. Warm and dry weather
reduces the producer&rsquo;s perception of the need for a disease preventative product like <B>First Defense</B></FONT><B><FONT STYLE="font-family: Symbol"><SUP>&#210;</SUP></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">,
but heat stress on calves caused by extremely hot summer weather can increase the incidence of scours. Harsher winter weather benefits
our sales. The animal health distribution segment has been aggressively consolidating over the last few years. Larger distributors
have been acquiring smaller distributors. Our two largest distributors have been acquired by larger companies. Beef herd numbers
were reduced because of the 2012 drought conditions in many parts of North America. This has resulted in an increase in the value
of newborn calves today, as producers re-build their herd levels. Such an upswing increases a producer&rsquo;s likelihood to invest
in <B>First Defense</B></FONT><B><FONT STYLE="font-family: Symbol"><SUP>&#210;</SUP></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">
for their calf crop. Our product sales benefited from the relatively strong prices of cows and calves, as well as a stable to moderately
lower cost of feed, despite a decrease in milk prices since 2014. We believe that our sales have also benefited from a lack of
supply in the market of a competitive product sold by Elanco Animal Health during the early part of 2015. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Bookman Old Style, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
are selling product line extensions of <B>First Defense</B></FONT><B><FONT STYLE="font-family: Symbol"><SUP>&#210;</SUP></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">
under the description <B>First Defense Technology<SUP>TM</SUP></B>, which is a unique whey protein concentrate that is processed
utilizing our proprietary milk protein purification methods, for the nutritional and feed supplement markets without disease prevention
claims approved by the U.S. Department of Agriculture (USDA). Through our <B>First Defense Technology<SUP>TM</SUP></B>, we are
selling concentrated whey proteins in different formats. During the first quarter of 2011, we initiated sales of <B>First Defense
Technology<SUP>TM </SUP></B>in a bulk powder format (no capsule), which is delivered with a scoop and mixed with colostrum for
feeding to calves. During the fourth quarter of 2011, Milk Products, LLC of Chilton, Wisconsin launched commercial sales of their
product, Ultra Start</FONT><FONT STYLE="font-family: Symbol"><SUP>&#210;</SUP></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
150 Plus, and other private label brands of colostrum replacers with <B>First Defense Technology<SUP>TM </SUP>Inside</B>. During
the first quarter of 2012, we initiated a limited launch of a tube delivery format of our <B>First Defense Technology<SUP>TM</SUP></B>
in a gel solution. Sales of these new product formats have increased steadily since launch.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->&nbsp;-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0; font-size: 10pt">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0; font-size: 10pt"><B>ImmuCell Corporation</B></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0; font-size: 10pt">&nbsp;</P>

<P STYLE="font: 10pt Bookman Old Style, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Sales
of <B>First Defense</B></FONT><B><FONT STYLE="font-family: Symbol"><SUP>&#210;</SUP></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">
and related product line extensions aggregated 88% and 90% of our total product sales during the three-month periods ended September
30, 2015 and 2014, respectively. These sales increased by 37%, or $585,000, during the three-month period ended September 30,
2015 in comparison to the same period in 2014. These sales aggregated 92% and 90% of our total product sales during the nine-month
periods ended September 30, 2015 and 2014, respectively. These sales increased by 43%, or $2,079,000, during the nine-month period
ended September 30, 2015 in comparison to the same period in 2014. Sales of <B>First Defense</B></FONT><B><FONT STYLE="font-family: Symbol"><SUP>&#210;
</SUP></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">and related product line extensions increased by 27%,
14% and 5% during the years ended December 31, 2014, 2013 and 2012, respectively, in comparison to the immediately prior years.
During the three-month period ended September 30, 2015, domestic sales of <B>First Defense</B></FONT><B><FONT STYLE="font-family: Symbol"><SUP>&#210;
</SUP></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">and related product line extensions increased by 45%,
and international sales decreased by 22% in comparison to the three-month period ended September 30, 2014. During the nine-month
period ended September 30, 2015, domestic sales of this product line increased by 45%, and international sales increased by 32%
in comparison to the nine-month period ended September 30, 2014. This new level of sales demand has exceeded our current production
capacity and available inventory, resulting in a backlog of orders as of September 30, 2015. We completed the investment to increase
our liquid processing capacity by approximately 50% during the fourth quarter of 2015, and the investment to increase our freeze-drying
capacity by approximately 100% is proceeding on schedule and is expected to be completed before the end of the first quarter of
2016. With the single exception of the second quarter of 2012, we have realized consistently positive sales growth of <B>First
Defense</B></FONT><B><FONT STYLE="font-family: Symbol"><SUP>&#210;</SUP></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">
and related product line extensions during nineteen of the last twenty quarters (including the last thirteen consecutive quarters)
in comparison to the same quarters of the prior year, as demonstrated in the following table:</FONT></P>

<P STYLE="font: 10pt Bookman Old Style, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"></FONT>&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0; font-size: 10pt"><IMG SRC="img01.jpg" ALT="">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0; font-size: 10pt">&nbsp;</P>

<P STYLE="font: 10pt Bookman Old Style, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
also sell topical wipes (our second leading source of animal health product sales) that are pre-moistened with a Nisin-based formulation
in two product formats. Since 1999, we have been selling <B>Wipe Out</B></FONT><B><FONT STYLE="font-family: Symbol"><SUP>&#210;</SUP></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
Dairy Wipes</FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif"> for use in preparing the teat area of a cow for
milking. We are competing aggressively on selling price against less expensive products and alternative teat sanitizing methods.
We believe that the sales growth potential for <B>Wipe Out</B></FONT><B><FONT STYLE="font-family: Symbol"><SUP>&#210;</SUP></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">
Dairy Wipes</FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif"> is limited. During the first quarter of 2013, we
initiated sales of Nisin-based wipes for pets in a 120-count canister (Preva&trade; wipes) to Bayer HealthCare Animal Health of
St. Joseph, Missouri for commercial sales to pet owners through their veterinarians. Sales of our topical wipes increased by 60%
during the three-month period ended September 30, 2015 and decreased by 16% during the nine-month period ended September 30, 2015
in comparison to the same periods during 2014. Sales of our topical wipes aggregated approximately 4% and 3% of total product sales
during the three-month and nine-month periods ending September 30, 2015, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Sales of our <B>California Mastitis Test (CMT)</B>
(our third leading source of animal health product sales) decreased by 12% during the three-month period ended September 30, 2015
and increased by 41% during the nine-month period ended September 30, 2015 in comparison to the same periods during 2014. Sales
of <B>CMT</B> aggregated approximately 1% and 2% of total product sales during the three-month and nine-month periods ended September
30, 2015, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We make and sell bulk reagents for Isolate&trade;
(formerly known as Crypto-Scan<SUP>&reg;</SUP>), which is a drinking water test that is sold by our distributor in Europe. Sales
of Isolate&trade; increased by 46% during the nine-month period ended September 30, 2015 in comparison to the same period in 2014.
Sales of these bulk reagents aggregated approximately 7% and 3% of total product sales during the three-month and nine-month periods
ended September 30, 2015, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->&nbsp;-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 8pt"><B>ImmuCell Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-indent: 0.5in"><I>Gross Margin</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-indent: 0.5in">Changes in the gross margin from product
sales are summarized in the following tables for the respective periods (in thousands, except for percentages):</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>For the Three-Month
                                                                                 Periods&nbsp;</B><BR> <B>Ended September 30,</B></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Increase</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2015</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2014</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: left">Gross margin</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1,612</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1,078</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">534</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">50</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Percent of product sales</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">65</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">61</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7</TD><TD STYLE="text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>For
                                         the Nine-Month Periods&nbsp;</B><BR> <B>Ended September 30,</B></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Increase</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2015</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2014</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: left">Gross margin</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">4,593</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">3,106</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1,487</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">48</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Percent of product sales</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">61</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">58</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6</TD><TD STYLE="text-align: left">%</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>For
                                         the Twelve-Month Periods Ended September 30,</B></P></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Increase</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2015</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2014</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Amount</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">%</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: left">Gross margin</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">5,936</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">3,714</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">2,222</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">60</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">Percent of product sales</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">61</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">53</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">14</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0 0 8pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Our
objective for the foreseeable future is to maintain the full-year gross margin percentage over 50%, and we have achieved this objective
during all of the periods being reported. The gross margin as a percentage of product sales was 59% and 51% during the years ended
December 31, 2014 and 2013, respectively. We reduced production output during the last six months of 2013 in order to upgrade and
increase our freeze-drying capacity by approximately 50%. During this period, we used more expensive subcontractors temporarily,
which resulted in an increase in our cost of goods sold during that period. This production slow-down resulted in a few, short
delays in shipping customer orders of <B>First Defense</B></FONT><B><FONT STYLE="font-family: Symbol"><SUP>&Ograve;</SUP></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">
during the first quarter of 2014. This investment was completed during the fourth quarter of 2013, and our gross margin percentage
was again in line with historical norms during 2014. A number of other factors account for the variability in our costs, resulting
in some fluctuations in gross margin percentages from quarter to quarter. The gross margin on <B>First Defense</B></FONT><B><FONT STYLE="font-family: Symbol"><SUP>&Ograve;
</SUP></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">is affected by biological yields from our raw material,
which do vary over time. Like most U.S. manufacturers, we have been experiencing increases in the cost of raw materials that we
purchase. The costs for production of <B>First Defense</B></FONT><B><FONT STYLE="font-family: Symbol"><SUP>&Ograve;</SUP></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">
and <B>Wipe Out</B></FONT><FONT STYLE="font-family: Symbol"><SUP>&Ograve; </SUP></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Dairy
Wipes</B> have increased due to increased labor costs and other expenses associated with our efforts to sustain compliance with
current Good Manufacturing Practice (cGMP) regulations in our production processes. We have been able to minimize the impact of
these cost increases by implementing yield improvements. Product mix also affects gross margin in that we earn a higher gross margin
on <B>First Defense</B></FONT><B><FONT STYLE="font-family: Symbol"><SUP>&Ograve; </SUP></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">and
a much lower gross margin on <B>Wipe Out</B></FONT><FONT STYLE="font-family: Symbol"><SUP>&Ograve; </SUP></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Dairy
Wipes.</B></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-indent: 0.5in"><I>Sales and Marketing Expenses </I></P>


<P STYLE="font: 10pt Bookman Old Style, Times, Serif; margin: 0 0 8pt; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Sales
and marketing expenses during the three-month period ended September 30, 2015 increased by approximately 2%, or $8,000, to $382,000
in comparison to $374,000 during the three-month period ended September 30, 2014, amounting to 15% and 21% of product sales during
the 2015 and the 2014 periods, respectively. These expenses during the nine-month period ended September 30, 2015 increased by
approximately 18%, or $165,000, to $1,087,000 in comparison to $922,000 during the nine-month period ended September 30, 2014,
amounting to 14% and 17% of product sales during the 2015 and the 2014 periods, respectively. We continue to leverage the efforts
of our small sales force by using veterinary distributors. These expenses have increased due principally to a strategic decision
to invest more to grow <B>First Defense</B></FONT><B><FONT STYLE="font-family: Symbol"><SUP>&Ograve;</SUP></FONT><SUP><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT></SUP></B><FONT STYLE="font-family: Times New Roman, Times, Serif">sales. Our sales and marketing team currently consists
of one vice president and five regional managers. Our inside sales and customer service representative performs most of the order
entry and inside sales duties, and our facility manager processes most shipments. This investment may have created, at least in
part, our recent increase in product sales. Our current budgetary objective in 2015 is to invest up to 20% of product sales in
sales and marketing expenses on an annual basis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-indent: 0.5in"><I>Administrative Expenses </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 8pt; text-indent: 0.5in">Administrative expenses were essentially
unchanged at approximately $302,000 during the three-month periods ended September 30, 2015 and 2014. These expenses increased
by approximately 8%, or $68,000, to $941,000 during the nine-month period ended September 30, 2015 as compared to $874,000 during
the nine-month period ended September 30, 2014. We strive to be efficient with these expenses while funding costs associated with
complying with the Sarbanes-Oxley Act of 2002 and other costs associated with being a publicly-held company. Prior to 2014, we
had limited our investment in investor relations spending. Beginning in the second quarter of 2014, we initiated an investment
in a more actively managed investor relations program. Additionally, we continue to provide full disclosure of the status of our
business and financial condition in three quarterly reports and one annual report each year, as well as in Current Reports on
Form 8-K when legally required or deemed appropriate by management. Additional information about us is available in our annual
Proxy Statement. All of these reports are filed with the SEC and are available on-line or upon request to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->&nbsp;-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><B>ImmuCell Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><I>Product Development Expenses </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Bookman Old Style, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Product
development expenses decreased by 16%, or $59,000, to $302,000 during the three-month period ended September 30, 2015 as compared
to $361,000 during the same period in 2014. These expenses decreased by 47%, or $812,000, to $904,000 during the nine-month period
ended September 30, 2015 as compared to $1,716,000 during the same period in 2014. Product development expenses aggregated 12%
and 20% of product sales during the three-month periods ended September 30, 2015 and 2014, and 12% and 32% of product sales during
the nine-month periods ended September 30, 2015 and 2014, respectively. The majority of our product development budget is focused
on the development of <B>Mast Out</B></FONT><B><FONT STYLE="font-family: Symbol"><SUP>&#210;</SUP></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">,
a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. During the 15.75 year period that began on
January 1, 2000 (the year we began the development of <B>Mast Out</B></FONT><B><FONT STYLE="font-family: Symbol"><SUP>&#210;</SUP></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">)
and ended on September 30, 2015, we invested an aggregate of approximately $11,612,000 in the development of <B>Mast Out</B></FONT><B><FONT STYLE="font-family: Symbol"><SUP>&#210;</SUP></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">.
This estimated allocation to <B>Mast Out</B></FONT><B><FONT STYLE="font-family: Symbol"><SUP>&#210;</SUP></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">
reflects only direct expenses and includes no allocation of product development or administrative overhead expenses. Approximately
$2,891,000 of this investment was offset by product licensing revenues and grant income related to <B>Mast Out</B></FONT><B><FONT STYLE="font-family: Symbol"><SUP>&#210;</SUP></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Bookman Old Style, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Nisin,
the same active ingredient contained in our topical wipe products, is<B> </B>an antibacterial peptide known to be effective against
most Gram-positive and some Gram-negative bacteria. Nisin is a well characterized substance, having been used in food preservation
applications for over 50 years. Food-grade Nisin, however, cannot be used in pharmaceutical applications because of its low purity.
Our Nisin technology includes methods to achieve pharmaceutical-grade purity. In our pivotal effectiveness study of <B>Mast Out</B></FONT><B><FONT STYLE="font-family: Symbol"><SUP>&#210;</SUP></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">,
statistically significant cure rates were associated with a statistically significant reduction in milk somatic cell count, which
is an important measure of milk quality.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Bookman Old Style, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">It
is estimated that mastitis (inflammation of the mammary gland) costs the dairy industry approximately $2 billion per year in the
United States alone. This is the single largest cause of economic harm to the dairy industry. The USDA&rsquo;s National Animal
Health Monitoring System through its Dairy 2014 study suggests that 21% of all dairy cows are treated with a mastitis drug, of
which approximately 51% are treated with third generation cephalosporins. We continue to believe in the value of making this unique
treatment option available to dairy producers in order to reduce their reliance on traditional antibiotics such as penicillin and
cephalosporins. There is a growing concern that the overuse of antibiotics is contributing to a rising number of life-threatening
human infections from antibiotic-resistant bacteria known as &ldquo;superbugs&rdquo;. Several major food processors and retailers
are implementing policies to address this public health concern. We believe that this changing environment of new regulations and
public opinion is very favorable towards the introduction of new alternatives to traditional antibiotics, such as Nisin. Additionally,
we believe that the use of <B>First Defense</B></FONT><B><FONT STYLE="font-family: Symbol"><SUP>&#210;</SUP></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">
is consistent with this trend of reducing the use of antibiotics because the prevention of calf scours early in life with our purified
milk antibodies can reduce the need for treatment antibiotics.</FONT></P>

<P STYLE="font: 10pt Bookman Old Style, Times, Serif; margin: 0; text-indent: 0.05in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The use of all mastitis drugs currently on the
market is permitted only if the milk from treated cows is discarded during treatment and for a period of time thereafter to allow
the antibiotic residues to clear from the milk to be consumed by humans. We have estimated that the cost of this discarded milk
may be approximately $300 million per year. As a result of this milk discard requirement, presently the treatment of mastitis is
largely reserved for clinical infections where the cow is so sick that she cannot produce saleable milk. Because milk from cows
with subclinical infections can be sold, this disease is largely left untreated to avoid the milk discard penalty. Subclinical
mastitis is associated with reduced milk production (some have estimated approximately 1,500 pounds of lost milk, or about $240
at $16.00 per hundredweight, per infected cow), reduced milk premiums, reproduction inefficiencies and an increased incidence of
clinical mastitis. We intend to introduce the first mastitis treatment that is not subject to milk discard or meat withhold requirements,
which would be a significant competitive advantage for our product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->&nbsp;-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><B>ImmuCell Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Bookman Old Style, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Due
to this zero milk discard feature, there is a risk that Nisin from the milk of cows treated with <B>Mast Out</B></FONT><B><FONT STYLE="font-family: Symbol"><SUP>&#210;</SUP></FONT><SUP><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT></SUP></B><FONT STYLE="font-family: Times New Roman, Times, Serif">could interfere with the manufacture of certain (but
not all) commercial cultured dairy products, such as some kinds of cheese and yogurt, if a process tank contains a high enough
percentage of milk from treated cows. In 2004, we entered into a product development and marketing agreement with Pfizer Animal
Health (now doing business as Zoetis since 2013) covering <B>Mast Out</B></FONT><B><FONT STYLE="font-family: Symbol"><SUP>&#210;</SUP></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">.
Zoetis elected to terminate the agreement in 2007. We believe that this decision was not based on any unanticipated efficacy or
regulatory issues. Rather, we believe the decision was primarily driven by a marketing concern relating to their fear that the
milk from treated cows could interfere with the manufacture of certain cultured dairy products. The impact of this potential interference
ranges from a delay in the manufacturing process, which does happen at times for other reasons, to the less likely stopping of
a cheese starter culture. Milk from cows that have been treated with <B>Mast Out</B></FONT><B><FONT STYLE="font-family: Symbol"><SUP>&#210;</SUP></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">
that is sold exclusively for fluid milk products presents no such risk. We worked with scientists and mastitis experts to conduct
a formal risk assessment to quantify the impact that milk from treated cows may have on cultured dairy products. This study concluded
that the dilution of milk from treated cows through comingling with milk from untreated cows during normal milk hauling and storage
practices reduces the risk of interference with commercial dairy cultures to a negligible level when <B>Mast Out</B></FONT><B><FONT STYLE="font-family: Symbol"><SUP>&#210;</SUP></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">
is used in accordance with the product label. We do not believe that a premium-priced product such as <B>Mast Out</B></FONT><B><FONT STYLE="font-family: Symbol"><SUP>&#210;</SUP></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">
will be used as part of a whole herd (&ldquo;blitz&rdquo;) treatment protocol, which reduces the risk of cheese interference. We
do not see this as a significant problem as modern &ldquo;precision dairying&rdquo; practices support reducing the indiscriminate
use of drug treatments. </FONT></P>

<P STYLE="font: 10pt Bookman Old Style, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">It is difficult to know the potential size of
the subclinical mastitis market because this market is largely unserved at this point. We have estimated that first year domestic
sales potential of our product could be approximately $5,800,000 and that this sales potential could grow to approximately $36,100,000
by the fifth year after market launch. Key assumptions underlying these estimates include there being 7,650,000 cows in lactation
in the United States and the treatment of 1.15 quarters per cow on average with three doses per treatment at approximately $9.99
per dose. We assumed that 2.2% of all cows in lactation would be treated during the first year after market launch and that 13.7%
would be treated during the fifth year after market launch. We believe that approximately 20-30% of the U.S. dairy herd is affected
by subclinical mastitis caused by Gram-positive organisms falling within the <B>Mast Out<SUP>&reg;</SUP></B> claim spectrum. This
compares to approximately 2% of the herd that is thought to be infected with clinical mastitis, where approximately $55,000,000
per year is spent on drug treatments. Achieving the estimated level of sales would require commercial-scale production capacity
that we do not have today. The first Drug Substance production facility that we intend to build, subject to obtaining sufficient
financing, is expected to have capacity to meet approximately 35% of the market potential for the fifth year after market launch.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Bookman Old Style, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Commercial
introduction of <B>Mast Out</B></FONT><B><FONT STYLE="font-family: Symbol"><SUP>&#210;</SUP></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">
in the United States is subject to approval of our New Animal Drug Application (NADA) by the U.S. Food and Drug Administration&rsquo;s
Center for Veterinary Medicine (FDA), which approval cannot be assured. Foreign regulatory approvals would be required for sales
in key markets outside of the United States, which would involve some similar and some different requirements. The NADA is comprised
of five principal Technical Sections and one administrative submission that are subject to the FDA&rsquo;s phased review. By statute,
each Technical Section submission is generally subject to a six-month review cycle by the FDA. Each Technical Section can be reviewed
and approved separately. Upon review and assessment by the FDA that all requirements for a Technical Section have been met, the
FDA may issue a Technical Section Complete Letter. The current status of our work on these submissions to the FDA is as follows:</FONT></P>

<P STYLE="font: 10pt Bookman Old Style, Times, Serif; margin: 0; text-indent: 0.05in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">1) Environmental Impact: During the third quarter
of 2008, we received the Environmental Impact Technical Section Complete Letter from the FDA.</P>

<P STYLE="font: 10pt Bookman Old Style, Times, Serif; margin: 0; text-indent: 0.05in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">2) Target Animal Safety: During the second
quarter of 2012, we received the Target Animal Safety Technical Section Complete Letter from the FDA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">3) Effectiveness: During the third quarter of
2012, we received the Effectiveness Technical Section Complete Letter from the FDA. The draft product label carries claims for
the treatment of subclinical mastitis associated with <I>Streptococcus agalactiae</I>, <I>Streptococcus dysgalactiae</I>, <I>Streptococcus
uberis</I>, and coagulase-negative staphylococci<I> </I>in lactating dairy cattle.</P>

<P STYLE="font: 10pt Bookman Old Style, Times, Serif; margin: 0; text-indent: 4.5pt">&nbsp;</P>

<P STYLE="font: 10pt Bookman Old Style, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">4)
Human Food Safety (HFS): The HFS Technical Section submission was made during the fourth quarter of 2010. This Technical Section
includes several subsections such as: a) toxicology, b) total metabolism, c) effects of drug residues in food on human intestinal
microbiology, d) effects on bacteria of human health concern (antimicrobial resistance) and e) pivotal residue chemistry. During
the second quarter of 2011, we announced that the FDA had accepted the subsections described above and granted <B>Mast Out</B></FONT><B><FONT STYLE="font-family: Symbol"><SUP>&#210;
</SUP></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">a zero milk discard period and a zero meat withhold
period during and after treatment. Before we can obtain this Technical Section Complete Letter, we must transfer our analytical
method that measures Nisin residues in milk to a government laboratory. Due to unexpected regulatory demands and review delays,
completion of the HFS Technical Section is currently anticipated during 2016.&#9;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">5) Chemistry, Manufacturing and Controls (CMC):
Obtaining FDA approval of the CMC Technical Section defines the critical path to FDA approval and to initial commercial sales.
During the third quarter of 2014, we substantially completed an investment in facility modifications and processing equipment necessary
to produce the Drug Substance (the Active Pharmaceutical Ingredient, which is our pharmaceutical-grade Nisin) at small-scale. This
small-scale facility has been used to i) establish the equivalence of the Drug Substance produced in this facility to the Drug
Substance that was used in our pivotal batches for all clinical studies, ii) optimize process yields and iii) verify the cost of
production. We believe these efforts will reduce risk if we invest in a commercial-scale production facility.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->&nbsp;-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><B>ImmuCell Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Bookman Old Style, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">We
are party to a long-term, exclusive supply agreement with Plas-Pak Inc. of Norwich, Connecticut covering the proprietary syringe
that was developed specifically for treating cows with <B>Mast Out</B></FONT><B><FONT STYLE="font-family: Symbol"><SUP>&#210;</SUP></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">.
These syringes were used for all pivotal studies of <B>Mast Out</B></FONT><B><FONT STYLE="font-family: Symbol"><SUP>&#210;</SUP></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">.
During the fourth quarter of 2015, this contract was extended through December 31, 2020.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Bookman Old Style, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">Since
2010, we have been party to long-term, exclusive Contract Manufacture Agreement with Norbrook Laboratories Limited of Newry, Northern
Ireland, an FDA-approved Drug Product (filled and packaged syringes) manufacturer, covering the formulating and sterile-filling
of the Drug Substance into Drug Product for <B>Mast Out</B></FONT><B><FONT STYLE="font-family: Symbol"><SUP>&#210;</SUP></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">.
Norbrook provided these services for clinical material used in all pivotal studies of <B>Mast Out</B></FONT><B><FONT STYLE="font-family: Symbol"><SUP>&#210;</SUP></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">.
We are negotiating a revised agreement with Norbrook covering the final development and commercial-scale (but not at small-scale)
launch of <B>Mast Out</B></FONT><B><FONT STYLE="font-family: Symbol"><SUP>&#210;</SUP></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">
after FDA approval. This means we would no longer seek FDA approval at small-scale, which would not have provided inventory for
significant commercial sales.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The construction of and the financing for the
commercial-scale Drug Substance production facility is the most critical decision in front of us. Our initial plan was to have
the Drug Substance produced for us under a Development and Manufacturing Agreement with Lonza Sales, Ltd. of Basel, Switzerland,
in order to avoid the investment in a manufacturing facility. By the end of 2011, we determined that the required minimum volumes
were too large to permit efficient, continuous production and that the cost of goods under this contract would not be commercially
feasible. This contract was terminated during the fourth quarter of 2014 by mutual consent. We have presented this product opportunity
to a variety of large and small animal health companies. During the second quarter of 2013, we received a non-refundable $250,000
exclusive license option fee from a prospective partner that considered manufacturing the Drug Substance in a plant of its own.
During the third quarter of 2013, this prospective partner decided not to execute a development and marketing license because it
had determined that, in its opinion, it could not cost effectively commercialize the product. We are encouraged by the feedback
from prospective partners, following their due diligence, that our novel mastitis treatment can achieve FDA approval and have a
significant, positive impact on the dairy industry.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">We are taking initial steps towards constructing
our own facility for the commercial-scale production of the Drug Substance. During the third quarter of 2015, we paid $23,800 for
an option to acquire land nearby to our existing Portland facility. During the fourth quarter of 2015, our Board of Directors voted
to exercise this option to acquire the land before year-end. The option payment of $23,800 would reduce the agreed-to purchase
price of the land by 10%. We have sufficient cash to construct the building shell, which could be completed by the end of 2016
if we break ground in the spring of 2016. Given the need to secure funding to acquire and install the processing equipment required
for the commercial-scale Drug Substance facility (estimated at approximately $10,000,000 to $15,000,000), we are pursuing debt
and/or equity financing options. If we secure the necessary financing to complete the Drug Substance facility during 2017, we could
make the first CMC Technical Section submission to the FDA during late 2017 or 2018. It is common for each CMC Technical Section
submission to require two, six-month review periods by the FDA. This timeline is about two years longer than the previously disclosed
timeline for approval of a small-scale facility. However, this adjustment in our strategy is not a set back to the commercial-scale
launch plans, which would not have been materially different if we had continued to seek FDA approval at small-scale. It is important
to remember that an FDA approval at small-scale would not have created an opportunity for commercial success.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">6) Administrative Submission: After obtaining
the final Technical Section Complete Letter and after preparing materials responsive to other administrative requirements, the
administrative NADA submission will be assembled for review by the FDA. This final administrative submission is subject to a statutory
sixty-day review period. We will continue to provide detailed disclosures about the current status of this drug development process
in our periodic filings with the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence -->&nbsp;-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><B>ImmuCell Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Bookman Old Style, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">In
addition to our work on <B>Mast Out</B></FONT><B><FONT STYLE="font-family: Symbol"><SUP>&#210;</SUP></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">,
we are actively developing further improvements, extensions or additions to our current <B>First Defense<SUP>&reg;</SUP></B> product
line. For example, we currently are developing treatments that could prevent calf scours caused by enteric pathogens in addition
to <I>E. coli</I> K99 and bovine coronavirus (the current disease claims for <B>First Defense<SUP>&reg;</SUP></B>). In connection
with that effort, during the second quarter of 2009 we entered into an exclusive license with the Baylor College of Medicine covering
the underlying rotavirus vaccine technology used to generate the specific antibodies. This perpetual license (if not terminated
for cause) is subject to milestone and royalty payments. If approved by the USDA, this would be the first passive antibody product
on the market with disease claims against the three leading causes of calf scours, <I>E. coli</I>, coronavirus and rotavirus. Results
from pilot studies completed during the first quarter of 2009 justified continued product development. We initiated a second pivotal
effectiveness study at Cornell University College of Veterinary Medicine during the second quarter of 2014 and completed the enrollment
of calves during the fourth quarter of 2014. During the first quarter of 2015, we announced positive effectiveness results from
this pivotal study. During the third quarter of 2015, we obtained concurrence from the USDA that we have been granted disease claims
against bovine rotavirus. We are working to complete the other laboratory and manufacturing objectives required for product license
approval. This could position us to achieve product licensure and market launch in 2016. At the same time, we are working to expand
our product development pipeline of bacteriocins that can be used as alternatives to traditional antibiotics. During the second
quarter of 2015, we entered into an exclusive option agreement to license new bacteriocin technology from the University of Massachusetts
Amherst. This technology focuses on bacteriocins having activity against Gram-negative infections for use in combating mastitis
in dairy cattle. Subject to the availability of needed financial and other resources, we intend to begin new development projects
that are aligned with our core competencies and market focus. We also remain interested in acquiring, on suitable terms, other
new products and technologies that fit with our sales focus on the dairy and beef industries. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><I>Net Operating Income (Loss)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The net operating income of $627,000 during
the three-month period ended September 30, 2015 compares to net operating income of $41,000 during the three-month period ended
September 30, 2014. The net operating income of $1,661,000 during the nine-month period ended September 30, 2015 contrasts to net
operating (loss) of ($405,000) during the nine-month period ended September 30, 2014. We recorded net operating (losses) of ($206,000)
and ($20,000) during the years ended December 31, 2014 and 2013, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><I>Other expenses, net</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Interest income was essentially unchanged at
approximately $4,000 during both of the three-month periods ended September 30, 2015 and 2014. Interest income decreased by approximately
8%, or $1,000, to $11,000 during the nine-month period ended September 30, 2015 in comparison to $12,000 during the nine-month
period ended September 30, 2014. Interest expense was essentially unchanged at approximately $15,000 during both of the three-month
periods ended September 30, 2015 and 2014. Interest expense decreased by approximately 7%, or $3,000 to $41,000 during the nine-month
period ended September 30, 2015 in comparison to $44,000 during the nine-month period ended September 30, 2014.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><I>Income (Loss) Before Income Taxes and Net
Income (Loss)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our income before income taxes of $612,000 during
the three-month period ended September 30, 2015 compares to income before income taxes of $30,000 during the same period in 2014.
We recorded income tax expense equal to 43% of our income before income taxes during the three-month period ended September 30,
2015. Our net income of $351,000, or $0.11 per diluted share, during the three-month period ended September 30, 2015 compares to
net income of $10,000, or $0.00 per diluted share, during the same period in 2014. During the third quarter of 2015, we earned
just $128,000 less than we earned during the first quarter of 2015 despite the seasonality in sales of <B>First Defense<SUP>&reg;</SUP></B>
(described above) favoring the first quarter. The first quarter of 2015, with net income of $479,000, or $0.15 per diluted share,
was our most profitable quarter since the first quarter of 2003.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our income before income taxes of $1,634,000
during the nine-month period ended September 30, 2015 is in contrast to a (loss) before income taxes of ($444,000) during the same
period in 2014. We recorded income tax expense equal to 43% of our income before income taxes during the nine-month period ended
September 30, 2015. Our net income of $924,000, or $0.29 per diluted share, during the nine-month period ended September 30, 2015,
is in contrast to net (loss) of ($298,000), or ($0.10) per share, during the same period in 2014. The first nine months of 2015
were more profitable than any full year since the Company&rsquo;s inception, with the single exception of the year ended December
31, 2000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence -->&nbsp;-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><B>ImmuCell Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>ITEM 3 - QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET
RISK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">None</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>ITEM 4 - CONTROLS AND PROCEDURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><I>Disclosure Controls and Procedures. </I>Our
management, with the participation of the individual who serves as our principal executive and principal financial officer, evaluated
the effectiveness of our disclosure controls and procedures as of September 30, 2015. Based on this evaluation, that officer concluded
that our disclosure controls and procedures were effective as of that date. Disclosure controls and procedures are designed to
ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is (i) recorded,
processed, summarized and reported within the time periods specified in the Securities and Exchange Commission&rsquo;s rules and
forms and (ii) accumulated and communicated to our management, including our principal executive and principal financial officer,
as appropriate to allow timely decisions regarding required disclosures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><I>Changes in Internal Controls over Financial
Reporting. </I>The individual who serves as our principal executive and principal financial officer periodically evaluates any
change in internal control over financial reporting which has occurred during the prior fiscal quarter. Management has concluded
that there was no change in our internal control over financial reporting that occurred during the quarter ended September 30,
2015 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence -->&nbsp;-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><B>ImmuCell Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PART II. OTHER INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>ITEM 1 - LEGAL PROCEEDINGS</B></P>

<P STYLE="font: 10pt Bookman Old Style, Times, Serif; margin: 0; text-indent: 0.05in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">None</P>

<P STYLE="font: 10pt Bookman Old Style, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>ITEM 1A - RISK FACTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Safe Harbor Statement</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">This Quarterly Report on Form 10-Q contains
&ldquo;forward-looking statements&rdquo; within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to: projections of future
financial performance; the scope and timing of future product development work and commercialization of our products; future costs
of product development efforts; the estimated prevalence rate of subclinical mastitis; future market share of and revenue generated
by products still in development; future sources of financial support for our product development, manufacturing and marketing
efforts; the future adequacy of our own manufacturing facilities or those of third parties with which we have contractual relationships
to meet demand for our products on a timely basis; the amount and timing of future investments in facility modifications and production
equipment; the future adequacy of our working capital and the availability of third party financing; timing and future costs of
a facility to produce the Drug Substance (active pharmaceutical ingredient) for <B>Mast Out<SUP>&reg;</SUP></B>; the timing and
outcome of pending or anticipated applications for future regulatory approvals; future regulatory requirements relating to our
products; future expense ratios and margins; future compliance with bank debt covenants; future realization of deferred tax assets;
costs associated with sustaining compliance with cGMP regulations in our current operations and attaining such compliance for the
facility to produce the Drug Substance for <B>Mast Out<SUP>&reg;</SUP></B>; factors that may affect the dairy and beef industries
and future demand for our products; the cost-effectiveness of additional sales and marketing expenditures and resources; the accuracy
of our understanding of our distributors&rsquo; ordering patterns; anticipated changes in our manufacturing capabilities and efficiencies;
anticipated competitive and market conditions; and any other statements that are not historical facts. Forward-looking statements
can be identified by the use of words such as &ldquo;expects&rdquo;, &ldquo;may&rdquo;, &ldquo;anticipates&rdquo;, &ldquo;aims&rdquo;,
&ldquo;intends&rdquo;, &ldquo;would&rdquo;, &ldquo;could&rdquo;, &ldquo;should&rdquo;, &ldquo;will&rdquo;, &ldquo;plans&rdquo;,
&ldquo;believes&rdquo;, &ldquo;estimates&rdquo;, &ldquo;targets&rdquo;, &ldquo;projects&rdquo;, &ldquo;forecasts&rdquo; and similar
words and expressions. In addition, there can be no assurance that future developments affecting us will be those that we anticipate.
Such statements involve risks and uncertainties, including, but not limited to, those risks and uncertainties relating to difficulties
or delays in development, testing, regulatory approval, production and marketing of our products, competition within our anticipated
product markets, alignment between our manufacturing resources and product demand, the uncertainties associated with product development
and Drug Substance manufacturing, our potential reliance upon third parties for financial support, products and services, changes
in laws and regulations, decision making by regulatory authorities, possible dilutive impacts on existing stockholders from any
equity financing transactions in which we may engage, currency fluctuations and other risks detailed from time to time in filings
we make with the Securities and Exchange Commission, including our Quarterly Reports on Form 10-Q, our Annual Reports on Form 10-K
and our Current Reports on Form 8-K. Such statements are based on our current expectations, but actual results may differ materially
due to various factors, including the risk factors summarized below and uncertainties otherwise referred to in this Quarterly Report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><I>Projection of net income:</I> Generally speaking,
our financial performance can differ significantly from management projections, due to numerous factors that are difficult to predict
or that are beyond our control. Stronger than expected sales of <B>First Defense<SUP>&reg;</SUP></B>, for example, could increase
our net income. Conversely, weaker than expected sales of <B>First Defense<SUP>&reg;</SUP></B> or continued or extended shortfalls
in production relative to the growing product sales demand could lead to less profits or an operating loss. Large investments in
product development can result in a net loss. Given our strategic decision to invest approximately $973,000 during 2014 in facilities
for the manufacture of the Drug Substance at small-scale, we recorded a net (loss) of ($167,000) during the year ended December
31, 2014 as expected, despite a return to profitability during the last six months of 2014. We continued to be profitable during
the first nine months of 2015. Subject to the temporary production constraints described above, we expect the sales growth trend
for <B>First Defense<SUP>&reg;</SUP></B> and the recent profitability trend to continue.</P>

<P STYLE="font: 10pt Bookman Old Style, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><I>Reliance on sales of <B>First Defense<SUP>&reg;</SUP></B>:
</I> We are heavily reliant on the market acceptance of <B>First Defense<SUP>&reg;</SUP></B> to generate product sales and fund
our operations. Our business would not have been profitable during the nine consecutive years in the period ended December 31,
2007, or during the years ended December 31, 2012 and 2013, or during the twelve-month, nine-month and three-month periods ended
September 30, 2015, without the gross margin that we earned on sales of <B>First Defense<SUP>&reg;</SUP></B>, which accounted for
over 87% of our product sales during the 2015 periods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence -->&nbsp;-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><B>ImmuCell Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><I>Product risks generally:</I> The sale of
our products is subject to financial, efficacy, regulatory, competitive and other market risks. We cannot be sure that we will
be able to maintain the regulatory compliance required to continue selling our products. There is no assurance that we will continue
to achieve market acceptance at a profitable price level or that we can continue to manufacture our products at a low enough cost
to result in a sufficient gross margin to justify their continued manufacture and sale.</P>

<P STYLE="font: 10pt Bookman Old Style, Times, Serif; margin: 0; text-indent: 0.05in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><I>Product liability</I>: The manufacture and
sale of our products entails a risk of product liability. Our exposure to product liability is mitigated to some extent by the
fact that our products are principally directed towards the animal health market. We have maintained product liability insurance
in an amount which we believe is reasonable in relation to our potential exposure in this area. We have no history of claims of
this nature being made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Bookman Old Style, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Regulatory
requirements for <B>First Defense<SUP>&reg;</SUP></B></I>: <B>First Defense<SUP>&reg;</SUP></B> is sold in the United States subject
to a product license from the Center for Veterinary Biologics, USDA, which was first obtained in 1991. The potency of serial lots
is directly traceable to the original serial used to obtain the product performance claims (the &ldquo;Reference Standard&rdquo;).
Due to the unique nature of the <B>First Defense</B></FONT><B><FONT STYLE="font-family: Symbol"><SUP>&#210;</SUP></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">
label claims, host animal re-testing is not required as long as periodic laboratory analyses continue to support the stability
of stored Reference Standard. To date, these analyses have demonstrated strong stability. However, if the USDA were not to approve
requalification of the Reference Standard, additional clinical studies could be required to meet regulatory requirements and allow
for continued sales of the product. Similar regulatory oversight risks exist in territories outside of the United States where
we sell our products. </FONT></P>

<P STYLE="font: 10pt Bookman Old Style, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Bookman Old Style, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Regulatory
requirements for <B>Wipe Out</B></I></FONT><B><FONT STYLE="font-family: Symbol"><SUP>&#210;</SUP></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>
Dairy Wipes</I></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">: While the FDA regulates the manufacture and
sale of <B>Wipe Out</B></FONT><B><FONT STYLE="font-family: Symbol"><SUP>&#210;</SUP></FONT><SUP><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT></SUP><FONT STYLE="font-family: Times New Roman, Times, Serif">Dairy Wipes</FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">,
this type of product is permitted to be sold without a NADA approval, in accordance with the FDA&rsquo;s Compliance Policy Guide
7125.30 (&ldquo;Teat Dips and Udder Washes for Dairy Cows and Goats&rdquo;). This policy guide could be withdrawn at the FDA&rsquo;s
discretion, in which case we would likely discontinue sales of the product. The manufacture of <B>Wipe Out</B></FONT><B><FONT STYLE="font-family: Symbol"><SUP>&#210;</SUP></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">
<B>Dairy Wipes </B>is subject to Part 211 of the cGMP regulations. As a result, our operations are subject to inspection by the
FDA. During the second quarter of 2007, the FDA inspected our facilities and operations and issued a Warning Letter to us, citing
deficiencies in specific areas of the cGMP regulations. We filed an initial response to the FDA during the second quarter of 2007,
and we responded to a request for additional information during the second quarter of 2008. During the first quarter of 2013, the
FDA again inspected our facilities and operations. The report from this inspection was very favorable, and we responded to the
few, minor observations that were noted. We remain subject to the risk of adverse action by the FDA in this respect. </FONT></P>

<P STYLE="font: 10pt Bookman Old Style, Times, Serif; margin: 0; text-indent: 0.05in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><I>Concentration of sales:</I> Approximately
83% of our product sales were made to customers in the U.S. dairy and beef industries during both of the years ended December 31,
2014 and 2013. Approximately 83% and 82% of our product sales were made to customers in the U.S. dairy and beef industries during
the nine-month periods ended September 30, 2015 and 2014, respectively. During the year ended December 31, 2014, 96% of our product
sales were made to customers in the dairy and beef industries throughout the world, in comparison to 97% during 2013. During the
nine-month period ended September 30, 2015, 96% of our product sales were made to customers in the dairy and beef industries throughout
the world, in comparison to 95% during the same period in 2014. A large portion of our product sales (61%, 60% and 55% for the
years ended December 31, 2014, 2013, and 2012, respectively) was made to two large distributors. These two distributors accounted
for 63% and 60% of our product sales during the nine-month period ended September 30, 2015 and 2014, respectively. A large portion
of our trade accounts receivable (71% and 65% as of December 31, 2014 and 2013, respectively) was due from these two distributors.
These two distributors accounted for 62% of our trade accounts receivable as of September 30, 2015. We have a good history with
these distributors, but the concentration of sales and accounts receivable with a small number of customers does present a risk
to us, including risks related to such customers experiencing financial difficulties or altering the basis on which they do business
with us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><I>Economics of the dairy and beef industries</I>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Bookman Old Style, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; font-size: 10pt">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0; font-size: 10pt"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">All
                                         cattle and calves in the United States as of July 1, 2014 totaled 96,300,000 head, which
                                         is 1.5% below the 97,800,000 head reported on July 1, 2012 (this data point was not reported
                                         as of July 1, 2013). The July 1, 2014 amount of 96,300,000 was the lowest inventory count
                                         as of July 1<SUP>st</SUP> in decades. All cattle and calves in the United States as of
                                         July 1, 2015 totaled 98,400,000, which is 2.2% higher than July 1, 2014. This is the
                                         first increase in the cattle inventory since 2006, suggesting the rebuilding of the U.S.
                                         herd has begun. </FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
<TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
<TD STYLE="padding: 0; text-indent: 0; font-size: 10pt"></TD><TD STYLE="padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">From
                                         1998 through 2014, the size (annual average) of the U.S. dairy herd ranged from approximately
                                         the low of 9,011,000 (2004) to the high of 9,314,000 (2008). The average for 2013 was
                                         9,218,000 which represents a slight reduction from the average of 9,236,000 reported
                                         for 2012. This average increased slightly to 9,256,000 during 2014. This average increased
                                         further during the first nine months of 2015 to 9,313,000, which is almost back up to
                                         the 2008 level.</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence -->&nbsp;-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><B>ImmuCell Corporation</B></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Bookman Old Style, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR STYLE="vertical-align: top; font-size: 10pt">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0; font-size: 10pt"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">While
                                         the number of cows in the U.S. herd and the production of milk per cow directly influence
                                         the supply of milk, demand for milk is also influenced by very volatile international
                                         demand for milk products. The Class III milk price (an industry benchmark that reflects
                                         the value of product used to make cheese) is an important indicator because it defines
                                         our customers&rsquo; revenue level. This milk price (measured in dollars per hundred
                                         pounds of milk) in each of the first eleven months of 2014 was the highest ever for those
                                         months, and nine out of ten of the highest Class III milk prices of all time occurred
                                         during 2014. This annual average price level for 2014 of $22.34 (peaking at $24.60 in
                                         September 2014) was the highest level since these records were first reported in 1980.
                                         This strong price level has declined recently to the average of $16.04 during the first
                                         nine months of 2015. The September 2015 price of $15.82 was down 36% in twelve months
                                         since the September 2014 high point. The recent annual fluctuations in this milk price
                                         level are demonstrated in the following table:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 60%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Average Class III Milk Price<BR>
for the year ended December 31,</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>(Decrease)</B></FONT><BR> <FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Increase</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2011</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2012</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 33%; text-align: center">$18.37</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 33%; text-align: center">$17.44</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 32%; text-align: center">(5%)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-decoration: none; text-align: center; border-bottom: Black 1.5pt solid">2012</TD><TD STYLE="font-weight: bold; text-decoration: none; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-decoration: none; text-align: center; border-bottom: Black 1.5pt solid">2013</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">$17.44</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">$17.99</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">3%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-decoration: none; text-align: center; border-bottom: Black 1.5pt solid">2013</TD><TD STYLE="font-weight: bold; text-decoration: none; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-decoration: none; text-align: center; border-bottom: Black 1.5pt solid">2014</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">$17.99</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">$22.34</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">24%</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Bookman Old Style, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; font-size: 10pt">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0; font-size: 10pt"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
                                         actual level of milk prices may be less important than its level relative to feed costs.
                                         The 2014 improvement in milk prices was matched by slightly lower feed costs. One measure
                                         of this relationship is known as the milk-to-feed price ratio, which represents the amount
                                         of feed that one pound of milk can buy. The 2012 ratio of 1.52 was the lowest recorded
                                         since this ratio was first reported in 1985. The highest annual average this ratio has
                                         ever reached since 1985 was 3.64 in 1987. Since this ratio reached 3.24 in 2005, it has
                                         not exceeded 3.0. The annual average of 2.54 for 2014 was the highest this ratio has
                                         been since it was 2.81 in 2007. This ratio dropped to an average of 2.06 during the first
                                         nine months of 2015. The following table demonstrates the annual volatility and the low
                                         values of this ratio recently:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 60%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Average Milk-To-Feed Price Ratio<BR>
for the year ended December 31,</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="text-align: center; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(Decrease)</B></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Increase</B></P></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2011</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2012</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 33%; text-align: center">1.88</TD><TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 33%; text-align: center">1.52</TD><TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 32%; text-align: center">(19%)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2012</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2013</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">1.52</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">1.75</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">15%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2013</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2014</TD><TD STYLE="padding-bottom: 1.5pt; text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1.5pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">1.75</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">2.54</TD><TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">45%</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Bookman Old Style, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; font-size: 10pt">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0; font-size: 10pt"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font: 10pt Symbol"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9679;</FONT></FONT></TD><TD STYLE="padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">An increase in feed costs also has a negative impact on the beef industry.
Widespread severe drought conditions in key U.S. agricultural regions during 2012 drove feed costs higher and the inventory of
all cattle and calves lower. The recent positive trend in these market indices has resulted in an increase in the value of milk
cows. The 2014 annual average price for a milk cow increased to $1,835. This annual average price since 1970 was only higher when
it reached $1,840 in 2007 and $1,953 in 2008. The price for July 2015 was $2,030, which is down 4% from the peak level for 2014
in October of $2,120. The industry data referred to above is compiled from USDA databases. Recently, the value of newborn bull
calves has risen to the unusually high level
of approximately $300 to $400. At this price, producers are more likely to invest in <B>First Defense<SUP>&reg; </SUP></B>for their
bull calves. Given our focus on the dairy and beef industries, the financial insecurity of our primary end users is a risk to our
ability to maintain and grow sales at a profitable level. It also heightens the challenge of selling premium-priced animal health
products (such as <B>Mast Out</B></FONT><B><FONT STYLE="font-family: Symbol"><SUP>&#210;</SUP></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">)
into the dairy market.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Bookman Old Style, Times, Serif; margin: 0 0 0 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><I>&nbsp;</I></P>


<P STYLE="font: 10pt Bookman Old Style, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Product
development risks:</I> The development of new products is subject to financial, scientific, regulatory and market risks. Our current
business growth strategy relies heavily on the development of <B>Mast Out</B></FONT><B><FONT STYLE="font-family: Symbol"><SUP>&#210;</SUP></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">,
which requires (and will continue to require) a substantial investment. Our efforts will be subject to inspection and approval
by the FDA. There is no assurance whether or when we will obtain all of the data necessary to support regulatory approval for this
product. </FONT></P>

<P STYLE="font: 10pt Bookman Old Style, Times, Serif; margin: 0; text-indent: 0.05in">&nbsp;</P>

<P STYLE="font: 12pt Bookman Old Style, Times, Serif; margin: 0; text-indent: 0.05in"></P>

<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence -->&nbsp;-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Bookman Old Style, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Bookman Old Style, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>ImmuCell
Corporation</B></FONT></P>

<P STYLE="font: 10pt Bookman Old Style, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Bookman Old Style, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Regulatory
requirements for <B>Mast Out</B></I></FONT><B><FONT STYLE="font-family: Symbol"><SUP>&#210;</SUP></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">:
Completing the development of <B>Mast Out</B></FONT><B><FONT STYLE="font-family: Symbol"><SUP>&#210;</SUP></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">
through to the submission of the administrative NADA to the FDA involves a great deal of risk. The commercial introduction of <B>Mast
Out</B></FONT><B><FONT STYLE="font-family: Symbol"><SUP>&#210;</SUP></FONT><SUP><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT></SUP></B><FONT STYLE="font-family: Times New Roman, Times, Serif">in the United States will require us to obtain appropriate
FDA approval for this product. It presently is uncertain when or if this approval will be achieved, but we have disclosed a timeline
of events that could lead to our achieving FDA approval during late 2018 or 2019. We are exposed to additional regulatory compliance
risks through the subcontractors that we choose to work with to produce <B>Mast Out</B></FONT><B><FONT STYLE="font-family: Symbol"><SUP>&#210;</SUP></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">,
who also need to satisfy certain regulatory requirements in order to provide us with the products and services we need. International
regulatory approvals would be required for sales outside of the United States. European regulatory authorities are not expected
to approve a product with a zero milk discard claim, which would remove a significant competitive advantage of <B>Mast Out</B></FONT><B><FONT STYLE="font-family: Symbol"><SUP>&#210;</SUP></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">
in that territory. However, the assigned milk discard period may be shorter for <B>Mast Out</B></FONT><B><FONT STYLE="font-family: Symbol"><SUP>&#210;</SUP></FONT><SUP><FONT STYLE="font-family: Times New Roman, Times, Serif">
</FONT></SUP></B><FONT STYLE="font-family: Times New Roman, Times, Serif">than it is for other products on the market in Europe.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Bookman Old Style, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Risks
associated with <B>Mast Out</B></I></FONT><I><B><FONT STYLE="font-family: Symbol"><SUP>&#210;</SUP></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">
funding strategy:</FONT></I><FONT STYLE="font-family: Times New Roman, Times, Serif"> Uncertainty concerning the availability and
terms of financing to build a commercial-scale production facility is a risk that could delay or preclude commercialization of
<B>Mast Out</B></FONT><B><FONT STYLE="font-family: Symbol"><SUP>&#210;</SUP></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">.
Based on our preliminary discussions with potential funding sources, we anticipate that current stockholders could experience substantial
dilution in connection with an equity raise used to fund a commercial-scale Drug Substance production facility, if we elect to
pursue this strategy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Bookman Old Style, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Uncertainty
of market size and product sales estimates</I>: Even assuming that <B>Mast Out</B></FONT><B><FONT STYLE="font-family: Symbol"><SUP>&#210;</SUP></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">
achieves regulatory approval in the United States with a zero milk discard requirement, estimating the size of the market for this
product is subject to numerous uncertainties. Some of the uncertainties surrounding our product include the development of the
subclinical mastitis treatment market, the effect of a premium selling price on market penetration, cost of manufacture, integration
of milk from treated cows with susceptible cheese starter cultures and market acceptance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Bookman Old Style, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Competition
from others:</I> Many of our competitors are significantly larger and more diversified in the relevant markets than we are and
have substantially greater financial, marketing, manufacturing and human resources and more extensive product development capabilities
than we do, including greater ability to withstand adverse economic or market conditions and declining revenues and/or profitability.
Zoetis, Elanco and Boehringer Ingelheim, among other companies, sell products that compete directly with <B>First Defense</B></FONT><B><FONT STYLE="font-family: Symbol"><SUP>&#210;</SUP></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">
in preventing scours in newborn calves. The product sold by Elanco experienced a lack of supply in the market during the early
part of 2015. The product sold by Zoetis does carry a rotavirus claim, which we do not yet have, but it does not have an <I>E.
coli</I> claim, and it sells for approximately half the price of our product. The market for the treatment of mastitis in dairy
cows is highly competitive, and presently is dominated by large companies such as Zoetis, Merck and Boehringer Ingelheim. There
is no assurance that <B>Mast Out</B></FONT><B><FONT STYLE="font-family: Symbol"><SUP>&#210;</SUP></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">
will compete successfully in this market. We may not be aware of other companies that compete with us or intend to compete with
us in the future. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Bookman Old Style, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Access
to raw materials</I>: Our policy is to maintain more than one source of supply for the components used to manufacture and test
our products. However, there is a risk that we could have difficulty in efficiently acquiring essential supplies. The loss of farms
from which we buy raw material for <B>First Defense<SUP>&reg; </SUP></B>could make it difficult for us to produce enough inventory
until supply agreements are reached with replacement farms on suitable terms. We are dependent on our manufacturing facility and
operations at 56 Evergreen Drive in Portland, Maine for the production of <B>First Defense</B></FONT><B><FONT STYLE="font-family: Symbol"><SUP>&#210;</SUP></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">
and our topical wipes. The specific antibodies that we purify for <B>First Defense</B></FONT><B><FONT STYLE="font-family: Symbol"><SUP>&#210;</SUP></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">
and the Nisin we produce by fermentation for our topical wipes<B> </B>are not readily available from other sources. We expect to
be dependent on Plas-Pak for the supply of the syringes used for <B>Mast Out</B></FONT><B><FONT STYLE="font-family: Symbol"><SUP>&#210;</SUP></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">.
We expect to be dependent on Norbrook for the sterile-filling and final packaging of our Drug Substance into Drug Product. Given
the requirement that such a facility be inspected and approved by the FDA, it could be costly and time-consuming to find an adequate
alternative source for these services. Any significant damage to or other disruption in the services at these facilities (including
due to regulatory non-compliance) could adversely affect the production of inventory and result in significant added expenses and
loss of future sales.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Bookman Old Style, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Risk
of sales order backlog:</I> Given our recent and significant increase in sales demand for <B>First Defense</B></FONT><B><FONT STYLE="font-family: Symbol"><SUP>&#210;</SUP></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">,
our manufacturing resources (internal and third party) are no longer sufficient to avoid a backlog of orders. Until we complete
the additional investments required to further increase our production capacity, we are at risk of losing customers that are unable
to acquire our product on a timely basis. We understand that the competitive product marketed by Elanco experienced disruptions
in supply to the market earlier in the year, but more recently has returned to the market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence -->&nbsp;-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><B>ImmuCell Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><I>Small size; dependence on key personnel:
</I>We are a small company with 38 employees (including 2 part-time employees). As such, we rely on certain key employees to support
different operational functions, with limited redundancy in capacity. The loss of any of these key employees could adversely affect
our operations until a qualified replacement is hired and trained. Our competitive position will be highly influenced by our ability
to attract and retain key scientific, managerial and sales and marketing personnel, to develop proprietary technologies and products,
to obtain USDA or FDA approval for new products and to continue to profitably sell our current products. We currently compete on
the basis of product performance, price and distribution capability. We continue to monitor our network of independent distributors
to maintain our competitive position.</P>

<P STYLE="font: 12pt Bookman Old Style, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><I>Failure to protect intellectual property:</I>
In some cases, we have chosen (and may choose in the future) not to seek patent protection for certain products or processes. Instead,
we have sought (and may seek in the future) to maintain the confidentiality of any relevant proprietary technology through operational
safeguards and contractual agreements. Reliance upon trade secret, rather than patent, protection may cause us to be vulnerable
to competitors who successfully replicate our manufacturing techniques and processes. Additionally, there can be no assurance that
others may not independently develop similar trade secrets or technology or obtain access to our unpatented trade secrets or proprietary
technology. Other companies may have filed patent applications and may have been issued patents involving products or technologies
potentially useful to us or necessary for us to commercialize our products or achieve our business goals. There can be no assurance
that we will be able to obtain licenses to such patents on terms that are acceptable. There is also a risk that competitors could
challenge the claims in patents that have been issued to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><I>No expectation to pay any dividends or repurchase
stock for the foreseeable future: </I>We do not anticipate paying any dividends to, or repurchasing stock from, our stockholders
for the foreseeable future. Instead, we expect to use cash to fund product development costs and investments in our facility and
production equipment and to reduce debt. Any debt or equity financing we obtain to assist in funding our product development programs
may include terms prohibiting or restricting our paying dividends or repurchasing stock for a lengthy period. Stockholders must
be prepared to rely on sales of their common stock after price appreciation to&nbsp;earn an investment return, which may never
occur. Any determination to pay dividends in the future will be made at the discretion of our Board of Directors and will depend
on our financial condition, results of operations, contractual restrictions, restrictions imposed by applicable laws, current
and anticipated needs for liquidity and other factors our Board of Directors deems relevant.&#9;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><I>Market for common stock</I>: Our common
stock trades on the NASDAQ Stock Market (NASDAQ: ICCC). Our average daily trading volume (although it has increased recently) is
lower than the volume for most other companies and the bid/ask stock price spread can be larger, which could result in investors
facing difficulty selling their stock for proceeds that they may expect or desire. There are companies in the animal health sector
with market capitalization values that greatly exceed our current market capitalization of approximately $20,000,000. The stock
price of some of these companies has been volatile. Before gross margin from the sale of new products is achieved, our market capitalization
may be heavily dependent on the perceived potential for growth from our products under development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><I>Certain provisions might discourage, delay
or prevent a change in control of our Company or changes in our management: </I>Provisions of our certificate of incorporation,
our bylaws, our Common Stock Rights Plan or Delaware law may discourage, delay or prevent a merger, acquisition or other change
in control that stockholders may consider favorable, including transactions in which stockholders might otherwise receive a premium
for their shares of our common stock. These provisions may also prevent or frustrate attempts by our stockholders to replace or
remove our management. These provisions include:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Bookman Old Style, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; font-size: 10pt">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0; font-size: 10pt"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">limitations
                                         on the removal of directors; advance notice requirements for stockholder proposals and
                                         nominations; </FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
<TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0; font-size: 10pt"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
                                         ability of our Board of Directors to alter or repeal our bylaws;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
<TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0; font-size: 10pt"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">the
                                         ability of our Board of Directors to refuse to redeem rights issued under our Common
                                         Stock Rights Plan or otherwise to limit or suspend its operation that would work to dilute
                                         the stock ownership of a potential hostile acquirer, likely preventing acquisitions that
                                         have not been approved by our Board of Directors; and</FONT></TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
<TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; font-size: 10pt">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0; font-size: 10pt"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&#9679;</FONT></TD><TD STYLE="padding: 0; text-indent: 0; font-size: 10pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Section
                                         203 of the Delaware General Corporation Law, which prohibits a publicly-held Delaware
                                         corporation from engaging in a business combination with an interested stockholder (generally
                                         defined as a person which together with its affiliates owns, or within the last three
                                         years has owned, 15% of our voting stock, for a period of three years after the date
                                         of the transaction in which the person became an interested stockholder) unless the business
                                         combination is approved in a prescribed manner.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The existence of the foregoing provisions and
anti-takeover measures could depress the trading price of our common stock or limit the price that investors might be willing to
pay in the future for shares of our common stock. They could also deter potential acquirers of our Company, thereby reducing the
likelihood of obtaining a premium for our common stock in an acquisition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence -->&nbsp;-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><B>ImmuCell Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><I>Cost burdens of our reporting obligations
as a public company:</I> Operating a public company involves substantial costs to comply with reporting obligations under federal
securities laws and the provisions of the Sarbanes-Oxley Act of 2002.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.45in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><I>Exposure to risks associated with the financial
downturn and global economic crisis:</I> The U.S. economy has technically come out of a recession, which was caused principally
by the housing, credit and financial crises of the late 2000&rsquo;s. However, such recent positive indications could prove temporary
and further downturn could occur, and the European economy remains sluggish and precarious. Certain emerging markets also show
signs of slower growth or, in some areas, downturns in economic performance. The credit markets continue to be very turbulent and
uncertain. This extraordinary period of instability in the U.S. economy and the financial markets has been troubling for nearly
all Americans. Some observers believe that the national unemployment rate is too high, the housing market remains problematic for
the overall U.S. economy, the United States has taken on too much national debt and the equity markets are overvalued. A combination
of the conditions, trends and concerns summarized above could have a corresponding negative effect on our business and operations,
including the demand for our products in the U.S. market and our ability to penetrate international markets.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Bookman Old Style, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Bovine
diseases</I>: The potential for epidemics of bovine diseases such as Foot and Mouth Disease, Bovine Tuberculosis, Brucellosis and
Bovine Spongiform Encephalopathy (BSE) presents a risk to us and our customers. Documented cases of BSE in the United States have
led to an overall tightening of regulations pertaining to ingredients of animal origin, especially bovine. <B>First Defense</B></FONT><B><FONT STYLE="font-family: Symbol"><SUP>&#210;</SUP></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">
is considered a veterinary medicine rather than a feed ingredient, and it is manufactured from bovine milk (colostrum), which is
not considered a BSE risk material. Future regulatory action to increase protection of the human food supply could affect <B>First
Defense</B></FONT><B><FONT STYLE="font-family: Symbol"><SUP>&#210;</SUP></FONT></B><FONT STYLE="font-family: Times New Roman, Times, Serif">,
although presently we do not anticipate that this will be the case.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><I>Biological terrorism</I>: The threat of biological
terrorism is a risk to both the economic health of our customers and our ability to economically acquire and collect good quality
raw material from our contract farms. Any act of widespread bioterrorism against the dairy industry could adversely affect our
operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.05in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><B>ITEM 2 - UNREGISTERED SALES OF EQUITY SECURITIES
AND USE OF PROCEEDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.05in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">None</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>ITEM 3 - DEFAULTS UPON SENIOR SECURITIES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.05in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">None</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>ITEM 4 - MINE SAFETY DISCLOSURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">None</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence -->&nbsp;-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><B>ImmuCell Corporation</B></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>ITEM 5 - OTHER INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">None</P>



<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>ITEM 6 - EXHIBITS</B></P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="text-align: justify">Exhibit 10.1</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -1in">Supply Agreement between the Company
and Plas-Pak Industries, Inc. dated as of October 14, 2015.</P>



</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="text-align: justify">Exhibit 31</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Certifications required by Rule 13a-14(a).</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="text-align: left; vertical-align: top">Exhibit 32</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Certification pursuant to Section 1350, as adopted pursuant to Section 906 of the Sarbanes- Oxley Act of 2002.</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 0.5in; background-color: White">&nbsp;</TD>
    <TD STYLE="width: 10%; text-align: justify">101.INS</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: justify">XBRL Instance Document.</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="text-align: justify">101.SCH</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">XBRL Taxonomy Extension Schema Document.</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="text-align: justify">101.CAL</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">XBRL Taxonomy Extension Calculation Linkbase Document.</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="text-align: justify">101.DEF</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">XBRL Taxonomy Extension Definition Linkbase Document.</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="text-align: justify">101.LAB</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">XBRL Taxonomy Extension Label Linkbase Document.</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="background-color: White">&nbsp;</TD>
    <TD STYLE="text-align: justify">101.PRE</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">XBRL Taxonomy Extension Presentation Linkbase Document.</TD></TR>
</TABLE>
<P STYLE="margin: 0">&nbsp;&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence -->&nbsp;-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><B>ImmuCell Corporation</B></P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SIGNATURE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Pursuant to the requirements of Section 13
or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; layout-grid-mode: line; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; layout-grid-mode: line; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding: 0; layout-grid-mode: line; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><U>ImmuCell
    Corporation</U></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; layout-grid-mode: line; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; layout-grid-mode: line; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="padding: 0; layout-grid-mode: line; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Registrant</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; layout-grid-mode: line; text-indent: 0; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; layout-grid-mode: line; text-indent: 0; width: 55%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; layout-grid-mode: line; text-indent: 0; width: 4%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; layout-grid-mode: line; text-indent: 0; width: 36%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; layout-grid-mode: line; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date:</FONT></TD>
    <TD STYLE="padding: 0; layout-grid-mode: line; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">November
    12, 2015</FONT></TD>
    <TD STYLE="padding: 0; layout-grid-mode: line; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By:</FONT></TD>
    <TD STYLE="padding: 0; layout-grid-mode: line; text-indent: 0; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">/s/
    Michael F. Brigham</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; layout-grid-mode: line; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; layout-grid-mode: line; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; layout-grid-mode: line; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; layout-grid-mode: line; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Michael
    F. Brigham</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; layout-grid-mode: line; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; layout-grid-mode: line; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; layout-grid-mode: line; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; layout-grid-mode: line; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">President,
    Chief Executive Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; layout-grid-mode: line; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; layout-grid-mode: line; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; layout-grid-mode: line; text-indent: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding: 0; layout-grid-mode: line; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">and
    Principal Financial Officer</FONT></TD></TR>
</TABLE>
<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 34; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">-&nbsp;<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence -->&nbsp;-</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center"><B>ImmuCell Corporation</B></P>

<P STYLE="font: 10pt/normal Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>EXHIBIT
INDEX</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Exhibit 10.1</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: -1in">Supply Agreement between the Company
and Plas-Pak Industries, Inc. dated as of October 14, 2015.</P>



</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Exhibit 31</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Certifications required by Rule 13a-14(a).</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">Exhibit 32</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">Certification pursuant to Section 1350, as adopted pursuant to Section 906 of the Sarbanes- Oxley Act of 2002.</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 11%; text-align: justify">101.INS</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 88%; text-align: justify">XBRL Instance Document.</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">101.SCH</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">XBRL Taxonomy Extension Schema Document.</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">101.CAL</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">XBRL Taxonomy Extension Calculation Linkbase Document.</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">101.DEF</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">XBRL Taxonomy Extension Definition Linkbase Document.</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">101.LAB</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">XBRL Taxonomy Extension Label Linkbase Document.</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">101.PRE</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">XBRL Taxonomy Extension Presentation Linkbase Document.<BR>
</TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"></P>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: center"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>f10q0915ex10i_immucell.htm
<DESCRIPTION>SUPPLY AGREEMENT BETWEEN THE COMPANY AND PLAS-PAK INDUSTRIES, INC. DATED AS OF OCTOBER 14, 2015.
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: center; text-indent: 0"><B>ImmuCell Corporation</B></P>

<P STYLE="margin: 0; text-align: center; text-indent: 0">&nbsp;</P>



<P STYLE="margin: 0; text-align: center; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>EXHIBIT
10.1</B></FONT></P>

<P STYLE="margin: 0; text-align: center; text-indent: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase"><B>Supply
Agreement between the Company and Plas-Pak Industries, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase"><B>dated
as of October 14, 2015.</B></FONT></P>

<P STYLE="font: 11.5pt Times New Roman, Times, Serif; margin: 0; background-color: white; color: #121212; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">This
Agreement between ImmuCell Corporation of 56 Evergreen Drive in Portland, Maine (&quot;ImmuCell&quot;) and Plas-Pak
Industries, Inc. of 10 Connecticut Avenue in Norwich, Connecticut (&quot;Plas-Pak&quot;) is made this 13<SUP>th</SUP> day of
October, 2015.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white; color: #121212; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white; color: #121212; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Whereas,
</B>ImmuCell and Plas-Pak have entered into a similar agreement dated January 4, 2010.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white; color: #121212; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white; color: #121212; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Whereas,
</B>ImmuCell and Plas-Pak wish to enter into this new agreement to effectively extend the term of the 2010 agreement by an additional
five years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white; color: #121212; text-indent: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white; color: #121212; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Whereas, </B>ImmuCell
is developing mastitis treatment products (principally &ldquo;Mast Out&rdquo;) to be delivered in an intramammary syringe and </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white; color: #121212; text-indent: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white; color: #121212; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Whereas,
</B>Plas-Pak has expertise in making such syringes and </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white; color: #121212; text-indent: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white; color: #121212; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Whereas,
</B>both parties wish to cooperate to commercialize this product opportunity. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white; color: #121212; text-indent: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white; color: #121212; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Agreements
of ImmuCell: </FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 12.7pt; margin-bottom: 0; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1)</FONT></TD><TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">ImmuCell will purchase all of
                                                                                                                                                                                      its requirements for syringes from Plas- Pak, provided Plas-Pak maintains product quality consistent with current production
                                                                                                                                                                                      (See <U>Appendix A</U>) and product pricing consistent with current pricing, subject to normal market adjustment such as the
                                                                                                                                                                                      price of oil that can affect resin costs with reference made to the Consumer Price Index for all Urban Consumers (CPI-U) when
                                                                                                                                                                                      relevant (See <U>Appendix B</U>) and is able to deliver syringes timely in accordance with ImmuCell&rsquo;s orders.
                                                                                                                                                                                      Final pricing is to be determined by mutual agreement between the parties through good faith negotiations.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2)</FONT></TD><TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">If
                                         ImmuCell commercializes any new products requiring a syringe package/delivery system,
                                         and if Plas-Pak can provide the needed quantities of that syringe timely and at mutually
                                         agreed upon pricing, then ImmuCell agrees to purchase those syringes exclusively from
                                         Plas-Pak. </FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3)</FONT></TD><TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">ImmuCell
                                         hereby grants to Plas-Pak a worldwide, non-exclusive and royalty-free license for the
                                         duration of this agreement to any intellectual property that ImmuCell obtains with regard
                                         to the syringes, for use by Plas-Pak to produce syringes for other customers, provided
                                         that these customers do not use the syringe to deliver Nisin. To the extent that this
                                         license covers a patent(s), the term of the license shall cover the life of the patent(s).
                                         </FONT></TD></TR></TABLE>

<P STYLE="margin: 0; text-indent: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white; color: #121212; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Agreements
of Plas-Pak: </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white; color: #121212; text-indent: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 12pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; background-color: white"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1)</FONT></TD><TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Plas-Pak
will sell syringes to ImmuCell based on current design and materials of construction (See <U>Appendix A</U>) at prices consistent
to current pricing subject to normal market adjustments such as the price of oil that can affect resin costs and with reference
made to the Consumer Price Index for all Urban Consumers (CPI-U) when relevant (See <U>Appendix B</U>). Final pricing is to be
determined by mutual agreement between the parties through good faith negotiations.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2)</FONT></TD><TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Plas-Pak
will not sell or supply this syringe, or a substantially similar syringe, to any other party that intends to deliver Nisin in
a product that is competitive to ImmuCell's product. </FONT></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD><TD STYLE="padding: 0; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in; padding: 0; text-indent: 0"></TD><TD STYLE="width: 0.25in; padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">3)</FONT></TD><TD STYLE="padding: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">ImmuCell
                                         retains the right to purchase syringes elsewhere should Plas-Pak not be able to supply
                                         ImmuCell's needs, using the design and materials of construction that has been mutually
                                         agreed upon (See <U>Appendix A</U>) and as adjusted from time to time by agreement between
                                         the parties. </FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white; color: #121212; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white; color: #121212; text-indent: 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0; background-color: white; color: #121212">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0; background-color: white; color: #121212"><B>ImmuCell
Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0; background-color: white; color: #121212">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><U>Appendix
A</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><U></U>Syringe design and Bill of Materials (which was attached to the January 4, 2010 agreement).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><U>Appendix
B </U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white; color: #121212; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Memo
from Michael Basil regarding pricing dated 2007 (which was attached to the January 4, 2010 agreement) and the revised Appendix
B attached hereto. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white; color: #121212; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
Term of this agreement is approximately five years, expiring on January 1, 2021, and may be renewed by mutual written agreement.
</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white; color: #121212; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">The
obligations of both parties where applicable in this agreement shall be binding upon any assignee, transferee or successor. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white; color: #121212; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By
signature below, both parties agree that the above Agreement is acceptable and legally enforceable. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white; color: #121212; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; background-color: white; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Plas-Pak Industries, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0; width: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 35%; border-bottom: Black 1.5pt solid">/s/ <FONT STYLE="font: 10pt Times New Roman, Times, Serif">Charles M.
    Frey</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; background-color: white; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Charles
M. Frey, CEO</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; background-color: white; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date:
October 14, 2015</FONT></P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; background-color: white; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; background-color: white; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">ImmuCell
Corporation</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">By:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; background-color: white; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-indent: 0; width: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></TD>
    <TD STYLE="padding: 0; text-indent: 0; width: 35%; border-bottom: Black 1.5pt solid">/s/ <FONT STYLE="font: 10pt Times New Roman, Times, Serif">Michael F.
    Brigham</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; background-color: white; text-indent: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><U></U>Michael F. Brigham, President &amp; CEO</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: 0; background-color: white"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Date:
October 13, 2015</FONT></P>



<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 0; margin-bottom: 0"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0; text-indent: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31
<SEQUENCE>3
<FILENAME>f10q0915ex31_immucell.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><B>ImmuCell Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>EXHIBIT 31</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATIONS REQUIRED BY RULE 13a-14(a)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0">I, Michael F. Brigham, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I have reviewed this Quarterly Report on Form 10-Q of
ImmuCell Corporation (the Company);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based on my knowledge, this report does not contain any
untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances
under which such statements were made, not misleading with respect to the period covered by this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based on my knowledge, the financial statements, and other
financial information included in this report, fairly present in all material respects the financial condition, results of operations
and cash flows of the Company as of, and for, the periods presented in this report;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I am responsible for establishing and maintaining disclosure
controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting
(as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the Company and have:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.05in">a) designed such disclosure controls and procedures,
or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating
to the Company is made known to me by others within the Company, particularly during the period in which this report is being prepared;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.05in">b) designed such internal control over financial
reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable
assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in
accordance with generally accepted accounting principles;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.05in">c) evaluated the effectiveness of the Company&rsquo;s
disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls
and procedures, as of the end of the period covered by this report based on such evaluation; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.05in">d) disclosed in this report any change in the
Company&rsquo;s internal control over financial reporting that occurred during the Company&rsquo;s most recent fiscal quarter (the
Company&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to
materially affect, the Company&rsquo;s internal control over financial reporting; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I have disclosed, based on my most recent evaluation of
internal control over financial reporting, to the Company&rsquo;s auditors and the audit committee of the Company&rsquo;s Board
of Directors (or persons performing the equivalent function):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.05in">a) all significant deficiencies and material
weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect
the Company&rsquo;s ability to record, process, summarize and report financial information; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.05in">b) any fraud, whether or not material, that
involves management or other employees who have a significant role in the Company&rsquo;s internal control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Date:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;November 12, 2015</P>



<P STYLE="margin: 0">&nbsp;</P>

<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top; text-align: left">
    <td style="width: 40%; border-bottom: Black 1.5pt solid">/s/ Michael F. Brigham</td>
    <td style="width: 60%">&nbsp;</td></tr>
<tr style="vertical-align: top; text-align: left">
    <td>Michael F. Brigham</td>
    <td>&nbsp;</td></tr>
<tr style="vertical-align: top; text-align: left">
    <td>President, Chief Executive Officer and<br>
 Principal Financial Officer</td>
    <td>&nbsp;</td></tr>
</table>
<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32
<SEQUENCE>4
<FILENAME>f10q0915ex32_immucell.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>ImmuCell Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>EXHIBIT 32</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CERTIFICATION PURSUANT TO SECTION 1350, AS
ADOPTED PURSUANT TO SECTION 906 OF THE<BR>
SARBANES-OXLEY ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In connection with the Quarterly Report on Form 10-Q of ImmuCell
Corporation (the &ldquo;Company&rdquo;) for the period ended September 30, 2015, as filed with the Securities and Exchange Commission
on the date hereof (the &ldquo;Report&rdquo;), I, Michael F. Brigham, President, Chief Executive Officer and Principal Financial
Officer of the Company, certify, pursuant to 18 U.S.C. &sect; 1350, as adopted pursuant to &sect; 906 of the Sarbanes-Oxley Act
of 2002, that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.05in">(1) the Report fully complies with the requirements
of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;);
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.05in">(2) the information contained in the Report
fairly presents, in all material respects, the financial condition, results of operations and cash flows of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0">This certification is provided pursuant to
18 U.S.C. Section 1350 and Item 601(b)(32) of Regulation S-K (&ldquo;Item 601(b)(32)&rdquo;) promulgated under the Securities Act
of 1933, as amended (the &ldquo;Securities Act&rdquo;), and the Exchange Act. In accordance with clause (ii) of Item 601(b)(32),
this certification (A) shall not be deemed &ldquo;filed&rdquo; for the purposes of Section 18 of the Exchange Act, or otherwise
subject to the liability of that section, and (B) shall not be deemed to be incorporated by reference into any filing under the
Securities Act or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 40%; border-bottom: Black 1.5pt solid">/s/ Michael F. Brigham</TD>
    <TD STYLE="width: 60%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>Michael F. Brigham</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>President, Chief Executive Officer and<BR>
 Principal Financial Officer</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD>November 12, 2015</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">A signed original of this written statement required by Section
906 has been provided to ImmuCell Corporation and will be retained by ImmuCell Corporation and furnished to the Securities and
Exchange Commission or its staff upon request.</P>



<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>img01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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MG1_PCWQ/_P"AP\!_^$A=_P#RSH /^$A^)_\ T)_@/_PK[O\ ^5E'_"0_$_\
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M$_\ Z$_P'_X5]W_\K*/^$>^)_P#T.'@/_P )"[_^6='_  CWQ/\ ^AP\!_\
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M?_T)_@/_ ,*^[_\ E91_PD/Q/_Z$_P !_P#A7W?_ ,K*/^$>^)__ $.'@/\
M\)"[_P#EG1_PCWQ/_P"AP\!_^$A=_P#RSH /^$A^)_\ T)_@/_PK[O\ ^5E'
M_"0_$_\ Z$_P'_X5]W_\K*/^$>^)_P#T.'@/_P )"[_^6='_  CWQ/\ ^AP\
M!_\ A(7?_P LZ #_ (2'XG_]"?X#_P#"ON__ )64?\)#\3_^A/\  ?\ X5]W
M_P#*RC_A'OB?_P!#AX#_ /"0N_\ Y9T?\(]\3_\ H</ ?_A(7?\ \LZ #_A(
M?B?_ -"?X#_\*^[_ /E91_PD/Q/_ .A/\!_^%?=__*RC_A'OB?\ ]#AX#_\
M"0N__EG1_P (]\3_ /H</ ?_ (2%W_\ +.@ _P"$A^)__0G^ _\ PK[O_P"5
ME'_"0_$__H3_  '_ .%?=_\ RLH_X1[XG_\ 0X> _P#PD+O_ .6='_"/?$__
M *'#P'_X2%W_ /+.@ _X2'XG_P#0G^ __"ON_P#Y64?\)#\3_P#H3_ ?_A7W
M?_RLH_X1[XG_ /0X> __  D+O_Y9T?\ "/?$_P#Z'#P'_P"$A=__ "SH /\
MA(?B?_T)_@/_ ,*^[_\ E91_PD/Q/_Z$_P !_P#A7W?_ ,K*/^$>^)__ $.'
M@/\ \)"[_P#EG1_PCWQ/_P"AP\!_^$A=_P#RSH /^$A^)_\ T)_@/_PK[O\
M^5E'_"0_$_\ Z$_P'_X5]W_\K*/^$>^)_P#T.'@/_P )"[_^6='_  CWQ/\
M^AP\!_\ A(7?_P LZ #_ (2'XG_]"?X#_P#"ON__ )64?\)#\3_^A/\  ?\
MX5]W_P#*RC_A'OB?_P!#AX#_ /"0N_\ Y9T?\(]\3_\ H</ ?_A(7?\ \LZ
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MQ/\ ^AP\!_\ A(7?_P LZ #_ (2'XG_]"?X#_P#"ON__ )64?\)#\3_^A/\
M ?\ X5]W_P#*RC_A'OB?_P!#AX#_ /"0N_\ Y9T?\(]\3_\ H</ ?_A(7?\
M\LZ #_A(?B?_ -"?X#_\*^[_ /E91_PD/Q/_ .A/\!_^%?=__*RC_A'OB?\
M]#AX#_\ "0N__EG1_P (]\3_ /H</ ?_ (2%W_\ +.@ _P"$A^)__0G^ _\
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M_0X> _\ PD+O_P"6= !_PD/Q/_Z$_P !_P#A7W?_ ,K*/^$A^)__ $)_@/\
M\*^[_P#E91_PCWQ/_P"AP\!_^$A=_P#RSH_X1[XG_P#0X> __"0N_P#Y9T '
M_"0_$_\ Z$_P'_X5]W_\K*/^$A^)_P#T)_@/_P *^[_^5E'_  CWQ/\ ^AP\
M!_\ A(7?_P LZ/\ A'OB?_T.'@/_ ,)"[_\ EG0 ?\)#\3_^A/\  ?\ X5]W
M_P#*RK'@#XAZ[K/CK5O#WB'1-)TF^TVPM=1C?3M6DU"*:.>2XC )>W@*L#;M
MQA@0PY[57_X1[XG_ /0X> __  D+O_Y9UD?#.SUZQ_:*\4+XAU+2=4O3X<TL
MI+IVFR6$2Q_:=1PI1YYB6SN.[< 00-HQD@'J=%%% '!_M'?\D^T__L:/#O\
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MKL>L5P?A[_DY[QA_V*^A_P#I7K%=Y7!^'O\ DY[QA_V*^A_^E>L4@.\HHHH
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M)2=^ZUBM+/22:;35^2E44J4*LM.:/,UU7NN22Z.Z35[JTO=:O>W[NT5_/?\
M';]G#QYX _X)B^$_@+<>&]8M=';]HWQ%IWA_P?XQA\0O::UX;MH;JXM$-GI>
M=9O;,2;)T:R20!P)'8*"U+/^P->>&O\ @BUH_A7X2PWGQ.L;7XROJOQP\&^#
M- \0/=1QJ&C72QH]Y=:?JT\-J19?N7EMYI L<Y8!#*.>,E*,IQV]RW_;ZI/W
MK7Y>55-7JDXV;7,C7E:E&$MWSWM_==1>[>W,Y.G[JT;YM%HS^@^L+XH>.?\
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M_P!#AX#_ /"0N_\ Y9UWE%(9P?\ PCWQ/_Z'#P'_ .$A=_\ RSH_X1[XG_\
M0X> _P#PD+O_ .6==Y10!P?_  CWQ/\ ^AP\!_\ A(7?_P LZ/\ A'OB?_T.
M'@/_ ,)"[_\ EG7>44 <'_PCWQ/_ .AP\!_^$A=__+.C_A'OB?\ ]#AX#_\
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M2IM/?JODFX+5^LU\DWT2?UE_PCWQ/_Z'#P'_ .$A=_\ RSH_X1[XG_\ 0X>
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M=V#:K!H3>'Y5U*:S5Q&URMO_ &IYC0AR%,@7:&(&<U^7_P#P3B^-'Q$MM/\
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M-0N)+B>0C?+-/-JKS3/@*H:1V(1$0$*BJ/ES_@I?^T%XA_9X_P""EW@77/\
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M_:B\=>++O]FG4?!OQ4^('Q _:0\2:UKX^-O@?5O$][?6^BVD:W9N/MFBR/\
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M!W7C#X;FR_X2+37\":E ]@+R)IK9PTE^J2I(BL0\3.H*LI(8$5W'_"/?$_\
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M@#@_^$>^)_\ T.'@/_PD+O\ ^6=?*/\ P5H\*>--1^&_PYL_$&I>&/$MC?\
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MP\!_^$A=_P#RSH_X1[XG_P#0X> __"0N_P#Y9UWE% '!_P#"/?$__H</ ?\
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M .6= '>45P?_  CWQ/\ ^AP\!_\ A(7?_P LZ/\ A'OB?_T.'@/_ ,)"[_\
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M_P#A'OB?_P!#AX#_ /"0N_\ Y9T?\(]\3_\ H</ ?_A(7?\ \LZ .\HK@_\
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M_P#EG6DI.4G*6[ [RBN#_P"$>^)__0X> _\ PD+O_P"6='_"/?$__H</ ?\
MX2%W_P#+.I PO 7['7AOP#^U]X^^-D>I^(M2\7?$#2--T&:"]N(GL=(LK+S"
MD-HBQ*Z"225Y)/,>0ESE=HXKUFN#_P"$>^)__0X> _\ PD+O_P"6='_"/?$_
M_H</ ?\ X2%W_P#+.A:145LO\VW][;;[MMO5@]9.3W=OP22_!)?([RBN#_X1
M[XG_ /0X> __  D+O_Y9T?\ "/?$_P#Z'#P'_P"$A=__ "SH R_AK^R3X9^&
M7[3/Q&^+5O=:UJ7B[XF6^G6-\]]/')!IUI8Q,D-K:*J*8XBTDDK!B[-)(3NP
M%4>H5P?_  CWQ/\ ^AP\!_\ A(7?_P LZ/\ A'OB?_T.'@/_ ,)"[_\ EG1L
ME%;+^OZ[O4'JW)[O_*WY))>22.\HKX?L/VMOV@-6^##?%V#6/@ZOP^7Q8V@K
MI$GA#4?[6>P75_[*;4/M(U3RQ)Y@:<6OD'* )YP8Y'9?!W]H[XO_ !A_:2U7
MP[9ZU\-H_!*Z=>SZ-JO_  BEXT^K/974%K<3*!JFT6YFEEC3(RWV8R E)$-$
M/>DH+=WT](\S_#\;K=-)2DHQ<WLFE?U?*OQ_#79IOZNHK@_^$>^)_P#T.'@/
M_P )"[_^6='_  CWQ/\ ^AP\!_\ A(7?_P LZ!G>45P?_"/?$_\ Z'#P'_X2
M%W_\LZ/^$>^)_P#T.'@/_P )"[_^6= '>5\>?\%F-*_M_P"$/PWT_P"Q?VE]
MN\6WMO\ 8_L7V[[7O\+:^OE?9_L=]YV[./+^PWF_./LT^?+;Z'_X1[XG_P#0
MX> __"0N_P#Y9U\H_P#!6CPIXTU'X;_#FS\0:EX8\2V-_P"*;ZV&FZ?X4G$M
MV[^%]> 3RW_M03JPROD_V=>%]P'V>?\ U3@&5\7/^*B_X3;_ )BG_"2?\)!H
M'_/_ /VYY'_"PO\ B6_\Q#^T/)Q_R#_^)]Y&/^1;TO'R=W^QEJO]M_\ !17X
MP7'VS^T-OA&SM_.^V?;-OE>-/&T?E>9]LO,>7MV>7YZ^5L\O[+8[?L<'"?%S
M_BHO^$V_YBG_  DG_"0:!_S_ /\ ;GD?\+"_XEO_ #$/[0\G'_(/_P")]Y&/
M^1;TO'R;O[-$OB?Q3_P44^+$_AOQ)H,)B\)6MO/-J5I+KF_R_&?C6-8E>/59
M?+\K84,9G_=[1']EL-GV.$ ^XJ*X/_A'OB?_ -#AX#_\)"[_ /EG1_PCWQ/_
M .AP\!_^$A=__+.@#O**\WUZQ^*6BZ%>WD7B+P;J4EI \R6EKX/N//NBJDB.
M/?JJIO;&!N91DC) YKYYNO\ @H=XNUSP@NL^"+&Z^)4,/A6T\8:A%H7@RWMI
M-(L[EIU2.X.H>(+5%N5-K<[X%9G3R6! )4-$JD8IN6RW\M&_NLGZ=>A48MV2
MZ_YI?FU;N?9U%?%MI^WM\7M3\/>![BR^&/BR\UGXA6MWJ6D:%'X:T);YK"WC
MM9&O'=_%:VRQM]LB"IYQFR&S&H )]C^ 7Q4\9?M(?"VP\6>'_%_A*&SNY)K:
MXL]0\#7MK?:7=P2O!<VES"VIYCGAFCDC=>1N0X+*0QUE"2;3W6_]>3T?9Z/4
MSC-22DMGL^G]/==UJM#V^BN#_P"$>^)__0X> _\ PD+O_P"6='_"/?$__H</
M ?\ X2%W_P#+.I*.\K@]&_Y.>\2?]BOI7_I7J5'_  CWQ/\ ^AP\!_\ A(7?
M_P LZR/AG9Z]8_M%>*%\0ZEI.J7I\.:64ET[39+")8_M.HX4H\\Q+9W'=N (
M(&T8R0#U.BBB@#@_VCO^2?:?_P!C1X=_]/5C7>5P?[1W_)/M/_[&CP[_ .GJ
MQK<^*WQ3T'X(_#K5_%GB:^;3M!T.W-S>3K;RW#JHP J11*TDLC,0JQQJSNS*
MJJ6(!F4E%.4G9(J,7)J,5=LZ"BO&_%?[?OPH\%>*?#&CZAXCOA=>+K;3KRRD
MM]!U&ZM+6'49A!827MQ% T-@MS-F.(W;P^8ZLJY*L!<\&_MO_#/Q['K#:;KU
MY_Q)-7M]$F6ZT2_LWNKFXF>"#[*LT*&[ADDCE5)[<20MY4I#D1N1HXM.S75K
MYII->J;2:[M+J9\R:NNR?R:NGZ-:KRUV/6*X/P]_R<]XP_[%?0__ $KUBN\K
M@_#W_)SWC#_L5]#_ /2O6*DH[RBBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHKD?C7\=O"_[//@Y=<\5W]Q9V<UU'8VL-I87&HWVHW,F=EO;6EM')<7,
MS88B.&-WVJS8PK$*4DMQI-['745XU)^WW\,1\*%\90ZCXGO-.&I/HTNGV?@[
M6;K7K2\1#));SZ1':MJ$,B1#S662W4K&RR'",K'TWX?>/M'^*O@31?$_AW4+
M?5M \16,.I:;>P$F.[MYD$D<BYP<,K \@'FJL]?*U_*ZNK^JU7=$\R_/\'9_
M<]'YFQ1112&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 55US6K7PWHMYJ-],MO
M9:? ]S<2M]V*-%+,Q^@!-6JJZ[HMKXET2\TV^A6XLM0@>VN(FZ21NI5E/U!(
MK.MS^SE[/XK.U]K]+ET^7G7/M?6V]NMCYS^%'[<_C#QAJ'@'6_$7POL?#OPW
M^+4@B\(ZM;^*/MNL;I;:2[L_[2L&M8HK3[1!$V/)NKDI(T:.%W%EU/V*/VV;
M[]K#Q%XXL;K1/!=M:^#WME75_"7C-/%6E22R^?YEC/<I;P)#J%L(D:>W7S5C
M6YA(E8.*\BD_90^)'PRUGX3:#)\<OAIX@\"_!348CI/AO5-%DT76KFV6TDL;
M:6]U-;RXBFN;2WG,J!=/BBN)8U#K%N62*I\=_AU=>!_V:OVC?'_COXK>!/'7
MCC6OA+J'AR&3PWHB:!"UI:6=_/&9(6O;N2:Z:2YDRXE2-5VA(4)=GZ/<YY6^
M'5*^]K)Q;M]J]U*UHV::;<9)Y/GY-;<UHWMM>[4K7UY>6S5_>NFGHTUT'Q4_
M84\)^*HY[?PM^T%XC\)>'8_$Z>-;'P8]QHNI>%4U=;S[?NGADMA?S6CWN;A[
M5;^- S'RC#MCV>A?!C]B']G7X;?M"6/Q!\"^"_A/H/CJ#3+FP\[PUHFF6+3&
M9E>:X_<Q^;YI"LN[S#\DC@YR37Y=Z]^RQX!_85TS0?VSO@9\/?!7[1'[)?Q%
MTFWU'XE^!O[%M=6N_"*J")]<T+[0A:!8)/.%U8L4$+)(DBQQ(KZ;WWPW_P""
M?/PY^%__  41_9X_:9_9D\3>%=2_9Y^.GBPS7.@V]FC#0]5_LO5&2?2Y&C$M
MI;.%NXKBP)B\B950QLJ1Q66=/W+<O2_XQY7_ .2I+T2[(JI[]U+K;\'S)^M]
M;[W;?5W_ &.HHHH **** "OCS_@LQI7]O_"'X;Z?]B_M+[=XMO;?[']B^W?:
M]_A;7U\K[/\ 8[[SMV<>7]AO-^<?9I\^6WV'7QY_P68TK^W_ (0_#?3_ +%_
M:7V[Q;>V_P!C^Q?;OM>_PMKZ^5]G^QWWG;LX\O[#>;\X^S3Y\M@#@_BY_P 5
M%_PFW_,4_P"$D_X2#0/^?_\ MSR/^%A?\2W_ )B']H>3C_D'_P#$^\C'_(MZ
M7CY.[_8RU7^V_P#@HK\8+C[9_:&WPC9V_G?;/MFWRO&GC:/RO,^V7F/+V[/+
M\]?*V>7]EL=OV.#A/BY_Q47_  FW_,4_X23_ (2#0/\ G_\ [<\C_A87_$M_
MYB']H>3C_D'_ /$^\C'_ "+>EX^3N_V,M5_MO_@HK\8+C[9_:&WPC9V_G?;/
MMFWRO&GC:/RO,^V7F/+V[/+\]?*V>7]EL=OV.  ^Q*\<^-?[8L/PL^(LOA'P
M_P##_P"('Q1\2:=IL>LZQ8^$X]/W:'9R/(D,L[WUW:HS2M#-LAA:69A"Y\O&
M"?8Z^</BW\'_ (Q?#3]H7QA\0/@[IWPU\33?$+0+#3-0T_QAKU[HJ:1>V!NA
M;W<4EM97AN8Y$NMKP,L!7[.I65O,(3.I)K5>?ST;2Z;NRW7:ZW51C?3^M]?F
ME=_H_A>SXE_;\\/Z,O@35-/\(^/O$7@?QZ=*2W\7Z?96T>E:<^IW"V]DD\=Q
M<17C,\CH&6"VE,.\&7RQG$?PG_9!D^%?PZ^.&D6,.@V=U\4O$.L:U:O;,X11
M>6Z1IYQ* JP<.Q5 RC<2,DFODCXS_L]?$KX(?L3Z#XLU'X7_  SL]=_9_P#!
MW]L3^-KS7VB\9:;-I32WFI1:;):6<BR6.I+ Z(7N;0K#?.)[1MK0/A^!?^"[
M'QD^./PUU+XE?"_X0_#7XD?!/PFLI\8?$'3_ !=>Z?I_A(V\2W-\)[*_LK?4
MKC[-:/%<-]DM9]ZR!(O,E#1BZV'A*$X2UYN>&_V&XM6T6MXZ.RTTMU93J2C*
M$E]EQE_V\E)>>FNUWKVT/K'Q=\ OBQ\/KSX&:SX$T?X>>*M6^&OA.\\-:M9:
M]XHO-"MY6GAT]?.@GATZ\9PK63?*\29#@Y!!%>G_ +)OP5U?X(?"RXM?$FI6
M6K>*O$6L7_B36YK&,QV4=Y>W#SO!;AOF,,(98D9\.ZQ!V 9B!\9?L8?\%M?%
MW[7_ ,<_A_;^'O O@?Q9\&?&FOW/A"X^(?AS7[Z&'2]<BTRZU+^SS8:C96MY
M(_V>"-S*L/D;9U E+JT8_1JM9U'.I*K+XI7U\F^9KT<DGZI&,*:A3A2C\,;6
M7HFD_5)M?-A11169H%<'HW_)SWB3_L5]*_\ 2O4J[RN#T;_DY[Q)_P!BOI7_
M *5ZE0!WE%%% '!_M'?\D^T__L:/#O\ Z>K&N%_;H_9R\??M#>'?#J^"/%WA
M/0&\-W-QJ<VF^(?"TNNVFLW @9+7(CO[,QM#(YE1F9U$HB?;F)37=?M'?\D^
MT_\ [&CP[_Z>K&N\K*M156#A+K_7X&E*HZ<N9?\ #]U\UH?GO:?LO_'#PY\/
MKKP!J7@N+Q1<?$SPKX2TK4?%.E7-EIND^%)M/=HKQ+JUGO9+I_+MQ&T;6OV@
M3R[E/V=<,+'Q^_8H^)'P\\3ZEXR^"7AWQ'H>I6_B*9--M(-7L-8U!(WM+O.H
M0C6IY;.VM6NYHXA:PF-[>SDOC L<UY)&OZ 45TU:CJ576E\3;?WM.WHK6MV>
MMVHM<]&G&E35*.R27W1<;^KO>_?163:=-(]0F\/JKRVL&J-;X:1(VD@CFV_>
M"D@L@;G!()'<=:\:T+PKXZ;]HKQ5&OC'15NU\.:,TDQ\/$K(AN=5V*$^T\%2
M').3G>!@;<GW&N#\/?\ )SWC#_L5]#_]*]8J).[N7%65@_X0_P"(?_0\:#_X
M3+?_ "51_P (?\0_^AXT'_PF6_\ DJN\HI#.#_X0_P"(?_0\:#_X3+?_ "51
M_P (?\0_^AXT'_PF6_\ DJN\HH X/_A#_B'_ -#QH/\ X3+?_)5'_"'_ !#_
M .AXT'_PF6_^2J[RB@#@_P#A#_B'_P!#QH/_ (3+?_)5'_"'_$/_ *'C0?\
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M_P#H>-!_\)EO_DJC_A#_ (A_]#QH/_A,M_\ )5=Y10!P?_"'_$/_ *'C0?\
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M[N[]].U:[M(;2\UC2?MLW]FWEQ##'%%%/-9?9Y'1(XP&<_(ARBN-I1YH[?\
M!:_.+6MKV;5UJ$KQ?*][V^^*DOE9I^5TG9NQTG_"'_$/_H>-!_\ "9;_ .2J
M/^$/^(?_ $/&@_\ A,M_\E5WE% '!_\ "'_$/_H>-!_\)EO_ )*H_P"$/^(?
M_0\:#_X3+?\ R57>44 <'_PA_P 0_P#H>-!_\)EO_DJC_A#_ (A_]#QH/_A,
MM_\ )5=Y10!P?_"'_$/_ *'C0?\ PF6_^2J/^$/^(?\ T/&@_P#A,M_\E5WE
M% '!_P#"'_$/_H>-!_\ "9;_ .2J/^$/^(?_ $/&@_\ A,M_\E5WE% '!_\
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MM)^T?V5:_P##$7_*-7RD_P"&B.GW\#_A)_\ D+_\3O\ Y 'V+_D'<?\ /O\
MO]] ':?LJVGAF_\ V^?V?X?V(;Z#3OV)6\6W?]IW$UM<7*1_$7^P-7\[,>J,
MFK-G1_L8^1A9C.1^]WBOV6_X0_XA_P#0\:#_ .$RW_R57X\?L8_\(3_P\3_9
MX_X8V_Y,5_X2Z\_M?_7_ /)1?^$?U?S?^0K_ ,37_D$_8ON?Z'Z?O=]?N'0!
MP?\ PA_Q#_Z'C0?_  F6_P#DJC_A#_B'_P!#QH/_ (3+?_)5=Y10!P?_  A_
MQ#_Z'C0?_"9;_P"2JR/AIINLZ7^T5XHCUS5;36+MO#FELDUO8FS54^TZCA2G
MF/D@ACG/<#'&3ZG7!Z-_R<]XD_[%?2O_ $KU*@#O**** .#_ &CO^2?:?_V-
M'AW_ -/5C5CXY?'_ ,-?LZ^%8-8\3-KS6]U<?98+?1?#^H:]?7#[&<[+2QAF
MN&541V9EC*HJDL0.:K_M'?\ )/M/_P"QH\._^GJQKE_VWM&O_$WPIM=+M_ ?
MQ,^(%E?7H2\M/ /C1?"NM6BB.0K,MPU_8"2'< CQ_:1G>I\N0 @9UI2C"\=_
M2_7R_KOH:4XQ<K2V*^K_ /!1+X/:-K'A&S;Q9-=_\)O9Z9J.F7=AHNH7UA%;
M:E*(=/FN[J&!X+%+F4^7$UV\0D965<E6 U/!O[;_ ,,_'L>L-INO7G_$DU>W
MT29;K1+^S>ZN;B9X(/LJS0H;N&22.54GMQ)"WE2D.1&Y'R;8?LM_&WPO\/;O
MX?WW@6'7YOB7X6\)Z5J'B72;_2K+1_"4UA(T=XEQ;AK>1E2W$;1?8;5DE?*%
M+= 'JU\?OV*/B1\//$^I>,O@EX=\1Z'J5OXBF33;2#5[#6-02-[2[SJ$(UJ>
M6SMK5KN:.(6L)C>WLY+XP+'->21KO/E51Q6W-)7\E**7X-^\KI[I<L9&,>9Q
MN][)_/E;?XVTTM\+?-8_0"N#\/?\G/>,/^Q7T/\ ]*]8KL$CU";P^J22VL&J
M-;X:1(S)#'-MY8*2"RAN<$@D=Q7C6A>%?'3?M%>*HU\8Z*MVOAS1FDF/AXE9
M$-SJNQ0GVG@J0Y)R<[P,#;DS)6=AQE=7/<:*X/\ X0_XA_\ 0\:#_P"$RW_R
M51_PA_Q#_P"AXT'_ ,)EO_DJD,[RBN#_ .$/^(?_ $/&@_\ A,M_\E4?\(?\
M0_\ H>-!_P#"9;_Y*H [RBN#_P"$/^(?_0\:#_X3+?\ R51_PA_Q#_Z'C0?_
M  F6_P#DJ@#O**X/_A#_ (A_]#QH/_A,M_\ )5'_  A_Q#_Z'C0?_"9;_P"2
MJ .\HK@_^$/^(?\ T/&@_P#A,M_\E4?\(?\ $/\ Z'C0?_"9;_Y*H [RBN#_
M .$/^(?_ $/&@_\ A,M_\E4?\(?\0_\ H>-!_P#"9;_Y*H [RBN#_P"$/^(?
M_0\:#_X3+?\ R57*?&/XD77[.OA%?$'Q!^-?PV\"Z"TZVHU+Q#80Z79F9@2L
M?FSWJIO8*Q"YR=I]*3DEJQI-['L]?)O[1_Q5G^$7_!2OP'JBZ=93:;'\,]=F
MUO5-2U6'2M*\,Z5%JND37NHW=Q)G:D4$;[$16+RO$',,'GW4'J%[XZU#3O#7
MA[6KCXS?#NWT?Q=/;6NA7\FFQ+;:U-<C=;1VTAO-LSRCF-8RQ<?=S7B7Q:\?
M>)_@9_P4H\%ZGKEUHFOZ>OPTUR;5M6N7B\.Z3X4TJ'5-(FOM1O+B627Y(X4;
M8B*2\K1*YAA\^ZMZ::NGT=OGV]=42I)[>OR[GI__  W/C_CY\+_V#N_XJ"?_
M (2#4O[)_P"$:\()_K/$.N>;$/[*\WR;W[+92[KB;R5\T6OE:E_9N'_P34\<
MCXE7_P ?]>CTG6]%M]3^*=S-;6NL6;65]Y!T71_+DEMW_>0&1 L@BF"31APL
ML<4H>)-S_AN?'_'SX7_L'=_Q4$__  D&I?V3_P (UX03_6>(=<\V(?V5YODW
MOV6REW7$WDKYHM?*U+^S?'_V4/C%?Q:!^TS\39]>;X<^"]/^(5[JMS'XD\,R
M_;X+2+0])?[3+!YR30F2(*XMY(UN$#*DD<<V^))E))7>Q48MNR/N"BOD[P)^
MUOX^\3:M>:7KFB>.O VM-HEQXAT33-:\%V4UUXHM(-@E^R"RU6X59E,L ,%R
MT$P\]3LPLA3K?V;?C!X\_:,TGQ(S7M[X'UKPCK!T/6-%\0^&+1KRRN/L\%RO
M[RSU*YMI%:&YA<-%,^-Q5MK*RBE%MV\K_*_*_N>C6Z>CLR>96NN]OPO]S6J>
MS6Q]"45YOK^G>-/">A7NJ:I\1O"NFZ9IL#W5W>77A_R8+6%%+/)([7854502
M6)  !)KA_A+^T7I/Q]6W/@3]HCX.^-1>7$UK =!2TU+SIH8UEEC7R;YMSI&Z
M.RCE5=2< @TEK=+H-Z:L^@**\R\*#Q9X[T./5-#^)GA#6=-F>2..[L="%Q [
M1R-'(H=+LJ2LB.C 'AE8'!!%:/\ PA_Q#_Z'C0?_  F6_P#DJ@#O**X/_A#_
M (A_]#QH/_A,M_\ )5'_  A_Q#_Z'C0?_"9;_P"2J .\HK@_^$/^(?\ T/&@
M_P#A,M_\E4?\(?\ $/\ Z'C0?_"9;_Y*H [RBN#_ .$/^(?_ $/&@_\ A,M_
M\E4?\(?\0_\ H>-!_P#"9;_Y*H [RBN#_P"$/^(?_0\:#_X3+?\ R51_PA_Q
M#_Z'C0?_  F6_P#DJ@#O**X/_A#_ (A_]#QH/_A,M_\ )5'_  A_Q#_Z'C0?
M_"9;_P"2J .\HK@_^$/^(?\ T/&@_P#A,M_\E4?\(?\ $/\ Z'C0?_"9;_Y*
MH [RBN#_ .$/^(?_ $/&@_\ A,M_\E4?\(?\0_\ H>-!_P#"9;_Y*H [RBN#
M_P"$/^(?_0\:#_X3+?\ R51_PA_Q#_Z'C0?_  F6_P#DJ@#O*YWXL_"7P[\=
M/AYJ7A7Q7I<.L:%JR*MQ;N[QL&5U>.6.1"LD4T<BI)'+&RR1R(CHRLJL,7_A
M#_B'_P!#QH/_ (3+?_)5'_"'_$/_ *'C0?\ PF6_^2J32>C'&33NMSQR^_X)
M$?"'4AXHMKBZ^*-YH_CJ&T3Q/87_ ,1-<U!]=DLI4EL9I+VXNI+^)[9E8(+>
MYB1A(PD27;'L]W^$/PATGX(>#4T'1;OQ1>V,<KS"77_$NH^(;PLW)!NK^>><
MKZ*9-J]@*R_^$/\ B'_T/&@_^$RW_P E4?\ "'_$/_H>-!_\)EO_ )*JDVMO
MZ]>_3Y)+9(5DSO**X/\ X0_XA_\ 0\:#_P"$RW_R51_PA_Q#_P"AXT'_ ,)E
MO_DJD!WE%<'_ ,(?\0_^AXT'_P )EO\ Y*H_X0_XA_\ 0\:#_P"$RW_R50!W
ME%<'_P (?\0_^AXT'_PF6_\ DJC_ (0_XA_]#QH/_A,M_P#)5 '>45P?_"'_
M !#_ .AXT'_PF6_^2J/^$/\ B'_T/&@_^$RW_P E4 =Y17!_\(?\0_\ H>-!
M_P#"9;_Y*H_X0_XA_P#0\:#_ .$RW_R50!WE%<'_ ,(?\0_^AXT'_P )EO\
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MS1:^5J7]F^4_L=_MF^"OAGX%^(NN>((_&&GR>,?BKK[Z-HD/A34]1\17T2K
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M;XG64.N_%'X<Z')YK>%I?+6.Y\0Z)&Q'DF%HV2[LVV>3Y+1R".*-'TW\X_\
M@XY_9(^$GPA\,?"7XN_LX^,TO_@-^T!=:IXCT[PI8,W]AZ#JD:6L=W<V$1Q]
ME$X,<<UJT:/;R67E'")'!;9C/&/^(D_]M;_HN&L?^"NP_P#C%?NW_P &LO[=
MGQ6_;X_8U\>>)/BWXNNO&.M:3XO:PL[F>V@@:"W^R6[^6/*1 1N9F^;)RQYQ
MQ7\GM?TS?\&4G_*/WXF?]CTW_I#;4 ?LM1110 5\>?\ !9C2O[?^$/PWT_[%
M_:7V[Q;>V_V/[%]N^U[_  MKZ^5]G^QWWG;LX\O[#>;\X^S3Y\MOL.OCS_@L
MQI7]O_"'X;Z?]B_M+[=XMO;?[']B^W?:]_A;7U\K[/\ 8[[SMV<>7]AO-^<?
M9I\^6P!P?Q<_XJ+_ (3;_F*?\))_PD&@?\__ /;GD?\ "PO^);_S$/[0\G'_
M "#_ /B?>1C_ )%O2\?)D>$?VTO"W[,/[>?Q@\0>+%\7ZMI%OX%6YO=4T?2K
MOQ!:Z-:V7C'QJ)6O+F"XODM8XE!4++<1B,0R(+:Q$+V=OK_%S_BHO^$V_P"8
MI_PDG_"0:!_S_P#]N>1_PL+_ (EO_,0_M#R<?\@__B?>1C_D6]+Q\D'PA_:(
M_P"%;?\ !1SXI7'DKK%JW@^UGUG6]0UD0:'X5T>Q\:>-A?7E]J+W=]'"+>$&
M.*U\U9&D41_9M-MX+I=. /8-=_X*\_"_PM_;7]K>'/C-I/\ PC>C+XBUG[=\
M.-8MO[%TUO.VWEWYD ^SPM]FN</+M4_9I\']U)M_)6S\86_Q!^(OQ.URUMM4
ML[;6/B/XKO([?4K&6QO+=7UR]8)-!*JR0RKG#1NH96!! ((K]D/^&Y\?\?/A
M?^P=W_%03_\ "0:E_9/_  C7A!/]9XAUSS8A_97F^3>_9;*7=<3>2OFBU\K4
MO[-_&S3?$UOXT^(WQ4UBSCU"&TU;XF^+[R"._L)["Z1)-?OG42V\Z)-#( 1N
MCE1)$.5958$  \J_X*&;?^&/O%WF?ZO_ $+=]/MMOFO8M)^T?V5:_P##$7_*
M-7RD_P"&B.GW\#_A)_\ D+_\3O\ Y 'V+_D'<?\ /O\ O]]>._\ !0S;_P ,
M?>+O,_U?^A;OI]MM\U[%I/VC^RK7_AB+_E&KY2?\-$=/OX'_  D__(7_ .)W
M_P @#[%_R#N/^??]_OH ]#_8Q_X0G_AXG^SQ_P ,;?\ )BO_  EUY_:_^O\
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M6EU1^5O_  >2:-XJT7]A#X:S:UXDT_58?^$W41):Z2;)XW^Q7/S;_.?/&1C
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M9:O>6D;,L$T48/EPIPJ#W+'+'US_ (0_XA_]#QH/_A,M_P#)5>?^%[7X#?\
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M7,AAEA++-%)\CHI60Q@'U!_PA_Q#_P"AXT'_ ,)EO_DJC_A#_B'_ -#QH/\
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MF4MXPL:'<\LGE@^5 ES=6Z_\*M^$(_X^?!?Q T'=_P 5!/\ \)!\6O$FD_\
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MS7H- T6.3RED:&6XFN'"/(4B@A5Y966..61EC1BL<4CG"(S"/]H[_DGVG_\
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MQ_8?MWVO?KU@OE_9_L5_YV[.WR_L-WOSM^S7&?*?Z"_X4/\ ]3GX]_\ !O\
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M\F);EPUW\R2(3)#^5'[1B>9\#?$ZY9=UBXR#R.G2OWX_X4/_ -3GX]_\&_\
M]A1RJ]VK_P##-?K]]GNDU7,UMOW_ !].B_+9M/\ #K_@Z1_9C\3_ +-7_!/Z
MR7Q)\1?$7Q"_X2KXN#5;*;5H--BEMHO[)>++"QL;1!(QC.X;60+''MVDOG\!
M:_I!_P"#RCX;_P#"&_L&?#>X_M[Q+JWF>-U3R]1OO/C7_0K@Y VC!XZU_-]3
MYG9+LDEZ122_!&<8I7MU;?S;;?XL_H6_X,</^1 _:0_["'A__P!%ZC7[S5_/
MS_P93> /^$V\"?M#M_;7B#2?L]_H(QIMY]G$N8]0^]P<XQQ]37[D_P#"A_\
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MX+_A0_\ U.?CW_P;_P#V%'_"A_\ J<_'O_@W_P#L*D#O:*X+_A0__4Y^/?\
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M5@&!X(!!%(#'_:D_Y(3KO_;O_P"E$5?37P0TS6O^"2/P6\(?M8?LRM<?%?\
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M^0C_ .B(<L-IR?>OV/\ ^%#_ /4Y^/?_  ;_ /V% '>T5P7_  H?_J<_'O\
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M2-+6.[N;"(X^RB<&..:U:-'MY++RCA$C@M@#\L:_IF_X,I/^4?OQ,_['IO\
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MM?-61I%$?V;3;>"Z73I_BY_Q47_";?\ ,4_X23_A(- _Y_\ ^W/(_P"%A?\
M$M_YB']H>3C_ )!__$^\C'_(MZ7CY*_PA_:(_P"%;?\ !1WXI7'DKK%JW@^U
MGUG6]0UD0:'X5T>Q\:>-A?7E]J+W=]'"+>$&.*U\U9&D41_9M-MX+I=. /H?
M_AN?'_'SX7_L'=_Q4$__  D&I?V3_P (UX03_6>(=<\V(?V5YODWOV6REW7$
MWDKYHM?*U+^S?QLTWQ-;^-/B-\5-8LX]0AM-6^)OB^\@CO[">PND237[YU$M
MO.B30R $;HY421#E656! _9/_AN?'_'SX7_L'=_Q4$__  D&I?V3_P (UX03
M_6>(=<\V(?V5YODWOV6REW7$WDKYHM?*U+^S?QLTSQ-;^-/B-\5-8LX]0AM-
M6^)OB^\@CO[">PND237[YU$MO.B30R $!HY421#E656!  /*O^"AFW_AC[Q=
MYG^K_P!"W?3[;;YKV+2?M']E6O\ PQ%_RC5\I/\ AHCI]_ _X2?_ )"__$[_
M .0!]B_Y!W'_ #[_ +_?7C?_  4.56_8]\7B3(C_ -"W8]/MMOFO9-)^T?V5
M:_\ #$7_ "C5\I/^&B.GW\#_ (2?_D+_ /$[_P"0!]B_Y!W'_/O^_P!] 'H?
M[&/_  A/_#Q/]GC_ (8V_P"3%?\ A+KS^U_]?_R47_A']7\W_D*_\37_ )!/
MV+[G^A^G[W?7[AU^%O[*VA>"?$O[?/[/]E^QM>7VG_L*S>+;O^UY[.6>*>/X
MBC0-7,NUM5!U49TD60^3_0\$X_>[Z_97_A0__4Y^/?\ P;__ &% '>T5P7_"
MA_\ J<_'O_@W_P#L*/\ A0__ %.?CW_P;_\ V% '>UP>C?\ )SWB3_L5]*_]
M*]2I/^%#_P#4Y^/?_!O_ /85D?#/PE_PAO[17BBU_M/5]6\SPYI<OG:C<>?*
MN;G41M#8'R\9QZD^M 'JE%%% '!_M'?\D^T__L:/#O\ Z>K&N\K@_P!H[_DG
MVG_]C1X=_P#3U8UWE !17E?Q8_;4^&_P1^*>E^#/$FN7UIKVJFS 6WT2_O;3
M3_MER;6S-[=00O;V*W%P&BB:ZDB$CJP4L5.(_!O[;_PS\>QZPVFZ]>?\235[
M?1)ENM$O[-[JYN)G@@^RK-"ANX9)(Y52>W$D+>5*0Y$;D$=5==[?--)KUNTO
M5KN$M'9_U=77X)OTU/6*X/P]_P G/>,/^Q7T/_TKUBN\K@_#W_)SWC#_ +%?
M0_\ TKUB@#O**** "BBB@ K/\6?\BKJ?_7I+_P"@&M"L_P 6?\BKJ?\ UZ2_
M^@&@#\3?V1/#GB[_ ((]_LG_  O_ &IO@')??%K]F+X@>$M*U3XU_#O3;X:A
M=>&-32SBAU#Q%I#,Y DBFBE6\MF8",PNDFR&-)--]7_9W_8X\$_"3_@HE^SC
M\:/V9?B#8WG[*_QZ\2ZOKK^![+/]EZ1XA'AC64%]IT;*#:H\27,-Q:$1-!+"
MD94K'%#9^4?LB>'/%W_!'O\ 9/\ A?\ M3? .2^^+7[,7Q \):5JGQK^'>FW
MPU"Z\,:FEG%#J'B+2&9R!)%-%*MY;,P$9A=)-D,:2:;ZO^SO^QQX)^$G_!1+
M]G'XT?LR_$&QO/V5_CUXEU?77\#V6?[+TCQ"/#&LH+[3HV4&U1XDN8;BT(B:
M"6%(RI6.*&S /UKHHHH **** "OD#_@NAI'_  D'_!/'5K#[#_:?V[Q7X7M_
ML?V'[=]KWZ]8+Y?V?[%?^=NSM\O[#=[\[?LUQGRG^OZ^0/\ @NAI'_"0?\$\
M=6L/L/\ :?V[Q7X7M_L?V'[=]KWZ]8+Y?V?[%?\ G;L[?+^PW>_.W[-<9\IP
M#S_XN?\ %1?\)M_S%/\ A)/^$@T#_G__ +<\C_A87_$M_P"8A_:'DX_Y!_\
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M);S3XR ;598P\4]H5C>WEMEB(V1QP6OY(T ?T+?\&.'_ "('[2'_ &$/#_\
MZ+U&OWFK\&?^#'#_ )$#]I#_ +"'A_\ ]%ZC7[S4 %%%% 'R!_P6WTC_ (2#
M]C:QL/L/]I_;O%>F6_V/[#]N^U[V=?+^S_8K_P [=G;Y?V&[WYV_9KC/E/Y_
M\7/^*B_X3;_F*?\ "2?\)!H'_/\ _P!N>1_PL+_B6_\ ,0_M#R<?\@__ (GW
MD8_Y%O2\?)Z!_P %M](_X2#]C:QL/L/]I_;O%>F6_P!C^P_;OM>]G7R_L_V*
M_P#.W9V^7]AN]^=OV:XSY3^?_%S_ (J+_A-O^8I_PDG_  D&@?\ /_\ VYY'
M_"PO^);_ ,Q#^T/)Q_R#_P#B?>1C_D6]+Q\@!L?LRW/]K_\ !7#6-0\W[=N^
M'6OV?VSS?M6[R/'6I)Y'VCS;O/D_<\C[<WD?<^PZ7_Q['[GKX8_9EN?[7_X*
MX:QJ'F_;MWPZU^S^V>;]JW>1XZU)/(^T>;=Y\G[GD?;F\C[GV'2_^/8_<] '
M\]?A;[VN_P#8QZS_ .G.YKE_VF_^2$>(_P#KW7_T8E=1X6^]KO\ V,>L_P#I
MSN:Y?]IO_DA'B/\ Z]U_]&)0!]'?L]Z-XB_X)$? /P/^U9^SB]U\6/V4?B+X
M?L-8^,7PZTFZ%Y/X7O5MXXK[Q%HX9L(\4D<BW=JQ7RS"Z2;(8T?3>)_:OUCX
M7?\ !+[QO\&_VBO@7\1K&X_8Q^/_ (]T[Q+KW@;3K26XM-&U2S?SVU/1XMH^
MRY6![>XLW\MH741&-ECBCL>V_9[T;Q%_P2(^ ?@?]JS]G%[KXL?LH_$7P_8:
MQ\8OAUI-T+R?PO>K;QQ7WB+1PS81XI(Y%N[5BOEF%TDV0QH^F_$G_!Q%^Q]\
M._A'^SUX$^,G[-/CRUO/V:?CYK[Z_'X,L2W]D:-KJV[(]YI\9 -JLL8DAGM"
ML;P2VRQ%=D<4-H ?IMI7_!UU^PWH7@^/P]8MXLL] AMOL<>F0>#3'9I!C;Y0
MB!"!-I(V@8QQBOKS_@FC_P %/_@O_P %+?A_KES\%Y]2_LGP+-;Z7=6EWI#:
M:+-7C)A6-/N^7M1@ I^79C &,_Q-5_11_P &/7_)$?V@O^PYH_\ Z(NJ/Z_K
M[W]X'[J4444 %?,__!6/X@S>"OV2+C3[?PCHOC:X\6ZM:Z+#I^J#4#"DC;YT
MG0:=%+?>?&T"M$;-&N$E$;Q R*JGZ8KX_P#^"UFD?\)!^RQX?L/L/]I_;O%=
MO;_8_L/V[[7OM+Q?+^S_ &*_\[=G;Y?V&[WYV_9KC/E.FD]&.,FG=;GR/:_"
M+XG?#?6?&MSH7]F"'QRMWH&M1I\3O&.JW7B6[TEM<,>S4$NKK47GA70KI!9:
M+=37ZQWQ6]TY F(^B_8L^*6M?LP_MQ2>$;KP_P"'(?"_@OX<W$+ZE_PFU[?:
M)X3T2P\2W]IJ5W>ZKJ%Q>>6ENNG2>3:+*TJ-)#%-%9)'=26OJ_Q<_P"*B_X3
M;_F*?\))_P )!H'_ #__ -N>1_PL+_B6_P#,0_M#R<?\@_\ XGWD8_Y%O2\?
M)R_P^^.4GPX_X*X^*=6%O;ZM8#X=7_\ ;6NZCK:6VC^&-)LO'7B$WUW>:A)<
MWJQK;0HR1VRW!82F.-K328$N!94I-7MUW\[;7[VZ=MD+_A_GM^-M3ZG_ .&Y
M\?\ 'SX7_L'=_P 5!/\ \)!J7]D_\(UX03_6>(=<\V(?V5YODWOV6REW7$WD
MKYHM?*U+^S?Q7^#VIQZUX(^V0K<)#=ZA?S(L\#V\JJUY.0'CD"NC8/*L P/!
M ((K]J/^&Y\?\?/A?^P=W_%03_\ "0:E_9/_  C7A!/]9XAUSS8A_97F^3>_
M9;*7=<3>2OFBU\K4O[-_%?X/:G'K7@C[9"MPD-WJ%_,BSP/;RJK7DY >.0*Z
M-@\JP# \$ @BD!C_ +4G_)"==_[=_P#THBKZ:^"&F:U_P21^"WA#]K#]F5KC
MXK_LC_$G1++6OBW\.M&G%S+X7NA D=YXAT96($;0O&ZW=HQ7RC"Z2;(8T?3?
MF7]J3_DA.N_]N_\ Z415]-?!#3-:_P""2/P6\(?M8?LRM<?%?]D?XDZ)9:U\
M6_AUHTXN9?"]T($CO/$.C*Q C:%XW6[M&*^487239#&CZ: ? 7_!QG^R+\*_
MA%\.OA=\7_V;_&T5]^S[\?M2O_$5EX2L&;^Q=#U=(H8[BZL(CC[*)EQ%-:LD
M;V\MH(B B1P6WY35^K/_  <9_LB_"OX1?#KX7?%_]F_QM%??L^_'[4K_ ,16
M7A*P9O[%T/5TBACN+JPB./LHF7$4UJR1O;RV@B(")'!;?E-0!_2I_P &3'_)
ME/Q<_P"QQB_](TK]J*_%?_@R8_Y,I^+G_8XQ?^D:5^U% !1110!\>_\ !:G3
M[KQ!^S?X2TBUFUI/[8\6+;O%I4UQ'<W172]2EC11!;7<DC>=%$RHMG=DLBXM
MISB-OG+Q_P#L:_#N#_A(/[)T?4%W7>O6.C_8=<OYMU[;?\)M^[M-DU]YUXG]
MG6>^"'^VYD^S+O\ #^FX.WZ-_P""T>D_V_\ L_>"]/\ L7]I?;O%KV_V/[%]
MN^U[]%U9?*^S_8[[SMV<>7]AO-^<?9I\^4W!?%S_ (J+_A-O^8I_PDG_  D&
M@?\ /_\ VYY'_"PO^);_ ,Q#^T/)Q_R#_P#B?>1C_D6]+Q\@!Y[^R]K'AS]D
M;_@I9XZMO"6BVB>'I/!$UYKFI7>OF'0?"^G6/C'Q%!?:A>W\UY?I$8+6U2-8
M%F$CS(JO;:;%'=?8?L'_ (;GQ_Q\^%_[!W?\5!/_ ,)!J7]D_P#"->$$_P!9
MXAUSS8A_97F^3>_9;*7=<3>2OFBU\K4O[-^9?AK\?&^''_!5'QMJ AAU:S7P
M%.^M:YJ.MI;Z-X6TBR\<>)_MUY>ZA)=7J1+;0HT<=L)M_FA(S:Z7!%<K8?37
M_#<^/^/GPO\ V#N_XJ"?_A(-2_LG_A&O""?ZSQ#KGFQ#^RO-\F]^RV4NZXF\
ME?-%KY6I?V: ?C39>*+?QO\ &;XS:S:0:E;6FK?$_P 37D$6H6,UA=I')J4S
M*);>94FADVD;HI421#E756!4<#^VO.+;]F;Q)(V=L;6C''7 O(#7?67BBW\;
M_&;XS:S:0:E;6FK?$_Q->01:A8S6%VD<FI3,HEMYE2:&3:1NBE1)$.5=58%1
MP/[:\XMOV9O$DC9VQM:,<=<"\@- 'V%X(MKS_@D]X+T?]K;]E0R?%;]C;XG6
M4.N_%'X<Z')YK>%I?+6.Y\0Z)&Q'DF%HV2[LVV>3Y+1R".*-'TW\X_\ @XY_
M9(^$GPA\,?"7XN_LX^,TO_@-^T!=:IXCT[PI8,W]AZ#JD:6L=W<V$1Q]E$X,
M<<UJT:/;R67E'")'!;?HYX(MKS_@D]X+T?\ :V_94,GQ6_8V^)UE#KOQ1^'.
MAR>:WA:7RUCN?$.B1L1Y)A:-DN[-MGD^2T<@CBC1]-_./_@XY_9(^$GPA\,?
M"7XN_LX^,TO_ (#?M 76J>(].\*6#-_8>@ZI&EK'=W-A$<?91.#''-:M&CV\
MEEY1PB1P6P!^6-?TS?\ !E)_RC]^)G_8]-_Z0VU?S,U_3-_P92?\H_?B9_V/
M3?\ I#;4 ?LM1110 5\>?\%F-*_M_P"$/PWT_P"Q?VE]N\6WMO\ 8_L7V[[7
MO\+:^OE?9_L=]YV[./+^PWF_./LT^?+;[#KX\_X+,:5_;_PA^&^G_8O[2^W>
M+;VW^Q_8OMWVO?X6U]?*^S_8[[SMV<>7]AO-^<?9I\^6P!P?Q<_XJ+_A-O\
MF*?\))_PD&@?\_\ _;GD?\+"_P");_S$/[0\G'_(/_XGWD8_Y%O2\?)!\(?V
MB/\ A6W_  4<^*5QY*ZQ:MX/M9]9UO4-9$&A^%='L?&GC87UY?:B]W?1PBWA
M!CBM?-61I%$?V;3;>"Z73I_BY_Q47_";?\Q3_A)/^$@T#_G_ /[<\C_A87_$
MM_YB']H>3C_D'_\ $^\C'_(MZ7CY(/A#^T1_PK;_ (*.?%*X\E=8M6\'VL^L
MZWJ&LB#0_"NCV/C3QL+Z\OM1>[OHX1;P@QQ6OFK(TBB/[-IMO!=+IP!]#?\
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M\S_5_P"A;OI]MM\U[%I/VC^RK7_AB+_E&KY2?\-$=/OX'_"3_P#(7_XG?_(
M^Q?\@[C_ )]_W^^O'?\ @H9M_P"&/O%WF?ZO_0MWT^VV^:]BTG[1_95K_P ,
M1?\ *-7RD_X:(Z??P/\ A)_^0O\ \3O_ ) 'V+_D'<?\^_[_ 'T >A_L8_\
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M (162W\8_P#"*_VK)KBZ(NH6ZZ;'?/&(GN4MQ;^6DC1JB%D4$K&BGA5 P?\
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MVB@#R70/@AK$OC;Q!'>^+?'B:3']F_LU_P"UA^\S&?-_ASPV.H'XUB_M _L
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M%X_B+XG/=:M?7.IWDQUN+?<W-Q,\TTSGR/F=Y'=V8\DL2<DU]G44 ?#7C_\
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M[C6]5U+4XM+TGPSI4.JV<M[J-Y=2 A4BA1MD:JS22O&&,, GNK?M/^&Y\?\
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M<%_PH?\ ZG/Q[_X-_P#["C_A0_\ U.?CW_P;_P#V% '>T5P7_"A_^IS\>_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MQN'!R*?;?\$\?A;9:[%JD.BW4.IPZA%JT=XEY(L\=[%;?9(KD.#N$R6W[A9
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M (4][_\ '*/^&?=/_P"AA\>?^%/>_P#QRN\HH X/_AGW3_\ H8?'G_A3WO\
M\<H_X9]T_P#Z&'QY_P"%/>__ !RN\HH X/\ X9]T_P#Z&'QY_P"%/>__ !RC
M_AGW3_\ H8?'G_A3WO\ \<KO** .#_X9]T__ *&'QY_X4][_ /'*/^&?=/\
M^AA\>?\ A3WO_P <KO** .#_ .&?=/\ ^AA\>?\ A3WO_P <H_X9]T__ *&'
MQY_X4][_ /'*[RB@#@_^&?=/_P"AA\>?^%/>_P#QRC_AGW3_ /H8?'G_ (4]
M[_\ '*[RB@#@_P#AGW3_ /H8?'G_ (4][_\ '*/^&?=/_P"AA\>?^%/>_P#Q
MRN\HH X/_AGW3_\ H8?'G_A3WO\ \<H_X9]T_P#Z&'QY_P"%/>__ !RN\HH
MX/\ X9]T_P#Z&'QY_P"%/>__ !RC_AGW3_\ H8?'G_A3WO\ \<KO** .#_X9
M]T__ *&'QY_X4][_ /'*/^&?=/\ ^AA\>?\ A3WO_P <KO** .#_ .&?=/\
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M4][_ /'*[RB@#@_^&?=/_P"AA\>?^%/>_P#QRC_AGW3_ /H8?'G_ (4][_\
M'*[RB@#@_P#AGW3_ /H8?'G_ (4][_\ '*/^&?=/_P"AA\>?^%/>_P#QRN\H
MH X/_AGW3_\ H8?'G_A3WO\ \<H_X9]T_P#Z&'QY_P"%/>__ !RN\HH X/\
MX9]T_P#Z&'QY_P"%/>__ !RC_AGW3_\ H8?'G_A3WO\ \<KO** .#_X9]T__
M *&'QY_X4][_ /'*/^&?=/\ ^AA\>?\ A3WO_P <KO** .#_ .&?=/\ ^AA\
M>?\ A3WO_P <H_X9]T__ *&'QY_X4][_ /'*[RB@#@_^&?=/_P"AA\>?^%/>
M_P#QRC_AGW3_ /H8?'G_ (4][_\ '*[RB@#@_P#AGW3_ /H8?'G_ (4][_\
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M]_\ CE '>45P?_#/NG_]##X\_P#"GO?_ (Y1_P ,^Z?_ -##X\_\*>]_^.4
M=Y17!_\ #/NG_P#0P^//_"GO?_CE'_#/NG_]##X\_P#"GO?_ (Y0!WE%<'_P
MS[I__0P^//\ PI[W_P".4?\ #/NG_P#0P^//_"GO?_CE '>45P?_  S[I_\
MT,/CS_PI[W_XY1_PS[I__0P^//\ PI[W_P".4 =Y17!_\,^Z?_T,/CS_ ,*>
M]_\ CE'_  S[I_\ T,/CS_PI[W_XY0!WE%<'_P ,^Z?_ -##X\_\*>]_^.4?
M\,^Z?_T,/CS_ ,*>]_\ CE '>45P?_#/NG_]##X\_P#"GO?_ (Y1_P ,^Z?_
M -##X\_\*>]_^.4 =Y17!_\ #/NG_P#0P^//_"GO?_CE'_#/NG_]##X\_P#"
MGO?_ (Y0!WE%<'_PS[I__0P^//\ PI[W_P".4?\ #/NG_P#0P^//_"GO?_CE
M '>45P?_  S[I_\ T,/CS_PI[W_XY1_PS[I__0P^//\ PI[W_P".4 =Y17!_
M\,^Z?_T,/CS_ ,*>]_\ CE'_  S[I_\ T,/CS_PI[W_XY0!WE%<'_P ,^Z?_
M -##X\_\*>]_^.4?\,^Z?_T,/CS_ ,*>]_\ CE '>45P?_#/NG_]##X\_P#"
MGO?_ (Y1_P ,^Z?_ -##X\_\*>]_^.4 =Y17!_\ #/NG_P#0P^//_"GO?_CE
M'_#/NG_]##X\_P#"GO?_ (Y0!WE%<'_PS[I__0P^//\ PI[W_P".4?\ #/NG
M_P#0P^//_"GO?_CE '>45P?_  S[I_\ T,/CS_PI[W_XY1_PS[I__0P^//\
MPI[W_P".4 =Y17!_\,^Z?_T,/CS_ ,*>]_\ CE'_  S[I_\ T,/CS_PI[W_X
MY0!WE%<'_P ,^Z?_ -##X\_\*>]_^.4?\,^Z?_T,/CS_ ,*>]_\ CE '>45P
M?_#/NG_]##X\_P#"GO?_ (Y1_P ,^Z?_ -##X\_\*>]_^.4 =Y17!_\ #/NG
M_P#0P^//_"GO?_CE'_#/NG_]##X\_P#"GO?_ (Y0!WE%<'_PS[I__0P^//\
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M_8KZ5_Z5ZE2-#O**** ,'XE^ X_B3X2;2WO;K36%U:WT-S;JC2036US%<Q,
MZLI'F1+D$$$9%8/_  K#Q9_T4K7O_!7IW_QBBB@ _P"%8>+/^BE:]_X*]._^
M,4?\*P\6?]%*U[_P5Z=_\8HHH /^%8>+/^BE:]_X*]._^,4?\*P\6?\ 12M>
M_P#!7IW_ ,8HHH /^%8>+/\ HI6O?^"O3O\ XQ1_PK#Q9_T4K7O_  5Z=_\
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M3O\ XQ1_PK#Q9_T4K7O_  5Z=_\ &*** #_A6'BS_HI6O?\ @KT[_P",4?\
M"L/%G_12M>_\%>G?_&*** #_ (5AXL_Z*5KW_@KT[_XQ1_PK#Q9_T4K7O_!7
MIW_QBBB@ _X5AXL_Z*5KW_@KT[_XQ1_PK#Q9_P!%*U[_ ,%>G?\ QBBB@ _X
M5AXL_P"BE:]_X*]._P#C%'_"L/%G_12M>_\ !7IW_P 8HHH /^%8>+/^BE:]
M_P""O3O_ (Q1_P *P\6?]%*U[_P5Z=_\8HHH /\ A6'BS_HI6O?^"O3O_C%'
M_"L/%G_12M>_\%>G?_&*** #_A6'BS_HI6O?^"O3O_C%'_"L/%G_ $4K7O\
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=<P00K%%"\SJ%6%$&2T[DDY[>E%% '74444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>6
<FILENAME>iccc-20150930.xml
<DESCRIPTION>XBRL INSTANCE FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<!-- Generated using Ez-XBRL version 7.3.0.6 [11/12/2015 08:31:07 PM] -->
<!-- Based on XBRL 2.1 -->

<xbrli:xbrl xmlns:iccc="http://www.immucell.com/20150930"
 xmlns:link="http://www.xbrl.org/2003/linkbase"
 xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
 xmlns:xlink="http://www.w3.org/1999/xlink"
 xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
 xmlns:xbrli="http://www.xbrl.org/2003/instance"
 xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
 xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
 xmlns:num="http://www.xbrl.org/dtr/type/numeric"
 xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
 xmlns:country="http://xbrl.sec.gov/country/2013-01-31"
 xmlns:currency="http://xbrl.sec.gov/currency/2014-01-31"
 xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31"
 xmlns:exch="http://xbrl.sec.gov/exch/2015-01-31"
 xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31"
 xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31"
 xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31"
 xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31"
 xmlns:us-gaap="http://fasb.org/us-gaap/2015-01-31"
 xmlns:us-types="http://fasb.org/us-types/2015-01-31"
 xmlns:xl="http://www.xbrl.org/2003/XLink"
 xmlns:utr="http://www.xbrl.org/2009/utr"
>
<link:schemaRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:type="simple" xlink:href="iccc-20150930.xsd" />
<!-- Context Section  -->
<xbrli:context id="Context_3ME_01_Oct_2004T00_00_00_TO_31_Dec_2004T00_00_00_FairValueByAssetClassAxis_IndefinitelivedIntangibleAssetsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:IndefinitelivedIntangibleAssetsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2004-10-01
</xbrli:startDate>
<xbrli:endDate>
2004-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2010T00_00_00_TO_30_Sep_2010T00_00_00_DebtInstrumentAxis_MortgagesOneMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">iccc:MortgagesOneMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2010-07-01
</xbrli:startDate>
<xbrli:endDate>
2010-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_31_Dec_2009T00_00_00_TO_30_Sep_2010T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2009-12-31
</xbrli:startDate>
<xbrli:endDate>
2010-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2010T00_00_00_TO_30_Sep_2010T00_00_00_DebtInstrumentAxis_InterestRateSwapMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2010-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2010T00_00_00_TO_30_Sep_2010T00_00_00_DebtInstrumentAxis_MortgagesOneMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">iccc:MortgagesOneMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2010-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jan_2011T00_00_00_TO_31_Mar_2011T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2011-01-01
</xbrli:startDate>
<xbrli:endDate>
2011-03-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Mar_2011T00_00_00_TO_31_Mar_2011T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2011-03-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_TreasuryStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2013-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2014T00_00_00_TO_30_Sep_2014T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-07-01
</xbrli:startDate>
<xbrli:endDate>
2014-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2014T00_00_00_TO_30_Sep_2014T00_00_00_ConcentrationRiskByBenchmarkAxis_SalesRevenueNetMember_MajorCustomersAxis_ForeignCustomersMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">iccc:ForeignCustomersMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-07-01
</xbrli:startDate>
<xbrli:endDate>
2014-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2014T00_00_00_TO_30_Sep_2014T00_00_00_StatementBusinessSegmentsAxis_MwiVeterinarySupplyCompanyMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">iccc:MwiVeterinarySupplyCompanyMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-07-01
</xbrli:startDate>
<xbrli:endDate>
2014-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2014T00_00_00_TO_30_Sep_2014T00_00_00_StatementBusinessSegmentsAxis_AnimalHealthInternationalIncMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">iccc:AnimalHealthInternationalIncMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-07-01
</xbrli:startDate>
<xbrli:endDate>
2014-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2014T00_00_00_TO_30_Sep_2014T00_00_00_ConcentrationRiskByBenchmarkAxis_SalesRevenueNetMember_MajorCustomersAxis_UnitedStatesDairyAndBeefIndustriesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">iccc:UnitedStatesDairyAndBeefIndustriesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-07-01
</xbrli:startDate>
<xbrli:endDate>
2014-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_StatementEquityComponentsAxis_TreasuryStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_ConcentrationRiskByBenchmarkAxis_SalesRevenueNetMember_MajorCustomersAxis_ForeignCustomersMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">iccc:ForeignCustomersMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_StatementBusinessSegmentsAxis_MwiVeterinarySupplyCompanyMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">iccc:MwiVeterinarySupplyCompanyMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_StatementBusinessSegmentsAxis_AnimalHealthInternationalIncMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">iccc:AnimalHealthInternationalIncMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_ConcentrationRiskByBenchmarkAxis_SalesRevenueNetMember_MajorCustomersAxis_UnitedStatesDairyAndBeefIndustriesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">iccc:UnitedStatesDairyAndBeefIndustriesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00_StatementEquityComponentsAxis_TreasuryStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_IncomeTaxAuthorityAxis_StateAndLocalJurisdictionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_IncomeTaxAuthorityAxis_DomesticCountryMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_IncomeStatementLocationAxis_InvestmentIncomeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InvestmentIncomeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2014-01-01
</xbrli:startDate>
<xbrli:endDate>
2014-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_TreasuryStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementBusinessSegmentsAxis_MwiVeterinarySupplyCompanyMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">iccc:MwiVeterinarySupplyCompanyMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementBusinessSegmentsAxis_AnimalHealthInternationalIncMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">iccc:AnimalHealthInternationalIncMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_IncomeTaxAuthorityAxis_StateAndLocalJurisdictionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_IncomeTaxAuthorityAxis_DomesticCountryMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementBusinessSegmentsAxis_AnimartLlcMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">iccc:AnimartLlcMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2014-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-07-01
</xbrli:startDate>
<xbrli:endDate>
2015-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00_DebtInstrumentAxis_MortgagesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:MortgagesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-07-01
</xbrli:startDate>
<xbrli:endDate>
2015-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00_ConcentrationRiskByBenchmarkAxis_SalesRevenueNetMember_MajorCustomersAxis_ForeignCustomersMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">iccc:ForeignCustomersMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-07-01
</xbrli:startDate>
<xbrli:endDate>
2015-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementBusinessSegmentsAxis_MwiVeterinarySupplyCompanyMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">iccc:MwiVeterinarySupplyCompanyMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-07-01
</xbrli:startDate>
<xbrli:endDate>
2015-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementBusinessSegmentsAxis_AnimalHealthInternationalIncMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">iccc:AnimalHealthInternationalIncMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-07-01
</xbrli:startDate>
<xbrli:endDate>
2015-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00_ConcentrationRiskByBenchmarkAxis_SalesRevenueNetMember_MajorCustomersAxis_UnitedStatesDairyAndBeefIndustriesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">iccc:UnitedStatesDairyAndBeefIndustriesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-07-01
</xbrli:startDate>
<xbrli:endDate>
2015-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00_DebtInstrumentAxis_MortgagesTwoMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">iccc:MortgagesTwoMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-07-01
</xbrli:startDate>
<xbrli:endDate>
2015-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementEquityComponentsAxis_TreasuryStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_ConcentrationRiskByBenchmarkAxis_SalesRevenueNetMember_MajorCustomersAxis_ForeignCustomersMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">iccc:ForeignCustomersMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementBusinessSegmentsAxis_MwiVeterinarySupplyCompanyMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">iccc:MwiVeterinarySupplyCompanyMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementBusinessSegmentsAxis_AnimalHealthInternationalIncMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">iccc:AnimalHealthInternationalIncMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_ConcentrationRiskByBenchmarkAxis_SalesRevenueNetMember_MajorCustomersAxis_UnitedStatesDairyAndBeefIndustriesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">iccc:UnitedStatesDairyAndBeefIndustriesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_DebtInstrumentAxis_LineOfCreditMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_PropertyPlantAndEquipmentByTypeAxis_ManufacturingFacilityMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ManufacturingFacilityMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_PropertyPlantAndEquipmentByTypeAxis_BuildingImprovementsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingImprovementsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_PropertyPlantAndEquipmentByTypeAxis_ConstructionInProgressMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_PropertyPlantAndEquipmentByTypeAxis_LandMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_PropertyPlantAndEquipmentByTypeAxis_BuildingAdditionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">iccc:BuildingAdditionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_PropertyPlantAndEquipmentByTypeAxis_ComputerEquipmentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_PropertyPlantAndEquipmentByTypeAxis_OtherAssetsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_ConcentrationRiskByBenchmarkAxis_SalesRevenueNetMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_PropertyPlantAndEquipmentByTypeAxis_PropertyPlantAndEquipmentOtherTypesMember_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentOtherTypesMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_PropertyPlantAndEquipmentByTypeAxis_PropertyPlantAndEquipmentOtherTypesMember_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentOtherTypesMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-09-30
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00_DebtInstrumentAxis_MortgagesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:MortgagesMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00_DebtInstrumentAxis_InterestRateSwapMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementEquityComponentsAxis_TreasuryStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementBusinessSegmentsAxis_MwiVeterinarySupplyCompanyMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">iccc:MwiVeterinarySupplyCompanyMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementBusinessSegmentsAxis_AnimalHealthInternationalIncMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">iccc:AnimalHealthInternationalIncMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementBusinessSegmentsAxis_AnimartLlcMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">iccc:AnimartLlcMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00_DebtInstrumentAxis_NotesPayableToBanksMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00_DebtInstrumentAxis_MortgagesTwoMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">iccc:MortgagesTwoMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-09-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_26_Oct_2015T00_00_00_TO_28_Oct_2015T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember_LegalEntityAxis_PlasPakIncMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">iccc:PlasPakIncMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-10-26
</xbrli:startDate>
<xbrli:endDate>
2015-10-28
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_09_Nov_2015T00_00_00_TO_09_Nov_2015T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-11-09
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_3ME_01_Oct_2015T00_00_00_TO_31_Dec_2015T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember_LegalEntityAxis_PlasPakIncMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">iccc:PlasPakIncMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-10-01
</xbrli:startDate>
<xbrli:endDate>
2015-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember_LegalEntityAxis_PlasPakIncMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0000811641</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">iccc:PlasPakIncMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<!-- Unit Section  -->
<!--
I~1\FVPHexeD5678YReqi>IhkevEkirxw7<c444c555cT{h>G=45I7=G1=45518JI:1=8971GE7;I:I;F85< -->
<xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit>
<xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit>
<xbrli:unit id="USD_per_Share"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>
<xbrli:unit id="pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit>
<!-- Element Section  --><dei:EntityRegistrantName contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">IMMUCELL CORP /DE/</dei:EntityRegistrantName>
<dei:EntityCentralIndexKey contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">0000811641</dei:EntityCentralIndexKey>
<dei:CurrentFiscalYearEndDate contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">--12-31</dei:CurrentFiscalYearEndDate>
<dei:EntityFilerCategory contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">Smaller Reporting Company</dei:EntityFilerCategory>
<dei:DocumentType contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">10-Q</dei:DocumentType>
<dei:AmendmentFlag contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">false</dei:AmendmentFlag>
<dei:DocumentPeriodEndDate contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">2015-09-30</dei:DocumentPeriodEndDate>
<dei:DocumentFiscalPeriodFocus contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">Q3</dei:DocumentFiscalPeriodFocus>
<dei:DocumentFiscalYearFocus contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">2015</dei:DocumentFiscalYearFocus>
<dei:EntityCommonStockSharesOutstanding contextRef="Context_As_Of_09_Nov_2015T00_00_00_TO_09_Nov_2015T00_00_00" unitRef="shares" decimals="INF">3055034</dei:EntityCommonStockSharesOutstanding>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">2270385</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_30_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">1166211</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">850028</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">2469087</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:ShortTermInvestments contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">2489000</us-gaap:ShortTermInvestments>
<us-gaap:ShortTermInvestments contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">3720000</us-gaap:ShortTermInvestments>
<us-gaap:AccountsReceivableNetCurrent contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">1005292</us-gaap:AccountsReceivableNetCurrent>
<us-gaap:AccountsReceivableNetCurrent contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">789214</us-gaap:AccountsReceivableNetCurrent>
<us-gaap:InventoryNet contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">945755</us-gaap:InventoryNet>
<us-gaap:InventoryNet contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">864444</us-gaap:InventoryNet>
<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">148399</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">275559</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
<us-gaap:DeferredTaxAssetsNetCurrent contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">30463</us-gaap:DeferredTaxAssetsNetCurrent>
<us-gaap:DeferredTaxAssetsNetCurrent contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">69011</us-gaap:DeferredTaxAssetsNetCurrent>
<us-gaap:AssetsCurrent contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">5468937</us-gaap:AssetsCurrent>
<us-gaap:AssetsCurrent contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">8187315</us-gaap:AssetsCurrent>
<us-gaap:PropertyPlantAndEquipmentNet contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">3837647</us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:PropertyPlantAndEquipmentNet contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">4955614</us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:LongTermInvestments contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">496000</us-gaap:LongTermInvestments>
<us-gaap:LongTermInvestments contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">487000</us-gaap:LongTermInvestments>
<us-gaap:DeferredTaxAssetsNetNoncurrent contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">1230340</us-gaap:DeferredTaxAssetsNetNoncurrent>
<us-gaap:DeferredTaxAssetsNetNoncurrent contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">543602</us-gaap:DeferredTaxAssetsNetNoncurrent>
<us-gaap:OtherAssetsNoncurrent contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">18930</us-gaap:OtherAssetsNoncurrent>
<us-gaap:OtherAssetsNoncurrent contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">49615</us-gaap:OtherAssetsNoncurrent>
<us-gaap:Assets contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">11051854</us-gaap:Assets>
<us-gaap:Assets contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">14223146</us-gaap:Assets>
<us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">851677</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent>
<us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">545927</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent>
<us-gaap:LoansPayableToBankCurrent contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">150382</us-gaap:LoansPayableToBankCurrent>
<us-gaap:LoansPayableToBankCurrent contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">133959</us-gaap:LoansPayableToBankCurrent>
<us-gaap:DeferredRevenueCurrent contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">6690</us-gaap:DeferredRevenueCurrent>
<us-gaap:DeferredRevenueCurrent contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">0</us-gaap:DeferredRevenueCurrent>
<us-gaap:LiabilitiesCurrent contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">1008749</us-gaap:LiabilitiesCurrent>
<us-gaap:LiabilitiesCurrent contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">679886</us-gaap:LiabilitiesCurrent>
<us-gaap:LongTermLoansFromBank contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">745920</us-gaap:LongTermLoansFromBank>
<us-gaap:LongTermLoansFromBank contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">3126004</us-gaap:LongTermLoansFromBank>
<iccc:InterestRateSwap contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">38817</iccc:InterestRateSwap>
<iccc:InterestRateSwap contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">118773</iccc:InterestRateSwap>
<us-gaap:LiabilitiesNoncurrent contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">784737</us-gaap:LiabilitiesNoncurrent>
<us-gaap:LiabilitiesNoncurrent contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">3244777</us-gaap:LiabilitiesNoncurrent>
<us-gaap:Liabilities contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">1793486</us-gaap:Liabilities>
<us-gaap:Liabilities contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">3924663</us-gaap:Liabilities>
<us-gaap:CommonStockValue contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">326115</us-gaap:CommonStockValue>
<us-gaap:CommonStockValue contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">326115</us-gaap:CommonStockValue>
<us-gaap:AdditionalPaidInCapitalCommonStock contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">10042305</us-gaap:AdditionalPaidInCapitalCommonStock>
<us-gaap:AdditionalPaidInCapitalCommonStock contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">10144794</us-gaap:AdditionalPaidInCapitalCommonStock>
<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">-574567</us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">349865</us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:TreasuryStockValue contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">512154</us-gaap:TreasuryStockValue>
<us-gaap:TreasuryStockValue contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">450901</us-gaap:TreasuryStockValue>
<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">-23331</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">-71390</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00" unitRef="USD" decimals="0">9395869</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">326115</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">10011339</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="0">-407408</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USD" decimals="0">-514341</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="0">-19836</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_30_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">9123691</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_30_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">326115</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_30_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">10034566</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_30_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="0">-705194</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_30_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USD" decimals="0">-512153</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_30_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="0">-19643</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">9258368</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">326115</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">10042305</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="0">-574567</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USD" decimals="0">-512154</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="0">-23331</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">10298483</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">326115</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">10144794</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="0">349865</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USD" decimals="0">-450901</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="0">-71390</us-gaap:StockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">11051854</us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">14223146</us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD_per_Share" decimals="2">0.10</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD_per_Share" decimals="2">0.10</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockSharesAuthorized contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="shares" decimals="INF">8000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesAuthorized contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="shares" decimals="INF">8000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesIssued contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="shares" decimals="INF">3261148</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesIssued contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="shares" decimals="INF">3261148</us-gaap:CommonStockSharesIssued>
<us-gaap:TreasuryStockShares contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="shares" decimals="INF">234114</us-gaap:TreasuryStockShares>
<us-gaap:TreasuryStockShares contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="shares" decimals="INF">206114</us-gaap:TreasuryStockShares>
<us-gaap:SalesRevenueGoodsNet contextRef="Context_3ME_01_Jul_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">1770129</us-gaap:SalesRevenueGoodsNet>
<us-gaap:SalesRevenueGoodsNet contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">5391599</us-gaap:SalesRevenueGoodsNet>
<us-gaap:SalesRevenueGoodsNet contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">2472428</us-gaap:SalesRevenueGoodsNet>
<us-gaap:SalesRevenueGoodsNet contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">7534281</us-gaap:SalesRevenueGoodsNet>
<us-gaap:CostOfGoodsSold contextRef="Context_3ME_01_Jul_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">692233</us-gaap:CostOfGoodsSold>
<us-gaap:CostOfGoodsSold contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">2285285</us-gaap:CostOfGoodsSold>
<us-gaap:CostOfGoodsSold contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">860526</us-gaap:CostOfGoodsSold>
<us-gaap:CostOfGoodsSold contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">2940881</us-gaap:CostOfGoodsSold>
<us-gaap:GrossProfit contextRef="Context_3ME_01_Jul_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">1077896</us-gaap:GrossProfit>
<us-gaap:GrossProfit contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">3106314</us-gaap:GrossProfit>
<us-gaap:GrossProfit contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">1611902</us-gaap:GrossProfit>
<us-gaap:GrossProfit contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">4593400</us-gaap:GrossProfit>
<us-gaap:SellingAndMarketingExpense contextRef="Context_3ME_01_Jul_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">373595</us-gaap:SellingAndMarketingExpense>
<us-gaap:SellingAndMarketingExpense contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">921588</us-gaap:SellingAndMarketingExpense>
<us-gaap:SellingAndMarketingExpense contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">381740</us-gaap:SellingAndMarketingExpense>
<us-gaap:SellingAndMarketingExpense contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">1086928</us-gaap:SellingAndMarketingExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_3ME_01_Jul_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">302216</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">873866</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">301566</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">941417</us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_3ME_01_Jul_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">361232</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">1716114</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">301746</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">904170</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:OperatingExpenses contextRef="Context_3ME_01_Jul_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">1037043</us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">3511568</us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">985052</us-gaap:OperatingExpenses>
<us-gaap:OperatingExpenses contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">2932515</us-gaap:OperatingExpenses>
<us-gaap:OperatingIncomeLoss contextRef="Context_3ME_01_Jul_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">40853</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">-405254</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">626850</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">1660885</us-gaap:OperatingIncomeLoss>
<us-gaap:OtherNonoperatingExpense contextRef="Context_3ME_01_Jul_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">11246</us-gaap:OtherNonoperatingExpense>
<us-gaap:OtherNonoperatingExpense contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">38633</us-gaap:OtherNonoperatingExpense>
<us-gaap:OtherNonoperatingExpense contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">15111</us-gaap:OtherNonoperatingExpense>
<us-gaap:OtherNonoperatingExpense contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">27059</us-gaap:OtherNonoperatingExpense>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="Context_3ME_01_Jul_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">29607</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">-443887</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">611739</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">1633826</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
<us-gaap:IncomeTaxExpenseBenefit contextRef="Context_3ME_01_Jul_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">19277</us-gaap:IncomeTaxExpenseBenefit>
<us-gaap:IncomeTaxExpenseBenefit contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">-146101</us-gaap:IncomeTaxExpenseBenefit>
<us-gaap:IncomeTaxExpenseBenefit contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">260447</us-gaap:IncomeTaxExpenseBenefit>
<us-gaap:IncomeTaxExpenseBenefit contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">709394</us-gaap:IncomeTaxExpenseBenefit>
<us-gaap:NetIncomeLoss contextRef="Context_3ME_01_Jul_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">10330</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">-297786</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">0</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">0</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="0">-297786</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USD" decimals="0">0</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="0">0</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">351292</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">924432</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">0</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">0</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="0">924432</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USD" decimals="0">0</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="0">0</us-gaap:NetIncomeLoss>
<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="Context_3ME_01_Jul_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="shares" decimals="0">3027034</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="shares" decimals="0">3026990</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="shares" decimals="0">3052175</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="shares" decimals="0">3038111</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="Context_3ME_01_Jul_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="shares" decimals="0">3105832</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="shares" decimals="0">3026990</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="shares" decimals="0">3188349</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="shares" decimals="0">3162620</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
<us-gaap:EarningsPerShareBasic contextRef="Context_3ME_01_Jul_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD_per_Share" decimals="2">0.00</us-gaap:EarningsPerShareBasic>
<us-gaap:EarningsPerShareBasic contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD_per_Share" decimals="2">-0.10</us-gaap:EarningsPerShareBasic>
<us-gaap:EarningsPerShareBasic contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD_per_Share" decimals="2">0.12</us-gaap:EarningsPerShareBasic>
<us-gaap:EarningsPerShareBasic contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD_per_Share" decimals="2">0.30</us-gaap:EarningsPerShareBasic>
<us-gaap:EarningsPerShareDiluted contextRef="Context_3ME_01_Jul_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD_per_Share" decimals="2">0.00</us-gaap:EarningsPerShareDiluted>
<us-gaap:EarningsPerShareDiluted contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD_per_Share" decimals="2">-0.10</us-gaap:EarningsPerShareDiluted>
<us-gaap:EarningsPerShareDiluted contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD_per_Share" decimals="2">0.11</us-gaap:EarningsPerShareDiluted>
<us-gaap:EarningsPerShareDiluted contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD_per_Share" decimals="2">0.29</us-gaap:EarningsPerShareDiluted>
<iccc:InterestRateSwapBeforeTaxes contextRef="Context_3ME_01_Jul_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">8347</iccc:InterestRateSwapBeforeTaxes>
<iccc:InterestRateSwapBeforeTaxes contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">322</iccc:InterestRateSwapBeforeTaxes>
<iccc:InterestRateSwapBeforeTaxes contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">-81767</iccc:InterestRateSwapBeforeTaxes>
<iccc:InterestRateSwapBeforeTaxes contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">-79956</iccc:InterestRateSwapBeforeTaxes>
<iccc:IncomeTaxApplicableToInterestRateSwap contextRef="Context_3ME_01_Jul_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">-3330</iccc:IncomeTaxApplicableToInterestRateSwap>
<iccc:IncomeTaxApplicableToInterestRateSwap contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">-129</iccc:IncomeTaxApplicableToInterestRateSwap>
<iccc:IncomeTaxApplicableToInterestRateSwap contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">32620</iccc:IncomeTaxApplicableToInterestRateSwap>
<iccc:IncomeTaxApplicableToInterestRateSwap contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">31897</iccc:IncomeTaxApplicableToInterestRateSwap>
<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="Context_3ME_01_Jul_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">5017</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">193</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">-49147</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
<us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">-48059</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
<us-gaap:ComprehensiveIncomeNetOfTax contextRef="Context_3ME_01_Jul_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">15347</us-gaap:ComprehensiveIncomeNetOfTax>
<us-gaap:ComprehensiveIncomeNetOfTax contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">-297593</us-gaap:ComprehensiveIncomeNetOfTax>
<us-gaap:ComprehensiveIncomeNetOfTax contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">302145</us-gaap:ComprehensiveIncomeNetOfTax>
<us-gaap:ComprehensiveIncomeNetOfTax contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">876373</us-gaap:ComprehensiveIncomeNetOfTax>
<us-gaap:SharesOutstanding contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">3261148</us-gaap:SharesOutstanding>
<us-gaap:SharesOutstanding contextRef="Context_As_Of_31_Dec_2013T00_00_00_TO_31_Dec_2013T00_00_00_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="shares" decimals="INF">235114</us-gaap:SharesOutstanding>
<us-gaap:SharesOutstanding contextRef="Context_As_Of_30_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">3261148</us-gaap:SharesOutstanding>
<us-gaap:SharesOutstanding contextRef="Context_As_Of_30_Sep_2014T00_00_00_TO_30_Sep_2014T00_00_00_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="shares" decimals="INF">234114</us-gaap:SharesOutstanding>
<us-gaap:SharesOutstanding contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">3261148</us-gaap:SharesOutstanding>
<us-gaap:SharesOutstanding contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="shares" decimals="INF">234114</us-gaap:SharesOutstanding>
<us-gaap:SharesOutstanding contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">3261148</us-gaap:SharesOutstanding>
<us-gaap:SharesOutstanding contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="shares" decimals="INF">206114</us-gaap:SharesOutstanding>
<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">193</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="0">0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USD" decimals="0">0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="0">193</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">-48059</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="0">0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USD" decimals="0">0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
<us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="0">-48059</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">3150</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">962</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USD" decimals="0">2188</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">120210</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">58957</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USD" decimals="0">61253</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="shares" decimals="INF">-1000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="shares" decimals="INF">-28000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">25707</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">25707</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USD" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="0">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">22265</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">22265</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="0">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USD" decimals="0">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="0">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">17825</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="0">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">17825</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="0">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementEquityComponentsAxis_TreasuryStockMember" unitRef="USD" decimals="0">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="0">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:Depreciation contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">330796</us-gaap:Depreciation>
<us-gaap:Depreciation contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">378475</us-gaap:Depreciation>
<us-gaap:AdjustmentForAmortization contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">2158</us-gaap:AdjustmentForAmortization>
<us-gaap:AdjustmentForAmortization contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00_DebtInstrumentAxis_MortgagesMember" unitRef="USD" decimals="0">2500000</us-gaap:AdjustmentForAmortization>
<us-gaap:AdjustmentForAmortization contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">2074</us-gaap:AdjustmentForAmortization>
<us-gaap:DeferredIncomeTaxesAndTaxCredits contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">-146401</us-gaap:DeferredIncomeTaxesAndTaxCredits>
<us-gaap:DeferredIncomeTaxesAndTaxCredits contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">680087</us-gaap:DeferredIncomeTaxesAndTaxCredits>
<us-gaap:ShareBasedCompensation contextRef="Context_3ME_01_Jul_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">4974</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">22265</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">6342</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">17825</us-gaap:ShareBasedCompensation>
<us-gaap:GainLossOnDispositionOfAssets contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">-4519</us-gaap:GainLossOnDispositionOfAssets>
<us-gaap:GainLossOnDispositionOfAssets contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">3984</us-gaap:GainLossOnDispositionOfAssets>
<us-gaap:IncreaseDecreaseInReceivables contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">-67846</us-gaap:IncreaseDecreaseInReceivables>
<us-gaap:IncreaseDecreaseInReceivables contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">-216078</us-gaap:IncreaseDecreaseInReceivables>
<us-gaap:IncreaseDecreaseInInventories contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">-167062</us-gaap:IncreaseDecreaseInInventories>
<us-gaap:IncreaseDecreaseInInventories contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">-81311</us-gaap:IncreaseDecreaseInInventories>
<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">185676</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">127160</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
<us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">78992</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
<us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">-92332</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
<us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">6690</us-gaap:IncreaseDecreaseInDeferredRevenue>
<us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">-6690</us-gaap:IncreaseDecreaseInDeferredRevenue>
<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">50465</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">2070116</us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">520142</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">1772091</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
<us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">2489000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments>
<us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">2489000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments>
<us-gaap:PaymentsToAcquireShortTermInvestments contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">2985000</us-gaap:PaymentsToAcquireShortTermInvestments>
<us-gaap:PaymentsToAcquireShortTermInvestments contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">3711000</us-gaap:PaymentsToAcquireShortTermInvestments>
<us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
<us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">66215</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">-1016142</us-gaap:NetCashProvidedByUsedInInvestingActivities>
<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">-2927876</us-gaap:NetCashProvidedByUsedInInvestingActivities>
<us-gaap:ProceedsFromIssuanceOfDebt contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">0</us-gaap:ProceedsFromIssuanceOfDebt>
<us-gaap:ProceedsFromIssuanceOfDebt contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">2500000</us-gaap:ProceedsFromIssuanceOfDebt>
<us-gaap:RepaymentsOfDebt contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">141647</us-gaap:RepaymentsOfDebt>
<us-gaap:RepaymentsOfDebt contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">136339</us-gaap:RepaymentsOfDebt>
<us-gaap:PaymentsOfDebtIssuanceCosts contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">0</us-gaap:PaymentsOfDebtIssuanceCosts>
<us-gaap:PaymentsOfDebtIssuanceCosts contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">32759</us-gaap:PaymentsOfDebtIssuanceCosts>
<us-gaap:ProceedsFromStockOptionsExercised contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">3150</us-gaap:ProceedsFromStockOptionsExercised>
<us-gaap:ProceedsFromStockOptionsExercised contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">120210</us-gaap:ProceedsFromStockOptionsExercised>
<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">-138497</us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">2476819</us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">-1104174</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">1619059</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
<us-gaap:IncomeTaxesPaid contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">1752</us-gaap:IncomeTaxesPaid>
<us-gaap:IncomeTaxesPaid contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">3600</us-gaap:IncomeTaxesPaid>
<us-gaap:InterestPaid contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">44771</us-gaap:InterestPaid>
<us-gaap:InterestPaid contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">38324</us-gaap:InterestPaid>
<us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">84031</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
<us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">-213418</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
<us-gaap:IncreaseDecreaseInFairValueOfInterestRateFairValueHedgingInstruments1 contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">-193</us-gaap:IncreaseDecreaseInFairValueOfInterestRateFairValueHedgingInstruments1>
<us-gaap:IncreaseDecreaseInFairValueOfInterestRateFairValueHedgingInstruments1 contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">48059</us-gaap:IncreaseDecreaseInFairValueOfInterestRateFairValueHedgingInstruments1>
<us-gaap:NatureOfOperations contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="padding-left: 0pt; text-indent: 0pt; width: 0.5in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;1.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-left: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;BUSINESS OPERATIONS&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;ImmuCell Corporation (the Company) is a growing animal health company whose purpose is to create scientifically-proven and practical products that result in a measurable economic impact on animal health and productivity in the dairy and beef industries. The Company was originally incorporated in Maine in 1982 and reincorporated in Delaware in 1987, in conjunction with its initial public offering of common stock. We market products that provide immediate immunity to newborn dairy and beef cattle. We are developing product line extensions of our existing products and are in the late stages of developing a new product that addresses mastitis, the most significant cause of economic loss to the dairy industry. The Company is subject to certain risks associated with its stage of development including dependence on key individuals, competition from other larger companies, the successful sale of existing products and the development and acquisition of additional commercially viable products with appropriate regulatory approvals, where applicable. These and other risks to our company are further detailed under &lt;b&gt;PART II: OTHER INFORMATION, ITEM 1A &amp;#8211; RISK FACTORS&lt;/b&gt;.&lt;/font&gt;&lt;/p&gt;</us-gaap:NatureOfOperations>
<us-gaap:SignificantAccountingPoliciesTextBlock contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="padding-left: 0pt; text-indent: 0pt; width: 0.5in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;2.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-left: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="text-align: justify; padding-left: 0pt; text-indent: 0pt; width: 0.5in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;(a)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify; padding-left: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Basis of presentation&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;We have prepared the accompanying unaudited financial statements reflecting all adjustments, all of which are of a normal recurring nature, that are, in our opinion, necessary in order to ensure that the financial statements are not misleading. We follow accounting standards set by the Financial Accounting Standards Board (FASB). The FASB sets generally accepted accounting principles (GAAP) that we follow to ensure we consistently report our financial condition, results of operations, earnings per share and cash flows. References to GAAP in these footnotes are to the FASB&lt;i&gt;&amp;#160;Accounting Standards Codification&lt;/i&gt;&amp;#8482; (Codification). Certain prior year accounts have been reclassified to conform with the 2015 financial statement presentation. Certain information and footnote disclosures normally included in the annual financial statements have been condensed or omitted. Accordingly, we believe that although the disclosures are adequate to ensure that the information presented is not misleading, these financial statements should be read in conjunction with the financial statements for the year ended December 31, 2014 and the notes thereto, contained in our Annual Report on Form 10-K as filed with the Securities and Exchange Commission (SEC).&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="padding-left: 0pt; text-indent: 0pt; width: 0.5in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;(b)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-left: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Cash, Cash Equivalents, Short-Term Investments and Long-Term Investments&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color:
 #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;We consider all highly liquid investment instruments that mature within three months of their purchase dates to be cash equivalents. Cash equivalents are principally invested in securities backed by the U.S. government. Certain cash balances in excess of Federal Deposit Insurance Corporation (FDIC) limits of $250,000 per financial institution per depositor are maintained in money market accounts at financial institutions that are secured, in part, by the Securities Investor Protection Corporation. Amounts in excess of these FDIC limits per bank that are not invested in securities backed by the U.S. government aggregated $1,968,787 and $566,637 as of September 30, 2015 and December 31, 2014, respectively. Short-term investments are classified as held to maturity and are comprised principally of certificates of deposit that mature in more than three months from their purchase dates and not more than twelve months from the balance sheet date. Long-term investments are classified as held to maturity and are comprised principally of certificates of deposit that mature in more than twelve months from the balance sheet date. Short-term and long-term investments are held at different financial institutions that are insured by the FDIC, within the FDIC limits per financial institution. See Note 3.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="text-align: justify; padding-left: 0pt; text-indent: 0pt; width: 0.5in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;(c)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify; padding-left: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Inventory&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;Inventory includes raw materials, work-in-process and finished goods and is recorded at the lower of cost, on the first-in, first-out method, or market (net realizable value). Work-in-process and finished goods inventories include materials, labor and manufacturing overhead. See Note 4.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="padding-left: 0pt; text-indent: 0pt; width: 0.5in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;(d)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-left: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Trade Receivables&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif;
 font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;Trade receivables are carried at the original invoice amount less an estimate made for doubtful collection. Management determines the allowance for doubtful accounts on a monthly basis by identifying troubled accounts and by using historical experience applied to an aging of accounts. Trade receivables are written off when deemed uncollectible. Recoveries of trade receivables previously written off are recorded as income when received. A trade receivable is considered to be past due if any portion of the receivable balance is outstanding for more than 30 days. Interest is charged on past due trade receivables. See Note 5.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="padding-left: 0pt; text-indent: 0pt; width: 0.5in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;(e)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-left: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Property, Plant and Equipment&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;We depreciate property, plant and equipment on the straight-line method by charges to operations in amounts estimated to expense the cost of the assets from the date they are first put into service to the end of the estimated useful lives of the assets. The cost of our building (which was acquired in 1993) and the 2001 and 2007 additions thereto are being depreciated through 2023. We are depreciating the building addition that was completed during the first quarter of 2015 over twenty-five years. Related building improvements are depreciated over ten year periods. Large and durable fixed assets are depreciated over their useful lives that are generally estimated to be five to ten years. Other fixed assets and computer equipment are depreciated over their useful lives that are generally estimated to be five and three years, respectively. See Note 7.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="padding-left: 0pt; text-indent: 0pt; width: 0.5in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;(f)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-left: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Intangible Assets&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal;
 font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;We amortize intangible assets on the straight-line method by charges to operations in amounts estimated to expense the cost of the assets from the date they are first put into service to the end of the estimated useful lives of the assets. In connection with certain credit facilities entered into during the third quarters of 2010 and 2015, we incurred debt issue costs of $26,489 and $32,759, respectively, which costs are being amortized to other expenses, net over the terms of the credit facilities. See Notes 6 and 9.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;We continually assess the realizability of these assets in accordance with the impairment provisions of Codification Topic 360,&amp;#160;&lt;i&gt;Accounting for the Impairment or Disposal of Long-Lived Assets&lt;/i&gt;. If an impairment review is triggered, we evaluate the carrying value of long-lived assets by determining if impairment exists based on estimated undiscounted future cash flows over the remaining useful life of the assets and comparing that value to the carrying value of the assets. If the carrying value of the asset is greater than the estimated future cash flows, the asset is written down to its estimated fair value. The cash flow estimates that are used contain our best estimates, using appropriate and customary assumptions and projections at the time. We also review the estimated useful life of intangible assets at the end of each reporting period, making any necessary adjustments.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="padding-left: 0pt; text-indent: 0pt; width: 0.5in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;(g)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-left: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Disclosure of Fair Value of Financial Instruments and Concentration of Risk&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;Financial instruments consist mainly of cash, cash equivalents, short-term investments, long-term investments, accounts receivable, accounts payable, bank debt and interest rate swaps. Financial instruments that potentially subject the Company to concentrations of credit risk are principally cash, cash equivalents, short-term investments, long-term investments and accounts receivable. We make short-term and long-term investments in financial instruments that are insured by the FDIC. We account for fair value measurements in accordance with Codification Topic 820,&amp;#160;&lt;i&gt;Fair Value Measurements and Disclosures&lt;/i&gt;, which defines fair value, establishes a framework for measuring fair value and requires additional disclosures about fair value measurements. The estimated fair value of cash, cash equivalents, short-term investments, long-term investments, accounts receivable and accounts payable approximate their carrying value due to their short maturities. The estimated fair value of bank debt approximates its carrying value because the interest rates are variable. Interest rate swaps are carried at fair value. See Note 9.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"&gt;&lt;font style="font-style: normal; font-variant:
 normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;Concentration of credit risk with respect to accounts receivable is principally limited to certain customers to whom we make substantial sales. To reduce risk, we routinely assess the financial strength of our customers and, as a consequence, believe that our accounts receivable credit risk exposure is limited. We maintain an allowance for potential credit losses, but historically we have not experienced significant credit losses related to an individual customer or groups of customers in any particular industry or geographic area.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;We believe that supplies and raw materials for the production of our products are available from more than one vendor or farm. Our policy is to maintain more than one source of supply for the components used in our products. However, there is a risk that we could have difficulty in efficiently acquiring essential supplies.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="padding-left: 0pt; text-indent: 0pt; width: 0.5in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;(h)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-left: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Interest Rate Swap Agreements&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;All derivatives are recognized on the balance sheet at their fair value. We entered into interest rate swap agreements in 2010 and 2015. On the dates the agreements were entered into, we designated the derivatives as hedges of the variability of cash flows to be paid related to our long-term debt. The agreements have been determined to be highly effective in hedging the variability of identified cash flows, so changes in the fair market value of the interest rate swap agreements are recorded as comprehensive income (loss), until earnings are affected by the variability of cash flows (e.g. when periodic settlements on a variable-rate asset or liability are recorded in earnings). We formally documented the relationship between the interest rate swap agreements and the related hedged items. We also formally assess, both at the interest rate swap agreements&amp;#8217; inception and on an ongoing basis, whether the agreements are highly effective in offsetting changes in cash flow of hedged items. See Note 9.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal;
 font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="padding-left: 0pt; text-indent: 0pt; width: 0.5in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;(i)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-left: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Revenue Recognition&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;We recognize revenue in accordance with Staff Accounting Bulletin (SAB) No. 104, &amp;#8220;Revenue Recognition&amp;#8221;. SAB No. 104 requires that four criteria are met before revenue is recognized. These include i) persuasive evidence that an arrangement exists, ii) delivery has occurred or services have been rendered, iii) the seller&amp;#8217;s price is fixed and determinable and iv) collectability is reasonably assured. We recognize revenue at the time of shipment (including to distributors) for substantially all products, as title and risk of loss pass to the customer on delivery to the common carrier after concluding that collectability is reasonably assured. We recognize service revenue at the time the service is performed.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.5in; padding-left: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;(j)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-left: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Expense Recognition&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;Advertising costs are expensed when incurred, which is generally during the month in which the advertisement is published. Advertising expenses amounted to $27,545 and $15,844 during the three-month periods ended September 30, 2015 and 2014, respectively, and $72,539 and $42,915 during the nine-month periods ended September 30, 2015 and 2014, respectively. All product development expenses are expensed as incurred, as are all related patent costs.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.5in; padding-left: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-style: normal; font-variant: normal;
 font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;(k)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-left: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Income Taxes&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;We account for income taxes in accordance with Codification Topic 740,&amp;#160;&lt;i&gt;Income Taxes&lt;/i&gt;,&lt;i&gt;&amp;#160;&lt;/i&gt;which requires that we recognize a current tax liability or asset for current taxes payable or refundable and a deferred tax liability or asset for the estimated future tax effects of temporary differences and carryforwards to the extent they are realizable. We believe it is more likely than not that the deferred tax assets will be realized through future taxable income and future tax effects of temporary differences between book income and taxable income. Accordingly, we have not established a valuation allowance for the deferred tax assets. Codification Topic 740-10 clarifies the accounting for income taxes by prescribing a minimum recognition threshold that a tax position must meet before being recognized in the financial statements. In the ordinary course of business, there are transactions and calculations where the ultimate tax outcome is uncertain. In addition, we are subject to periodic audits and examinations by the Internal Revenue Service and other taxing authorities. We have evaluated the positions taken on our filed tax returns. We have concluded that no uncertain tax positions exist as of September 30, 2015. Although we believe that our estimates are reasonable, actual results could differ from these estimates. See Note 11.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.5in; padding-left: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;(l)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-left: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Stock-Based Compensation&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;We account for stock-based compensation in accordance with Codification Topic 718,&amp;#160;&lt;i&gt;Compensation-Stock Compensation&lt;/i&gt;, which generally requires us to recognize non-cash compensation expense for stock-based payments using the fair-value-based method. The fair value of each stock option grant has been estimated on the date of grant using the Black-Scholes option pricing model. Accordingly, we recorded compensation expense pertaining to stock-based compensation of $6,342 and $4,974 during the three-month periods ended September 30, 2015 and 2014, respectively, and $17,825 and $22,265 during the nine-month periods ended September 30, 2015 and 2014, respectively, which resulted in a decrease to income before income taxes of less than $0.01 per share during each of the periods reported. Codification Topic 718 requires us to reflect gross tax savings resulting from tax deductions in excess of expense reflected in our financial statements as a financing cash flow.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin:
 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.5in; padding-left: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;(m)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-left: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Net Income (Loss) Per Common Share&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;Net Income (Loss) per common share has been computed in accordance with Codification Topic 260-10,&amp;#160;&lt;i&gt;Earnings Per Share.&lt;/i&gt;&amp;#160;The basic Net Income per share has been computed by dividing Net Income by the weighted average number of common shares outstanding during this period. Diluted Net Income per share has been computed by dividing Net Income by the weighted average number of shares outstanding during the period plus all outstanding stock options with an exercise price that is less than the average market price of the common stock during the period less the number of shares that could have been repurchased at this average market price with the proceeds from the hypothetical stock option exercises.&lt;i&gt;&amp;#160;&lt;/i&gt;The Net (Loss) per common share in 2014 has been computed by dividing the Net (Loss) by the weighted average number of common shares outstanding during the period, without giving consideration to outstanding stock options because the impact would be anti-dilutive.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6"&gt;&lt;p style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin: 0px; text-align: center;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Three-Month Period&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Ended September 30,&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6"&gt;&lt;p style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin: 0px; text-align: center;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Nine-Month Period&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Ended September 30,&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2015&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2014&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2015&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td
 style="font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2014&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 814.078px; padding-left: 0.7pt;"&gt;Weighted average number of shares outstanding&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;3,052,175&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;3,027,034&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;3,038,111&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;3,026,990&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.7pt;"&gt;Effect of dilutive stock options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;"&gt;136,174&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;"&gt;78,798&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;"&gt;124,509&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;"&gt;0&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding-bottom: 4pt; padding-left: 0.7pt;"&gt;Diluted number of shares outstanding&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;"&gt;3,188,349&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;"&gt;3,105,832&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;"&gt;3,162,620&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;"&gt;3,026,990&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-left: 0.7pt;"&gt;Stock options outstanding as of September 30th not included in the calculation because the effect would be anti-dilutive&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;"&gt;0&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;"&gt;85,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;"&gt;3,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;"&gt;251,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align:
 top;"&gt;&lt;td style="width: 0.5in; padding-left: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;(n)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-left: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Use of Estimates&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual amounts could differ from those estimates.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.5in; padding-left: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;(o)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-left: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;New Accounting Pronouncement&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;In May 2014, the FASB issued Accounting Standards Update No. 2014-09,&amp;#160;&lt;i&gt;Revenue from Contracts with Customers&amp;#160;&lt;/i&gt;(ASU 2014-09), which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. ASU 2014-09 will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. ASU 2014-09 was initially effective for the Company on January 1, 2017. Early application was not permitted. In July 2015, the FASB approved a one-year deferral in the effective date to January 1, 2018, with the option of applying the standard on the original effective date. ASU 2014-09 permits the use of either the retrospective or cumulative effect transition method. We have evaluated the effect that ASU 2014-09 would have on our financial statements and related disclosures. We expect that ASU 2014-09 will have no significant effect on our ongoing financial reporting, but we continue to evaluate this pending accounting standard.&lt;/font&gt;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
<us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">&lt;div&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.5in; text-indent: 0pt; padding-left: 0pt;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"&gt;&lt;b&gt;3.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-left: 0pt;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"&gt;&lt;b&gt;CASH, CASH EQUIVALENTS, SHORT-TERM INVESTMENTS AND LONG-TERM INVESTMENTS&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"&gt;Cash, cash equivalents, short-term investments and long-term investments consisted of the following:&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"&gt;&lt;b&gt;As of&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"&gt;&lt;b&gt;September&amp;#160;30, 2015&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"&gt;&lt;b&gt;As of&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"&gt;&lt;b&gt;December&amp;#160;31, 2014&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"&gt;&lt;b&gt;Increase&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"&gt;&lt;b&gt;(Decrease)&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1003px; text-align: left; padding-left: 0pt;"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 16px; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; padding-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right; padding-left: 0pt;"&gt;2,469,087&lt;/td&gt;&lt;td style="width: 16px; text-align: left; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; padding-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right; padding-left: 0pt;"&gt;850,028&lt;/td&gt;&lt;td style="width: 15px; text-align: left; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; padding-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right; padding-left: 0pt;"&gt;1,619,059&lt;/td&gt;&lt;td style="width: 15px; text-align: left; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;Short-term investments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;3,720,000&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style:
 solid;"&gt;2,489,000&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;1,231,000&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding-left: 0pt;"&gt;&amp;#160;&amp;#160;&amp;#160;Subtotal&lt;/td&gt;&lt;td style="padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0pt;"&gt;6,189,087&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0pt;"&gt;3,339,028&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0pt;"&gt;2,850,059&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;Long-term investments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;487,000&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;496,000&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(9,000&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding-bottom: 4pt; padding-left: 0pt;"&gt;&amp;#160;&amp;#160;&amp;#160;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;6,676,087&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;3,835,028&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;2,841,059&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:CashCashEquivalentsAndShortTermInvestmentsTextBlock>
<us-gaap:InventoryDisclosureTextBlock contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">&lt;div&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.5in;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"&gt;&lt;b&gt;4.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"&gt;&lt;b&gt;INVENTORY&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"&gt;Inventory consisted of the following:&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: justify; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"&gt;&lt;b&gt;As of&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"&gt;&lt;b&gt;September&amp;#160;30, 2015&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"&gt;&lt;b&gt;As of&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"&gt;&lt;b&gt;December&amp;#160;31, 2014&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"&gt;&lt;b&gt;Increase&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"&gt;&lt;b&gt;(Decrease)&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1003px; text-align: justify; text-indent: 0pt; padding-left: 0pt;"&gt;Raw materials&lt;/td&gt;&lt;td style="width: 16px; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;337,538&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;306,444&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;31,094&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: justify; text-indent: 0pt; padding-left: 0pt;"&gt;Work-in-process&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;468,059&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;355,745&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left:
 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;112,314&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;Finished goods&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;58,847&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;283,566&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(224,719&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-indent: 0pt; padding-bottom: 4pt; padding-left: 10pt;"&gt;Total&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;864,444&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;945,755&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;(81,311&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
<us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">&lt;div&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.5in; text-align: justify;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"&gt;&lt;b&gt;5.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"&gt;&lt;b&gt;ACCOUNTS RECEIVABLE&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"&gt;Accounts receivable consisted of the following:&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"&gt;&lt;b&gt;As of&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"&gt;&lt;b&gt;September&amp;#160;30, 2015&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"&gt;&lt;b&gt;As of&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"&gt;&lt;b&gt;December&amp;#160;31, 2014&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"&gt;&lt;b&gt;(Decrease)&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"&gt;&lt;b&gt;Increase&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1003px; text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;Trade accounts receivable, gross&lt;/td&gt;&lt;td style="width: 16px; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;783,547&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;1,004,990&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;(221,443&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;Accumulated allowance for bad debt and product returns&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style:
 solid;"&gt;(16,958&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(16,194&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(764&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Trade accounts receivable, net&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;766,589&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;988,796&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;(222,207&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;Other receivables&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;22,625&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;16,496&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;6,129&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Accounts receivable, net&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;789,214&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;1,005,292&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;(216,078&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock>
<iccc:PrepaidExpensesAndOtherAssetsTextBlock contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">&lt;div&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.5in; text-align: justify;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;6.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;PREPAID EXPENSES AND OTHER ASSETS&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;Prepaid expenses and other assets consisted of the following:&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;As of&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;September&amp;#160;30, 2015&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0pt; padding-left: 0pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;As of&lt;br /&gt;December&amp;#160;31, 2014&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;Increase&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;(Decrease)&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1003px; text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;Prepaid expenses and other assets&lt;/td&gt;&lt;td style="width: 16px; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;234,628&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;133,119&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;101,509&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;Security deposits&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;40,931&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;15,280&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style:
 solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;25,651&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Current subtotal&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;275,559&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;148,399&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;127,160&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;Debt issue costs&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;59,248&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;26,489&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;32,759&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;Accumulated amortization of debt issue costs&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;(18,553&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;(16,479&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;(2,074&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;Security deposits&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;8,920&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;8,920&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;0&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left:
 0pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Long-term subtotal&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;49,615&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;18,930&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;30,685&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Total&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;325,174&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;167,329&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;157,845&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;&lt;/div&gt;</iccc:PrepaidExpensesAndOtherAssetsTextBlock>
<us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="text-align: justify; width: 0.5in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;7.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;PROPERTY, PLANT AND EQUIPMENT&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;Property, plant and equipment consisted of the following, at cost:&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding-left: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; padding-left: 0pt; text-indent: 0pt;" colspan="2"&gt;&lt;p style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin: 0px; text-align: center;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;As of&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin: 0px; text-align: center;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;September&amp;#160;30, 2015&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; padding-left: 0pt; text-indent: 0pt;" colspan="2"&gt;&lt;p style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin: 0px; text-align: center;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;As of&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin: 0px; text-align: center;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;December&amp;#160;31, 2014&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; padding-left: 0pt; text-indent: 0pt;" colspan="2"&gt;&lt;p style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin: 0px; text-align: center;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Increase&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin: 0px; text-align: center;"&gt;&lt;font style="font-style:
 normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;(Decrease)&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1003px; text-align: left; padding-left: 0pt; text-indent: 0pt;"&gt;Laboratory and manufacturing equipment&lt;/td&gt;&lt;td style="width: 16px; padding-left: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; padding-left: 0pt; text-indent: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right; padding-left: 0pt; text-indent: 0pt;"&gt;3,602,690&lt;/td&gt;&lt;td style="width: 16px; text-align: left; padding-left: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; padding-left: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; padding-left: 0pt; text-indent: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right; padding-left: 0pt; text-indent: 0pt;"&gt;3,522,465&lt;/td&gt;&lt;td style="width: 15px; text-align: left; padding-left: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; padding-left: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; padding-left: 0pt; text-indent: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right; padding-left: 0pt; text-indent: 0pt;"&gt;80,225&lt;/td&gt;&lt;td style="width: 15px; text-align: left; padding-left: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: justify; padding-left: 0pt; text-indent: 0pt;"&gt;Building and improvements&lt;/td&gt;&lt;td style="padding-left: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0pt; text-indent: 0pt;"&gt;4,579,852&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0pt; text-indent: 0pt;"&gt;2,969,891&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0pt; text-indent: 0pt;"&gt;1,609,961&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; padding-left: 0pt; text-indent: 0pt;"&gt;Office furniture and equipment&lt;/td&gt;&lt;td style="padding-left: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0pt; text-indent: 0pt;"&gt;569,567&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0pt; text-indent: 0pt;"&gt;470,607&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0pt; text-indent: 0pt;"&gt;98,960&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-left: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;Construction in progress&lt;sup&gt;(1)&lt;/sup&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-left: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0pt; text-indent: 0pt;"&gt;738,282&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0pt; text-indent: 0pt;"&gt;1,270,672&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0pt; text-indent: 0pt;"&gt;(532,390&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt; text-indent: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt;"&gt;Land&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left; padding-left: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right; padding-left: 0pt; text-indent: 0pt;"&gt;72,807&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left; padding-left: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right; padding-left: 0pt; text-indent: 0pt;"&gt;50,000&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left; padding-left: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right; padding-left: 0pt; text-indent: 0pt;"&gt;22,807&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-left: 0pt; text-indent: 0pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Property, plant and equipment, gross&lt;/td&gt;&lt;td style="padding-left: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0pt; text-indent: 0pt;"&gt;9,563,198&lt;/td&gt;&lt;td style="text-align:
 left; padding-left: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0pt; text-indent: 0pt;"&gt;8,283,635&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0pt; text-indent: 0pt;"&gt;1,279,563&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt;"&gt;Accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left; padding-left: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right; padding-left: 0pt; text-indent: 0pt;"&gt;(4,607,584&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt; text-indent: 0pt;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left; padding-left: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right; padding-left: 0pt; text-indent: 0pt;"&gt;(4,445,988&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt; text-indent: 0pt;"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left; padding-left: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right; padding-left: 0pt; text-indent: 0pt;"&gt;(161,596&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt; text-indent: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Property, plant and equipment, net&lt;/td&gt;&lt;td style="padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left; padding-left: 0pt; text-indent: 0pt;"&gt;$&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right; padding-left: 0pt; text-indent: 0pt;"&gt;4,955,614&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left; padding-left: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left; padding-left: 0pt; text-indent: 0pt;"&gt;$&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right; padding-left: 0pt; text-indent: 0pt;"&gt;3,837,647&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left; padding-left: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left; padding-left: 0pt; text-indent: 0pt;"&gt;$&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right; padding-left: 0pt; text-indent: 0pt;"&gt;1,117,967&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left; padding-left: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;sup&gt;&amp;#160;&lt;/sup&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;sup&gt;(1)&lt;/sup&gt;As of December 31, 2014, construction in progress consisted of a building addition that was completed during the first quarter of 2015. As of September 30, 2015, construction in progress consisted principally of partial payments towards new manufacturing equipment.&lt;/font&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
<us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">&lt;div&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.5in; text-align: justify; text-indent: 0pt; padding-left: 0pt;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"&gt;&lt;b&gt;8.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify; text-indent: 0pt; padding-left: 0pt;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"&gt;&lt;b&gt;ACCOUNTS PAYABLE AND ACCRUED EXPENSES&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"&gt;Accounts payable and accrued expenses consisted of the following:&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"&gt;&lt;b&gt;As of&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"&gt;&lt;b&gt;September&amp;#160;30, 2015&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"&gt;&lt;b&gt;As of&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"&gt;&lt;b&gt;December&amp;#160;31, 2014&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"&gt;&lt;b&gt;(Decrease)&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"&gt;&lt;b&gt;Increase&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1003px; text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;Accounts payable &amp;#8211; capital&lt;/td&gt;&lt;td style="width: 16px; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;37,965&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;251,383&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;(213,418&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;Accounts payable &amp;#8211; trade&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;178,542&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-left:
 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;204,810&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;(26,268&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;Accrued payroll&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;134,466&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;145,176&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;(10,710&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;Accrued clinical studies&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;68,428&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;131,945&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;(63,517&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;Accrued professional fees&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;55,462&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;42,250&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;13,212&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;Accrued other&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;71,064&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;76,113&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(5,049&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;"&gt;&amp;#160;&amp;#160;&amp;#160;Total&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;545,927&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;851,677&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;(305,750&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt;
 padding-bottom: 4pt; padding-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
<us-gaap:DebtDisclosureTextBlock contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">&lt;div&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.5in; padding-right: 0pt; padding-left: 0pt;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;9.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-right: 0pt; padding-left: 0pt;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;BANK DEBT&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;We have in place certain credit facilities with TD Bank, N.A. (a wholly owned subsidiary of TD Financial Group, which is a multinational bank with approximately $944 billion in assets and over 22 million clients worldwide) which are secured by substantially all of our assets. Proceeds from the $1,000,000 mortgage note were received during the third quarter of 2010. Based on a 15-year amortization schedule, a balloon principal payment of approximately $451,885 will be due during the third quarter of 2020. Proceeds from the $2,500,000 mortgage note were received during the third quarter of 2015. Based on a 20-year amortization schedule, a balloon principal payment of approximately $1,550,007 will be due during the third quarter of 2025. We hedged our interest rate exposure on these mortgage notes with interest rate swap agreements that effectively converted floating interest rates based on the one-month LIBOR plus a bank profit margin to the fixed rates of 6.04% and 4.38%, respectively. As of September 30, 2015, the variable rates on these two mortgage notes were 3.46% and 2.45%, respectively. All derivatives are recognized on the balance sheet at their fair value. At the time of the closings and thereafter, the agreements were determined to be highly effective in hedging the variability of the identified cash flows and have been designated as cash flow hedges of the variability in the hedged interest payments. Changes in the fair value of the interest rate swap agreements are recorded in other comprehensive income (loss), net of taxes. The original notional amounts of the interest rate swap agreements of $1,000,000 and $2,500,000 amortize in accordance with the amortization of the mortgage notes. The notional amount of the interest rate swaps was $3,259,963 as of September 30, 2015. Payments required by the interest rate swaps totaled $5,112 and $5,538 during the three-month periods ended September 30, 2015 and 2014, and $15,549 and $16,726 during the nine-month periods ended September 30, 2015 and 2014, respectively. As the result of our decision to hedge this interest rate risk, we recorded other comprehensive (loss) income, net of taxes, in the amount of ($49,147) and $5,017 during the three-month periods ended September 30, 2015 and 2014, and ($48,059) and $193 during the nine-month periods ended September 30, 2015 and 2014, respectively, which reflects the change in the fair value of the interest rate swap assets (liabilities), net of taxes. The fair values of the interest rate swaps have been determined using observable market-based inputs or unobservable inputs that are corroborated by market data. Accordingly, the interest rate swaps are classified as level 2 within the fair value hierarchy provided in Codification Topic 820,&amp;#160;&lt;i&gt;Fair Value Measurements and Disclosures&lt;/i&gt;. Proceeds from a $600,000 note bearing interest at 4.25% were received during the first quarter of 2011. This note was repaid during the third quarter of 2015. The $500,000 line of credit is available as needed and has been extended through May 31, 2016 and is renewable annually thereafter. The line of credit was unused as of September 30, 2015 and December 31, 2014. Interest on any borrowings against the line of credit would be variable at the higher of 4.25% per annum or the one-month LIBOR plus 3.5% per annum. These credit facilities are subject to certain financial covenants. We are in compliance with all applicable covenants as of September 30, 2015. Principal payments due under debt outstanding as of September 30, 2015 are reflected in the following table by the year that payments are due:&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center; padding-left: 0pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;Period&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; padding-left: 0pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; padding-left: 0pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;$1,000,000 Mortgage Note&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; padding-left: 0pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; padding-left: 0pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; padding-left: 0pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;$2,500,000 Mortgage Note&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; padding-left: 0pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; padding-left: 0pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; padding-left: 0pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; padding-left: 0pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1003px;
 text-align: justify; padding-left: 0pt;"&gt;Three months ending December 31, 2015&lt;/td&gt;&lt;td style="width: 16px; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; padding-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right; padding-left: 0pt;"&gt;14,043&lt;/td&gt;&lt;td style="width: 16px; text-align: left; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; padding-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right; padding-left: 0pt;"&gt;19,371&lt;/td&gt;&lt;td style="width: 15px; text-align: left; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; padding-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right; padding-left: 0pt;"&gt;33,414&lt;/td&gt;&lt;td style="width: 15px; text-align: left; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: justify; padding-left: 0pt;"&gt;Year ending December 31, 2016&lt;/td&gt;&lt;td style="padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0pt;"&gt;57,384&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0pt;"&gt;78,456&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0pt;"&gt;135,840&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: justify; padding-left: 0pt;"&gt;Year ending December 31, 2017&lt;/td&gt;&lt;td style="padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0pt;"&gt;61,056&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0pt;"&gt;82,308&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0pt;"&gt;143,364&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: justify; padding-left: 0pt;"&gt;Year ending December 31, 2018&lt;/td&gt;&lt;td style="padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0pt;"&gt;64,876&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0pt;"&gt;86,097&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0pt;"&gt;150,973&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: justify; padding-left: 0pt;"&gt;Year ending December 31, 2019&lt;/td&gt;&lt;td style="padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0pt;"&gt;68,908&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0pt;"&gt;89,997&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0pt;"&gt;158,905&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;After December 31, 2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;493,696&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;2,143,771&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;2,637,467&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 10pt;"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;759,963&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;2,500,000&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt;
 border-bottom-style: double;"&gt;3,259,963&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
<us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.5in; text-align: justify; text-indent: 0pt; padding-left: 0pt;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;10.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify; text-indent: 0pt; padding-left: 0pt;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;OTHER EXPENSES, NET&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;Other expenses, net, consisted of the following:&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center; text-indent: 0pt; padding-left: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0pt; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6"&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;Three-Month Periods&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;Ended September 30,&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0pt; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6"&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;Nine-Month Periods&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;Ended September 30,&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: 0pt; padding-left: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0px; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0pt; padding-left: 0px; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2015&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0px; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0px; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0pt; padding-left: 0px; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2014&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0px; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0px; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0pt; padding-left: 0px; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2015&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0px; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0px; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0pt; padding-left: 0px; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2014&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0px; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 815px; text-align: left; text-indent: 0pt; padding-left: 0px;"&gt;Interest income&lt;/td&gt;&lt;td style="width: 16px; text-indent: 0pt; padding-left: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0pt; padding-left: 0px;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right; text-indent: 0pt; padding-left: 0px;"&gt;(4,461&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0pt; padding-left: 0px;"&gt;)&lt;/td&gt;&lt;td style="width: 16px; text-indent: 0pt; padding-left: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0pt; padding-left: 0px;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right; text-indent: 0pt; padding-left: 0px;"&gt;(3,912&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0pt; padding-left: 0px;"&gt;)&lt;/td&gt;&lt;td style="width: 15px; text-indent: 0pt; padding-left: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0pt; padding-left: 0px;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right; text-indent: 0pt; padding-left: 0px;"&gt;(10,634&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0pt; padding-left: 0px;"&gt;)&lt;/td&gt;&lt;td style="width: 15px; text-indent: 0pt; padding-left: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0pt; padding-left: 0px;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right; text-indent: 0pt; padding-left: 0px;"&gt;(11,607&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0pt; padding-left: 0px;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left:
 0px;"&gt;Interest expense&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-left: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0px;"&gt;15,084&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-left: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0px;"&gt;14,514&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-left: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0px;"&gt;41,039&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-left: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0px;"&gt;44,148&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0px;"&gt;Other&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;4,488&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;644&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(3,346&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0px;"&gt;)&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;6,092&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 4pt; padding-left: 10pt;"&gt;Other expenses, net&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 4pt; padding-left: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;15,111&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 4pt; padding-left: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 4pt; padding-left: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;11,246&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 4pt; padding-left: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 4pt; padding-left: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;27,059&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 4pt; padding-left: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 4pt; padding-left: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;38,633&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 4pt; padding-left: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock>
<us-gaap:IncomeTaxDisclosureTextBlock contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">&lt;div&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.5in; padding-left: 0pt;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;11.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-left: 0pt;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;INCOME TAXES&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;Our income tax expense (benefit) aggregated $260,447 and $19,277 (amounting to 43% and 65% of our income (loss) before income taxes) for the three-month periods ended September 30, 2015 and 2014, respectively, and $709,394 and ($146,101) (amounting to 43% and 33% of our income (loss) before income taxes) for the nine-month periods ended September 30, 2015 and 2014, respectively. As of December 31, 2014, we have state net operating loss carryforwards of approximately $1,920,000 that expire in 2028 through 2031, if not utilized before then, and federal net operating loss carryforwards of approximately $1,750,000 that expire in 2029 through 2034, if not utilized before then. Additionally, we have general business tax credit carryforwards of approximately $220,000 that expire in 2027 through 2034, if not utilized before then, which effectively protects approximately $549,000 in taxable income (assuming a 40% tax rate) from taxes, which can be utilized only after all net operating loss carryforwards are utilized. The $965,000 licensing payment that we made during the fourth quarter of 2004 was treated as an intangible asset and is being amortized over 15 years, for tax return purposes only. Approximately $1,112,000 of our investment to produce the Drug Substance (our Active Pharmaceutical Ingredient, Nisin) for&amp;#160;&lt;b&gt;Mast Out&lt;sup&gt;&amp;#174;&lt;/sup&gt;&lt;/b&gt;&amp;#160;was expensed as incurred for our books. Included in this amount is approximately $820,000 that was capitalized and is being depreciated over statutory periods for tax return purposes only.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;Deferred tax assets are recognized only when it is probable that sufficient taxable income will be available in future periods against which deductible temporary differences and credits may be utilized. However, the amount of the deferred tax asset could be reduced if projected income is not achieved due to various factors, such as unfavorable business conditions. If projected income is not expected to be achieved, we would decrease the deferred tax asset to the amount that we believe can be realized.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;Net operating loss carryforwards, credits, and other tax attributes are subject to review and possible adjustment by the Internal Revenue Service. Section 382 of the Internal Revenue Code contains provisions that could place annual limitations on the future utilization of net operating loss carryforwards and credits in the event of a change in ownership of the Company, as defined.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;The Company files income tax returns in the U.S. federal jurisdiction and several state jurisdictions. With few exceptions, the Company is no longer subject to income tax examinations by tax authorities for years before 2011. We currently have no tax examinations in progress. We also have not paid additional taxes, interest or penalties as a result of tax examinations nor do we have any unrecognized tax benefits for any of the periods in the accompanying financial statements.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">&lt;div&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.5in; text-indent: 0pt; padding-left: 0pt;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;12.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-left: 0pt;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;COMMITMENTS AND CONTINGENT LIABILITIES&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;Our bylaws, as amended, in effect provide that the Company will indemnify its officers and directors to the maximum extent permitted by Delaware law. In addition, we make similar indemnity undertakings to each director through a separate indemnification agreement with that director. The maximum payment that we may be required to make under such provisions is theoretically unlimited and is impossible to determine. We maintain directors&amp;#8217; and officers&amp;#8217; liability insurance, which may provide reimbursement to the Company for payments made to, or on behalf of, officers and directors pursuant to the indemnification provisions. Our indemnification obligations were grandfathered under the provisions of Codification Topic 460&lt;i&gt;, Guarantees&lt;/i&gt;. Accordingly, we have recorded no liability for such obligations as of September 30, 2015. Since our incorporation, we have had no occasion to make any indemnification payment to any of our officers or directors for any reason.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;As of September 30, 2015, we had committed approximately $728,000 to capital expenditures, $576,000 to the production of inventory and an additional $261,000 to other obligations.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;We enter into agreements with third parties in the ordinary course of business under which we are obligated to indemnify such third parties from and against various risks and losses. The precise terms of such indemnities vary with the nature of the agreement. In many cases, we limit the maximum amount of our indemnification obligations, but in some cases those obligations may be theoretically unlimited. We have not incurred material expenses in discharging any of these indemnification obligations, and based on our analysis of the nature of the risks involved, we believe that the fair value of the liabilities potentially arising under these agreements is minimal. Accordingly, we have recorded no liabilities for such obligations as of September 30, 2015.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;The development, manufacturing and marketing of animal health care products entails an inherent risk that liability claims will be asserted against us. We feel that we have reasonable levels of liability insurance to support our operations.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
<iccc:CommonStockRightsPlanTextBlock contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">&lt;div&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.5in; text-indent: 0pt; padding-left: 0pt;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;13.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-left: 0pt;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;COMMON STOCK RIGHTS PLAN&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;During the second quarter of 2015, we amended our Common Stock Rights Plan by removing a provision that prevented a new group of directors elected following the emergence of an Acquiring Person (an owner of more than 20% of our stock) from controlling the Rights Plan by maintaining exclusive authority over the Rights Plan with pre-existing directors. We did this because such provisions have come to be viewed with disfavor by Delaware courts.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</iccc:CommonStockRightsPlanTextBlock>
<us-gaap:SegmentReportingDisclosureTextBlock contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">&lt;div&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.5in; text-indent: 0pt; padding-left: 0pt;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;14.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-left: 0pt;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;SEGMENT AND SIGNIFICANT CUSTOMER INFORMATION&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;We principally operate in the business segment described in Note 1. Pursuant to Codification Topic 280,&amp;#160;&lt;i&gt;Segment Reporting&lt;/i&gt;, we operate in one reportable business segment, that being the development, acquisition, manufacture and sale of products that improve the health and productivity of cows for the dairy and beef industries. Almost all of our internally funded product development expenses are in support of such products. The significant accounting policies of this segment are described in Note 2.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;Our primary customers for the majority of our product sales (85% and 84% for the three-month periods ended September 30, 2015 and 2014, and 83% and 82% for the nine-month periods ended September 30, 2015 and 2014, respectively) are in the U.S. dairy and beef industries. Product sales to international customers, who are also in the dairy and beef industries, aggregated 6% and 11% of our total product sales for the three-month periods ended September 30, 2015 and 2014, respectively, and 13% for both of the nine-month periods ended September 30, 2015 and 2014. Sales to significant customers that amounted to 10% or more of total product sales are detailed in the following table:&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: 0pt; padding-right: 0pt; padding-bottom: 1.5pt; padding-left: 0pt; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-right: 0pt; padding-bottom: 1.5pt; padding-left: 0pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6"&gt;Three-Month Periods&amp;#160;&lt;br /&gt;Ended September 30,&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-right: 0pt; padding-bottom: 1.5pt; padding-left: 0pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-right: 0pt; padding-bottom: 1.5pt; padding-left: 0pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6"&gt;Nine-Month Periods&amp;#160;&lt;br /&gt;Ended September 30,&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-right: 0pt; padding-bottom: 1.5pt; padding-left: 0pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: 0pt; padding-right: 0pt; padding-bottom: 1.5pt; padding-left: 0pt; font-family: calibri, sans-serif;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-right: 0pt; padding-bottom: 1.5pt; padding-left: 0pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2015&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-right: 0pt; padding-bottom: 1.5pt; padding-left: 0pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-right: 0pt; padding-bottom: 1.5pt; padding-left: 0pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2014&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-right: 0pt; padding-bottom: 1.5pt; padding-left: 0pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-right: 0pt; padding-bottom: 1.5pt; padding-left: 0pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2015&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-right: 0pt; padding-bottom: 1.5pt; padding-left: 0pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-right: 0pt; padding-bottom: 1.5pt; padding-left: 0pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt;
 border-bottom-style: solid;" colspan="2"&gt;2014&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-right: 0pt; padding-bottom: 1.5pt; padding-left: 0pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 815px; text-align: left; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt;"&gt;&lt;font style="font: 10pt/normal 'times new roman', serif; font-stretch: normal;"&gt;Animal Health International, Inc.&lt;sup&gt;(1)&lt;/sup&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 16px; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 142px; text-align: right; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt;"&gt;39&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 16px; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 142px; text-align: right; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt;"&gt;34&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 15px; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 141px; text-align: right; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt;"&gt;41&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 15px; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 141px; text-align: right; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt;"&gt;37&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt;"&gt;&lt;font style="font: 10pt/normal 'times new roman', serif; font-stretch: normal;"&gt;MWI Animal Health&lt;sup&gt;(2)&lt;/sup&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt;"&gt;22&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt;"&gt;23&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt;"&gt;21&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt;"&gt;22&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;Accounts receivable due from significant customers amounted to the percentages of total trade accounts receivable as detailed in the following table:&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;As of&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;September&amp;#160;30, 2015&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0pt; padding-left: 0pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;As of&lt;br /&gt;December&amp;#160;31, 2014&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt; font-weight:
 bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1191px; text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;Animal Health International, Inc.&lt;sup&gt;(1)&lt;/sup&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 16px; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 142px; text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;37&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 15px; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 141px; text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;45&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;MWI Animal Health&lt;sup&gt;(2)&lt;/sup&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;25&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;26&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;TCS Biosciences, Ltd.&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;13&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;*&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;sup&gt;(1)&lt;/sup&gt;During June 2015, Patterson Companies, Inc. (NASDAQ: PDCO) acquired Animal Health International, Inc.&lt;/font&gt;&lt;font style="font-size: 10pt;"&gt;&lt;br /&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;sup&gt;(2)&lt;/sup&gt;During March 2015, AmerisourceBergen Corporation (NYSE: ABC) acquired MWI Animal Health.&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;*Amount is less than 10%.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
<us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">&lt;div&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.5in; padding-left: 0pt;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;15.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-left: 0pt;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;RELATED PARTY TRANSACTIONS&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Dr. David S. Tomsche (Chair of our Board of Directors) is a controlling owner of Leedstone Inc. (formerly Stearns Veterinary Outlet, Inc.), a domestic distributor of ImmuCell products (&lt;b&gt;First Defense&lt;sup&gt;&amp;#174;&lt;/sup&gt;&lt;/b&gt;,&amp;#160;&lt;b&gt;Wipe Out&lt;sup&gt;&amp;#174;&lt;/sup&gt;&lt;/b&gt;&amp;#160;&lt;b&gt;Dairy Wipes&lt;/b&gt;,&lt;b&gt;&amp;#160;&lt;/b&gt;and&lt;b&gt;&amp;#160;CMT&lt;/b&gt;) and of J-t Enterprises of Melrose, Inc., an exporter. His affiliated companies purchased $452,207 and $283,287 of products from ImmuCell during the nine-month periods ended September 30, 2015 and 2014, respectively, on terms consistent with those offered to other distributors of similar status. We made marketing-related payments of $3,222 and $6,355 to these affiliate companies during the nine-month periods ended September 30, 2015 and 2014, respectively. Our accounts receivable (subject to standard and customary payment terms) due from these affiliated companies aggregated $12,864 and $18,796 as of September 30, 2015 and December 31, 2014, respectively.&lt;/p&gt;&lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
<us-gaap:CompensationAndEmployeeBenefitPlansTextBlock contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">&lt;div&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.5in; padding-left: 0pt;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;16.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-left: 0pt;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;EMPLOYEE BENEFITS&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;We have a 401(k) savings plan (the Plan) in which all employees completing one month of service with the Company are eligible to participate. Participants may contribute up to the maximum amount allowed by the Internal Revenue Service. Since August 2012 we have matched 100% of the first 3% of each employee&amp;#8217;s salary that is contributed to the Plan and 50% of the next 2% of each employee&amp;#8217;s salary that is contributed to the Plan. Under this matching plan, we paid $17,102 and $17,117 into the plan for the three-month periods ended September 30, 2015 and 2014, respectively, and $54,157 and $47,920 for the nine-month periods ended September 30, 2015 and 2014, respectively.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
<us-gaap:SubsequentEventsTextBlock contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">&lt;div&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.5in; padding-left: 0pt;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;17.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-left: 0pt;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;SUBSEQUENT EVENTS&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;We have adopted the disclosure provisions of Codification Topic 855-10-50-1,&amp;#160;&lt;i&gt;Subsequent Events&lt;/i&gt;, which provides guidance to establish general standards of accounting for and disclosures of events that occur after the balance sheet date but before financial statements are issued. Codification Topic 855-10-50-1 requires additional disclosures only, and therefore did not have an impact on our financial condition, results of operations, earnings per share or cash flows. Entities are required to disclose the date through which subsequent events were evaluated as well as the rationale for why that date was selected. Public entities must evaluate subsequent events through the date that financial statements are issued. Accordingly, we have evaluated subsequent events through the time of filing on November 12, 2015, the date we have issued this Quarterly Report on Form 10-Q. This disclosure should alert all users of financial statements that an entity has not evaluated subsequent events after that date in the set of financial statements being presented.&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;During the fourth quarter of 2015, we entered into a revised agreement with Plas-Pak Inc. of Norwich, Connecticut covering the supply of plastic syringes used to deliver&amp;#160;&lt;b&gt;Mast Out&lt;sup&gt;&amp;#174;&lt;/sup&gt;&lt;/b&gt;, effective through the year ending December 31, 2020. On October 28, 2015, we filed a registration statement on Form S-3 with the SEC for the potential issuance of up to $10,000,000 in equity (subject to certain limitations). We filed Pre-Effective Amendment No. 1 on November 5, 2015, and our registration statement became effective on November 10, 2015. During the fourth quarter of 2015, our Board of Directors voted to exercise an option to acquire land nearby to our existing Portland facility for a potential site for a&amp;#160;&lt;b&gt;Mast Out&lt;sup&gt;&amp;#174;&lt;/sup&gt;&lt;/b&gt;&amp;#160;production facility for $238,000 (less the $23,800 option payment that was paid during the third quarter of 2015).&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
<us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="text-align: justify; padding-left: 0pt; text-indent: 0pt; width: 0.5in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;(a)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify; padding-left: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Basis of presentation&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;We have prepared the accompanying unaudited financial statements reflecting all adjustments, all of which are of a normal recurring nature, that are, in our opinion, necessary in order to ensure that the financial statements are not misleading. We follow accounting standards set by the Financial Accounting Standards Board (FASB). The FASB sets generally accepted accounting principles (GAAP) that we follow to ensure we consistently report our financial condition, results of operations, earnings per share and cash flows. References to GAAP in these footnotes are to the FASB&lt;i&gt;&amp;#160;Accounting Standards Codification&lt;/i&gt;&amp;#8482; (Codification). Certain prior year accounts have been reclassified to conform with the 2015 financial statement presentation. Certain information and footnote disclosures normally included in the annual financial statements have been condensed or omitted. Accordingly, we believe that although the disclosures are adequate to ensure that the information presented is not misleading, these financial statements should be read in conjunction with the financial statements for the year ended December 31, 2014 and the notes thereto, contained in our Annual Report on Form 10-K as filed with the Securities and Exchange Commission (SEC).&lt;/font&gt;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
<us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="padding-left: 0pt; text-indent: 0pt; width: 0.5in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;(b)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-left: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Cash, Cash Equivalents, Short-Term Investments and Long-Term Investments&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;We consider all highly liquid investment instruments that mature within three months of their purchase dates to be cash equivalents. Cash equivalents are principally invested in securities backed by the U.S. government. Certain cash balances in excess of Federal Deposit Insurance Corporation (FDIC) limits of $250,000 per financial institution per depositor are maintained in money market accounts at financial institutions that are secured, in part, by the Securities Investor Protection Corporation. Amounts in excess of these FDIC limits per bank that are not invested in securities backed by the U.S. government aggregated $1,968,787 and $566,637 as of September 30, 2015 and December 31, 2014, respectively. Short-term investments are classified as held to maturity and are comprised principally of certificates of deposit that mature in more than three months from their purchase dates and not more than twelve months from the balance sheet date. Long-term investments are classified as held to maturity and are comprised principally of certificates of deposit that mature in more than twelve months from the balance sheet date. Short-term and long-term investments are held at different financial institutions that are insured by the FDIC, within the FDIC limits per financial institution. See Note 3.&lt;/font&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
<us-gaap:InventoryPolicyTextBlock contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="text-align: justify; padding-left: 0pt; text-indent: 0pt; width: 0.5in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;(c)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: justify; padding-left: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Inventory&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;Inventory includes raw materials, work-in-process and finished goods and is recorded at the lower of cost, on the first-in, first-out method, or market (net realizable value). Work-in-process and finished goods inventories include materials, labor and manufacturing overhead. See Note 4.&lt;/font&gt;&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
<us-gaap:TradeAndOtherAccountsReceivablePolicy contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="padding-left: 0pt; text-indent: 0pt; width: 0.5in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;(d)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-left: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Trade Receivables&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;Trade receivables are carried at the original invoice amount less an estimate made for doubtful collection. Management determines the allowance for doubtful accounts on a monthly basis by identifying troubled accounts and by using historical experience applied to an aging of accounts. Trade receivables are written off when deemed uncollectible. Recoveries of trade receivables previously written off are recorded as income when received. A trade receivable is considered to be past due if any portion of the receivable balance is outstanding for more than 30 days. Interest is charged on past due trade receivables. See Note 5.&lt;/font&gt;&lt;/p&gt;</us-gaap:TradeAndOtherAccountsReceivablePolicy>
<us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="padding-left: 0pt; text-indent: 0pt; width: 0.5in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;(e)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-left: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Property, Plant and Equipment&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;We depreciate property, plant and equipment on the straight-line method by charges to operations in amounts estimated to expense the cost of the assets from the date they are first put into service to the end of the estimated useful lives of the assets. The cost of our building (which was acquired in 1993) and the 2001 and 2007 additions thereto are being depreciated through 2023. We are depreciating the building addition that was completed during the first quarter of 2015 over twenty-five years. Related building improvements are depreciated over ten year periods. Large and durable fixed assets are depreciated over their useful lives that are generally estimated to be five to ten years. Other fixed assets and computer equipment are depreciated over their useful lives that are generally estimated to be five and three years, respectively. See Note 7.&lt;/font&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
<us-gaap:IntangibleAssetsFiniteLivedPolicy contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="padding-left: 0pt; text-indent: 0pt; width: 0.5in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;(f)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-left: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Intangible Assets&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;We amortize intangible assets on the straight-line method by charges to operations in amounts estimated to expense the cost of the assets from the date they are first put into service to the end of the estimated useful lives of the assets. In connection with certain credit facilities entered into during the third quarters of 2010 and 2015, we incurred debt issue costs of $26,489 and $32,759, respectively, which costs are being amortized to other expenses, net over the terms of the credit facilities. See Notes 6 and 9.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;We continually assess the realizability of these assets in accordance with the impairment provisions of Codification Topic 360,&amp;#160;&lt;i&gt;Accounting for the Impairment or Disposal of Long-Lived Assets&lt;/i&gt;. If an impairment review is triggered, we evaluate the carrying value of long-lived assets by determining if impairment exists based on estimated undiscounted future cash flows over the remaining useful life of the assets and comparing that value to the carrying value of the assets. If the carrying value of the asset is greater than the estimated future cash flows, the asset is written down to its estimated fair value. The cash flow estimates that are used contain our best estimates, using appropriate and customary assumptions and projections at the time. We also review the estimated useful life of intangible assets at the end of each reporting period, making any necessary adjustments.&lt;/font&gt;&lt;/p&gt;</us-gaap:IntangibleAssetsFiniteLivedPolicy>
<us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="padding-left: 0pt; text-indent: 0pt; width: 0.5in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;(g)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-left: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Disclosure of Fair Value of Financial Instruments and Concentration of Risk&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;Financial instruments consist mainly of cash, cash equivalents, short-term investments, long-term investments, accounts receivable, accounts payable, bank debt and interest rate swaps. Financial instruments that potentially subject the Company to concentrations of credit risk are principally cash, cash equivalents, short-term investments, long-term investments and accounts receivable. We make short-term and long-term investments in financial instruments that are insured by the FDIC. We account for fair value measurements in accordance with Codification Topic 820,&amp;#160;&lt;i&gt;Fair Value Measurements and Disclosures&lt;/i&gt;, which defines fair value, establishes a framework for measuring fair value and requires additional disclosures about fair value measurements. The estimated fair value of cash, cash equivalents, short-term investments, long-term investments, accounts receivable and accounts payable approximate their carrying value due to their short maturities. The estimated fair value of bank debt approximates its carrying value because the interest rates are variable. Interest rate swaps are carried at fair value. See Note 9.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;Concentration of credit risk with respect to accounts receivable is principally limited to certain customers to whom we make substantial sales. To reduce risk, we routinely assess the financial strength of our customers and, as a consequence, believe that our accounts receivable credit risk exposure is limited. We maintain an allowance for potential credit losses, but historically we have not experienced significant credit losses related to an individual customer or groups of customers in any particular industry or geographic area.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;We believe that supplies and raw materials for the production of our products are available from more than one vendor or farm. Our policy is to maintain more than one source of supply for the components used in our products. However, there is a risk that we could have difficulty in efficiently acquiring essential supplies.&lt;/font&gt;&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
<iccc:InterestRateSwapAgreementPolicyTextBlock contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="padding-left: 0pt; text-indent: 0pt; width: 0.5in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;(h)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-left: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Interest Rate Swap Agreements&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;All derivatives are recognized on the balance sheet at their fair value. We entered into interest rate swap agreements in 2010 and 2015. On the dates the agreements were entered into, we designated the derivatives as hedges of the variability of cash flows to be paid related to our long-term debt. The agreements have been determined to be highly effective in hedging the variability of identified cash flows, so changes in the fair market value of the interest rate swap agreements are recorded as comprehensive income (loss), until earnings are affected by the variability of cash flows (e.g. when periodic settlements on a variable-rate asset or liability are recorded in earnings). We formally documented the relationship between the interest rate swap agreements and the related hedged items. We also formally assess, both at the interest rate swap agreements&amp;#8217; inception and on an ongoing basis, whether the agreements are highly effective in offsetting changes in cash flow of hedged items. See Note 9.&lt;/font&gt;&lt;/p&gt;</iccc:InterestRateSwapAgreementPolicyTextBlock>
<us-gaap:RevenueRecognitionPolicyTextBlock contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="padding-left: 0pt; text-indent: 0pt; width: 0.5in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;(i)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-left: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Revenue Recognition&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;We recognize revenue in accordance with Staff Accounting Bulletin (SAB) No. 104, &amp;#8220;Revenue Recognition&amp;#8221;. SAB No. 104 requires that four criteria are met before revenue is recognized. These include i) persuasive evidence that an arrangement exists, ii) delivery has occurred or services have been rendered, iii) the seller&amp;#8217;s price is fixed and determinable and iv) collectability is reasonably assured. We recognize revenue at the time of shipment (including to distributors) for substantially all products, as title and risk of loss pass to the customer on delivery to the common carrier after concluding that collectability is reasonably assured. We recognize service revenue at the time the service is performed.&lt;/font&gt;&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
<iccc:ExpenseRecognitionPolicyTextBlock contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.5in; padding-left: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;(j)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-left: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Expense Recognition&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;Advertising costs are expensed when incurred, which is generally during the month in which the advertisement is published. Advertising expenses amounted to $27,545 and $15,844 during the three-month periods ended September 30, 2015 and 2014, respectively, and $72,539 and $42,915 during the nine-month periods ended September 30, 2015 and 2014, respectively. All product development expenses are expensed as incurred, as are all related patent costs.&lt;/font&gt;&lt;/p&gt;</iccc:ExpenseRecognitionPolicyTextBlock>
<us-gaap:IncomeTaxPolicyTextBlock contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.5in; padding-left: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;(k)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-left: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Income Taxes&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;We account for income taxes in accordance with Codification Topic 740,&amp;#160;&lt;i&gt;Income Taxes&lt;/i&gt;,&lt;i&gt;&amp;#160;&lt;/i&gt;which requires that we recognize a current tax liability or asset for current taxes payable or refundable and a deferred tax liability or asset for the estimated future tax effects of temporary differences and carryforwards to the extent they are realizable. We believe it is more likely than not that the deferred tax assets will be realized through future taxable income and future tax effects of temporary differences between book income and taxable income. Accordingly, we have not established a valuation allowance for the deferred tax assets. Codification Topic 740-10 clarifies the accounting for income taxes by prescribing a minimum recognition threshold that a tax position must meet before being recognized in the financial statements. In the ordinary course of business, there are transactions and calculations where the ultimate tax outcome is uncertain. In addition, we are subject to periodic audits and examinations by the Internal Revenue Service and other taxing authorities. We have evaluated the positions taken on our filed tax returns. We have concluded that no uncertain tax positions exist as of September 30, 2015. Although we believe that our estimates are reasonable, actual results could differ from these estimates. See Note 11.&lt;/font&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
<us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.5in; padding-left: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;(l)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-left: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Stock-Based Compensation&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;We account for stock-based compensation in accordance with Codification Topic 718,&amp;#160;&lt;i&gt;Compensation-Stock Compensation&lt;/i&gt;, which generally requires us to recognize non-cash compensation expense for stock-based payments using the fair-value-based method. The fair value of each stock option grant has been estimated on the date of grant using the Black-Scholes option pricing model. Accordingly, we recorded compensation expense pertaining to stock-based compensation of $6,342 and $4,974 during the three-month periods ended September 30, 2015 and 2014, respectively, and $17,825 and $22,265 during the nine-month periods ended September 30, 2015 and 2014, respectively, which resulted in a decrease to income before income taxes of less than $0.01 per share during each of the periods reported. Codification Topic 718 requires us to reflect gross tax savings resulting from tax deductions in excess of expense reflected in our financial statements as a financing cash flow.&lt;/font&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
<us-gaap:EarningsPerSharePolicyTextBlock contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.5in; padding-left: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;(m)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-left: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Net Income (Loss) Per Common Share&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;Net Income (Loss) per common share has been computed in accordance with Codification Topic 260-10,&amp;#160;&lt;i&gt;Earnings Per Share.&lt;/i&gt;&amp;#160;The basic Net Income per share has been computed by dividing Net Income by the weighted average number of common shares outstanding during this period. Diluted Net Income per share has been computed by dividing Net Income by the weighted average number of shares outstanding during the period plus all outstanding stock options with an exercise price that is less than the average market price of the common stock during the period less the number of shares that could have been repurchased at this average market price with the proceeds from the hypothetical stock option exercises.&lt;i&gt;&amp;#160;&lt;/i&gt;The Net (Loss) per common share in 2014 has been computed by dividing the Net (Loss) by the weighted average number of common shares outstanding during the period, without giving consideration to outstanding stock options because the impact would be anti-dilutive.&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6"&gt;&lt;p style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin: 0px; text-align: center;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Three-Month Period&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Ended September 30,&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6"&gt;&lt;p style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin: 0px; text-align: center;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Nine-Month Period&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Ended September 30,&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2015&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2014&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2015&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2014&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr
 style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 814.078px; padding-left: 0.7pt;"&gt;Weighted average number of shares outstanding&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;3,052,175&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;3,027,034&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;3,038,111&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;3,026,990&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.7pt;"&gt;Effect of dilutive stock options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;"&gt;136,174&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;"&gt;78,798&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;"&gt;124,509&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;"&gt;0&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding-bottom: 4pt; padding-left: 0.7pt;"&gt;Diluted number of shares outstanding&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;"&gt;3,188,349&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;"&gt;3,105,832&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;"&gt;3,162,620&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;"&gt;3,026,990&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-left: 0.7pt;"&gt;Stock options outstanding as of September 30th not included in the calculation because the effect would be anti-dilutive&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;"&gt;0&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;"&gt;85,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;"&gt;3,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;"&gt;251,000&lt;/td&gt;&lt;td style="padding-bottom: 4pt; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&amp;#160;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
<us-gaap:UseOfEstimates contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.5in; padding-left: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;(n)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-left: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;Use of Estimates&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual amounts could differ from those estimates.&lt;/font&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: top;"&gt;&lt;td style="width: 0.5in; padding-left: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;(o)&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-left: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;New Accounting Pronouncement&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;In May 2014, the FASB issued Accounting Standards Update No. 2014-09,&amp;#160;&lt;i&gt;Revenue from Contracts with Customers&amp;#160;&lt;/i&gt;(ASU 2014-09), which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. ASU 2014-09 will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. ASU 2014-09 was initially effective for the Company on January 1, 2017. Early application was not permitted. In July 2015, the FASB approved a one-year deferral in the effective date to January 1, 2018, with the option of applying the standard on the original effective date. ASU 2014-09 permits the use of either the retrospective or cumulative effect transition method. We have evaluated the effect that ASU 2014-09 would have on our financial statements and related disclosures. We expect that ASU 2014-09 will have no significant effect on our ongoing financial reporting, but we continue to evaluate this pending accounting standard.&lt;/font&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
<us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">&lt;div&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6"&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;Three-Month Period&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;Ended September 30,&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6"&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;Nine-Month Period&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;Ended September 30,&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2015&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2014&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2015&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2014&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 814.07px; padding-left: 0.7pt;"&gt;Weighted average number of shares outstanding&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;3,052,175&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 142px; text-align: right;"&gt;3,027,034&lt;/td&gt;&lt;td style="width: 16px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;3,038,111&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 141px; text-align: right;"&gt;3,026,990&lt;/td&gt;&lt;td style="width: 15px; text-align: left;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.7pt;"&gt;Effect of dilutive stock options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;136,174&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;78,798&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;124,509&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;0&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding-bottom: 4pt; padding-left: 0.7pt;"&gt;Diluted number of shares outstanding&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;3,188,349&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;3,105,832&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;3,162,620&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;3,026,990&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;
 background-color: white;"&gt;&lt;td style="text-align: left; padding-left: 0.7pt;"&gt;Stock options outstanding as of September 30th not included in the calculation because the effect would be anti-dilutive&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;0&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;85,000&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;3,000&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;251,000&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock>
<us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">&lt;div&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;As of&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;September&amp;#160;30, 2015&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;As of&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;December&amp;#160;31, 2014&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;Increase&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;(Decrease)&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1003px; text-align: left; padding-left: 0pt;"&gt;Cash and cash equivalents&lt;/td&gt;&lt;td style="width: 16px; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; padding-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right; padding-left: 0pt;"&gt;2,469,087&lt;/td&gt;&lt;td style="width: 16px; text-align: left; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; padding-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right; padding-left: 0pt;"&gt;850,028&lt;/td&gt;&lt;td style="width: 15px; text-align: left; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; padding-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right; padding-left: 0pt;"&gt;1,619,059&lt;/td&gt;&lt;td style="width: 15px; text-align: left; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;Short-term investments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;3,720,000&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;2,489,000&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;1,231,000&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding-left: 0pt;"&gt;&amp;#160;&amp;#160;&amp;#160;Subtotal&lt;/td&gt;&lt;td style="padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0pt;"&gt;6,189,087&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0pt;"&gt;3,339,028&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0pt;"&gt;2,850,059&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;Long-term investments&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;487,000&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;496,000&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt;
 padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(9,000&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="padding-bottom: 4pt; padding-left: 0pt;"&gt;&amp;#160;&amp;#160;&amp;#160;Total&lt;/td&gt;&lt;td style="padding-bottom: 4pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;6,676,087&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;3,835,028&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 4pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;2,841,059&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 4pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
<us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">&lt;div&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: justify; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;As of&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;September&amp;#160;30, 2015&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;As of&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;December&amp;#160;31, 2014&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;Increase&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;(Decrease)&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1003px; text-align: justify; text-indent: 0pt; padding-left: 0pt;"&gt;Raw materials&lt;/td&gt;&lt;td style="width: 16px; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;337,538&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;306,444&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;31,094&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: justify; text-indent: 0pt; padding-left: 0pt;"&gt;Work-in-process&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;468,059&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;355,745&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;112,314&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;Finished goods&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;58,847&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;283,566&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(224,719&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-indent: 0pt; padding-bottom: 4pt; padding-left: 10pt;"&gt;Total&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 4pt;
 padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;864,444&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;945,755&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;(81,311&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
<us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">&lt;div&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"&gt;&lt;b&gt;As of&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"&gt;&lt;b&gt;September&amp;#160;30, 2015&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"&gt;&lt;b&gt;As of&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"&gt;&lt;b&gt;December&amp;#160;31, 2014&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"&gt;&lt;b&gt;(Decrease)&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"&gt;&lt;b&gt;Increase&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1003px; text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;Trade accounts receivable, gross&lt;/td&gt;&lt;td style="width: 16px; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;783,547&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;1,004,990&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;(221,443&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;Accumulated allowance for bad debt and product returns&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(16,958&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(16,194&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(764&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Trade accounts receivable, net&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;766,589&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;988,796&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td
 style="text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;(222,207&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;Other receivables&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;22,625&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;16,496&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;6,129&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Accounts receivable, net&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;789,214&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;1,005,292&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;(216,078&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
<us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"&gt;&lt;b&gt;As of&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"&gt;&lt;b&gt;September&amp;#160;30, 2015&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0pt; padding-left: 0pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;As of&lt;br /&gt;December&amp;#160;31, 2014&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"&gt;&lt;b&gt;Increase&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"&gt;&lt;b&gt;(Decrease)&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1003px; text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;Prepaid expenses and other assets&lt;/td&gt;&lt;td style="width: 16px; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;234,628&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;133,119&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;101,509&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;Security deposits&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;40,931&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;15,280&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;25,651&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Current subtotal&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;275,559&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;148,399&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black;
 border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;127,160&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;Debt issue costs&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;59,248&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;26,489&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;32,759&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;Accumulated amortization of debt issue costs&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;(18,553&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;(16,479&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;(2,074&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;Security deposits&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;8,920&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;8,920&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;0&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Long-term subtotal&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;49,615&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;18,930&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;30,685&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-indent: 0pt; padding-left:
 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Total&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;325,174&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;167,329&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;157,845&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
<us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">&lt;div&gt;&lt;br class="apple-interchange-newline" /&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;As of&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;September&amp;#160;30, 2015&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;As of&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;December&amp;#160;31, 2014&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;Increase&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;(Decrease)&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1003px; text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;Laboratory and manufacturing equipment&lt;/td&gt;&lt;td style="width: 16px; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;3,602,690&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;3,522,465&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;80,225&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: justify; text-indent: 0pt; padding-left: 0pt;"&gt;Building and improvements&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;4,579,852&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;2,969,891&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;1,609,961&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;Office furniture and equipment&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;569,567&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;470,607&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;98,960&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;Construction in progress&lt;sup&gt;(1)&lt;/sup&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;738,282&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left:
 0pt;"&gt;1,270,672&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;(532,390&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;Land&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;72,807&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;50,000&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;22,807&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Property, plant and equipment, gross&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;9,563,198&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;8,283,635&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;1,279,563&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;Accumulated depreciation&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(4,607,584&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(4,445,988&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(161,596&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Property, plant and equipment, net&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;4,955,614&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;3,837,647&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;1,117,967&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch:
 normal;"&gt;&lt;sup&gt;&amp;#160;&lt;/sup&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;sup&gt;(1)&lt;/sup&gt;As of December 31, 2014, construction in progress consisted of a building addition that was completed during the first quarter of 2015. As of September 30, 2015, construction in progress consisted principally of partial payments towards new manufacturing equipment.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
<us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"&gt;&lt;b&gt;As of&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"&gt;&lt;b&gt;September&amp;#160;30, 2015&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"&gt;&lt;b&gt;As of&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"&gt;&lt;b&gt;December&amp;#160;31, 2014&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"&gt;&lt;b&gt;(Decrease)&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"&gt;&lt;b&gt;Increase&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1003px; text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;Accounts payable &amp;#8211; capital&lt;/td&gt;&lt;td style="width: 16px; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;37,965&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;251,383&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;(213,418&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;Accounts payable &amp;#8211; trade&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;178,542&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;204,810&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;(26,268&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;Accrued payroll&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;134,466&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;145,176&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;(10,710&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;Accrued clinical studies&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;68,428&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left:
 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;131,945&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;(63,517&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;Accrued professional fees&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;55,462&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;42,250&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;13,212&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;Accrued other&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;71,064&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;76,113&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(5,049&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;"&gt;&amp;#160;&amp;#160;&amp;#160;Total&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;545,927&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;851,677&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;(305,750&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
<us-gaap:ScheduleOfDebtInstrumentsTextBlock contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">&lt;div&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center; padding-left: 0pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;Period&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; padding-left: 0pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; padding-left: 0pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;$1,000,000 Mortgage Note&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; padding-left: 0pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; padding-left: 0pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; padding-left: 0pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;$2,500,000 Mortgage Note&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; padding-left: 0pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; padding-left: 0pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; padding-left: 0pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;Total&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; padding-left: 0pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 1003px; text-align: justify; padding-left: 0pt;"&gt;Three months ending December 31, 2015&lt;/td&gt;&lt;td style="width: 16px; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; padding-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right; padding-left: 0pt;"&gt;14,043&lt;/td&gt;&lt;td style="width: 16px; text-align: left; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; padding-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right; padding-left: 0pt;"&gt;19,371&lt;/td&gt;&lt;td style="width: 15px; text-align: left; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; padding-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right; padding-left: 0pt;"&gt;33,414&lt;/td&gt;&lt;td style="width: 15px; text-align: left; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: justify; padding-left: 0pt;"&gt;Year ending December 31, 2016&lt;/td&gt;&lt;td style="padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0pt;"&gt;57,384&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0pt;"&gt;78,456&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0pt;"&gt;135,840&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: justify; padding-left: 0pt;"&gt;Year ending December 31, 2017&lt;/td&gt;&lt;td style="padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0pt;"&gt;61,056&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0pt;"&gt;82,308&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0pt;"&gt;143,364&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: justify; padding-left: 0pt;"&gt;Year ending December 31, 2018&lt;/td&gt;&lt;td style="padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0pt;"&gt;64,876&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0pt;"&gt;86,097&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0pt;"&gt;150,973&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: justify; padding-left: 0pt;"&gt;Year ending December 31, 2019&lt;/td&gt;&lt;td style="padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0pt;"&gt;68,908&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0pt;"&gt;89,997&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0pt;"&gt;158,905&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;After December 31, 2019&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;493,696&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;2,143,771&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style:
 solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;2,637,467&lt;/td&gt;&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="font: 13px/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; padding-bottom: 4pt; padding-left: 10pt; word-spacing: 0px; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;Total&lt;/td&gt;&lt;td style="font: 13px/normal 'times new roman', times, serif; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; padding-bottom: 4pt; padding-left: 0pt; word-spacing: 0px; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 13px/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; padding-left: 0pt; word-spacing: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;$&lt;/td&gt;&lt;td style="font: 13px/normal 'times new roman', times, serif; text-align: right; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; padding-left: 0pt; word-spacing: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;759,963&lt;/td&gt;&lt;td style="font: 13px/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; padding-bottom: 4pt; padding-left: 0pt; word-spacing: 0px; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 13px/normal 'times new roman', times, serif; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; padding-bottom: 4pt; padding-left: 0pt; word-spacing: 0px; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 13px/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; padding-left: 0pt; word-spacing: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;$&lt;/td&gt;&lt;td style="font: 13px/normal 'times new roman', times, serif; text-align: right; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; padding-left: 0pt; word-spacing: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;2,500,000&lt;/td&gt;&lt;td style="font: 13px/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; padding-bottom: 4pt; padding-left: 0pt; word-spacing: 0px; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 13px/normal 'times new roman', times, serif; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; padding-bottom: 4pt; padding-left: 0pt; word-spacing: 0px; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font: 13px/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; padding-left: 0pt; word-spacing: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;$&lt;/td&gt;&lt;td style="font: 13px/normal 'times new roman', times, serif; text-align: right; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; padding-left: 0pt; word-spacing: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;3,259,963&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
<us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">&lt;div&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-align: center; text-indent: 0pt; padding-left: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0pt; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6"&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;Three-Month Periods&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;Ended September 30,&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0pt; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6"&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;Nine-Month Periods&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;br /&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;Ended September 30,&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: 0pt; padding-left: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0px; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0pt; padding-left: 0px; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2015&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0px; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0px; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0pt; padding-left: 0px; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2014&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0px; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0px; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0pt; padding-left: 0px; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2015&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0px; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0px; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0pt; padding-left: 0px; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;2014&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0px; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 815px; text-align: left; text-indent: 0pt; padding-left: 0px;"&gt;Interest income&lt;/td&gt;&lt;td style="width: 16px; text-indent: 0pt; padding-left: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0pt; padding-left: 0px;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right; text-indent: 0pt; padding-left: 0px;"&gt;(4,461&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0pt; padding-left: 0px;"&gt;)&lt;/td&gt;&lt;td style="width: 16px; text-indent: 0pt; padding-left: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0pt; padding-left: 0px;"&gt;$&lt;/td&gt;&lt;td style="width: 142px; text-align: right; text-indent: 0pt; padding-left: 0px;"&gt;(3,912&lt;/td&gt;&lt;td style="width: 16px; text-align: left; text-indent: 0pt; padding-left: 0px;"&gt;)&lt;/td&gt;&lt;td style="width: 15px; text-indent: 0pt; padding-left: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0pt; padding-left: 0px;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right; text-indent: 0pt; padding-left: 0px;"&gt;(10,634&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0pt; padding-left: 0px;"&gt;)&lt;/td&gt;&lt;td style="width: 15px; text-indent: 0pt; padding-left: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0pt; padding-left: 0px;"&gt;$&lt;/td&gt;&lt;td style="width: 141px; text-align: right; text-indent: 0pt; padding-left: 0px;"&gt;(11,607&lt;/td&gt;&lt;td style="width: 15px; text-align: left; text-indent: 0pt; padding-left: 0px;"&gt;)&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0px;"&gt;Interest expense&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-left: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0px;"&gt;15,084&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-left: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0px;"&gt;14,514&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-left: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0px;"&gt;41,039&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-left: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0px;"&gt;44,148&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0px;"&gt;Other&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;4,488&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt;
 padding-bottom: 1.5pt; padding-left: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;644&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;(3,346&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0px;"&gt;)&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;"&gt;6,092&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 4pt; padding-left: 10pt;"&gt;Other expenses, net&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 4pt; padding-left: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;15,111&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 4pt; padding-left: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 4pt; padding-left: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;11,246&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 4pt; padding-left: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 4pt; padding-left: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;27,059&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 4pt; padding-left: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 4pt; padding-left: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;$&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;"&gt;38,633&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-bottom: 4pt; padding-left: 0px;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
<iccc:ScheduleOfSalesToSignificantCustomersTableTextBlock contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: calibri, sans-serif; padding-left: 0pt; padding-bottom: 1.5pt; padding-right: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-left: 0pt; padding-bottom: 1.5pt; padding-right: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-left: 0pt; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; padding-right: 0pt; text-indent: 0pt;" colspan="6"&gt;Three-Month Periods&amp;#160;&lt;br /&gt;Ended September 30,&lt;/td&gt;&lt;td style="font-weight: bold; padding-left: 0pt; padding-bottom: 1.5pt; padding-right: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-left: 0pt; padding-bottom: 1.5pt; padding-right: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-left: 0pt; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; padding-right: 0pt; text-indent: 0pt;" colspan="6"&gt;Nine-Month Periods&amp;#160;&lt;br /&gt;Ended September 30,&lt;/td&gt;&lt;td style="font-weight: bold; padding-left: 0pt; padding-bottom: 1.5pt; padding-right: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: calibri, sans-serif; padding-left: 0pt; padding-bottom: 1.5pt; padding-right: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-left: 0pt; padding-bottom: 1.5pt; padding-right: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-left: 0pt; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; padding-right: 0pt; text-indent: 0pt;" colspan="2"&gt;2015&lt;/td&gt;&lt;td style="font-weight: bold; padding-left: 0pt; padding-bottom: 1.5pt; padding-right: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-left: 0pt; padding-bottom: 1.5pt; padding-right: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-left: 0pt; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; padding-right: 0pt; text-indent: 0pt;" colspan="2"&gt;2014&lt;/td&gt;&lt;td style="font-weight: bold; padding-left: 0pt; padding-bottom: 1.5pt; padding-right: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-left: 0pt; padding-bottom: 1.5pt; padding-right: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-left: 0pt; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; padding-right: 0pt; text-indent: 0pt;" colspan="2"&gt;2015&lt;/td&gt;&lt;td style="font-weight: bold; padding-left: 0pt; padding-bottom: 1.5pt; padding-right: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-left: 0pt; padding-bottom: 1.5pt; padding-right: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-left: 0pt; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; padding-right: 0pt; text-indent: 0pt;" colspan="2"&gt;2014&lt;/td&gt;&lt;td style="font-weight: bold; padding-left: 0pt; padding-bottom: 1.5pt; padding-right: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 815px; text-align: left; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', serif;"&gt;Animal Health International, Inc.&lt;sup&gt;(1)&lt;/sup&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 16px; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 142px; text-align: right; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt;"&gt;39&lt;/td&gt;&lt;td style="width: 16px; text-align: left; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 16px; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 16px; text-align: left; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 142px; text-align: right; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt;"&gt;34&lt;/td&gt;&lt;td style="width: 16px; text-align: left; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 15px; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 141px; text-align: right; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt;"&gt;41&lt;/td&gt;&lt;td style="width: 15px; text-align: left; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 15px; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 15px; text-align: left; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 141px; text-align: right; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt;"&gt;37&lt;/td&gt;&lt;td style="width: 15px; text-align: left; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', serif;"&gt;MWI Animal Health&lt;sup&gt;(2)&lt;/sup&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="padding-left: 0pt; padding-right: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt;"&gt;22&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt;"&gt;%&lt;/td&gt;&lt;td style="padding-left: 0pt; padding-right: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt;"&gt;23&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt;"&gt;%&lt;/td&gt;&lt;td style="padding-left: 0pt; padding-right: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt;"&gt;21&lt;/td&gt;&lt;td style="text-align: left; padding-left:
 0pt; padding-right: 0pt; text-indent: 0pt;"&gt;%&lt;/td&gt;&lt;td style="padding-left: 0pt; padding-right: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt;"&gt;22&lt;/td&gt;&lt;td style="text-align: left; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;br /&gt;&lt;/font&gt;&lt;font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"&gt;&lt;sup&gt;&lt;font size="2"&gt;(1)&lt;/font&gt;&lt;/sup&gt;During June 2015, Patterson Companies, Inc. (NASDAQ: PDCO) acquired Animal Health International, Inc.&lt;font style="font: 10pt/normal 'times new roman', times, serif; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"&gt;&lt;br /&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;sup&gt;(2)&lt;/sup&gt;During March 2015, AmerisourceBergen Corporation (NYSE: ABC) acquired MWI Animal Health&lt;/font&gt;&lt;/font&gt;&lt;br /&gt;&lt;/font&gt;&lt;/p&gt;</iccc:ScheduleOfSalesToSignificantCustomersTableTextBlock>
<iccc:ScheduleOfAccountsReceivableDueFromSignificantCustomersTableTextBlock contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">&lt;div&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;/p&gt;&lt;table style="font: 10pt/normal 'times new roman', times, serif; width: 1250.4px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;As of&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-stretch: normal;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;September&amp;#160;30, 2015&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: center; text-indent: 0pt; padding-left: 0pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"&gt;As of&lt;br /&gt;December&amp;#160;31, 2014&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt; font-weight: bold;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="width: 950.4px; text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;Animal Health International, Inc.&lt;sup&gt;(1)&lt;/sup&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="width: 12.8px; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12.8px; text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 112.8px; text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;37&lt;/td&gt;&lt;td style="width: 12.8px; text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 12.8px; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 12px; text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="width: 112px; text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;45&lt;/td&gt;&lt;td style="width: 12px; text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: white;"&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;MWI Animal Health&lt;sup&gt;(2)&lt;/sup&gt;&lt;/font&gt;&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;25&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;26&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;&lt;tr style="vertical-align: bottom; background-color: #cceeff;"&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;TCS Biosciences, Ltd.&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;13&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;td style="text-align: right; text-indent: 0pt; padding-left: 0pt;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;*&lt;/font&gt;&lt;/td&gt;&lt;td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;&lt;sup&gt;(1)&lt;/sup&gt;During June 2015, Patterson Companies, Inc. (NASDAQ: PDCO) acquired Animal Health International, Inc.&lt;/font&gt;&lt;font style="font-size: 10pt;"&gt;&lt;br /&gt;&lt;font style="font-family: 'times new roman', times, serif;"&gt;&lt;sup&gt;(2)&lt;/sup&gt;During March 2015, AmerisourceBergen Corporation (NYSE: ABC) acquired MWI Animal Health.&lt;/font&gt;&lt;/font&gt;&lt;/p&gt;&lt;p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"&gt;&lt;font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"&gt;*Amount is less than 10%.&lt;/font&gt;&lt;/p&gt;&lt;/div&gt;</iccc:ScheduleOfAccountsReceivableDueFromSignificantCustomersTableTextBlock>
<iccc:EffectOfDilutiveStockOptions contextRef="Context_3ME_01_Jul_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="shares" decimals="INF">78798</iccc:EffectOfDilutiveStockOptions>
<iccc:EffectOfDilutiveStockOptions contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="shares" decimals="INF">0</iccc:EffectOfDilutiveStockOptions>
<iccc:EffectOfDilutiveStockOptions contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="shares" decimals="INF">136174</iccc:EffectOfDilutiveStockOptions>
<iccc:EffectOfDilutiveStockOptions contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="shares" decimals="INF">124509</iccc:EffectOfDilutiveStockOptions>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_3ME_01_Jul_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="shares" decimals="INF">85000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="shares" decimals="INF">251000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="shares" decimals="INF">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="shares" decimals="INF">3000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<iccc:ShareBasedCompensationDecreaseIncreaseInIncomeLossBeforeIncomeTaxDescription contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00">Less than $0.01</iccc:ShareBasedCompensationDecreaseIncreaseInIncomeLossBeforeIncomeTaxDescription>
<iccc:ShareBasedCompensationDecreaseIncreaseInIncomeLossBeforeIncomeTaxDescription contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">Less than $0.01</iccc:ShareBasedCompensationDecreaseIncreaseInIncomeLossBeforeIncomeTaxDescription>
<us-gaap:AdvertisingExpense contextRef="Context_3ME_01_Jul_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">15844</us-gaap:AdvertisingExpense>
<us-gaap:AdvertisingExpense contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">42915</us-gaap:AdvertisingExpense>
<us-gaap:AdvertisingExpense contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">27545</us-gaap:AdvertisingExpense>
<us-gaap:AdvertisingExpense contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">72539</us-gaap:AdvertisingExpense>
<us-gaap:CashFDICInsuredAmount contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">250000</us-gaap:CashFDICInsuredAmount>
<us-gaap:DebtIssuanceCosts contextRef="Context_9ME_31_Dec_2009T00_00_00_TO_30_Sep_2010T00_00_00" unitRef="USD" decimals="0">26489</us-gaap:DebtIssuanceCosts>
<us-gaap:DebtIssuanceCosts contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">32759</us-gaap:DebtIssuanceCosts>
<us-gaap:USGovernmentSecuritiesAtCarryingValue contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">566637</us-gaap:USGovernmentSecuritiesAtCarryingValue>
<us-gaap:USGovernmentSecuritiesAtCarryingValue contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">1968787</us-gaap:USGovernmentSecuritiesAtCarryingValue>
<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_PropertyPlantAndEquipmentByTypeAxis_BuildingImprovementsMember">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_PropertyPlantAndEquipmentByTypeAxis_BuildingAdditionMember">P25Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_PropertyPlantAndEquipmentByTypeAxis_ComputerEquipmentMember">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_PropertyPlantAndEquipmentByTypeAxis_OtherAssetsMember">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_PropertyPlantAndEquipmentByTypeAxis_PropertyPlantAndEquipmentOtherTypesMember_RangeAxis_MinimumMember">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_PropertyPlantAndEquipmentByTypeAxis_PropertyPlantAndEquipmentOtherTypesMember_RangeAxis_MaximumMember">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
<us-gaap:CashCashEquivalentsAndShortTermInvestments contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">3339028</us-gaap:CashCashEquivalentsAndShortTermInvestments>
<us-gaap:CashCashEquivalentsAndShortTermInvestments contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">6189087</us-gaap:CashCashEquivalentsAndShortTermInvestments>
<iccc:CashAndCashEquivalentsShortTermAndLongTermInvestments contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">3835028</iccc:CashAndCashEquivalentsShortTermAndLongTermInvestments>
<iccc:CashAndCashEquivalentsShortTermAndLongTermInvestments contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">6676087</iccc:CashAndCashEquivalentsShortTermAndLongTermInvestments>
<iccc:IncreaseDecreaseInShortTermInvestments contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">1231000</iccc:IncreaseDecreaseInShortTermInvestments>
<iccc:IncreaseDecreaseInCashAndCashEquivalentsAndShortTermInvestments contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">2850059</iccc:IncreaseDecreaseInCashAndCashEquivalentsAndShortTermInvestments>
<iccc:IncreaseDecreaseInLongTermInvestments contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">-9000</iccc:IncreaseDecreaseInLongTermInvestments>
<iccc:IncreaseDecreaseInCashAndCashEquivalentsShortTermAndLongtermInvestments contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">2841059</iccc:IncreaseDecreaseInCashAndCashEquivalentsShortTermAndLongtermInvestments>
<us-gaap:InventoryRawMaterials contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">306444</us-gaap:InventoryRawMaterials>
<us-gaap:InventoryRawMaterials contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">337538</us-gaap:InventoryRawMaterials>
<us-gaap:InventoryWorkInProcess contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">355745</us-gaap:InventoryWorkInProcess>
<us-gaap:InventoryWorkInProcess contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">468059</us-gaap:InventoryWorkInProcess>
<us-gaap:InventoryFinishedGoods contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">283566</us-gaap:InventoryFinishedGoods>
<us-gaap:InventoryFinishedGoods contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">58847</us-gaap:InventoryFinishedGoods>
<us-gaap:IncreaseDecreaseInRawMaterialsPackagingMaterialsAndSuppliesInventories contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">31094</us-gaap:IncreaseDecreaseInRawMaterialsPackagingMaterialsAndSuppliesInventories>
<iccc:IncreaseDecreaseInWorkInProcessInventories contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">112314</iccc:IncreaseDecreaseInWorkInProcessInventories>
<iccc:IncreaseDecreaseInFinishedGoodsInventories contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">-224719</iccc:IncreaseDecreaseInFinishedGoodsInventories>
<us-gaap:AccountsReceivableGrossCurrent contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">1004990</us-gaap:AccountsReceivableGrossCurrent>
<us-gaap:AccountsReceivableGrossCurrent contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">783547</us-gaap:AccountsReceivableGrossCurrent>
<us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">-16194</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
<us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">-16958</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
<us-gaap:AccountsReceivableNet contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">988796</us-gaap:AccountsReceivableNet>
<us-gaap:AccountsReceivableNet contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">766589</us-gaap:AccountsReceivableNet>
<us-gaap:OtherReceivables contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">16496</us-gaap:OtherReceivables>
<us-gaap:OtherReceivables contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">22625</us-gaap:OtherReceivables>
<iccc:IncreaseDecreaseInAccountsReceivableGross contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">-221443</iccc:IncreaseDecreaseInAccountsReceivableGross>
<us-gaap:AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">-764</us-gaap:AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease>
<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">-222207</us-gaap:IncreaseDecreaseInAccountsReceivable>
<us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">6129</us-gaap:IncreaseDecreaseInAccountsAndOtherReceivables>
<us-gaap:OtherPrepaidExpenseCurrent contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">133119</us-gaap:OtherPrepaidExpenseCurrent>
<us-gaap:OtherPrepaidExpenseCurrent contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">234628</us-gaap:OtherPrepaidExpenseCurrent>
<us-gaap:SecurityDeposit contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">15280</us-gaap:SecurityDeposit>
<us-gaap:SecurityDeposit contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">40931</us-gaap:SecurityDeposit>
<us-gaap:DeferredFinanceCostsNet contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">26489</us-gaap:DeferredFinanceCostsNet>
<us-gaap:DeferredFinanceCostsNet contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">59248</us-gaap:DeferredFinanceCostsNet>
<us-gaap:AccumulatedAmortizationDeferredFinanceCosts contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">16479</us-gaap:AccumulatedAmortizationDeferredFinanceCosts>
<us-gaap:AccumulatedAmortizationDeferredFinanceCosts contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">18553</us-gaap:AccumulatedAmortizationDeferredFinanceCosts>
<us-gaap:DepositAssets contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">8920</us-gaap:DepositAssets>
<us-gaap:DepositAssets contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">8920</us-gaap:DepositAssets>
<us-gaap:PrepaidExpenseAndOtherAssets contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">167329</us-gaap:PrepaidExpenseAndOtherAssets>
<us-gaap:PrepaidExpenseAndOtherAssets contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">325174</us-gaap:PrepaidExpenseAndOtherAssets>
<us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">101509</us-gaap:IncreaseDecreaseInPrepaidExpense>
<us-gaap:IncreaseDecreaseInSecurityDeposits contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">-25651</us-gaap:IncreaseDecreaseInSecurityDeposits>
<us-gaap:IncreaseDecreaseInOtherCurrentAssets contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">127160</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
<iccc:IncreaseDecreaseDebtIssueCosts contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">-32759</iccc:IncreaseDecreaseDebtIssueCosts>
<iccc:IncreaseDecreaseAccumulatedAmortizationOfDebtIssueCosts contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">2074</iccc:IncreaseDecreaseAccumulatedAmortizationOfDebtIssueCosts>
<us-gaap:IncreaseDecreaseInOtherDeposits contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">0</us-gaap:IncreaseDecreaseInOtherDeposits>
<us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">30685</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
<iccc:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssetsIncludingAmortization contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">157845</iccc:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssetsIncludingAmortization>
<us-gaap:MachineryAndEquipmentGross contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">3522465</us-gaap:MachineryAndEquipmentGross>
<us-gaap:MachineryAndEquipmentGross contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">3602690</us-gaap:MachineryAndEquipmentGross>
<us-gaap:BuildingsAndImprovementsGross contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">2969891</us-gaap:BuildingsAndImprovementsGross>
<us-gaap:BuildingsAndImprovementsGross contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">4579852</us-gaap:BuildingsAndImprovementsGross>
<us-gaap:FurnitureAndFixturesGross contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">470607</us-gaap:FurnitureAndFixturesGross>
<us-gaap:FurnitureAndFixturesGross contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">569567</us-gaap:FurnitureAndFixturesGross>
<us-gaap:ConstructionInProgressGross contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0" id="Item_1">1270672</us-gaap:ConstructionInProgressGross>
<us-gaap:ConstructionInProgressGross contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0" id="Item_3">738282</us-gaap:ConstructionInProgressGross>
<us-gaap:Land contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">50000</us-gaap:Land>
<us-gaap:Land contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">72807</us-gaap:Land>
<us-gaap:PropertyPlantAndEquipmentGross contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">8283635</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">9563198</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">-4445988</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">-4607584</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
<us-gaap:PropertyPlantAndEquipmentGrossPeriodIncreaseDecrease contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">1279563</us-gaap:PropertyPlantAndEquipmentGrossPeriodIncreaseDecrease>
<us-gaap:PropertyPlantAndEquipmentGrossPeriodIncreaseDecrease contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_PropertyPlantAndEquipmentByTypeAxis_ManufacturingFacilityMember" unitRef="USD" decimals="0">80225</us-gaap:PropertyPlantAndEquipmentGrossPeriodIncreaseDecrease>
<us-gaap:PropertyPlantAndEquipmentGrossPeriodIncreaseDecrease contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_PropertyPlantAndEquipmentByTypeAxis_BuildingImprovementsMember" unitRef="USD" decimals="0">1609961</us-gaap:PropertyPlantAndEquipmentGrossPeriodIncreaseDecrease>
<us-gaap:PropertyPlantAndEquipmentGrossPeriodIncreaseDecrease contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentMember" unitRef="USD" decimals="0">98960</us-gaap:PropertyPlantAndEquipmentGrossPeriodIncreaseDecrease>
<us-gaap:PropertyPlantAndEquipmentGrossPeriodIncreaseDecrease contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_PropertyPlantAndEquipmentByTypeAxis_ConstructionInProgressMember" unitRef="USD" decimals="0" id="Item_4">-532390</us-gaap:PropertyPlantAndEquipmentGrossPeriodIncreaseDecrease>
<us-gaap:PropertyPlantAndEquipmentGrossPeriodIncreaseDecrease contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_PropertyPlantAndEquipmentByTypeAxis_LandMember" unitRef="USD" decimals="0">22807</us-gaap:PropertyPlantAndEquipmentGrossPeriodIncreaseDecrease>
<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentPeriodIncreaseDecrease contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">-161596</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentPeriodIncreaseDecrease>
<iccc:PropertyPlantAndEquipmentnetPeriodIncreaseDecrease contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">1117967</iccc:PropertyPlantAndEquipmentnetPeriodIncreaseDecrease>
<us-gaap:AccountsPayableOtherCurrent contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">251383</us-gaap:AccountsPayableOtherCurrent>
<us-gaap:AccountsPayableOtherCurrent contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">37965</us-gaap:AccountsPayableOtherCurrent>
<us-gaap:AccountsPayableTradeCurrent contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">204810</us-gaap:AccountsPayableTradeCurrent>
<us-gaap:AccountsPayableTradeCurrent contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">178542</us-gaap:AccountsPayableTradeCurrent>
<us-gaap:AccruedPayrollTaxesCurrent contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">145176</us-gaap:AccruedPayrollTaxesCurrent>
<us-gaap:AccruedPayrollTaxesCurrent contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">134466</us-gaap:AccruedPayrollTaxesCurrent>
<iccc:AccruedClinicalStudies contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">131945</iccc:AccruedClinicalStudies>
<iccc:AccruedClinicalStudies contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">68428</iccc:AccruedClinicalStudies>
<us-gaap:AccruedProfessionalFeesCurrent contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">42250</us-gaap:AccruedProfessionalFeesCurrent>
<us-gaap:AccruedProfessionalFeesCurrent contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">55462</us-gaap:AccruedProfessionalFeesCurrent>
<us-gaap:OtherAccountsPayableAndAccruedLiabilities contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">76113</us-gaap:OtherAccountsPayableAndAccruedLiabilities>
<us-gaap:OtherAccountsPayableAndAccruedLiabilities contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">71064</us-gaap:OtherAccountsPayableAndAccruedLiabilities>
<us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">851677</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
<us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">545927</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
<us-gaap:IncreaseDecreaseInOperatingCapital contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">213418</us-gaap:IncreaseDecreaseInOperatingCapital>
<us-gaap:IncreaseDecreaseInAccountsPayableTrade contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">-26268</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
<us-gaap:IncreaseDecreaseInAccruedSalaries contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">-10710</us-gaap:IncreaseDecreaseInAccruedSalaries>
<iccc:IncreaseDecreaseInAccruedClinicalStudies contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">-63517</iccc:IncreaseDecreaseInAccruedClinicalStudies>
<iccc:IncreaseDecreaseInAccruedProfessionalFees contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">13212</iccc:IncreaseDecreaseInAccruedProfessionalFees>
<us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">-5049</us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities>
<iccc:IncreaseDecreaseInAccountsPayableAndAccruedExpenses contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">-305750</iccc:IncreaseDecreaseInAccountsPayableAndAccruedExpenses>
<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">33414</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00_DebtInstrumentAxis_MortgagesMember" unitRef="USD" decimals="0">14043</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00_DebtInstrumentAxis_NotesPayableToBanksMember" unitRef="USD" decimals="0">19371</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">135840</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo>
<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00_DebtInstrumentAxis_MortgagesMember" unitRef="USD" decimals="0">57384</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo>
<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00_DebtInstrumentAxis_NotesPayableToBanksMember" unitRef="USD" decimals="0">78456</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo>
<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">143364</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree>
<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00_DebtInstrumentAxis_MortgagesMember" unitRef="USD" decimals="0">61056</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree>
<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00_DebtInstrumentAxis_NotesPayableToBanksMember" unitRef="USD" decimals="0">82308</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree>
<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">150973</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour>
<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00_DebtInstrumentAxis_MortgagesMember" unitRef="USD" decimals="0">64876</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour>
<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00_DebtInstrumentAxis_NotesPayableToBanksMember" unitRef="USD" decimals="0">86097</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour>
<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">158905</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive>
<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00_DebtInstrumentAxis_MortgagesMember" unitRef="USD" decimals="0">68908</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive>
<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00_DebtInstrumentAxis_NotesPayableToBanksMember" unitRef="USD" decimals="0">89997</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive>
<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFive contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">2637467</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFive>
<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFive contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00_DebtInstrumentAxis_MortgagesMember" unitRef="USD" decimals="0">493696</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFive>
<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFive contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00_DebtInstrumentAxis_NotesPayableToBanksMember" unitRef="USD" decimals="0">2143771</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFive>
<iccc:TotalLiabilitiesDebtCurrentPortionAndLongTermPortion contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">3259963</iccc:TotalLiabilitiesDebtCurrentPortionAndLongTermPortion>
<iccc:TotalLiabilitiesDebtCurrentPortionAndLongTermPortion contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00_DebtInstrumentAxis_MortgagesMember" unitRef="USD" decimals="0">759963</iccc:TotalLiabilitiesDebtCurrentPortionAndLongTermPortion>
<iccc:TotalLiabilitiesDebtCurrentPortionAndLongTermPortion contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00_DebtInstrumentAxis_NotesPayableToBanksMember" unitRef="USD" decimals="0">2500000</iccc:TotalLiabilitiesDebtCurrentPortionAndLongTermPortion>
<us-gaap:DebtInstrumentMaturityDateDescription contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_DebtInstrumentAxis_LineOfCreditMember">The $500,000 line of credit is available as needed and has been extended through May 31, 2016 and is renewable annually thereafter.</us-gaap:DebtInstrumentMaturityDateDescription>
<us-gaap:DebtInstrumentTerm contextRef="Context_3ME_01_Jul_2010T00_00_00_TO_30_Sep_2010T00_00_00_DebtInstrumentAxis_MortgagesOneMember">P15Y</us-gaap:DebtInstrumentTerm>
<us-gaap:DebtInstrumentTerm contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00_DebtInstrumentAxis_MortgagesTwoMember">P20Y</us-gaap:DebtInstrumentTerm>
<us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="Context_3ME_01_Jul_2010T00_00_00_TO_30_Sep_2010T00_00_00_DebtInstrumentAxis_MortgagesOneMember" unitRef="USD" decimals="0">1000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
<us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00_DebtInstrumentAxis_MortgagesTwoMember" unitRef="USD" decimals="0">2500000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
<us-gaap:MortgageLoansOnRealEstatePeriodicPaymentTermsBalloonPaymentToBeReceived contextRef="Context_As_Of_30_Sep_2010T00_00_00_TO_30_Sep_2010T00_00_00_DebtInstrumentAxis_MortgagesOneMember" unitRef="USD" decimals="0">451885</us-gaap:MortgageLoansOnRealEstatePeriodicPaymentTermsBalloonPaymentToBeReceived>
<us-gaap:MortgageLoansOnRealEstatePeriodicPaymentTermsBalloonPaymentToBeReceived contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00_DebtInstrumentAxis_MortgagesTwoMember" unitRef="USD" decimals="0">1550007</us-gaap:MortgageLoansOnRealEstatePeriodicPaymentTermsBalloonPaymentToBeReceived>
<us-gaap:MortgageLoansOnRealEstatePeriodicPaymentTerms contextRef="Context_3ME_01_Jul_2010T00_00_00_TO_30_Sep_2010T00_00_00_DebtInstrumentAxis_MortgagesOneMember">Will be due during the third quarter of 2020.</us-gaap:MortgageLoansOnRealEstatePeriodicPaymentTerms>
<us-gaap:MortgageLoansOnRealEstatePeriodicPaymentTerms contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00_DebtInstrumentAxis_MortgagesTwoMember">Will be due during the third quarter of 2025.</us-gaap:MortgageLoansOnRealEstatePeriodicPaymentTerms>
<us-gaap:LongTermDebtPercentageBearingFixedInterestRate contextRef="Context_As_Of_30_Sep_2010T00_00_00_TO_30_Sep_2010T00_00_00_DebtInstrumentAxis_InterestRateSwapMember" unitRef="pure" decimals="4">0.0604</us-gaap:LongTermDebtPercentageBearingFixedInterestRate>
<us-gaap:LongTermDebtPercentageBearingFixedInterestRate contextRef="Context_As_Of_31_Mar_2011T00_00_00_TO_31_Mar_2011T00_00_00" unitRef="pure" decimals="4">0.0425</us-gaap:LongTermDebtPercentageBearingFixedInterestRate>
<us-gaap:LongTermDebtPercentageBearingFixedInterestRate contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00_DebtInstrumentAxis_InterestRateSwapMember" unitRef="pure" decimals="4">0.0438</us-gaap:LongTermDebtPercentageBearingFixedInterestRate>
<invest:DerivativeNotionalAmount contextRef="Context_As_Of_30_Sep_2010T00_00_00_TO_30_Sep_2010T00_00_00_DebtInstrumentAxis_InterestRateSwapMember" unitRef="USD" decimals="0">1000000</invest:DerivativeNotionalAmount>
<invest:DerivativeNotionalAmount contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00_DebtInstrumentAxis_InterestRateSwapMember" unitRef="USD" decimals="0">3259963</invest:DerivativeNotionalAmount>
<us-gaap:ProceedsFromNotesPayable contextRef="Context_3ME_01_Jan_2011T00_00_00_TO_31_Mar_2011T00_00_00" unitRef="USD" decimals="0">600000</us-gaap:ProceedsFromNotesPayable>
<us-gaap:DebtInstrumentDescriptionOfVariableRateBasis contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_DebtInstrumentAxis_LineOfCreditMember">&lt;div&gt;Interest on any borrowings against the line of credit would be variable at the higher of 4.25% per annum or the one-month LIBOR plus 3.5% per annum.&lt;/div&gt;</us-gaap:DebtInstrumentDescriptionOfVariableRateBasis>
<iccc:DerivativesInterestRateSwapPayments contextRef="Context_3ME_01_Jul_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">5538</iccc:DerivativesInterestRateSwapPayments>
<iccc:DerivativesInterestRateSwapPayments contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">16726</iccc:DerivativesInterestRateSwapPayments>
<iccc:DerivativesInterestRateSwapPayments contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">5112</iccc:DerivativesInterestRateSwapPayments>
<iccc:DerivativesInterestRateSwapPayments contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">15549</iccc:DerivativesInterestRateSwapPayments>
<us-gaap:LineOfCreditFacilityDescription contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">a wholly owned subsidiary of TD Financial Group, which is a multinational bank with approximately $944 billion in assets and over 22 million clients worldwide</us-gaap:LineOfCreditFacilityDescription>
<us-gaap:InterestIncomeOther contextRef="Context_3ME_01_Jul_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">-3912</us-gaap:InterestIncomeOther>
<us-gaap:InterestIncomeOther contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">-11607</us-gaap:InterestIncomeOther>
<us-gaap:InterestIncomeOther contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">-4461</us-gaap:InterestIncomeOther>
<us-gaap:InterestIncomeOther contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">-10634</us-gaap:InterestIncomeOther>
<us-gaap:InterestExpenseOther contextRef="Context_3ME_01_Jul_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">-14514</us-gaap:InterestExpenseOther>
<us-gaap:InterestExpenseOther contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">-44148</us-gaap:InterestExpenseOther>
<us-gaap:InterestExpenseOther contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">-15084</us-gaap:InterestExpenseOther>
<us-gaap:InterestExpenseOther contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">-41039</us-gaap:InterestExpenseOther>
<us-gaap:OtherNonoperatingGainsLosses contextRef="Context_3ME_01_Jul_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">644</us-gaap:OtherNonoperatingGainsLosses>
<us-gaap:OtherNonoperatingGainsLosses contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">6092</us-gaap:OtherNonoperatingGainsLosses>
<us-gaap:OtherNonoperatingGainsLosses contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">4488</us-gaap:OtherNonoperatingGainsLosses>
<us-gaap:OtherNonoperatingGainsLosses contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">-3346</us-gaap:OtherNonoperatingGainsLosses>
<us-gaap:NonoperatingIncomeExpense contextRef="Context_3ME_01_Jul_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">11246</us-gaap:NonoperatingIncomeExpense>
<us-gaap:NonoperatingIncomeExpense contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">38633</us-gaap:NonoperatingIncomeExpense>
<us-gaap:NonoperatingIncomeExpense contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">15111</us-gaap:NonoperatingIncomeExpense>
<us-gaap:NonoperatingIncomeExpense contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">27059</us-gaap:NonoperatingIncomeExpense>
<us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="Context_3ME_01_Jul_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="pure" decimals="2">0.65</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
<us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="pure" decimals="2">0.33</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
<us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="pure" decimals="2">0.43</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
<us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="pure" decimals="2">0.43</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
<us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_IncomeTaxAuthorityAxis_StateAndLocalJurisdictionMember" unitRef="USD" decimals="0">1920000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
<us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_IncomeTaxAuthorityAxis_DomesticCountryMember" unitRef="USD" decimals="0">1750000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
<us-gaap:TaxCreditCarryforwardDescription contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00">Expire in 2027 through 2034</us-gaap:TaxCreditCarryforwardDescription>
<us-gaap:TaxCreditCarryforwardDescription contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_IncomeTaxAuthorityAxis_StateAndLocalJurisdictionMember">Expire in 2028 through 2031</us-gaap:TaxCreditCarryforwardDescription>
<us-gaap:TaxCreditCarryforwardDescription contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_IncomeTaxAuthorityAxis_DomesticCountryMember">Expire in 2029 through 2034</us-gaap:TaxCreditCarryforwardDescription>
<us-gaap:LicenseCosts contextRef="Context_3ME_01_Oct_2004T00_00_00_TO_31_Dec_2004T00_00_00_FairValueByAssetClassAxis_IndefinitelivedIntangibleAssetsMember" unitRef="USD" decimals="0">965000</us-gaap:LicenseCosts>
<us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1 contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">P15Y</us-gaap:FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1>
<iccc:InvestmentsOwnedBalancePrincipalAmount contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">820000</iccc:InvestmentsOwnedBalancePrincipalAmount>
<iccc:InvestmentsOwnedBalancePrincipalAmount contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00_IncomeStatementLocationAxis_InvestmentIncomeMember" unitRef="USD" decimals="0">1112000</iccc:InvestmentsOwnedBalancePrincipalAmount>
<us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">220000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness>
<us-gaap:OperatingLossCarryforwardsValuationAllowance contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">549000</us-gaap:OperatingLossCarryforwardsValuationAllowance>
<us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther contextRef="Context_FYE_01_Jan_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="pure" decimals="2">0.40</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther>
<iccc:CapitalExpenditures contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">728000</iccc:CapitalExpenditures>
<iccc:OtherObligations contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">261000</iccc:OtherObligations>
<iccc:InventoryProduction contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">576000</iccc:InventoryProduction>
<us-gaap:CommonStockVotingRights contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">Owner of more than 20% of our stock)</us-gaap:CommonStockVotingRights>
<us-gaap:ConcentrationRiskPercentage1 contextRef="Context_3ME_01_Jul_2014T00_00_00_TO_30_Sep_2014T00_00_00_ConcentrationRiskByBenchmarkAxis_SalesRevenueNetMember_MajorCustomersAxis_ForeignCustomersMember" unitRef="pure" decimals="2">0.11</us-gaap:ConcentrationRiskPercentage1>
<us-gaap:ConcentrationRiskPercentage1 contextRef="Context_3ME_01_Jul_2014T00_00_00_TO_30_Sep_2014T00_00_00_StatementBusinessSegmentsAxis_MwiVeterinarySupplyCompanyMember" unitRef="pure" decimals="2" id="Item_5">0.23</us-gaap:ConcentrationRiskPercentage1>
<us-gaap:ConcentrationRiskPercentage1 contextRef="Context_3ME_01_Jul_2014T00_00_00_TO_30_Sep_2014T00_00_00_StatementBusinessSegmentsAxis_AnimalHealthInternationalIncMember" unitRef="pure" decimals="2" id="Item_7">0.34</us-gaap:ConcentrationRiskPercentage1>
<us-gaap:ConcentrationRiskPercentage1 contextRef="Context_3ME_01_Jul_2014T00_00_00_TO_30_Sep_2014T00_00_00_ConcentrationRiskByBenchmarkAxis_SalesRevenueNetMember_MajorCustomersAxis_UnitedStatesDairyAndBeefIndustriesMember" unitRef="pure" decimals="2">0.84</us-gaap:ConcentrationRiskPercentage1>
<us-gaap:ConcentrationRiskPercentage1 contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_ConcentrationRiskByBenchmarkAxis_SalesRevenueNetMember_MajorCustomersAxis_ForeignCustomersMember" unitRef="pure" decimals="2">0.13</us-gaap:ConcentrationRiskPercentage1>
<us-gaap:ConcentrationRiskPercentage1 contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_StatementBusinessSegmentsAxis_MwiVeterinarySupplyCompanyMember" unitRef="pure" decimals="2" id="Item_9">0.22</us-gaap:ConcentrationRiskPercentage1>
<us-gaap:ConcentrationRiskPercentage1 contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_StatementBusinessSegmentsAxis_AnimalHealthInternationalIncMember" unitRef="pure" decimals="2" id="Item_10">0.37</us-gaap:ConcentrationRiskPercentage1>
<us-gaap:ConcentrationRiskPercentage1 contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00_ConcentrationRiskByBenchmarkAxis_SalesRevenueNetMember_MajorCustomersAxis_UnitedStatesDairyAndBeefIndustriesMember" unitRef="pure" decimals="2">0.82</us-gaap:ConcentrationRiskPercentage1>
<us-gaap:ConcentrationRiskPercentage1 contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00_ConcentrationRiskByBenchmarkAxis_SalesRevenueNetMember_MajorCustomersAxis_ForeignCustomersMember" unitRef="pure" decimals="2">0.06</us-gaap:ConcentrationRiskPercentage1>
<us-gaap:ConcentrationRiskPercentage1 contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementBusinessSegmentsAxis_MwiVeterinarySupplyCompanyMember" unitRef="pure" decimals="2" id="Item_11">0.22</us-gaap:ConcentrationRiskPercentage1>
<us-gaap:ConcentrationRiskPercentage1 contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementBusinessSegmentsAxis_AnimalHealthInternationalIncMember" unitRef="pure" decimals="2" id="Item_12">0.39</us-gaap:ConcentrationRiskPercentage1>
<us-gaap:ConcentrationRiskPercentage1 contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00_ConcentrationRiskByBenchmarkAxis_SalesRevenueNetMember_MajorCustomersAxis_UnitedStatesDairyAndBeefIndustriesMember" unitRef="pure" decimals="2">0.85</us-gaap:ConcentrationRiskPercentage1>
<us-gaap:ConcentrationRiskPercentage1 contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_ConcentrationRiskByBenchmarkAxis_SalesRevenueNetMember_MajorCustomersAxis_ForeignCustomersMember" unitRef="pure" decimals="2">0.13</us-gaap:ConcentrationRiskPercentage1>
<us-gaap:ConcentrationRiskPercentage1 contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementBusinessSegmentsAxis_MwiVeterinarySupplyCompanyMember" unitRef="pure" decimals="2" id="Item_13">0.21</us-gaap:ConcentrationRiskPercentage1>
<us-gaap:ConcentrationRiskPercentage1 contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementBusinessSegmentsAxis_AnimalHealthInternationalIncMember" unitRef="pure" decimals="2" id="Item_14">0.41</us-gaap:ConcentrationRiskPercentage1>
<us-gaap:ConcentrationRiskPercentage1 contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_ConcentrationRiskByBenchmarkAxis_SalesRevenueNetMember_MajorCustomersAxis_UnitedStatesDairyAndBeefIndustriesMember" unitRef="pure" decimals="2">0.83</us-gaap:ConcentrationRiskPercentage1>
<us-gaap:ConcentrationRiskPercentage1 contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00_ConcentrationRiskByBenchmarkAxis_SalesRevenueNetMember" unitRef="pure" decimals="2">0.10</us-gaap:ConcentrationRiskPercentage1>
<iccc:AccountsReceivableDueFromSignificantCustomers contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementBusinessSegmentsAxis_MwiVeterinarySupplyCompanyMember" unitRef="pure" decimals="2" id="Item_15">0.26</iccc:AccountsReceivableDueFromSignificantCustomers>
<iccc:AccountsReceivableDueFromSignificantCustomers contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementBusinessSegmentsAxis_AnimalHealthInternationalIncMember" unitRef="pure" decimals="2" id="Item_16">0.45</iccc:AccountsReceivableDueFromSignificantCustomers>
<iccc:AccountsReceivableDueFromSignificantCustomers contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00_StatementBusinessSegmentsAxis_AnimartLlcMember" unitRef="pure" decimals="2" id="Item_17">0.00</iccc:AccountsReceivableDueFromSignificantCustomers>
<iccc:AccountsReceivableDueFromSignificantCustomers contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementBusinessSegmentsAxis_MwiVeterinarySupplyCompanyMember" unitRef="pure" decimals="2" id="Item_19">0.25</iccc:AccountsReceivableDueFromSignificantCustomers>
<iccc:AccountsReceivableDueFromSignificantCustomers contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementBusinessSegmentsAxis_AnimalHealthInternationalIncMember" unitRef="pure" decimals="2" id="Item_20">0.37</iccc:AccountsReceivableDueFromSignificantCustomers>
<iccc:AccountsReceivableDueFromSignificantCustomers contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00_StatementBusinessSegmentsAxis_AnimartLlcMember" unitRef="pure" decimals="2">0.13</iccc:AccountsReceivableDueFromSignificantCustomers>
<us-gaap:RevenueFromRelatedParties contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">283287</us-gaap:RevenueFromRelatedParties>
<us-gaap:RevenueFromRelatedParties contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">452207</us-gaap:RevenueFromRelatedParties>
<us-gaap:AccountsReceivableRelatedPartiesCurrent contextRef="Context_As_Of_31_Dec_2014T00_00_00_TO_31_Dec_2014T00_00_00" unitRef="USD" decimals="0">18796</us-gaap:AccountsReceivableRelatedPartiesCurrent>
<us-gaap:AccountsReceivableRelatedPartiesCurrent contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">12864</us-gaap:AccountsReceivableRelatedPartiesCurrent>
<us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">6355</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
<us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">3222</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
<iccc:EmployeeSavingsPlanDescription contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">One month</iccc:EmployeeSavingsPlanDescription>
<us-gaap:DefinedBenefitPlansGeneralInformation contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00">August 2012 we have matched 100% of the first 3% of each employee's salary that is contributed to the Plan and 50% of the next 2% of each employee's salary that is contributed to the Plan.</us-gaap:DefinedBenefitPlansGeneralInformation>
<us-gaap:DefinedBenefitPlanBenefitsPaid contextRef="Context_3ME_01_Jul_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">17117</us-gaap:DefinedBenefitPlanBenefitsPaid>
<us-gaap:DefinedBenefitPlanBenefitsPaid contextRef="Context_9ME_01_Jan_2014T00_00_00_TO_30_Sep_2014T00_00_00" unitRef="USD" decimals="0">47920</us-gaap:DefinedBenefitPlanBenefitsPaid>
<us-gaap:DefinedBenefitPlanBenefitsPaid contextRef="Context_3ME_01_Jul_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">17102</us-gaap:DefinedBenefitPlanBenefitsPaid>
<us-gaap:DefinedBenefitPlanBenefitsPaid contextRef="Context_9ME_01_Jan_2015T00_00_00_TO_30_Sep_2015T00_00_00" unitRef="USD" decimals="0">54157</us-gaap:DefinedBenefitPlanBenefitsPaid>
<us-gaap:PurchaseOptionsLand contextRef="Context_As_Of_31_Dec_2015T00_00_00_TO_31_Dec_2015T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember_LegalEntityAxis_PlasPakIncMember" unitRef="USD" decimals="0">238000</us-gaap:PurchaseOptionsLand>
<us-gaap:LandPurchaseOptionsDescription contextRef="Context_3ME_01_Oct_2015T00_00_00_TO_31_Dec_2015T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember_LegalEntityAxis_PlasPakIncMember">During the fourth quarter of 2015, our Board of Directors voted to exercise an option to acquire land nearby to our existing Portland facility for a potential site for a Mast Out&amp;#174; production facility for $238,000 (less the $23,800 option payment that was paid during the third quarter of 2015).</us-gaap:LandPurchaseOptionsDescription>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Context_Custom_26_Oct_2015T00_00_00_TO_28_Oct_2015T00_00_00_SubsequentEventTypeAxis_SubsequentEventMember_LegalEntityAxis_PlasPakIncMember" unitRef="USD" decimals="0">10000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:LongTermDebtPercentageBearingVariableInterestRate contextRef="Context_As_Of_30_Sep_2010T00_00_00_TO_30_Sep_2010T00_00_00_DebtInstrumentAxis_MortgagesOneMember" unitRef="pure" decimals="4">0.0346</us-gaap:LongTermDebtPercentageBearingVariableInterestRate>
<us-gaap:LongTermDebtPercentageBearingVariableInterestRate contextRef="Context_As_Of_30_Sep_2015T00_00_00_TO_30_Sep_2015T00_00_00_DebtInstrumentAxis_MortgagesTwoMember" unitRef="pure" decimals="4">0.0245</us-gaap:LongTermDebtPercentageBearingVariableInterestRate>

<!-- Footnote Section -->
<link:footnoteLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
<link:loc xlink:type="locator" xlink:href="#Item_1" xlink:label="lab_Item_1"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_1" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_3" xlink:label="lab_Item_3"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_3" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_4" xlink:label="lab_Item_4"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_4" xlink:to="Footnote_2" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_5" xlink:label="lab_Item_5"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_5" xlink:to="Footnote_6" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_7" xlink:label="lab_Item_7"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_7" xlink:to="Footnote_8" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_9" xlink:label="lab_Item_9"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_9" xlink:to="Footnote_6" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_10" xlink:label="lab_Item_10"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_10" xlink:to="Footnote_8" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_11" xlink:label="lab_Item_11"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_11" xlink:to="Footnote_6" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_12" xlink:label="lab_Item_12"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_12" xlink:to="Footnote_8" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_13" xlink:label="lab_Item_13"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_13" xlink:to="Footnote_6" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_14" xlink:label="lab_Item_14"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_14" xlink:to="Footnote_8" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_15" xlink:label="lab_Item_15"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_15" xlink:to="Footnote_6" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_16" xlink:label="lab_Item_16"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_16" xlink:to="Footnote_8" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_17" xlink:label="lab_Item_17"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_17" xlink:to="Footnote_18" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_19" xlink:label="lab_Item_19"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_19" xlink:to="Footnote_6" order="1.0"/>
<link:loc xlink:type="locator" xlink:href="#Item_20" xlink:label="lab_Item_20"/>
<link:footnoteArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" xlink:from="lab_Item_20" xlink:to="Footnote_8" order="1.0"/>
<link:footnote xlink:type="resource" xlink:label="Footnote_2" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">As of December 31, 2014, construction in progress consisted of a building addition that was completed during the first quarter of 2015. As of September 30, 2015, construction in progress consisted principally of partial payments towards new manufacturing equipment.</link:footnote>
<link:footnote xlink:type="resource" xlink:label="Footnote_6" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">During March 2015, AmerisourceBergen Corporation (NYSE: ABC) acquired MWI Animal Health.</link:footnote>
<link:footnote xlink:type="resource" xlink:label="Footnote_8" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">During June 2015, Patterson Companies, Inc. (NASDAQ: PDCO) acquired Animal Health International, Inc.</link:footnote>
<link:footnote xlink:type="resource" xlink:label="Footnote_18" xlink:role="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">Amount is less than 10%.</link:footnote>
</link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>iccc-20150930.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<schema targetNamespace="http://www.immucell.com/20150930" elementFormDefault="qualified"
xmlns:iccc="http://www.immucell.com/20150930"
 xmlns="http://www.w3.org/2001/XMLSchema"
 xmlns:link="http://www.xbrl.org/2003/linkbase"
 xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
 xmlns:xl="http://www.xbrl.org/2003/XLink"
 xmlns:xbrli="http://www.xbrl.org/2003/instance"
 xmlns:xlink="http://www.w3.org/1999/xlink"
 xmlns:negated="http://www.xbrl.org/2009/role/negated"
 xmlns:us-gaap="http://fasb.org/us-gaap/2015-01-31"
 xmlns:us-gaap-att="http://fasb.org/us-gaap/attributes"
 xmlns:country="http://xbrl.sec.gov/country/2013-01-31"
 xmlns:currency="http://xbrl.sec.gov/currency/2014-01-31"
 xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31"
 xmlns:exch="http://xbrl.sec.gov/exch/2015-01-31"
 xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31"
 xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31"
 xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31"
 xmlns:us-types="http://fasb.org/us-types/2015-01-31"
 xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31"
 xmlns:ref="http://www.xbrl.org/2006/ref"
 xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact"
 xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
 xmlns:num="http://www.xbrl.org/dtr/type/numeric"
>
<annotation><appinfo>
<link:roleType roleURI="http://www.immucell.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
<link:definition>001 - Document - Document And Entity Information</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immucell.com/role/BalanceSheets" id="BalanceSheets">
<link:definition>002 - Statement - Balance Sheets</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immucell.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
<link:definition>003 - Statement - Balance Sheets (Parenthetical)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immucell.com/role/StatementsOfOperationsUnaudited" id="StatementsOfOperationsUnaudited">
<link:definition>004 - Statement - Statements of Operations (Unaudited)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immucell.com/role/StatementsOfComprehensiveIncomeLossUnaudited" id="StatementsOfComprehensiveIncomeLossUnaudited">
<link:definition>005 - Statement - Statements of Comprehensive Income (Loss) (Unaudited)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immucell.com/role/StatementsOfStockholdersEquityUnaudited" id="StatementsOfStockholdersEquityUnaudited">
<link:definition>006 - Statement - Statements of Stockholders' Equity (Unaudited)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immucell.com/role/StatementsOfStockholdersEquityUnauditedParenthetical" id="StatementsOfStockholdersEquityUnauditedParenthetical">
<link:definition>007 - Statement - Statements of Stockholders' Equity (Unaudited) (Parenthetical)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immucell.com/role/StatementsOfCashFlowsUnaudited" id="StatementsOfCashFlowsUnaudited">
<link:definition>008 - Statement - Statements of Cash Flows (Unaudited)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immucell.com/role/BusinessOperations" id="BusinessOperations">
<link:definition>009 - Disclosure - Business Operations</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immucell.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
<link:definition>010 - Disclosure - Summary of Significant Accounting Policies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immucell.com/role/CashCashEquivalentsShortTermInvestmentsAndLongTermInvestments" id="CashCashEquivalentsShortTermInvestmentsAndLongTermInvestments">
<link:definition>011 - Disclosure - Cash, Cash Equivalents, Short-Term Investments and Long-Term Investments</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immucell.com/role/Inventory" id="Inventory">
<link:definition>012 - Disclosure - Inventory</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immucell.com/role/AccountsReceivable" id="AccountsReceivable">
<link:definition>013 - Disclosure - Accounts Receivable</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immucell.com/role/PrepaidExpensesAndOtherAssets" id="PrepaidExpensesAndOtherAssets">
<link:definition>014 - Disclosure - Prepaid Expenses and Other Assets</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immucell.com/role/PropertyPlantAndEquipment" id="PropertyPlantAndEquipment">
<link:definition>015 - Disclosure - Property, Plant and Equipment</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immucell.com/role/AccountsPayableAndAccruedExpenses" id="AccountsPayableAndAccruedExpenses">
<link:definition>016 - Disclosure - Accounts Payable and Accrued Expenses</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immucell.com/role/BankDebt" id="BankDebt">
<link:definition>017 - Disclosure - Bank Debt</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immucell.com/role/OtherExpensesNet" id="OtherExpensesNet">
<link:definition>018 - Disclosure - Other Expenses, Net</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immucell.com/role/IncomeTaxes" id="IncomeTaxes">
<link:definition>019 - Disclosure - Income Taxes</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immucell.com/role/CommitmentsAndContingentLiabilities" id="CommitmentsAndContingentLiabilities">
<link:definition>020 - Disclosure - Commitments and Contingent Liabilities</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immucell.com/role/CommonStockRightsPlan" id="CommonStockRightsPlan">
<link:definition>021 - Disclosure - Common Stock Rights Plan</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immucell.com/role/SegmentAndSignificantCustomerInformation" id="SegmentAndSignificantCustomerInformation">
<link:definition>022 - Disclosure - Segment and Significant Customer Information</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immucell.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
<link:definition>023 - Disclosure - Related Party Transactions</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immucell.com/role/EmployeeBenefits" id="EmployeeBenefits">
<link:definition>024 - Disclosure - Employee Benefits</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immucell.com/role/SubsequentEvents" id="SubsequentEvents">
<link:definition>025 - Disclosure - Subsequent Events</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immucell.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
<link:definition>026 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immucell.com/role/SummaryofSignificantAccountingPoliciesTables" id="SummaryofSignificantAccountingPoliciesTables">
<link:definition>027 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immucell.com/role/CashCashEquivalentsShortTermInvestmentsAndLongTermInvestmentsTables" id="CashCashEquivalentsShortTermInvestmentsAndLongTermInvestmentsTables">
<link:definition>028 - Disclosure - Cash, Cash Equivalents, Short-Term Investments and Long-Term Investments (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immucell.com/role/InventoryTables" id="InventoryTables">
<link:definition>029 - Disclosure - Inventory (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immucell.com/role/AccountsReceivableTables" id="AccountsReceivableTables">
<link:definition>030 - Disclosure - Accounts Receivable (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immucell.com/role/PrepaidExpensesandOtherAssetsTables" id="PrepaidExpensesandOtherAssetsTables">
<link:definition>031 - Disclosure - Prepaid Expenses and Other Assets (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immucell.com/role/PropertyPlantAndEquipmentTables" id="PropertyPlantAndEquipmentTables">
<link:definition>032 - Disclosure - Property, Plant and Equipment (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immucell.com/role/AccountsPayableandAccruedExpensesTables" id="AccountsPayableandAccruedExpensesTables">
<link:definition>033 - Disclosure - Accounts Payable and Accrued Expenses (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immucell.com/role/BankDebtTables" id="BankDebtTables">
<link:definition>034 - Disclosure - Bank Debt (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immucell.com/role/OtherExpensesNetTables" id="OtherExpensesNetTables">
<link:definition>035 - Disclosure - Other Expenses, Net (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immucell.com/role/SegmentAndSignificantCustomerInformationTables" id="SegmentAndSignificantCustomerInformationTables">
<link:definition>036 - Disclosure - Segment and Significant Customer Information (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immucell.com/role/SummaryOfSignificantAccountingPoliciesDetails" id="SummaryOfSignificantAccountingPoliciesDetails">
<link:definition>037 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immucell.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual" id="SummaryOfSignificantAccountingPoliciesDetailsTextual">
<link:definition>038 - Disclosure - Summary of Significant Accounting Policies (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immucell.com/role/CashCashEquivalentsShortTermInvestmentsAndLongTermInvestmentsDetails" id="CashCashEquivalentsShortTermInvestmentsAndLongTermInvestmentsDetails">
<link:definition>039 - Disclosure - Cash, Cash Equivalents, Short-Term Investments and Long-Term Investments (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immucell.com/role/InventoryDetails" id="InventoryDetails">
<link:definition>040 - Disclosure - Inventory (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immucell.com/role/AccountsReceivableDetails" id="AccountsReceivableDetails">
<link:definition>041 - Disclosure - Accounts Receivable (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immucell.com/role/PrepaidExpensesandOtherAssetsDetails" id="PrepaidExpensesandOtherAssetsDetails">
<link:definition>042 - Disclosure - Prepaid Expenses and Other Assets (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immucell.com/role/PropertyPlantAndEquipmentDetails" id="PropertyPlantAndEquipmentDetails">
<link:definition>043 - Disclosure - Property, Plant and Equipment (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immucell.com/role/AccountsPayableandAccruedExpensesDetails" id="AccountsPayableandAccruedExpensesDetails">
<link:definition>044 - Disclosure - Accounts Payable and Accrued Expenses (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immucell.com/role/BankDebtDetails" id="BankDebtDetails">
<link:definition>045 - Disclosure - Bank Debt (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immucell.com/role/BankDebtDetailsTextual" id="BankDebtDetailsTextual">
<link:definition>046 - Disclosure - Bank Debt (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immucell.com/role/OtherExpensesNetDetails" id="OtherExpensesNetDetails">
<link:definition>047 - Disclosure - Other Expenses, Net (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immucell.com/role/IncomeTaxesDetails" id="IncomeTaxesDetails">
<link:definition>048 - Disclosure - Income Taxes (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immucell.com/role/CommitmentsandContingentLiabilitiesDetails" id="CommitmentsandContingentLiabilitiesDetails">
<link:definition>049 - Disclosure - Commitments and Contingent Liabilities (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immucell.com/role/CommonStockRightsPlanDetails" id="CommonStockRightsPlanDetails">
<link:definition>050 - Disclosure - Common Stock Rights Plan (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immucell.com/role/SegmentAndSignificantCustomerInformationDetails" id="SegmentAndSignificantCustomerInformationDetails">
<link:definition>051 - Disclosure - Segment and Significant Customer Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immucell.com/role/SegmentAndSignificantCustomerInformationDetails1" id="SegmentAndSignificantCustomerInformationDetails1">
<link:definition>052 - Disclosure - Segment and Significant Customer Information (Details 1)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immucell.com/role/SegmentAndSignificantCustomerInformationDetailsTextual" id="SegmentAndSignificantCustomerInformationDetailsTextual">
<link:definition>053 - Disclosure - Segment and Significant Customer Information (Details Textual)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immucell.com/role/RelatedPartyTransactionsDetails" id="RelatedPartyTransactionsDetails">
<link:definition>054 - Disclosure - Related Party Transactions (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immucell.com/role/EmployeeBenefitsDetails" id="EmployeeBenefitsDetails">
<link:definition>055 - Disclosure - Employee Benefits (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.immucell.com/role/SubsequentEventsDetails" id="SubsequentEventsDetails">
<link:definition>056 - Disclosure - Subsequent Events (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:linkbaseRef xlink:type="simple" xlink:href="iccc-20150930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
<link:linkbaseRef xlink:type="simple" xlink:href="iccc-20150930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
<link:linkbaseRef xlink:type="simple" xlink:href="iccc-20150930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
<link:linkbaseRef xlink:type="simple" xlink:href="iccc-20150930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
</appinfo></annotation>
<import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
<import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
<import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
<import namespace="http://fasb.org/us-gaap/2015-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/country/2013-01-31" schemaLocation="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/currency/2014-01-31" schemaLocation="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/exch/2015-01-31" schemaLocation="http://xbrl.sec.gov/exch/2015/exch-2015-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd"/>
<import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
<import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd"/>
<import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd"/>
<import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd"/>
<import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
<import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
<import namespace="http://fasb.org/us-types/2015-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2015/elts/us-types-2015-01-31.xsd"/>
<element name="DocumentAndEntityInformationAbstract" id="iccc_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="InterestRateSwap" id="iccc_InterestRateSwap" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="InterestRateSwapBeforeTaxes" id="iccc_InterestRateSwapBeforeTaxes" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="IncomeTaxApplicableToInterestRateSwap" id="iccc_IncomeTaxApplicableToInterestRateSwap" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="PrepaidExpensesAndOtherAssetsTextBlock" id="iccc_PrepaidExpensesAndOtherAssetsTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="CommonStockRightsPlanAbstract" id="iccc_CommonStockRightsPlanAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="CommonStockRightsPlanTextBlock" id="iccc_CommonStockRightsPlanTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="InterestRateSwapAgreementPolicyTextBlock" id="iccc_InterestRateSwapAgreementPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ExpenseRecognitionPolicyTextBlock" id="iccc_ExpenseRecognitionPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ScheduleOfSalesToSignificantCustomersTableTextBlock" id="iccc_ScheduleOfSalesToSignificantCustomersTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ScheduleOfAccountsReceivableDueFromSignificantCustomersTableTextBlock" id="iccc_ScheduleOfAccountsReceivableDueFromSignificantCustomersTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="EffectOfDilutiveStockOptions" id="iccc_EffectOfDilutiveStockOptions" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="SummaryOfSignificantAccountingPoliciesTable" id="iccc_SummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" />
<element name="BuildingAdditionMember" id="iccc_BuildingAdditionMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="SignificantAccountingPoliciesLineItems" id="iccc_SignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="SummaryOfSignificantAccountingPoliciesTextualAbstract" id="iccc_SummaryOfSignificantAccountingPoliciesTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationDecreaseIncreaseInIncomeLossBeforeIncomeTaxDescription" id="iccc_ShareBasedCompensationDecreaseIncreaseInIncomeLossBeforeIncomeTaxDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ScheduleOfCashCashEquivalentsShortTermInvestmentsAndLongTermInvestmentAbstract" id="iccc_ScheduleOfCashCashEquivalentsShortTermInvestmentsAndLongTermInvestmentAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="CashAndCashEquivalentsShortTermAndLongTermInvestments" id="iccc_CashAndCashEquivalentsShortTermAndLongTermInvestments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="IncreaseDecreaseInShortTermInvestments" id="iccc_IncreaseDecreaseInShortTermInvestments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="IncreaseDecreaseInCashAndCashEquivalentsAndShortTermInvestments" id="iccc_IncreaseDecreaseInCashAndCashEquivalentsAndShortTermInvestments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="IncreaseDecreaseInLongTermInvestments" id="iccc_IncreaseDecreaseInLongTermInvestments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="IncreaseDecreaseInCashAndCashEquivalentsShortTermAndLongtermInvestments" id="iccc_IncreaseDecreaseInCashAndCashEquivalentsShortTermAndLongtermInvestments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="ScheduleOfInventoryAbstract" id="iccc_ScheduleOfInventoryAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="IncreaseDecreaseInWorkInProcessInventories" id="iccc_IncreaseDecreaseInWorkInProcessInventories" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="IncreaseDecreaseInFinishedGoodsInventories" id="iccc_IncreaseDecreaseInFinishedGoodsInventories" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="ScheduleOfAccountsNotesLoansAndFinancingReceivableAbstract" id="iccc_ScheduleOfAccountsNotesLoansAndFinancingReceivableAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="IncreaseDecreaseInAccountsReceivableGross" id="iccc_IncreaseDecreaseInAccountsReceivableGross" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="IncreaseDecreaseDebtIssueCosts" id="iccc_IncreaseDecreaseDebtIssueCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="IncreaseDecreaseAccumulatedAmortizationOfDebtIssueCosts" id="iccc_IncreaseDecreaseAccumulatedAmortizationOfDebtIssueCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssetsIncludingAmortization" id="iccc_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssetsIncludingAmortization" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="PropertyPlantAndEquipmentnetPeriodIncreaseDecrease" id="iccc_PropertyPlantAndEquipmentnetPeriodIncreaseDecrease" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="AccruedClinicalStudies" id="iccc_AccruedClinicalStudies" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="IncreaseDecreaseInAccruedClinicalStudies" id="iccc_IncreaseDecreaseInAccruedClinicalStudies" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="IncreaseDecreaseInAccruedProfessionalFees" id="iccc_IncreaseDecreaseInAccruedProfessionalFees" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="IncreaseDecreaseInAccountsPayableAndAccruedExpenses" id="iccc_IncreaseDecreaseInAccountsPayableAndAccruedExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="TotalLiabilitiesDebtCurrentPortionAndLongTermPortion" id="iccc_TotalLiabilitiesDebtCurrentPortionAndLongTermPortion" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="MortgagesOneMember" id="iccc_MortgagesOneMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="MortgagesTwoMember" id="iccc_MortgagesTwoMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="NotePayableMember" id="iccc_NotePayableMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="TdBankNaMember" id="iccc_TdBankNaMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="DerivativesInterestRateSwapPayments" id="iccc_DerivativesInterestRateSwapPayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="IncomeTaxDisclosureTextualAbstract" id="iccc_IncomeTaxDisclosureTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="InvestmentsOwnedBalancePrincipalAmount" id="iccc_InvestmentsOwnedBalancePrincipalAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="CommitmentsAndContingenciesLiabilitiesTextualAbstract" id="iccc_CommitmentsAndContingenciesLiabilitiesTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="CapitalExpenditures" id="iccc_CapitalExpenditures" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="OtherObligations" id="iccc_OtherObligations" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" />
<element name="InventoryProduction" id="iccc_InventoryProduction" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" />
<element name="CommonStockRightsPlanTextualAbstract" id="iccc_CommonStockRightsPlanTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="AnimalHealthInternationalIncMember" id="iccc_AnimalHealthInternationalIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="MwiVeterinarySupplyCompanyMember" id="iccc_MwiVeterinarySupplyCompanyMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="AnimartLlcMember" id="iccc_AnimartLlcMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="AccountsReceivableDueFromSignificantCustomers" id="iccc_AccountsReceivableDueFromSignificantCustomers" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" />
<element name="UnitedStatesDairyAndBeefIndustriesMember" id="iccc_UnitedStatesDairyAndBeefIndustriesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="ForeignCustomersMember" id="iccc_ForeignCustomersMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="SegmentAndSignificantCustomerInformationTextualAbstract" id="iccc_SegmentAndSignificantCustomerInformationTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="RelatedPartyTransactionsTextualAbstract" id="iccc_RelatedPartyTransactionsTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="EmployeeBenefitsTextualAbstract" id="iccc_EmployeeBenefitsTextualAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="EmployeeSavingsPlanDescription" id="iccc_EmployeeSavingsPlanDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
<element name="PlasPakIncMember" id="iccc_PlasPakIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>iccc-20150930_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="iccc-20150930.xsd#BalanceSheets" roleURI="http://www.immucell.com/role/BalanceSheets"/>
<calculationLink xlink:type="extended" xlink:role="http://www.immucell.com/role/BalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_ShortTermInvestments" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent" order="30" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_InventoryNet" order="40" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="50" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsNetCurrent" xlink:label="loc_us-gaap_DeferredTaxAssetsNetCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_DeferredTaxAssetsNetCurrent" order="60" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.immucell.com/role/BalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsCurrent" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaap_LongTermInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_LongTermInvestments" order="30" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsNetNoncurrent" xlink:label="loc_us-gaap_DeferredTaxAssetsNetNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_DeferredTaxAssetsNetNoncurrent" order="40" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_OtherAssetsNoncurrent" order="50" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.immucell.com/role/BalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LoansPayableToBankCurrent" xlink:label="loc_us-gaap_LoansPayableToBankCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_LoansPayableToBankCurrent" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_DeferredRevenueCurrent" order="30" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.immucell.com/role/BalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermLoansFromBank" xlink:label="loc_us-gaap_LongTermLoansFromBank" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="loc_us-gaap_LongTermLoansFromBank" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_InterestRateSwap" xlink:label="loc_iccc_InterestRateSwap" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="loc_iccc_InterestRateSwap" order="20" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.immucell.com/role/BalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LiabilitiesCurrent" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LiabilitiesNoncurrent" order="20" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.immucell.com/role/BalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_CommonStockValue" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit" order="30" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_TreasuryStockValue" order="40" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="50" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.immucell.com/role/BalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_Liabilities" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_StockholdersEquity" order="20" use="optional" weight="1"/>
</calculationLink>
<roleRef xlink:type="simple" xlink:href="iccc-20150930.xsd#StatementsOfOperationsUnaudited" roleURI="http://www.immucell.com/role/StatementsOfOperationsUnaudited"/>
<calculationLink xlink:type="extended" xlink:role="http://www.immucell.com/role/StatementsOfOperationsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit" xlink:to="loc_us-gaap_SalesRevenueGoodsNet" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_us-gaap_CostOfGoodsSold" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit" xlink:to="loc_us-gaap_CostOfGoodsSold" order="20" use="optional" weight="-1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.immucell.com/role/StatementsOfOperationsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaap_SellingAndMarketingExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_SellingAndMarketingExpense" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense" order="30" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.immucell.com/role/StatementsOfOperationsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_GrossProfit" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_OperatingExpenses" order="20" use="optional" weight="-1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.immucell.com/role/StatementsOfOperationsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_OperatingIncomeLoss" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="loc_us-gaap_OtherNonoperatingExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="loc_us-gaap_OtherNonoperatingExpense" order="20" use="optional" weight="-1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.immucell.com/role/StatementsOfOperationsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit" order="20" use="optional" weight="-1"/>
</calculationLink>
<roleRef xlink:type="simple" xlink:href="iccc-20150930.xsd#StatementsOfComprehensiveIncomeLossUnaudited" roleURI="http://www.immucell.com/role/StatementsOfComprehensiveIncomeLossUnaudited"/>
<calculationLink xlink:type="extended" xlink:role="http://www.immucell.com/role/StatementsOfComprehensiveIncomeLossUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_InterestRateSwapBeforeTaxes" xlink:label="loc_iccc_InterestRateSwapBeforeTaxes" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="loc_iccc_InterestRateSwapBeforeTaxes" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_IncomeTaxApplicableToInterestRateSwap" xlink:label="loc_iccc_IncomeTaxApplicableToInterestRateSwap" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="loc_iccc_IncomeTaxApplicableToInterestRateSwap" order="20" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.immucell.com/role/StatementsOfComprehensiveIncomeLossUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaap_NetIncomeLoss" order="20" use="optional" weight="1"/>
</calculationLink>
<roleRef xlink:type="simple" xlink:href="iccc-20150930.xsd#StatementsOfCashFlowsUnaudited" roleURI="http://www.immucell.com/role/StatementsOfCashFlowsUnaudited"/>
<calculationLink xlink:type="extended" xlink:role="http://www.immucell.com/role/StatementsOfCashFlowsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_NetIncomeLoss" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_Depreciation" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaap_AdjustmentForAmortization" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_AdjustmentForAmortization" order="30" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits" order="40" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ShareBasedCompensation" order="50" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets" order="60" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInReceivables" order="70" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories" order="80" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="90" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="100" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue" order="110" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.immucell.com/role/StatementsOfCashFlowsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="10" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments" order="30" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="40" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.immucell.com/role/StatementsOfCashFlowsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaap_RepaymentsOfDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_RepaymentsOfDebt" order="20" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts" order="30" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised" order="40" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense" order="50" use="optional" weight="-1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.immucell.com/role/StatementsOfCashFlowsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" order="30" use="optional" weight="1"/>
</calculationLink>
<roleRef xlink:type="simple" xlink:href="iccc-20150930.xsd#SummaryOfSignificantAccountingPoliciesDetails" roleURI="http://www.immucell.com/role/SummaryOfSignificantAccountingPoliciesDetails"/>
<calculationLink xlink:type="extended" xlink:role="http://www.immucell.com/role/SummaryOfSignificantAccountingPoliciesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_EffectOfDilutiveStockOptions" xlink:label="loc_iccc_EffectOfDilutiveStockOptions" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="loc_iccc_EffectOfDilutiveStockOptions" order="20" use="optional" weight="1"/>
</calculationLink>
<roleRef xlink:type="simple" xlink:href="iccc-20150930.xsd#CashCashEquivalentsShortTermInvestmentsAndLongTermInvestmentsDetails" roleURI="http://www.immucell.com/role/CashCashEquivalentsShortTermInvestmentsAndLongTermInvestmentsDetails"/>
<calculationLink xlink:type="extended" xlink:role="http://www.immucell.com/role/CashCashEquivalentsShortTermInvestmentsAndLongTermInvestmentsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="loc_us-gaap_ShortTermInvestments" order="20" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.immucell.com/role/CashCashEquivalentsShortTermInvestmentsAndLongTermInvestmentsDetails">
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_CashAndCashEquivalentsShortTermAndLongTermInvestments" xlink:label="loc_iccc_CashAndCashEquivalentsShortTermAndLongTermInvestments" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_iccc_CashAndCashEquivalentsShortTermAndLongTermInvestments" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaap_LongTermInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_iccc_CashAndCashEquivalentsShortTermAndLongTermInvestments" xlink:to="loc_us-gaap_LongTermInvestments" order="20" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.immucell.com/role/CashCashEquivalentsShortTermInvestmentsAndLongTermInvestmentsDetails">
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_IncreaseDecreaseInCashAndCashEquivalentsAndShortTermInvestments" xlink:label="loc_iccc_IncreaseDecreaseInCashAndCashEquivalentsAndShortTermInvestments" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_iccc_IncreaseDecreaseInCashAndCashEquivalentsAndShortTermInvestments" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_IncreaseDecreaseInShortTermInvestments" xlink:label="loc_iccc_IncreaseDecreaseInShortTermInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_iccc_IncreaseDecreaseInCashAndCashEquivalentsAndShortTermInvestments" xlink:to="loc_iccc_IncreaseDecreaseInShortTermInvestments" order="20" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.immucell.com/role/CashCashEquivalentsShortTermInvestmentsAndLongTermInvestmentsDetails">
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_IncreaseDecreaseInCashAndCashEquivalentsShortTermAndLongtermInvestments" xlink:label="loc_iccc_IncreaseDecreaseInCashAndCashEquivalentsShortTermAndLongtermInvestments" />
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_IncreaseDecreaseInCashAndCashEquivalentsAndShortTermInvestments" xlink:label="loc_iccc_IncreaseDecreaseInCashAndCashEquivalentsAndShortTermInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_iccc_IncreaseDecreaseInCashAndCashEquivalentsShortTermAndLongtermInvestments" xlink:to="loc_iccc_IncreaseDecreaseInCashAndCashEquivalentsAndShortTermInvestments" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_IncreaseDecreaseInLongTermInvestments" xlink:label="loc_iccc_IncreaseDecreaseInLongTermInvestments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_iccc_IncreaseDecreaseInCashAndCashEquivalentsShortTermAndLongtermInvestments" xlink:to="loc_iccc_IncreaseDecreaseInLongTermInvestments" order="20" use="optional" weight="1"/>
</calculationLink>
<roleRef xlink:type="simple" xlink:href="iccc-20150930.xsd#InventoryDetails" roleURI="http://www.immucell.com/role/InventoryDetails"/>
<calculationLink xlink:type="extended" xlink:role="http://www.immucell.com/role/InventoryDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_us-gaap_InventoryRawMaterials" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="loc_us-gaap_InventoryRawMaterials" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaap_InventoryWorkInProcess" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="loc_us-gaap_InventoryWorkInProcess" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaap_InventoryFinishedGoods" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet" xlink:to="loc_us-gaap_InventoryFinishedGoods" order="30" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.immucell.com/role/InventoryDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInRawMaterialsPackagingMaterialsAndSuppliesInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInRawMaterialsPackagingMaterialsAndSuppliesInventories" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="loc_us-gaap_IncreaseDecreaseInRawMaterialsPackagingMaterialsAndSuppliesInventories" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_IncreaseDecreaseInWorkInProcessInventories" xlink:label="loc_iccc_IncreaseDecreaseInWorkInProcessInventories" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="loc_iccc_IncreaseDecreaseInWorkInProcessInventories" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_IncreaseDecreaseInFinishedGoodsInventories" xlink:label="loc_iccc_IncreaseDecreaseInFinishedGoodsInventories" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="loc_iccc_IncreaseDecreaseInFinishedGoodsInventories" order="30" use="optional" weight="1"/>
</calculationLink>
<roleRef xlink:type="simple" xlink:href="iccc-20150930.xsd#PrepaidExpensesandOtherAssetsDetails" roleURI="http://www.immucell.com/role/PrepaidExpensesandOtherAssetsDetails"/>
<calculationLink xlink:type="extended" xlink:role="http://www.immucell.com/role/PrepaidExpensesandOtherAssetsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaap_SecurityDeposit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaap_SecurityDeposit" order="20" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.immucell.com/role/PrepaidExpensesandOtherAssetsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="loc_us-gaap_DeferredFinanceCostsNet" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedAmortizationDeferredFinanceCosts" xlink:label="loc_us-gaap_AccumulatedAmortizationDeferredFinanceCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="loc_us-gaap_AccumulatedAmortizationDeferredFinanceCosts" order="20" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DepositAssets" xlink:label="loc_us-gaap_DepositAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="loc_us-gaap_DepositAssets" order="30" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.immucell.com/role/PrepaidExpensesandOtherAssetsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssets" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssets" xlink:to="loc_us-gaap_OtherAssetsNoncurrent" order="20" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.immucell.com/role/PrepaidExpensesandOtherAssetsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:label="loc_us-gaap_IncreaseDecreaseInSecurityDeposits" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="loc_us-gaap_IncreaseDecreaseInSecurityDeposits" order="20" use="optional" weight="-1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.immucell.com/role/PrepaidExpensesandOtherAssetsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherDeposits" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherDeposits" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherDeposits" order="10" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_IncreaseDecreaseAccumulatedAmortizationOfDebtIssueCosts" xlink:label="loc_iccc_IncreaseDecreaseAccumulatedAmortizationOfDebtIssueCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="loc_iccc_IncreaseDecreaseAccumulatedAmortizationOfDebtIssueCosts" order="20" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_IncreaseDecreaseDebtIssueCosts" xlink:label="loc_iccc_IncreaseDecreaseDebtIssueCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="loc_iccc_IncreaseDecreaseDebtIssueCosts" order="30" use="optional" weight="-1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.immucell.com/role/PrepaidExpensesandOtherAssetsDetails">
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssetsIncludingAmortization" xlink:label="loc_iccc_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssetsIncludingAmortization" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_iccc_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssetsIncludingAmortization" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_iccc_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssetsIncludingAmortization" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="20" use="optional" weight="1"/>
</calculationLink>
<roleRef xlink:type="simple" xlink:href="iccc-20150930.xsd#AccountsPayableandAccruedExpensesDetails" roleURI="http://www.immucell.com/role/AccountsPayableandAccruedExpensesDetails"/>
<calculationLink xlink:type="extended" xlink:role="http://www.immucell.com/role/AccountsPayableandAccruedExpensesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="loc_us-gaap_AccountsPayableOtherCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableOtherCurrent" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableTradeCurrent" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedPayrollTaxesCurrent" xlink:label="loc_us-gaap_AccruedPayrollTaxesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedPayrollTaxesCurrent" order="30" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_AccruedClinicalStudies" xlink:label="loc_iccc_AccruedClinicalStudies" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="loc_iccc_AccruedClinicalStudies" order="40" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent" order="50" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_OtherAccountsPayableAndAccruedLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_OtherAccountsPayableAndAccruedLiabilities" order="60" use="optional" weight="1"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.immucell.com/role/AccountsPayableandAccruedExpensesDetails">
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_IncreaseDecreaseInAccountsPayableAndAccruedExpenses" xlink:label="loc_iccc_IncreaseDecreaseInAccountsPayableAndAccruedExpenses" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_iccc_IncreaseDecreaseInAccountsPayableAndAccruedExpenses" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_IncreaseDecreaseInAccruedProfessionalFees" xlink:label="loc_iccc_IncreaseDecreaseInAccruedProfessionalFees" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_iccc_IncreaseDecreaseInAccountsPayableAndAccruedExpenses" xlink:to="loc_iccc_IncreaseDecreaseInAccruedProfessionalFees" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_IncreaseDecreaseInAccruedClinicalStudies" xlink:label="loc_iccc_IncreaseDecreaseInAccruedClinicalStudies" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_iccc_IncreaseDecreaseInAccountsPayableAndAccruedExpenses" xlink:to="loc_iccc_IncreaseDecreaseInAccruedClinicalStudies" order="30" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedSalaries" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedSalaries" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_iccc_IncreaseDecreaseInAccountsPayableAndAccruedExpenses" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedSalaries" order="40" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_iccc_IncreaseDecreaseInAccountsPayableAndAccruedExpenses" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade" order="50" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapital" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapital" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_iccc_IncreaseDecreaseInAccountsPayableAndAccruedExpenses" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapital" order="60" use="optional" weight="-1"/>
</calculationLink>
<roleRef xlink:type="simple" xlink:href="iccc-20150930.xsd#BankDebtDetails" roleURI="http://www.immucell.com/role/BankDebtDetails"/>
<calculationLink xlink:type="extended" xlink:role="http://www.immucell.com/role/BankDebtDetails">
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_TotalLiabilitiesDebtCurrentPortionAndLongTermPortion" xlink:label="loc_iccc_TotalLiabilitiesDebtCurrentPortionAndLongTermPortion" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_iccc_TotalLiabilitiesDebtCurrentPortionAndLongTermPortion" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_iccc_TotalLiabilitiesDebtCurrentPortionAndLongTermPortion" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_iccc_TotalLiabilitiesDebtCurrentPortionAndLongTermPortion" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree" order="30" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_iccc_TotalLiabilitiesDebtCurrentPortionAndLongTermPortion" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour" order="40" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_iccc_TotalLiabilitiesDebtCurrentPortionAndLongTermPortion" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive" order="50" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFive" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_iccc_TotalLiabilitiesDebtCurrentPortionAndLongTermPortion" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFive" order="60" use="optional" weight="1"/>
</calculationLink>
<roleRef xlink:type="simple" xlink:href="iccc-20150930.xsd#OtherExpensesNetDetails" roleURI="http://www.immucell.com/role/OtherExpensesNetDetails"/>
<calculationLink xlink:type="extended" xlink:role="http://www.immucell.com/role/OtherExpensesNetDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaap_InterestIncomeOther" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_InterestIncomeOther" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestExpenseOther" xlink:label="loc_us-gaap_InterestExpenseOther" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_InterestExpenseOther" order="20" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNonoperatingGainsLosses" xlink:label="loc_us-gaap_OtherNonoperatingGainsLosses" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_OtherNonoperatingGainsLosses" order="30" use="optional" weight="1"/>
</calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>iccc-20150930_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" >
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll"/>
<roleRef xlink:type="simple" xlink:href="iccc-20150930.xsd#StatementsOfStockholdersEquityUnaudited" roleURI="http://www.immucell.com/role/StatementsOfStockholdersEquityUnaudited"/>
<roleRef xlink:type="simple" xlink:href="iccc-20150930.xsd#SummaryOfSignificantAccountingPoliciesDetailsTextual" roleURI="http://www.immucell.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="iccc-20150930.xsd#PropertyPlantAndEquipmentDetails" roleURI="http://www.immucell.com/role/PropertyPlantAndEquipmentDetails"/>
<roleRef xlink:type="simple" xlink:href="iccc-20150930.xsd#BankDebtDetails" roleURI="http://www.immucell.com/role/BankDebtDetails"/>
<roleRef xlink:type="simple" xlink:href="iccc-20150930.xsd#BankDebtDetailsTextual" roleURI="http://www.immucell.com/role/BankDebtDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="iccc-20150930.xsd#IncomeTaxesDetails" roleURI="http://www.immucell.com/role/IncomeTaxesDetails"/>
<roleRef xlink:type="simple" xlink:href="iccc-20150930.xsd#SegmentAndSignificantCustomerInformationDetails" roleURI="http://www.immucell.com/role/SegmentAndSignificantCustomerInformationDetails"/>
<roleRef xlink:type="simple" xlink:href="iccc-20150930.xsd#SegmentAndSignificantCustomerInformationDetails1" roleURI="http://www.immucell.com/role/SegmentAndSignificantCustomerInformationDetails1"/>
<roleRef xlink:type="simple" xlink:href="iccc-20150930.xsd#SegmentAndSignificantCustomerInformationDetailsTextual" roleURI="http://www.immucell.com/role/SegmentAndSignificantCustomerInformationDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="iccc-20150930.xsd#SubsequentEventsDetails" roleURI="http://www.immucell.com/role/SubsequentEventsDetails"/>
<definitionLink xlink:type="extended" xlink:role="http://www.immucell.com/role/StatementsOfStockholdersEquityUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_CommonStockMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_RetainedEarningsMember_6" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_TreasuryStockMember_7" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockholdersEquity_9" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_SharesOutstanding_10" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_NetIncomeLoss_11" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_12" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_13" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_13" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_14" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_14" order="60" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense_15" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense_15" order="70" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_16" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_16" order="80" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.immucell.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual">
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_SignificantAccountingPoliciesLineItems" xlink:label="loc_iccc_SignificantAccountingPoliciesLineItems_0" />
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_SummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_iccc_SummaryOfSignificantAccountingPoliciesTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_iccc_SignificantAccountingPoliciesLineItems_0" xlink:to="loc_iccc_SummaryOfSignificantAccountingPoliciesTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_iccc_SummaryOfSignificantAccountingPoliciesTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_BuildingAdditionMember" xlink:label="loc_iccc_BuildingAdditionMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_iccc_BuildingAdditionMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BuildingImprovementsMember" xlink:label="loc_us-gaap_BuildingImprovementsMember_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_us-gaap_BuildingImprovementsMember_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_6" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_us-gaap_ComputerEquipmentMember_7" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsMember" xlink:label="loc_us-gaap_OtherAssetsMember_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_us-gaap_OtherAssetsMember_8" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_iccc_SummaryOfSignificantAccountingPoliciesTable_1" xlink:to="loc_us-gaap_RangeAxis_9" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_9" xlink:to="loc_us-gaap_RangeMember_10" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_10_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_9" xlink:to="loc_us-gaap_RangeMember_10_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_10" xlink:to="loc_us-gaap_MinimumMember_11" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_10" xlink:to="loc_us-gaap_MaximumMember_12" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_SummaryOfSignificantAccountingPoliciesTextualAbstract" xlink:label="loc_iccc_SummaryOfSignificantAccountingPoliciesTextualAbstract_13" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_iccc_SignificantAccountingPoliciesLineItems_0" xlink:to="loc_iccc_SummaryOfSignificantAccountingPoliciesTextualAbstract_13" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_ShareBasedCompensationDecreaseIncreaseInIncomeLossBeforeIncomeTaxDescription" xlink:label="loc_iccc_ShareBasedCompensationDecreaseIncreaseInIncomeLossBeforeIncomeTaxDescription_14" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_iccc_SummaryOfSignificantAccountingPoliciesTextualAbstract_13" xlink:to="loc_iccc_ShareBasedCompensationDecreaseIncreaseInIncomeLossBeforeIncomeTaxDescription_14" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_15" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_iccc_SummaryOfSignificantAccountingPoliciesTextualAbstract_13" xlink:to="loc_us-gaap_ShareBasedCompensation_15" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdvertisingExpense" xlink:label="loc_us-gaap_AdvertisingExpense_16" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_iccc_SummaryOfSignificantAccountingPoliciesTextualAbstract_13" xlink:to="loc_us-gaap_AdvertisingExpense_16" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaap_CashFDICInsuredAmount_17" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_iccc_SummaryOfSignificantAccountingPoliciesTextualAbstract_13" xlink:to="loc_us-gaap_CashFDICInsuredAmount_17" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtIssuanceCosts" xlink:label="loc_us-gaap_DebtIssuanceCosts_18" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_iccc_SummaryOfSignificantAccountingPoliciesTextualAbstract_13" xlink:to="loc_us-gaap_DebtIssuanceCosts_18" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_USGovernmentSecuritiesAtCarryingValue" xlink:label="loc_us-gaap_USGovernmentSecuritiesAtCarryingValue_19" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_iccc_SummaryOfSignificantAccountingPoliciesTextualAbstract_13" xlink:to="loc_us-gaap_USGovernmentSecuritiesAtCarryingValue_19" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_20" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_iccc_SummaryOfSignificantAccountingPoliciesTextualAbstract_13" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_20" order="60" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.immucell.com/role/PropertyPlantAndEquipmentDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ManufacturingFacilityMember" xlink:label="loc_us-gaap_ManufacturingFacilityMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_us-gaap_ManufacturingFacilityMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BuildingImprovementsMember" xlink:label="loc_us-gaap_BuildingImprovementsMember_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_us-gaap_BuildingImprovementsMember_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaap_OfficeEquipmentMember_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_us-gaap_OfficeEquipmentMember_6" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_us-gaap_ConstructionInProgressMember_7" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LandMember" xlink:label="loc_us-gaap_LandMember_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_us-gaap_LandMember_8" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MachineryAndEquipmentGross" xlink:label="loc_us-gaap_MachineryAndEquipmentGross_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_MachineryAndEquipmentGross_9" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BuildingsAndImprovementsGross" xlink:label="loc_us-gaap_BuildingsAndImprovementsGross_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_BuildingsAndImprovementsGross_10" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FurnitureAndFixturesGross" xlink:label="loc_us-gaap_FurnitureAndFixturesGross_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_FurnitureAndFixturesGross_11" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConstructionInProgressGross" xlink:label="loc_us-gaap_ConstructionInProgressGross_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_ConstructionInProgressGross_12" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Land" xlink:label="loc_us-gaap_Land_13" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_Land_13" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_14" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_14" order="60" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_15" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_15" order="70" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_16" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_16" order="80" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGrossPeriodIncreaseDecrease" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGrossPeriodIncreaseDecrease_17" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGrossPeriodIncreaseDecrease_17" order="90" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentPeriodIncreaseDecrease" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentPeriodIncreaseDecrease_18" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentPeriodIncreaseDecrease_18" order="100" use="optional"  />
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_PropertyPlantAndEquipmentnetPeriodIncreaseDecrease" xlink:label="loc_iccc_PropertyPlantAndEquipmentnetPeriodIncreaseDecrease_19" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_iccc_PropertyPlantAndEquipmentnetPeriodIncreaseDecrease_19" order="110" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.immucell.com/role/BankDebtDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_us-gaap_DebtInstrumentAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_2" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_2" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MortgagesMember" xlink:label="loc_us-gaap_MortgagesMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3" xlink:to="loc_us-gaap_MortgagesMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NotesPayableToBanksMember" xlink:label="loc_us-gaap_NotesPayableToBanksMember_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3" xlink:to="loc_us-gaap_NotesPayableToBanksMember_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_6" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo_7" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree_8" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour_9" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive_10" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFive_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFive_11" order="60" use="optional"  />
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_TotalLiabilitiesDebtCurrentPortionAndLongTermPortion" xlink:label="loc_iccc_TotalLiabilitiesDebtCurrentPortionAndLongTermPortion_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_iccc_TotalLiabilitiesDebtCurrentPortionAndLongTermPortion_12" order="70" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.immucell.com/role/BankDebtDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_us-gaap_DebtInstrumentAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_2" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_2" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3" xlink:to="loc_us-gaap_InterestRateSwapMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MortgagesMember" xlink:label="loc_us-gaap_MortgagesMember_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3" xlink:to="loc_us-gaap_MortgagesMember_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_MortgagesOneMember" xlink:label="loc_iccc_MortgagesOneMember_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3" xlink:to="loc_iccc_MortgagesOneMember_6" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_MortgagesTwoMember" xlink:label="loc_iccc_MortgagesTwoMember_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3" xlink:to="loc_iccc_MortgagesTwoMember_7" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_NotePayableMember" xlink:label="loc_iccc_NotePayableMember_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3" xlink:to="loc_iccc_NotePayableMember_8" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditMember" xlink:label="loc_us-gaap_LineOfCreditMember_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3" xlink:to="loc_us-gaap_LineOfCreditMember_9" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_dei_LegalEntityAxis_10" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_10" xlink:to="loc_dei_EntityDomain_11" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_11_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_10" xlink:to="loc_dei_EntityDomain_11_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_TdBankNaMember" xlink:label="loc_iccc_TdBankNaMember_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_11" xlink:to="loc_iccc_TdBankNaMember_12" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentMaturityDateDescription" xlink:label="loc_us-gaap_DebtInstrumentMaturityDateDescription_13" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentMaturityDateDescription_13" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaap_DebtInstrumentTerm_14" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentTerm_14" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_15" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_15" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MortgageLoansOnRealEstatePeriodicPaymentTermsBalloonPaymentToBeReceived" xlink:label="loc_us-gaap_MortgageLoansOnRealEstatePeriodicPaymentTermsBalloonPaymentToBeReceived_16" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_MortgageLoansOnRealEstatePeriodicPaymentTermsBalloonPaymentToBeReceived_16" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MortgageLoansOnRealEstatePeriodicPaymentTerms" xlink:label="loc_us-gaap_MortgageLoansOnRealEstatePeriodicPaymentTerms_17" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_MortgageLoansOnRealEstatePeriodicPaymentTerms_17" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:label="loc_us-gaap_LongTermDebtPercentageBearingFixedInterestRate_18" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_LongTermDebtPercentageBearingFixedInterestRate_18" order="60" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:label="loc_us-gaap_LongTermDebtPercentageBearingVariableInterestRate_19" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_LongTermDebtPercentageBearingVariableInterestRate_19" order="70" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_DerivativeNotionalAmount" xlink:label="loc_invest_DerivativeNotionalAmount_20" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_invest_DerivativeNotionalAmount_20" order="80" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_21" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_21" order="90" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:label="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_22" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_22" order="100" use="optional"  />
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_DerivativesInterestRateSwapPayments" xlink:label="loc_iccc_DerivativesInterestRateSwapPayments_23" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_iccc_DerivativesInterestRateSwapPayments_23" order="110" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_24" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_24" order="120" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityDescription" xlink:label="loc_us-gaap_LineOfCreditFacilityDescription_25" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_LineOfCreditFacilityDescription_25" order="130" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaap_AdjustmentForAmortization_26" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_0" xlink:to="loc_us-gaap_AdjustmentForAmortization_26" order="140" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.immucell.com/role/IncomeTaxesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_0" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_1" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_2" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_2" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_3" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_3" xlink:to="loc_us-gaap_DomesticCountryMember_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_6" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_7" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_7_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_7_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentIncomeMember" xlink:label="loc_us-gaap_InvestmentIncomeMember_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7" xlink:to="loc_us-gaap_InvestmentIncomeMember_8" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_1" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_9" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_9" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_10" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_10_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_9" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_10_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndefinitelivedIntangibleAssetsMember" xlink:label="loc_us-gaap_IndefinitelivedIntangibleAssetsMember_11" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_10" xlink:to="loc_us-gaap_IndefinitelivedIntangibleAssetsMember_11" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_IncomeTaxDisclosureTextualAbstract" xlink:label="loc_iccc_IncomeTaxDisclosureTextualAbstract_12" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_0" xlink:to="loc_iccc_IncomeTaxDisclosureTextualAbstract_12" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_13" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_iccc_IncomeTaxDisclosureTextualAbstract_12" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_13" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_14" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_iccc_IncomeTaxDisclosureTextualAbstract_12" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_14" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_15" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_iccc_IncomeTaxDisclosureTextualAbstract_12" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_15" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_16" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_iccc_IncomeTaxDisclosureTextualAbstract_12" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_16" order="30" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_17" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_iccc_IncomeTaxDisclosureTextualAbstract_12" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_17" order="40" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxCreditCarryforwardDescription" xlink:label="loc_us-gaap_TaxCreditCarryforwardDescription_18" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_iccc_IncomeTaxDisclosureTextualAbstract_12" xlink:to="loc_us-gaap_TaxCreditCarryforwardDescription_18" order="50" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LicenseCosts" xlink:label="loc_us-gaap_LicenseCosts_19" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_iccc_IncomeTaxDisclosureTextualAbstract_12" xlink:to="loc_us-gaap_LicenseCosts_19" order="60" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_20" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_iccc_IncomeTaxDisclosureTextualAbstract_12" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_20" order="70" use="optional"  />
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_InvestmentsOwnedBalancePrincipalAmount" xlink:label="loc_iccc_InvestmentsOwnedBalancePrincipalAmount_21" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_iccc_IncomeTaxDisclosureTextualAbstract_12" xlink:to="loc_iccc_InvestmentsOwnedBalancePrincipalAmount_21" order="80" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_22" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_iccc_IncomeTaxDisclosureTextualAbstract_12" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_22" order="90" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:label="loc_us-gaap_OperatingLossCarryforwardsValuationAllowance_23" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_iccc_IncomeTaxDisclosureTextualAbstract_12" xlink:to="loc_us-gaap_OperatingLossCarryforwardsValuationAllowance_23" order="100" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther_24" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_iccc_IncomeTaxDisclosureTextualAbstract_12" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther_24" order="110" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.immucell.com/role/SegmentAndSignificantCustomerInformationDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_0" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_1" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_2" xlink:to="loc_us-gaap_SegmentDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_2" xlink:to="loc_us-gaap_SegmentDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_AnimalHealthInternationalIncMember" xlink:label="loc_iccc_AnimalHealthInternationalIncMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_3" xlink:to="loc_iccc_AnimalHealthInternationalIncMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_MwiVeterinarySupplyCompanyMember" xlink:label="loc_iccc_MwiVeterinarySupplyCompanyMember_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_3" xlink:to="loc_iccc_MwiVeterinarySupplyCompanyMember_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_0" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_6" order="10" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.immucell.com/role/SegmentAndSignificantCustomerInformationDetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_0" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_1" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_2" xlink:to="loc_us-gaap_SegmentDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_2" xlink:to="loc_us-gaap_SegmentDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_AnimalHealthInternationalIncMember" xlink:label="loc_iccc_AnimalHealthInternationalIncMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_3" xlink:to="loc_iccc_AnimalHealthInternationalIncMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_MwiVeterinarySupplyCompanyMember" xlink:label="loc_iccc_MwiVeterinarySupplyCompanyMember_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_3" xlink:to="loc_iccc_MwiVeterinarySupplyCompanyMember_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_AnimartLlcMember" xlink:label="loc_iccc_AnimartLlcMember_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_3" xlink:to="loc_iccc_AnimartLlcMember_6" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_AccountsReceivableDueFromSignificantCustomers" xlink:label="loc_iccc_AccountsReceivableDueFromSignificantCustomers_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_0" xlink:to="loc_iccc_AccountsReceivableDueFromSignificantCustomers_7" order="10" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.immucell.com/role/SegmentAndSignificantCustomerInformationDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_0" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_1" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_2" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_2" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaap_SalesRevenueNetMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3" xlink:to="loc_us-gaap_SalesRevenueNetMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="loc_us-gaap_MajorCustomersAxis_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_1" xlink:to="loc_us-gaap_MajorCustomersAxis_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MajorCustomersAxis_5" xlink:to="loc_us-gaap_NameOfMajorCustomerDomain_6" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_6_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MajorCustomersAxis_5" xlink:to="loc_us-gaap_NameOfMajorCustomerDomain_6_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_UnitedStatesDairyAndBeefIndustriesMember" xlink:label="loc_iccc_UnitedStatesDairyAndBeefIndustriesMember_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_6" xlink:to="loc_iccc_UnitedStatesDairyAndBeefIndustriesMember_7" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_ForeignCustomersMember" xlink:label="loc_iccc_ForeignCustomersMember_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_6" xlink:to="loc_iccc_ForeignCustomersMember_8" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_SegmentAndSignificantCustomerInformationTextualAbstract" xlink:label="loc_iccc_SegmentAndSignificantCustomerInformationTextualAbstract_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_0" xlink:to="loc_iccc_SegmentAndSignificantCustomerInformationTextualAbstract_9" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_iccc_SegmentAndSignificantCustomerInformationTextualAbstract_9" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_10" order="0" use="optional"  />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.immucell.com/role/SubsequentEventsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_SubsequentEventTable_1" order="0" use="optional"  xbrldt:contextElement="segment" xbrldt:closed="true" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_2" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_2" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_4" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_3" xlink:to="loc_us-gaap_SubsequentEventMember_4" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_5" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_dei_LegalEntityAxis_5" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_6" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_5" xlink:to="loc_dei_EntityDomain_6" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_6_Default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_5" xlink:to="loc_dei_EntityDomain_6_Default" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_PlasPakIncMember" xlink:label="loc_iccc_PlasPakIncMember_7" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_6" xlink:to="loc_iccc_PlasPakIncMember_7" order="0" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PurchaseOptionsLand" xlink:label="loc_us-gaap_PurchaseOptionsLand_8" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_PurchaseOptionsLand_8" order="10" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LandPurchaseOptionsDescription" xlink:label="loc_us-gaap_LandPurchaseOptionsDescription_9" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_LandPurchaseOptionsDescription_9" order="20" use="optional"  />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_10" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_10" order="30" use="optional"  />
</definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>iccc-20150930_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
<labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_DocumentAndEntityInformationAbstract" xlink:label="loc_HF82J1J2G963_iccc_DocumentAndEntityInformationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_iccc_DocumentAndEntityInformationAbstract" xml:lang="en-US">Document and Entity Information [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_iccc_DocumentAndEntityInformationAbstract" xlink:to="lab_JH04L3L4I185_iccc_DocumentAndEntityInformationAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_H456J84H45669KJ14908_dei_EntityRegistrantName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_dei_EntityRegistrantName" xlink:to="lab_J678L06J67881ML36120_dei_EntityRegistrantName"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_HF82J1J2G963_dei_EntityCentralIndexKey" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_dei_EntityCentralIndexKey" xlink:to="lab_JH04L3L4I185_dei_EntityCentralIndexKey"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_H456J84H45669KJ14908_dei_CurrentFiscalYearEndDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_dei_CurrentFiscalYearEndDate" xml:lang="en-US">Current Fiscal Year End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_dei_CurrentFiscalYearEndDate" xlink:to="lab_J678L06J67881ML36120_dei_CurrentFiscalYearEndDate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_HF82J1J2G963_dei_EntityFilerCategory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_dei_EntityFilerCategory" xlink:to="lab_JH04L3L4I185_dei_EntityFilerCategory"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_H456J84H45669KJ14908_dei_DocumentType" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_dei_DocumentType" xml:lang="en-US">Document Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_dei_DocumentType" xlink:to="lab_J678L06J67881ML36120_dei_DocumentType"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_HF82J1J2G963_dei_AmendmentFlag" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_dei_AmendmentFlag" xlink:to="lab_JH04L3L4I185_dei_AmendmentFlag"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_H456J84H45669KJ14908_dei_DocumentPeriodEndDate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_dei_DocumentPeriodEndDate" xml:lang="en-US">Document Period End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_dei_DocumentPeriodEndDate" xlink:to="lab_J678L06J67881ML36120_dei_DocumentPeriodEndDate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_HF82J1J2G963_dei_DocumentFiscalPeriodFocus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_dei_DocumentFiscalPeriodFocus" xml:lang="en-US">Document Fiscal Period Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_dei_DocumentFiscalPeriodFocus" xlink:to="lab_JH04L3L4I185_dei_DocumentFiscalPeriodFocus"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_H456J84H45669KJ14908_dei_DocumentFiscalYearFocus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_dei_DocumentFiscalYearFocus" xml:lang="en-US">Document Fiscal Year Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_dei_DocumentFiscalYearFocus" xlink:to="lab_J678L06J67881ML36120_dei_DocumentFiscalYearFocus"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_HF82J1J2G963_dei_EntityCommonStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_dei_EntityCommonStockSharesOutstanding" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_JH04L3L4I185_dei_EntityCommonStockSharesOutstanding"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_H456J84H45669KJ14908_us-gaap_StatementOfFinancialPositionAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement Of Financial Position [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_J678L06J67881ML36120_us-gaap_StatementOfFinancialPositionAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_HF82J1J2G963_us-gaap_AssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_AssetsAbstract" xml:lang="en-US">Assets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_AssetsAbstract" xml:lang="en-US">ASSETS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_AssetsAbstract" xlink:to="lab_JH04L3L4I185_us-gaap_AssetsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_H456J84H45669KJ14908_us-gaap_AssetsCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Assets, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">CURRENT ASSETS:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_AssetsCurrentAbstract" xlink:to="lab_J678L06J67881ML36120_us-gaap_AssetsCurrentAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_HF82J1J2G963_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_JH04L3L4I185_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">BEGINNING CASH AND CASH EQUIVALENTS</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_JH04L3L4I185_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">ENDING CASH AND CASH EQUIVALENTS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_JH04L3L4I185_us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_H456J84H45669KJ14908_us-gaap_ShortTermInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_ShortTermInvestments" xml:lang="en-US">Short-Term Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_ShortTermInvestments" xml:lang="en-US">Short-term investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_ShortTermInvestments" xlink:to="lab_J678L06J67881ML36120_us-gaap_ShortTermInvestments"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_HF82J1J2G963_us-gaap_AccountsReceivableNetCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US">Accounts Receivable, Net, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_AccountsReceivableNetCurrent" xml:lang="en-US">Accounts receivable, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_JH04L3L4I185_us-gaap_AccountsReceivableNetCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_H456J84H45669KJ14908_us-gaap_InventoryNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_InventoryNet" xml:lang="en-US">inventory</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_InventoryNet" xml:lang="en-US">Inventory</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_InventoryNet" xml:lang="en-US">Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_InventoryNet" xlink:to="lab_J678L06J67881ML36120_us-gaap_InventoryNet"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_HF82J1J2G963_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Prepaid expenses and other assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_JH04L3L4I185_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Current subtotal</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_JH04L3L4I185_us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsNetCurrent" xlink:label="loc_H456J84H45669KJ14908_us-gaap_DeferredTaxAssetsNetCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_DeferredTaxAssetsNetCurrent" xml:lang="en-US">Deferred Tax Assets, Net, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_DeferredTaxAssetsNetCurrent" xml:lang="en-US">Current portion of deferred tax asset</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_DeferredTaxAssetsNetCurrent" xlink:to="lab_J678L06J67881ML36120_us-gaap_DeferredTaxAssetsNetCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_HF82J1J2G963_us-gaap_AssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_AssetsCurrent" xml:lang="en-US">Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_JH04L3L4I185_us-gaap_AssetsCurrent" xml:lang="en-US">Total current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_AssetsCurrent" xlink:to="lab_JH04L3L4I185_us-gaap_AssetsCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_H456J84H45669KJ14908_us-gaap_PropertyPlantAndEquipmentNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, Plant and Equipment, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, plant and equipment, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">PROPERTY, PLANT AND EQUIPMENT, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_J678L06J67881ML36120_us-gaap_PropertyPlantAndEquipmentNet"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="loc_HF82J1J2G963_us-gaap_LongTermInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_LongTermInvestments" xml:lang="en-US">Long-term Investments, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_LongTermInvestments" xml:lang="en-US">Long-term investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_LongTermInvestments" xml:lang="en-US">LONG-TERM INVESTMENTS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_LongTermInvestments" xlink:to="lab_JH04L3L4I185_us-gaap_LongTermInvestments"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsNetNoncurrent" xlink:label="loc_H456J84H45669KJ14908_us-gaap_DeferredTaxAssetsNetNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_DeferredTaxAssetsNetNoncurrent" xml:lang="en-US">Deferred Tax Assets, Net, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_DeferredTaxAssetsNetNoncurrent" xml:lang="en-US">LONG-TERM PORTION OF DEFERRED TAX ASSET</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_DeferredTaxAssetsNetNoncurrent" xlink:to="lab_J678L06J67881ML36120_us-gaap_DeferredTaxAssetsNetNoncurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_HF82J1J2G963_us-gaap_OtherAssetsNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_OtherAssetsNoncurrent" xml:lang="en-US">Other Assets, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_OtherAssetsNoncurrent" xml:lang="en-US">OTHER ASSETS, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_JH04L3L4I185_us-gaap_OtherAssetsNoncurrent" xml:lang="en-US">Long-term subtotal</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_JH04L3L4I185_us-gaap_OtherAssetsNoncurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Assets" xlink:label="loc_H456J84H45669KJ14908_us-gaap_Assets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_Assets" xml:lang="en-US">Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_Assets" xml:lang="en-US">TOTAL ASSETS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_Assets" xlink:to="lab_J678L06J67881ML36120_us-gaap_Assets"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_HF82J1J2G963_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_JH04L3L4I185_us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_H456J84H45669KJ14908_us-gaap_LiabilitiesCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Liabilities, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">CURRENT LIABILITIES:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_J678L06J67881ML36120_us-gaap_LiabilitiesCurrentAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_HF82J1J2G963_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xml:lang="en-US">Accounts Payable and Accrued Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xml:lang="en-US">Accounts payable and accrued expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xml:lang="en-US">Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:to="lab_JH04L3L4I185_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LoansPayableToBankCurrent" xlink:label="loc_H456J84H45669KJ14908_us-gaap_LoansPayableToBankCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_LoansPayableToBankCurrent" xml:lang="en-US">Loans Payable To Bank, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_LoansPayableToBankCurrent" xml:lang="en-US">Current portion of bank debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_LoansPayableToBankCurrent" xlink:to="lab_J678L06J67881ML36120_us-gaap_LoansPayableToBankCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_HF82J1J2G963_us-gaap_DeferredRevenueCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_DeferredRevenueCurrent" xml:lang="en-US">Deferred Revenue, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_DeferredRevenueCurrent" xml:lang="en-US">Deferred revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_DeferredRevenueCurrent" xlink:to="lab_JH04L3L4I185_us-gaap_DeferredRevenueCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_H456J84H45669KJ14908_us-gaap_LiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_LiabilitiesCurrent" xlink:to="lab_J678L06J67881ML36120_us-gaap_LiabilitiesCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_HF82J1J2G963_us-gaap_LiabilitiesNoncurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_LiabilitiesNoncurrentAbstract" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_LiabilitiesNoncurrentAbstract" xml:lang="en-US">LONG-TERM LIABILITIES:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_JH04L3L4I185_us-gaap_LiabilitiesNoncurrentAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermLoansFromBank" xlink:label="loc_H456J84H45669KJ14908_us-gaap_LongTermLoansFromBank" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_LongTermLoansFromBank" xml:lang="en-US">Loans Payable To Bank, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_LongTermLoansFromBank" xml:lang="en-US">Long-term portion of bank debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_LongTermLoansFromBank" xlink:to="lab_J678L06J67881ML36120_us-gaap_LongTermLoansFromBank"/>
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_InterestRateSwap" xlink:label="loc_HF82J1J2G963_iccc_InterestRateSwap" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_iccc_InterestRateSwap" xml:lang="en-US">Interest Rate Swap</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_iccc_InterestRateSwap" xml:lang="en-US">Interest rate swaps</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_JH04L3L4I185_iccc_InterestRateSwap" xml:lang="en-US">The carrying amount as of the balance sheet date of interest rate swap due beyond one year or the operating cycle, whichever is longer.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_iccc_InterestRateSwap" xlink:to="lab_JH04L3L4I185_iccc_InterestRateSwap"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_H456J84H45669KJ14908_us-gaap_LiabilitiesNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_LiabilitiesNoncurrent" xml:lang="en-US">Liabilities, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_LiabilitiesNoncurrent" xml:lang="en-US">Total long-term liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_LiabilitiesNoncurrent" xlink:to="lab_J678L06J67881ML36120_us-gaap_LiabilitiesNoncurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_HF82J1J2G963_us-gaap_Liabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_Liabilities" xml:lang="en-US">Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_JH04L3L4I185_us-gaap_Liabilities" xml:lang="en-US">TOTAL LIABILITIES</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_Liabilities" xlink:to="lab_JH04L3L4I185_us-gaap_Liabilities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_H456J84H45669KJ14908_us-gaap_StockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders Equity Attributable To Parent [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">STOCKHOLDERS' EQUITY:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_StockholdersEquityAbstract" xlink:to="lab_J678L06J67881ML36120_us-gaap_StockholdersEquityAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_HF82J1J2G963_us-gaap_CommonStockValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_CommonStockValue" xml:lang="en-US">Common stock, $0.10 par value per share, 8,000,000 shares authorized, 3,261,148 shares issued as of September 30, 2015 and December 31, 2014</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_CommonStockValue" xlink:to="lab_JH04L3L4I185_us-gaap_CommonStockValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_H456J84H45669KJ14908_us-gaap_AdditionalPaidInCapitalCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_AdditionalPaidInCapitalCommonStock" xml:lang="en-US">Additional Paid In Capital, Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_AdditionalPaidInCapitalCommonStock" xml:lang="en-US">Capital in excess of par value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_J678L06J67881ML36120_us-gaap_AdditionalPaidInCapitalCommonStock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_HF82J1J2G963_us-gaap_RetainedEarningsAccumulatedDeficit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated surplus (deficit)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_JH04L3L4I185_us-gaap_RetainedEarningsAccumulatedDeficit"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_H456J84H45669KJ14908_us-gaap_TreasuryStockValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_TreasuryStockValue" xml:lang="en-US">Treasury Stock, Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_TreasuryStockValue" xml:lang="en-US">Treasury stock, at cost, 206,114 and 234,114 shares as of September 30, 2015 and December 31, 2014, respectively</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_TreasuryStockValue" xlink:to="lab_J678L06J67881ML36120_us-gaap_TreasuryStockValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_HF82J1J2G963_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net Of Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Accumulated other comprehensive loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_JH04L3L4I185_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_H456J84H45669KJ14908_us-gaap_StockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_StockholdersEquity" xml:lang="en-US">Stockholders Equity Attributable To Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_StockholdersEquity" xml:lang="en-US">Total stockholders' equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_StockholdersEquity" xml:lang="en-US">Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_StockholdersEquity" xml:lang="en-US">Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_StockholdersEquity" xlink:to="lab_J678L06J67881ML36120_us-gaap_StockholdersEquity"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_HF82J1J2G963_us-gaap_LiabilitiesAndStockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Liabilities and Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_JH04L3L4I185_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_JH04L3L4I185_us-gaap_LiabilitiesAndStockholdersEquity"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_H456J84H45669KJ14908_us-gaap_CommonStockParOrStatedValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common Stock, Par Or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common stock, par value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common stock, par value (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_J678L06J67881ML36120_us-gaap_CommonStockParOrStatedValuePerShare"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_HF82J1J2G963_us-gaap_CommonStockSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common stock, shares authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_JH04L3L4I185_us-gaap_CommonStockSharesAuthorized"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_H456J84H45669KJ14908_us-gaap_CommonStockSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, Shares, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common stock, shares issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_CommonStockSharesIssued" xlink:to="lab_J678L06J67881ML36120_us-gaap_CommonStockSharesIssued"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="loc_HF82J1J2G963_us-gaap_TreasuryStockShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_TreasuryStockShares" xml:lang="en-US">Treasury Stock, Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_TreasuryStockShares" xml:lang="en-US">Treasury stock, shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_TreasuryStockShares" xlink:to="lab_JH04L3L4I185_us-gaap_TreasuryStockShares"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_H456J84H45669KJ14908_us-gaap_IncomeStatementAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_IncomeStatementAbstract" xlink:to="lab_J678L06J67881ML36120_us-gaap_IncomeStatementAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_HF82J1J2G963_us-gaap_SalesRevenueGoodsNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_SalesRevenueGoodsNet" xml:lang="en-US">Sales Revenue, Goods, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_SalesRevenueGoodsNet" xml:lang="en-US">Product sales</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_SalesRevenueGoodsNet" xlink:to="lab_JH04L3L4I185_us-gaap_SalesRevenueGoodsNet"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_H456J84H45669KJ14908_us-gaap_CostOfGoodsSold" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_CostOfGoodsSold" xml:lang="en-US">Cost Of Goods Sold</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_CostOfGoodsSold" xml:lang="en-US">Costs of goods sold</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_CostOfGoodsSold" xlink:to="lab_J678L06J67881ML36120_us-gaap_CostOfGoodsSold"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_HF82J1J2G963_us-gaap_GrossProfit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_GrossProfit" xml:lang="en-US">Gross Profit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_GrossProfit" xml:lang="en-US">Gross margin</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_JH04L3L4I185_us-gaap_GrossProfit" xml:lang="en-US">Gross margin</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_GrossProfit" xlink:to="lab_JH04L3L4I185_us-gaap_GrossProfit"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_H456J84H45669KJ14908_us-gaap_SellingAndMarketingExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_SellingAndMarketingExpense" xml:lang="en-US">Selling and Marketing Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_SellingAndMarketingExpense" xml:lang="en-US">Sales and marketing expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_SellingAndMarketingExpense" xlink:to="lab_J678L06J67881ML36120_us-gaap_SellingAndMarketingExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_HF82J1J2G963_us-gaap_GeneralAndAdministrativeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and Administrative Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">Administrative expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_JH04L3L4I185_us-gaap_GeneralAndAdministrativeExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_H456J84H45669KJ14908_us-gaap_ResearchAndDevelopmentExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and Development Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Product development expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_J678L06J67881ML36120_us-gaap_ResearchAndDevelopmentExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_HF82J1J2G963_us-gaap_OperatingExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_OperatingExpenses" xml:lang="en-US">Operating Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_JH04L3L4I185_us-gaap_OperatingExpenses" xml:lang="en-US">Operating expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_OperatingExpenses" xlink:to="lab_JH04L3L4I185_us-gaap_OperatingExpenses"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_H456J84H45669KJ14908_us-gaap_OperatingIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating Income (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Net operating income (loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_OperatingIncomeLoss" xml:lang="en-US">NET OPERATING INCOME (LOSS)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_OperatingIncomeLoss" xlink:to="lab_J678L06J67881ML36120_us-gaap_OperatingIncomeLoss"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="loc_HF82J1J2G963_us-gaap_OtherNonoperatingExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_OtherNonoperatingExpense" xml:lang="en-US">Other Nonoperating Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_OtherNonoperatingExpense" xml:lang="en-US">Other expenses, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_JH04L3L4I185_us-gaap_OtherNonoperatingExpense" xml:lang="en-US">Other expenses, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_OtherNonoperatingExpense" xlink:to="lab_JH04L3L4I185_us-gaap_OtherNonoperatingExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_H456J84H45669KJ14908_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">Income (Loss) From Continuing Operations Before Income Taxes, Extraordinary Items, Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xml:lang="en-US">INCOME (LOSS) BEFORE INCOME TAXES</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_J678L06J67881ML36120_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_HF82J1J2G963_us-gaap_IncomeTaxExpenseBenefit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income tax expense (benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveVerboseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Total income tax (benefit) expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_JH04L3L4I185_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_JH04L3L4I185_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income tax expense (benefit)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_JH04L3L4I185_us-gaap_IncomeTaxExpenseBenefit"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_H456J84H45669KJ14908_us-gaap_NetIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_NetIncomeLoss" xml:lang="en-US">Net income (loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_NetIncomeLoss" xml:lang="en-US">Net income (loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_NetIncomeLoss" xml:lang="en-US">NET INCOME (LOSS)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_NetIncomeLoss" xlink:to="lab_J678L06J67881ML36120_us-gaap_NetIncomeLoss"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_HF82J1J2G963_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xml:lang="en-US">Weighted average common shares outstanding:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_JH04L3L4I185_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_H456J84H45669KJ14908_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Weighted average number of shares outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Basic</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_J678L06J67881ML36120_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_HF82J1J2G963_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Diluted number of shares outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_JH04L3L4I185_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Diluted number of shares outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_JH04L3L4I185_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_H456J84H45669KJ14908_us-gaap_EarningsPerShareAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_EarningsPerShareAbstract" xml:lang="en-US">Earnings Per Share [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_EarningsPerShareAbstract" xml:lang="en-US">NET INCOME (LOSS) PER SHARE:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_EarningsPerShareAbstract" xlink:to="lab_J678L06J67881ML36120_us-gaap_EarningsPerShareAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_HF82J1J2G963_us-gaap_EarningsPerShareBasic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_EarningsPerShareBasic" xml:lang="en-US">Earnings Per Share, Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_EarningsPerShareBasic" xml:lang="en-US">Basic (in dollar per share)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_EarningsPerShareBasic" xml:lang="en-US">Basic</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_EarningsPerShareBasic" xlink:to="lab_JH04L3L4I185_us-gaap_EarningsPerShareBasic"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_H456J84H45669KJ14908_us-gaap_EarningsPerShareDiluted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">Earnings Per Share, Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">Diluted (in dollar per share)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">Diluted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_EarningsPerShareDiluted" xlink:to="lab_J678L06J67881ML36120_us-gaap_EarningsPerShareDiluted"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_HF82J1J2G963_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xml:lang="en-US">Statement of Other Comprehensive Income [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_JH04L3L4I185_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="loc_H456J84H45669KJ14908_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xml:lang="en-US">Other Comprehensive Income (Loss), Net Of Tax [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xml:lang="en-US">Other comprehensive (loss) income:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_J678L06J67881ML36120_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_InterestRateSwapBeforeTaxes" xlink:label="loc_HF82J1J2G963_iccc_InterestRateSwapBeforeTaxes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_iccc_InterestRateSwapBeforeTaxes" xml:lang="en-US">Interest Rate Swap Before Taxes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_iccc_InterestRateSwapBeforeTaxes" xml:lang="en-US">Interest rate swaps, before taxes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_JH04L3L4I185_iccc_InterestRateSwapBeforeTaxes" xml:lang="en-US">Comprehensive income, before taxes, from forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_iccc_InterestRateSwapBeforeTaxes" xlink:to="lab_JH04L3L4I185_iccc_InterestRateSwapBeforeTaxes"/>
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_IncomeTaxApplicableToInterestRateSwap" xlink:label="loc_H456J84H45669KJ14908_iccc_IncomeTaxApplicableToInterestRateSwap" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_iccc_IncomeTaxApplicableToInterestRateSwap" xml:lang="en-US">Income Tax Applicable To Interest Rate Swap</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_J678L06J67881ML36120_iccc_IncomeTaxApplicableToInterestRateSwap" xml:lang="en-US">Income tax applicable to interest rate swaps</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_J678L06J67881ML36120_iccc_IncomeTaxApplicableToInterestRateSwap" xml:lang="en-US">This amount Represents income tax applicable to interest rate swap.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_iccc_IncomeTaxApplicableToInterestRateSwap" xlink:to="lab_J678L06J67881ML36120_iccc_IncomeTaxApplicableToInterestRateSwap"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_HF82J1J2G963_us-gaap_OtherComprehensiveIncomeLossNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Other Comprehensive Income (Loss), Net Of Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Other comprehensive income (loss), net of tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_JH04L3L4I185_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Other comprehensive (loss) income, net of taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_JH04L3L4I185_us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_H456J84H45669KJ14908_us-gaap_ComprehensiveIncomeNetOfTax" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_ComprehensiveIncomeNetOfTax" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_ComprehensiveIncomeNetOfTax" xml:lang="en-US">Total comprehensive income (loss)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_J678L06J67881ML36120_us-gaap_ComprehensiveIncomeNetOfTax"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_HF82J1J2G963_us-gaap_StatementOfStockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_StatementOfStockholdersEquityAbstract" xml:lang="en-US">Statement Of Stockholders Equity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_JH04L3L4I185_us-gaap_StatementOfStockholdersEquityAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_H456J84H45669KJ14908_us-gaap_StatementTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_StatementTable" xlink:to="lab_J678L06J67881ML36120_us-gaap_StatementTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_HF82J1J2G963_us-gaap_StatementEquityComponentsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_JH04L3L4I185_us-gaap_StatementEquityComponentsAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_H456J84H45669KJ14908_us-gaap_EquityComponentDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_EquityComponentDomain" xlink:to="lab_J678L06J67881ML36120_us-gaap_EquityComponentDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_HF82J1J2G963_us-gaap_CommonStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_CommonStockMember" xlink:to="lab_JH04L3L4I185_us-gaap_CommonStockMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_H456J84H45669KJ14908_us-gaap_AdditionalPaidInCapitalMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Capital in Excess of Par Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_J678L06J67881ML36120_us-gaap_AdditionalPaidInCapitalMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_HF82J1J2G963_us-gaap_RetainedEarningsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_RetainedEarningsMember" xml:lang="en-US">Retained Earnings [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_RetainedEarningsMember" xml:lang="en-US">Accumulated (Deficit) Surplus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_RetainedEarningsMember" xlink:to="lab_JH04L3L4I185_us-gaap_RetainedEarningsMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_H456J84H45669KJ14908_us-gaap_TreasuryStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_TreasuryStockMember" xml:lang="en-US">Treasury Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_TreasuryStockMember" xlink:to="lab_J678L06J67881ML36120_us-gaap_TreasuryStockMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_HF82J1J2G963_us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xml:lang="en-US">Accumulated Other Comprehensive Loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xml:lang="en-US">Accumulated Other Comprehensive (Loss)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_JH04L3L4I185_us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_H456J84H45669KJ14908_us-gaap_StatementLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_StatementLineItems" xlink:to="lab_J678L06J67881ML36120_us-gaap_StatementLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_HF82J1J2G963_us-gaap_SharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_SharesOutstanding" xml:lang="en-US">Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_JH04L3L4I185_us-gaap_SharesOutstanding" xml:lang="en-US">Balance (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_JH04L3L4I185_us-gaap_SharesOutstanding" xml:lang="en-US">Balance (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_SharesOutstanding" xlink:to="lab_JH04L3L4I185_us-gaap_SharesOutstanding"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_H456J84H45669KJ14908_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xml:lang="en-US">Other Comprehensive Income (Loss), Net Of Tax, Portion Attributable To Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xml:lang="en-US">Other comprehensive income (loss), net of taxes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xml:lang="en-US">Other comprehensive income (loss), net of taxes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_J678L06J67881ML36120_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xml:lang="en-US">Other comprehensive income, net of taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_J678L06J67881ML36120_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_HF82J1J2G963_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xml:lang="en-US">Exercise of stock options</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xml:lang="en-US">Option to acquire land</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_JH04L3L4I185_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_H456J84H45669KJ14908_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Exercise of stock options, Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Exercise of stock options, Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Exercises of stock options (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_J678L06J67881ML36120_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense" xlink:label="loc_HF82J1J2G963_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense" xml:lang="en-US">Stock Issued, Value, Stock Options Exercised, Net of Tax Benefit (Expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense" xml:lang="en-US">Tax benefits related to stock options</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_JH04L3L4I185_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense" xml:lang="en-US">Tax benefits related to stock options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense" xlink:to="lab_JH04L3L4I185_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_H456J84H45669KJ14908_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US">Adjustments To Additional Paid In Capital, Share-Based Compensation, Requisite Service Period Recognition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US">Stock-based compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_J678L06J67881ML36120_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_HF82J1J2G963_us-gaap_StatementOfCashFlowsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement Of Cash Flows [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_JH04L3L4I185_us-gaap_StatementOfCashFlowsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_H456J84H45669KJ14908_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Net Cash Provided By (Used In) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_J678L06J67881ML36120_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_HF82J1J2G963_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments To Reconcile Net Income (Loss) To Cash Provided By (Used In) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to reconcile net income (loss) to net cash provided by operating activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_JH04L3L4I185_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_H456J84H45669KJ14908_us-gaap_Depreciation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_Depreciation" xml:lang="en-US">Depreciation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_Depreciation" xml:lang="en-US">Depreciation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_Depreciation" xlink:to="lab_J678L06J67881ML36120_us-gaap_Depreciation"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_HF82J1J2G963_us-gaap_AdjustmentForAmortization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_AdjustmentForAmortization" xml:lang="en-US">Amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_AdjustmentForAmortization" xml:lang="en-US">Amortization of mortgage loan</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_AdjustmentForAmortization" xml:lang="en-US">Amortization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_AdjustmentForAmortization" xlink:to="lab_JH04L3L4I185_us-gaap_AdjustmentForAmortization"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:label="loc_H456J84H45669KJ14908_us-gaap_DeferredIncomeTaxesAndTaxCredits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_DeferredIncomeTaxesAndTaxCredits" xml:lang="en-US">Deferred Income Taxes and Tax Credits</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_DeferredIncomeTaxesAndTaxCredits" xml:lang="en-US">Deferred income taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:to="lab_J678L06J67881ML36120_us-gaap_DeferredIncomeTaxesAndTaxCredits"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_HF82J1J2G963_us-gaap_ShareBasedCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-based Compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_ShareBasedCompensation" xml:lang="en-US">Stock-based compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_ShareBasedCompensation" xlink:to="lab_JH04L3L4I185_us-gaap_ShareBasedCompensation"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="loc_H456J84H45669KJ14908_us-gaap_GainLossOnDispositionOfAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_GainLossOnDispositionOfAssets" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_GainLossOnDispositionOfAssets" xml:lang="en-US">Loss on disposal of fixed assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_GainLossOnDispositionOfAssets" xml:lang="en-US">(Gain) loss on disposal of fixed assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_GainLossOnDispositionOfAssets" xlink:to="lab_J678L06J67881ML36120_us-gaap_GainLossOnDispositionOfAssets"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_HF82J1J2G963_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Increase (Decrease) In Operating Capital [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Changes in:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_JH04L3L4I185_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="loc_H456J84H45669KJ14908_us-gaap_IncreaseDecreaseInReceivables" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_IncreaseDecreaseInReceivables" xml:lang="en-US">Increase (Decrease) in Receivables, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_IncreaseDecreaseInReceivables" xml:lang="en-US">(Decrease) in Accounts receivable, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_IncreaseDecreaseInReceivables" xml:lang="en-US">Receivables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_IncreaseDecreaseInReceivables" xlink:to="lab_J678L06J67881ML36120_us-gaap_IncreaseDecreaseInReceivables"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_HF82J1J2G963_us-gaap_IncreaseDecreaseInInventories" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_IncreaseDecreaseInInventories" xml:lang="en-US">Increase (Decrease) in inventories</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_JH04L3L4I185_us-gaap_IncreaseDecreaseInInventories" xml:lang="en-US">Increase (Decrease) in inventories</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_JH04L3L4I185_us-gaap_IncreaseDecreaseInInventories" xml:lang="en-US">Inventory</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_JH04L3L4I185_us-gaap_IncreaseDecreaseInInventories"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_H456J84H45669KJ14908_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US">(Decrease) Increase in Prepaid expenses and other assets, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US">Prepaid expenses and other assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_J678L06J67881ML36120_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_HF82J1J2G963_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Accounts payable and accrued expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Increase (decrease) in accounts payable and accrued liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_JH04L3L4I185_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_H456J84H45669KJ14908_us-gaap_IncreaseDecreaseInDeferredRevenue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_IncreaseDecreaseInDeferredRevenue" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_IncreaseDecreaseInDeferredRevenue" xml:lang="en-US">Deferred revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="lab_J678L06J67881ML36120_us-gaap_IncreaseDecreaseInDeferredRevenue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_HF82J1J2G963_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net Cash Provided By (Used In) Operating Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_JH04L3L4I185_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net cash provided by operating activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_JH04L3L4I185_us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_H456J84H45669KJ14908_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Net Cash Provided By (Used In) Investing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_J678L06J67881ML36120_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_HF82J1J2G963_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Payments To Acquire Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_JH04L3L4I185_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Purchase of property, plant and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_JH04L3L4I185_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:label="loc_H456J84H45669KJ14908_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xml:lang="en-US">Proceeds From Maturities, Prepayments and Calls Of Short-Term Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xml:lang="en-US">Maturities of investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:to="lab_J678L06J67881ML36120_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="loc_HF82J1J2G963_us-gaap_PaymentsToAcquireShortTermInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_PaymentsToAcquireShortTermInvestments" xml:lang="en-US">Payments To Acquire Short-Term Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_JH04L3L4I185_us-gaap_PaymentsToAcquireShortTermInvestments" xml:lang="en-US">Purchases of investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:to="lab_JH04L3L4I185_us-gaap_PaymentsToAcquireShortTermInvestments"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_H456J84H45669KJ14908_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xml:lang="en-US">Proceeds from sale of fixed assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="lab_J678L06J67881ML36120_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_HF82J1J2G963_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net Cash Provided By (Used In) Investing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_JH04L3L4I185_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net cash (used for) investing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_JH04L3L4I185_us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_H456J84H45669KJ14908_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Net Cash Provided By (Used In) Financing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_J678L06J67881ML36120_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_HF82J1J2G963_us-gaap_ProceedsFromIssuanceOfDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_ProceedsFromIssuanceOfDebt" xml:lang="en-US">Proceeds from Issuance of Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_ProceedsFromIssuanceOfDebt" xml:lang="en-US">Proceeds from debt issuance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="lab_JH04L3L4I185_us-gaap_ProceedsFromIssuanceOfDebt"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_H456J84H45669KJ14908_us-gaap_RepaymentsOfDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_RepaymentsOfDebt" xml:lang="en-US">Repayments Of Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_RepaymentsOfDebt" xml:lang="en-US">Debt principal repayments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_RepaymentsOfDebt" xlink:to="lab_J678L06J67881ML36120_us-gaap_RepaymentsOfDebt"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_HF82J1J2G963_us-gaap_PaymentsOfDebtIssuanceCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_PaymentsOfDebtIssuanceCosts" xml:lang="en-US">Payments of Debt Issuance Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_PaymentsOfDebtIssuanceCosts" xml:lang="en-US">Debt issuance costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_JH04L3L4I185_us-gaap_PaymentsOfDebtIssuanceCosts" xml:lang="en-US">Debt issuance costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_JH04L3L4I185_us-gaap_PaymentsOfDebtIssuanceCosts"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_H456J84H45669KJ14908_us-gaap_ProceedsFromStockOptionsExercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_ProceedsFromStockOptionsExercised" xml:lang="en-US">Proceeds from Stock Options Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_ProceedsFromStockOptionsExercised" xml:lang="en-US">Proceeds from exercise of stock options</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_ProceedsFromStockOptionsExercised" xml:lang="en-US">Proceeds from Stock Options Exercised</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_J678L06J67881ML36120_us-gaap_ProceedsFromStockOptionsExercised"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_HF82J1J2G963_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net Cash Provided By (Used In) Financing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_JH04L3L4I185_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net cash provided by (used for) financing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_JH04L3L4I185_us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_H456J84H45669KJ14908_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US">Increase (Decrease) in cash and cash equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US">Increase (Decrease) in cash and cash equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="lab_J678L06J67881ML36120_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_HF82J1J2G963_us-gaap_IncomeTaxesPaid" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_IncomeTaxesPaid" xml:lang="en-US">Income Taxes Paid</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_IncomeTaxesPaid" xml:lang="en-US">INCOME TAXES PAID</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_JH04L3L4I185_us-gaap_IncomeTaxesPaid" xml:lang="en-US">INCOME TAXES PAID</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_IncomeTaxesPaid" xlink:to="lab_JH04L3L4I185_us-gaap_IncomeTaxesPaid"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_H456J84H45669KJ14908_us-gaap_InterestPaid" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_InterestPaid" xml:lang="en-US">Interest Paid</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_InterestPaid" xml:lang="en-US">INTEREST EXPENSE PAID</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_InterestPaid" xml:lang="en-US">INTEREST EXPENSE PAID</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_InterestPaid" xlink:to="lab_J678L06J67881ML36120_us-gaap_InterestPaid"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_HF82J1J2G963_us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xml:lang="en-US">NON-CASH ACTIVITIES:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_JH04L3L4I185_us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_H456J84H45669KJ14908_us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xml:lang="en-US">Capital Expenditures Incurred But Not Yet Paid</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xml:lang="en-US">Change in capital expenditures included in accounts payable and accrued expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xml:lang="en-US">Change in capital expenditures included in accounts payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_J678L06J67881ML36120_us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInFairValueOfInterestRateFairValueHedgingInstruments1" xlink:label="loc_HF82J1J2G963_us-gaap_IncreaseDecreaseInFairValueOfInterestRateFairValueHedgingInstruments1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_IncreaseDecreaseInFairValueOfInterestRateFairValueHedgingInstruments1" xml:lang="en-US">Increase (Decrease) In Fair Value Of Interest Rate Fair Value Hedging Instruments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_IncreaseDecreaseInFairValueOfInterestRateFairValueHedgingInstruments1" xml:lang="en-US">Net change in fair value of interest rate swaps</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_JH04L3L4I185_us-gaap_IncreaseDecreaseInFairValueOfInterestRateFairValueHedgingInstruments1" xml:lang="en-US">Net change in fair value of interest rate swap</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_IncreaseDecreaseInFairValueOfInterestRateFairValueHedgingInstruments1" xlink:to="lab_JH04L3L4I185_us-gaap_IncreaseDecreaseInFairValueOfInterestRateFairValueHedgingInstruments1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_H456J84H45669KJ14908_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xml:lang="en-US">Business Operations [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_J678L06J67881ML36120_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="loc_HF82J1J2G963_us-gaap_NatureOfOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_NatureOfOperations" xml:lang="en-US">Nature of Operations [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_NatureOfOperations" xml:lang="en-US">BUSINESS OPERATIONS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_NatureOfOperations" xlink:to="lab_JH04L3L4I185_us-gaap_NatureOfOperations"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_H456J84H45669KJ14908_us-gaap_AccountingPoliciesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US">Summary of Significant Accounting Policies [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_J678L06J67881ML36120_us-gaap_AccountingPoliciesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_HF82J1J2G963_us-gaap_SignificantAccountingPoliciesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_JH04L3L4I185_us-gaap_SignificantAccountingPoliciesTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:label="loc_H456J84H45669KJ14908_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xml:lang="en-US">Cash, Cash Equivalents, Short-Term Investments and Long-Term Investments [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:to="lab_J678L06J67881ML36120_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:label="loc_HF82J1J2G963_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xml:lang="en-US">Cash, Cash Equivalents, and Short-Term Investments [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xml:lang="en-US">CASH, CASH EQUIVALENTS, SHORT-TERM INVESTMENTS AND LONG-TERM INVESTMENTS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:to="lab_JH04L3L4I185_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_H456J84H45669KJ14908_us-gaap_InventoryDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_InventoryDisclosureAbstract" xml:lang="en-US">Inventory [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_J678L06J67881ML36120_us-gaap_InventoryDisclosureAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_HF82J1J2G963_us-gaap_InventoryDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_InventoryDisclosureTextBlock" xml:lang="en-US">Inventory Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_InventoryDisclosureTextBlock" xml:lang="en-US">INVENTORY</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_JH04L3L4I185_us-gaap_InventoryDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReceivablesAbstract" xlink:label="loc_H456J84H45669KJ14908_us-gaap_ReceivablesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_ReceivablesAbstract" xml:lang="en-US">Accounts Receivable[Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_ReceivablesAbstract" xlink:to="lab_J678L06J67881ML36120_us-gaap_ReceivablesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:label="loc_HF82J1J2G963_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xml:lang="en-US">Loans, Notes, Trade and Other Receivables Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xml:lang="en-US">ACCOUNTS RECEIVABLE</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:to="lab_JH04L3L4I185_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_H456J84H45669KJ14908_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xml:lang="en-US">Prepaid Expenses and Other Assets [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:to="lab_J678L06J67881ML36120_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract"/>
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_PrepaidExpensesAndOtherAssetsTextBlock" xlink:label="loc_HF82J1J2G963_iccc_PrepaidExpensesAndOtherAssetsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_iccc_PrepaidExpensesAndOtherAssetsTextBlock" xml:lang="en-US">Prepaid Expenses And Other Assets [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_iccc_PrepaidExpensesAndOtherAssetsTextBlock" xml:lang="en-US">PREPAID EXPENSES AND OTHER ASSETS</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_JH04L3L4I185_iccc_PrepaidExpensesAndOtherAssetsTextBlock" xml:lang="en-US">The entire disclosure of prepaid expenses and other assets.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_iccc_PrepaidExpensesAndOtherAssetsTextBlock" xlink:to="lab_JH04L3L4I185_iccc_PrepaidExpensesAndOtherAssetsTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_H456J84H45669KJ14908_us-gaap_PropertyPlantAndEquipmentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_PropertyPlantAndEquipmentAbstract" xml:lang="en-US">Property, Plant and Equipment [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_J678L06J67881ML36120_us-gaap_PropertyPlantAndEquipmentAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_HF82J1J2G963_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xml:lang="en-US">PROPERTY, PLANT AND EQUIPMENT</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_JH04L3L4I185_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:label="loc_H456J84H45669KJ14908_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xml:lang="en-US">Accounts Payable and Accrued Expenses [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="lab_J678L06J67881ML36120_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_HF82J1J2G963_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xml:lang="en-US">ACCOUNTS PAYABLE AND ACCRUED EXPENSES</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_JH04L3L4I185_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_H456J84H45669KJ14908_us-gaap_DebtDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_DebtDisclosureAbstract" xml:lang="en-US">Bank Debt [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_DebtDisclosureAbstract" xlink:to="lab_J678L06J67881ML36120_us-gaap_DebtDisclosureAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_HF82J1J2G963_us-gaap_DebtDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_DebtDisclosureTextBlock" xml:lang="en-US">Debt Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_DebtDisclosureTextBlock" xml:lang="en-US">BANK DEBT</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_JH04L3L4I185_us-gaap_DebtDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_H456J84H45669KJ14908_us-gaap_OtherIncomeAndExpensesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_OtherIncomeAndExpensesAbstract" xml:lang="en-US">Other Expenses, Net [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="lab_J678L06J67881ML36120_us-gaap_OtherIncomeAndExpensesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:label="loc_HF82J1J2G963_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xml:lang="en-US">Other Income and Other Expense Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xml:lang="en-US">OTHER EXPENSES, NET</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:to="lab_JH04L3L4I185_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_H456J84H45669KJ14908_us-gaap_IncomeTaxDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_IncomeTaxDisclosureAbstract" xml:lang="en-US">Income Taxes [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_J678L06J67881ML36120_us-gaap_IncomeTaxDisclosureAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_HF82J1J2G963_us-gaap_IncomeTaxDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">INCOME TAXES</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_JH04L3L4I185_us-gaap_IncomeTaxDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_H456J84H45669KJ14908_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US">Commitments and Contingent Liabilities [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_J678L06J67881ML36120_us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_HF82J1J2G963_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">COMMITMENTS AND CONTINGENT LIABILITIES</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_JH04L3L4I185_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_CommonStockRightsPlanAbstract" xlink:label="loc_H456J84H45669KJ14908_iccc_CommonStockRightsPlanAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_iccc_CommonStockRightsPlanAbstract" xml:lang="en-US">Common Stock Rights Plan [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_J678L06J67881ML36120_iccc_CommonStockRightsPlanAbstract" xml:lang="en-US">Common Stock Rights Plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_iccc_CommonStockRightsPlanAbstract" xlink:to="lab_J678L06J67881ML36120_iccc_CommonStockRightsPlanAbstract"/>
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_CommonStockRightsPlanTextBlock" xlink:label="loc_HF82J1J2G963_iccc_CommonStockRightsPlanTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_iccc_CommonStockRightsPlanTextBlock" xml:lang="en-US">Common Stock Rights Plan [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_iccc_CommonStockRightsPlanTextBlock" xml:lang="en-US">COMMON STOCK RIGHTS PLAN</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_iccc_CommonStockRightsPlanTextBlock" xlink:to="lab_JH04L3L4I185_iccc_CommonStockRightsPlanTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_H456J84H45669KJ14908_us-gaap_SegmentReportingAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_SegmentReportingAbstract" xml:lang="en-US">Segment and Significant Customer Information [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_SegmentReportingAbstract" xlink:to="lab_J678L06J67881ML36120_us-gaap_SegmentReportingAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_HF82J1J2G963_us-gaap_SegmentReportingDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_SegmentReportingDisclosureTextBlock" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_SegmentReportingDisclosureTextBlock" xml:lang="en-US">SEGMENT AND SIGNIFICANT CUSTOMER INFORMATION</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_JH04L3L4I185_us-gaap_SegmentReportingDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_H456J84H45669KJ14908_us-gaap_RelatedPartyTransactionsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_RelatedPartyTransactionsAbstract" xml:lang="en-US">Related Party Transactions [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_J678L06J67881ML36120_us-gaap_RelatedPartyTransactionsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_HF82J1J2G963_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xml:lang="en-US">RELATED PARTY TRANSACTIONS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_JH04L3L4I185_us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="loc_H456J84H45669KJ14908_us-gaap_ShareBasedCompensationAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_ShareBasedCompensationAbstract" xml:lang="en-US">Employee Benefits [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_ShareBasedCompensationAbstract" xlink:to="lab_J678L06J67881ML36120_us-gaap_ShareBasedCompensationAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="loc_HF82J1J2G963_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xml:lang="en-US">Compensation and Employee Benefit Plans [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xml:lang="en-US">EMPLOYEE BENEFITS</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xml:lang="en-US">STOCK-BASED COMPENSATION</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="lab_JH04L3L4I185_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_H456J84H45669KJ14908_us-gaap_SubsequentEventsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_SubsequentEventsAbstract" xml:lang="en-US">Subsequent Events [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_SubsequentEventsAbstract" xml:lang="en-US">Subsequent Event, Description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_SubsequentEventsAbstract" xlink:to="lab_J678L06J67881ML36120_us-gaap_SubsequentEventsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_HF82J1J2G963_us-gaap_SubsequentEventsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">SUBSEQUENT EVENTS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_JH04L3L4I185_us-gaap_SubsequentEventsTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_H456J84H45669KJ14908_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xml:lang="en-US">Basis of presentation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_J678L06J67881ML36120_us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_HF82J1J2G963_us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US">Cash, Cash Equivalents, Short-Term Investments and Long-Term Investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_JH04L3L4I185_us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_H456J84H45669KJ14908_us-gaap_InventoryPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_InventoryPolicyTextBlock" xml:lang="en-US">Inventory, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_InventoryPolicyTextBlock" xml:lang="en-US">Inventory</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_J678L06J67881ML36120_us-gaap_InventoryPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="loc_HF82J1J2G963_us-gaap_TradeAndOtherAccountsReceivablePolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_TradeAndOtherAccountsReceivablePolicy" xml:lang="en-US">Trade and Other Accounts Receivable, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_TradeAndOtherAccountsReceivablePolicy" xml:lang="en-US">Trade Receivables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:to="lab_JH04L3L4I185_us-gaap_TradeAndOtherAccountsReceivablePolicy"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_H456J84H45669KJ14908_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US">Property, Plant and Equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_J678L06J67881ML36120_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="loc_HF82J1J2G963_us-gaap_IntangibleAssetsFiniteLivedPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_IntangibleAssetsFiniteLivedPolicy" xml:lang="en-US">Intangible Assets, Finite-Lived, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_IntangibleAssetsFiniteLivedPolicy" xml:lang="en-US">Intangible Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:to="lab_JH04L3L4I185_us-gaap_IntangibleAssetsFiniteLivedPolicy"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_H456J84H45669KJ14908_us-gaap_FairValueOfFinancialInstrumentsPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_FairValueOfFinancialInstrumentsPolicy" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_FairValueOfFinancialInstrumentsPolicy" xml:lang="en-US">Disclosure of Fair Value of Financial Instruments and Concentration of Risk</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_J678L06J67881ML36120_us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_InterestRateSwapAgreementPolicyTextBlock" xlink:label="loc_HF82J1J2G963_iccc_InterestRateSwapAgreementPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_iccc_InterestRateSwapAgreementPolicyTextBlock" xml:lang="en-US">Interest Rate Swap Agreement [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_iccc_InterestRateSwapAgreementPolicyTextBlock" xml:lang="en-US">Interest Rate Swap Agreements</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_JH04L3L4I185_iccc_InterestRateSwapAgreementPolicyTextBlock" xml:lang="en-US">Disclosure of accounting policy for determining the interest rate swap agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_iccc_InterestRateSwapAgreementPolicyTextBlock" xlink:to="lab_JH04L3L4I185_iccc_InterestRateSwapAgreementPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_H456J84H45669KJ14908_us-gaap_RevenueRecognitionPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_RevenueRecognitionPolicyTextBlock" xml:lang="en-US">Revenue Recognition, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_RevenueRecognitionPolicyTextBlock" xml:lang="en-US">Revenue Recognition</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_J678L06J67881ML36120_us-gaap_RevenueRecognitionPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_ExpenseRecognitionPolicyTextBlock" xlink:label="loc_HF82J1J2G963_iccc_ExpenseRecognitionPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_iccc_ExpenseRecognitionPolicyTextBlock" xml:lang="en-US">Expense Recognition [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_iccc_ExpenseRecognitionPolicyTextBlock" xml:lang="en-US">Expense Recognition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_JH04L3L4I185_iccc_ExpenseRecognitionPolicyTextBlock" xml:lang="en-US">Entire disclosure of accounting policy for expense recognition.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_iccc_ExpenseRecognitionPolicyTextBlock" xlink:to="lab_JH04L3L4I185_iccc_ExpenseRecognitionPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_H456J84H45669KJ14908_us-gaap_IncomeTaxPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_J678L06J67881ML36120_us-gaap_IncomeTaxPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_HF82J1J2G963_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xml:lang="en-US">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xml:lang="en-US">Stock-Based Compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_JH04L3L4I185_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_H456J84H45669KJ14908_us-gaap_EarningsPerSharePolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Net Income (Loss) Per Common Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_J678L06J67881ML36120_us-gaap_EarningsPerSharePolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_HF82J1J2G963_us-gaap_UseOfEstimates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_UseOfEstimates" xlink:to="lab_JH04L3L4I185_us-gaap_UseOfEstimates"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_H456J84H45669KJ14908_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">New Accounting Pronouncement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_J678L06J67881ML36120_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:label="loc_HF82J1J2G963_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xml:lang="en-US">Schedule of Weighted Average Number of Shares [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xml:lang="en-US">Schedule of net income (loss) per common share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:to="lab_JH04L3L4I185_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:label="loc_H456J84H45669KJ14908_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xml:lang="en-US">Schedule Of Cash, Cash Equivalents and Short-Term Investments [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xml:lang="en-US">Schedule of cash, cash equivalents and short-term investments and long-term investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="lab_J678L06J67881ML36120_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_HF82J1J2G963_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xml:lang="en-US">Schedule Of Inventory, Current [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xml:lang="en-US">Schedule of Inventory</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_JH04L3L4I185_us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:label="loc_H456J84H45669KJ14908_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xml:lang="en-US">Schedule of accounts receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="lab_J678L06J67881ML36120_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="loc_HF82J1J2G963_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xml:lang="en-US">Schedule of prepaid expenses and other assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="lab_JH04L3L4I185_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_H456J84H45669KJ14908_us-gaap_PropertyPlantAndEquipmentTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US">Schedule of property, plant and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_J678L06J67881ML36120_us-gaap_PropertyPlantAndEquipmentTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_HF82J1J2G963_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of accounts payable and accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="lab_JH04L3L4I185_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="loc_H456J84H45669KJ14908_us-gaap_ScheduleOfDebtInstrumentsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xml:lang="en-US">Schedule of principal payments due under debt outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xml:lang="en-US">Schedule Of Principal Payments Due [Table Text Block]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_J678L06J67881ML36120_us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="loc_HF82J1J2G963_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xml:lang="en-US">Schedule Of Other Nonoperating Income (Expense) [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xml:lang="en-US">Schedule of other expenses, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:to="lab_JH04L3L4I185_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_ScheduleOfSalesToSignificantCustomersTableTextBlock" xlink:label="loc_H456J84H45669KJ14908_iccc_ScheduleOfSalesToSignificantCustomersTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_iccc_ScheduleOfSalesToSignificantCustomersTableTextBlock" xml:lang="en-US">Schedule Of Sales To Significant Customers Table [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_J678L06J67881ML36120_iccc_ScheduleOfSalesToSignificantCustomersTableTextBlock" xml:lang="en-US">Schedule of sales to significant customers</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_J678L06J67881ML36120_iccc_ScheduleOfSalesToSignificantCustomersTableTextBlock" xml:lang="en-US">Tabular disclosure of sales to significant customers that amounted to 10% or more of total product sales by the entity during the period.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_iccc_ScheduleOfSalesToSignificantCustomersTableTextBlock" xlink:to="lab_J678L06J67881ML36120_iccc_ScheduleOfSalesToSignificantCustomersTableTextBlock"/>
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_ScheduleOfAccountsReceivableDueFromSignificantCustomersTableTextBlock" xlink:label="loc_HF82J1J2G963_iccc_ScheduleOfAccountsReceivableDueFromSignificantCustomersTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_iccc_ScheduleOfAccountsReceivableDueFromSignificantCustomersTableTextBlock" xml:lang="en-US">Schedule Of Accounts Receivable Due From Significant Customers Table [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_iccc_ScheduleOfAccountsReceivableDueFromSignificantCustomersTableTextBlock" xml:lang="en-US">Schedule of accounts receivable due from significant customers</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_JH04L3L4I185_iccc_ScheduleOfAccountsReceivableDueFromSignificantCustomersTableTextBlock" xml:lang="en-US">Tabular disclosure of accounts receivable due from significant customers that amounted to 10% or more of total trade accounts receivable as of the balance sheet date.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_iccc_ScheduleOfAccountsReceivableDueFromSignificantCustomersTableTextBlock" xlink:to="lab_JH04L3L4I185_iccc_ScheduleOfAccountsReceivableDueFromSignificantCustomersTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="loc_H456J84H45669KJ14908_us-gaap_EarningsPerShareBasicAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_EarningsPerShareBasicAbstract" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_EarningsPerShareBasicAbstract" xml:lang="en-US">Net Income (Loss) Per Common Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_EarningsPerShareBasicAbstract" xlink:to="lab_J678L06J67881ML36120_us-gaap_EarningsPerShareBasicAbstract"/>
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_EffectOfDilutiveStockOptions" xlink:label="loc_HF82J1J2G963_iccc_EffectOfDilutiveStockOptions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_iccc_EffectOfDilutiveStockOptions" xml:lang="en-US">Effect Of Dilutive Stock Options</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JH04L3L4I185_iccc_EffectOfDilutiveStockOptions" xml:lang="en-US">Effect of dilutive stock options</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_JH04L3L4I185_iccc_EffectOfDilutiveStockOptions" xml:lang="en-US">Number of dilutive stock options included in calculation of net income(loss) per share.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_iccc_EffectOfDilutiveStockOptions" xlink:to="lab_JH04L3L4I185_iccc_EffectOfDilutiveStockOptions"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_H456J84H45669KJ14908_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Stock options outstanding as of September 30th not included in the calculation because the effect would be anti-dilutive</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Outstanding stock options not included in the calculation because the effect would be anti-dilutive</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_J678L06J67881ML36120_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_SummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_HF82J1J2G963_iccc_SummaryOfSignificantAccountingPoliciesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_iccc_SummaryOfSignificantAccountingPoliciesTable" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_iccc_SummaryOfSignificantAccountingPoliciesTable" xlink:to="lab_JH04L3L4I185_iccc_SummaryOfSignificantAccountingPoliciesTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_H456J84H45669KJ14908_us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_J678L06J67881ML36120_us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_HF82J1J2G963_us-gaap_PropertyPlantAndEquipmentTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_PropertyPlantAndEquipmentTypeDomain" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_JH04L3L4I185_us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_BuildingAdditionMember" xlink:label="loc_H456J84H45669KJ14908_iccc_BuildingAdditionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_iccc_BuildingAdditionMember" xml:lang="en-US">Building Addition [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_J678L06J67881ML36120_iccc_BuildingAdditionMember" xml:lang="en-US">Building addition member.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_iccc_BuildingAdditionMember" xlink:to="lab_J678L06J67881ML36120_iccc_BuildingAdditionMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BuildingImprovementsMember" xlink:label="loc_HF82J1J2G963_us-gaap_BuildingImprovementsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_BuildingImprovementsMember" xml:lang="en-US">Building Improvements [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_BuildingImprovementsMember" xml:lang="en-US">Building and improvements [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_BuildingImprovementsMember" xlink:to="lab_JH04L3L4I185_us-gaap_BuildingImprovementsMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:label="loc_H456J84H45669KJ14908_us-gaap_PropertyPlantAndEquipmentOtherTypesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xml:lang="en-US">Property, Plant and Equipment, Other Types [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:to="lab_J678L06J67881ML36120_us-gaap_PropertyPlantAndEquipmentOtherTypesMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_HF82J1J2G963_us-gaap_ComputerEquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_ComputerEquipmentMember" xml:lang="en-US">Computer Equipment [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_ComputerEquipmentMember" xlink:to="lab_JH04L3L4I185_us-gaap_ComputerEquipmentMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsMember" xlink:label="loc_H456J84H45669KJ14908_us-gaap_OtherAssetsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_OtherAssetsMember" xml:lang="en-US">Other Assets [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_OtherAssetsMember" xml:lang="en-US">Other Fixed Assets [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_OtherAssetsMember" xlink:to="lab_J678L06J67881ML36120_us-gaap_OtherAssetsMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_HF82J1J2G963_us-gaap_RangeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_RangeAxis" xml:lang="en-US">Range [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_RangeAxis" xlink:to="lab_JH04L3L4I185_us-gaap_RangeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_H456J84H45669KJ14908_us-gaap_RangeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_RangeMember" xml:lang="en-US">Range [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_RangeMember" xlink:to="lab_J678L06J67881ML36120_us-gaap_RangeMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_HF82J1J2G963_us-gaap_MinimumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_MinimumMember" xml:lang="en-US">Minimum [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_MinimumMember" xlink:to="lab_JH04L3L4I185_us-gaap_MinimumMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_H456J84H45669KJ14908_us-gaap_MaximumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_MaximumMember" xml:lang="en-US">Maximum [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_MaximumMember" xlink:to="lab_J678L06J67881ML36120_us-gaap_MaximumMember"/>
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_SignificantAccountingPoliciesLineItems" xlink:label="loc_HF82J1J2G963_iccc_SignificantAccountingPoliciesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_iccc_SignificantAccountingPoliciesLineItems" xml:lang="en-US">Significant Accounting Policies [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_iccc_SignificantAccountingPoliciesLineItems" xlink:to="lab_JH04L3L4I185_iccc_SignificantAccountingPoliciesLineItems"/>
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_SummaryOfSignificantAccountingPoliciesTextualAbstract" xlink:label="loc_H456J84H45669KJ14908_iccc_SummaryOfSignificantAccountingPoliciesTextualAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_iccc_SummaryOfSignificantAccountingPoliciesTextualAbstract" xml:lang="en-US">Summary Of Significant Accounting Policies Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_J678L06J67881ML36120_iccc_SummaryOfSignificantAccountingPoliciesTextualAbstract" xml:lang="en-US">Summary of Significant Accounting Policies (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_iccc_SummaryOfSignificantAccountingPoliciesTextualAbstract" xlink:to="lab_J678L06J67881ML36120_iccc_SummaryOfSignificantAccountingPoliciesTextualAbstract"/>
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_ShareBasedCompensationDecreaseIncreaseInIncomeLossBeforeIncomeTaxDescription" xlink:label="loc_HF82J1J2G963_iccc_ShareBasedCompensationDecreaseIncreaseInIncomeLossBeforeIncomeTaxDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_iccc_ShareBasedCompensationDecreaseIncreaseInIncomeLossBeforeIncomeTaxDescription" xml:lang="en-US">Share Based Compensation Decrease Increase In Income Loss Before Income Tax Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JH04L3L4I185_iccc_ShareBasedCompensationDecreaseIncreaseInIncomeLossBeforeIncomeTaxDescription" xml:lang="en-US">Decrease (increase) in income (loss) before income taxes descripton</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_JH04L3L4I185_iccc_ShareBasedCompensationDecreaseIncreaseInIncomeLossBeforeIncomeTaxDescription" xml:lang="en-US">It represents share based compensation decrease(increase) in Income(loss) before income tax description.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_iccc_ShareBasedCompensationDecreaseIncreaseInIncomeLossBeforeIncomeTaxDescription" xlink:to="lab_JH04L3L4I185_iccc_ShareBasedCompensationDecreaseIncreaseInIncomeLossBeforeIncomeTaxDescription"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdvertisingExpense" xlink:label="loc_H456J84H45669KJ14908_us-gaap_AdvertisingExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_AdvertisingExpense" xml:lang="en-US">Advertising Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_AdvertisingExpense" xml:lang="en-US">Advertising expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_AdvertisingExpense" xlink:to="lab_J678L06J67881ML36120_us-gaap_AdvertisingExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_HF82J1J2G963_us-gaap_CashFDICInsuredAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_CashFDICInsuredAmount" xml:lang="en-US">Cash, FDIC Insured Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_CashFDICInsuredAmount" xml:lang="en-US">Federal deposit insurance corporation limits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_CashFDICInsuredAmount" xlink:to="lab_JH04L3L4I185_us-gaap_CashFDICInsuredAmount"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtIssuanceCosts" xlink:label="loc_H456J84H45669KJ14908_us-gaap_DebtIssuanceCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_DebtIssuanceCosts" xml:lang="en-US">Debt Issuance Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_DebtIssuanceCosts" xml:lang="en-US">Debt issue costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_DebtIssuanceCosts" xlink:to="lab_J678L06J67881ML36120_us-gaap_DebtIssuanceCosts"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_USGovernmentSecuritiesAtCarryingValue" xlink:label="loc_HF82J1J2G963_us-gaap_USGovernmentSecuritiesAtCarryingValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_USGovernmentSecuritiesAtCarryingValue" xml:lang="en-US">US Government Securities, at Carrying Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_USGovernmentSecuritiesAtCarryingValue" xml:lang="en-US">U.S. government aggregated amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_USGovernmentSecuritiesAtCarryingValue" xlink:to="lab_JH04L3L4I185_us-gaap_USGovernmentSecuritiesAtCarryingValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_H456J84H45669KJ14908_us-gaap_PropertyPlantAndEquipmentUsefulLife" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_PropertyPlantAndEquipmentUsefulLife" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_PropertyPlantAndEquipmentUsefulLife" xml:lang="en-US">Property, plant and equipment, useful life</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_J678L06J67881ML36120_us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_ScheduleOfCashCashEquivalentsShortTermInvestmentsAndLongTermInvestmentAbstract" xlink:label="loc_HF82J1J2G963_iccc_ScheduleOfCashCashEquivalentsShortTermInvestmentsAndLongTermInvestmentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_iccc_ScheduleOfCashCashEquivalentsShortTermInvestmentsAndLongTermInvestmentAbstract" xml:lang="en-US">Schedule Of Cash Cash Equivalentsshort Term Investments And Long Term Investment [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JH04L3L4I185_iccc_ScheduleOfCashCashEquivalentsShortTermInvestmentsAndLongTermInvestmentAbstract" xml:lang="en-US">Schedule of Cash, cash equivalents, short-term investments and long-term investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_iccc_ScheduleOfCashCashEquivalentsShortTermInvestmentsAndLongTermInvestmentAbstract" xlink:to="lab_JH04L3L4I185_iccc_ScheduleOfCashCashEquivalentsShortTermInvestmentsAndLongTermInvestmentAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="loc_H456J84H45669KJ14908_us-gaap_CashCashEquivalentsAndShortTermInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_CashCashEquivalentsAndShortTermInvestments" xml:lang="en-US">Cash, Cash Equivalents, and Short-Term Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_CashCashEquivalentsAndShortTermInvestments" xml:lang="en-US">Subtotal</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_J678L06J67881ML36120_us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_CashAndCashEquivalentsShortTermAndLongTermInvestments" xlink:label="loc_HF82J1J2G963_iccc_CashAndCashEquivalentsShortTermAndLongTermInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_iccc_CashAndCashEquivalentsShortTermAndLongTermInvestments" xml:lang="en-US">Cash And Cash Equivalents Short Term And Long Term Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_JH04L3L4I185_iccc_CashAndCashEquivalentsShortTermAndLongTermInvestments" xml:lang="en-US">Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_JH04L3L4I185_iccc_CashAndCashEquivalentsShortTermAndLongTermInvestments" xml:lang="en-US">Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term and long-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_iccc_CashAndCashEquivalentsShortTermAndLongTermInvestments" xlink:to="lab_JH04L3L4I185_iccc_CashAndCashEquivalentsShortTermAndLongTermInvestments"/>
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_IncreaseDecreaseInShortTermInvestments" xlink:label="loc_H456J84H45669KJ14908_iccc_IncreaseDecreaseInShortTermInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_iccc_IncreaseDecreaseInShortTermInvestments" xml:lang="en-US">Increase Decrease In Short Term Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_J678L06J67881ML36120_iccc_IncreaseDecreaseInShortTermInvestments" xml:lang="en-US">Increase (Decrease) in short-term investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_J678L06J67881ML36120_iccc_IncreaseDecreaseInShortTermInvestments" xml:lang="en-US">The increase (decrease) during the reporting period in short term investments.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_iccc_IncreaseDecreaseInShortTermInvestments" xlink:to="lab_J678L06J67881ML36120_iccc_IncreaseDecreaseInShortTermInvestments"/>
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_IncreaseDecreaseInCashAndCashEquivalentsAndShortTermInvestments" xlink:label="loc_HF82J1J2G963_iccc_IncreaseDecreaseInCashAndCashEquivalentsAndShortTermInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_iccc_IncreaseDecreaseInCashAndCashEquivalentsAndShortTermInvestments" xml:lang="en-US">Increase Decrease In Cash and Cash Equivalents and Short Term Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_JH04L3L4I185_iccc_IncreaseDecreaseInCashAndCashEquivalentsAndShortTermInvestments" xml:lang="en-US">Increase (Decrease) in cash and cash equivalents and short term investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_JH04L3L4I185_iccc_IncreaseDecreaseInCashAndCashEquivalentsAndShortTermInvestments" xml:lang="en-US">The increase (decrease) during the reporting period in cash and cash equivalents and short term investments.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_iccc_IncreaseDecreaseInCashAndCashEquivalentsAndShortTermInvestments" xlink:to="lab_JH04L3L4I185_iccc_IncreaseDecreaseInCashAndCashEquivalentsAndShortTermInvestments"/>
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_IncreaseDecreaseInLongTermInvestments" xlink:label="loc_H456J84H45669KJ14908_iccc_IncreaseDecreaseInLongTermInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_iccc_IncreaseDecreaseInLongTermInvestments" xml:lang="en-US">Increase Decrease In Long Term Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_J678L06J67881ML36120_iccc_IncreaseDecreaseInLongTermInvestments" xml:lang="en-US">Increase (Decrease) in long term investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_J678L06J67881ML36120_iccc_IncreaseDecreaseInLongTermInvestments" xml:lang="en-US">The increase (decrease) during the reporting period in long term investments.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_iccc_IncreaseDecreaseInLongTermInvestments" xlink:to="lab_J678L06J67881ML36120_iccc_IncreaseDecreaseInLongTermInvestments"/>
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_IncreaseDecreaseInCashAndCashEquivalentsShortTermAndLongtermInvestments" xlink:label="loc_HF82J1J2G963_iccc_IncreaseDecreaseInCashAndCashEquivalentsShortTermAndLongtermInvestments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_iccc_IncreaseDecreaseInCashAndCashEquivalentsShortTermAndLongtermInvestments" xml:lang="en-US">Increase Decrease In Cash And Cash Equivalents Short Term And LongTerm Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_JH04L3L4I185_iccc_IncreaseDecreaseInCashAndCashEquivalentsShortTermAndLongtermInvestments" xml:lang="en-US">Increase (Decrease) in cash and cash equivalents short term and long term investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_JH04L3L4I185_iccc_IncreaseDecreaseInCashAndCashEquivalentsShortTermAndLongtermInvestments" xml:lang="en-US">The increase (decrease) during the reporting period in cash and cash equivalents short term and long term investments.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_iccc_IncreaseDecreaseInCashAndCashEquivalentsShortTermAndLongtermInvestments" xlink:to="lab_JH04L3L4I185_iccc_IncreaseDecreaseInCashAndCashEquivalentsShortTermAndLongtermInvestments"/>
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_ScheduleOfInventoryAbstract" xlink:label="loc_H456J84H45669KJ14908_iccc_ScheduleOfInventoryAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_iccc_ScheduleOfInventoryAbstract" xml:lang="en-US">Schedule Of Inventory [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_J678L06J67881ML36120_iccc_ScheduleOfInventoryAbstract" xml:lang="en-US">Schedule of Inventory</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_iccc_ScheduleOfInventoryAbstract" xlink:to="lab_J678L06J67881ML36120_iccc_ScheduleOfInventoryAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_HF82J1J2G963_us-gaap_InventoryRawMaterials" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_InventoryRawMaterials" xml:lang="en-US">Raw Materials</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_InventoryRawMaterials" xml:lang="en-US">Raw materials</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_InventoryRawMaterials" xlink:to="lab_JH04L3L4I185_us-gaap_InventoryRawMaterials"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_H456J84H45669KJ14908_us-gaap_InventoryWorkInProcess" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_InventoryWorkInProcess" xml:lang="en-US">Work-In-Process</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_InventoryWorkInProcess" xml:lang="en-US">Work-in-process</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_InventoryWorkInProcess" xlink:to="lab_J678L06J67881ML36120_us-gaap_InventoryWorkInProcess"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_HF82J1J2G963_us-gaap_InventoryFinishedGoods" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_InventoryFinishedGoods" xml:lang="en-US">Finished Goods</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_InventoryFinishedGoods" xml:lang="en-US">Finished goods</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_InventoryFinishedGoods" xlink:to="lab_JH04L3L4I185_us-gaap_InventoryFinishedGoods"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInRawMaterialsPackagingMaterialsAndSuppliesInventories" xlink:label="loc_H456J84H45669KJ14908_us-gaap_IncreaseDecreaseInRawMaterialsPackagingMaterialsAndSuppliesInventories" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_IncreaseDecreaseInRawMaterialsPackagingMaterialsAndSuppliesInventories" xml:lang="en-US">Increase (Decrease) in Raw Materials, Packaging Materials and Supplies Inventories</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_IncreaseDecreaseInRawMaterialsPackagingMaterialsAndSuppliesInventories" xml:lang="en-US">Increase (Decrease) in Raw materials inventories</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_IncreaseDecreaseInRawMaterialsPackagingMaterialsAndSuppliesInventories" xlink:to="lab_J678L06J67881ML36120_us-gaap_IncreaseDecreaseInRawMaterialsPackagingMaterialsAndSuppliesInventories"/>
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_IncreaseDecreaseInWorkInProcessInventories" xlink:label="loc_HF82J1J2G963_iccc_IncreaseDecreaseInWorkInProcessInventories" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_iccc_IncreaseDecreaseInWorkInProcessInventories" xml:lang="en-US">Increase (Decrease) In Work In Process Inventories</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_iccc_IncreaseDecreaseInWorkInProcessInventories" xml:lang="en-US">Increase (Decrease) in Work-in-process inventories</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_JH04L3L4I185_iccc_IncreaseDecreaseInWorkInProcessInventories" xml:lang="en-US">The increase (decrease) during the reporting period in the book value of work in process inventory.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_iccc_IncreaseDecreaseInWorkInProcessInventories" xlink:to="lab_JH04L3L4I185_iccc_IncreaseDecreaseInWorkInProcessInventories"/>
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_IncreaseDecreaseInFinishedGoodsInventories" xlink:label="loc_H456J84H45669KJ14908_iccc_IncreaseDecreaseInFinishedGoodsInventories" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_iccc_IncreaseDecreaseInFinishedGoodsInventories" xml:lang="en-US">Increase (Decrease) In Finished Goods Inventories</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_J678L06J67881ML36120_iccc_IncreaseDecreaseInFinishedGoodsInventories" xml:lang="en-US">Increase (Decrease) in Finished goods inventories</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_J678L06J67881ML36120_iccc_IncreaseDecreaseInFinishedGoodsInventories" xml:lang="en-US">The increase (decrease) during the reporting period in the book value of finished goods inventory.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_iccc_IncreaseDecreaseInFinishedGoodsInventories" xlink:to="lab_J678L06J67881ML36120_iccc_IncreaseDecreaseInFinishedGoodsInventories"/>
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_ScheduleOfAccountsNotesLoansAndFinancingReceivableAbstract" xlink:label="loc_HF82J1J2G963_iccc_ScheduleOfAccountsNotesLoansAndFinancingReceivableAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_iccc_ScheduleOfAccountsNotesLoansAndFinancingReceivableAbstract" xml:lang="en-US">Schedule Of Accounts Notes Loans And Financing Receivable [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JH04L3L4I185_iccc_ScheduleOfAccountsNotesLoansAndFinancingReceivableAbstract" xml:lang="en-US">Schedule of accounts receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_iccc_ScheduleOfAccountsNotesLoansAndFinancingReceivableAbstract" xlink:to="lab_JH04L3L4I185_iccc_ScheduleOfAccountsNotesLoansAndFinancingReceivableAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent" xlink:label="loc_H456J84H45669KJ14908_us-gaap_AccountsReceivableGrossCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_AccountsReceivableGrossCurrent" xml:lang="en-US">Accounts Receivable, Gross, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_AccountsReceivableGrossCurrent" xml:lang="en-US">Trade accounts receivable, gross</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_AccountsReceivableGrossCurrent" xlink:to="lab_J678L06J67881ML36120_us-gaap_AccountsReceivableGrossCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_HF82J1J2G963_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xml:lang="en-US">Allowance for Doubtful Accounts Receivable, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xml:lang="en-US">Accumulated allowance for bad debt and product returns</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_JH04L3L4I185_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xml:lang="en-US">Accumulated allowance for bad debt and product returns</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_JH04L3L4I185_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsReceivableNet" xlink:label="loc_H456J84H45669KJ14908_us-gaap_AccountsReceivableNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_AccountsReceivableNet" xml:lang="en-US">Accounts Receivable, Net, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_AccountsReceivableNet" xml:lang="en-US">Trade accounts receivable, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_AccountsReceivableNet" xlink:to="lab_J678L06J67881ML36120_us-gaap_AccountsReceivableNet"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherReceivables" xlink:label="loc_HF82J1J2G963_us-gaap_OtherReceivables" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_OtherReceivables" xml:lang="en-US">Other Receivables</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_OtherReceivables" xml:lang="en-US">Other receivables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_OtherReceivables" xlink:to="lab_JH04L3L4I185_us-gaap_OtherReceivables"/>
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_IncreaseDecreaseInAccountsReceivableGross" xlink:label="loc_H456J84H45669KJ14908_iccc_IncreaseDecreaseInAccountsReceivableGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_iccc_IncreaseDecreaseInAccountsReceivableGross" xml:lang="en-US">Increase Decrease In Accounts Receivable Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_J678L06J67881ML36120_iccc_IncreaseDecreaseInAccountsReceivableGross" xml:lang="en-US">(Decrease) in Trade accounts receivable, gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_J678L06J67881ML36120_iccc_IncreaseDecreaseInAccountsReceivableGross" xml:lang="en-US">Represents net increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_iccc_IncreaseDecreaseInAccountsReceivableGross" xlink:to="lab_J678L06J67881ML36120_iccc_IncreaseDecreaseInAccountsReceivableGross"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease" xlink:label="loc_HF82J1J2G963_us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease" xml:lang="en-US">Allowance for Doubtful Accounts Receivable, Period Increase (Decrease)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease" xml:lang="en-US">(Decrease) in Accumulated allowance for bad debt and product returns</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease" xlink:to="lab_JH04L3L4I185_us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_H456J84H45669KJ14908_us-gaap_IncreaseDecreaseInAccountsReceivable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_IncreaseDecreaseInAccountsReceivable" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_IncreaseDecreaseInAccountsReceivable" xml:lang="en-US">(Decrease) in Trade accounts receivable, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_J678L06J67881ML36120_us-gaap_IncreaseDecreaseInAccountsReceivable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="loc_HF82J1J2G963_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xml:lang="en-US">Increase (Decrease) in Accounts and Other Receivables</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xml:lang="en-US">(Decrease) in Other receivables</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:to="lab_JH04L3L4I185_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_H456J84H45669KJ14908_us-gaap_OtherPrepaidExpenseCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_OtherPrepaidExpenseCurrent" xml:lang="en-US">Other Prepaid Expense, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_OtherPrepaidExpenseCurrent" xml:lang="en-US">Prepaid expenses and other assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_OtherPrepaidExpenseCurrent" xlink:to="lab_J678L06J67881ML36120_us-gaap_OtherPrepaidExpenseCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="loc_HF82J1J2G963_us-gaap_SecurityDeposit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_SecurityDeposit" xml:lang="en-US">Security Deposit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_SecurityDeposit" xml:lang="en-US">Security deposits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_SecurityDeposit" xlink:to="lab_JH04L3L4I185_us-gaap_SecurityDeposit"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_H456J84H45669KJ14908_us-gaap_DeferredFinanceCostsNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_DeferredFinanceCostsNet" xml:lang="en-US">Deferred Finance Costs, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_DeferredFinanceCostsNet" xml:lang="en-US">Debt issue costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_DeferredFinanceCostsNet" xlink:to="lab_J678L06J67881ML36120_us-gaap_DeferredFinanceCostsNet"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedAmortizationDeferredFinanceCosts" xlink:label="loc_HF82J1J2G963_us-gaap_AccumulatedAmortizationDeferredFinanceCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_AccumulatedAmortizationDeferredFinanceCosts" xml:lang="en-US">Accumulated Amortization, Deferred Finance Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_AccumulatedAmortizationDeferredFinanceCosts" xml:lang="en-US">Accumulated amortization of debt issue costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_JH04L3L4I185_us-gaap_AccumulatedAmortizationDeferredFinanceCosts" xml:lang="en-US">Accumulated amortization of debt issue costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_AccumulatedAmortizationDeferredFinanceCosts" xlink:to="lab_JH04L3L4I185_us-gaap_AccumulatedAmortizationDeferredFinanceCosts"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DepositAssets" xlink:label="loc_H456J84H45669KJ14908_us-gaap_DepositAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_DepositAssets" xml:lang="en-US">Deposit Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_DepositAssets" xml:lang="en-US">Security deposits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_DepositAssets" xlink:to="lab_J678L06J67881ML36120_us-gaap_DepositAssets"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets" xlink:label="loc_HF82J1J2G963_us-gaap_PrepaidExpenseAndOtherAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_PrepaidExpenseAndOtherAssets" xml:lang="en-US">Prepaid Expense and Other Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_PrepaidExpenseAndOtherAssets" xml:lang="en-US">Prepaid expenses and other assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_JH04L3L4I185_us-gaap_PrepaidExpenseAndOtherAssets" xml:lang="en-US">Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_PrepaidExpenseAndOtherAssets" xlink:to="lab_JH04L3L4I185_us-gaap_PrepaidExpenseAndOtherAssets"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_H456J84H45669KJ14908_us-gaap_IncreaseDecreaseInPrepaidExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_IncreaseDecreaseInPrepaidExpense" xml:lang="en-US">(Decrease) Increase in Prepaid expenses and other assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_IncreaseDecreaseInPrepaidExpense" xml:lang="en-US">Increase (Decrease) in Prepaid expenses and other assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="lab_J678L06J67881ML36120_us-gaap_IncreaseDecreaseInPrepaidExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:label="loc_HF82J1J2G963_us-gaap_IncreaseDecreaseInSecurityDeposits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_IncreaseDecreaseInSecurityDeposits" xml:lang="en-US">Increase (Decrease) in Security Deposits</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_IncreaseDecreaseInSecurityDeposits" xml:lang="en-US">(Decrease) Increase in Security deposits</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_JH04L3L4I185_us-gaap_IncreaseDecreaseInSecurityDeposits" xml:lang="en-US">Increase (Decrease) in Security deposits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:to="lab_JH04L3L4I185_us-gaap_IncreaseDecreaseInSecurityDeposits"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_H456J84H45669KJ14908_us-gaap_IncreaseDecreaseInOtherCurrentAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xml:lang="en-US">Increase (Decrease) in Other Current Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xml:lang="en-US">Increase (Decrease) in Current subtotal</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:to="lab_J678L06J67881ML36120_us-gaap_IncreaseDecreaseInOtherCurrentAssets"/>
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_IncreaseDecreaseDebtIssueCosts" xlink:label="loc_HF82J1J2G963_iccc_IncreaseDecreaseDebtIssueCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_iccc_IncreaseDecreaseDebtIssueCosts" xml:lang="en-US">Increase Decrease Debt Issue Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_iccc_IncreaseDecreaseDebtIssueCosts" xml:lang="en-US">Increase (Decrease) in Debt issue costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/negativeLabel" xlink:label="lab_JH04L3L4I185_iccc_IncreaseDecreaseDebtIssueCosts" xml:lang="en-US">Increase (Decrease) in Debt issue costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_JH04L3L4I185_iccc_IncreaseDecreaseDebtIssueCosts" xml:lang="en-US">The increase (decrease) during the reporting period in debt issuance costs.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_JH04L3L4I185_iccc_IncreaseDecreaseDebtIssueCosts" xml:lang="en-US">Increase (Decrease) in Debt issue costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_iccc_IncreaseDecreaseDebtIssueCosts" xlink:to="lab_JH04L3L4I185_iccc_IncreaseDecreaseDebtIssueCosts"/>
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_IncreaseDecreaseAccumulatedAmortizationOfDebtIssueCosts" xlink:label="loc_H456J84H45669KJ14908_iccc_IncreaseDecreaseAccumulatedAmortizationOfDebtIssueCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_iccc_IncreaseDecreaseAccumulatedAmortizationOfDebtIssueCosts" xml:lang="en-US">Increase Decrease Accumulated Amortization Of Debt Issue Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_J678L06J67881ML36120_iccc_IncreaseDecreaseAccumulatedAmortizationOfDebtIssueCosts" xml:lang="en-US">Increase (decrease) in accounts payable and accrued liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_J678L06J67881ML36120_iccc_IncreaseDecreaseAccumulatedAmortizationOfDebtIssueCosts" xml:lang="en-US">The increase (decrease) during the reporting period in accumulated amortization of debt issue costs.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_J678L06J67881ML36120_iccc_IncreaseDecreaseAccumulatedAmortizationOfDebtIssueCosts" xml:lang="en-US">Increase (Decrease) in Accumulated amortization of debt issue costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_iccc_IncreaseDecreaseAccumulatedAmortizationOfDebtIssueCosts" xlink:to="lab_J678L06J67881ML36120_iccc_IncreaseDecreaseAccumulatedAmortizationOfDebtIssueCosts"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherDeposits" xlink:label="loc_HF82J1J2G963_us-gaap_IncreaseDecreaseInOtherDeposits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_IncreaseDecreaseInOtherDeposits" xml:lang="en-US">Increase (Decrease) in Other Deposits</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_JH04L3L4I185_us-gaap_IncreaseDecreaseInOtherDeposits" xml:lang="en-US">Increase (Decrease) in Security deposits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_IncreaseDecreaseInOtherDeposits" xlink:to="lab_JH04L3L4I185_us-gaap_IncreaseDecreaseInOtherDeposits"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_H456J84H45669KJ14908_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xml:lang="en-US">Increase (Decrease) in Long-term subtotal</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="lab_J678L06J67881ML36120_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssetsIncludingAmortization" xlink:label="loc_HF82J1J2G963_iccc_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssetsIncludingAmortization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_iccc_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssetsIncludingAmortization" xml:lang="en-US">Increase Decrease In Prepaid Deferred Expense And Other Assets Including Amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_JH04L3L4I185_iccc_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssetsIncludingAmortization" xml:lang="en-US">Increase (Decrease) in Prepaid expenses and other assets, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_JH04L3L4I185_iccc_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssetsIncludingAmortization" xml:lang="en-US">The increase (decrease) during the reporting period in prepaid deferred expense and other assets including amortization.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_iccc_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssetsIncludingAmortization" xlink:to="lab_JH04L3L4I185_iccc_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssetsIncludingAmortization"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_H456J84H45669KJ14908_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_J678L06J67881ML36120_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ManufacturingFacilityMember" xlink:label="loc_HF82J1J2G963_us-gaap_ManufacturingFacilityMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_ManufacturingFacilityMember" xml:lang="en-US">Manufacturing Facility [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_ManufacturingFacilityMember" xml:lang="en-US">Laboratory and manufacturing equipment [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_ManufacturingFacilityMember" xlink:to="lab_JH04L3L4I185_us-gaap_ManufacturingFacilityMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_H456J84H45669KJ14908_us-gaap_OfficeEquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_OfficeEquipmentMember" xml:lang="en-US">Office Equipment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_OfficeEquipmentMember" xml:lang="en-US">Office furniture and equipment [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_OfficeEquipmentMember" xlink:to="lab_J678L06J67881ML36120_us-gaap_OfficeEquipmentMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_HF82J1J2G963_us-gaap_ConstructionInProgressMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_ConstructionInProgressMember" xml:lang="en-US">Construction in Progress [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_ConstructionInProgressMember" xlink:to="lab_JH04L3L4I185_us-gaap_ConstructionInProgressMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LandMember" xlink:label="loc_H456J84H45669KJ14908_us-gaap_LandMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_LandMember" xml:lang="en-US">Land [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_LandMember" xlink:to="lab_J678L06J67881ML36120_us-gaap_LandMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_HF82J1J2G963_us-gaap_PropertyPlantAndEquipmentLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_PropertyPlantAndEquipmentLineItems" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_JH04L3L4I185_us-gaap_PropertyPlantAndEquipmentLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MachineryAndEquipmentGross" xlink:label="loc_H456J84H45669KJ14908_us-gaap_MachineryAndEquipmentGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_MachineryAndEquipmentGross" xml:lang="en-US">Machinery and Equipment, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_MachineryAndEquipmentGross" xml:lang="en-US">Laboratory and manufacturing equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_MachineryAndEquipmentGross" xlink:to="lab_J678L06J67881ML36120_us-gaap_MachineryAndEquipmentGross"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BuildingsAndImprovementsGross" xlink:label="loc_HF82J1J2G963_us-gaap_BuildingsAndImprovementsGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_BuildingsAndImprovementsGross" xml:lang="en-US">Buildings and Improvements, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_BuildingsAndImprovementsGross" xml:lang="en-US">Building and improvements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_BuildingsAndImprovementsGross" xlink:to="lab_JH04L3L4I185_us-gaap_BuildingsAndImprovementsGross"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FurnitureAndFixturesGross" xlink:label="loc_H456J84H45669KJ14908_us-gaap_FurnitureAndFixturesGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_FurnitureAndFixturesGross" xml:lang="en-US">Furniture and Fixtures, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_FurnitureAndFixturesGross" xml:lang="en-US">Office furniture and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_FurnitureAndFixturesGross" xlink:to="lab_J678L06J67881ML36120_us-gaap_FurnitureAndFixturesGross"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConstructionInProgressGross" xlink:label="loc_HF82J1J2G963_us-gaap_ConstructionInProgressGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_ConstructionInProgressGross" xml:lang="en-US">Construction in Progress, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/definitionGuidance" xlink:label="lab_JH04L3L4I185_us-gaap_ConstructionInProgressGross" xml:lang="en-US">Construction in progress</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_ConstructionInProgressGross" xlink:to="lab_JH04L3L4I185_us-gaap_ConstructionInProgressGross"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Land" xlink:label="loc_H456J84H45669KJ14908_us-gaap_Land" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_Land" xml:lang="en-US">Land</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_Land" xml:lang="en-US">Land</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_Land" xlink:to="lab_J678L06J67881ML36120_us-gaap_Land"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_HF82J1J2G963_us-gaap_PropertyPlantAndEquipmentGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Property, plant and equipment, gross</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_JH04L3L4I185_us-gaap_PropertyPlantAndEquipmentGross"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_H456J84H45669KJ14908_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Accumulated depreciation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_J678L06J67881ML36120_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGrossPeriodIncreaseDecrease" xlink:label="loc_HF82J1J2G963_us-gaap_PropertyPlantAndEquipmentGrossPeriodIncreaseDecrease" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_PropertyPlantAndEquipmentGrossPeriodIncreaseDecrease" xml:lang="en-US">Property, Plant and Equipment, Gross, Period Increase (Decrease)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_PropertyPlantAndEquipmentGrossPeriodIncreaseDecrease" xml:lang="en-US">Property, plant and equipment, gross increase (decrease)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_PropertyPlantAndEquipmentGrossPeriodIncreaseDecrease" xlink:to="lab_JH04L3L4I185_us-gaap_PropertyPlantAndEquipmentGrossPeriodIncreaseDecrease"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentPeriodIncreaseDecrease" xlink:label="loc_H456J84H45669KJ14908_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentPeriodIncreaseDecrease" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentPeriodIncreaseDecrease" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant and Equipment, Period Increase (Decrease)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentPeriodIncreaseDecrease" xml:lang="en-US">Less: accumulated depreciation increase (decrease)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentPeriodIncreaseDecrease" xlink:to="lab_J678L06J67881ML36120_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentPeriodIncreaseDecrease"/>
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_PropertyPlantAndEquipmentnetPeriodIncreaseDecrease" xlink:label="loc_HF82J1J2G963_iccc_PropertyPlantAndEquipmentnetPeriodIncreaseDecrease" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_iccc_PropertyPlantAndEquipmentnetPeriodIncreaseDecrease" xml:lang="en-US">Property Plant And EquipmentNet Period Increase Decrease</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_iccc_PropertyPlantAndEquipmentnetPeriodIncreaseDecrease" xml:lang="en-US">Property, plant and equipment, net increase (decrease)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_JH04L3L4I185_iccc_PropertyPlantAndEquipmentnetPeriodIncreaseDecrease" xml:lang="en-US">Amount of increase (decrease) of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_iccc_PropertyPlantAndEquipmentnetPeriodIncreaseDecrease" xlink:to="lab_JH04L3L4I185_iccc_PropertyPlantAndEquipmentnetPeriodIncreaseDecrease"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="loc_H456J84H45669KJ14908_us-gaap_AccountsPayableOtherCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_AccountsPayableOtherCurrent" xml:lang="en-US">Accounts Payable, Other, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_AccountsPayableOtherCurrent" xml:lang="en-US">Accounts payable - capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_AccountsPayableOtherCurrent" xlink:to="lab_J678L06J67881ML36120_us-gaap_AccountsPayableOtherCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_HF82J1J2G963_us-gaap_AccountsPayableTradeCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_AccountsPayableTradeCurrent" xml:lang="en-US">Accounts Payable, Trade, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_AccountsPayableTradeCurrent" xml:lang="en-US">Accounts payable - trade</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_AccountsPayableTradeCurrent" xlink:to="lab_JH04L3L4I185_us-gaap_AccountsPayableTradeCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedPayrollTaxesCurrent" xlink:label="loc_H456J84H45669KJ14908_us-gaap_AccruedPayrollTaxesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_AccruedPayrollTaxesCurrent" xml:lang="en-US">Accrued Payroll Taxes, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_AccruedPayrollTaxesCurrent" xml:lang="en-US">Accrued payroll</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_AccruedPayrollTaxesCurrent" xlink:to="lab_J678L06J67881ML36120_us-gaap_AccruedPayrollTaxesCurrent"/>
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_AccruedClinicalStudies" xlink:label="loc_HF82J1J2G963_iccc_AccruedClinicalStudies" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_iccc_AccruedClinicalStudies" xml:lang="en-US">Accrued Clinical Studies</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JH04L3L4I185_iccc_AccruedClinicalStudies" xml:lang="en-US">Accrued clinical studies</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_JH04L3L4I185_iccc_AccruedClinicalStudies" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred through that date and payable arising from transactions not otherwise specified in the taxonomy.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_iccc_AccruedClinicalStudies" xlink:to="lab_JH04L3L4I185_iccc_AccruedClinicalStudies"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_H456J84H45669KJ14908_us-gaap_AccruedProfessionalFeesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_AccruedProfessionalFeesCurrent" xml:lang="en-US">Accrued Professional Fees, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_AccruedProfessionalFeesCurrent" xml:lang="en-US">Accrued professional fees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_J678L06J67881ML36120_us-gaap_AccruedProfessionalFeesCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_HF82J1J2G963_us-gaap_OtherAccountsPayableAndAccruedLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_OtherAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Other Accounts Payable and Accrued Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_OtherAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Accrued other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:to="lab_JH04L3L4I185_us-gaap_OtherAccountsPayableAndAccruedLiabilities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_H456J84H45669KJ14908_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xml:lang="en-US">Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_J678L06J67881ML36120_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapital" xlink:label="loc_HF82J1J2G963_us-gaap_IncreaseDecreaseInOperatingCapital" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_IncreaseDecreaseInOperatingCapital" xml:lang="en-US">Increase (Decrease) in Operating Capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_IncreaseDecreaseInOperatingCapital" xml:lang="en-US">(Decrease) Increase in Accounts payable - capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_JH04L3L4I185_us-gaap_IncreaseDecreaseInOperatingCapital" xml:lang="en-US">(Decrease) Increase in Accounts payable - capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_IncreaseDecreaseInOperatingCapital" xlink:to="lab_JH04L3L4I185_us-gaap_IncreaseDecreaseInOperatingCapital"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_H456J84H45669KJ14908_us-gaap_IncreaseDecreaseInAccountsPayableTrade" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Trade</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xml:lang="en-US">(Decrease) Increase in Accounts payable - trade</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:to="lab_J678L06J67881ML36120_us-gaap_IncreaseDecreaseInAccountsPayableTrade"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedSalaries" xlink:label="loc_HF82J1J2G963_us-gaap_IncreaseDecreaseInAccruedSalaries" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_IncreaseDecreaseInAccruedSalaries" xml:lang="en-US">Increase (Decrease) in Accrued Salaries</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_IncreaseDecreaseInAccruedSalaries" xml:lang="en-US">(Decrease) Increase in Accrued payroll</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_IncreaseDecreaseInAccruedSalaries" xlink:to="lab_JH04L3L4I185_us-gaap_IncreaseDecreaseInAccruedSalaries"/>
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_IncreaseDecreaseInAccruedClinicalStudies" xlink:label="loc_H456J84H45669KJ14908_iccc_IncreaseDecreaseInAccruedClinicalStudies" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_iccc_IncreaseDecreaseInAccruedClinicalStudies" xml:lang="en-US">Increase (Decrease) In Accrued Clinical Studies</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_J678L06J67881ML36120_iccc_IncreaseDecreaseInAccruedClinicalStudies" xml:lang="en-US">(Decrease) Increase in Accrued clinical studies</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_J678L06J67881ML36120_iccc_IncreaseDecreaseInAccruedClinicalStudies" xml:lang="en-US">The increase (decrease) during the period in accrued clinical studies.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_iccc_IncreaseDecreaseInAccruedClinicalStudies" xlink:to="lab_J678L06J67881ML36120_iccc_IncreaseDecreaseInAccruedClinicalStudies"/>
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_IncreaseDecreaseInAccruedProfessionalFees" xlink:label="loc_HF82J1J2G963_iccc_IncreaseDecreaseInAccruedProfessionalFees" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_iccc_IncreaseDecreaseInAccruedProfessionalFees" xml:lang="en-US">Increase (Decrease) In Accrued Professional Fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JH04L3L4I185_iccc_IncreaseDecreaseInAccruedProfessionalFees" xml:lang="en-US">(Decrease) Increase in Accrued professional fees</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_JH04L3L4I185_iccc_IncreaseDecreaseInAccruedProfessionalFees" xml:lang="en-US">The increase (decrease) during the period in accrued professional fees.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_JH04L3L4I185_iccc_IncreaseDecreaseInAccruedProfessionalFees" xml:lang="en-US">(Decrease) Increase in Accrued professional fees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_iccc_IncreaseDecreaseInAccruedProfessionalFees" xlink:to="lab_JH04L3L4I185_iccc_IncreaseDecreaseInAccruedProfessionalFees"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_H456J84H45669KJ14908_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Increase (Decrease) in Other Accounts Payable and Accrued Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xml:lang="en-US">(Decrease) Increase in Accrued other</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xml:lang="en-US">(Decrease) Increase in Accrued other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:to="lab_J678L06J67881ML36120_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities"/>
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_IncreaseDecreaseInAccountsPayableAndAccruedExpenses" xlink:label="loc_HF82J1J2G963_iccc_IncreaseDecreaseInAccountsPayableAndAccruedExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_iccc_IncreaseDecreaseInAccountsPayableAndAccruedExpenses" xml:lang="en-US">Increase Decrease In Accounts Payable And Accrued Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_JH04L3L4I185_iccc_IncreaseDecreaseInAccountsPayableAndAccruedExpenses" xml:lang="en-US">(Decrease) Increase in Accounts payable and accrued expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_JH04L3L4I185_iccc_IncreaseDecreaseInAccountsPayableAndAccruedExpenses" xml:lang="en-US">Increase decrease in accounts payable and accrued expenses.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_iccc_IncreaseDecreaseInAccountsPayableAndAccruedExpenses" xlink:to="lab_JH04L3L4I185_iccc_IncreaseDecreaseInAccountsPayableAndAccruedExpenses"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_H456J84H45669KJ14908_us-gaap_DebtInstrumentTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_DebtInstrumentTable" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_DebtInstrumentTable" xlink:to="lab_J678L06J67881ML36120_us-gaap_DebtInstrumentTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_HF82J1J2G963_us-gaap_DebtInstrumentAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_DebtInstrumentAxis" xml:lang="en-US">Debt Instrument [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_DebtInstrumentAxis" xml:lang="en-US">Line of Credt [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_DebtInstrumentAxis" xlink:to="lab_JH04L3L4I185_us-gaap_DebtInstrumentAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_H456J84H45669KJ14908_us-gaap_DebtInstrumentNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_DebtInstrumentNameDomain" xml:lang="en-US">Debt Instrument, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_J678L06J67881ML36120_us-gaap_DebtInstrumentNameDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MortgagesMember" xlink:label="loc_HF82J1J2G963_us-gaap_MortgagesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_MortgagesMember" xml:lang="en-US">Mortgages [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_MortgagesMember" xml:lang="en-US">$1,000,000 Mortgage Note [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_MortgagesMember" xml:lang="en-US">Mortgages [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_MortgagesMember" xlink:to="lab_JH04L3L4I185_us-gaap_MortgagesMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NotesPayableToBanksMember" xlink:label="loc_H456J84H45669KJ14908_us-gaap_NotesPayableToBanksMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_NotesPayableToBanksMember" xml:lang="en-US">Notes Payable to Banks [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_NotesPayableToBanksMember" xml:lang="en-US">$ 2,500,000 Mortgage note [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_NotesPayableToBanksMember" xlink:to="lab_J678L06J67881ML36120_us-gaap_NotesPayableToBanksMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_HF82J1J2G963_us-gaap_DebtInstrumentLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_DebtInstrumentLineItems" xml:lang="en-US">Debt Instrument [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_DebtInstrumentLineItems" xlink:to="lab_JH04L3L4I185_us-gaap_DebtInstrumentLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:label="loc_H456J84H45669KJ14908_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal, Remainder of Fiscal Year</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xml:lang="en-US">Three months ending December 31, 2015</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:to="lab_J678L06J67881ML36120_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo" xlink:label="loc_HF82J1J2G963_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Rolling Year Two</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo" xml:lang="en-US">Year ending December 31, 2016</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo" xlink:to="lab_JH04L3L4I185_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree" xlink:label="loc_H456J84H45669KJ14908_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Rolling Year Three</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree" xml:lang="en-US">Year ending December 31, 2017</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree" xlink:to="lab_J678L06J67881ML36120_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour" xlink:label="loc_HF82J1J2G963_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Rolling Year Four</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour" xml:lang="en-US">Year ending December 31, 2018</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour" xlink:to="lab_JH04L3L4I185_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive" xlink:label="loc_H456J84H45669KJ14908_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Rolling Year Five</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive" xml:lang="en-US">Year ending December 31, 2019</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive" xlink:to="lab_J678L06J67881ML36120_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFive" xlink:label="loc_HF82J1J2G963_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFive" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFive" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Rolling after Year Five</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFive" xml:lang="en-US">After December 31, 2019</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFive" xml:lang="en-US">Eight months ending August 31, 2020</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFive" xlink:to="lab_JH04L3L4I185_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFive"/>
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_TotalLiabilitiesDebtCurrentPortionAndLongTermPortion" xlink:label="loc_H456J84H45669KJ14908_iccc_TotalLiabilitiesDebtCurrentPortionAndLongTermPortion" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_iccc_TotalLiabilitiesDebtCurrentPortionAndLongTermPortion" xml:lang="en-US">Total Liabilities Debt Current Portion and Long Term Portion</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_J678L06J67881ML36120_iccc_TotalLiabilitiesDebtCurrentPortionAndLongTermPortion" xml:lang="en-US">Total outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_J678L06J67881ML36120_iccc_TotalLiabilitiesDebtCurrentPortionAndLongTermPortion" xml:lang="en-US">Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_J678L06J67881ML36120_iccc_TotalLiabilitiesDebtCurrentPortionAndLongTermPortion" xml:lang="en-US">Carrying amount of total liabilities debt current portion and long-term portion, net of unamortized discount or premium, including current and noncurrent amounts.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/disclosureGuidance" xlink:label="lab_J678L06J67881ML36120_iccc_TotalLiabilitiesDebtCurrentPortionAndLongTermPortion" xml:lang="en-US">Total outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_iccc_TotalLiabilitiesDebtCurrentPortionAndLongTermPortion" xlink:to="lab_J678L06J67881ML36120_iccc_TotalLiabilitiesDebtCurrentPortionAndLongTermPortion"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_HF82J1J2G963_us-gaap_InterestRateSwapMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_InterestRateSwapMember" xml:lang="en-US">Interest Rate Swap [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_InterestRateSwapMember" xlink:to="lab_JH04L3L4I185_us-gaap_InterestRateSwapMember"/>
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_MortgagesOneMember" xlink:label="loc_H456J84H45669KJ14908_iccc_MortgagesOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_iccc_MortgagesOneMember" xml:lang="en-US">Mortgages 1 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_J678L06J67881ML36120_iccc_MortgagesOneMember" xml:lang="en-US">Mortgages One [Member].</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_iccc_MortgagesOneMember" xlink:to="lab_J678L06J67881ML36120_iccc_MortgagesOneMember"/>
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_MortgagesTwoMember" xlink:label="loc_HF82J1J2G963_iccc_MortgagesTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_iccc_MortgagesTwoMember" xml:lang="en-US">Mortgages Two [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_iccc_MortgagesTwoMember" xml:lang="en-US">Mortgages 2 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_JH04L3L4I185_iccc_MortgagesTwoMember" xml:lang="en-US">Mortgages Member.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_iccc_MortgagesTwoMember" xlink:to="lab_JH04L3L4I185_iccc_MortgagesTwoMember"/>
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_NotePayableMember" xlink:label="loc_H456J84H45669KJ14908_iccc_NotePayableMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_iccc_NotePayableMember" xml:lang="en-US">Note Payable [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_J678L06J67881ML36120_iccc_NotePayableMember" xml:lang="en-US">$600,000 note [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_J678L06J67881ML36120_iccc_NotePayableMember" xml:lang="en-US">Note Payable.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_iccc_NotePayableMember" xlink:to="lab_J678L06J67881ML36120_iccc_NotePayableMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditMember" xlink:label="loc_HF82J1J2G963_us-gaap_LineOfCreditMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_LineOfCreditMember" xml:lang="en-US">Line of Credit [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_LineOfCreditMember" xml:lang="en-US">Line Of Credit [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_LineOfCreditMember" xlink:to="lab_JH04L3L4I185_us-gaap_LineOfCreditMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_H456J84H45669KJ14908_dei_LegalEntityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_dei_LegalEntityAxis" xml:lang="en-US">Legal Entity [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_dei_LegalEntityAxis" xlink:to="lab_J678L06J67881ML36120_dei_LegalEntityAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_HF82J1J2G963_dei_EntityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_dei_EntityDomain" xml:lang="en-US">Entity [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_dei_EntityDomain" xlink:to="lab_JH04L3L4I185_dei_EntityDomain"/>
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_TdBankNaMember" xlink:label="loc_H456J84H45669KJ14908_iccc_TdBankNaMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_iccc_TdBankNaMember" xml:lang="en-US">TD Bank NA [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_iccc_TdBankNaMember" xlink:to="lab_J678L06J67881ML36120_iccc_TdBankNaMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentMaturityDateDescription" xlink:label="loc_HF82J1J2G963_us-gaap_DebtInstrumentMaturityDateDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_DebtInstrumentMaturityDateDescription" xml:lang="en-US">Debt Instrument, Maturity Date, Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_DebtInstrumentMaturityDateDescription" xml:lang="en-US">Debt instrument, maturity date, description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_DebtInstrumentMaturityDateDescription" xlink:to="lab_JH04L3L4I185_us-gaap_DebtInstrumentMaturityDateDescription"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_H456J84H45669KJ14908_us-gaap_DebtInstrumentTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_DebtInstrumentTerm" xml:lang="en-US">Debt Instrument, Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_DebtInstrumentTerm" xml:lang="en-US">Debt instrument term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_DebtInstrumentTerm" xlink:to="lab_J678L06J67881ML36120_us-gaap_DebtInstrumentTerm"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_HF82J1J2G963_us-gaap_ProceedsFromIssuanceOfLongTermDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xml:lang="en-US">Proceeds From Issuance Of Long-Term Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xml:lang="en-US">Proceeds from issuance of long-term debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_JH04L3L4I185_us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MortgageLoansOnRealEstatePeriodicPaymentTermsBalloonPaymentToBeReceived" xlink:label="loc_H456J84H45669KJ14908_us-gaap_MortgageLoansOnRealEstatePeriodicPaymentTermsBalloonPaymentToBeReceived" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_MortgageLoansOnRealEstatePeriodicPaymentTermsBalloonPaymentToBeReceived" xml:lang="en-US">Mortgage Loans on Real Estate, Periodic Payment Terms, Balloon Payment to be Received</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_MortgageLoansOnRealEstatePeriodicPaymentTermsBalloonPaymentToBeReceived" xml:lang="en-US">Balloon principal payment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_MortgageLoansOnRealEstatePeriodicPaymentTermsBalloonPaymentToBeReceived" xlink:to="lab_J678L06J67881ML36120_us-gaap_MortgageLoansOnRealEstatePeriodicPaymentTermsBalloonPaymentToBeReceived"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MortgageLoansOnRealEstatePeriodicPaymentTerms" xlink:label="loc_HF82J1J2G963_us-gaap_MortgageLoansOnRealEstatePeriodicPaymentTerms" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_MortgageLoansOnRealEstatePeriodicPaymentTerms" xml:lang="en-US">Mortgage Loans On Real Estate, Periodic Payment Terms</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_MortgageLoansOnRealEstatePeriodicPaymentTerms" xml:lang="en-US">Mortgage loans on real estate periodic payment terms</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_MortgageLoansOnRealEstatePeriodicPaymentTerms" xlink:to="lab_JH04L3L4I185_us-gaap_MortgageLoansOnRealEstatePeriodicPaymentTerms"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:label="loc_H456J84H45669KJ14908_us-gaap_LongTermDebtPercentageBearingFixedInterestRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xml:lang="en-US">Long-Term Debt, Percentage Bearing Fixed Interest, Percentage Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xml:lang="en-US">Long-term debt, percentage bearing fixed interest, percentage rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:to="lab_J678L06J67881ML36120_us-gaap_LongTermDebtPercentageBearingFixedInterestRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:label="loc_HF82J1J2G963_us-gaap_LongTermDebtPercentageBearingVariableInterestRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xml:lang="en-US">Long-term Debt, Percentage Bearing Variable Interest, Percentage Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xml:lang="en-US">Long-term debt, percentage bearing variable interest, percentage rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:to="lab_JH04L3L4I185_us-gaap_LongTermDebtPercentageBearingVariableInterestRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_DerivativeNotionalAmount" xlink:label="loc_H456J84H45669KJ14908_invest_DerivativeNotionalAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_invest_DerivativeNotionalAmount" xml:lang="en-US">Derivative, Notional Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_J678L06J67881ML36120_invest_DerivativeNotionalAmount" xml:lang="en-US">Derivative notional amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_invest_DerivativeNotionalAmount" xlink:to="lab_J678L06J67881ML36120_invest_DerivativeNotionalAmount"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_HF82J1J2G963_us-gaap_ProceedsFromNotesPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_ProceedsFromNotesPayable" xml:lang="en-US">Proceeds From Notes Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_ProceedsFromNotesPayable" xml:lang="en-US">Proceeds from notes payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_ProceedsFromNotesPayable" xlink:to="lab_JH04L3L4I185_us-gaap_ProceedsFromNotesPayable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:label="loc_H456J84H45669KJ14908_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xml:lang="en-US">Debt Instrument, Description Of Variable Rate Basis</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xml:lang="en-US">Debt Instrument, Description of Variable Rate Basis</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:to="lab_J678L06J67881ML36120_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis"/>
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_DerivativesInterestRateSwapPayments" xlink:label="loc_HF82J1J2G963_iccc_DerivativesInterestRateSwapPayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_iccc_DerivativesInterestRateSwapPayments" xml:lang="en-US">Derivatives Interest Rate Swap Payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_iccc_DerivativesInterestRateSwapPayments" xml:lang="en-US">Derivatives interest rate swap payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_JH04L3L4I185_iccc_DerivativesInterestRateSwapPayments" xml:lang="en-US">Represents payment required by the interest rate swap during the period.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_iccc_DerivativesInterestRateSwapPayments" xlink:to="lab_JH04L3L4I185_iccc_DerivativesInterestRateSwapPayments"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityDescription" xlink:label="loc_H456J84H45669KJ14908_us-gaap_LineOfCreditFacilityDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_LineOfCreditFacilityDescription" xml:lang="en-US">Line of Credit Facility, Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_LineOfCreditFacilityDescription" xml:lang="en-US">Line of credit facility, description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_LineOfCreditFacilityDescription" xlink:to="lab_J678L06J67881ML36120_us-gaap_LineOfCreditFacilityDescription"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_HF82J1J2G963_us-gaap_InterestIncomeOther" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_InterestIncomeOther" xml:lang="en-US">Interest Income, Other</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_InterestIncomeOther" xml:lang="en-US">Interest income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_InterestIncomeOther" xlink:to="lab_JH04L3L4I185_us-gaap_InterestIncomeOther"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestExpenseOther" xlink:label="loc_H456J84H45669KJ14908_us-gaap_InterestExpenseOther" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_InterestExpenseOther" xml:lang="en-US">Interest Expense, Other</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_InterestExpenseOther" xml:lang="en-US">Interest expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_InterestExpenseOther" xlink:to="lab_J678L06J67881ML36120_us-gaap_InterestExpenseOther"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNonoperatingGainsLosses" xlink:label="loc_HF82J1J2G963_us-gaap_OtherNonoperatingGainsLosses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_OtherNonoperatingGainsLosses" xml:lang="en-US">Other Nonoperating Gains (Losses)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_OtherNonoperatingGainsLosses" xml:lang="en-US">Other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_OtherNonoperatingGainsLosses" xlink:to="lab_JH04L3L4I185_us-gaap_OtherNonoperatingGainsLosses"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_H456J84H45669KJ14908_us-gaap_NonoperatingIncomeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Nonoperating Income (Expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Other expenses, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_J678L06J67881ML36120_us-gaap_NonoperatingIncomeExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_HF82J1J2G963_us-gaap_OperatingLossCarryforwardsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_OperatingLossCarryforwardsTable" xml:lang="en-US">Operating Loss Carryforwards [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_JH04L3L4I185_us-gaap_OperatingLossCarryforwardsTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_H456J84H45669KJ14908_us-gaap_IncomeTaxAuthorityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_IncomeTaxAuthorityAxis" xml:lang="en-US">Income Tax Authority [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_J678L06J67881ML36120_us-gaap_IncomeTaxAuthorityAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_HF82J1J2G963_us-gaap_IncomeTaxAuthorityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_IncomeTaxAuthorityDomain" xml:lang="en-US">Income Tax Authority [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_JH04L3L4I185_us-gaap_IncomeTaxAuthorityDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_H456J84H45669KJ14908_us-gaap_StateAndLocalJurisdictionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_StateAndLocalJurisdictionMember" xml:lang="en-US">State and Local Jurisdiction [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_J678L06J67881ML36120_us-gaap_StateAndLocalJurisdictionMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_HF82J1J2G963_us-gaap_DomesticCountryMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_DomesticCountryMember" xml:lang="en-US">Domestic Tax Authority [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_DomesticCountryMember" xlink:to="lab_JH04L3L4I185_us-gaap_DomesticCountryMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_H456J84H45669KJ14908_us-gaap_IncomeStatementLocationAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_IncomeStatementLocationAxis" xml:lang="en-US">Income Statement Location [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_J678L06J67881ML36120_us-gaap_IncomeStatementLocationAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_HF82J1J2G963_us-gaap_IncomeStatementLocationDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_IncomeStatementLocationDomain" xml:lang="en-US">Income Statement Location [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_JH04L3L4I185_us-gaap_IncomeStatementLocationDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentIncomeMember" xlink:label="loc_H456J84H45669KJ14908_us-gaap_InvestmentIncomeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_InvestmentIncomeMember" xml:lang="en-US">Investment Income [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_InvestmentIncomeMember" xml:lang="en-US">Investment [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_InvestmentIncomeMember" xlink:to="lab_J678L06J67881ML36120_us-gaap_InvestmentIncomeMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_HF82J1J2G963_us-gaap_FairValueByAssetClassAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_FairValueByAssetClassAxis" xml:lang="en-US">Asset Class [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_JH04L3L4I185_us-gaap_FairValueByAssetClassAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_H456J84H45669KJ14908_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xml:lang="en-US">Asset Class [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_J678L06J67881ML36120_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndefinitelivedIntangibleAssetsMember" xlink:label="loc_HF82J1J2G963_us-gaap_IndefinitelivedIntangibleAssetsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_IndefinitelivedIntangibleAssetsMember" xml:lang="en-US">Indefinite-lived Intangible Assets [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_IndefinitelivedIntangibleAssetsMember" xml:lang="en-US">Intangible asset [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_IndefinitelivedIntangibleAssetsMember" xlink:to="lab_JH04L3L4I185_us-gaap_IndefinitelivedIntangibleAssetsMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_H456J84H45669KJ14908_us-gaap_OperatingLossCarryforwardsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_OperatingLossCarryforwardsLineItems" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_J678L06J67881ML36120_us-gaap_OperatingLossCarryforwardsLineItems"/>
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_IncomeTaxDisclosureTextualAbstract" xlink:label="loc_HF82J1J2G963_iccc_IncomeTaxDisclosureTextualAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_iccc_IncomeTaxDisclosureTextualAbstract" xml:lang="en-US">Income Tax Disclosure Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_iccc_IncomeTaxDisclosureTextualAbstract" xml:lang="en-US">Income Tax [Textual]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_iccc_IncomeTaxDisclosureTextualAbstract" xlink:to="lab_JH04L3L4I185_iccc_IncomeTaxDisclosureTextualAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_H456J84H45669KJ14908_us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xml:lang="en-US">Income tax rate percenatge</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_J678L06J67881ML36120_us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_HF82J1J2G963_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xml:lang="en-US">U.S. federal corporate tax rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xml:lang="en-US">State income taxes, net of federal (benefit) expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_JH04L3L4I185_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_H456J84H45669KJ14908_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xml:lang="en-US">State net operating loss carryforward</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xml:lang="en-US">State net operating loss carryforward</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="lab_J678L06J67881ML36120_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="loc_HF82J1J2G963_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Domestic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xml:lang="en-US">Federal net operating loss carryforward</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xml:lang="en-US">Federal net operating loss carryforward</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="lab_JH04L3L4I185_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxCreditCarryforwardDescription" xlink:label="loc_H456J84H45669KJ14908_us-gaap_TaxCreditCarryforwardDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_TaxCreditCarryforwardDescription" xml:lang="en-US">Tax Credit Carryforward, Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_TaxCreditCarryforwardDescription" xml:lang="en-US">Tax credit carryforward, description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_TaxCreditCarryforwardDescription" xlink:to="lab_J678L06J67881ML36120_us-gaap_TaxCreditCarryforwardDescription"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LicenseCosts" xlink:label="loc_HF82J1J2G963_us-gaap_LicenseCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_LicenseCosts" xml:lang="en-US">License Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_LicenseCosts" xml:lang="en-US">License costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_LicenseCosts" xml:lang="en-US">License option fee(1)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_JH04L3L4I185_us-gaap_LicenseCosts" xml:lang="en-US">License option fee(1)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_LicenseCosts" xlink:to="lab_JH04L3L4I185_us-gaap_LicenseCosts"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="loc_H456J84H45669KJ14908_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xml:lang="en-US">Finite-Lived Intangible Assets, Remaining Amortization Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xml:lang="en-US">Finite-Lived intangible assets, remaining amortization period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:to="lab_J678L06J67881ML36120_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1"/>
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_InvestmentsOwnedBalancePrincipalAmount" xlink:label="loc_HF82J1J2G963_iccc_InvestmentsOwnedBalancePrincipalAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_iccc_InvestmentsOwnedBalancePrincipalAmount" xml:lang="en-US">Investments Owned Balance Principal Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_iccc_InvestmentsOwnedBalancePrincipalAmount" xml:lang="en-US">Investment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_JH04L3L4I185_iccc_InvestmentsOwnedBalancePrincipalAmount" xml:lang="en-US">For investments which are quantified by principal amount, the principle balance held at close of period.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_iccc_InvestmentsOwnedBalancePrincipalAmount" xlink:to="lab_JH04L3L4I185_iccc_InvestmentsOwnedBalancePrincipalAmount"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" xlink:label="loc_H456J84H45669KJ14908_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, General Business</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" xml:lang="en-US">General business tax credit carryforwards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" xlink:to="lab_J678L06J67881ML36120_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:label="loc_HF82J1J2G963_us-gaap_OperatingLossCarryforwardsValuationAllowance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_OperatingLossCarryforwardsValuationAllowance" xml:lang="en-US">Operating Loss Carryforwards, Valuation Allowance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_OperatingLossCarryforwardsValuationAllowance" xml:lang="en-US">Effective taxable income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:to="lab_JH04L3L4I185_us-gaap_OperatingLossCarryforwardsValuationAllowance"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:label="loc_H456J84H45669KJ14908_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Other, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xml:lang="en-US">Effective assuming income tax rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:to="lab_J678L06J67881ML36120_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther"/>
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_CommitmentsAndContingenciesLiabilitiesTextualAbstract" xlink:label="loc_HF82J1J2G963_iccc_CommitmentsAndContingenciesLiabilitiesTextualAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_iccc_CommitmentsAndContingenciesLiabilitiesTextualAbstract" xml:lang="en-US">Commitments And Contingencies Liabilities Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JH04L3L4I185_iccc_CommitmentsAndContingenciesLiabilitiesTextualAbstract" xml:lang="en-US">Commitments and Contingencies Liabilities [Textual]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_iccc_CommitmentsAndContingenciesLiabilitiesTextualAbstract" xlink:to="lab_JH04L3L4I185_iccc_CommitmentsAndContingenciesLiabilitiesTextualAbstract"/>
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_CapitalExpenditures" xlink:label="loc_H456J84H45669KJ14908_iccc_CapitalExpenditures" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_iccc_CapitalExpenditures" xml:lang="en-US">Capital Expenditures</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_J678L06J67881ML36120_iccc_CapitalExpenditures" xml:lang="en-US">Capital expenditure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_J678L06J67881ML36120_iccc_CapitalExpenditures" xml:lang="en-US">Capital expenditure</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_iccc_CapitalExpenditures" xlink:to="lab_J678L06J67881ML36120_iccc_CapitalExpenditures"/>
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_OtherObligations" xlink:label="loc_HF82J1J2G963_iccc_OtherObligations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_iccc_OtherObligations" xml:lang="en-US">Other Obligations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_iccc_OtherObligations" xml:lang="en-US">Other obligations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_JH04L3L4I185_iccc_OtherObligations" xml:lang="en-US">Other obligations.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_iccc_OtherObligations" xlink:to="lab_JH04L3L4I185_iccc_OtherObligations"/>
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_InventoryProduction" xlink:label="loc_H456J84H45669KJ14908_iccc_InventoryProduction" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_iccc_InventoryProduction" xml:lang="en-US">Inventory Production</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_J678L06J67881ML36120_iccc_InventoryProduction" xml:lang="en-US">Production of inventory</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_J678L06J67881ML36120_iccc_InventoryProduction" xml:lang="en-US">Production of inventory.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_iccc_InventoryProduction" xlink:to="lab_J678L06J67881ML36120_iccc_InventoryProduction"/>
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_CommonStockRightsPlanTextualAbstract" xlink:label="loc_HF82J1J2G963_iccc_CommonStockRightsPlanTextualAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_iccc_CommonStockRightsPlanTextualAbstract" xml:lang="en-US">Common Stock Rights Plan Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JH04L3L4I185_iccc_CommonStockRightsPlanTextualAbstract" xml:lang="en-US">Common Stock Rights Plan [Textual]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_iccc_CommonStockRightsPlanTextualAbstract" xlink:to="lab_JH04L3L4I185_iccc_CommonStockRightsPlanTextualAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockVotingRights" xlink:label="loc_H456J84H45669KJ14908_us-gaap_CommonStockVotingRights" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_CommonStockVotingRights" xml:lang="en-US">Common Stock, Voting Rights</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_CommonStockVotingRights" xml:lang="en-US">Common stock, controlling the rights percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_CommonStockVotingRights" xlink:to="lab_J678L06J67881ML36120_us-gaap_CommonStockVotingRights"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:label="loc_HF82J1J2G963_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xml:lang="en-US">Schedule of Revenue by Major Customers, by Reporting Segments [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:to="lab_JH04L3L4I185_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_H456J84H45669KJ14908_us-gaap_StatementBusinessSegmentsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_StatementBusinessSegmentsAxis" xml:lang="en-US">Business Segments [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_J678L06J67881ML36120_us-gaap_StatementBusinessSegmentsAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_HF82J1J2G963_us-gaap_SegmentDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_SegmentDomain" xml:lang="en-US">Segment [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_SegmentDomain" xlink:to="lab_JH04L3L4I185_us-gaap_SegmentDomain"/>
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_AnimalHealthInternationalIncMember" xlink:label="loc_H456J84H45669KJ14908_iccc_AnimalHealthInternationalIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_iccc_AnimalHealthInternationalIncMember" xml:lang="en-US">Animal Health International, Inc [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_J678L06J67881ML36120_iccc_AnimalHealthInternationalIncMember" xml:lang="en-US">Animal Health International, Inc. [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_J678L06J67881ML36120_iccc_AnimalHealthInternationalIncMember" xml:lang="en-US">Animal Health International, Inc.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_iccc_AnimalHealthInternationalIncMember" xlink:to="lab_J678L06J67881ML36120_iccc_AnimalHealthInternationalIncMember"/>
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_MwiVeterinarySupplyCompanyMember" xlink:label="loc_HF82J1J2G963_iccc_MwiVeterinarySupplyCompanyMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_iccc_MwiVeterinarySupplyCompanyMember" xml:lang="en-US">Mwi Veterinary Supply Company [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_iccc_MwiVeterinarySupplyCompanyMember" xml:lang="en-US">MWI Animal Health [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_JH04L3L4I185_iccc_MwiVeterinarySupplyCompanyMember" xml:lang="en-US">MWI Veterinary Supply Company.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_iccc_MwiVeterinarySupplyCompanyMember" xlink:to="lab_JH04L3L4I185_iccc_MwiVeterinarySupplyCompanyMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:label="loc_H456J84H45669KJ14908_us-gaap_EntityWideRevenueMajorCustomerLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_EntityWideRevenueMajorCustomerLineItems" xml:lang="en-US">Revenue, Major Customer [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:to="lab_J678L06J67881ML36120_us-gaap_EntityWideRevenueMajorCustomerLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_HF82J1J2G963_us-gaap_ConcentrationRiskPercentage1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_ConcentrationRiskPercentage1" xml:lang="en-US">Concentration Risk, Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_ConcentrationRiskPercentage1" xml:lang="en-US">Concentration risk percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_JH04L3L4I185_us-gaap_ConcentrationRiskPercentage1"/>
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_AnimartLlcMember" xlink:label="loc_H456J84H45669KJ14908_iccc_AnimartLlcMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_iccc_AnimartLlcMember" xml:lang="en-US">Animart, Llc [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_J678L06J67881ML36120_iccc_AnimartLlcMember" xml:lang="en-US">TCS Biosciences, Ltd. [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_iccc_AnimartLlcMember" xlink:to="lab_J678L06J67881ML36120_iccc_AnimartLlcMember"/>
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_AccountsReceivableDueFromSignificantCustomers" xlink:label="loc_HF82J1J2G963_iccc_AccountsReceivableDueFromSignificantCustomers" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_iccc_AccountsReceivableDueFromSignificantCustomers" xml:lang="en-US">Accounts Receivable Due From Significant Customers</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JH04L3L4I185_iccc_AccountsReceivableDueFromSignificantCustomers" xml:lang="en-US">Accounts receivable due from significant customers</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_JH04L3L4I185_iccc_AccountsReceivableDueFromSignificantCustomers" xml:lang="en-US">The percentage amounts represents to accounts receivable due from significant customers as of the balance sheet date.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_iccc_AccountsReceivableDueFromSignificantCustomers" xlink:to="lab_JH04L3L4I185_iccc_AccountsReceivableDueFromSignificantCustomers"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_H456J84H45669KJ14908_us-gaap_ConcentrationRiskByBenchmarkAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_ConcentrationRiskByBenchmarkAxis" xml:lang="en-US">Concentration Risk Benchmark [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_J678L06J67881ML36120_us-gaap_ConcentrationRiskByBenchmarkAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_HF82J1J2G963_us-gaap_ConcentrationRiskBenchmarkDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_ConcentrationRiskBenchmarkDomain" xml:lang="en-US">Concentration Risk Benchmark [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_JH04L3L4I185_us-gaap_ConcentrationRiskBenchmarkDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_H456J84H45669KJ14908_us-gaap_SalesRevenueNetMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_SalesRevenueNetMember" xml:lang="en-US">Sales Revenue, Net [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_SalesRevenueNetMember" xlink:to="lab_J678L06J67881ML36120_us-gaap_SalesRevenueNetMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="loc_HF82J1J2G963_us-gaap_MajorCustomersAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_MajorCustomersAxis" xml:lang="en-US">Customer [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_MajorCustomersAxis" xlink:to="lab_JH04L3L4I185_us-gaap_MajorCustomersAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_H456J84H45669KJ14908_us-gaap_NameOfMajorCustomerDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_NameOfMajorCustomerDomain" xml:lang="en-US">Customer [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_NameOfMajorCustomerDomain" xlink:to="lab_J678L06J67881ML36120_us-gaap_NameOfMajorCustomerDomain"/>
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_UnitedStatesDairyAndBeefIndustriesMember" xlink:label="loc_HF82J1J2G963_iccc_UnitedStatesDairyAndBeefIndustriesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_iccc_UnitedStatesDairyAndBeefIndustriesMember" xml:lang="en-US">United States Dairy And Beef Industries [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_iccc_UnitedStatesDairyAndBeefIndustriesMember" xml:lang="en-US">U.S. dairy and beef industries [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_JH04L3L4I185_iccc_UnitedStatesDairyAndBeefIndustriesMember" xml:lang="en-US">United states dairy and beef industries.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_iccc_UnitedStatesDairyAndBeefIndustriesMember" xlink:to="lab_JH04L3L4I185_iccc_UnitedStatesDairyAndBeefIndustriesMember"/>
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_ForeignCustomersMember" xlink:label="loc_H456J84H45669KJ14908_iccc_ForeignCustomersMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_iccc_ForeignCustomersMember" xml:lang="en-US">Foreign Customers [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_J678L06J67881ML36120_iccc_ForeignCustomersMember" xml:lang="en-US">Foreign dairy and beef industries [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_iccc_ForeignCustomersMember" xlink:to="lab_J678L06J67881ML36120_iccc_ForeignCustomersMember"/>
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_SegmentAndSignificantCustomerInformationTextualAbstract" xlink:label="loc_HF82J1J2G963_iccc_SegmentAndSignificantCustomerInformationTextualAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_iccc_SegmentAndSignificantCustomerInformationTextualAbstract" xml:lang="en-US">Segment And Significant Customer Information Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JH04L3L4I185_iccc_SegmentAndSignificantCustomerInformationTextualAbstract" xml:lang="en-US">Segment and Significant Customer Information (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_iccc_SegmentAndSignificantCustomerInformationTextualAbstract" xlink:to="lab_JH04L3L4I185_iccc_SegmentAndSignificantCustomerInformationTextualAbstract"/>
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_RelatedPartyTransactionsTextualAbstract" xlink:label="loc_H456J84H45669KJ14908_iccc_RelatedPartyTransactionsTextualAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_iccc_RelatedPartyTransactionsTextualAbstract" xml:lang="en-US">Related Party Transactions Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_J678L06J67881ML36120_iccc_RelatedPartyTransactionsTextualAbstract" xml:lang="en-US">Related Party Transactions (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_iccc_RelatedPartyTransactionsTextualAbstract" xlink:to="lab_J678L06J67881ML36120_iccc_RelatedPartyTransactionsTextualAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueFromRelatedParties" xlink:label="loc_HF82J1J2G963_us-gaap_RevenueFromRelatedParties" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_RevenueFromRelatedParties" xml:lang="en-US">Revenue from Related Parties</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_RevenueFromRelatedParties" xml:lang="en-US">Revenues from transactions with related party</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_RevenueFromRelatedParties" xlink:to="lab_JH04L3L4I185_us-gaap_RevenueFromRelatedParties"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:label="loc_H456J84H45669KJ14908_us-gaap_AccountsReceivableRelatedPartiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_AccountsReceivableRelatedPartiesCurrent" xml:lang="en-US">Accounts Receivable, Related Parties, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_AccountsReceivableRelatedPartiesCurrent" xml:lang="en-US">Accounts receivable, related parties</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:to="lab_J678L06J67881ML36120_us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="loc_HF82J1J2G963_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xml:lang="en-US">Related Party Transaction, Expenses from Transactions with Related Party</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xml:lang="en-US">Related party transaction, expenses from transactions with related party</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="lab_JH04L3L4I185_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_EmployeeBenefitsTextualAbstract" xlink:label="loc_H456J84H45669KJ14908_iccc_EmployeeBenefitsTextualAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_iccc_EmployeeBenefitsTextualAbstract" xml:lang="en-US">Employee Benefits Textual [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_J678L06J67881ML36120_iccc_EmployeeBenefitsTextualAbstract" xml:lang="en-US">Employee Benefits (Textual)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_iccc_EmployeeBenefitsTextualAbstract" xlink:to="lab_J678L06J67881ML36120_iccc_EmployeeBenefitsTextualAbstract"/>
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_EmployeeSavingsPlanDescription" xlink:label="loc_HF82J1J2G963_iccc_EmployeeSavingsPlanDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_iccc_EmployeeSavingsPlanDescription" xml:lang="en-US">Employee Savings Plan Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_iccc_EmployeeSavingsPlanDescription" xml:lang="en-US">Employee savings plan description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_JH04L3L4I185_iccc_EmployeeSavingsPlanDescription" xml:lang="en-US">Description of employee completing service under saving plan.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_iccc_EmployeeSavingsPlanDescription" xlink:to="lab_JH04L3L4I185_iccc_EmployeeSavingsPlanDescription"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DefinedBenefitPlansGeneralInformation" xlink:label="loc_H456J84H45669KJ14908_us-gaap_DefinedBenefitPlansGeneralInformation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_DefinedBenefitPlansGeneralInformation" xml:lang="en-US">Defined Benefit Plans, General Information</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_DefinedBenefitPlansGeneralInformation" xml:lang="en-US">Defined benefit plans general information</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_DefinedBenefitPlansGeneralInformation" xlink:to="lab_J678L06J67881ML36120_us-gaap_DefinedBenefitPlansGeneralInformation"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitsPaid" xlink:label="loc_HF82J1J2G963_us-gaap_DefinedBenefitPlanBenefitsPaid" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_DefinedBenefitPlanBenefitsPaid" xml:lang="en-US">Defined Benefit Plan, Benefits Paid</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_DefinedBenefitPlanBenefitsPaid" xml:lang="en-US">Defined benefit plan benefits paid</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_DefinedBenefitPlanBenefitsPaid" xlink:to="lab_JH04L3L4I185_us-gaap_DefinedBenefitPlanBenefitsPaid"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_H456J84H45669KJ14908_us-gaap_SubsequentEventTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_SubsequentEventTable" xml:lang="en-US">Subsequent Event [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_SubsequentEventTable" xlink:to="lab_J678L06J67881ML36120_us-gaap_SubsequentEventTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_HF82J1J2G963_us-gaap_SubsequentEventTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_SubsequentEventTypeAxis" xml:lang="en-US">Subsequent Event Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_JH04L3L4I185_us-gaap_SubsequentEventTypeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_H456J84H45669KJ14908_us-gaap_SubsequentEventTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_SubsequentEventTypeDomain" xml:lang="en-US">Subsequent Event Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_J678L06J67881ML36120_us-gaap_SubsequentEventTypeDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_HF82J1J2G963_us-gaap_SubsequentEventMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Event [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Event [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_SubsequentEventMember" xlink:to="lab_JH04L3L4I185_us-gaap_SubsequentEventMember"/>
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_PlasPakIncMember" xlink:label="loc_H456J84H45669KJ14908_iccc_PlasPakIncMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_iccc_PlasPakIncMember" xml:lang="en-US">Plas Pak Inc [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_J678L06J67881ML36120_iccc_PlasPakIncMember" xml:lang="en-US">Plas pak inc member.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_iccc_PlasPakIncMember" xlink:to="lab_J678L06J67881ML36120_iccc_PlasPakIncMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_HF82J1J2G963_us-gaap_SubsequentEventLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_SubsequentEventLineItems" xml:lang="en-US">Subsequent Event [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_SubsequentEventLineItems" xlink:to="lab_JH04L3L4I185_us-gaap_SubsequentEventLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PurchaseOptionsLand" xlink:label="loc_H456J84H45669KJ14908_us-gaap_PurchaseOptionsLand" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_PurchaseOptionsLand" xml:lang="en-US">Purchase Options, Land</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_PurchaseOptionsLand" xml:lang="en-US">Option to acquire land</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_PurchaseOptionsLand" xlink:to="lab_J678L06J67881ML36120_us-gaap_PurchaseOptionsLand"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LandPurchaseOptionsDescription" xlink:label="loc_HF82J1J2G963_us-gaap_LandPurchaseOptionsDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_JH04L3L4I185_us-gaap_LandPurchaseOptionsDescription" xml:lang="en-US">Land Purchase Options, Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_JH04L3L4I185_us-gaap_LandPurchaseOptionsDescription" xml:lang="en-US">Land purchase options, description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_HF82J1J2G963_us-gaap_LandPurchaseOptionsDescription" xlink:to="lab_JH04L3L4I185_us-gaap_LandPurchaseOptionsDescription"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_H456J84H45669KJ14908_us-gaap_StockIssuedDuringPeriodValueNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_J678L06J67881ML36120_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_J678L06J67881ML36120_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Potential issuance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_H456J84H45669KJ14908_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_J678L06J67881ML36120_us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
</labelLink></linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>iccc-20150930_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8" ?>
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="iccc-20150930.xsd#DocumentAndEntityInformation" roleURI="http://www.immucell.com/role/DocumentAndEntityInformation"/>
<roleRef xlink:type="simple" xlink:href="iccc-20150930.xsd#BalanceSheets" roleURI="http://www.immucell.com/role/BalanceSheets"/>
<roleRef xlink:type="simple" xlink:href="iccc-20150930.xsd#BalanceSheetsParenthetical" roleURI="http://www.immucell.com/role/BalanceSheetsParenthetical"/>
<roleRef xlink:type="simple" xlink:href="iccc-20150930.xsd#StatementsOfOperationsUnaudited" roleURI="http://www.immucell.com/role/StatementsOfOperationsUnaudited"/>
<roleRef xlink:type="simple" xlink:href="iccc-20150930.xsd#StatementsOfComprehensiveIncomeLossUnaudited" roleURI="http://www.immucell.com/role/StatementsOfComprehensiveIncomeLossUnaudited"/>
<roleRef xlink:type="simple" xlink:href="iccc-20150930.xsd#StatementsOfStockholdersEquityUnaudited" roleURI="http://www.immucell.com/role/StatementsOfStockholdersEquityUnaudited"/>
<roleRef xlink:type="simple" xlink:href="iccc-20150930.xsd#StatementsOfStockholdersEquityUnauditedParenthetical" roleURI="http://www.immucell.com/role/StatementsOfStockholdersEquityUnauditedParenthetical"/>
<roleRef xlink:type="simple" xlink:href="iccc-20150930.xsd#StatementsOfCashFlowsUnaudited" roleURI="http://www.immucell.com/role/StatementsOfCashFlowsUnaudited"/>
<roleRef xlink:type="simple" xlink:href="iccc-20150930.xsd#BusinessOperations" roleURI="http://www.immucell.com/role/BusinessOperations"/>
<roleRef xlink:type="simple" xlink:href="iccc-20150930.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://www.immucell.com/role/SummaryOfSignificantAccountingPolicies"/>
<roleRef xlink:type="simple" xlink:href="iccc-20150930.xsd#CashCashEquivalentsShortTermInvestmentsAndLongTermInvestments" roleURI="http://www.immucell.com/role/CashCashEquivalentsShortTermInvestmentsAndLongTermInvestments"/>
<roleRef xlink:type="simple" xlink:href="iccc-20150930.xsd#Inventory" roleURI="http://www.immucell.com/role/Inventory"/>
<roleRef xlink:type="simple" xlink:href="iccc-20150930.xsd#AccountsReceivable" roleURI="http://www.immucell.com/role/AccountsReceivable"/>
<roleRef xlink:type="simple" xlink:href="iccc-20150930.xsd#PrepaidExpensesAndOtherAssets" roleURI="http://www.immucell.com/role/PrepaidExpensesAndOtherAssets"/>
<roleRef xlink:type="simple" xlink:href="iccc-20150930.xsd#PropertyPlantAndEquipment" roleURI="http://www.immucell.com/role/PropertyPlantAndEquipment"/>
<roleRef xlink:type="simple" xlink:href="iccc-20150930.xsd#AccountsPayableAndAccruedExpenses" roleURI="http://www.immucell.com/role/AccountsPayableAndAccruedExpenses"/>
<roleRef xlink:type="simple" xlink:href="iccc-20150930.xsd#BankDebt" roleURI="http://www.immucell.com/role/BankDebt"/>
<roleRef xlink:type="simple" xlink:href="iccc-20150930.xsd#OtherExpensesNet" roleURI="http://www.immucell.com/role/OtherExpensesNet"/>
<roleRef xlink:type="simple" xlink:href="iccc-20150930.xsd#IncomeTaxes" roleURI="http://www.immucell.com/role/IncomeTaxes"/>
<roleRef xlink:type="simple" xlink:href="iccc-20150930.xsd#CommitmentsAndContingentLiabilities" roleURI="http://www.immucell.com/role/CommitmentsAndContingentLiabilities"/>
<roleRef xlink:type="simple" xlink:href="iccc-20150930.xsd#CommonStockRightsPlan" roleURI="http://www.immucell.com/role/CommonStockRightsPlan"/>
<roleRef xlink:type="simple" xlink:href="iccc-20150930.xsd#SegmentAndSignificantCustomerInformation" roleURI="http://www.immucell.com/role/SegmentAndSignificantCustomerInformation"/>
<roleRef xlink:type="simple" xlink:href="iccc-20150930.xsd#RelatedPartyTransactions" roleURI="http://www.immucell.com/role/RelatedPartyTransactions"/>
<roleRef xlink:type="simple" xlink:href="iccc-20150930.xsd#EmployeeBenefits" roleURI="http://www.immucell.com/role/EmployeeBenefits"/>
<roleRef xlink:type="simple" xlink:href="iccc-20150930.xsd#SubsequentEvents" roleURI="http://www.immucell.com/role/SubsequentEvents"/>
<roleRef xlink:type="simple" xlink:href="iccc-20150930.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.immucell.com/role/SummaryOfSignificantAccountingPoliciesPolicies"/>
<roleRef xlink:type="simple" xlink:href="iccc-20150930.xsd#SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.immucell.com/role/SummaryofSignificantAccountingPoliciesTables"/>
<roleRef xlink:type="simple" xlink:href="iccc-20150930.xsd#CashCashEquivalentsShortTermInvestmentsAndLongTermInvestmentsTables" roleURI="http://www.immucell.com/role/CashCashEquivalentsShortTermInvestmentsAndLongTermInvestmentsTables"/>
<roleRef xlink:type="simple" xlink:href="iccc-20150930.xsd#InventoryTables" roleURI="http://www.immucell.com/role/InventoryTables"/>
<roleRef xlink:type="simple" xlink:href="iccc-20150930.xsd#AccountsReceivableTables" roleURI="http://www.immucell.com/role/AccountsReceivableTables"/>
<roleRef xlink:type="simple" xlink:href="iccc-20150930.xsd#PrepaidExpensesandOtherAssetsTables" roleURI="http://www.immucell.com/role/PrepaidExpensesandOtherAssetsTables"/>
<roleRef xlink:type="simple" xlink:href="iccc-20150930.xsd#PropertyPlantAndEquipmentTables" roleURI="http://www.immucell.com/role/PropertyPlantAndEquipmentTables"/>
<roleRef xlink:type="simple" xlink:href="iccc-20150930.xsd#AccountsPayableandAccruedExpensesTables" roleURI="http://www.immucell.com/role/AccountsPayableandAccruedExpensesTables"/>
<roleRef xlink:type="simple" xlink:href="iccc-20150930.xsd#BankDebtTables" roleURI="http://www.immucell.com/role/BankDebtTables"/>
<roleRef xlink:type="simple" xlink:href="iccc-20150930.xsd#OtherExpensesNetTables" roleURI="http://www.immucell.com/role/OtherExpensesNetTables"/>
<roleRef xlink:type="simple" xlink:href="iccc-20150930.xsd#SegmentAndSignificantCustomerInformationTables" roleURI="http://www.immucell.com/role/SegmentAndSignificantCustomerInformationTables"/>
<roleRef xlink:type="simple" xlink:href="iccc-20150930.xsd#SummaryOfSignificantAccountingPoliciesDetails" roleURI="http://www.immucell.com/role/SummaryOfSignificantAccountingPoliciesDetails"/>
<roleRef xlink:type="simple" xlink:href="iccc-20150930.xsd#SummaryOfSignificantAccountingPoliciesDetailsTextual" roleURI="http://www.immucell.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="iccc-20150930.xsd#CashCashEquivalentsShortTermInvestmentsAndLongTermInvestmentsDetails" roleURI="http://www.immucell.com/role/CashCashEquivalentsShortTermInvestmentsAndLongTermInvestmentsDetails"/>
<roleRef xlink:type="simple" xlink:href="iccc-20150930.xsd#InventoryDetails" roleURI="http://www.immucell.com/role/InventoryDetails"/>
<roleRef xlink:type="simple" xlink:href="iccc-20150930.xsd#AccountsReceivableDetails" roleURI="http://www.immucell.com/role/AccountsReceivableDetails"/>
<roleRef xlink:type="simple" xlink:href="iccc-20150930.xsd#PrepaidExpensesandOtherAssetsDetails" roleURI="http://www.immucell.com/role/PrepaidExpensesandOtherAssetsDetails"/>
<roleRef xlink:type="simple" xlink:href="iccc-20150930.xsd#PropertyPlantAndEquipmentDetails" roleURI="http://www.immucell.com/role/PropertyPlantAndEquipmentDetails"/>
<roleRef xlink:type="simple" xlink:href="iccc-20150930.xsd#AccountsPayableandAccruedExpensesDetails" roleURI="http://www.immucell.com/role/AccountsPayableandAccruedExpensesDetails"/>
<roleRef xlink:type="simple" xlink:href="iccc-20150930.xsd#BankDebtDetails" roleURI="http://www.immucell.com/role/BankDebtDetails"/>
<roleRef xlink:type="simple" xlink:href="iccc-20150930.xsd#BankDebtDetailsTextual" roleURI="http://www.immucell.com/role/BankDebtDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="iccc-20150930.xsd#OtherExpensesNetDetails" roleURI="http://www.immucell.com/role/OtherExpensesNetDetails"/>
<roleRef xlink:type="simple" xlink:href="iccc-20150930.xsd#IncomeTaxesDetails" roleURI="http://www.immucell.com/role/IncomeTaxesDetails"/>
<roleRef xlink:type="simple" xlink:href="iccc-20150930.xsd#CommitmentsandContingentLiabilitiesDetails" roleURI="http://www.immucell.com/role/CommitmentsandContingentLiabilitiesDetails"/>
<roleRef xlink:type="simple" xlink:href="iccc-20150930.xsd#CommonStockRightsPlanDetails" roleURI="http://www.immucell.com/role/CommonStockRightsPlanDetails"/>
<roleRef xlink:type="simple" xlink:href="iccc-20150930.xsd#SegmentAndSignificantCustomerInformationDetails" roleURI="http://www.immucell.com/role/SegmentAndSignificantCustomerInformationDetails"/>
<roleRef xlink:type="simple" xlink:href="iccc-20150930.xsd#SegmentAndSignificantCustomerInformationDetails1" roleURI="http://www.immucell.com/role/SegmentAndSignificantCustomerInformationDetails1"/>
<roleRef xlink:type="simple" xlink:href="iccc-20150930.xsd#SegmentAndSignificantCustomerInformationDetailsTextual" roleURI="http://www.immucell.com/role/SegmentAndSignificantCustomerInformationDetailsTextual"/>
<roleRef xlink:type="simple" xlink:href="iccc-20150930.xsd#RelatedPartyTransactionsDetails" roleURI="http://www.immucell.com/role/RelatedPartyTransactionsDetails"/>
<roleRef xlink:type="simple" xlink:href="iccc-20150930.xsd#EmployeeBenefitsDetails" roleURI="http://www.immucell.com/role/EmployeeBenefitsDetails"/>
<roleRef xlink:type="simple" xlink:href="iccc-20150930.xsd#SubsequentEventsDetails" roleURI="http://www.immucell.com/role/SubsequentEventsDetails"/>
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
<presentationLink xlink:type="extended" xlink:role="http://www.immucell.com/role/DocumentAndEntityInformation">
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_DocumentAndEntityInformationAbstract" xlink:label="loc_iccc_DocumentAndEntityInformationAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_iccc_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityRegistrantName_1" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_iccc_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityCentralIndexKey_2" order="10" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_iccc_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_CurrentFiscalYearEndDate_3" order="20" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_iccc_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityFilerCategory_4" order="30" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_iccc_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_DocumentType_5" order="40" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_iccc_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_AmendmentFlag_6" order="50" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_iccc_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_DocumentPeriodEndDate_7" order="60" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_iccc_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_DocumentFiscalPeriodFocus_8" order="70" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_iccc_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_DocumentFiscalYearFocus_9" order="80" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_iccc_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_10" order="90" use="optional" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immucell.com/role/BalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_AssetsAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_AssetsCurrentAbstract_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2" xlink:to="loc_us-gaap_ShortTermInvestments_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_5" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2" xlink:to="loc_us-gaap_InventoryNet_6" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsNetCurrent" xlink:label="loc_us-gaap_DeferredTaxAssetsNetCurrent_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2" xlink:to="loc_us-gaap_DeferredTaxAssetsNetCurrent_8" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2" xlink:to="loc_us-gaap_AssetsCurrent_9" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_10" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaap_LongTermInvestments_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_LongTermInvestments_11" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsNetNoncurrent" xlink:label="loc_us-gaap_DeferredTaxAssetsNetNoncurrent_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsNetNoncurrent_12" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_13" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_1" xlink:to="loc_us-gaap_Assets_14" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_15" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_15" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_16" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_17" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_16" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_17" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LoansPayableToBankCurrent" xlink:label="loc_us-gaap_LoansPayableToBankCurrent_18" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_16" xlink:to="loc_us-gaap_LoansPayableToBankCurrent_18" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="loc_us-gaap_DeferredRevenueCurrent_19" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_16" xlink:to="loc_us-gaap_DeferredRevenueCurrent_19" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_20" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_16" xlink:to="loc_us-gaap_LiabilitiesCurrent_20" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesNoncurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_21" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_15" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_21" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermLoansFromBank" xlink:label="loc_us-gaap_LongTermLoansFromBank_22" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_21" xlink:to="loc_us-gaap_LongTermLoansFromBank_22" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_InterestRateSwap" xlink:label="loc_iccc_InterestRateSwap_23" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_21" xlink:to="loc_iccc_InterestRateSwap_23" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesNoncurrent" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_24" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_21" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_24" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_25" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_21" xlink:to="loc_us-gaap_Liabilities_25" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_26" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_15" xlink:to="loc_us-gaap_StockholdersEquityAbstract_26" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_27" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_26" xlink:to="loc_us-gaap_CommonStockValue_27" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_28" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_26" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_28" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_29" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_26" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_29" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_30" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_26" xlink:to="loc_us-gaap_TreasuryStockValue_30" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_31" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_26" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_31" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_32" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_26" xlink:to="loc_us-gaap_StockholdersEquity_32" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_33" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_26" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_33" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immucell.com/role/BalanceSheetsParenthetical">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesIssued_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="loc_us-gaap_TreasuryStockShares_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_TreasuryStockShares_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immucell.com/role/StatementsOfOperationsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueGoodsNet" xlink:label="loc_us-gaap_SalesRevenueGoodsNet_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_SalesRevenueGoodsNet_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CostOfGoodsSold" xlink:label="loc_us-gaap_CostOfGoodsSold_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_CostOfGoodsSold_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GrossProfit" xlink:label="loc_us-gaap_GrossProfit_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_GrossProfit_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SellingAndMarketingExpense" xlink:label="loc_us-gaap_SellingAndMarketingExpense_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_SellingAndMarketingExpense_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_OperatingExpenses_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_OperatingIncomeLoss_8" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNonoperatingExpense" xlink:label="loc_us-gaap_OtherNonoperatingExpense_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_OtherNonoperatingExpense_9" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_10" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_11" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_NetIncomeLoss_12" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_13" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_13" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_13" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_15" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_EarningsPerShareAbstract_16" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_17" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_16" xlink:to="loc_us-gaap_EarningsPerShareBasic_17" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_18" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_16" xlink:to="loc_us-gaap_EarningsPerShareDiluted_18" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immucell.com/role/StatementsOfComprehensiveIncomeLossUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_0" xlink:to="loc_us-gaap_NetIncomeLoss_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_InterestRateSwapBeforeTaxes" xlink:label="loc_iccc_InterestRateSwapBeforeTaxes_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_2" xlink:to="loc_iccc_InterestRateSwapBeforeTaxes_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_IncomeTaxApplicableToInterestRateSwap" xlink:label="loc_iccc_IncomeTaxApplicableToInterestRateSwap_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_2" xlink:to="loc_iccc_IncomeTaxApplicableToInterestRateSwap_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_2" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_6" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immucell.com/role/StatementsOfStockholdersEquityUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_CommonStockMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_RetainedEarningsMember_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_TreasuryStockMember_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_us-gaap_StockholdersEquity_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_us-gaap_SharesOutstanding_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_us-gaap_NetIncomeLoss_12" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_14" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_15" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense_16" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_17" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_17" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_18" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_us-gaap_StockholdersEquity_18" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_19" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_us-gaap_SharesOutstanding_19" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immucell.com/role/StatementsOfStockholdersEquityUnauditedParenthetical">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_0" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immucell.com/role/StatementsOfCashFlowsUnaudited">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:to="loc_us-gaap_NetIncomeLoss_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_Depreciation_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaap_AdjustmentForAmortization_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_AdjustmentForAmortization_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredIncomeTaxesAndTaxCredits" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndTaxCredits_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_ShareBasedCompensation_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9" xlink:to="loc_us-gaap_IncreaseDecreaseInReceivables_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_12" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_9" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_14" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_15" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_16" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_17" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_16" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_17" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_18" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_16" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_18" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_19" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_16" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_19" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_20" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_16" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_20" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_21" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_16" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_21" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_22" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_22" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfDebt_23" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_22" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfDebt_23" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaap_RepaymentsOfDebt_24" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_22" xlink:to="loc_us-gaap_RepaymentsOfDebt_24" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_25" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_22" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_25" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_26" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_22" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_26" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense_27" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_22" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense_27" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_28" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_22" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_28" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_29" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_29" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_30" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_30" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_31" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_31" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaap_IncomeTaxesPaid_32" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_IncomeTaxesPaid_32" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaap_InterestPaid_33" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_InterestPaid_33" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_34" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_34" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_35" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_34" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_35" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInFairValueOfInterestRateFairValueHedgingInstruments1" xlink:label="loc_us-gaap_IncreaseDecreaseInFairValueOfInterestRateFairValueHedgingInstruments1_36" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_34" xlink:to="loc_us-gaap_IncreaseDecreaseInFairValueOfInterestRateFairValueHedgingInstruments1_36" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immucell.com/role/BusinessOperations">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaap_NatureOfOperations_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_NatureOfOperations_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immucell.com/role/SummaryOfSignificantAccountingPolicies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immucell.com/role/CashCashEquivalentsShortTermInvestmentsAndLongTermInvestments">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_0" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immucell.com/role/Inventory">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_0" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immucell.com/role/AccountsReceivable">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReceivablesAbstract" xlink:label="loc_us-gaap_ReceivablesAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock" xlink:label="loc_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_0" xlink:to="loc_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immucell.com/role/PrepaidExpensesAndOtherAssets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_PrepaidExpensesAndOtherAssetsTextBlock" xlink:label="loc_iccc_PrepaidExpensesAndOtherAssetsTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_0" xlink:to="loc_iccc_PrepaidExpensesAndOtherAssetsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immucell.com/role/PropertyPlantAndEquipment">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immucell.com/role/AccountsPayableAndAccruedExpenses">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_0" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immucell.com/role/BankDebt">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immucell.com/role/OtherExpensesNet">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:label="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_0" xlink:to="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immucell.com/role/IncomeTaxes">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immucell.com/role/CommitmentsAndContingentLiabilities">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immucell.com/role/CommonStockRightsPlan">
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_CommonStockRightsPlanAbstract" xlink:label="loc_iccc_CommonStockRightsPlanAbstract_0" />
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_CommonStockRightsPlanTextBlock" xlink:label="loc_iccc_CommonStockRightsPlanTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_iccc_CommonStockRightsPlanAbstract_0" xlink:to="loc_iccc_CommonStockRightsPlanTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immucell.com/role/SegmentAndSignificantCustomerInformation">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_0" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immucell.com/role/RelatedPartyTransactions">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immucell.com/role/EmployeeBenefits">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_0" xlink:to="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immucell.com/role/SubsequentEvents">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_0" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immucell.com/role/SummaryOfSignificantAccountingPoliciesPolicies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TradeAndOtherAccountsReceivablePolicy" xlink:label="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_TradeAndOtherAccountsReceivablePolicy_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IntangibleAssetsFiniteLivedPolicy" xlink:label="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_IntangibleAssetsFiniteLivedPolicy_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_InterestRateSwapAgreementPolicyTextBlock" xlink:label="loc_iccc_InterestRateSwapAgreementPolicyTextBlock_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_iccc_InterestRateSwapAgreementPolicyTextBlock_8" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_9" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_ExpenseRecognitionPolicyTextBlock" xlink:label="loc_iccc_ExpenseRecognitionPolicyTextBlock_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_iccc_ExpenseRecognitionPolicyTextBlock_10" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_11" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_12" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_13" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_UseOfEstimates_14" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_15" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immucell.com/role/SummaryofSignificantAccountingPoliciesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immucell.com/role/CashCashEquivalentsShortTermInvestmentsAndLongTermInvestmentsTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immucell.com/role/InventoryTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immucell.com/role/AccountsReceivableTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReceivablesAbstract" xlink:label="loc_us-gaap_ReceivablesAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_0" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immucell.com/role/PrepaidExpensesandOtherAssetsTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_0" xlink:to="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immucell.com/role/PropertyPlantAndEquipmentTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immucell.com/role/AccountsPayableandAccruedExpensesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_0" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immucell.com/role/BankDebtTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immucell.com/role/OtherExpensesNetTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_0" xlink:to="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immucell.com/role/SegmentAndSignificantCustomerInformationTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_0" />
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_ScheduleOfSalesToSignificantCustomersTableTextBlock" xlink:label="loc_iccc_ScheduleOfSalesToSignificantCustomersTableTextBlock_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_0" xlink:to="loc_iccc_ScheduleOfSalesToSignificantCustomersTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_ScheduleOfAccountsReceivableDueFromSignificantCustomersTableTextBlock" xlink:label="loc_iccc_ScheduleOfAccountsReceivableDueFromSignificantCustomersTableTextBlock_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_0" xlink:to="loc_iccc_ScheduleOfAccountsReceivableDueFromSignificantCustomersTableTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immucell.com/role/SummaryOfSignificantAccountingPoliciesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_1" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_EffectOfDilutiveStockOptions" xlink:label="loc_iccc_EffectOfDilutiveStockOptions_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_1" xlink:to="loc_iccc_EffectOfDilutiveStockOptions_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_1" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_5" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immucell.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0" />
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_SummaryOfSignificantAccountingPoliciesTable" xlink:label="loc_iccc_SummaryOfSignificantAccountingPoliciesTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_iccc_SummaryOfSignificantAccountingPoliciesTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_iccc_SummaryOfSignificantAccountingPoliciesTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_BuildingAdditionMember" xlink:label="loc_iccc_BuildingAdditionMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_iccc_BuildingAdditionMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BuildingImprovementsMember" xlink:label="loc_us-gaap_BuildingImprovementsMember_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_us-gaap_BuildingImprovementsMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentOtherTypesMember" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentOtherTypesMember_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_us-gaap_ComputerEquipmentMember_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsMember" xlink:label="loc_us-gaap_OtherAssetsMember_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_us-gaap_OtherAssetsMember_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_iccc_SummaryOfSignificantAccountingPoliciesTable_1" xlink:to="loc_us-gaap_RangeAxis_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_9" xlink:to="loc_us-gaap_RangeMember_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_10" xlink:to="loc_us-gaap_MinimumMember_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_10" xlink:to="loc_us-gaap_MaximumMember_12" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_SignificantAccountingPoliciesLineItems" xlink:label="loc_iccc_SignificantAccountingPoliciesLineItems_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_iccc_SummaryOfSignificantAccountingPoliciesTable_1" xlink:to="loc_iccc_SignificantAccountingPoliciesLineItems_13" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_SummaryOfSignificantAccountingPoliciesTextualAbstract" xlink:label="loc_iccc_SummaryOfSignificantAccountingPoliciesTextualAbstract_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_iccc_SignificantAccountingPoliciesLineItems_13" xlink:to="loc_iccc_SummaryOfSignificantAccountingPoliciesTextualAbstract_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_ShareBasedCompensationDecreaseIncreaseInIncomeLossBeforeIncomeTaxDescription" xlink:label="loc_iccc_ShareBasedCompensationDecreaseIncreaseInIncomeLossBeforeIncomeTaxDescription_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_iccc_SummaryOfSignificantAccountingPoliciesTextualAbstract_14" xlink:to="loc_iccc_ShareBasedCompensationDecreaseIncreaseInIncomeLossBeforeIncomeTaxDescription_15" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_iccc_SummaryOfSignificantAccountingPoliciesTextualAbstract_14" xlink:to="loc_us-gaap_ShareBasedCompensation_16" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdvertisingExpense" xlink:label="loc_us-gaap_AdvertisingExpense_17" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_iccc_SummaryOfSignificantAccountingPoliciesTextualAbstract_14" xlink:to="loc_us-gaap_AdvertisingExpense_17" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaap_CashFDICInsuredAmount_18" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_iccc_SummaryOfSignificantAccountingPoliciesTextualAbstract_14" xlink:to="loc_us-gaap_CashFDICInsuredAmount_18" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtIssuanceCosts" xlink:label="loc_us-gaap_DebtIssuanceCosts_19" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_iccc_SummaryOfSignificantAccountingPoliciesTextualAbstract_14" xlink:to="loc_us-gaap_DebtIssuanceCosts_19" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_USGovernmentSecuritiesAtCarryingValue" xlink:label="loc_us-gaap_USGovernmentSecuritiesAtCarryingValue_20" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_iccc_SummaryOfSignificantAccountingPoliciesTextualAbstract_14" xlink:to="loc_us-gaap_USGovernmentSecuritiesAtCarryingValue_20" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_21" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_iccc_SummaryOfSignificantAccountingPoliciesTextualAbstract_14" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_21" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immucell.com/role/CashCashEquivalentsShortTermInvestmentsAndLongTermInvestmentsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_0" />
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_ScheduleOfCashCashEquivalentsShortTermInvestmentsAndLongTermInvestmentAbstract" xlink:label="loc_iccc_ScheduleOfCashCashEquivalentsShortTermInvestmentsAndLongTermInvestmentAbstract_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_0" xlink:to="loc_iccc_ScheduleOfCashCashEquivalentsShortTermInvestmentsAndLongTermInvestmentAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_iccc_ScheduleOfCashCashEquivalentsShortTermInvestmentsAndLongTermInvestmentAbstract_1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_iccc_ScheduleOfCashCashEquivalentsShortTermInvestmentsAndLongTermInvestmentAbstract_1" xlink:to="loc_us-gaap_ShortTermInvestments_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_iccc_ScheduleOfCashCashEquivalentsShortTermInvestmentsAndLongTermInvestmentAbstract_1" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_4" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaap_LongTermInvestments_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_iccc_ScheduleOfCashCashEquivalentsShortTermInvestmentsAndLongTermInvestmentAbstract_1" xlink:to="loc_us-gaap_LongTermInvestments_5" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_CashAndCashEquivalentsShortTermAndLongTermInvestments" xlink:label="loc_iccc_CashAndCashEquivalentsShortTermAndLongTermInvestments_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_iccc_ScheduleOfCashCashEquivalentsShortTermInvestmentsAndLongTermInvestmentAbstract_1" xlink:to="loc_iccc_CashAndCashEquivalentsShortTermAndLongTermInvestments_6" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_iccc_ScheduleOfCashCashEquivalentsShortTermInvestmentsAndLongTermInvestmentAbstract_1" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_7" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_IncreaseDecreaseInShortTermInvestments" xlink:label="loc_iccc_IncreaseDecreaseInShortTermInvestments_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_iccc_ScheduleOfCashCashEquivalentsShortTermInvestmentsAndLongTermInvestmentAbstract_1" xlink:to="loc_iccc_IncreaseDecreaseInShortTermInvestments_8" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_IncreaseDecreaseInCashAndCashEquivalentsAndShortTermInvestments" xlink:label="loc_iccc_IncreaseDecreaseInCashAndCashEquivalentsAndShortTermInvestments_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_iccc_ScheduleOfCashCashEquivalentsShortTermInvestmentsAndLongTermInvestmentAbstract_1" xlink:to="loc_iccc_IncreaseDecreaseInCashAndCashEquivalentsAndShortTermInvestments_9" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_IncreaseDecreaseInLongTermInvestments" xlink:label="loc_iccc_IncreaseDecreaseInLongTermInvestments_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_iccc_ScheduleOfCashCashEquivalentsShortTermInvestmentsAndLongTermInvestmentAbstract_1" xlink:to="loc_iccc_IncreaseDecreaseInLongTermInvestments_10" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_IncreaseDecreaseInCashAndCashEquivalentsShortTermAndLongtermInvestments" xlink:label="loc_iccc_IncreaseDecreaseInCashAndCashEquivalentsShortTermAndLongtermInvestments_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_iccc_ScheduleOfCashCashEquivalentsShortTermInvestmentsAndLongTermInvestmentAbstract_1" xlink:to="loc_iccc_IncreaseDecreaseInCashAndCashEquivalentsShortTermAndLongtermInvestments_11" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immucell.com/role/InventoryDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_ScheduleOfInventoryAbstract" xlink:label="loc_iccc_ScheduleOfInventoryAbstract_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_0" xlink:to="loc_iccc_ScheduleOfInventoryAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_us-gaap_InventoryRawMaterials_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_iccc_ScheduleOfInventoryAbstract_1" xlink:to="loc_us-gaap_InventoryRawMaterials_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaap_InventoryWorkInProcess_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_iccc_ScheduleOfInventoryAbstract_1" xlink:to="loc_us-gaap_InventoryWorkInProcess_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaap_InventoryFinishedGoods_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_iccc_ScheduleOfInventoryAbstract_1" xlink:to="loc_us-gaap_InventoryFinishedGoods_4" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_iccc_ScheduleOfInventoryAbstract_1" xlink:to="loc_us-gaap_InventoryNet_5" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInRawMaterialsPackagingMaterialsAndSuppliesInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInRawMaterialsPackagingMaterialsAndSuppliesInventories_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_iccc_ScheduleOfInventoryAbstract_1" xlink:to="loc_us-gaap_IncreaseDecreaseInRawMaterialsPackagingMaterialsAndSuppliesInventories_6" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_IncreaseDecreaseInWorkInProcessInventories" xlink:label="loc_iccc_IncreaseDecreaseInWorkInProcessInventories_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_iccc_ScheduleOfInventoryAbstract_1" xlink:to="loc_iccc_IncreaseDecreaseInWorkInProcessInventories_7" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_IncreaseDecreaseInFinishedGoodsInventories" xlink:label="loc_iccc_IncreaseDecreaseInFinishedGoodsInventories_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_iccc_ScheduleOfInventoryAbstract_1" xlink:to="loc_iccc_IncreaseDecreaseInFinishedGoodsInventories_8" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_iccc_ScheduleOfInventoryAbstract_1" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_9" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immucell.com/role/AccountsReceivableDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ReceivablesAbstract" xlink:label="loc_us-gaap_ReceivablesAbstract_0" />
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_ScheduleOfAccountsNotesLoansAndFinancingReceivableAbstract" xlink:label="loc_iccc_ScheduleOfAccountsNotesLoansAndFinancingReceivableAbstract_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivablesAbstract_0" xlink:to="loc_iccc_ScheduleOfAccountsNotesLoansAndFinancingReceivableAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent" xlink:label="loc_us-gaap_AccountsReceivableGrossCurrent_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_iccc_ScheduleOfAccountsNotesLoansAndFinancingReceivableAbstract_1" xlink:to="loc_us-gaap_AccountsReceivableGrossCurrent_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_iccc_ScheduleOfAccountsNotesLoansAndFinancingReceivableAbstract_1" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsReceivableNet" xlink:label="loc_us-gaap_AccountsReceivableNet_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_iccc_ScheduleOfAccountsNotesLoansAndFinancingReceivableAbstract_1" xlink:to="loc_us-gaap_AccountsReceivableNet_4" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherReceivables" xlink:label="loc_us-gaap_OtherReceivables_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_iccc_ScheduleOfAccountsNotesLoansAndFinancingReceivableAbstract_1" xlink:to="loc_us-gaap_OtherReceivables_5" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_iccc_ScheduleOfAccountsNotesLoansAndFinancingReceivableAbstract_1" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_6" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_IncreaseDecreaseInAccountsReceivableGross" xlink:label="loc_iccc_IncreaseDecreaseInAccountsReceivableGross_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_iccc_ScheduleOfAccountsNotesLoansAndFinancingReceivableAbstract_1" xlink:to="loc_iccc_IncreaseDecreaseInAccountsReceivableGross_7" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_iccc_ScheduleOfAccountsNotesLoansAndFinancingReceivableAbstract_1" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease_8" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_iccc_ScheduleOfAccountsNotesLoansAndFinancingReceivableAbstract_1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_9" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_iccc_ScheduleOfAccountsNotesLoansAndFinancingReceivableAbstract_1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables_10" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_iccc_ScheduleOfAccountsNotesLoansAndFinancingReceivableAbstract_1" xlink:to="loc_us-gaap_IncreaseDecreaseInReceivables_11" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immucell.com/role/PrepaidExpensesandOtherAssetsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_0" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SecurityDeposit" xlink:label="loc_us-gaap_SecurityDeposit_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_0" xlink:to="loc_us-gaap_SecurityDeposit_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_0" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_0" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedAmortizationDeferredFinanceCosts" xlink:label="loc_us-gaap_AccumulatedAmortizationDeferredFinanceCosts_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_0" xlink:to="loc_us-gaap_AccumulatedAmortizationDeferredFinanceCosts_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DepositAssets" xlink:label="loc_us-gaap_DepositAssets_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_0" xlink:to="loc_us-gaap_DepositAssets_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_0" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_0" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssets_8" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_0" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_9" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInSecurityDeposits" xlink:label="loc_us-gaap_IncreaseDecreaseInSecurityDeposits_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_0" xlink:to="loc_us-gaap_IncreaseDecreaseInSecurityDeposits_10" order="90" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherCurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_0" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherCurrentAssets_11" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_IncreaseDecreaseDebtIssueCosts" xlink:label="loc_iccc_IncreaseDecreaseDebtIssueCosts_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_0" xlink:to="loc_iccc_IncreaseDecreaseDebtIssueCosts_12" order="110" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_IncreaseDecreaseAccumulatedAmortizationOfDebtIssueCosts" xlink:label="loc_iccc_IncreaseDecreaseAccumulatedAmortizationOfDebtIssueCosts_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_0" xlink:to="loc_iccc_IncreaseDecreaseAccumulatedAmortizationOfDebtIssueCosts_13" order="120" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherDeposits" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherDeposits_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_0" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherDeposits_14" order="130" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_0" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_15" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssetsIncludingAmortization" xlink:label="loc_iccc_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssetsIncludingAmortization_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract_0" xlink:to="loc_iccc_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssetsIncludingAmortization_16" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immucell.com/role/PropertyPlantAndEquipmentDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ManufacturingFacilityMember" xlink:label="loc_us-gaap_ManufacturingFacilityMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_us-gaap_ManufacturingFacilityMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BuildingImprovementsMember" xlink:label="loc_us-gaap_BuildingImprovementsMember_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_us-gaap_BuildingImprovementsMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OfficeEquipmentMember" xlink:label="loc_us-gaap_OfficeEquipmentMember_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_us-gaap_OfficeEquipmentMember_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_us-gaap_ConstructionInProgressMember_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LandMember" xlink:label="loc_us-gaap_LandMember_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_us-gaap_LandMember_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MachineryAndEquipmentGross" xlink:label="loc_us-gaap_MachineryAndEquipmentGross_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9" xlink:to="loc_us-gaap_MachineryAndEquipmentGross_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_BuildingsAndImprovementsGross" xlink:label="loc_us-gaap_BuildingsAndImprovementsGross_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9" xlink:to="loc_us-gaap_BuildingsAndImprovementsGross_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FurnitureAndFixturesGross" xlink:label="loc_us-gaap_FurnitureAndFixturesGross_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9" xlink:to="loc_us-gaap_FurnitureAndFixturesGross_12" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConstructionInProgressGross" xlink:label="loc_us-gaap_ConstructionInProgressGross_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9" xlink:to="loc_us-gaap_ConstructionInProgressGross_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/definitionGuidance" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_Land" xlink:label="loc_us-gaap_Land_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9" xlink:to="loc_us-gaap_Land_14" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_15" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_16" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_17" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_17" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGrossPeriodIncreaseDecrease" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGrossPeriodIncreaseDecrease_18" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGrossPeriodIncreaseDecrease_18" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentPeriodIncreaseDecrease" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentPeriodIncreaseDecrease_19" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentPeriodIncreaseDecrease_19" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_PropertyPlantAndEquipmentnetPeriodIncreaseDecrease" xlink:label="loc_iccc_PropertyPlantAndEquipmentnetPeriodIncreaseDecrease_20" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9" xlink:to="loc_iccc_PropertyPlantAndEquipmentnetPeriodIncreaseDecrease_20" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immucell.com/role/AccountsPayableandAccruedExpensesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableOtherCurrent" xlink:label="loc_us-gaap_AccountsPayableOtherCurrent_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_0" xlink:to="loc_us-gaap_AccountsPayableOtherCurrent_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableTradeCurrent" xlink:label="loc_us-gaap_AccountsPayableTradeCurrent_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_0" xlink:to="loc_us-gaap_AccountsPayableTradeCurrent_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedPayrollTaxesCurrent" xlink:label="loc_us-gaap_AccruedPayrollTaxesCurrent_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_0" xlink:to="loc_us-gaap_AccruedPayrollTaxesCurrent_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_AccruedClinicalStudies" xlink:label="loc_iccc_AccruedClinicalStudies_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_0" xlink:to="loc_iccc_AccruedClinicalStudies_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_0" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_OtherAccountsPayableAndAccruedLiabilities_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_0" xlink:to="loc_us-gaap_OtherAccountsPayableAndAccruedLiabilities_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_0" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapital" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapital_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_0" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapital_8" order="70" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_0" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_9" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedSalaries" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedSalaries_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_0" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedSalaries_10" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_IncreaseDecreaseInAccruedClinicalStudies" xlink:label="loc_iccc_IncreaseDecreaseInAccruedClinicalStudies_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_0" xlink:to="loc_iccc_IncreaseDecreaseInAccruedClinicalStudies_11" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_IncreaseDecreaseInAccruedProfessionalFees" xlink:label="loc_iccc_IncreaseDecreaseInAccruedProfessionalFees_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_0" xlink:to="loc_iccc_IncreaseDecreaseInAccruedProfessionalFees_12" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_0" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities_13" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_IncreaseDecreaseInAccountsPayableAndAccruedExpenses" xlink:label="loc_iccc_IncreaseDecreaseInAccountsPayableAndAccruedExpenses_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_0" xlink:to="loc_iccc_IncreaseDecreaseInAccountsPayableAndAccruedExpenses_14" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immucell.com/role/BankDebtDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_DebtInstrumentTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_us-gaap_DebtInstrumentAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_2" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MortgagesMember" xlink:label="loc_us-gaap_MortgagesMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3" xlink:to="loc_us-gaap_MortgagesMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NotesPayableToBanksMember" xlink:label="loc_us-gaap_NotesPayableToBanksMember_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3" xlink:to="loc_us-gaap_NotesPayableToBanksMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_us-gaap_DebtInstrumentLineItems_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour_10" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive_11" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFive" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFive_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFive_12" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_TotalLiabilitiesDebtCurrentPortionAndLongTermPortion" xlink:label="loc_iccc_TotalLiabilitiesDebtCurrentPortionAndLongTermPortion_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_6" xlink:to="loc_iccc_TotalLiabilitiesDebtCurrentPortionAndLongTermPortion_13" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immucell.com/role/BankDebtDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0" xlink:to="loc_us-gaap_DebtInstrumentTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_us-gaap_DebtInstrumentAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_2" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestRateSwapMember" xlink:label="loc_us-gaap_InterestRateSwapMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3" xlink:to="loc_us-gaap_InterestRateSwapMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MortgagesMember" xlink:label="loc_us-gaap_MortgagesMember_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3" xlink:to="loc_us-gaap_MortgagesMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_MortgagesOneMember" xlink:label="loc_iccc_MortgagesOneMember_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3" xlink:to="loc_iccc_MortgagesOneMember_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_MortgagesTwoMember" xlink:label="loc_iccc_MortgagesTwoMember_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3" xlink:to="loc_iccc_MortgagesTwoMember_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_NotePayableMember" xlink:label="loc_iccc_NotePayableMember_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3" xlink:to="loc_iccc_NotePayableMember_8" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditMember" xlink:label="loc_us-gaap_LineOfCreditMember_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_3" xlink:to="loc_us-gaap_LineOfCreditMember_9" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_dei_LegalEntityAxis_10" order="10" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_10" xlink:to="loc_dei_EntityDomain_11" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_TdBankNaMember" xlink:label="loc_iccc_TdBankNaMember_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_11" xlink:to="loc_iccc_TdBankNaMember_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_1" xlink:to="loc_us-gaap_DebtInstrumentLineItems_13" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentMaturityDateDescription" xlink:label="loc_us-gaap_DebtInstrumentMaturityDateDescription_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_13" xlink:to="loc_us-gaap_DebtInstrumentMaturityDateDescription_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaap_DebtInstrumentTerm_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_13" xlink:to="loc_us-gaap_DebtInstrumentTerm_15" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_13" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_16" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MortgageLoansOnRealEstatePeriodicPaymentTermsBalloonPaymentToBeReceived" xlink:label="loc_us-gaap_MortgageLoansOnRealEstatePeriodicPaymentTermsBalloonPaymentToBeReceived_17" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_13" xlink:to="loc_us-gaap_MortgageLoansOnRealEstatePeriodicPaymentTermsBalloonPaymentToBeReceived_17" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MortgageLoansOnRealEstatePeriodicPaymentTerms" xlink:label="loc_us-gaap_MortgageLoansOnRealEstatePeriodicPaymentTerms_18" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_13" xlink:to="loc_us-gaap_MortgageLoansOnRealEstatePeriodicPaymentTerms_18" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtPercentageBearingFixedInterestRate" xlink:label="loc_us-gaap_LongTermDebtPercentageBearingFixedInterestRate_19" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_13" xlink:to="loc_us-gaap_LongTermDebtPercentageBearingFixedInterestRate_19" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LongTermDebtPercentageBearingVariableInterestRate" xlink:label="loc_us-gaap_LongTermDebtPercentageBearingVariableInterestRate_20" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_13" xlink:to="loc_us-gaap_LongTermDebtPercentageBearingVariableInterestRate_20" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_DerivativeNotionalAmount" xlink:label="loc_invest_DerivativeNotionalAmount_21" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_13" xlink:to="loc_invest_DerivativeNotionalAmount_21" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaap_ProceedsFromNotesPayable_22" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_13" xlink:to="loc_us-gaap_ProceedsFromNotesPayable_22" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DebtInstrumentDescriptionOfVariableRateBasis" xlink:label="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_23" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_13" xlink:to="loc_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis_23" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_DerivativesInterestRateSwapPayments" xlink:label="loc_iccc_DerivativesInterestRateSwapPayments_24" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_13" xlink:to="loc_iccc_DerivativesInterestRateSwapPayments_24" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_25" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_13" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_25" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LineOfCreditFacilityDescription" xlink:label="loc_us-gaap_LineOfCreditFacilityDescription_26" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_13" xlink:to="loc_us-gaap_LineOfCreditFacilityDescription_26" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AdjustmentForAmortization" xlink:label="loc_us-gaap_AdjustmentForAmortization_27" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_13" xlink:to="loc_us-gaap_AdjustmentForAmortization_27" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immucell.com/role/OtherExpensesNetDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaap_InterestIncomeOther_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_0" xlink:to="loc_us-gaap_InterestIncomeOther_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InterestExpenseOther" xlink:label="loc_us-gaap_InterestExpenseOther_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_0" xlink:to="loc_us-gaap_InterestExpenseOther_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OtherNonoperatingGainsLosses" xlink:label="loc_us-gaap_OtherNonoperatingGainsLosses_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_0" xlink:to="loc_us-gaap_OtherNonoperatingGainsLosses_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_0" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immucell.com/role/IncomeTaxesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_1" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_2" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_3" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_3" xlink:to="loc_us-gaap_DomesticCountryMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_InvestmentIncomeMember" xlink:label="loc_us-gaap_InvestmentIncomeMember_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_7" xlink:to="loc_us-gaap_InvestmentIncomeMember_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_1" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_9" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IndefinitelivedIntangibleAssetsMember" xlink:label="loc_us-gaap_IndefinitelivedIntangibleAssetsMember_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_10" xlink:to="loc_us-gaap_IndefinitelivedIntangibleAssetsMember_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_12" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_1" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_12" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_IncomeTaxDisclosureTextualAbstract" xlink:label="loc_iccc_IncomeTaxDisclosureTextualAbstract_13" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_12" xlink:to="loc_iccc_IncomeTaxDisclosureTextualAbstract_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_14" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_iccc_IncomeTaxDisclosureTextualAbstract_13" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_15" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_iccc_IncomeTaxDisclosureTextualAbstract_13" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_15" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_16" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_iccc_IncomeTaxDisclosureTextualAbstract_13" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_16" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_17" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_iccc_IncomeTaxDisclosureTextualAbstract_13" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_17" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_18" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_iccc_IncomeTaxDisclosureTextualAbstract_13" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_18" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_TaxCreditCarryforwardDescription" xlink:label="loc_us-gaap_TaxCreditCarryforwardDescription_19" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_iccc_IncomeTaxDisclosureTextualAbstract_13" xlink:to="loc_us-gaap_TaxCreditCarryforwardDescription_19" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LicenseCosts" xlink:label="loc_us-gaap_LicenseCosts_20" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_iccc_IncomeTaxDisclosureTextualAbstract_13" xlink:to="loc_us-gaap_LicenseCosts_20" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_21" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_iccc_IncomeTaxDisclosureTextualAbstract_13" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1_21" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_InvestmentsOwnedBalancePrincipalAmount" xlink:label="loc_iccc_InvestmentsOwnedBalancePrincipalAmount_22" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_iccc_IncomeTaxDisclosureTextualAbstract_13" xlink:to="loc_iccc_InvestmentsOwnedBalancePrincipalAmount_22" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_23" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_iccc_IncomeTaxDisclosureTextualAbstract_13" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness_23" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:label="loc_us-gaap_OperatingLossCarryforwardsValuationAllowance_24" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_iccc_IncomeTaxDisclosureTextualAbstract_13" xlink:to="loc_us-gaap_OperatingLossCarryforwardsValuationAllowance_24" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther_25" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_iccc_IncomeTaxDisclosureTextualAbstract_13" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther_25" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immucell.com/role/CommitmentsandContingentLiabilitiesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" />
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_CommitmentsAndContingenciesLiabilitiesTextualAbstract" xlink:label="loc_iccc_CommitmentsAndContingenciesLiabilitiesTextualAbstract_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_iccc_CommitmentsAndContingenciesLiabilitiesTextualAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_CapitalExpenditures" xlink:label="loc_iccc_CapitalExpenditures_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_iccc_CommitmentsAndContingenciesLiabilitiesTextualAbstract_1" xlink:to="loc_iccc_CapitalExpenditures_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_OtherObligations" xlink:label="loc_iccc_OtherObligations_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_iccc_CommitmentsAndContingenciesLiabilitiesTextualAbstract_1" xlink:to="loc_iccc_OtherObligations_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_InventoryProduction" xlink:label="loc_iccc_InventoryProduction_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_iccc_CommitmentsAndContingenciesLiabilitiesTextualAbstract_1" xlink:to="loc_iccc_InventoryProduction_4" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immucell.com/role/CommonStockRightsPlanDetails">
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_CommonStockRightsPlanAbstract" xlink:label="loc_iccc_CommonStockRightsPlanAbstract_0" />
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_CommonStockRightsPlanTextualAbstract" xlink:label="loc_iccc_CommonStockRightsPlanTextualAbstract_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_iccc_CommonStockRightsPlanAbstract_0" xlink:to="loc_iccc_CommonStockRightsPlanTextualAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_CommonStockVotingRights" xlink:label="loc_us-gaap_CommonStockVotingRights_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_iccc_CommonStockRightsPlanTextualAbstract_1" xlink:to="loc_us-gaap_CommonStockVotingRights_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immucell.com/role/SegmentAndSignificantCustomerInformationDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_0" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_1" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_2" xlink:to="loc_us-gaap_SegmentDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_AnimalHealthInternationalIncMember" xlink:label="loc_iccc_AnimalHealthInternationalIncMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_3" xlink:to="loc_iccc_AnimalHealthInternationalIncMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_MwiVeterinarySupplyCompanyMember" xlink:label="loc_iccc_MwiVeterinarySupplyCompanyMember_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_3" xlink:to="loc_iccc_MwiVeterinarySupplyCompanyMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_1" xlink:to="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_6" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immucell.com/role/SegmentAndSignificantCustomerInformationDetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_0" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_1" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_2" xlink:to="loc_us-gaap_SegmentDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_AnimalHealthInternationalIncMember" xlink:label="loc_iccc_AnimalHealthInternationalIncMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_3" xlink:to="loc_iccc_AnimalHealthInternationalIncMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_MwiVeterinarySupplyCompanyMember" xlink:label="loc_iccc_MwiVeterinarySupplyCompanyMember_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_3" xlink:to="loc_iccc_MwiVeterinarySupplyCompanyMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_AnimartLlcMember" xlink:label="loc_iccc_AnimartLlcMember_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_3" xlink:to="loc_iccc_AnimartLlcMember_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_1" xlink:to="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_AccountsReceivableDueFromSignificantCustomers" xlink:label="loc_iccc_AccountsReceivableDueFromSignificantCustomers_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_7" xlink:to="loc_iccc_AccountsReceivableDueFromSignificantCustomers_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immucell.com/role/SegmentAndSignificantCustomerInformationDetailsTextual">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable" xlink:label="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_0" xlink:to="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_1" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_2" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="loc_us-gaap_SalesRevenueNetMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3" xlink:to="loc_us-gaap_SalesRevenueNetMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="loc_us-gaap_MajorCustomersAxis_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_1" xlink:to="loc_us-gaap_MajorCustomersAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorCustomersAxis_5" xlink:to="loc_us-gaap_NameOfMajorCustomerDomain_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_UnitedStatesDairyAndBeefIndustriesMember" xlink:label="loc_iccc_UnitedStatesDairyAndBeefIndustriesMember_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_6" xlink:to="loc_iccc_UnitedStatesDairyAndBeefIndustriesMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_ForeignCustomersMember" xlink:label="loc_iccc_ForeignCustomersMember_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_6" xlink:to="loc_iccc_ForeignCustomersMember_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_EntityWideRevenueMajorCustomerLineItems" xlink:label="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideRevenueByMajorCustomersByReportingSegmentsTable_1" xlink:to="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_SegmentAndSignificantCustomerInformationTextualAbstract" xlink:label="loc_iccc_SegmentAndSignificantCustomerInformationTextualAbstract_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideRevenueMajorCustomerLineItems_9" xlink:to="loc_iccc_SegmentAndSignificantCustomerInformationTextualAbstract_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_iccc_SegmentAndSignificantCustomerInformationTextualAbstract_10" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immucell.com/role/RelatedPartyTransactionsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0" />
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_RelatedPartyTransactionsTextualAbstract" xlink:label="loc_iccc_RelatedPartyTransactionsTextualAbstract_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0" xlink:to="loc_iccc_RelatedPartyTransactionsTextualAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RevenueFromRelatedParties" xlink:label="loc_us-gaap_RevenueFromRelatedParties_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_iccc_RelatedPartyTransactionsTextualAbstract_1" xlink:to="loc_us-gaap_RevenueFromRelatedParties_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:label="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_iccc_RelatedPartyTransactionsTextualAbstract_1" xlink:to="loc_us-gaap_AccountsReceivableRelatedPartiesCurrent_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_iccc_RelatedPartyTransactionsTextualAbstract_1" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_4" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immucell.com/role/EmployeeBenefitsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationAbstract_0" />
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_EmployeeBenefitsTextualAbstract" xlink:label="loc_iccc_EmployeeBenefitsTextualAbstract_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAbstract_0" xlink:to="loc_iccc_EmployeeBenefitsTextualAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_EmployeeSavingsPlanDescription" xlink:label="loc_iccc_EmployeeSavingsPlanDescription_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_iccc_EmployeeBenefitsTextualAbstract_1" xlink:to="loc_iccc_EmployeeSavingsPlanDescription_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DefinedBenefitPlansGeneralInformation" xlink:label="loc_us-gaap_DefinedBenefitPlansGeneralInformation_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_iccc_EmployeeBenefitsTextualAbstract_1" xlink:to="loc_us-gaap_DefinedBenefitPlansGeneralInformation_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitsPaid" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitsPaid_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_iccc_EmployeeBenefitsTextualAbstract_1" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitsPaid_4" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.immucell.com/role/SubsequentEventsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_0" xlink:to="loc_us-gaap_SubsequentEventTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_2" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_4" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_3" xlink:to="loc_us-gaap_SubsequentEventMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_5" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_dei_LegalEntityAxis_5" order="10" use="optional" />
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_6" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_5" xlink:to="loc_dei_EntityDomain_6" order="0" use="optional" />
<loc xlink:type="locator" xlink:href="iccc-20150930.xsd#iccc_PlasPakIncMember" xlink:label="loc_iccc_PlasPakIncMember_7" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_6" xlink:to="loc_iccc_PlasPakIncMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_8" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventLineItems_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_PurchaseOptionsLand" xlink:label="loc_us-gaap_PurchaseOptionsLand_9" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_8" xlink:to="loc_us-gaap_PurchaseOptionsLand_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_LandPurchaseOptionsDescription" xlink:label="loc_us-gaap_LandPurchaseOptionsDescription_10" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_8" xlink:to="loc_us-gaap_LandPurchaseOptionsDescription_10" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2015/elts/us-gaap-2015-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_11" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_8" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_11" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140666867290960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, Cash Equivalents, Short-Term Investments and Long-Term Investments (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_iccc_ScheduleOfCashCashEquivalentsShortTermInvestmentsAndLongTermInvestmentAbstract', window );"><strong>Schedule of Cash, cash equivalents, short-term investments and long-term investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 2,469,087<span></span>
</td>
<td class="nump">$ 1,166,211<span></span>
</td>
<td class="nump">$ 850,028<span></span>
</td>
<td class="nump">$ 2,270,385<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">3,720,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,489,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Subtotal</a></td>
<td class="nump">6,189,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,339,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investments</a></td>
<td class="nump">487,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">496,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_iccc_CashAndCashEquivalentsShortTermAndLongTermInvestments', window );">Total</a></td>
<td class="nump">6,676,087<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,835,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Increase (Decrease) in cash and cash equivalents</a></td>
<td class="nump">1,619,059<span></span>
</td>
<td class="num">$ (1,104,174)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_iccc_IncreaseDecreaseInShortTermInvestments', window );">Increase (Decrease) in short-term investments</a></td>
<td class="nump">1,231,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_iccc_IncreaseDecreaseInCashAndCashEquivalentsAndShortTermInvestments', window );">Increase (Decrease) in cash and cash equivalents and short term investments</a></td>
<td class="nump">2,850,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_iccc_IncreaseDecreaseInLongTermInvestments', window );">Increase (Decrease) in long term investments</a></td>
<td class="num">(9,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_iccc_IncreaseDecreaseInCashAndCashEquivalentsShortTermAndLongtermInvestments', window );">Increase (Decrease) in cash and cash equivalents short term and long term investments</a></td>
<td class="nump">$ 2,841,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_CashAndCashEquivalentsShortTermAndLongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term and long-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_CashAndCashEquivalentsShortTermAndLongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_IncreaseDecreaseInCashAndCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in cash and cash equivalents and short term investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_IncreaseDecreaseInCashAndCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_IncreaseDecreaseInCashAndCashEquivalentsShortTermAndLongtermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in cash and cash equivalents short term and long term investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_IncreaseDecreaseInCashAndCashEquivalentsShortTermAndLongtermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_IncreaseDecreaseInLongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in long term investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_IncreaseDecreaseInLongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_IncreaseDecreaseInShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in short term investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_IncreaseDecreaseInShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_ScheduleOfCashCashEquivalentsShortTermInvestmentsAndLongTermInvestmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_ScheduleOfCashCashEquivalentsShortTermInvestmentsAndLongTermInvestmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3044-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 24<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 830<br><br><br><br> -SubTopic 230<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49171198&amp;loc=d3e33268-110906<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.12)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments which are intended to be sold in the short term (usually less than one year or the normal operating cycle, whichever is longer) including trading securities, available-for-sale securities, held-to-maturity securities, and other short-term investments not otherwise listed in the existing taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph g<br><br><br><br> -Article 7<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140666936823456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_iccc_RelatedPartyTransactionsTextualAbstract', window );"><strong>Related Party Transactions (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromRelatedParties', window );">Revenues from transactions with related party</a></td>
<td class="nump">$ 452,207<span></span>
</td>
<td class="nump">$ 283,287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedPartiesCurrent', window );">Accounts receivable, related parties</a></td>
<td class="nump">12,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,796<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Related party transaction, expenses from transactions with related party</a></td>
<td class="nump">$ 3,222<span></span>
</td>
<td class="nump">$ 6,355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_RelatedPartyTransactionsTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_RelatedPartyTransactionsTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of receivables arising from transactions with related parties due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.3(a)(2))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 850<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(k)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 850<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (d)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 850<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 850<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.1(e))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Related Parties<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=16382449<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 946<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.6-07.1(c))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6488393&amp;loc=d3e606610-122999<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140666933806416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Dec. 31, 2004</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_iccc_IncomeTaxDisclosureTextualAbstract', window );"><strong>Income Tax [Textual]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="nump">$ 260,447<span></span>
</td>
<td class="nump">$ 19,277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 709,394<span></span>
</td>
<td class="num">$ (146,101)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Income tax rate percenatge</a></td>
<td class="nump">43.00%<span></span>
</td>
<td class="nump">65.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43.00%<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardDescription', window );">Tax credit carryforward, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Expire in 2027 through 2034<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1', window );">Finite-Lived intangible assets, remaining amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_iccc_InvestmentsOwnedBalancePrincipalAmount', window );">Investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 820,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness', window );">General business tax credit carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">220,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsValuationAllowance', window );">Effective taxable income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 549,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther', window );">Effective assuming income tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_IndefinitelivedIntangibleAssetsMember', window );">Intangible asset [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_iccc_IncomeTaxDisclosureTextualAbstract', window );"><strong>Income Tax [Textual]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicenseCosts', window );">License costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 965,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InvestmentIncomeMember', window );">Investment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_iccc_IncomeTaxDisclosureTextualAbstract', window );"><strong>Income Tax [Textual]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_iccc_InvestmentsOwnedBalancePrincipalAmount', window );">Investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,112,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_iccc_IncomeTaxDisclosureTextualAbstract', window );"><strong>Income Tax [Textual]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">State net operating loss carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,920,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardDescription', window );">Tax credit carryforward, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Expire in 2028 through 2031<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_iccc_IncomeTaxDisclosureTextualAbstract', window );"><strong>Income Tax [Textual]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Federal net operating loss carryforward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,750,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardDescription', window );">Tax credit carryforward, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Expire in 2029 through 2034<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_IncomeTaxDisclosureTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_IncomeTaxDisclosureTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_InvestmentsOwnedBalancePrincipalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For investments which are quantified by principal amount, the principle balance held at close of period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_InvestmentsOwnedBalancePrincipalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 20<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51675352&amp;loc=d3e28680-109314<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 20<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51675352&amp;loc=d3e28680-109314<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible general business tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32632-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32621-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsGeneralBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 13<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(h)(2))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 12<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 12<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32687-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 6.I)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 13<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32698-109319<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 9<br><br><br><br> -Subparagraph (a),(b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(h))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Income Tax Expense (or Benefit)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicenseCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Costs incurred and are directly related to generating license revenue. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.2(e))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LicenseCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of the valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from net operating loss carryforwards for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 30<br><br><br><br> -Paragraph 5<br><br><br><br> -Subparagraph (e)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907311&amp;loc=d3e30536-109315<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A description of the origin, nature, and characteristics of the tax credit carryforward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Carryforwards<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506874<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_IndefinitelivedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_IndefinitelivedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InvestmentIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_InvestmentIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>15
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0````(`.>,;$>DF6I)^P$``%$B```3````6T-O;G1E;G1?5'EP97-=
M+GAM;,W:S4[C,!`'\%>I<ETUKC_"?HAR`:Z`M+R`-YDV5N/8LDTI;[]V"FBW
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M?4\AS_?XN_'K@M/U4>8Z??_3T*=@9-/AA$B\JP\!TH<$Z4.!]-&`]'$&TL=G
MD#Z^@/3Q%:0/OD!I!$54CD(J1S&5HZ#*453E**QR%%<Y"JP<15:!(JM`D56@
MR"I09!4HL@H4606*K`)%5H$BJT"15:+(*E%DE2BR2A19)8JL$D56B2*K1)%5
MHL@J4615*+(J%%D5BJP*15:%(JM"D56AR*I09%4HLBH461L461L461L461L4
M61L461L469M76=GT3Y*+GU!+`P04````"`#GC&Q'2'4%[L4````K`@``"P``
M`%]R96QS+RYR96QSK9++;L)`#$5_)9I]<4HE%A%AQ88=0OR`.^,\E,QXY#$B
M_?N.V(#"0ZW$TJ][CZZ\#JFL#C2B]AQ2U\=43'X,J<K]VG2JL0)(MB./:<&1
M0IXV+!XUE])"1#M@2[`LRQ7(K8[9K.?:Q<[51G;NTQ1'E):T-M,(9Y;AFWE8
M9.D\^(GT%V-NFM[2ENW)4]`'_K,-`\]YEE<>QW8OG*\M"_V/Z'D4X$G1H>)%
M]2-F`Q+M*;V"^GH`A3&^.R6:E((C-Z."N[_8_`)02P,$%`````@`YXQL1U,R
M;J;]`0``)2(``!H```!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<\7:S6Z;
M0!B%X5NQN(`,W\\XB15GE4VV36\`V6-CQ0;$3-7F[D.]J-PD'&5AZ6Q`@/3-
MNWJ$!AZZ7*]^I&-3#GV7V\.0%W].QRZOIOOKJBUE6(60-VTZ-?FF'U(W/=WU
MXZDIT^6X#T.S>6WV*6A=+\-X.:=Z?/@X>_&\75?C\U:JQ<]FW*>RKG[WXVMN
M4RHYG$]R,RTP/7X;TG>6[W>[PR8]]9M?I]25+RK"OP6J,!^D\T%*";+Y(*,$
M^7R04X+B?%"D!"WG@Y:4H-OYH%M*T-U\T!TEZ'X^Z)X2)#60L>8D(:PY6@O@
M6CA>"P!;.&(+(%LX9@M`6SAJ"V!;.&X+@%LX<@N@6SAV"\!;.'HKT%LY>BO0
M6TGOVNAEFZ.W`KV5H[<"O96CMP*]E:.W`KV5H[<"O96CMP*]E:.W`KV5H[<!
MO8VCMP&]C:.W`;V-M%>"-DLX>AO0VSAZ&]#;.'H;T-LX>AO0VSAZ&]#;.'H;
MT-LX>CO0VSEZ.]#;.7H[T-LY>CO0VTE[W6BSFZ.W`[V=H[<#O9VCMP.]G:.W
M`[V=H[<#O9VC=P1Z1X[>$>@=.7I'H'?DZ!V!WI&C=P1Z1]*W2O2QDJ-W!'I'
MCM[Q0N_<-F/:OI3QT.WSM6O^&PZ++O#.Y>V8KI]RG@H;+K0NTTHIG(]7%^@\
M]6](^/1'R.,[4$L#!!0````(`.>,;$=8<(<'7@,``,X-```0````9&]C4')O
M<',O87!P+GAM;+U776_:,!3]*Q8OZZ1N84"[K6*16LJT2=V*"NV>C7,A5AT[
MLQU&]NMWG106AN,6'M8GQSGG?IY[28?2="\F6N6@+0=#UIF0Y@(O/W52:_.+
M*#(LA8R:MPB1^':A=$8M/NIEI!8+SN!:L2(#::->MWL>P=J"3"!YDV^-=N*A
M\W*9YX(S:KF2\3?.M#)J8<EXS4`,HW\!%0,M3X$5FMLR[M:8YE6%F3(J8(2^
MX@45!FK4W\L*,U)93F49U4\W7#Z:^WRFKJF%)FOW16T]I1H2=+IC?7M98;Z4
MF*=PW%%*Y1*2)G;_Y:86#Z"-R_1=[VT7_[8EV-S7MH$F7"XGE&L3#U?V8@7,
M*OW4II4]MDN)8J[IYF&&\9D.F5,#[OBILZ*:4VD[Q/#?^-CKU&[KV^HL<F-U
M_$/I1Y,"6#.,MI?5L8EMGOD@/CNO$'C:14;;S.*GLNWD[6YFW`HPMXL)U?8_
ME:+*:5.(L_-.(_N-"7(I$S*6%N5(OLK:%3:O69+MZ8H**AF0Z5[56B#D!)-%
M)RE8'`OQVDN96A2K"\40M2"WJ+8J`B3?2UHD+^"XZ="0@C1\!9@%>P%G:A5[
M3)5(4*ROR/AG<03G_4MBHR8EGX7Z%<SGJC!<@C&-]/VVBRRCNJR"X4O)40S4
M]9`Q56`/O1P7P6D=!Z;)5[A8,+93;)'2]LW,R_DJ5PA2NO2^?7)GR!TP0(-S
M`5[<1$-..<IKC4(VN)LI:NT6U:#)I3%MG&KIEJ=D(EQJCN+"SEU%P]%,:.E"
MJ2AXJ0MPKEMD*A_)-<S]%NL0-U&?DN_@QZ'25`9D1M?@;Q<*,^.VUH*+:J2P
M2;A#,:\;3N>M'"5KK9$[ODQ=9E@*OQY@60VQ,]X4Q*@P%D/S<NY`H$`3XO90
M26::2D-9N^3&62Y4"4"N0,*"M\S]M)@;^%FX6,9..D?(MW=^!,<_@D')]SZ$
M)4].9DY&QK^M/-H/$X)#T']W^!"0D\/'H-\/CT$X!<\\A`E!6?:/Z'._9=4&
M.?X^![71__B<-J[!4BX.$4>0$53'H'>X.@;^3@?5,1@\IXY@#OLX,L./Z*+M
M!]\KIZ"'YJ)]!AI<N0-_>]M6[I.KPR5^YA_K,,??[##'W^SV#5]E]+(U_TR=
M]Q:^'[_W7?S/5W"T^]];_`=02P,$%`````@`YXQL1^@X?%D^`0``:0,``!$`
M``!D;V-0<F]P<R]C;W)E+GAM;,V334_#,`R&_PKJO<NR"1!5UP,@3DQ"8@C$
M+23>%M9\*/'4]=^3>5W+@,MNW.K:[^/7<5)*7T@7X"DX#P$UQ(N=J6TLI)]E
M:T1?,!;E&HR(HU1A4W+I@A&8PK!B7LB-6`&;C,=7S``*)5"P/3#W/3&K2B4+
M&4"@"QU>R1[OMZ$FF)(,:C!@,3(^XBRK7NS&NL:6;-!797)<BXASI_12@[IM
MA[+?J=09(9AXD(/JV]/?/SU0AF5=Y2[JOJIIFE$SI;HT,&=O\\=G.IM<VXC"
M2DBJJ`ML/<RR8^?7Z=W]XB&K)F-^F7.>\\F"7Q?3FX+S]_UD)_X&PZ8;XM\Z
M/AJD[:+&&L[<+6D4+9<^":0@RJ`]:F?/PA'FFYA@<?OQ"1+/!W5"NFP;:!L7
M5*SH?@W1_N6DE:U<:`^I']')JZJ^`%!+`P04````"`#GC&Q'F5R<(Q`&``"<
M)P``$P```'AL+W1H96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!
MMK03<VEVV[29A.U.'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H
M.'GS[BYBZ(:(E/)X8-DOV]:[MR_>X%<R)!%!,!FGK_#`"J5,7K5::0##.'W)
M$Q+#W(*+"$MX%,O67.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"T
MY1\S^!7+5(UEHP$35T$FN8BT\OELQ?S:WCYES^DZ'3*!;C`;6"!_SF^GY$Y:
MB.%4PL3`:F<_5FO'T=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT
M-&T:X./Q>#BVR]*+<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]
MW^N;:)P*C5M/TVMWW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&
MX^MZ$A6UY4#3(`!8<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9
MEC1&<IV0!0X`-\313%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67
MN\FD,WJ=?3K.:Y1_::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[
M$W(Z'&="?,_V]I&E)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7
MJ<"S(M>41B1%G\@MNN01.+5)#3(3/PB=AIAJ4!P"I`DQEJ&&^+3&K!'@$WVW
MO@C(WXV(]ZMOFCU7H5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?
M-*HU+,76>)7`\:V</!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z
M2I&/:;,CIW0FS>@S&L%&KQMUAVC2/'K^!?F<-0H<D1L=`F<;LT8AA&F[\!ZO
M)(Z:K<(1*T(^8ADV&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6
MD0X1DEXW0CYBSHN0$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='
MU!=*Y`\FIS_I,C0'HYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z>`HWEL:\4*Z"
M>P'_T=HWPJOX@L`Y?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH
M8U=RS<C'5*^3*=@YG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)
MZ&1;)0G+5--E-XH2GD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS
M0[=R2^JVE+ZU)CA*]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^
M`VVZG=PZ.)Z8D;D*TU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=
MQXCRHB'NH8:8S\-#AWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+:`'@Z]1
M`O)256`Q6\8#*Y"B?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>K
MRMYEL<%5'<]56_*POFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$
M53B_13.V$I<8O./FQW%.4[@2=K8/`C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=
M[=7GFYRN>B)V^I=WP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41`71%
M`B.5'`86%S+D4.Z2D`83`<V4R43P`H)DIAR`F/H+O?(,N2D5SJT^.7]%+(.&
M3E[2)1(4BK`,!2$7<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:
M)@N%V^)4S;L:OB9@2\-Z;ITM)__;7M0]M!<]1O.CF>`>LX=SFWJXPD6L_UC6
M'ODRWSEPVSK>`U[F$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=
MX`Q\U*M:I60K$3]+!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F`6/,,H68XWX=%
MFAHSU8NL.8T*;T'50.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'M
MB[\!4$L#!!0````(`.>,;$<$!!KE.0(``.<(```-````>&PO<W1Y;&5S+GAM
M;,U6;6O;,!#^*T(=HX41VQG-Z&H;1B$PV,J@^=!O1;9E1Z`73Y8SI[]^)\FQ
MXT!(EW5E^:+3H[OGGCLK9\>-V7+ZL*;4H$YPV21X;4S].0B:?$T%:6:JIA).
M2J4%,;#55=#4FI*BL4&"!_,P7`2",(G36+9B*4R#<M5*D^#Y`"$??Z<*FN"G
MR_<_6V5NWR&_7GRXN`B?KFX/\4MW<(61Y_A:)#A:7./@Y:2S\#@OG!U0+RQU
MT->0QJ62TU(LD,;-,]H0#OZ1=<\55QH9Z!5H<(@D@GJ/.\)9IID%2R(8WWIX
M;@'7WMY/,*FTR^TS'.:9A6,F764)#OO?R]-E([M;;'F,\VEY`*1Q38RA6BYA
M@WI[M:VA.*DD]2*=WPGO2I-M-+_>"W`+Y,V4+J@>,D=X!Z4QIZ6!`,VJM5V-
MJJUT98P28!2,5$H2;BEW$;T!M#GE_,%>YL=RPMV5R/O89QQB9%7L3&A$;X[7
MP#4UV&?SW'NT-V?1HJX<^"&:U#7??N&LDH)ZK1Y:JGYWBCXZ0I_&9,>*UDJS
M9_"W]R`'@&J,-E0;EN\COS2I5[0S_04.NO*8PG-+_I>:7K]KHQJX@6_=GK.3
M.^B^%1G52S<7_US2QT^G'YG[<^(#F6][:\Z0\`K-L:^>_U;:XB^E!?V(VYNC
MDRDZH"AK&3=,[C00^]Z[M[KY9,*-$Q0XBVX<GN[4D`R^.B99@*R@)6FY^<$V
MRKC#!(_V-RL_6@Q>JX$BP:/]G1:L%3=.P?AID_X&4$L#!!0````(`.>,;$=B
M8</LOP0``-X1```/````>&PO=V]R:V)O;VLN>&ULE9A;;]LX$(7_"J&7S0+9
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M^XGML:8_]J*,MZE"H1-9R:90HH_`P;@$QB6OC1-[5]+2<M:J#_IWT$E!)WVI
M<^-I%T(D3IB5N&R5W<(J]OYM9%>"4`9"V6M"IZ8F>->J<;3UE)D"A'(0RE\3
MNO&FN%N;JB3F?A/G7SL0FH'0[*U"!R!T`$('KX8FW5I\I+IB<G0(0H?,IG5.
M-\HYR#,,/H+!1\PJNKJ6=M/'HF\;34XC`X!%83H"$)&;(G/3EU(AA/UM()11
M?2^K$-P^P62L_V.!4@-\&7XOFGL::^P&!R&[,0/O;LU.7*M"T?2A]&`X(ALS
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MA8#.0Y4-!B.0"6>C8W9!#VV00B`3SDA'I=!($\0T83`==9[D$*40V81%=N<\
M8F\1*L[A4R]!<!,&7,:".)T4J4T9:D>]*(U1"N%-&7A'O4CLH13"FXX9+.=&
M:8I2@_Z`(?C9C=CT(,(I@S!C2ZP.TIQR-(\5=HHTITAS^E::4Z0Y19I3KC$8
ME4*:4Z0Y96@>+8ST"*40[91!&PKC3'FIJT&J,R0Z8XAF*X,30IXSEN>1TL@2
ME$*>,X;GT=+(D.<,><X8GD=+(\M0:M#Q,G!#:7#Y0:8SANF7P\5"/?INV+]G
MR'/&\,R6&+<>I#EC:,8>@%=`B#,.XK%N($.(,X0X^T5CP74#NX7AZP0"G3-`
MCWI'CA:=(]+Y6_N+')'.$>F<07I<"I'.$>F<0?K7K4J?+91"I',&Z1?]"@M"
M/GB%8YN/GSH77@;1SF>[M^\?+]PEK:!19?@<X?HIZ-6V"-\HZ&?[GI'EH4,-
MQ_^8DN8-'Q<BL>JJZI3.73:?C.Q?P;?*3U\EWG\'4$L#!!0````(`.>,;$<!
M2.'Z/P(``(P'```8````>&PO=V]R:W-H965T<R]S:&5E=#$N>&UL?57;CILP
M$/T5Q`<LV`9R$4%*4E7M0Z75/K3/#C@!K8VI[83MW]<VA*78]`5?.&?.C.V9
MR7LNWF5-B`H^&&WE(:R5ZO91),N:,"Q?>$=:_>?*!<-*+\4MDIT@N+(D1B,8
MQUG$<-.&16[W7D61\[NB34M>12#OC&'QYT0H[P\A")\;;\VM5F8C*O)HXE4-
M(ZUL>!L(<CV$1[`_`V0@%O&S(;V<S0/C_(7S=[/X7AW"V/A`*"F5,8'U\"!G
M0JFQI)5_CT8_-0UQ/G]:_VK#U>Y?L"1G3G\UE:JUMW$85.2*[U2]\?X;&6-(
MC<&24VF_07F7BK,G)0P8_AC&IK5C/_Q)T$CS$^!(@!,!9O\EH)&`)@)(;*2#
M9S:N+UCA(A>\#\1P&1TV=P[V2)]<:3;M0=E_.C*I=Q]%G$</8V9$G`8$G"'`
MA(BT[4D`^@1.T*'#?P7.+@+Y!9`W`F3I:$9/_/3$2T\L/9G1T\4!N(C,+Y!Z
M!5*'OED(#(C4(EJ+V`*0)2O'G'E5,D=ENU!Q$3N_P,8KL''H8/E2/)"5&+9>
MB:W+7[R5DP>R\EAV7HF=RT\6$AY(ZI<P]<&74K%K(5LFE0>S65%925S@6EA>
M^8C)YIB52P?>[#T"Z*A`IT!`Y_W">/7,_$D,D*L#%G5BQ,QU4)RF,5KF>S0K
M?HR(FVT*,BCYO;4]:+8[-9XCM,7S$U[D';Z1'UC<FE8&%ZYT";:%\LJY(MJ?
M^$5[4NO6."THN2HSW>BY&)K%L%"\>_:^J0$7?P%02P,$%`````@`YXQL1Z90
MTH<T!```21,``!@```!X;"]W;W)K<VAE971S+W-H965T,BYX;6R%F$UOXS80
MAO^*X7M6G!E2)`/'0.VB:`\%%GMHSTK,Q,9*EBLI\?;?EY(=5^8,VQQB?;Q#
MOA3)9T9:G=ON>[\/85C\:.IC_[3<#\/IL2CZEWUHJOY+>PK'>.>U[9IJB*?=
M6]&?NE#MIJ"F+E"ILFBJPW&Y7DW7OG;K5?L^U(=C^-HM^O>FJ;J_-Z%NST]+
M6'Y>^'9XVP_CA6*]*FYQNT,3COVA/2ZZ\/JT_`D>MX2C9%+\<0CG?G:\&,T_
MM^WW\>2WW=-2C1Y"'5Z&L8DJ_GR$;:CKL:78\U_71O_M<PR<'W^V_LLTW&C_
MN>K#MJW_/.R&?72KEHM=>*W>Z^%;>_XU7,=@Q@9?VKJ?_B]>WONA;3Y#EHNF
M^G'Y/1RGW_/ECE/7,#D`KP%X"P#]GP%T#:`DH+@XF\;U<S54ZU77GA?=93).
MU3CG\$CQR;V,%Z<'-=V+(^OCU8\UXJKX&-NY2C87"<XE]XJMH*";I(C]WTR@
M:`*G>)K':SF>Q'B:XO4\WB2#N$CL)#E>NRB]<C89"M<YHQ0ZV8X6[6ANITSL
M7"1FU@W9N+642NQP'6KGY[H[/T;T8[B?9-@;P_JQSB/HQ`Z7@5(&/<IV2M%.
MR>VXQ$[)^G&ECG^)'2[SVEAC9#=6=&.Y&Y^XL7P28B<FD6VY#+0C[V4W3G3C
MF!M*EL3&L6[B.@9(S'`5*5UF=J47O7CN)>EEX_D\@;,$R>[;<IW1I?-D93\C
M>"56*>Z(P4JQKK0WIF1+61"2(UOJG*<,/X%[HM03<$_.\LTNZ7R9W>P@PQ20
M.]*I(Q0FA$K%P,YU@*1(YRS)?`8.:$H!?=4D@V<K29!!7$@Y/S*@@1.:4D(#
M1R]H1`)=II8$)2@#SF22&,B8!L/28':#R&0%CE9*T0H<FD8;GV:$K:!S!DJ;
M<R33%3A>*<4K".`D\HRODLXH<IGD`S)A@2-6IX@%3D^V5P4,1PYGK,B`!4Y8
MG1(6.#I+ZYUCBY#K8FIV5F?2#\J(1<76H,X\7Y2!B!R(.@4B<M`18"1="FE!
M:,?%FGG.F"DO.1'34F*#`NEB*K.4.N(Z<@XRNP)E'B+GH4YYB!QTA%I;FVY4
M06B=MCETH(Q$Y$A,0;=!H6KUL8PNV4,2B&@]Z=FJO?<D`Q$Y$'/9&64@(@>B
M3H&(''2$);#,\_^Z>T<R$)$#4:=`1`%T"N+<>[8_)*72,47G7,E01`Y%DT(1
MA9)2>U>RY\1U#R;NVC(W=3(<D</1I'!$#KT';50LAU-/@M``0BY#DTQ'X@6H
M20M0XG7E@P7R:0*1=$@T*['O'<FT)4Y;D]*6.$1!H7?QY23UQ)4>C:,R\_I+
M,F^)\]:DO+UJYB_:F?)*4LKE53'[Z'&JWL+O5?=V./:+YW88VF;ZRO':MD.(
MK:HO<9#[4.UN)W5X'<9#&X^[RY>>R\G0GCX_7-V^GJW_`5!+`P04````"`#G
MC&Q'VY%N`^`!``!:!0``&````'AL+W=O<FMS:&5E=',O<VAE970S+GAM;(64
MVVZC,!"&7P7Q`#'G9"."U%!5W8N5JE[L7CLP!%0;4]L)[=O7!\(20&TN8GO\
M_S/?`';:,_XF:@#I?%#2BH-;2]GM$1)%#12+#>N@53L5XQ1+M>1G)#H.N#0F
M2E#@>0FBN&G=+#6Q%YZE["))T\(+=\2%4LP_CT!8?W!]]Q9X;<ZUU`&4I6CT
ME0V%5C2L=3A4!_?!W^>)5AC!WP9Z,9D[FOW$V)M>_"X/KJ<1@$`A=0:LABOD
M0(A.I`J_#SG_E]3&Z?R6_<ETJ^A/6$#.R+^FE+6"]5RGA`I?B'QE_3,,+<0Z
M8<&(,/].<1&2T9O%=2C^L&/3FK&W.]%VL*T;@L$0C`8_^M80#H9P9D"6S/3U
MB"7.4LYZA]MWT6']ROU]J)Y<H8/F09D]U9E0T6L6QRFZZCR#Y&@EP402W"OR
M%44X2I"J/T($JQ"!\8=3B&3='Z[Z0^./IO[MK`DKV1E):R3>QI^U\;WFCB-:
MY8B6'+L9AY7$DQH[S_QF+#_K[GCB59YXR?-KQA,OZH1!XOO1C#O_67?'DZSR
M)`N>9-;W,5G4"3Q=9X:S(@NCJ<S2H,DQZ/`9_F!^;EKAG)A4)\I\]Q5C$E1*
M;Z.RU>JB&Q<$*JFG6S7G]NS;A63=[28;K]/L"U!+`P04````"`#GC&Q'*U58
MUUH$```7$P``&````'AL+W=O<FMS:&5E=',O<VAE970T+GAM;(V876_J.!"&
M_PKBOHW''[&-*%*!K'8O5CHZ%WNN4W`+.@EAD[2<_??K?)32F4EWI:HDYAE[
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MQU/_>1F^T78TXPWD:""O!M=Q>`,U&J@/`_VE@1X-]/\=P8P&!HV0#-K[F=OF
M;;Y:UM5E5@_+?<Z[J(*%B6NSZQK[I>B_BW/7Q-:W50K+Y*WK9T36`R)O$?D9
MV5+DHY,DCG]U0G).K"4Q1P-L*)$JY,-_=I)]V<DG-Q4[5ZJW5[?VFK?7K+WN
M[?6MO4%S/2"V1TZ#"&VEE@[-!^7`6@'2HTFAG#4J=H?6.*.<41Z,][P^P^HS
M5%^*]`V(N1G'I<)(A&THEGHI%5YRBDFOA2/J&$XZ$_]X=2FK+J7J+%*7DG$@
M!?`"1S/#"6N=1].PI9PV7FDAD#[**1"I@HGHM*P^2_6AJ%M;.HX#JY$[&P:S
MRG@4ZUN*@7!QG=&H&>6\!.,<+\ZQXAP5A[;*VE&O!1@<P1L.DQ+PTE',:]"`
M(B:CF+/*W0SZ29MGM7FBS:(567M.F]58&X.E(!4^[2GF192&HY)B8+O],!&5
M73[G$I2@\DB&$M0C9^*Y@O0Q'`AEA<8'"P-*KZ0!%,,9`RH#,6PFHA,FLC!0
MD1*+!'HHRC3*Q"(I%\]$0R12#-(T'IY$(@7O=)Q;,[6.;(Y_!$DE*BQ14I_B
M;`)6R&`@<31O&4Q:83S61[&X`]5$90!\:0"*JM-8G:(+"&"5Q_(H)WTJ+)9'
M,8AN.YQ,,P:\TUHY9R<D\M4+T/+%XO)E9#ZYG@JM+99(.?#2$HD4L\(KK[%"
MRMV!3D%,5*'`UR]`"QB+"YB1L9\WO/3DJ*%</&J4P`HIYF5<'%RZ,MR=]+%F
MF,@4P-<PD)(2UDY%`5\E`"T3+"X3@"D`XH$!.%PV+!CWJ-)XFC@PUA[X:,CX
M'E/OQ81*OEP`6B]87"\`4PF`<TJ3_<R!PCB25UDPGO$29U8._%(E7SB`)]'@
M)GJ0?'*63'+&T3`R[L99<0_D!YX@`8[W"ML12B$9`]W%X294\=E8,MD8K_[(
M(%4X4XW4EZJXCO#ON(RA&%G)S:_^,M0O_7U+,]M5KZ>V6^>;UNN=SJ/L;@U0
M^QH6&V#:M[#(AAN;C^Y7RW/^$O[,ZY?CJ9D]56U;E?V-PG-5M2$Z+^YCH!Y"
MOK^^%.&Y[1YM?*Z'>YOAI:W.[]=0U[NPU;]02P,$%`````@`YXQL1WN_%>.>
M`@``%0D``!@```!X;"]W;W)K<VAE971S+W-H965T-2YX;6R-5DUSFS`0_2L,
M]P0D(3X\F)F`W6D/G<GDT)QE6[:9`'*1;*?_OI+`F$A*V@M(RWN[^W8EI/S*
M^C=^I%1X[VW3\:5_%.*T"`*^/=*6\$=VHIW\LF=]2X2<]H>`GWI*=IK4-@$,
MPSAH2=WY1:YMSWV1L[-HZHX^]QX_MRWI_Y2T8=>E#_R;X:4^'(4R!$4>3+Q=
MW=*.UZSS>KI?^D]@L<X40@-^U?3*9V-/Y;YA[$U-?NR6?JA2H`W="N6!R->%
M5K1IE",9^/?H\QY2$>?CF_=O6JW,?D,XK5CS6N_$428;^MZ.[LFY$2_L^IV.
M$K!RN&4-UT]O>^:"M3>*[[7D?7C7G7Y?AR]Q--+<!#@2X$28XK@):"2@.^'K
M"-%(B/XW`AX)V(@0#-IUY59$D"+OV=7KAVZ?B%I48(%E;[;*J%NAO\G:<6F]
M%"G(@XOR,T+*`0)GD!A^A*QLR-U)(.-/24!7$B6TZ$:`RD;$R,CAGT[67SKY
MD"9RU@II/IK7"KKYD9,?:7XTYQLBR@&2:$BG(0@#F)GEL&$@1"@T*F*C,AA%
MR"R+#7N`69*DL5L;=FK#=FTB-S]V\F.[-MBHS0#!\SQ3D,2)41L;EJ+(`*T<
MOI(LP[%1&AN&X"<M3YRR$EN6$:-,'#%B:/2RLE$/R.ZXPQ=(,T/\VN%+KC&W
MK-0I*[5E&4'*U`X29<!L1&7#<`C,;KE\I2'.#%TV#&2?;/#,*2NS9:6&K,S>
MH"$$D;%6*QL&L+T*;52:Q"@Q?@IK&Z8V*+:T!;.??DO[@SYNN;=EYTZHO3FS
M3B?Z$U2'AF$OP:("#OM*W@"&`_ONOLA/Y$!_DOY0=]S;,"&/*GV@[!D35*8?
M/LJ.'.4=99HT="_4,)'C?CBVAXE@I]LE9+H)%7\!4$L#!!0````(`.>,;$=!
M6!4'5@0``$\6```8````>&PO=V]R:W-H965T<R]S:&5E=#8N>&ULC5A-DZ)(
M$/TKAG='LCXHZ+"-6&UE][`1$W.8/=-M=6L,B`MT._OOMT#:ELR4XJ*`+U\F
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MOGP?CNWW^?*+-ET8'R"Z`'$-`#D8(+L`.39`=0'J&B!A,$!W`?HK(!@,"+N`
M\*LD/1A@N@#SE2%NNW51M^W-4UJGRT59G"?E94&=TF;=PH-QW7]I+K;-;G]S
MW:G<U8]E%"_F'PU/!UE=(.(&$@=]R)J!0!_RQ$!$'[)A(+(/V3(0U8<D#$1?
M(7,GQE41P2HBVGAU&Q\B12X0TT*.7:&QCD*DW)KBI`@!-)*&PB`(`*1$?!L*
MG*G`J"!"*C$X#4HJU).$P4$<R9"72[)R22J703)<(!K+H'#9%">D=CB^',66
MHT@Y$5I#*T72S$1L3(2ZO%9$';3LGR@30FQ&YMIZ<R5#N7JZ:%873=N$Y%]I
MD@'P_V]-,5@3+V+C16R]B&2XUIX>(:M'2/7`<R^DRQ8TGGRA=Y%0FCC$DX]B
ML"0TCX`(=3`9HNEI8EA-#-'$S2%TO\9;*47,',V=0B*VD(@I!,VN542'A1`A
M&JWKR-N>43P;BL*W[<V4#''T1(E946)&%+2.5C%=:R!DB#?C=3QN8Z)TKI-2
MZ1"-KPT%SDR@`>_-6YK7;4P"-!HS"<,'<:CN_,,;K\E9FX!1#`^T#N3?G!B@
M<#OJO=T)[M@M8&I"*JTZ4*^-0KM].<+%P[@^,H2ND4K(`*]S!CG3QG7<8#EH
MZDLKB1UC&(64$N[HQILRH*X,</'K#C2BEQ0XV$O>^0"U/L1K`/4TL5!*"ERZ
M]`XJA@KOK".S;?W9DL%L?75X(P;4B1''`8P]4E&@L8]F<$0=OQ?S0[9^2.*O
MN:\.;\>`\6/DN8LQ.2(00!Z^M'_M4"H=Q=I@A?S6C$D6@B`#?)"I+Q#OSX`:
M-&I&P.^;&,A,1'?]"/#."#AKA)\*@3H?H4V`GX8ZV&"[1C%M&!BY?6^R9)"E
M+P[OUF",70/J?L!$@HQPK]%Z&L>T\3-M_9!D$-(7AW=MP-DV@\6AOLAYNSA2
M>#]9,TA^Q^<802F#+=F&8U1QA!WPEL'-E`YBW.F$`QJ0\1W=!&_>!&?>L/\1
M8\T;`Q1!2#?\^<UKLU/Z9O].R[?#L9H\%W5=Y.U[LM>BJ*WC#+XYMKU-=]>3
MS+[6S:%QQ^7E?>?EI"Y.GZ]OK^^0E_\#4$L#!!0````(`.>,;$>5"D%PF0$`
M`*\#```8````>&PO=V]R:W-H965T<R]S:&5E=#<N>&UL?5/;CML@$/T5Q`<$
M7_;21HZEKJNJ?:BTVH?VF=CC&"TP+I!X^_?EXKC>R-H7,S.<<S@SF&I"\VH'
M`$?>E-3V0`?GQCUCMAU`<;O#$;3?Z=$H[GQJ3LR.!G@724JR(LL>F.)"T[J*
MM6=35WAV4FAX-L2>E>+F[Q-(G`XTI]?"BS@-+A187;&%UPD%V@K4Q$!_H%_R
M?5,&1`3\$C#954R"]R/B:TA^=`>:!0L@H75!@?OE`@U(&83\P7]FS?]'!N(Z
MOJI_B]UZ]T=NH4'Y6W1N\&8S2CKH^5FZ%YR^P]S"?1!L4=KX)>W9.E17"B6*
MOZ55Z+A.:>?Q8:9M$XJ94"R$_.Y#0CD3RAL"2\YB7U^YXW5E<"(FW<7(PY7G
M^])/K@W%.*BXYSNSOGJI\^QSQ2Y!:,8\)4RQPA3O$<T&HEP@S!M87!2;+HK(
M+]<N\FQ;H-P4**/`W3N!_*:-A/D4,3IBLMT-IOD8DXRPU6Q'?H*?W)R$MN2(
MSE]3'&:/Z,#K9;M[2@;_>I9$0N]"^.ACDWZHE#@<K\]C>:/U/U!+`P04````
M"`#GC&Q'3%KH.Y\$``#P%0``&````'AL+W=O<FMS:&5E=',O<VAE970X+GAM
M;(V83V_C-A#%OXKAN]?D#$52@6,@5E&TAP*+/;1GQ59B8RW+E93U]MN7DAS'
MX3P">['^^''XAA1_&G%U:=KOW;ZJ^MG/^GCJ'N?[OC\_+)?==E_59?>E.5>G
M\,]+T]9E'R[;UV5W;JMR-S:JCTM2RB[K\G":KU?CO:_M>M6\]<?#J?K:SKJW
MNB[;_S;5L;D\SO7\_<:WP^N^'VXLUZOEK=WN4%>G[M"<9FWU\CA_T@\%^T$R
M*OX^5)?N[GPVF']NFN_#Q9^[Q[D:/%3':ML/(<IP^%$5U?$X1`H]_WL-^M'G
MT/#^_#WZ[V.ZP?YSV55%<_SGL.OWP:V:SW;52_EV[+\UES^J:P[9$'#;'+OQ
M=[9]Z_JF?F\RG]7ES^EX.(W'R_2/5]=FN`%=&]"MP:T?W("O#?BC@1DSG9R-
M>?U6]N5ZU3:763M-QKD<YEP_<!BY[7!S'*CQOY!9%^[^6&M-J^6/(=!5LYDT
M=*^Y*98A^JT+0EUL2#2/.BBDPC+N@6$2/+;G3TDD`A@8P(P!S%T`S]$@3!(W
M2DZC)"=C.$Y%RA:4.^<MMI-!.QG(Q^``%@:P(A^MLRBA29/=.67GC8MD!9"Q
M<GDB'P?M.&#'1G:<Z(>4,Y$9(-*9QU8\M.*!%1=9\:(7ZY7RD:R0LH4VUJC$
MXLBAGUSZN0LP^<E%1]IYBB=*JHC(9MC,@#9$`P6&Q\<X4#)QSGT\5T!F,ITG
M_"3HI,%*2(6`]'G2)%,B%:=$X,&RRODX)ZFS8=$D%H/&M-(L')$88Q8=><U:
MQWZD3%NG+"4,8?IIB3_*8T,&/.WDPB#%EI#09]:E!@DC4&?"$XM!RF17.;%@
M,M`YG^>I0<)(U9*I1CQ&$I8+:W,Q1%+V2?79#D:J!DRE&!P:0E4)^!9`F"F3
MA`=&J_9RL5)JD#$--<`AQ6]B+4FWT,Z1RL7R`,J,E#8)5X2I2("*%.%N0Q)W
M9'RN5#S[OR#\;`JCD30P%;_CKZ+/J'9:`U=`2;G/TK8P;@GA-G[7$\"HI;A"
M*8`L90:3EB1I`[-B,Y*A(7-RWL6K!"G#V]JFGR?,6S)@H22J&,)X)(E'+9A-
MDGLT3*B<?"E,#32&(X&"DV,Z$J"C9LN<QW:0T&AK7,(41B0!1'*,2)+D6S"Y
M3'B2NM0083H2J#SC-]6&9$T9BA728L*DCG66,H192ZCT%"L55)694XF)8,Q/
M!OSDF.J,L.BLU_%,`&%XC+S)4Z8P/QGPDV.HLZ1B6.ZY$H\'$"X"9HUVB>\V
MQOAD@$^.J<Z2BP.HXR*R`#HBI]@GWNN<^+H&%.7X06')1C*AJ!%?34`8ZI%`
M_\1G$V.&LJQ9-<=H9UF+LA7T`RKML@32&?.8`8]%O<H2L^PYKB0*(#/&N=3X
M8"*SE>\83GPY,>8G`WZ*DI<!/RDLI/BKL0!";Q2GLL(090!1$R/]*KK?@S$>
M+%DI6^@\WC9:WFVDU57[.FXP=K-M\W;JARVKN[NW3<PG&C;BHOL;_5!,6Y$?
M8=:K<_E:_56VKX=3-WMN^KZIQ\VXEZ;IJV!2?0GCM:_*W>WB6+WTPZD+Y^VT
M(3E=],WY?7_UMLF[_A]02P,$%`````@`YXQL1[:FWJNA`0``L0,``!@```!X
M;"]W;W)K<VAE971S+W-H965T.2YX;6QM4\%NW"`0_17$!P0;>]MJY;64316U
MATI1#NV9M<<V"G@<P.OT[PO8ZSBI+\`,\]Z\&89B0O-B.P!'WK3J[8EVS@U'
MQFS5@1;V#@?H_4V#1@OG3=,R.Q@0=01IQ7B2?&%:R)Z61?0]F;+`T2G9PY,A
M=M1:F+]G4#B=:$IOCF?9=BXX6%FP%5=+#;V5V!,#S8G>I\=S'B)BP&\)D]V<
M2=!^07P)QL_Z1),@`114+C`(OUWA`90*1#[QZ\+YGC(`M^<;^V.LUJN_"`L/
MJ/[(VG5>;$))#8T8E7O&Z0<L)1P"887*QI54HW6H;Q!*M'B;=]G'?9IOLG2!
M[0/X`N`KX%L2A<^)HLSOPHFR,#@1,[=V$.$%TR/WC:B",]8=[[Q0Z[W7,LUY
MP:Z!:(DYSS%\&[-&,,^^IN![*<[\/SC?AV>["K,(SSXHS/8)\EV"/!+D'PCR
M3R7NQ1P^)6&;GFHP;1P=2RH<^SBH&^\ZG?<\OLE[>%D,HH5?PK2RM^2"SK]L
M['^#Z,!+2>X.E'3^_ZR&@L:%XU=_-O-(S8;#X?9!UE]:_@-02P,$%`````@`
MYXQL1ZE[X:*B`0``L0,``!D```!X;"]W;W)K<VAE971S+W-H965T,3`N>&UL
M;5/!;N,@$/T5Y`\H#G':;N18:KJJVL-*50_=,[''-BHP+N"X^_<%[+ANUQ=@
MAGEOW@Q#/J!YLRV`(Q]*:GM(6N>Z/:6V;$%Q>X4=:']3HU'<>=,TU'8&>!5!
M2E*6IM=4<:&3(H^^9U/DV#LI-#P;8GNEN/EW!(G#(=DD%\>+:%H7'+3(Z8RK
MA`)M!6IBH#XD=YO],0L1,>!5P&`79Q*TGQ#?@O%4'9(T2``)I0L,W&]GN`<I
M`Y%/_#YQ?J4,P.7YPOX0J_7J3]S"/<J_HG*M%YLFI(*:]]*]X/`(4PF[0%BB
MM'$E96\=J@LD(8I_C+O0<1_&FUTVP=8!;`*P&7";1N%CHBCS-W>\R`T.Q(RM
M[7AXP<V>^4:4P1GKCG=>J/7><[')KG-Z#D13S'&,8<N8.8)Z]CD%6TMQ9/_!
MV3I\NZIP&^';;PIOU@FR58(L$F3?"&Y_E+@6\^M'$KKHJ0+3Q-&QI,1>QT%=
M>.?IO&/Q3;["B[SC#?SAIA':DA,Z_[*Q_S6B`R\EO=HEI/7_9S8DU"X<;_S9
MC",U&@Z[RP>9?VGQ"5!+`P04````"`#GC&Q'+R/+9I\!``"Q`P``&0```'AL
M+W=O<FMS:&5E=',O<VAE970Q,2YX;6QU4U%OVR`0_BN('U`<DFQ3Y%AJ.E7;
MPZ2J#]LSL<\V*G`NX+C[]P/LN&[JO0!WW/?==\>1#VA?7`O@R9M6QAUIZWUW
M8,R5+6CA[K`#$VYJM%KX8-J&N<Z"J!)(*\:S[`O30AI:Y,GW9(L<>Z^D@2=+
M7*^UL']/H'`XT@V].IYET_KH8$7.9EPE-1@GT1`+]9'>;PZG78Q(`;\E#&YQ
M)E'[&?$E&C^K(\VB!%!0^L@@PG:!!U`J$H7$KQ/G>\H(7)ZO[(^IVJ#^+!P\
MH/HC*]\&L1DE%=2B5_X9AQ\PE;"/A"4JEU92]LZCOD(HT>)MW*5)^S#>?,LF
MV#J`3P!^`V!CHB3SN_"BR"T.Q(ZM[41\P<V!AT:4T9GJ3G=!J`O>2['99SF[
M1*(IYC3&\&7,',$"^YR"KZ4X\4]PO@[?KBK<)OCV@\+_Y-^M$NP2P>X#`;\I
M<2UF>Y.$+7JJP39I=!PIL3=I4!?>>3KO>7J3]_`B[T0#OX1MI''DC#Z\;.I_
MC>@A2,GN]I2TX?_,AH+:Q^/7<+;C2(V&Q^[Z0>9?6OP#4$L#!!0````(`.>,
M;$>7=9W_H@$``+`#```9````>&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;&U3
MP6[D(`S]%90/*`F3Z5:C3*1.J]7N8:6JA_;,)$Z""C@+9-+]^P622=,V%\#&
M[_G9F&)$\V8[`$?>E=3VF'3.]0=*;=6!XO8&>]#^ID&CN/.F::GM#?`Z@I2D
M+$UOJ>)")V41?4^F+'!P4FAX,L0.2G'S[P02QV.2)5?'LV@[%QRT+.B"JX4"
M;05J8J`Y)O?9X92'B!CP(F"TJS,)VL^(;\'X71^3-$@`"94+#-QO%W@`*0.1
M3_QWYOQ(&8#K\Y7]9ZS6JS]S"P\H7T7M.B\V34@-#1^D>\;Q%\PE[`-AA=+&
ME52#=:BND(0H_C[M0L=]G&Y8-L.V`6P&L`5PET;A4Z(H\Y$[7A8&1V*FUO8\
MO&!V8+X157#&NN.=%VJ]]U*RNX)>`L\<<II"V"HD6R*H)U\RL*T,)_8-SK;A
MNTV!NPC?K;/O\VV"?),@CP3Y)X+]EQ*W8FZ_)*&KEBHP;9P<2RH<=)S3E7<9
MSGL6G^0CO"QZWL(?;EJA+3FC\P\;V]\@.O!2TIM]0CK_?19#0N/"\8<_FVFB
M)L-A?_T?RR<M_P-02P,$%`````@`YXQL1ZZ4-K"C`0``L0,``!D```!X;"]W
M;W)K<VAE971S+W-H965T,3,N>&UL;5/!;MP@$/T5Q`<$+[N;I"NOI6RJJ#U4
MBG)HSZP]ME&`<0"OT[\O8*_CI+X`,\Q[\V88\@'MJVL!/'G7RK@C;;WO#HRY
ML@4MW`UV8,)-C58+'TS;,-=9$%4":<5XEMTR+:2A19Y\S[;(L?=*&GBVQ/5:
M"_OW!`J'(]W0J^-%-JV/#E;D;,954H-Q$@VQ4!_IP^9PVL6(%/!;PN`69Q*U
MGQ%?H_&S.M(L2@`%I8\,(FP7>`2E(E%(_#9Q?J2,P.7YROZ4J@WJS\+!(ZH_
MLO)M$)M14D$M>N5?</@!4PG[2%BB<FDE9>\\ZBN$$BW>QUV:M`_CS3:;8.L`
M/@'X#+A/`#8F2C*_"R^*W.)`[-C:3L07W!QX:$09G:GN=!>$NN"]%)O]7<XN
MD6B*.8TQ?!DS1[#`/J?@:RE._#\X7X=O5Q5N$WS[2>'].L%NE6"7"':?"+Y]
M*7$EYC;[DH0M>JK!-FET'"FQ-VE0%]YY.A]X>I./\"+O1`._A&VD<>2,/KQL
MZG^-Z"%(R6[VE+3A_\R&@MK'XUTXVW&D1L-C=_T@\R\M_@%02P,$%`````@`
MYXQL1U/V_:F@`0``L0,``!D```!X;"]W;W)K<VAE971S+W-H965T,30N>&UL
M=5/!;N0@#/T5Q`>4))-V5Z-,I$ZKJCU4JGK8/3.)DZ`"3H%,NG^_0"9IVLU>
M`!N_YV=CBA'-F^T`'/E04ML#[9SK]XS9J@/%[17VH/U-@T9QYTW3,ML;X'4$
M*<FR)+EAB@M-RR+Z7DQ9X."DT/!BB!V4XN;/$22.!YK2V?$JVLX%!RL+MN!J
MH4!;@9H8:`[T-MT?\Q`1`WX)&.WJ3(+V$^);,)[J`TV"!)!0N<#`_7:&.Y`R
M$/G$[Q?.SY0!N#[/[`^Q6J_^Q"W<H?PM:M=YL0DE-31\D.X5QT>XE'`=""N4
M-JZD&JQ#-4,H4?QCVH6.^SC=Y#-L&Y!=`-D"^)E$X5.B*/.>.UX6!D=BIM;V
M/+Q@NL]\(ZK@C'7'.R_4>N^Y3&_2@IT#T27F.,5DZY@E@GGV)46VE>*8_0//
MMN&[386["-]]4?@?@GR3((\$^1>"W;<2MV+R;TG8JJ<*3!M'QY(*!QT'=>5=
MIO,VBV_R&5X6/6_AF9M6:$M.Z/S+QOXWB`Z\E.3JFI+._Y_%D-"X</SASV8:
MJ<EPV,\?9/FEY5]02P,$%`````@`YXQL1^@^H%:B`0``L0,``!D```!X;"]W
M;W)K<VAE971S+W-H965T,34N>&UL;5/!;MP@$/T5Q`<$V^O=1"NOI6RJJCU4
MBG)HSZP]ME&`<0&OT[\O8*_C)+X`,\Q[\V88BA'-J^T`''E34ML3[9SKCXS9
MJ@/%[1WVH/U-@T9QYTW3,ML;X'4$*<FR)#DPQ86F91%]SZ8L<'!2:'@VQ`Y*
M<?/O#!+'$TWIS?$BVLX%!RL+MN!JH4!;@9H8:$[T,3V>\Q`1`WX+&.WJ3(+V
M"^)K,'[6)YH$"2"A<H&!^^T*3R!E(/*)_\Z<[RD#<'V^L7^/U7KU%V[A">4?
M4;O.BTTHJ:'A@W0O./Z`N81](*Q0VKB2:K`.U0U"B>)OTRYTW,?I)D]GV#8@
MFP'9`GA(HO`I493YC3M>%@9'8J;6]CR\8'K,?".JX(QUQSLOU'KOM4P/^X)=
M`]$<<YYBLG7,$L$\^Y(BVTIQSK[`LVWX;E/A+L)W'Q0>M@GR38(\$N0?".X_
ME;@5\_`I"5OU5(%IX^A84N&@XZ"NO,MT/F;Q3=[#RZ+G+?SBIA7:D@LZ_[*Q
M_PVB`R\EN=M3TOG_LQ@2&A>.]_YLII&:#(?][8,LO[3\#U!+`P04````"`#G
MC&Q'&ZQ<JJ$!``"Q`P``&0```'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6QM
M4]MNY"`,_17$!Y0DD]Y&F4B=KE;MPTI5'W:?F<1)4`%G@4RZ?U\@F33MY@6P
M\3D^-J88T;S9#L"1=R6U/=#.N7[/F*TZ4-Q>80_:WS1H%'?>-"VSO0%>1Y"2
M+$N2&Z:XT+0LHN_%E`4.3@H-+X;802EN_AU!XGB@*;TX7D7;N>!@9<$67"T4
M:"M0$P/-@3ZD^V,>(F+`;P&C79U)T'Y"?`O&<WV@29``$BH7&+C?SO`(4@8B
MG_COS/F9,@#7YPO[SUBM5W_B%AY1_A&UZ[S8A)(:&CY(]XKC$\PE7`?""J6-
M*ZD&ZU!=()0H_C[M0L=]G&[R^QFV#<AF0+8`[I(H?$H49?[@CI>%P9&8J;4]
M#R^8[C/?B"HX8]WQS@NUWGLNTYO[@IT#T1QSG&*R=<P2P3S[DB+;2G',_H-G
MV_#=IL)=A._6V6^3;8)\DR"/!/D7@O1;B5LQWU6R54\5F#:.CB45#CH.ZLJ[
M3.=#%M_D,[PL>M["+VY:H2TYH?,O&_O?(#KP4I*K:THZ_W\60T+CPO'6G\TT
M4I/AL+]\D.67EA]02P,$%`````@`YXQL1RCJRC:A`0``L0,``!D```!X;"]W
M;W)K<VAE971S+W-H965T,3<N>&UL;5/!;N0@#/T5E`\H"9-IJU$F4J>KU>YA
MI:J']LPD3H(*.`MDTOW[`LFD:3<7P,;O^=F88D3S9CL`1]Z5U/:8=,[U!TIM
MU8'B]@9[T/ZF0:.X\Z9IJ>T-\#J"E*0L36^IXD(G91%]3Z8L<'!2:'@RQ`Y*
M<?/O!!+'8Y(E5\>S:#L7'+0LZ(*KA0)M!6IBH#DF#]GAE(>(&/`B8+2K,PG:
MSXAOP?A='Y,T2``)E0L,W&\7>`0I`Y%/_'?F_$P9@.OSE?UGK-:K/W,+CRA?
M1>TZ+S9-2`T-'Z1[QO$7S"7L`V&%TL:55(-UJ*Z0A"C^/NU"QWV<;E@VP[8!
M;`:P!7"?1N%3HBCS!W>\+`R.Q$RM[7EXP>S`?".JX(QUQSLOU'KOI<SN=@6]
M!*(YYC3%L'7,$D$]^Y*";:4XL?_@;!N^VU2XB_#=%X7Y-D&^29!'@OP+P?Y;
MB5LQM]^2T%5/%9@VCHXE%0XZ#NK*NTSG`XMO\AE>%CUOX0\WK="6G-'YEXW]
M;Q`=>"GIS3XAG?\_BR&A<>%XY\]F&JG)<-A?/\CR2\L/4$L#!!0````(`.>,
M;$<.?DQ*HP$``+$#```9````>&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;&U3
MP6[C(!#]%<0'%-M)-]G(L=1TM6H/*U4]=,_$'MNHP'@!Q]V_+V#'=5M?@!GF
MO7DS#/F`YM6V`(Z\*:GMD;;.=0?&;-F"XO8&.]#^ID:CN/.F:9CM#/`J@I1D
M69+\8(H+38L\^IY,D6/OI-#P9(CME>+F_PDD#D>:TJOC632M"PY6Y&S&54*!
MM@(U,5`?Z5UZ.&U#1`QX$3#8Q9D$[6?$UV`\5D>:!`D@H72!@?OM`O<@92#R
MB?]-G!\I`W!YOK+_CM5Z]6=NX1[E7U&YUHM-**F@YKUTSS@\P%3";2`L4=JX
MDK*W#M450HGB;^,N=-R'\6:33K!U0#8!LAFP3Z+P,5&4^8L[7N0&!V+&UG8\
MO&!ZR'PCRN",=<<[+]1Z[Z5(=[N<70+1%',:8[)ES!S!//N<(EM+<<J^P;-U
M^&95X2;"-Y\4[M<)MJL$VTBP_43P\TN)*S'[Y$L2MNBI`M/$T;&DQ%['05UX
MY^F\R^*;?(07><<;^,--([0E9W3^96/_:T0'7DIR<TM)Z__/;$BH73CN_-F,
M(S4:#KOK!YE_:?$.4$L#!!0````(`.>,;$?)J=0(H0$``+$#```9````>&PO
M=V]R:W-H965T<R]S:&5E=#$Y+GAM;'53P6[D(`S]%<0'E(1)N]4H$ZG3JFH/
M*U4][)Z9Q$E0(4Z!3+I_OT`R:=K-7@`;O^=G8_(1S9MM`1SYT*JS!]HZU^\9
MLV4+6M@K[*'S-S4:+9PW3<-L;T!4$:05XTERP[20'2WRZ'LQ18Z#4[*#%T/L
MH+4P?XZ@<#S0E%X<K[)I77"P(F<+KI(:.BNQ(P;J`[U+]\<L1,2`7Q)&NSJ3
MH/V$^!:,Y^I`DR`!%)0N,`B_G>$>E`I$/O'[S/F9,@#7YPO[8ZS6JS\)"_>H
M?LO*M5YL0DD%M1B4>\7Q">82K@-AB<K&E92#=:@O$$JT^)AVV<5]G&YX-L.V
M`7P&\`5PFT3A4Z(H\T$X4>0&1V*FUO8BO&"ZY[X197#&NN.=%VJ]]URDMVG.
MSH%HCCE.,7P=LT0PS[ZDX%LICOP?.-^&[S85[B)\]T7A?PBR38(L$F1?"';?
M2MR*R;XE8:N>:C!-'!U+2ARZ.*@K[S*==SR^R6=XD?>B@9_"-+*SY(3.OVSL
M?XWHP$M)KJXI:?W_60P%M0O''_YLII&:#(?]Y8,LO[3X"U!+`P04````"`#G
MC&Q'_IB7KZ(!``"Q`P``&0```'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6QM
M4\%NXR`0_17$!Q2')&T4.9::KE:[AY6J'G;/Q![;J,!X`<?=OU_`CNNVO@`S
MS'OS9ACR`>VK:P$\>=/*N!-MO>^.C+FR!2W<'79@PDV-5@L?3-LPUUD050)I
MQ7B6W3,MI*%%GGS/MLBQ]TH:>+;$]5H+^^\,"H<3W=";XT4VK8\.5N1LQE52
M@W$2#;%0G^CCYGC>Q8@4\%O"X!9G$K5?$%^C\;,ZT2Q*``6ECPPB;%=X`J4B
M44C\=^)\3QF!R_.-_7NJ-JB_"`=/J/[(RK=!;$9)!;7HE7_!X0=,)>PC88G*
MI964O?.H;Q!*M'@;=VG2/HPW^VR"K0/X!.`SX)``;$R49'X37A2YQ8'8L;6=
MB"^X.?+0B#(Z4]WI+@AUP7LM-H=]SJZ1:(HYCS%\&3-'L,`^I^!K*<[\"YRO
MP[>K"K<)OOV@\'Z=8+=*L$L$NP\$#Y]*7(LY?$K"%CW58)LT.HZ4V)LTJ`OO
M/)V//+W)>WB1=Z*!7\(VTCAR01]>-O6_1O00I&1W>TK:\']F0T'MX_$AG.TX
M4J/AL;M]D/F7%O\!4$L#!!0````(`.>,;$?/6L'XH@$``+$#```9````>&PO
M=V]R:W-H965T<R]S:&5E=#(Q+GAM;&U3P6[<(!#]%<0'!)O=I,G*:RF;JFH/
ME:(<VC-KCVT48%S`Z_3O"]CK.*DOP`SSWKP9AF)$^^HZ`$_>M#+N2#OO^P-C
MKNI`"W>#/9APTZ#5P@?3MLSU%D2=0%HQGF5W3`MI:%DDW[,M"QR\D@:>+7&#
MUL+^/8'"\4AS>G6\R+;ST<'*@BVX6FHP3J(A%IHC?<P/IWV,2`&_)(QN=291
M^QGQ-1H_ZB/-H@104/G((,)V@2=0*A*%Q']FSO>4$;@^7]F_I6J#^K-P\(3J
MMZQ]%\1FE-30B$'Y%QR_PUS";22L4+FTDFIP'O450HD6;],N3=K'Z69W-\.V
M`7P&\`5PGR7A4Z(D\ZOPHBPLCL1.K>U%?,'\P$,CJNA,=:>[(-0%[Z7,[Q\*
M=HE$<\QIBN'KF"6"!?8E!=]*<>+_P?DV?+>I<)?@NW7VAVR;8+])L$\$^P\$
M^:<2MV(^JV2KGFJP;1H=1RH<3!K4E7>9SD>>WN0]O"QZT<)/85MI'#FC#R^;
M^M\@>@A2LIM;2KKP?Q9#0>/C\4LXVVFD)L-C?_T@RR\M_P%02P,$%`````@`
MYXQL1RGGZ"&B`0``L0,``!D```!X;"]W;W)K<VAE971S+W-H965T,C(N>&UL
M;5/!;N,@$/T5Y`\H#G&RNY%CJ>FJ:@\K53WLGHD]ME&!<0''[=\7L..Z75^`
M&>:]>3,,^8#FQ;8`CKPIJ>TQ:9WK#I3:L@7%[0UVH/U-C49QYTW34-L9X%4$
M*4E9FNZIXD(G11Y]3Z;(L7=2:'@RQ/9*<?-^`HG#,=DD5\>S:%H7'+3(Z8RK
MA`)M!6IBH#XFMYO#*0L1,>"O@,$NSB1H/R.^!..Q.B9ID``22A<8N-\N<`=2
M!B*?^'7B_$P9@,OSE?T^5NO5G[F%.Y3_1.5:+S9-2`4U[Z5[QN$!IA)V@;!$
M:>-*RMXZ5%=(0A1_&W>AXSZ,-[O]!%L'L`G`9L#/-`H?$T69O[GC16YP(&9L
M;<?#"VX.S#>B#,Y8=[SS0JWW7HK-KVU.+X%HBCF-,6P9,T=0SSZG8&LI3NP_
M.%N';U<5;B-\^T5AMDZ0K1)DD2#[0K#[5N):S/Y;$KKHJ0+3Q-&QI,1>QT%=
M>.?IO&7Q33[#B[SC#?SAIA':DC,Z_[*Q_S6B`R\EO=DEI/7_9S8DU"X<?_BS
M&4=J-!QVUP\R_]+B`U!+`P04````"`#GC&Q'!L1F.Z0!``"Q`P``&0```'AL
M+W=O<FMS:&5E=',O<VAE970R,RYX;6QM4\%NW"`0_17$!P0ONVDV*Z^E;**J
M/52*<FC/K#VV48!Q`:_3OR]@K^,DO@`SS'OS9ACR`>VK:P$\>=/*N"-MO>\.
MC+FR!2W<#79@PDV-5@L?3-LPUUD050)IQ7B6?6-:2$.+//F>;9%C[Y4T\&R)
MZ[46]M\)%`Y'NJ%7QXML6A\=K,C9C*ND!N,D&F*A/M*'S>&TBQ$IX+>$P2W.
M)&H_([Y&XV=UI%F4``I*'QE$V"[P"$I%HI#X[\3YGC("E^<K^_=4;5!_%@X>
M4?V1E6^#V(R2"FK1*_^"PP^82KB-A"4JEU92]LZCOD(HT>)MW*5)^S#>;/<3
M;!W`)P"?`?LL"1\3)9E/PHLBMS@0.[:V$_$%-P<>&E%&9ZH[W06A+G@OQ>;^
M+F>72#3%G,88OHR9(UA@GU/PM10G_@7.U^';587;!-]^4+A?)]BM$NP2P>X#
MP?VG$K_&A+']E(0M>JK!-FET'"FQ-VE0%]YY.A]X>I/W\"+O1`._A&VD<>2,
M/KQLZG^-Z"%(R6YN*6G#_YD-!;6/Q[MPMN-(C8;'[OI!YE]:_`=02P,$%```
M``@`YXQL1TX<WB.B`0``L0,``!D```!X;"]W;W)K<VAE971S+W-H965T,C0N
M>&UL=5/;;MP@$/T5Q`<$+^OTLO):RJ:JVH=*41[:9]8>VRC`N(#7Z=\7L-?K
MI.X+,,.<,V>&H1C1OK@.P)-7K8P[TL[[_L"8JSK0PMUA#R;<-&BU\,&T+7.]
M!5$GD%:,9]D'IH4TM"R2[\F6!0Y>20-/EKA!:V'_G$#A>*0[>G4\R[;ST<'*
M@BVX6FHP3J(A%IHC?=@=3GF,2`$_)8QN=291^QGQ)1K?ZR/-H@104/G((,)V
M@4=0*A*%Q+]GSEO*"%R?K^Q?4[5!_5DX>$3U2]:^"V(S2FIHQ*#\,X[?8"[A
M/A)6J%Q:234XC_H*H42+UVF7)NWC=,,_S[!M`)\!?`%\RI+P*5&2^45X4186
M1V*GUO8BON#NP$,CJNA,=:>[(-0%[Z7DV:Y@ET@TQYRF&+Z*N46PP+ZDX%LI
M3OP?.-^&[S<5[A-\_T;A?PCR38(\$>1O"/;O2MR*R=\E8:N>:K!M&AU'*AQ,
M&M25=YG.!Y[>Y!9>%KUHX8>PK32.G-&'ETW];Q`]!"G9W3TE7?@_BZ&@\?'X
M,9SM-%*3X;&_?I#EEY9_`5!+`P04````"`#GC&Q'/ZKD$Z,!``"Q`P``&0``
M`'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6QM4\%NW"`0_17$!P0ONYND*Z^E
M;*JH/52*<FC/K#VV48!Q`*_3OR]@K^.DO@`SS'OS9ACR`>VK:P$\>=?*N"-M
MO>\.C+FR!2W<#79@PDV-5@L?3-LPUUD050)IQ7B6W3(MI*%%GGS/MLBQ]TH:
M>+;$]5H+^_<$"H<CW="KXT4VK8\.5N1LQE52@W$2#;%0'^G#YG#:Q8@4\%O"
MX!9G$K6?$5^C\;,ZTBQ*``6ECPPB;!=X!*4B44C\-G%^I(S`Y?G*_I2J#>K/
MPL$CJC^R\FT0FU%202UZY5]P^`%3"?M(6*)R:25E[SSJ*X02+=['79JT#^,-
M_S;!U@%\`O`9<)\EX6.B)/.[\*+(+0[$CJWM1'S!S8&'1I31F>I.=T&H"]Y+
MP;-]SBZ1:(HYC3%\$;.9(UA@GU/PM10G_A^<K\.WJPJW";[]I/!VG6"W2K!+
M!+M/!'=?2ER+N?^2A"UZJL$V:70<*;$W:5`7WGDZ'WAZDX_P(N]$`[^$;:1Q
MY(P^O&SJ?XWH(4C);O:4M.'_S(:"VL?C73C;<:1&PV-W_2#S+RW^`5!+`P04
M````"`#GC&Q';13G^&<"``!2"0``&0```'AL+W=O<FMS:&5E=',O<VAE970R
M-BYX;6QU5MN.FS`0_17$!RR,N28B2,E65?M0:;4/[;-#G(`6,+6=9/OWM4W"
M(C.\X`MGSAD;SMC%G8L/63.FO,^N[>7.KY4:MD$@JYIU5+[P@?7ZS9F+CBH]
M%)=`#H+1DPWJVH"$81ITM.G]LK!S;Z(L^%6U3<_>A">O74?%OP-K^7WG@_^<
M>&\NM3(305D$4]RIZ5@O&]Y[@IUW_AZV!\@-Q")^-^PN9WW/)'_D_,,,?IYV
M?FAR8"VKE*&@NKFQ5]:VADDK_WV0?FF:P'G_R?[=+E>G?Z22O?+V3W-2M<XV
M]+T3.]-KJ][Y_0=[K"$QA!5OI7UZU54JWCU#?*^CGV/;]+:]CV^R]!&&!Y!'
M`)D"\M`F/@K9-+]11<M"\+LGQKT=J/F$L"5Z(RHS:==MW^E$I9Z]E23<%,'-
M$#TPAQ%#9AB8$(%FGR0()G$@BW""AT=HAI$-C^;J<883Q"A!;`GBN3Z$SA(Q
MS,HB$U0D61!`XHHL,016MB)%1=(E0>YH(!"(<(T,U<@0@M@1P3`)+I*C(OER
MM]+$$5EB"*2XR`85V2`$F2."87)<Q)@;,U"(4"P<A(!(N**S8E1`*,#5P4`K
MOQB@;MT#02@B5P<#Q2LZN*TA0BC<?P`%K?P$@+L?EM:&?+%OB/_)2I$!O```
MXNZ%.U'09D4'KP&`.#QR*PT*6JEG@-<!0$P>$5<'`ZV4&\!+`2`^C]R"@X+<
MBA/,SKR.B8L]VJ57\6MO;Q*SV>GZL"?VS/R"E\5`+^P7%9>FE]Z1*WWRVO/Q
MS+EB.I?P17_#6E]PID'+SLIT,]T7XY$_#A0?GC>8Z1I5_@=02P,$%`````@`
MYXQL1T[`BFNC`0``L0,``!D```!X;"]W;W)K<VAE971S+W-H965T,C<N>&UL
M;5/!;N,@$/T5Q`<4ASA-%3F6FE:KW<-*50_MF=AC&Q4\+N"X_?L"=EQOUQ=@
MAGEOW@Q#-J!YLPV`(Q]:M?9(&^>Z`V.V:$`+>X,=M/ZF0J.%\Z:IF>T,B#*"
MM&(\26Z9%K*E>19]3R;/L'=*MO!DB.VU%N;S!`J'(]W0J^-9UHT+#I9G;,:5
M4D-K);;$0'6D]YO#*0T1,>!%PF`79Q*TGQ'?@O&G/-(D2``%A0L,PF\7>`"E
M`I%/_#YQ?J<,P.7YROXK5NO5GX6%!U2OLG2-%YM04D(E>N6><?@-4PF[0%B@
MLG$E16\=ZBN$$BT^QEVV<1_&FUTZP=8!?`+P&7"71.%CHBCS43B19P8'8L;6
M=B*\X.;`?2.*X(QUQSLOU'KO)>?;VXQ=`M$4<QIC^")F,T<PSSZGX&LI3OP_
M.%^';U<5;B-\N\R>[M<)TE6"-!*D_Y2X_U'B6LS=CR1LT5,-IHZC8TF!?1L'
M=>&=I_.>QS?Y#L^S3M3P5YA:MI:<T?F7C?VO$!UX*<G-CI+&_Y_94%"Y<-S[
MLQE':C0<=M</,O_2_`M02P,$%`````@`YXQL1S,KG]&@`0``L0,``!D```!X
M;"]W;W)K<VAE971S+W-H965T,C@N>&UL=5/;CML@$/T5Q`<L#G%ZB1Q+FZVJ
M]J'2:A_:9V*/;;3`N(#C[=\7L..U4O<%F&'..3/#4(QH7UT'X,F;5L:=:.=]
M?V3,51UHX1ZP!Q-N&K1:^&#:EKG>@J@32"O&L^P#TT(:6A;)]VS+`@>OI(%G
M2]R@M;!_SJ!P/-$=O3E>9-OYZ&!EP19<+348)]$0"\V)/NZ.YSQ&I("?$D:W
M.I.8^P7Q-1K?ZQ/-8@J@H/*1083M"D^@5"0*PK]GSG?)"%R?;^Q?4[4A^XMP
M\(3JEZQ]%Y+-**FA$8/R+SA^@[F$0R2L4+FTDFIP'O4-0HD6;],N3=K'Z>93
M-L.V`7P&\#L`FX12FE^$%V5A<21V:FTOX@ONCCPTHHK.5'>Z"XFZX+V6?/^Y
M8-=(-,><IQB^BMDM$2RP+Q)\2^+,_X'S;?A^,\-]@N_7ZH?_Z.>;!'DBR-?Z
M>797XE;,O0A;]52#;=/H.%+A8-*@KKS+=#[R]";OX671BQ9^"-M*X\@%?7C9
MU/\&T4-()7LX4-*%_[,8"AH?CQ_#V4XC-1D>^]L'67YI^1=02P,$%`````@`
MYXQL1R2+#[RA`0``L0,``!D```!X;"]W;W)K<VAE971S+W-H965T,CDN>&UL
M;5/!;MP@$/T5Q`<$+^MMJY774C95U!XJ13FT9]8>VRC`.(#7Z=\7L-=Q4E^`
M&>:]>3,,Q8CVQ74`GKQI9=R)=M[W1\9<U8$6[@Y[,.&F0:N%#Z9MF>LMB#J!
MM&(\R[XP+:2A99%\3[8L</!*&GBRQ`U:"_OW#`K'$]W1F^-9MIV/#E86;,'5
M4H-Q$@VQT)SH_>YXSF-$"O@M872K,XG:+X@OT?A9GV@6)8""RD<&$;8K/(!2
MD2@D?ITYWU-&X/I\8W],U0;U%^'@`=4?6?LNB,THJ:$1@_+/./Z`N81#)*Q0
MN;22:G`>]0U"B19OTRY-VL?IAO,9M@W@,X`O@&]9$CXE2C*_"R_*PN)([-3:
M7L07W!UY:$05G:GN=!>$NN"]ECSG!;M&HCGF/,7P5<QNB6"!?4G!MU*<^7]P
MO@W?;RK<)_A^G?V0;Q/DFP1Y(L@_E+C_5.)6S.<D;-53#;9-H^-(A8-)@[KR
M+M-YGQZ1O8>712]:^"5L*XTC%_3A95/_&T0/04IV=Z"D"_]G,10T/AZ_AK.=
M1FHR//:W#[+\TO(?4$L#!!0````(`.>,;$=N!FEGHP$``+$#```9````>&PO
M=V]R:W-H965T<R]S:&5E=#,P+GAM;&U3P6[<(!#]%<0'!"_K3:*5UU(V5=4>
M*D4YM&?6'MLHP+B`U^G?%[#7<5-?@!GFO7DS#,6(]LUU`)Z\:V7<B7;>]T?&
M7-6!%NX.>S#AID&KA0^F;9GK+8@Z@;1B/,ONF1;2T+)(OA=;%CAX)0V\6.(&
MK87]<P:%XXGNZ,WQ*MO.1P<K"[;@:JG!.(F&6&A.]&EW/.<Q(@7\E#"ZU9E$
M[1?$MVA\KT\TBQ)`0>4C@PC;%9Y!J4@4$O^>.3]21N#Z?&/_FJH-ZB_"P3.J
M7[+V71";45)#(P;E7W'\!G,)ATA8H7)I)=7@/.H;A!(MWJ==FK2/T\V>S[!M
M`)\!?`$\9DGXE"C)_"*\*`N+([%3:WL17W!WY*$1572FNM-=$.J"]UKR_%"P
M:R2:8\Y3#%_%[)8(%MB7%'PKQ9G_!^?;\/VFPGV"[]?9#X_;!/DF09X(\G]*
MO/]4XE;,PZ<D;-53#;9-H^-(A8-)@[KR+M/YE!Z1?82712]:^"%L*XTC%_3A
M95/_&T0/04IV=Z"D"_]G,10T/AX?PME.(S49'OO;!UE^:?D74$L#!!0````(
M`.>,;$?C74THI0$``+$#```9````>&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM
M;'53P6[<(!#]%>0/"%[6NTU77DO95%5[J!3ED)Y9>VRC`.,"7J=_'\!>QTF<
M"S##O#=OAB$?T#S;%L"1%R6U/2:M<]V!4ENVH+B]P0ZTOZG1*.Z\:1IJ.P.\
MBB`E*4O3/55<Z*3(H^_!%#GV3@H-#X;87BEN_I]`XG!,-LG5\2B:U@4'+7(Z
MXRJA0%N!FABHC\G=YG#*0D0,>!(PV,69!.UGQ.=@_*Z.21HD@(32!0;NMPO<
M@Y2!R"?^-W&^I0S`Y?G*_C-6Z]6?N85[E']%Y5HO-DU(!37OI7O$X1=,)>P"
M88G2QI64O76HKI"$*/XR[D+'?1AOLOT$6P>P"<!FP&T:A8^)HLP?W/$B-S@0
M,[:VX^$%-P?F&U$&9ZP[WGFAUGLO!<MN<WH)1%/,:8QABYC-'$$]^YR"K:4X
ML4]PM@[?KBK<1OAVF7W_!4&V2I!%@NQ=B=\_E+@2LTL_)*&+GBHP31P=2TKL
M=1S4A7>>SCL6W^0MO,@[WL`?;AJA+3FC\R\;^U\C.O!2TIM=0EK_?V9#0NW"
M\9L_FW&D1L-A=_T@\R\M7@%02P,$%`````@`YXQL1^_6G;6B`0``L0,``!D`
M``!X;"]W;W)K<VAE971S+W-H965T,S(N>&UL;5/!;N,@$/T5Y`\H#G&RJ\BQ
MU+2JVD.EJH?=,[''-BHP+N"X^_<+V'&\75^`&>:]>3,,^8#FP[8`CGPIJ>TQ
M:9WK#I3:L@7%[1UVH/U-C49QYTW34-L9X%4$*4E9FNZIXD(G11Y];Z;(L7=2
M:'@SQ/9*<?/G!!*'8[))KHYWT;0N.&B1TQE7"07:"M3$0'U,[C>'4Q8B8L`O
M`8-=G$G0?D;\",9+=4S2(`$DE"XP<+]=X`&D#$0^\>?$>4L9@,OSE?TI5NO5
MG[F%!Y2_1>5:+S9-2`4U[Z5[Q^$9IA)V@;!$:>-*RMXZ5%=(0A3_&G>AXSZ,
M-QF;8.L`-@'8#/B91N%CHBCSD3M>Y`8'8L;6=CR\X.;`?"/*X(QUQSLOU'KO
MI6"[34XO@6B*.8TQ;!%SBZ">?4[!UE*<V']PM@[?KBK<1OAVF7V_7R?(5@FR
M2)#]4R+[5N):S/9;$KKHJ0+3Q-&QI,1>QT%=>.?IO(^/2&_A1=[Q!EZY:82V
MY(S.OVSL?XWHP$M)[W8):?W_F0T)M0O''_YLQI$:#8?=]8/,O[3X"U!+`P04
M````"`#GC&Q'0+6:S:(!``"Q`P``&0```'AL+W=O<FMS:&5E=',O<VAE970S
M,RYX;6QM4\%NY"`,_164#R@9)FFK4292I]5J][!2U</NF4F<!!5P%LBD^_<%
MDDG3-A?`QN_YV9AB1/-J.P!'WI34]IATSO4'2FW5@>+V!GO0_J9!H[CSIFFI
M[0WP.H*4I"Q-;ZGB0B=E$7W/IBQP<%)H>#;$#DIQ\_\$$L=CLDNNCA?1=BXX
M:%G0!5<+!=H*U,1`<TP>=H=3%B)BP!\!HUV=2=!^1GP-QJ_ZF*1!`DBH7&#@
M?KO`(T@9B'SB?S/G1\H`7)^O[#]BM5[]F5MX1/E7U*[S8M.$U-#P0;H7''_"
M7$(>""N4-JZD&JQ#=84D1/&W:1<Z[N-TDZ<S;!O`9@!;`/<10*=$4>83=[PL
M#([$3*WM>7C!W8'Y1E3!&>N.=UZH]=Y+R?*LH)=`-,><IABVBMDM$=2S+RG8
M5HH3^P9GV_#]IL)]A._7V>_2;8)LDR"+!-FG$O,O)6[%W'Y)0E<]56#:.#J6
M5#CH.*@K[S*=#RR^R4=X6?2\A=_<M$);<D;G7S;VOT%TX*6D-WE".O]_%D-"
MX\+QSI_--%*3X;"_?I#EEY;O4$L#!!0````(`.>,;$<N/:X5I`$``+$#```9
M````>&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;&U3P7+;(!#]%48?$&0LUZY'
MUDR<3B<Y=":30WK&TDIB`JP*R$K_/H!D14UU`7;9]_;MLN0#FC?;`CCRKJ2V
MIZ1UKCM2:LL6%+=WV('V-S4:Q9TW34-M9X!7$:0D96GZC2HN=%+DT?=LBAQ[
M)X6&9T-LKQ0W?\\@<3@EF^3F>!%-ZX*#%CF=<950H*U`30S4I^1^<SQG(2(&
MO`H8[.),@O8+XELPGJI3D@8)(*%T@8'[[0H/(&4@\HG_3)R?*0-P>;ZQ_XS5
M>O47;N$!Y6]1N=:+31-20<U[Z5YP>(2IA%T@+%':N)*RMP[5#9(0Q=_'7>BX
M#^/-[C#!U@%L`K`9<$BC\#%1E/F#.U[D!@=BQM9V/+S@YLA\(\K@C'7'.R_4
M>N^U8+M]3J^!:(HYCS%L$;.9(ZAGGU.PM11G]A^<K<.WJPJW$;Y=9M]GZP39
M*D$6";)_2CQ\*7$MYON7)'314P6FB:-C28F]CH.Z\,[3><_BFWR&%WG'&_C%
M32.T)1=T_F5C_VM$!UY*>K=+2.O_SVQ(J%TX[OW9C",U&@Z[VP>9?VGQ`5!+
M`P04````"`#GC&Q'T'YRBZ(!``"Q`P``&0```'AL+W=O<FMS:&5E=',O<VAE
M970S-2YX;6QM4]MNW"`0_17$!P2;W5RT\EK*)JK:ATI1'MIGUA[;*,`X@-?I
MWQ>PUW%3OP`SS#ES9AB*$>V;ZP`\^=#*N"/MO.\/C+FJ`RW<#?9@PDV#5@L?
M3-LRUUL0=0)IQ7B6W3$MI*%ED7POMBQP\$H:>+'$#5H+^^<$"L<CS>G5\2K;
MSD<'*PNVX&JIP3B)AEAHCO0Q/YSV,2(%_)(PNM691.UGQ+=H_*B/-(L20$'E
M(X,(VP6>0*E(%!*_SYR?*2-P?;ZR?TO5!O5GX>`)U6]9^RZ(S2BIH1&#\J\X
M?H>YA-M(6*%R:275X#SJ*X02+3ZF79JTC]/-CL^P;0"?`7P!/&1)^)0HR7P6
M7I2%Q9'8J;6]B"^8'WAH1!6=J>YT%X2ZX+V4_"XKV"42S3&G*8:O8O(E@@7V
M)07?2G'B_\'Y-GRWJ7"7X+MU]ON';8+])L$^$>S_*3'_4N)6S%>5;-53#;9-
MH^-(A8-)@[KR+M/YF!Z1?8:712]:^"EL*XTC9_3A95/_&T0/04IV<TM)%_[/
M8BAH?#S>A[.=1FHR//;7#[+\TO(O4$L#!!0````(`.>,;$?_=<`FKP$``!8$
M```9````>&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;&U4W9*;(!1^%<8'6`R:
M;)LQSFRVTVDO.K.S%^TUT:,R"QX+&+=O7T#CVI2;`(?O[PBDF%"_F0[`DG<E
M>W-*.FN'(Z6FZD!Q\X`#]&ZG0:VX=4O=4C-HX'4@*4E9FAZHXJ)/RB+47G19
MX&BEZ.%%$S,JQ?6?,TB<3LDNN15>1=M97Z!E05=>+13T1F!/-#2GY&EW/.\]
M(@!^"IC,9DY\]@OBFU]\KT])ZB.`A,IZ!>Z&*SR#E%[(&?]>-#\L/7$[OZE_
M#=VZ]!=NX!GE+U';SH5-$U)#PT=I7W'Z!DL+(6&%TH1?4HW&HKI1$J+X^SR*
M/HS3O'/(%EJ<P!8"6PF?TA!\-@HQOW#+RT+C1/3\:0?N3W!W9.Y#5+X8^@Y[
M+JAQU6O)#EE!KUYHP9QG#-M@=BN".O75@L4LSNP_.HO3LVC"+-"SK?OG/"Z0
M1P7R()#_TV)^UV(,LX^;[*,F^XC`X<XDAGF\,Z&;@U.@VW`_#:EP[,-KV%37
M)_#$PL%_P,MBX"W\X+H5O2$7M.[ZA$-N$"VX*.F#R]*Y1[HN)#363Q_=7,_W
M=EY8'&ZO</TK*/\"4$L#!!0````(`.>,;$>-(\D4<`(```@(```9````>&PO
M=V]R:W-H965T<R]S:&5E=#,W+GAM;(U5VXZ;,!#]%<0'++Y@(!%!VERJ]J'2
M:A_:9X<X"5K`J>ULMG]?VQ!"C#?;EV`/Y\R<,PZ>_,+%FSPRIH*/IF[E(CPJ
M=9I'D2R/K*'RB9]8J]_LN6BHTEMQB.1),+JSI*:.$`!)U-"J#8O<QEY$D?.S
MJJN6O8A`GIN&BK]+5O/+(H3A-?!:'8[*!*(BCP;>KFI8*RO>!H+M%^$SG&]2
M@["`7Q6[R-$Z,-JWG+^9S8_=(@1&`JM9J4P&JA_O;,7JVB32A?_T.6\E#7&\
MOF;_9MUJ]5LJV8K7OZN=.FJQ(`QV;$_/M7KEE^^LMT!,PI+7TOX&Y5DJWEPI
M8=#0C^Y9M?9YZ=YDH*?Y":@GH($PU/$3<$_`-T+\D!#WA/A_*Y">0)P*4>?=
M=FY-%2URP2^!Z$[[1,V?"LZ)/IO2!.U1V'>Z=U)'WPN49'GT;A+UF&6'02-,
M@NXAZRD$#HA("QA4()^*)9K0G0*K*2+!CH8ODVP>)KF3B;W-PI:/QQ4P\">(
MO0EBFR"^Z_;,Z7:'(1;36@P&!,&4.!WQX5`*<.RTQ8?#&830:8XW7S*;?6*0
M>`V2J<$4.`;)I!#$"4P=W:LI+,W2F?/?7'N2H9@`IZF;*>P36XG75N*QY?1O
MF4S[![,,QXZ4E0\'2(;=3\J'2U""G'9N/+A'YY9Z#:8>@XZ@9?J@AYVU*2(C
M`#BH]12%)Z#-%(0(',,Z4]'HGFN8.-@)(X.2GUMEOM11=!ABS\C<DTY\"><K
MZ(FO]=#K9M0M?9&?Z(']I.)0M3+8<J5O9WN'[CE73*L'3UKX48_E85.SO3++
M5*]%-ZFZC>*GZ]P=AG_Q#U!+`P04````"`#GC&Q'7N586D4#``#E#@``&0``
M`'AL+W=O<FMS:&5E=',O<VAE970S."YX;6R55U%SHC`0_BL,/Z"0!1)PU)FJ
M9^\>;J;3A^LSU:A,@7@0:^_?7P*(FBRM^B`0OF_WVTUV2<9'4;W7.\ZE\UGD
M93UQ=U+N1YY7KW:\2.L'L>>E>K,159%*]5AMO7I?\73=D(K<`]^G7I%FI3L=
M-V//U70L#C+/2OY<.?6A*-+JWXSGXCAQB7L:>,FV.ZD'O.G8ZWGKK.!EG8G2
MJ?AFXCZ2T1,P#6D0?S)^K"_N'2W^38AW_?!K/7%]K8'G?"6UB51=/OB<Y[FV
MI#S_[8R>?6KBY?W)^K()5\E_2VL^%_EKMI8[I=9WG37?I(=<OHCC3][%$&F#
M*Y'7S;^S.M12%">*ZQ3I9WO-RN9Z;-\PTM%P`G0$Z`F]'YP0=(3@3`B_)(0=
M(3P3Z)>$J"-$MQ)H1Z"W2F(=@1D$K\UN,S>+5*;3<26.3M4NJ'VJURT9,37[
M*SW83';S3LU.K48_IL""L?>A#76868N!"PR%:\C"AI`>X2D!O0K`5,S`HAL.
MYC:"&C(7WQKY\;V1)6*$A=>8)P03X-$&:,Z#AA]<^8AP`R%J(&P,A%<&J)$-
M#,.,?'R-N1(2H4(BRP#QB;%Z6@QK,&67]-"<7AL4)F;>%S:(L!@B(R@;!0!T
M(+\4#8LB>8F-L%I,=.F&1:$A9DYMR5$<FH'9MAA$06($9ML*(2$#@3$T,(8$
M9KB9,3NPR%<_0_.WL"LY,2HGMN7$II_8\A.H1!NBE[$]Z32,$UQ,@HI)$#'F
M6D[LZ4QHS&*CL!8WXIYL7$0I#09J4']3L1;N(\IAP,3`5X#<WI((VL(?"2`J
MS!:-@L(!/WCS)`%B8D@JWCY)>$>T>.,C=N=#HL5`=,`/WHD(THKBH>6!USQA
M=T2+URG!"M6*%@/%`W[P$B18#0X4,>#%`/[MT0)>#$!NB!8%#<PMX!4#2#$D
M`_T3\&*`.[82@!<#()L`.UH$E`SM\/"*`:08DH$N!7@Q`+TC6KP8`/D"VM%B
M(',E>Q<[[()7V^;T5#LK<2BEUG@QVI_0'D'OT(WQ&1G-"3*^(*-E>_XZFY^.
M]^F6_TZK;5;6SIN0ZES0[-XW0DBNM/L/*LT[=>;L'W*^D?J6J?NJ/86U#U+L
M3X?*_F0[_0]02P,$%`````@`YXQL1\O=]4;%`@``P0D``!D```!X;"]W;W)K
M<VAE971S+W-H965T,SDN>&ULC59+<YLP&/PK#/<$/7C)@YD)3CKMH3.9')JS
M8LLV$T`NDN/TWU<2F&!)='KA(7:_7:W0H[CP_ET<&9/!9]MT8AT>I3RMHDAL
MCZREXIZ?6*>^['G?4JE>^T,D3CVC.T-JFP@!D$8MK;NP+$S;<U\6_"R;NF//
M?2#.;4O[/Q5K^&4=PO#:\%(?CE(W1&413;Q=W;).U+P+>K9?AP]P]02QAAC$
MKYI=Q.PYT.;?.'_7+S]VZQ!H#ZQA6ZE+4'7[8!O6-+J24OX]%OW2U,3Y\[7Z
M-]-=9?^-"K;AS6N]DT?E%H3!CNWIN9$O_/*=C7U(=,$M;X2Y!MNSD+R]4L*@
MI9_#O>[,_3)\R<%(\Q/02$`38=+Q$_!(P%^$^)^$>"3$_TM(1D)B$:*A[R:Y
M1RII6?3\$O3#<)^H_JO@*E%CL]6-9BC,-Y6=4*T?)2*XB#YTH1%3#1@TP\`)
M$:GJDP3R253(H:-;@8V+2"T/CYXB%N3)`R&QWRCV9H%-`7Q3(/$7B+T%8E,@
MGA=(K"P'2&8@W0")4P+RS(K$Q4&8I@A"*Q<7ER<`H-S*QB.+,H#SA>XEWNXE
M;O=2JWL#))GIX$PM2@!8MET<BG,RQ]WX2;U^4M</L0VECE`*<S?O1Q>',2;S
M(&\,95Y#F<>0)51ECE"<9VY`'AA)%_/)O79RQPZQ9*K<C2?-4C>>W/E_<(Z3
MQ7B(UP_QQ&/]J!5Q#,$4$I`0:WX0Q]`=A""&V<*,U[N%;_D#'D_$7O^`:PIA
MN#@:<&&IA8X6ML>]&D$W,T//Z%D`MUK>-?<!(H\6M+60HW6W/`>A?]&$V*.$
M;"7LKC]Y#-U>1;-]JV7]P9P81+#EYT[JM7W6.IU*'I#>]ZSV"JXVP]GBJTQ9
MG.B!_:3]H>Y$\,:EVE7-WK?G7#+E$]RK+([J/#6]-&PO]6.FGOOAA#&\2'ZZ
M'IBF4UOY%U!+`P04````"`#GC&Q'`NA2[7T"```6"```&0```'AL+W=O<FMS
M:&5E=',O<VAE970T,"YX;6Q]5DV/VC`0_2M1[KOQ9SY0B+2`JO90:;6']FS`
M0+1)3&VS;/]];2>$K&-Z(?;DO7G/,]&8\BKDNSIQKJ//MNG4,CYI?5XDB=J=
M>,O4LSCSSKPY"-DR;;;RF*BSY&SO2&V3(`#2I&5U%U>EB[W*JA07W=0=?Y61
MNK0MDW]7O!'790SC6^"M/IZT#215F8R\?=WR3M6BBR0_+.,7N-A`!W&(7S6_
MJLDZLN:W0KS;S8_],@;6`V_X3ML4S#P^^)HWC<UDE/\,2>^:ECA=W[)_<\<U
M]K=,\;5H?M=[?3)N01SM^8%=&OTFKM_Y<`9J$^Y$H]QOM+LH+=H;)8Y:]MD_
MZ\X]K_T;"@=:F(`&`AH)HTZ8@`<"OA/(?PED(!"/D/1'<878,,VJ4HIK)/ON
MG9G]2.""F%+O;-!5UKTSI5`F^E%A@,ODPR8:,*L>@R88."(2DWV40"&)%9K1
MT5>!]1R1>AXV@20X;`('SXD='T_YY$$"$DQ`7`+RI5#$*U2/R1RFZS$XHSCW
MSA*`@900$K9#@W9HP`[U[/08.M$A:0YHX=F9PS"E&:%A.VG03AJPDWIVTID.
MS7.2>6[F*)1CFJ9A-UG0339S4P#/3#:3R6T+O(YNLEFK"D(S^J`V>=!-'JB-
M=^I5/N\!!,6#+Z((RA0!&>_+6Q4S&0@1A@]T[,`,C0P04"K\F0%F4D\(D0P6
M#[0>C"<XUX)^+P?0M$M/.<00>F,FA(-I!E+D>4HFT[/E\NBN(17MQ*73=@A-
MHN-5]X+L]/7B*[A8]Q?6/4U5GMF1_V3R6'<JV@IM9KN;P`<A-#<^P;.IVLE<
MTN.FX0=MEYE9R_[:ZC=:G&^W\/A7H/H'4$L#!!0````(`.>,;$>,W\J*H@(`
M`!()```9````>&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;'U6P8Z;,!#]%<1]
M%VR,P1%!6A)5[:'2:@_MF4V<!"W@%#N;[=_7-H00,_02;//>O#>#XW%V%=V'
M/'&NO*^F;N7:/REU7@6!W)UX4\IG<>:M?G,075,J/>V.@3QWO-Q;4E,'.`QI
MT)15Z^>977OM\DQ<5%VU_+7SY*5IRNYOP6MQ7?O(ORV\5<>3,@M!G@4C;U\U
MO)65:+V.'];^"UIM460@%O&KXE<Y&7O&_+L0'V;R8[_V0^.!UWRG3(A2/S[Y
MAM>UB:25_PQ![YJ&.!W?HG^SZ6K[[Z7D&U'_KO;JI-V&OK?GA_)2JS=Q_<Z'
M'&(3<"=J:7^]W44JT=PHOM>47_VS:NWSVK^A;*#!!#P0\$@8=6!"-!"B.X'\
MET`&`G$(09^*+<2V5&6>=>+J=?W7.Y=FDZ`5T:7>F45;6?M.ET+JU<\\0B@+
M/DV@`5/T&#S!W!&!CCY*8$BBP#,Z?A38S!$T>H1L@2`1;"("\XPL/YKR"84#
M$#``L0'(0Z&</(H>DUA,:S%)&L4D<7*9PU`8$L9"V$\,^HD!/T[1BAX33X2>
M$&5QZO@!88@1V`X%[5#`#G'LT)E.0FF<,L?.',;2-&$+7RL![22`G=BQD\QT
M,*;806WG*$3)DID4-)/.S&!G2Q3IO#0IPVX%MRFT<V+,,&R'@7884!OJ^&'S
M+8&U';+PGS-'*W2XA("4F_H`>M!*Z,+F0PNG&`*$4E<(04EA'"8+6N!Q]H(P
MH,5<+3S3H@BS!2'XR$+17`B'KE`TVQ)/&-$P<;+?0$":I+-#,)ATCH9W1]N"
MI;<3EU:9`WBR.K;Y%VPZC[->H-6F;];W,'EV+H_\9]D=JU9Z[T+IOF:[ST$(
MQ;7-\%F7[*0O*..DY@=EAHD>=WW+[B=*G&\WD/$:E/\#4$L#!!0````(`.>,
M;$=0R`T@_`(``&0+```9````>&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;(U6
MP8Z;,!#]%<1]%\;&!E8$:4-5M8=*JSVT9S9Q$K2`4W`VV[^O,20A]J#V$L"\
MF?=F;%XF.\ONO3\(H;S/IF[[E7]0ZO@4!/WF()JR?Y1'T>HW.]DUI=*/W3[H
MCYTHMR:HJ0,2ACQHRJKU\\RLO71Y)D^JKEKQTGG]J6G*[L]:U/*\\L&_++Q6
M^X,:%H(\"ZYQVZH1;5_)UNO$;N4_PU,!Z0`QB)^5./>S>V\0_R;E^_#P?;OR
MPT&#J,5&#2E*??D0A:CK(9-F_CTEO7$.@?/[2_:OIEPM_ZWL12'K7]56';3:
MT/>V8E>>:O4JS]_$5`,;$FYDW9M?;W/JE6PN(;[7E)_CM6K-]3R^X<D4A@>0
M*8!<`ZX\>`"=`N@M(#*5CLI,75]*5>99)\]>-V[&L1SV')ZH[MQF6#2-,N]T
M9;U>_<@I@2SX&!)-F/6((3/,#1'H[%<*@E&LB1-.[@D*!$%Q!HH604T\G0OD
M!$\0H0DBDR":"TBM)HR0V$#:26/$26*5XL*`4H`45\-0-<Q10XG5LO6(83.>
M*$RIM7.%BP)&DA`7PU$Q'!%#+3'<H2$Q8\QJ8>'"($IHNM";&)43NSLUJV>4
M$SL\+"61O5,NBO`H61"3H&(2I#>1)29Q:!X@8<QJ88'!>!0OR$E1.>E_G)O4
MX4E28C6P^`?H3LI@DIBOA(@89AM+Z)[BE(,%*Q`8)"E=$K1@=.`(2NV#,V'F
M1%HTQ)$M"-ROG,>4+.P6H+[X#`1I$;<E$;?V$%BX1(4;)%"$*K:IJ/M%,,X6
MO!YP)P772JEMDNL)=%<4B8$O[2ANDX#YI&W;X%J@KIPMM0_W0$!,D#J'Q[6W
M!Q+.SLX]$VYOX/H;LE&N=2UU#O<M0(S+_N]8@VM)-.0)6V#"+0D03Z*V)TV@
MN\^)Q4ED4P6SH:81W=X,>[VWD:?6S):SU>M`^4S,4'2#Y]FQW(L?9;>OVMY[
MDTJ/5F8`VDFIA)83/NJ2#WKDO3[48J>&VUC?=^,0.#XH>;S,M-?!.O\+4$L#
M!!0````(`.>,;$?LH5/KCP,``&T/```9````>&PO=V]R:W-H965T<R]S:&5E
M=#0S+GAM;)5738^;,!#]*RCW%GO\`5YE(S6)JO90J>JA/;.)DZ`"3H%LVG]?
M&U@VL<=5-X<`YLW,F['?&"^OIOW9G;3ND]]UU72/BU/?GQ_2M-N==%UT[\U9
M-_;-P;1UT=O']IAVYU87^\&HKE(@1*9U43:+U7(8^]JNEN;25V6CO[9)=ZGK
MHOVSUI6Y/B[HXF7@6WD\]6X@72W3V6Y?UKKI2M,DK3X\+C[0ART;(`/B>ZFO
MW<U]XL@_&?/3/7S>/RZ(XZ`KO>N=B\)>GO5&5Y7S9"/_FIR^QG2&M_<OWC\.
MZ5KZ3T6G-Z;Z4>[[DV5+%LE>'XI+U7\SUT]ZRD$XASM3=<-_LKMTO:E?3!9)
M7?P>KV4S7*_C&Y%-9K@!3`8P&^3DGP9L,F"SP4P,-^"3`7\UX$-IQE2&0FR+
MOE@M6W--VG'VSH5;)/2!VU+OW.!0V>&=+45G1Y]7C+%E^NP<39C-B($;#)T1
MJ?4^AP`LQ`8"<[@/L$40#(_`T"388,_NDN"X`XXZX(,#?N=`>%48,=F`:4:,
M)"`5\9)!<`*`2X$3$B@A@1"2'J$1(VX"<9&I7/C5#7&@I,I59!(E2D@BA#*/
MD`P"":F$]&#;$,8S(DF&T\E0.AE")[^/L\8PRJ.<!5PRED/NES"$4;"<,\`Y
MYRCG/.3#O<6SR4,^D!._@B%*$/O#R2B4C$+(4(^,"L+8V614>87>ACA;0B99
M9,6[/HQU(H)0`K\5D2#6.V[7CLBY1PI%<BY4GD=H11HD16@%'9*&:UH)(6G`
MBH;=(6>9Y)'53]&6^H$"0HK[I`!;M6X*(['PYDH9$LMOCA/HKMI44J%D)!;>
MARG2B+G?]R;075Z49DK&:HBW6(KTV.@TX$V1RO_?>"C>R"C2I<*9#/M/3@!B
M^L+;#\7Z3TP+>-.@ZO_S!5SE@*G<SQ="[5))E)*Q[PY<NH!)5T5<X$(#>$/&
MN'X`TT^0<:@?NT/+2$L'7#V`J$?$7."B`/&&?'%1`/*IX.>[QD#!Y@SAE\([
MP8"I6$ZXQ`"1F(BM)%P[D+^A++AV`-MQ@V6@@NT![O;_^X]A7&)N>#(/37"E
M,$0I_G2L,9#POX#2FX-'K=OC<(+KDIVY-+TKX,WH?$I<@SNX^..,/&P80=Y8
M(O;->`Y\#;%:GHNC_E*TQ[+IDB?3VR/3<+`Y&--KRY^\MPOI9,^^\T.E#[V[
MS>Q].YX&QX?>G%\.M_,)>_474$L#!!0````(`.>,;$?[G[K-V`(``'0*```9
M````>&PO=V]R:W-H965T<R]S:&5E=#0T+GAM;'5637.;,!#]*PSW!%:?D+$]
M$]SIM(?.9')HS\26;2:`7,!Q^N\K!,9$6BY&$F_WO97$\ZZNNGEO3TIUP6=5
MUNTZ/'7=^2F*VMU)57G[J,^J-F\.NJGRSDR;8]2>&Y7O;5!51B2.153E11UN
M5G;MI=FL]*4KBUJ]-$%[J:J\^9>I4E_7(82WA=?B>.KZA6BSBJ:X?5&INBUT
M'33JL`Z?X6D+LH=8Q.]"7=O9..C%OVG]WD]^[M=AW&M0I=IU?8K</#[45I5E
MG\DP_QV3WCG[P/GXEOV[+=?(?\M;M=7EGV+?G8S:.`SVZI!?RNY57W^HL0;>
M)]SILK6_P>[2=KJZA81!E7\.SZ*VS^OP1L`8A@>0,8!,`1,/'D#'`'H/8+;2
M09FMZUO>Y9M5HZ]!,QS&.>_/')ZHV;E=OV@WRKXSE;5F]6-#.5U%'WVB$9,-
M&#+#P(2(3/:)@F`4&?'"R5>"+8*@.`-%BZ`VGLX%RAA/P-`$S"9@7W:!.;LP
M8*3%U`-&IH([I?@HPH$F"^5P5`U'U#@\V8#A,QZ0"6?NSOHP$K,$%C9'H'($
M(D<X<H0OAS(F'-@6@3$.4N!R)"I'(G*D(T=Z/")A)''4^"B@D#*.JTE0-0FB
MQN')$H^'<R;<H_)1C!"^<%(I*B9%Q*2.F-2CD1`+Y[)O$90`6+C%O4]BUA)[
M<M+8M9;8WQO&4^(<Z';$S;^KA(.0<D'1@MF!OT'"DP2>I`=B;C,D"URHZST#
M0;C`Y2((ER!BB0JW/Z`(%7&IJ$\%L5RR`L"-$A"G%-[_!?.I!#7?^0(5[H*`
MV*![3S-`?)`2(`M,N,$!XG"NL6?@>]<#CUFZP(1[%R#FY9ID-H+F=_V!QEQZ
M7A#-_N0KU1QM\],&.WVI;:\U6YT:K&=BFX0[?+,ZYT?U*V^.1=T&;[HSK89M
M"`Y:=\KHB1]-S2?3`DZ34AVZ?BC-N!F:HF'2Z?.MQYL:S<U_4$L#!!0````(
M`.>,;$?EF+;:\`(``(D,```9````>&PO=V]R:W-H965T<R]S:&5E=#0U+GAM
M;(V7S8Z;,!"`7P7Q`,4>\^=5$JF[5=4>*JWVT)Z]B9.@!9R"L]F^?6T@*=CC
M*CD$,./YQN`/S.JBNK?^**6./IJZ[=?Q4>O30Y+TVZ-L1/])G61KSNQ5UPAM
M#KM#TI\Z*79#IZ9.@)`\:435QIO5T/;<;5;JK.NJE<]=U)^;1G1_'F6M+NN8
MQM>&E^IPU+8AV:R26[]=U<BVKU0;=7*_CC_3AT<H;,@0\;.2EWZV']GB7Y5Z
MLP??=^N8V!ID+;?:IA!F\RZ?9%W;3(;\>TKZCVD[SO>OV;\.PS7EOXI>/JGZ
M5[731U,MB:.=W(MSK5_4Y9N<QI#9A%M5]\-_M#WW6C77+G'4B(]Q6[7#]C*>
M8>74#>\`4P>X=8"Q\!$TE/E%:+%9=>H2=>.U/0E["^D#F`NQM8W#N(=SIM#>
MM+YO6%ZLDG>;:(IY'&-@$5/>8A*3_P8!%`)#`K9(P/$$#$W`A@3I/$%!G"K'
MF&*(:<<8EM(4QZ0H)D4PU,&,,=D,0UE6I@3G9"@G0SC@<#*?DS*6!\:3HYP<
MX3"'D_N<C/!9V()3H)P"X:0.IT`X)2<9SBE13HEP,H=3>AS(336S2;T`<13$
M/1!WIQOW.`PRSO/`A;./!DP_@@PI#Z0(&$SOMXOB?E*XPZ\I:#DC21H:+RXR
MQ4QV%9N"YJ2L8&5@ZE/<98K)[$I&?9MS2K+0#<!MIIC.KF;4]SE/R^"MQGVF
MF-"N:-0W.C>B!1[8%#>:8DJ[JE'?Z92;N1<:%"XU]:WV9*.^U<7_9,.MIK[6
MK`@\%P#W%<C]L@'N*]`[9)N"%K+QN2E+4N"UBVGMR@:^UD69AA0`7&O`M'9E
M`U_K$EAH8@*N-6!:N[*!KW69FY=:@(1K#9C6KFS@:UUR'B3A6@.FM2L;^%J#
M61$4P3F!BPV^V)YM4\Q\*049L3\'E<Q6F2=QD#]$=ZC:/GI5VBQ8AV7E7BDM
M35+RR51^--\%MX-:[K7=+<Q^-ZZ4QP.M3M>%_^WK8_,74$L#!!0````(`.>,
M;$?[C?:NS@,``&@2```9````>&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;)58
MR7*C2!#]%4+W:6IE4<B*,+:EF<-$=/2A^XRETA+-H@9D]?S]L)D660]9]L&"
MXF6^S*I\"56+2U[\+`_&5,[O-,G*A]FAJDYSURTW!Y/&Y9?\9++ZR2XOTKBJ
M;XN]6YX*$V];HS1Q!6.>F\;';+9<M&-?B^4B/U?),3-?"Z<\IVE<_!>9)+\\
MS/CL?>#;<7^HF@%WN7`'N^TQ-5EYS#.G,+N'V2.?KZ5J("WB^]%<RJMKIPG^
M-<]_-C?_;!]FK(G!)&93-2[B^N?-/)DD:3S5S+]ZIW\X&\/KZW?OJS;=.OS7
MN#1/>?+CN*T.=;1LYFS-+CXGU;?\\K?I<]"-PTV>E.U_9W,NJSQ]-YDY:?R[
M^SUF[>^E>^*SW@P;B-Y`#`;*NVD@>P,Y&'!UTT#U!NI>`]T;Z'M#\GH#;S`(
M;B?M]P8^"<GM9K==F^>XBI>+(K\X15=0I[BI6S[WZ]7?-(/M8K?/ZM4IZ]&W
MI?2#A?O6..HQ48<15QA/C"$K&\('A%L',$0A4!21L,P)P9.-\.08\FQ#I!^.
M,2^`R%<DEP^#6=\,9I2NA),N6WMY':D78@<*.E"M`W7M(&!D.A!F8E$T)-'`
M`9F)YP[CMYBLFPG6_&$>#_)X@(>L;>19/)IS6B,`I"4IYI4-XEHK4B=K@/)\
MX>&T?)B6#](BI1;Y%LU?*N3*)XG9,,TX`:V0KX!IFED'T]>9A1/%&\"\`I"7
M)K$@S,3DA9`D!`YHPJ&5L&!4S&L`XCK`H33O+-0B&0AFRL5$E^7W*Y[#%OG(
MQ<>:CR"(]D`$"AEMZ+<]C2/&78Y+P,-IQ-):("ET&-+N_@*`G(U[31_YQQ['
MT>,6RT'_#,6$"]Q`N?[$JN/>R%%S].D<VMU*Z!MMF..&Q4''FFH-'/<&'GPB
M8ZQ\#J0?*EH,"*0QC\"J%D#5H4=X>M"MHAMS8?D+#KA\RL4M+J5Y$$REA=N$
M0.(.*!4"32R3P.(6MK@5E>(+!$U]&&(9"EN&BDW(4&`9BD_(4&`9"B!#6I01
M`"DVH1^!)2B0!#W*8[_I;\I=8*T*\)*F11GU(/*Y5%/1E_$=P'%06/T""9ON
M1P!(,85Y)%:_M-5OE6\$0?13YP/0.!C<'J3='A2;^%R26/92W%_C<F)3@L1*
MEQF")KZ%)%:T1(H.*0\`<5K?[M4F-S7%OCW`*)U-?LZJ9BZN1H=#DD?1;)+)
M>,3G+QR,K_A\W1V!_'&_7)SBO?DW+O;'K'1>\ZK>FK<;Z%V>5Z:.G7VI^\W!
MQ-OA)C&[JKGTZ^NB.PCI;JK\]'ZN,QPN+?\'4$L#!!0````(`.>,;$=78A<"
M;0(``/L'```9````>&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;(U5P7*;,!#]
M%89[`D("'`]F)D`Z[:$SF1S:LXQEPP00E623_GTE@3$6:MJ+D9;WWN[3&FTR
M4/;.*T*$\]$V'=^YE1#]UO-X69$6\T?:DTZ^.5+68B&W[.3QGA%\T*2V\0+?
MC[P6UYV;)CKVRM*$GD53=^25.?S<MIC]SDA#AYT+W&O@K3Y50@6\-/%FWJ%N
M2<=KVCF,''?N,]B^Q`JA`3]J,O#%VE&U[RE]5YMOAYWKJQ)(0TJA%+!\7$A.
MFD8)R<2_)LU;2D5<KJ_J7[1;6?T><Y+3YF=]$)4LUG>=`SGB<R/>Z/"53!9"
M)5C2ANM?ISQS0=LKQ75:_#$^ZTX_A_$-\B>:G1!,A&`FS'GL!#@1X(V`/B6@
MB8#^-T,X$4(C@S=ZUR=78('3A-'!86.W>ZS^5&`;RMZ4*JA;H=_)L^,R>DD1
M`(EW44(3)ALQP0(3!?>08@VYB7BR@+F*P%9%%JSH1H)\C8B@4<,_15X^%;DK
M$UH/"VH^7+J,-W8!9!5`6@#=G;919#9B8HWI-.8!H<CH26Y!P2=3J["@@!]!
M9)R+#08B/[9;"ZW60HLUHT/9B`D7>4#H;XQJ<@L*A<!`%6L4`CY\,IQ94`B@
MO_0LLAJ++,:,8K+(DF:S,7RM01$R7:TQ#Q"BR'!E4?*?`KNIV&HJ7IF*S6;%
MJS\%"(%Y-^06%`C,@HLU*HC]T&S6&@4W$32_4&]QM;6$G?10X4Y)SYU0'^<B
M.L^MYT!=C48\`]L<6.*%G'/C6+K)ITF/3^0[9J>ZX\Z>"GDAZVOS2*D@LGC_
M4;:CDI-XWC3D*-0REFLV#J=Q(VA_';7SO$__`%!+`P04````"`#GC&Q',EY@
M'3D#```9#@``&0```'AL+W=O<FMS:&5E=',O<VAE970T."YX;6R55TUSFS`0
M_2L,]P96B"\/9B;^;`^=R?30GHDMVTP`N2#'Z;^O$)C8TI(X%T#B[;Y=26\E
M)6=>OS0'QH3U5A95,[4/0APGCM-L#JS,F@=^9)7\L^-UF0G9K/=.<ZQ9ME5&
M9>$0UPV<,LLK.TU4WU.=)OPDBKQB3[75G,HRJ__-6,'/4QOL2\>O?'\0;8>3
M)LY@M\U+5C4YKZR:[:;V(TS6Q&\A"O$[9^?FZMMJ@W_F_*5M_-A.;;>-@15L
M(UH7F7R]LCDKBM:39/[;.WWG;`VOOR_>5RI=&?YSUK`Y+_[D6W&0T;JVM66[
M[%2(7_S\G?4YJ`@WO&C4T]J<&L'+BXEME=E;]\XK]3YW?P+2F^$&I#<@@\'`
M@QMXO8'W;D`_-*"]`;W7P.\-_'M#"GJ#X%Z&L#<(!P,2J=GJ1E?-S2(369K4
M_&S5W8(Z9NVZA4DH9W_3=JK)5O_D[#2R]S6EX"?.:^NHQ\PZ#+G"!.06LC0A
M<(M8FP@*P8!Q9)!#I`2+=$8,!UH0<Q,1>+>0A0FA$&JY?$JT^IQHC3CQ\&P]
M=%X\9>_=!!KA#BCJ@"H'],I!J,]K!PD5I.IB#%Q*M?&8FS"(2:B/FHD*W=B+
MJ39T)NP;T`!<P'/ST=Q\(S<*L98<@B&NEAF&T=;M\@X_*PQ#\(0"-*$`<:"O
M*`Q#<9(0)0D1!]J26)H8+_9QD@@EB1"20,LD,M9`)+=&U\5Y8I0G1GBT);GN
M,/[U^OZ`I]VQL`+I(DR17MQ<(R6?QN-4([48$*I8IT)`WA@/6DD?@2`N1@0(
M>'F"+]0GP`L4F!6*>EJE78!9+^+`'Q]8O%X`(E!OI!P#KE`(OI`PKC_`!*AK
MHP?=5%L`,IXQ+D-`=.B-5`O`%0;Q_1D37#L$T8ZGE9PU,;4C]Y=QG1)</`03
MC[$K8^(9.X7@XB&8>,(1%[AXR!?$0W#Q$$P\>E4BR,X=^A^,+*X>@FUOQLAB
M$HLU'N?J5%JR>J]N'(VUX:=*M.-QU3O<:A[5V5_KG\%D`4C_$B:K[L[R[CY-
MCMF>_<SJ?5XUUC,7\BRM3KP[S@63L;L/,O:#O*<-C8+M1/L9RN^ZN[ET#<&/
MEXO8<!M,_P-02P,$%`````@`YXQL1TNWH2>M`0``#`0``!D```!X;"]W;W)K
M<VAE971S+W-H965T-#DN>&UL=53;;J,P$/T5BP^HC8&DB@A2TVJU^[!2U8?N
MLP-#0+4Q:SNA^_?UA;`T=5^P9WSFG#.^4$Y2O>D.P*!WP0>]3SICQAW&NNY`
M,'TG1QCL2BN58,:&ZH3UJ(`UODAP3`G98,'Z(:E*GWM652G/AO<#/"NDST(P
M]>\`7$[[)$VNB9?^U!F7P%6)E[JF%S#H7@Y(0;M/'M+=H7`(#WCM8=*K.7+>
MCU*^N>!7LT^(LP`<:N,8F!TN\`B<.R(K_'?F_"_I"M?S*_L/WZUU?V0:'B7_
MTS>FLV9)@AIHV9F;%SG]A+D%[["67/LOJL_:2'$M29!@[V'L!S].8:6@<UF\
M@,X%="F@P7@0\C:?F&%5J>2$5-C:D;D33'?4;D3MDKYOOV:-:IN]5'E.2GQQ
M1#/F$#!TA<DV]PL&6_Y%A$9%J"?(/HFD<8(L2I!Y@OP3`;UQ&3!;CQD\9DOO
M"2%QG3RJDT=TLAN=@"E6.G23?JM31'6*B$Y^HU-\Z:?8;K[JX-5)C^P$OYDZ
M]8-&1VGLI?%'VTIIP%*2.\O9V:>Y!!Q:XZ9;.U?AMH;`R/'Z]I8?0/4!4$L#
M!!0````(`.>,;$>'MB`&H@$``+$#```9````>&PO=V]R:W-H965T<R]S:&5E
M=#4P+GAM;&U3P6[C(!#]%>0/*`YQFBIR+#5=5=W#2E4/[9G88QL5&"_@N/OW
M"]AQW=878(9Y;]X,0SZ@>;<M@",?2FI[3%KGN@.EMFQ!<7N#'6A_4Z-1W'G3
M--1V!G@504I2EJ:W5'&ADR*/OF=3Y-@[*30\&V)[I;CY=P*)PS'9)%?'BVA:
M%QRTR.F,JX0";05J8J`^)O>;PRD+$3'@5<!@%V<2M)\1WX/QNSHF:9``$DH7
M&+C?+O``4@8BG_COQ/F9,@"7YRO[8ZS6JS]S"P\HWT3E6B\V34@%->^E>\'A
M":82=H&P1&GC2LK>.E172$(4_QAWH>,^C#?9W01;![`)P&;`=A^%CXFBS%_<
M\2(W.!`SMK;CX04W!^8;409GK#O>>:'6>R]%ENUR>@E$4\QIC&&+F,T<03W[
MG(*MI3BQ'W"V#M^N*MQ&^/:+PMMU@FR5((L$V1>"_;<2UV+NOB6ABYXJ,$T<
M'4M*['4<U(5WGLY[%M_D,[S(.][`'VX:H2TYH_,O&_M?(SKP4M*;74):_W]F
M0T+MPG'OSV8<J=%PV%T_R/Q+B_]02P,$%`````@`YXQL1^B5"A)J`@``Q@@`
M`!D```!X;"]W;W)K<VAE971S+W-H965T-3$N>&ULC5;;DJ,@%/P5RP\8Q5L2
MRU@UN=7NPU9-S</N,S$D6J/B`AEG_WX!C3%X)LF+PJ&[SZ%!,&DI^^`Y(<+Z
MJLJ:+^U<B"9V')[EI,+\A3:DEB-'RBHL9)>='-XP@@^:5)6.Y[J14^&BMM-$
MQ]Y8FM"S*(N:O#&+GZL*LW\K4M)V:2/[$G@O3KE0`2=-G(%W*"I2\X+6%B/'
MI?V*XAW2$(WX79"6C]J6*GY/Z8?J_#PL;5?50$J2"26!Y>N3K$E9*B69^6\O
M>LVIB./V17VGIRO+WV-.UK3\4QQ$+JMU;>M`COA<BG?:_B#]'$(EF-&2ZZ>5
MG;F@U85B6Q7^ZMY%K=]M-Q)>:##!ZPG>0)B[=PE^3_`'`KJ?(>@)P940W"6$
M/2%\-D/4$R(C@].9I:W>8('3A-'68MW^:+#:ABB.Y&)F*JC73H])L[F,?J9!
ML$B<3R748]8=QAMA(N\6LIU"T(!P9`%#%1Y4Q=J;T(T$FRDB\HT:'HKL[HK<
ME.F#9OF:'XS-"EU8(``%`BW@WPA\8U0("H1`!<8L5U.,[YM+"ND8?FX@3&!X
M#F%"PW4($\&3CL!)1X#`#!:8@0*SYVV?@P+S)VR','/#=@AC+,T&P$2N83N$
M08;M]W/=3'H!3GJAJ>KNF1#480T=)N[CK;<"0,'H/+G-\\VAA1Y[O8)`D\_=
M&9V3%6$G?:5Q*Z/G6JCM.(H.U^;*4^>L$5^C>(.`^%9=LT#\=1%O%T!<VA-O
MD0N.(#G27;#74M.DP2?R"[-347-K3X6\*?1Y?J14$.F#^R*_OUS^5`R=DAR%
M:LYDFW77;-<1M+G\-0R_+NE_4$L#!!0````(`.>,;$>7>&?G<0(``/\(```9
M````>&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;(U679.:,!3]*PP_8,,WZB`S
M5;?3/G1F9Q_:YXA1F$T(3:)L_WV3@"S"==<7(?>><W)R8W+)6B[>9$F(<MX9
MK>7:+95J5@C)HB0,RR?>D%IGCEPPK/10G)!L!,$'2V(4!9Z7((:KVLTS&WL1
M><;/BE8U>1&./#.&Q;\-H;Q=N[Y[#;Q6IU*9`,HS-/`.%2.UK'CM"')<N]_\
MU;,?&8A%_*Y(*T?OCC&_Y_S-#'X>UJYG/!!*"F4DL'Y<R)90:I3TS'][T8\Y
M#7'\?E7_;I>K[>^Q)%M._U0'56JWGNL<R!&?J7KE[0_2KR$V@@6GTOXZQ5DJ
MSJX4UV'XO7M6M7VV729.>QI,"'I",!`6WJ>$L">$`Z$KW5U"U!.B1PEQ3X@'
M@L6C;NFV<#NL<)X)WCJBV^T&FS^5OXKUUA0F:'?"YG3II(Y>\BB),G0Q0CUF
MVV&"$2:X1>P`1#A`D#8PN`A`%X'E1V,7L0<+A*!`:`7"&P$?%HA`@6CN((EO
M5[F98\)P.:D5H!,GDVI!<R6PV1@T&P.3I+!``@HDCY<K!072!\H%8.+%I%R0
M3CHI%X19P&87H-D%(+"$!9:@P/+Q<IE+"3IFWM<%VT*@U)L>-0CDWX*>05!P
MQ_&=BZ&[$TPCF5/@4^S/C_'L@&P`4)3<LP8?=C_\^I^U@4#)G4O)A^\$'SBH
M:3"=!P)-YT&CZY@1<;)]4#H%/]?*G-%1=.BU&]L9)_&=Z<%`7&_7:N=#&5UP
MG0G`3*@S(9B)=*9K)Q]V\ZS!)_(+BU-52V?/E>Y)MG4<.5=$U\)[TA=3J;]&
MA@$E1V5>4_TNNO[<#11OKI\;PS=/_A]02P,$%`````@`YXQL1^T&!0`V`@``
MK`<``!D```!X;"]W;W)K<VAE971S+W-H965T-3,N>&ULC57+<ML@%/T5C3X@
M>C_BD343V^FTB\YDLFC76,:6)B!4P%;Z]P4DRS*^C;T1<#GGW`>"6_2,?X@:
M8^E\4M**I5M+V2T\3U0UID@\L0ZW:F?/.$52+?G!$QW':&=(E'BA[Z<>14WK
MEH6QO?&R8$=)FA:_<4<<*47\[PH3UB_=P#T;WIM#+;7!*PMOXNT:BEO1L-;A
M>+]T7X+%:^!KB$'\:G`O9G-'![]E[$,O?NR6KJ]CP`174DL@-9SP&A.BE93G
M/Z/HQ:<FSN=G]6\F717^%@F\9N1WLY.UBM9WG1W>HR.1[ZS_CL<<$BU8,2+,
MUZF.0C)ZIK@.19_#V+1F[(>=W!]I,"$<">%$F/S`A&@D1!="_"4A'@GQHQZ2
MD9!8'KPA=U.Y#9*H+#CK'3X<=X?T7Q4L$G4VE3::HS![JG9"64]EG,6%=])"
M(V8U8,(9)@VO(9M;2#`A/!7`%$4(1;$*;^B6@_4M(HVL&.Z*O'XI<A5F!!8K
M,OSHJE@)+!"#`K$1B.<"B5U*`).EL),$=)(``ADLD(("Z>-I9J!`=C_-%8#)
M<NO0(<RS52X`D_O6N4.8__R?.9A0#@B$L,`S*/#\>$GUNP9=5/^!HD*@W+HG
M:Q`4VQ<:`&5V7>^`AK2\V5-$,3^8)B"<BAU;J4LRLTZ-YB743YEE7P6+=0#8
M-[HQF:?O(E\6'3K@GX@?FE8X6R;5`VJ>N3UC$JO8_2=U36K5.J<%P7NIIYF:
M\Z&9#`O)NG-OG!IT^0]02P,$%`````@`YXQL1T7EF#L-`@``LP4``!D```!X
M;"]W;W)K<VAE971S+W-H965T-30N>&UL?51=CZ,@%/TKQA\P**CM--9DVF8R
M^[#)9!YVGZFEU0R("[3._OOEPUH_F'T1N)QS[N$*-^^X^)05(2KX8K21V[!2
MJMT`(,N*,"R?>$L:O7/F@F&EE^("9"L(/ED2HP!&4088KINPR&WL710YORI:
M-^1=!/+*&!9_=X3R;AO&X3WP45\J90*@R,'`.]6,-++F32#(>1N^Q)M#9A`6
M\*LFG1S-`^/]R/FG6?PX;</(6""4E,HH8#W<R)Y0:H1TXC^]YB.E(8[G=_57
M>UKM_H@EV7/ZNSZI2IN-PN!$SOA*U0?OWDA_A-0(EIQ*^PW*JU2<W2EAP/"7
M&^O&CIW;6:&>YB?`G@`'PI#'3T`]`3T(R7\)24](9@3@CF(+<<`*%[G@72#<
MSVNQN2/Q)M&E+DW05M;NZ5)(';T5R3K-P<T(]9B=P\`1)AX00*L/*:`OQ0XN
MZ'":8+]$9&@*.7A$D-\$\IX363Z:G#/S"R1>@<0*)!.!U:Q0#K.RF,9A4@BC
M&6R_A,$U@B.UB9W4:R?UV%G/[#A,.LH3PW66S"J;+MS$Z]7S-[7)O&8RCYGG
MF9ELD09!.+\(2U"&TG1F!8SN-B/B8IN$#$I^;92Y(J/HT(=>H'D;L_@NWNQ=
M.WG(%'F++^0G%I>ZD<&1*_WR[/LX<ZZ(]A@]Z8)5NH,."TK.RDQ7>BY<4W$+
MQ=M[BQSZ=/$/4$L#!!0````(`.>,;$?&NMB6%P(``#T&```9````>&PO=V]R
M:W-H965T<R]S:&5E=#4U+GAM;(55VX[;(!#]%<L?L/B"G6[D6-I<JO:ATFH?
MVF?B3&)KP;A`XNW?%[#C)(3-O@08SCES8,RDZ+EXES6`"CX8;>4BK)7JY@C)
MJ@9&Y!/OH-4[>RX847HI#DAV`LC.DAA%213EB)&F#<O"QEY%6?"CHDT+KR*0
M1\:(^+<$ROM%&(?GP%MSJ)4)H+)`$V_7,&AEP]M`P'X1OL3S36X0%O"[@5Y>
MS0/C?<OYNUG\W"W"R%@`"I4R"D0/)U@!I49()_X[:EY2&N+U_*S^W9Y6N]\2
M"2M._S0[56NS41CL8$^.5+WQ_@>,1\B,8,6IM+]!=92*LS,E#!CY&,:FM6,_
M[.!DI/D)R4A()L*4QT](1T)Z(>"'!#P2\$3X%CTD9",A<S*@X>SVYM9$D;(0
MO`_$4.V.F(\JGF>Z-I4)VE+8/7UW4D=/)7Z."G0R0B-F.6"2*TR>W$+6]Y!X
M0B!M8'*1^%PLDSNZDV!UC\A3Q\.7(IN'(C<V4^]EI9:?WES6)^?$7@%L!?"-
M@'N5/LPG+C-ODLPC@)TD/DSF3Y)[D^0>@=SY;@;,S&+:X:.8Q9%;62\JGCF&
M[U$9CC,'M;E'X=ES$CD'0U>/@X$XV+8D@XH?6V7*>Q6=.M^+;1!.?!G/5[$G
MOM:=<FAL%_FRZ,@!?A%Q:%H9;+G23]H^O#WG"K3YZ$D7I=:]?%I0V"LSG>FY
M&-K;L%"\.S?KZ1^C_`]02P,$%`````@`YXQL1^)2#%>U`0``8`0``!D```!X
M;"]W;W)K<VAE971S+W-H965T-38N>&UL?53;;ILP&'X5Q`/4YK2D$4%:4TW;
MQ:2J%]NU`S_!J@_4=D+W]O.!L(1YRT5L__Y./\;4DU1O>@`PR0=G0N_3P9AQ
MAY!N!^!$/\@1A-WII>+$V*4Z(3TJ()TG<89RC#\A3JA(F]K77E13R[-A5,"+
M2O29<Z)^/0&3TS[-TFOAE9X&XPJHJ='"ZR@'H:D4B8)^GW[.=H?*(3S@!X5)
MW\P3E_THY9M;?.OV*781@$%KG`*QPP4.P)@3LL;OL^8?2T>\G5_5O_AN;?HC
MT7"0["?MS&##XC3IH"=G9E[E]!7F%GS"5C+M_Y/VK(WD5TJ:</(11BK\.(6=
M+9YI<4(^$_*%D)7_)10SH5@YH)#,]_5,#&EJ):=$A;,8B3OR;%?8)]>ZHG]0
M?L]VIFWUTI2/FQI=G-",>0J8_`ZSO<<<8IC'!8-LAB5('@V2>X'B1J#"."Y0
M1`4*+U#>"62KE`&S\1CA,7FQQ?_R*:,^9<0G7_G$,$7<I(J:5!&!<G4LU5_-
M9#C\5D[HYF48R0F^$W6B0B=':>Q[Y4^_E]*`%<4/5G6PUWU9,.B-FV[L7(4;
M$!9&CM?[O'Q4FM]02P,$%`````@`YXQL1^RZA8]5-```^O8``!0```!X;"]S
M:&%R9613=')I;F=S+GAM;.U]VW+C1I;@\^Q79'CE;6D"8A'@W=/M"$JBRIK6
MK465/0['/H`D1,(%$FP`E$H=^]#_,$\3L?L+\Q'S*?TE>RZ9B003`*DJN=OC
MT(/+%)G7DR?/_9S\?9IF8K,*_[P)3N/-*OO#5YUFYROQ:1FMTC]\M<BR]3?O
MWJ731;#TTT:\#E;PRT.<+/T,_DSF[])U$OBS=!$$V3)ZYS6;W7=+/UQ]]>WO
MT_#;WV??GL73S3)896*XFHG1*@NS9W&QXA'">"6.1;KPDR#]_;OLV]^_PS[<
M;R"NXE6V2*'/+)AM_SH.U@W1:CK":[J=[1^OX\>&:`[*?]3K\<O7\]-PDF:)
M/\W^]W9/V?@NF(?8`H:X]I?!=JN+JZL/IZ/+2W%Z<W<KWIV-WE6,<PJ+2/P(
M)I\%G\0?@^?M=J>;),&%GH?I%-K]&/@)`D.<^9DUZ_&QZQVWW(JISL,H2,0I
M])O'B37/>.E'^/M=L(Z3+%S-Q6F\7/LKJZ$&W?WSVEJ!VSS^T_9W0V@]HQ[G
MD3_?_O7!CU)K&#W';9"$\:QRPPH!_L<__5/M*4O@R='.X6L+T_[4VM6;0%_:
M5YUEO%P"[HRS>/K1$6-":'&SR=(,L`P@NMWMQ(_\U32`EG!M4K@#'\9GXO#@
MR%I(,(5=NH3);0L_/MS=C:[OQ7`\'MV/O[%^]M,%(?D4/P1_WH2/?@2;LO8P
M7L"Q'V=!LA3AZC%(LV59J^%TBN0A%4DP#6"H210X8A5D%O[#$*NL!,UNDV#M
MAS,1?`(BD@)\<&UQM@#,\],TL&=4^$]8"="-'\0L>`C@RYG(_$_<:[O3?9S!
M@4UEU_*!;^]N;D=W]S\ZXO9RB`"\/A.C/WVXN+T"<)9NZO+F^OWQ_>CN2EQ<
M?S\:WV/#<76CVYN[^XN;:W%S+LY&YR,XIC-Q/_PW/JGM;C?WWXWNY"&63GY_
M<S^\E`VJ<.#R8GAR<7EQ?S&R$4&?W-I_QF,CP/O3:;()\M/8`_@3?_413F!B
M+?!,G4H2P-EOK+M:/),H]"=A%&:A/6D.P;K]7,:K.:/K/HN[6$%30&J1`!41
MZ9._MJ;E]45ZV)H5\ED8J[,NT_W-Z1^_N[D\&]V-?T=8=?^C?3697*1,+@Z:
M#;<)AY,(N*";0*SA1A!/=$3?:3:;^)]DDL+?9'!;P[\$,T>T'*_K.FZ[KWX,
MTQ2/U$\1($`@LV`Y@;$4FZ1S!XHBOZVB*OXZ1'"$*\"-:9#28'IQ);BU66XB
M`.U,I)MD'6U2<0BW-)R&F47-[D%2@$;/:N-^)J9QFN$ZNH[KMFF!7JM-G]6&
M7[09!U`P70?3+'P,(HL"F8MEPC,%1I<$"[@!T`$P(*W`#5KP(HYF09+^CFAI
M9HUNH0;1E3)\V,$-#F]]O"B+(`N!^1P!=S@0[RJDI'$&NR%6=?,`W&H%XX3(
M[N(TW"'-%'$PQ[Y#./A9'$5^DN:8:!UEL;>%G'LU9W3=A20[]DWH<0,+)>D-
M@/=AY6]F(1SQ435;;>TM6UK7XV(%.`-'I>%>#>';))YMIIE(@>W:]!40G]8^
MC^-9*E+`K>TF[Q/`1['TDWFXLM:(8](=@-\_!B2U59'RX6P9KDADQ6M1V4PM
M=P9$/(K7M+FJMA+@-9->C^X%<MGA_<7U>^":IS=7(W%X>3,>6Z=Q0U=1#50N
M5)C]Q<GH_.9NI`8%QFJ387E,*";(@<7A)%@!8;+)$BZU=H$_!.%\@43#?X1M
MSP,D&X3.C,=Q+N=9E/[$3\.IQ2_#:)/9>&>M0P#\Q/B[X=W(&K>(_Z<%,B;W
M?G@)Z'.TWX7(T1EO$YU'Z9C5R'X=9,`R>&*DHQ6G7"2XW%+VL_98PKD=,0E`
M5:.#M7'..'1_O8Z`>J*TD\4PP4X98.?R""\1/*532Q&GT+T6',4#'!?XRXCX
MRWXG1Q-7D%L:M8:_CS1_!XXCOM_%WP_/)%\78^;TE:2[=&)SJ#(48WRMXHT@
M*YC*D*6RJ7;(OOA>'NWL4W;FA4.K/_/1IR"9AD!9H`$Q*Q&OB0GMW5"IBC9R
M0*/CB9\"J'!YL#9B;S7`J65:%<#9J\\6$/<=N[;//=Q028U1GV2<@'M:"\6*
MS5JJ_QZ;M?J\\#9^MH1FCJP&?K&(MH,7H+9_'L5/>\I"I\/Q=^+\\N:'L3B_
MN[DRF/;P]/[B^PJ5<O;S1MH)\-R28!J#X`G$=K7-!O!G_)*,$.LD?@Q!XA*3
M9SAE)4+X**Z3MF7-<Q;`U02)M@SYATO4_OY2^IO62$/-$NR3.7SOAZLCDOH%
M@'D6INL89#4$XD/XB12I4K/$PE_-47Q=6<N]TZ816Q[:%P:[SH<-$#O.YW:3
M3!<^4QR8$*;)G@&#(E_:/5&#(0EON^.5GVT26@=VK3$'J1EVMDOB:1"`A/N0
MQ$L2A7?!5T/J<(/T#]C]D9S@98`ZO[@>7I_N`E1A>6@_(+4$"8B-4_#C.@&,
M"M>`)6C->B[=\IDY"FFX.Z`2[,M(2I'(`-,#*X"U8))2YMUH.`8Y\VS$GX[@
M.T$01*65/J"N^OWPLLS2=3)Z?W%]C:#=N\OH^NQ%[4WA7MP.+\[L!O>C.[@)
M8O1OMZ-KV$M9H^N;ZV.>LAH%^#ZC/#25HA%I#$`W-Z2EKJ;19D:D!(UF+[>D
MT:'I.1[\4&G:='%V"J8GFS1<H9B6*[E[-*GA*B<?QA?7H_%84?J;:POX;D.4
MM!(7R^7F-(@B$-R2=<PSB4-@@\IA`!<5E%(Q3^(G0L)5N`1P+@(_RA8DR$`;
M\;2(`=77($+B_T-B(%.0'!$`TQ`N5/B`7#5Z/D8L#U8$Y#5N!;]&U$<U%;HM
M@*L#\#911F<CEB1]TKD@/XJ7X52$,"?HM/%J:S$\)HV$]^091\"-S.!XGNG7
M21#@^<R`SR5PC1KB/M^G>$*S5!*"8HX+)2[#$&$\N0+&0J?M#OH>C98$VVW.
M0.QY`H%!-NLYA('QZN?-:DJ`?0IAG2@@@?*>H5%GO9F`3@-H`[P-P0OX,S4D
MA(;X(9#6@"T@26H!P%@&LQ`!#9\V*]PV<>>G29RLMK<^];,L"FA07*6T"N"\
M<G`1X2:#3QE*SHARL)YX@XI\R*1:+X)N">\481S146?^G)F',;*/B]'CT]K]
MV0S.&/G,TH=ALQ"$9AQD"615I.%\1=BR0KJX80JJSYX8.VPP/U=YG,_%PP04
M3#>3GP.<$E`1>"4<GTC"]".:'],8Y0\X,WT>M'1CY23<,9G`3<P"I!X!TGXX
MFH\!30M(-MOX$2R>Y/F,K7-$_=D2&?G)7"HC@*F!W&6ZF:**]K")-.LL!R_M
MT5@.$R;@\M(."!T!DO29]=0ELAQ"WL>0KHP>CO8)^C.(#0DA2Q+,46V+$3OP
MZT?:QQ.L.C#T;()I&AA>'88@@!2Q0MU^Q(.'34(-9@%`.@+0;@!>"1#P.V!-
M%]\(]HA<7)_?W%T1Z7'$Q?WH2KA#\;>__KNXNQC_49P#1;^YL\WOFR5<@6>2
MX@WDD"X0!-MM#`LNX8O[]ZRAK>,/5U?#NQ_1\3.^>']]<7YQ2@ZFT].;#]<D
MM-W>7%Z<VGX#]+=_DP*M"O[P%8B\:9`\!E]]ZS7$_B.*0_](H+V)+?8XR"IC
M&@UW>.$_XAF#T$+N,T`79&9T)KBWC=(4E`Q!1F^M5R3!0X16=;RC0/_]7/QW
MZ`N8\&D13A=TO(AK8H4.=922T.V#_58H60:.O-7X"2X98@9>?5@DZMJ(ZS[=
M4Z"NB!*`/$!=-FCPP6ZX[-+UX;2K.!/+,(T"'Z\A$:Z'.`)%2+%M7`49ZOP$
M+:Y`)D%ZPB%SN[EQVF/=\B2&_XG#\^'XY(@I!W[$`5(Q!RTVH6L$DZ"38F;.
M)J5%--4>OA\.;X]X&T]Z9?G^GE!2!$*:`CG-8+B$G/$$H'S'T(+OL",9'Q-=
MS?4=$?C)"F8V3/>Y"_@!E<*&N$/=",D3W4U<EB3,*2XKS@".`4-4TD[:;2ED
M3N,9W1,6!"9'I'PZK(*.<H<SFCG0Q7R/SK6+7%>@I9$WS_KE!PD.1`)$L$4X
M7P!4HA!&G1GZ!GR$J[B1FB@"=TEX1E2,MI4$R"S(VH^&G$4`\M=:J4<S/V,P
M3`++3=[@?1C?$%"T!D!\']?!_#Q%3&?-:>)//[)LCN#[T!@WQ!PDF62%RX1A
M)8>A"2=LK4B+_K;S8(9H!4+"&CTY`!J4;)"E%$2O\[.+4U!@PV7(F'#@==A;
MB*>?HPW""*19ZK,FNDNCQ@EM"*-U<#V\#0`5<"PI1FAY%^!:.ERJKS/O']V2
M,`@0F<Q1^Q_G@.$3AGE!_\D"%G.,#34$Z/0T7P$8C)JX5[55W`0Y?/7L>/D_
MYS2$/Y\#?R,&?^`Z@V[?Z?5[A)@'G6[7Z;9Z7^2";(CRZ`I:]#0"\0(N$/ML
M%T%$1K`EJ^#/6FPB`V6(2IZ)>RC]`2+Q_5.2%&.+>0_H2)E^;MT&$CY*[P-.
M3-0T[_@41(]63X6\@J*_J'-#Y-[Y?_QV]U^U<4JXCJAR$[1LF`\('Y'1W1<C
M)`*O$1#QV,G)DXW8I>/!"N'DKN'6B%9#'$Z/A(ZS,3Y)717XM?^$$`$]@66U
M./EX'*Y0H:)+A5M\0)_@`M;%#DC\*J3@'N2\M$62U>,G6!)I&NBHCU>2!R=I
M!@,Z\E.\@0,(LD4,UQ]NMZ0>AVCW`\4N"O]"$B9IO<!!?]B]FE!N*<P5<',_
MD3]!XD7>S]7F`22Q#6M$<*U!P9L9T&H#M&9'XC[Q80C#/B>_28QO"/E\D%;R
M[2L=#Q<4AVA\)@(E(EZW0*,4K@O6,4/N";0UWDPRE->GP.&9Q#5`'UR!RD#T
M!F1>0"M4UUD(0S&`L+'061/>F!1;1&"X`Q,2[@"/@"VBFDR26Y9`IRB7.QB>
MT`B-`G-@G$AP27-&`P5LCFSH*+:SS1UVX<^E.JF&:%1`YPDN*L@GJ(*B_`\Z
M8P"[0OE=[984`0`SGH0T(F;64""&/H;Q)H4MF2/B##G^I<IV2Q-Q]P!.=F@-
MB'BKA`7>$W#S-6B+8K:!'V%@T#N,4"&$N]%;D8.PX,FE\\A)2:L)A.(9`*.=
MDCCI`I6V&1Z2GL[:K8&+'<#%X`B9GS3(WFJ#[$@99%'RF2FK=U!OO%77$941
M]%`?DT;.%Q$Q@-?'*EAN&4);B62S"GT):,I/CB/B;5>@8BMM3CZ18.('J<LA
M`0`&@NP7/3B@N.`]D:)C@,H@#Y//!7HZXG@$YYD6)V'I6DV.LN]D$T9T'(>L
M7Z#AA?1:-NX+=S!H'6D-V&LV70XB:C9[6N&EFY8$B.NPX$D@E70)8NP)5VB^
M@$Y>R[!W*,\#WC'D&FHE:E@IR_LI<:PHP*%F3(<TC11_WH`HQ!241`:\%\B7
M5MGS\0/Z&Y]!8B>AG)U@>I9P2=:OG/&8*^91X%I@;V0:(1!-8+UXW+3_F;2#
MF7;VBE%(`"@<B>9<N7)30)0)COO(9RS7`).S,[4XX8K=EQN$0(ZUK[T./GV4
M;&@IE@"FKE\/KM\#,DZXXG.D5&+(Z_R!Z#HZDY!;ZU_E+GY[E^R"#(VKP+`S
M*JO7%.X5B%3`4F4`)(R>!7S98#H#OT%^`:U8XG<J$;PI;Y_;<5"C!0J^(3><
M=JQ(?P@K*UVGW1^PK-WRG%YG4#PZ1]H4N$=^=]59$4!C.WA((Y1`5JMW;VTM
M1XU4=&D9@X94/.'6;UBK1]-C*ED&2S+8^SG72^3)2>]`,B->0C#%3FA_#A-"
M>[+":DMI076^C]?A5+2ZH%@8>C9R(!SC(A\#OCDSW)0D:U\B7U2H?#@_PA;3
M*":K`JJ2Z'#X7CD<<E/'A:$XX]Y/8UCX*I.J)32]"]./1GM3T9:6"E(=I6Q.
MBO^V"HW1>V7:CU,N8#NY#&,&F6][79P\V)?%5MN)TJA8.)O#8[2QL/%3&WX-
M>S`:@4U@T'E)[$&;IF4&>)7-*U_2]OZE6?]C8`Y7K:.@BZEZZQ7Z"',]GIO0
MSO!2L5<ET*-O8WD)(O<]0&0#[Z[,(4AIUAB:VGAG0IIFD#2!A%4;/BB(F8=!
MFA33!DW4-B`#+Y%*P9=/"R"Q3PJDFPD*?.1>H3!-D$`PG&&V@>WA"HB,@7@`
M%S(HD@/3#@EZX!P6*F66?#K8JX.2K$\W!G`#A6^,80/A^U':-+%'V;9,,`!Y
MX_L,>Y7[DVC!IAL2X@N:A,9Q-0XZ0Y`^3H")Y#H!2N#2-HP*?ZXAS(J^%7,,
M,V`'YLV=&WKC2*;F`+0UWQP-#EKH,UF'PNDF`M%%.62H1Q#/$W\-)!_1U*<-
M%B"5;DAK810J:+B:5"J7'F,2@C;WDJ`I]-$/(Q:,D-'FXGT,+!TTSEE,:W_P
MDR4(--@;3?[/TDFIH5WLE\(T4_;=XP*?]6)0]($&>*[DHI?V;K6BAO@.E&M@
M50[+I^P[I?-65F+`BFC&QX/V!@0:NRH#_"-D2S&+PQ2+FZ;RT!6H0.)9'.4Z
MRQT2R#$02#&<)X&\D,,H`EJ:`-IE)"PH-0R._R^LW-A&$U:/0Y-0T'D5A`6;
M+H.FJ:>%710$!@#X2HL^4CG.6S\A@,S1Z6+.`L12*<0'Q5V@A6DVSX6?1S\)
M#>:=6\2UPAC.3-3&H\I)+#(;UDZ,1='!3`+2@Z56KP13::^&<V)I!K>+ZU'2
MT]9JI$*/*GF^,&`@L8P<2)7OE.`M[2LZBH`$C5I@;ZO6M3&/*'Y$N2>!+@[M
M(V<:U<`\#!KS!NOLK)?`=0;))(M4A!H:-+A[%!S38DF"PGL7Z3$+ZT5\EXLY
MDFX=]"T!>&<R3T^>/YT>,NQ%N(9#`#4K6.T#G)71'88BO(%ILV"9,F>,X"#T
MI,P#@)+&Z"?-=D_PM[_^!X(XH)@>]H\2Q0;DBA$?R*Q##E629;<PGXR.)=@4
M/SP@7'$``T?T2>"Q%#>B]2"0<@_#(U`Y*5F+K#7S5:@<A?KJJVRN,J8_S@`C
M3%GU9!-%F(4@#L?#DR.8IR'<9ML1?_OK_RV9YV]__7^PGN&):@=3D4HOI90'
MXJ))2-2=?13HK./(;[VJU*!2ROFL;(6P/<"^=.,3?@<8_8!K9QD(MI,D"#&9
MX@#<$,`?0I]9@/H2L*,%VORG4GD!S)0:EWGE$W3RL\,#NY**&&`>+1PW221L
M4I(*,>KDDD;HP*'P\4A9"17>TZ;\-,9&A&DHJ37*CT6B'BA\S'P64KT^S$,1
M4&/#Q(\0N'Z<I$?$F@R9!^>(\I`:DE6R,)/K(U8$(U,<Q=K/@RER/K_*0:9^
MXX@4MJ."9/.0451#OJ0%97V]>-=*YRW;/<.>?P_)B(Z7%8<X_/E(C*3*;>+Y
M</:(S@2RD.;JI=0B9TR^E/*JU-#0]/8:BC!99_&2<#.ZOG)XQC!<$H;NH'V[
M49@Z3X4E6P%SCP.OYW3:[%TZ`$6ZWVX7]6X@#<<\J;3\H`4`^E9XJ&RGE,-C
M]SRGTY+Z=]MS!M#>F`?H[1=.TR#18EV35E2$.IM\)<Q]R7BB2-/EM8\R+9\7
M'.W'(Y65<H_1O=LJC!GYNZ?>TFO#A@IC'D9''+-]?$+!^*=&,/[VA&E%T/Z^
MD[M]IS#^,4U<G/)P";0UR+92?&XYEX)2/LCE;S=9<VR1SEHB"D=T3!KH9GLN
MT^LVCUT`TTB)!S@YS8HT&%&34NN,]'T+9:X1LW:V(L1"I#(^68E8JPVU)_*W
MG8LE6DZSXSENKX.?X%(U6VW\U.H[KNO2=UUG,&B*$;%5\BAB8A9RC$(4KG!;
M71BF+7I]IS?H"]=K.YWF0#2%3.3:M0RWWW=:[0%^:L)];GGXJ>LY7:]I+&-<
MF-,<P79``^C8XYW'IA+Q]2/4J^BX)@%'Q)%9D'?X1.K$!*E[%A[KS39%OT-1
M`RWZU^NX]/_#U9'XP"%U(VE63$D"YB@BK:^7!N1P+".2823PA$P4::(9_3)W
MB9%J]3$W7DI3"+"!Y=KTI?(F6%)#=P[B@;2QHN\JMSD;^=O,>0L&,3;OS?/R
M`':?++?!2O&Z/.I("X[V<B2?XD::WAGTE8DJT,AIAKJSZLHJ'WN7E3D8XV0U
M<(#RQ4@$G@JA:4F\@L]3!N@%1J`^2XJL(WAD=GAI(,^'-6T6Q3'L=8S%4Y3<
M1HLXC5<4\2;#`T^U3E]6=>(U(H!^J7'KTFV&X^\<*S`=IOCNYN[>JOY`4>S[
MU(4H#^UK-<1KS2>CKO:U/]88#U4$FO8G<)@:)K:*8544#/]@Q<$@`T*I+L"\
M0?[$\6&E-4G$@?"<=G?@-/L]^-S'.":O#Y]<I^O"MYU!52!-R^EY'/3DH3N!
M/KF.UV(B-MY,,DK-!`K>Y]%;3JLUH-$]A^:!L<N#5MK]'@W2'G29(O+H1X*S
M/0]@T&ZO*Y?<`L+>D8N&@=LN#5Q9':4&#_%HK^]O[JPZ`>V&T+\941^_^*G=
M%6QML-462*@MW&BKV77:()\>X`#-0=N*[6AW^P2'5J?C]$"H=5W/:<$TY\5X
MCTX?(-837K_E=+I=<>@!B^VY`P/4_6Y;SC1HPU"=#GPZ[+LPF"NLG#9=\20/
M^-BC2?6)R&C;L;@;G8[@HIY<CK:;=!JBI)48EEEV7_.\C&/21\?!&Z6^E#G5
M%#@`408@W>[1!6N"HHX"R`'"W04HMP#N9K9NT;0\\6>Y[T5)]TF0;1(LO^""
M,-/IPP#XR06,@$^]+OZO9E7HM.MUNTZG/Q"#/DI9A`.>XS5[T)-=RV8$B8?"
M$V`38!\TA8F\01FH>63<[<#QW+;<;<?Q!A[M%OHW>WT;?U2IHI%9JHA7,2RO
M*+2K0UV9B+L1IBZI/"8F]&91H+WX2;<A=@XD=I9@^A+<+*,<NR<\H((O7:;U
M+9"+X=;#IZ9+(K:,'7U6L7Y`4)K.H.4*T(N]/LJJ3K?C"E6L*%74WNMUG`Z0
M';<-DO<`_@_BO]L%@7W;#]T!Q&@#)V!7-'NAB[AO9)ERT.'6"(>@MW4Z+8GQ
M[1X2K4,/\`IQWEY_WQF`U,__-@V^HY?>'@#'`]2&)JTFPKC;[V@JV((-HR8"
M$.KVG)9'L.KT@'AV+%93&V;THL:UR%M32FLOQ,6PC-I1C'BILABH:HS5!89>
MB0U>8M2AS(.Q0@_S!:$HT&T"@2*2"F360\D&^56_Z7A`M4YT)!$:`<TX']`K
M>P,02CR0(`8@#/4'+@I`((T/NJZX0:</9<^L*#=Q"Q`=Z-#I]D2[!S@#=',`
M&`0H#Y([.H&GRA0!T\TQHPK0]4CT0!GV^AX*3-BKYXG##ER"U@"EG$L<OP>R
M#`PFX\H]_JOV1!23P=7`?0:%&><`F+0Z-`]]7[AC,R/+6QRV<?7`"HAU(-/O
M.,`3^'X!50!Z?[1K`4SU@:N!U-$ENH_26<_I2H[GNCV`30]!4"D7W!HIGD.9
MXCFJJK"S3Z>:6Z0EA]OACRPVP`6`+^\^C')ROMVI;T@<=?URQEB7M?K+2R76
M,C"72Z7<P@GAD>`M0?M#J]]B!MURVFZ?Q1&[,\=:NCT@P&VX,B#&]%V0TH&8
M>UW9B?8(?1+8#/`70"<0+]TV4E$0,=PF2)E-H^4T`KET2EK^9H:F`!!?V\";
M7-@9R)WB$#"ZX_;,L9/X`6X3Y]4]!-`%<*[=]40;I)<.J"(MD#P\W9QY7P_$
M$)")>ECUK`57SFFV35FW@RCOL1X$U[^'GPY;311[F[:P<H+!,&<EE>_T#W7)
MP,/K/XJST<E^M'K0$+J#3BI#FA+YF.E>&4-&-H/[,X$K<L1U8]@0ASY&8E!D
M_].*BL=-TG`6R@P\:)L'\+S'4`+#"N\+(!P9_"RS&2D:*,]:_$1V$ACX8`#Z
MPB2,(F6$S:T]%"'F>6(I?X5S9S=SG$2SIW`&>)OGL\G,%O1]VKX3&6:@0NN*
MB?UXC0Y<7<,/18DYF2W1#4<N;1777!E9IP+K&H(MT.0_=3O'%/E9$$ZP1N]L
M0P%3Z*V/8@Q+UN4*9+$"LI05H=0&'.N#C/$$L$#C($8QUZ_&:Y9NU`.1[8LW
MVBELU&N^XD:!>1`;Z[UDJQWR0TE/*IYTT=6K(W-BE4)7V+M$_7K_,UDWM6\W
M(H4>?428C!G%'(%<&`%SFM(\-"/6CIK+BY.;.T%%&'V^%DB>PDP6D5,^.O9)
M)BJ/IMMHMK^F:]%NM/I?6TZ<"N+O&)$`0)#E<`H,V5-L@0+QH-5H=WDRK]'N
MV).]5C#*L.@=)>MX%*<<T<!V6V!+Z)UT2F--OC2B@Z("RJ(Z:'8S<D2'L&!<
MAG;?5P>O2%N_<NXKQ%#52!KBM"1DY'-C13#0('M1E2R.DM&),W#T3*4-V_CN
M-6!X<$XWR4.94Q<C5KLTYG9;96,GK8F*O,:MI56O+*4H_P/@Y!V4Q%N5&8$-
M%`!5QK1,4I`1,V6CDL*'B8<@CKB>3#HDR]J7^WN5][C3EAY>4$Y[7O?5/;PJ
M-IK*<$AF.`-A/J4,B9C1%"EKN@6"/+I2X5H9HM64X',4@N?'=W@`VK/;[ATI
M6#9!5GL=6,+09,F40[N#UNN"4LDW,M.>P9J7C=G_(LLX<,.?57I!\\%JKF1%
MB!MGEL43E`J)]G-`FO1]AZOU!J]P(C8KHXW\6H<APZ$G\4360YGHE..9G_D-
M$O<3U)$1,%5KLW-*(XPQ$)Z976D`;1$&B9],%\]Y^:1P]<7QR]*%;9"K*T5K
M*-K*(%S%'UC:OS=3<@/V]V[K4Z@5`;XTVZ@4N0.GU7/)"@^Z49MKTU=T[(I.
M#W0I\ERW.Z#XM#"<I%G;IR>ZZ+KH`A2<5A-4GW;+:77KY^F++NA>H%'UNTYS
MT`/YM.D,>JW:/@/4K08P01]H*O7!/T&EI(@ANW5[T'*ZH/Q[#JZH!R#P,#L;
M=*V>5IQZDCZC!T8!'75_1;?+"T".=/+(M5UYMJ1)C3K%UE:E>4-KJ]Q[N6*%
M\GU)7U%2&M>IU=3M$(QTOQB,\F9E01AY!B0+`0=DI>FZH,"BFNH,@)711]"N
MNZVV_.R23<J(15:94,"CFH"A@-\=&!S=9BTX[#;5->?MP^A]Q+`VCMYJH_T'
MT<PK@P[90RF^`SZXC@>M`1EZY(,"3.C#BFPT,$-^ZGZK]=E5UR)VW4:A5C%%
MEH<U!8H+10F\;M-IMWN*[3A>KP?*\U+Y\('%MELL4'<[7RL.7"S!*",GS8BH
M(QVE_HKQ9$T@38.V9)=NN^NX3?>H8K&MUN<L]I5$EC*;E:,S(2C"@UFFKL](
M,9`8U/@,2WFBF(DR!7,@7=&LTGU:AUR2P$.W<)YFBE.&#Q3!L\F`2:-FH^H:
M@^##X'R0)4`^:QV]3M4Z!N8ZVK7KP%A%53**!!0)'QD%*2:J[!PBL33Z[%J:
M5PF@WOX+4[*2J3.ON:)(NCTAR+\T(8H#_B<IB3"^4801EQUK-[^F7:!T<21-
M&BQCRA1$'P.J\L7$F/;&L:UH!-IY1BBJJ,XL?QT,NAQT%853E'6Q6I"T7*CL
M#ZHI8&84QU@WJVB?:+9)-\FH?A[)0)224\QA5<4=MM,GR0H&-T6FS=(E0R"0
M+U=5Z$MILX`+VSB&KGS<@+[%NB8/7'/V"W/TV5FRF6,@!EK.L"XOMAZR#GV[
M\),E\,(-U_:[6,T1C<B&?XTALGSSKS"Y_F:3B?_Z3W%FO0!38B3`M"8*X>7@
M6Y`SN1(X9Q&IW)EMA%!6H3Q+")/I-N1J4=3&G_N85"?18A90MA&-'2RQC$WR
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M-;1+-,$GE#4C-R%382D,&U]S62FRI7)D'\(H2$TA1@6`R&FHS))B83\##4MG
MX53GOZ2(]RJ6LO`S)MR@'><!3@4K0*DZZ69^+N$?1;`%B7F8!9'*7TH'`15,
M(2S@UTG((8%4A:B>8BL@`;B<_,VA!-&SRHJTQS.<J'EZD,ZAI'@'H]:BME5(
MN1>3,P/X@2--*>5/&T^LJ594%$9S7MS]9F60NLPLI/Y`-7&T]5&1+&4E,<O]
ME86S-LK*CX=&S.!I'CA[6?U"TGZ]ZL(P;ZZN+HR8Q],;JG.X]<J5)61[#;%?
M3Q*_)\^1_\0)+_Z21$A'YE4B,JF"J;KHH*[[BBPBA.;+5?CP++CL&GKE$Q5I
M#(>#)%;1MJ4/+'.SY#*I&9[)$@O>D,5#5X"%_U%1!H4U3IZ?#*1`YLGBE-DS
ME\K,_(]DR,:"$C[R(3FM%J%\N&(4HQWHU2H3A[:R*H,I%;/B_GS'U9IM>>29
M";*T;*JX;:[>22S%H&XAF;#@;F4RT7BS4JG94AP)EYKF8J*2LB\5,YLU1#&+
MCLBZA#?^'1E&<5D@3TELN%AUC$D0+B>;)-7AYN:14K:TLMJ2R(7)I3$E-TV"
MA1^!>//@5!TS"$E8YUN/N@WM'"`-J?85?X\G43B7EYW\#G/8Q>S!)_>$*HR:
M<69S??6(=K<I'/$>A$-8#OJAJ_TV1$XH244BXY;,W//Z+*3'I26Q'9"J>UW5
M(K/2KD,=F4J!!BN3&A[@DV6R)S-H`P)Y"C$G$)L^&<95],]1^GCNWB`[H4]A
ML'C$N``MR3#X9.4@KNLCIV/TS6\R86]Q?-(":`=2YE-2E*P,3%'4F`O:4%D1
M5,-=UQRA(=7%Q0$?<97:2\'U4'5I%K55(@1+1,RI3T8-6#?=FP(YR:7%N!ZI
M..$?"R(B:Z0A94*!B7GR9E?<UX9V]<N<$TZ+5!'!>0@)7=>4"N)P>)-1)J5V
MC52Q3+DTR9T.N/(L*]G:P.(#P))LD1(X"X4"RHWE9H:'60($3C7E$KCRKJ4%
M;R`L`I_/6OK1EEE:,67MOT"AQ)B#<RT!!TQ(5WN.[A>%"L[.5GR97WCJ"^6W
M8G%UKDDB:QT$2#LCJ0LNN$QA7E@@IYK3R`^7::[X`#9S'HO$^`U?R8<@B#07
MD'N6Z9H!V]QI5R74F!YUV:QU*=N\0E*IM*'>+!)WF.>54BSBONUV2!0WU_P4
MG[B[>/\=1DQ=#J\M&:+%,D196W&6*^(IEABW`A<((Z0P09NM7.D$R_LN@9Z3
M[4%3=B&+M9.(CJ=`U="ID`8GIRFF$T2L>&F[+TOVRR"9<]EQQ`Y`5E47XA;X
M%D;6^5+2QP9Y#0NOJ2UQE/8F[1^HL6#4E!I^:P.*07,:ZS3:D+M.R=C/>0TF
MLQ\1/]C@L2YBKC=%B#8+9^PJ5,EKVT(%(1]+^:1THO86R-+L0'I(F2V(5L@4
M2D3;<3#79=+-:M\JK\E\$?I+^M:5"A^]I^A6>B32J.Q]^@%P[ZI8_]Q"U#:H
MGB_HC[`M%%.E:Z@=BYI?IG)KLR"=@L;,#C)R5H%R=&N(.F6)H7T@90HV^5/2
M5$4E":FT>EX)1MESE_[/$ET*U5JX%H\X['?86-QO?_VE]FH:1MJ>^][7KVA1
M/C+?-B"]M^81B<*;D/II.AW*IB&$8FPL,Z#36(U>.;!CN@QD?(WKZGO-D>5%
MX+ZZ_=]M,52I+H;BVY\!74!M!9Q"#:*\B!.YD(V,>1<IF*S6B1.7[)9K#LKG
M!I1K.">?R,G*G6<ECK(RI]B0N?%WS(TOS$.EE/(&A5NW!N)KT6K#/VT7/_7@
MGZL?+K9Z'WI'&)OXM?!:^`^VI#_+<HEF*D&S'%0FE*1-`(MMJ:<W&%)956(.
M6W]V`&U';/">@$%(M#O5X,"?O"[\<W\Z%B=A3"_%3!'Q+S,04%V$U#_34-C\
MG[F..)7+XGI=P'P`2RP^H,INW@(G?\8,I57J3TO?V*EN64/C[T:7P_O1&;UL
M\:.XOQM>C_$AHK(7=T`"K&XMSD`U/_-!F15CK%"VQ!!(<7BZ0"%7WG%^I0`]
M6XJERM=X3$:NV?\EQFYF6+Z*SX`*9B01/MV(M792\3VJXZQ8W6RR"/W.V/((
M@RYG@%S`OJ=F<1'*`%+O`VE!]%"<4^E*M-JCB_.__E/\$*X#;<PG>H;?I.+T
MRGH9?;1<1_%S$(@3:>+:V:#F+$97MY<W/XY&XF1T/3J_L%^<<KL-8372J@_Z
MB%RL.9'ZC_S``@HT]/@1BC9'>0$0=`@%<F&Z-BP!?Z6*A:!V*.N5:'WPU'@@
M!929N;*+<+6T<$UERF_5'ROI4*##)=NV`"EQR^@DM41*W\LCT6JLV5BE2`PW
M<Z`?>(<]+>^#-(-!MW"'6%CD*%(\67;CDA5*;9H*X`#91=PA6LWUF>4Z-2TB
MB1")?B<?<Q5\@IF_:,B&^"`5.=3<<-WD6X-?2$`G\^R!VW/<IHRXP\]NCRT.
M1"-Q7:_O'>^T';<CW?CM'N5_O:)7VW[-9L+U!C,Q>BS+I[<:U+YJ<S(>_>D#
M2INC[\L>:W-[^%#-5J/\ZLSBM2[1EI=BV&G1ZG<ZQV[SN-,\=AUAK_>LWC,J
M%;)"13J?'#Y4:Z9H!07$28]O_8],#:'_=9P\P67&BBQ<*'>Z05_-8Y`K@5SL
M#]H"PA`U3)_QQT!6^R.3)M5&*O@OC<]?\`+1H?I4D@U2\@"0]?+EVTM!;R\%
M_<->"K*P\>WAH+>'@]X>#GI[..CMX:!?^.$@B_*^O2.T_SM"UB/VVT\*6=!]
M>W?H[=VA7\>[0Q9JOCU#]/8,T=LS1/^@9XCL').M%XFLZ_KV;-';LT6_X6>+
MMO']%5\PLJ[2VP-);P\DO3V0%+P]D/3V0-+;`TEV9%CM6TD6,WE[7.GM<:6W
MQY7>'E<R'U>R(X>L]X\L.O+V'-/;<TR__>>8K)`L^V4FZV:\/>#T&WW`::^Z
M.'^71YZL.)R*!Y\LW/QU/0ZUO;S=[T3M=P1O3TZ]/3GU=WIR:AN%MY^?LF[@
MVQ-5O\HGJFQ25/U:U7Y$Z-?\Y-5+XC;OR3=K16V.94EC5=6C6!)KFY+N]Z["
M&VG\+9/&5PN8W`<ER^WW7,KEA6^,[8>[;X^-O>YC8_L<LF[]=SRBW\++8GL!
MM\2!\0N!^>U!L'_$@V![(<%ZUVM8KX(2;^]P_3=ZAVM/O*F)OOL[4NNW![#>
M'L"2].-%/*_NW:F_(Q=\>X`J^&4?H-J3F&V]U)-2_#)77R*J;BA;%BU]*[;_
MWZ78_CZ%]/?!EY)(R<^U?[R5PM]9"O]%Q8WV.;ZTMI;+YY_DKZ@NBZPZ\D+U
M;T?IEE?AB[_NXBLOL9N>41F:]$@<2Z/>]F`O,D9:CN@=-D<[/GFWI;'4J_@/
M,"B^`M3%??`)/0`(_0_C,W%X8"-[L&XH[&M^D8%<3F6!7-42QW@**=F%JRU#
M><G;$;*6V3JS':27&CL/FHVF:PG"MI]_NXG*ME8)I7G=PZF1;<TIFO:&B@JL
MY?NJSC=F1XPEABFM2KW:('ZZ(H2R'VVN5QYT#L:#M6%//A90.?>%J<U5S0\2
M;^DHM9JR(WG<_3-6"U)#B_\CKK`ZYV99.5O%DC]S,EE:IVJR4Y5G9#R>7=&T
M5;XNGOB<XI34V_%5D[V:#\`@KQ47'.Y?0\F'EFQGLKK3%\7Z[^TH^%89UZU;
MO$_G,FN&"N@K\Q#LV;]\3U\Z>>Y7$9\Y-`+T<_M6+\M8DCJU/2;1+HC=.%;P
M!E@,OFC_MTAQP>R_YUZ+[@<C67S/_ML^B9>/<%Z9K[[G`#4]2GT5NT]AE[.@
M9)K/<`R\8%9;X_O6<@!8D2$%(+UT2\7>K[/!O5=4LMUBWQ=NOLH-\AD^CMW(
M8QG:+9ZUY2*HQ:8=-O]J5E`U>L4EVND>V7.<G;NOZ+<+*!7==HF0%=V^!,05
M0_YRD'?8WO1"I\IN1*T?X*=+S):^P-A^2^K:SPM2*2%O^SPLTE;KY+#ES7+G
MQG:[G]R2?:QF+]0,=M)_TY'QPK%+*=(>7I90(Y9Z;LHZ:U3TOD%B6^YPV6.$
M/=PM^ZQC/_]9E;A?[3:KZK'#85:MQ!21ZE9YS*HZD*.LZL?*]Q:G58ZYP@.G
M_NN4O*A[QWZ/A6Q5E*(,3=.%D<7\XA96[*\X5\O^M:>G;3<MLWQ3Q\JMM4=+
M\F&5M#,=5U4_;WNK*H?9]E%5-23*7R/.:"YBRC4[=[W_`*7`J.Y>!Z,=O7:!
M;M>DNR"ZH_\7`7H//Z[I%%0(7&<S[%2:'2:948FAEC'OY=W;[E3KT7M)X]Y+
M&O=?TGA@W99RK]UVLTHO:16E-CUYNL>JKH=]RGO8BJ_\1)N2+*OK92$KV#$J
MUHL)P(@?K_L4Y$4M"DTP0W1[Q';#ZWQ=PM"G6`*=/3!<R%2BMXV">>)S22JJ
M8@'E*FIM+C`5?:%7_RPH();GI1YD\1<0/Y0UNT2^\K%R`_&G)TR5QKS"<!9*
MN_O]F5'PXSV6'C"RXGP!<E$6ZE<HJ'H(!;UO/0PV:+?%)(PBE;B4YR90[1K/
M$TOY*Y`W3BV/DVCV%)9PF"W%8ZGP+8KM-W]*<NRK,++=:/6MT^XVFFWKR_Q<
M\?QYY^66=747J@6@O(5;V8:UM9R4(9);EO%J8[6!KJB?^?*AGV(6O7T_HRBF
M9^BV@BZJ-D#@IT1RK!N$*1U4_DTEF^LG`;%"D66AD\](H6.SJN(2BV->TQ*&
M]KCW*K%]_ZO?:K2[UKGG9^55GI57X:%XP1;MHGM>HVT3(KKI-P_BE&_ZGLCC
MY-5/,8NEEBY@/M2!(NM1D;#@Y=<E/WP47X.9S(_6V7KT=.7,*%"'B38ZYD77
M^P3)5PH'L@85U>R@A&,+$EM<W0$6HI>/J_M>G33==ZI47DD28JZ9`II50N^2
MY&\T4]W1XGZUBU3CDDRDPB(`?'3$+BCE!G>R%+)62:R3:2\O3F[N0`_<I*+5
M,)M:VRP->=DMSF]%E53^7.&4O"D3[0H)KWNLP?7$%0M2%`M3XPUJMJOG$C])
M:<#"YPOCY6!)8>`B^]G<9M^M1K-I4_1.V;>MTK;WY<_3UUZ:4?73]&6>ARR0
M]<RL.GR84;V4[Z05C&U,4\O\)>Q*V?[E/:>NYX]U9>7;LA])T84MBN^=5[>C
MO$:J_E@\)>MHFF7@OMA^?;[2:A!.*>RIPM"H*[57]1\3;V*O)FI2_VH^,UW?
M:<?+V;78T#>QP9)?S]3;.(AU0_T<7M5R5`3!ERQH4(N>>[['7*FE5?:G>(W"
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M?NGQ]4M)0K_T0/JE]_<<R"[L\#-65(HY;NG%KWDN<)]`F)K>5;"_4]4<N"*#
MV4<6"55%>&#,/:Z@4^A18J&^,P<T)W1R;^[GK,5^U&\/B)5TJ@*4;EIXR:]&
M%[A1[_;96M`#526<\)PTD*XQ!0A5^83P%S^Q][O7?F!O[P%+='D;".J/E`H_
M6K3&>LK-/.#M7_/HRV-ZIDW(9]K,[RN0XF::-837+S?\FP&-UH_V(FH$G1NV
M6U#U76*>(BIQK9./5+^7(^/`:W70/1ZX*W_X4SS&NFX[2%PAEOM>R2FWEPD8
MX2>39U644S_,?0NJ*OVN;,\4\.0;=7-3T'KEE^I1N__E+]?_\C_=7OM?S$*S
MA1$.O%:?ZQM$JE`P?.7TX1NY0&UC5$Y>"A"IM[:YG2,+,6_U2I6]-&_Q+DVS
M;_\_4$L!`A0#%`````@`YXQL1Z29:DG[`0``42(``!,``````````````(`!
M`````%M#;VYT96YT7U1Y<&5S72YX;6Q02P$"%`,4````"`#GC&Q'2'4%[L4`
M```K`@``"P``````````````@`$L`@``7W)E;',O+G)E;'-02P$"%`,4````
M"`#GC&Q'4S)NIOT!```E(@``&@``````````````@`$:`P``>&PO7W)E;',O
M=V]R:V)O;VLN>&UL+G)E;'-02P$"%`,4````"`#GC&Q'6'"'!UX#``#.#0``
M$```````````````@`%/!0``9&]C4')O<',O87!P+GAM;%!+`0(4`Q0````(
M`.>,;$?H.'Q9/@$``&D#```1``````````````"``=L(``!D;V-0<F]P<R]C
M;W)E+GAM;%!+`0(4`Q0````(`.>,;$>97)PC$`8``)PG```3````````````
M``"``4@*``!X;"]T:&5M92]T:&5M93$N>&UL4$L!`A0#%`````@`YXQL1P0$
M&N4Y`@``YP@```T``````````````(`!B1```'AL+W-T>6QE<RYX;6Q02P$"
M%`,4````"`#GC&Q'8F'#[+\$``#>$0``#P``````````````@`'M$@``>&PO
M=V]R:V)O;VLN>&UL4$L!`A0#%`````@`YXQL1P%(X?H_`@``C`<``!@`````
M`````````(`!V1<``'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+`0(4`Q0`
M```(`.>,;$>F4-*'-`0``$D3```8``````````````"``4X:``!X;"]W;W)K
M<VAE971S+W-H965T,BYX;6Q02P$"%`,4````"`#GC&Q'VY%N`^`!``!:!0``
M&```````````````@`&X'@``>&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L!
M`A0#%`````@`YXQL1RM56-=:!```%Q,``!@``````````````(`!SB```'AL
M+W=O<FMS:&5E=',O<VAE970T+GAM;%!+`0(4`Q0````(`.>,;$=[OQ7CG@(`
M`!4)```8``````````````"``5XE``!X;"]W;W)K<VAE971S+W-H965T-2YX
M;6Q02P$"%`,4````"`#GC&Q'05@5!U8$``!/%@``&```````````````@`$R
M*```>&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L!`A0#%`````@`YXQL1Y4*
M07"9`0``KP,``!@``````````````(`!OBP``'AL+W=O<FMS:&5E=',O<VAE
M970W+GAM;%!+`0(4`Q0````(`.>,;$=,6N@[GP0``/`5```8````````````
M``"``8TN``!X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"%`,4````"`#G
MC&Q'MJ;>JZ$!``"Q`P``&```````````````@`%B,P``>&PO=V]R:W-H965T
M<R]S:&5E=#DN>&UL4$L!`A0#%`````@`YXQL1ZE[X:*B`0``L0,``!D`````
M`````````(`!.34``'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"%`,4
M````"`#GC&Q'+R/+9I\!``"Q`P``&0``````````````@`$2-P``>&PO=V]R
M:W-H965T<R]S:&5E=#$Q+GAM;%!+`0(4`Q0````(`.>,;$>7=9W_H@$``+`#
M```9``````````````"``>@X``!X;"]W;W)K<VAE971S+W-H965T,3(N>&UL
M4$L!`A0#%`````@`YXQL1ZZ4-K"C`0``L0,``!D``````````````(`!P3H`
M`'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"%`,4````"`#GC&Q'4_;]
MJ:`!``"Q`P``&0``````````````@`&;/```>&PO=V]R:W-H965T<R]S:&5E
M=#$T+GAM;%!+`0(4`Q0````(`.>,;$?H/J!6H@$``+$#```9````````````
M``"``7(^``!X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L!`A0#%`````@`
MYXQL1QNL7*JA`0``L0,``!D``````````````(`!2T```'AL+W=O<FMS:&5E
M=',O<VAE970Q-BYX;6Q02P$"%`,4````"`#GC&Q'*.K*-J$!``"Q`P``&0``
M````````````@`$C0@``>&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+`0(4
M`Q0````(`.>,;$<.?DQ*HP$``+$#```9``````````````"``?M#``!X;"]W
M;W)K<VAE971S+W-H965T,3@N>&UL4$L!`A0#%`````@`YXQL1\FIU`BA`0``
ML0,``!D``````````````(`!U44``'AL+W=O<FMS:&5E=',O<VAE970Q.2YX
M;6Q02P$"%`,4````"`#GC&Q'_IB7KZ(!``"Q`P``&0``````````````@`&M
M1P``>&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+`0(4`Q0````(`.>,;$?/
M6L'XH@$``+$#```9``````````````"``89)``!X;"]W;W)K<VAE971S+W-H
M965T,C$N>&UL4$L!`A0#%`````@`YXQL1RGGZ"&B`0``L0,``!D`````````
M`````(`!7TL``'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"%`,4````
M"`#GC&Q'!L1F.Z0!``"Q`P``&0``````````````@`$X30``>&PO=V]R:W-H
M965T<R]S:&5E=#(S+GAM;%!+`0(4`Q0````(`.>,;$=.'-XCH@$``+$#```9
M``````````````"``1-/``!X;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L!
M`A0#%`````@`YXQL1S^JY!.C`0``L0,``!D``````````````(`![%```'AL
M+W=O<FMS:&5E=',O<VAE970R-2YX;6Q02P$"%`,4````"`#GC&Q';13G^&<"
M``!2"0``&0``````````````@`'&4@``>&PO=V]R:W-H965T<R]S:&5E=#(V
M+GAM;%!+`0(4`Q0````(`.>,;$=.P(IKHP$``+$#```9``````````````"`
M`615``!X;"]W;W)K<VAE971S+W-H965T,C<N>&UL4$L!`A0#%`````@`YXQL
M1S,KG]&@`0``L0,``!D``````````````(`!/E<``'AL+W=O<FMS:&5E=',O
M<VAE970R."YX;6Q02P$"%`,4````"`#GC&Q')(L/O*$!``"Q`P``&0``````
M````````@`$560``>&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+`0(4`Q0`
M```(`.>,;$=N!FEGHP$``+$#```9``````````````"``>U:``!X;"]W;W)K
M<VAE971S+W-H965T,S`N>&UL4$L!`A0#%`````@`YXQL1^-=32BE`0``L0,`
M`!D``````````````(`!QUP``'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q0
M2P$"%`,4````"`#GC&Q'[]:=M:(!``"Q`P``&0``````````````@`&C7@``
M>&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+`0(4`Q0````(`.>,;$=`M9K-
MH@$``+$#```9``````````````"``7Q@``!X;"]W;W)K<VAE971S+W-H965T
M,S,N>&UL4$L!`A0#%`````@`YXQL1RX]KA6D`0``L0,``!D`````````````
M`(`!56(``'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"%`,4````"`#G
MC&Q'T'YRBZ(!``"Q`P``&0``````````````@`$P9```>&PO=V]R:W-H965T
M<R]S:&5E=#,U+GAM;%!+`0(4`Q0````(`.>,;$?_=<`FKP$``!8$```9````
M``````````"``0EF``!X;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L!`A0#
M%`````@`YXQL1XTCR11P`@``"`@``!D``````````````(`![V<``'AL+W=O
M<FMS:&5E=',O<VAE970S-RYX;6Q02P$"%`,4````"`#GC&Q'7N586D4#``#E
M#@``&0``````````````@`&6:@``>&PO=V]R:W-H965T<R]S:&5E=#,X+GAM
M;%!+`0(4`Q0````(`.>,;$?+W?5&Q0(``,$)```9``````````````"``1)N
M``!X;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L!`A0#%`````@`YXQL1P+H
M4NU]`@``%@@``!D``````````````(`!#G$``'AL+W=O<FMS:&5E=',O<VAE
M970T,"YX;6Q02P$"%`,4````"`#GC&Q'C-_*BJ("```2"0``&0``````````
M````@`'"<P``>&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+`0(4`Q0````(
M`.>,;$=0R`T@_`(``&0+```9``````````````"``9MV``!X;"]W;W)K<VAE
M971S+W-H965T-#(N>&UL4$L!`A0#%`````@`YXQL1^RA4^N/`P``;0\``!D`
M`````````````(`!SGD``'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"
M%`,4````"`#GC&Q'^Y^ZS=@"``!T"@``&0``````````````@`&4?0``>&PO
M=V]R:W-H965T<R]S:&5E=#0T+GAM;%!+`0(4`Q0````(`.>,;$?EF+;:\`(`
M`(D,```9``````````````"``:.```!X;"]W;W)K<VAE971S+W-H965T-#4N
M>&UL4$L!`A0#%`````@`YXQL1_N-]J[.`P``:!(``!D``````````````(`!
MRH,``'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"%`,4````"`#GC&Q'
M5V(7`FT"``#[!P``&0``````````````@`'/AP``>&PO=V]R:W-H965T<R]S
M:&5E=#0W+GAM;%!+`0(4`Q0````(`.>,;$<R7F`=.0,``!D.```9````````
M``````"``7.*``!X;"]W;W)K<VAE971S+W-H965T-#@N>&UL4$L!`A0#%```
M``@`YXQL1TNWH2>M`0``#`0``!D``````````````(`!XXT``'AL+W=O<FMS
M:&5E=',O<VAE970T.2YX;6Q02P$"%`,4````"`#GC&Q'A[8@!J(!``"Q`P``
M&0``````````````@`''CP``>&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+
M`0(4`Q0````(`.>,;$?HE0H2:@(``,8(```9``````````````"``:"1``!X
M;"]W;W)K<VAE971S+W-H965T-3$N>&UL4$L!`A0#%`````@`YXQL1Y=X9^=Q
M`@``_P@``!D``````````````(`!090``'AL+W=O<FMS:&5E=',O<VAE970U
M,BYX;6Q02P$"%`,4````"`#GC&Q'[08%`#8"``"L!P``&0``````````````
M@`'IE@``>&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+`0(4`Q0````(`.>,
M;$=%Y9@[#0(``+,%```9``````````````"``5:9``!X;"]W;W)K<VAE971S
M+W-H965T-30N>&UL4$L!`A0#%`````@`YXQL1\:ZV)87`@``/08``!D`````
M`````````(`!FIL``'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6Q02P$"%`,4
M````"`#GC&Q'XE(,5[4!``!@!```&0``````````````@`'HG0``>&PO=V]R
M:W-H965T<R]S:&5E=#4V+GAM;%!+`0(4`Q0````(`.>,;$?LNH6/530``/KV
M```4``````````````"``=2?``!X;"]S:&%R9613=')I;F=S+GAM;%!+!08`
1````00!!`+D1``!;U```````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140666867287728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefits (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_iccc_EmployeeBenefitsTextualAbstract', window );"><strong>Employee Benefits (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_iccc_EmployeeSavingsPlanDescription', window );">Employee savings plan description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">One month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansGeneralInformation', window );">Defined benefit plans general information</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">August 2012 we have matched 100% of the first 3% of each employee's salary that is contributed to the Plan and 50% of the next 2% of each employee's salary that is contributed to the Plan.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitsPaid', window );">Defined benefit plan benefits paid</a></td>
<td class="nump">$ 17,102<span></span>
</td>
<td class="nump">$ 17,117<span></span>
</td>
<td class="nump">$ 54,157<span></span>
</td>
<td class="nump">$ 47,920<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_EmployeeBenefitsTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_EmployeeBenefitsTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_EmployeeSavingsPlanDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of employee completing service under saving plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_EmployeeSavingsPlanDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of payments made for which participants are entitled under a pension plan, including pension benefits, death benefits, and benefits due on termination of employment. Also includes payments made under a postretirement benefit plan, including prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services. This item represents a periodic decrease to the plan obligations and a decrease to plan assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 715<br><br><br><br> -SubTopic 60<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39716-114964<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Benefits<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49170737<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 715<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)(6)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=58740216&amp;loc=d3e1928-114920<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Postretirement Benefits<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6521376<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 715<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)(5)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=58740216&amp;loc=d3e1928-114920<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlansGeneralInformation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>General information regarding defined benefit plans. A defined benefit pension plan is a plan that defines an amount of pension benefit to be provided, usually as a function of one or more factors such as age, years of service, or compensation. An other postretirement defined benefit plan is an arrangement that is mutually understood by an employer and its employees, whereby an employer undertakes to provide its employees with benefits other than pensions, after they retire in exchange for their services over a specified period of time, upon attaining a specified age while in service, or a combination of both. Any plan that is not a defined contribution plan is a defined benefit plan. General descriptive information about the employer's defined benefit plans, including employee groups covered, type of benefit formula, type of benefits, cost sharing arrangements, funding policy, types of assets held, and significant nonbenefit liabilities, if any. Also includes information pertaining to multiple employer plans, which are accounted for as single-employer plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 715<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=58740216&amp;loc=d3e1928-114920<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Defined Benefit Plan<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49172387<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlansGeneralInformation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140666933964256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Bank Debt (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Mar. 31, 2011</div></th>
<th class="th"><div>Sep. 30, 2010</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingFixedInterestRate', window );">Long-term debt, percentage bearing fixed interest, percentage rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_iccc_DerivativesInterestRateSwapPayments', window );">Derivatives interest rate swap payments</a></td>
<td class="nump">$ 5,112<span></span>
</td>
<td class="nump">$ 5,538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,549<span></span>
</td>
<td class="nump">$ 16,726<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">$ (49,147)<span></span>
</td>
<td class="nump">$ 5,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (48,059)<span></span>
</td>
<td class="nump">193<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityDescription', window );">Line of credit facility, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">a wholly owned subsidiary of TD Financial Group, which is a multinational bank with approximately $944 billion in assets and over 22 million clients worldwide<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization of mortgage loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,074<span></span>
</td>
<td class="nump">$ 2,158<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=us-gaap_InterestRateSwapMember', window );">Interest Rate Swap [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingFixedInterestRate', window );">Long-term debt, percentage bearing fixed interest, percentage rate</a></td>
<td class="nump">4.38%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.04%<span></span>
</td>
<td class="nump">4.38%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_DerivativeNotionalAmount', window );">Derivative notional amount</a></td>
<td class="nump">$ 3,259,963<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="nump">$ 3,259,963<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=us-gaap_MortgagesMember', window );">Mortgages [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization of mortgage loan</a></td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=iccc_MortgagesOneMember', window );">Mortgages 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MortgageLoansOnRealEstatePeriodicPaymentTermsBalloonPaymentToBeReceived', window );">Balloon principal payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 451,885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MortgageLoansOnRealEstatePeriodicPaymentTerms', window );">Mortgage loans on real estate periodic payment terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Will be due during the third quarter of 2020.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingVariableInterestRate', window );">Long-term debt, percentage bearing variable interest, percentage rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.46%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=iccc_MortgagesTwoMember', window );">Mortgages 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument term</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of long-term debt</a></td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MortgageLoansOnRealEstatePeriodicPaymentTermsBalloonPaymentToBeReceived', window );">Balloon principal payment</a></td>
<td class="nump">$ 1,550,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,550,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MortgageLoansOnRealEstatePeriodicPaymentTerms', window );">Mortgage loans on real estate periodic payment terms</a></td>
<td class="text">Will be due during the third quarter of 2025.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtPercentageBearingVariableInterestRate', window );">Long-term debt, percentage bearing variable interest, percentage rate</a></td>
<td class="nump">2.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=us-gaap_LineOfCreditMember', window );">Line Of Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDateDescription', window );">Debt instrument, maturity date, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The $500,000 line of credit is available as needed and has been extended through May 31, 2016 and is renewable annually thereafter.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis', window );">Debt Instrument, Description of Variable Rate Basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div>Interest on any borrowings against the line of credit would be variable at the higher of 4.25% per annum or the one-month LIBOR plus 3.5% per annum.</div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_DerivativesInterestRateSwapPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents payment required by the interest rate swap during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_DerivativesInterestRateSwapPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_invest_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate notional amount specified by the derivative(s). Expressed as an absolute value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Article 12<br><br><br><br> -Section 13<br><br><br><br> -Sentence Column B<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">invest_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>invest_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentForAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentDescriptionOfVariableRateBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The reference rate for the variable rate of the debt instrument, such as LIBOR or the US Treasury rate and the maturity of the reference rate used, such as three months or six months LIBOR.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentDescriptionOfVariableRateBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDateDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the maturity date of the debt instrument including whether the debt matures serially and, if so, a brief description of the serial maturities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22(a)(2))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDateDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the terms of a credit facility arrangement. Terms typically include interest rate, collateral required, guarantees required, repayment requirements, and restrictions on use of assets and activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(b),22(b))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtPercentageBearingFixedInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a set, unchanging rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtPercentageBearingFixedInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtPercentageBearingVariableInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The interest rate applicable to the portion of the carrying amount of long-term borrowings outstanding as of the balance sheet date, including current maturities, which accrues interest at a rate subject to change from time to time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtPercentageBearingVariableInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MortgageLoansOnRealEstatePeriodicPaymentTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the contractual payment terms of the loan receivable including whether principal and interest is payable at a level or varying amount over the life of the loan, the amount of any balloon payment required at maturity, and any prepayment penalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 205<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 6<br><br><br><br> -Subparagraph (SX 210.5-04.(c) Schedule IV)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27047687&amp;loc=d3e5864-122674<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 948<br><br><br><br> -SubTopic 310<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.12-29.5)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6589523&amp;loc=d3e617274-123014<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MortgageLoansOnRealEstatePeriodicPaymentTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MortgageLoansOnRealEstatePeriodicPaymentTermsBalloonPaymentToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of large payment to be received at final maturity date of mortgage loans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 948<br><br><br><br> -SubTopic 310<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.12-29.5)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6589523&amp;loc=d3e617274-123014<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 205<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 6<br><br><br><br> -Subparagraph (SX 210.5-04.(c) Schedule IV)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27047687&amp;loc=d3e5864-122674<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MortgageLoansOnRealEstatePeriodicPaymentTermsBalloonPaymentToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1A<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669619-108580<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1B<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669625-108580<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 15<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51821188&amp;loc=d3e1436-108581<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3255-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Financing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3255-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Financing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=us-gaap_MortgagesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=us-gaap_MortgagesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=iccc_MortgagesOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=iccc_MortgagesOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=iccc_MortgagesTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=iccc_MortgagesTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140667078116144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract', window );"><strong>Accounts Payable and Accrued Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of accounts payable and accrued expenses</a></td>
<td class="text"><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: center; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"><b>As of</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"><b>September&#160;30, 2015</b></font></p></td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: center; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"><b>As of</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"><b>December&#160;31, 2014</b></font></p></td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: center; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"><b>(Decrease)</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"><b>Increase</b></font></p></td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1003px; text-align: left; text-indent: 0pt; padding-left: 0pt;">Accounts payable &#8211; capital</td><td style="width: 16px; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="width: 16px; text-align: left; text-indent: 0pt; padding-left: 0pt;">$</td><td style="width: 142px; text-align: right; text-indent: 0pt; padding-left: 0pt;">37,965</td><td style="width: 16px; text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="width: 16px; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="width: 16px; text-align: left; text-indent: 0pt; padding-left: 0pt;">$</td><td style="width: 141px; text-align: right; text-indent: 0pt; padding-left: 0pt;">251,383</td><td style="width: 15px; text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="width: 15px; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="width: 15px; text-align: left; text-indent: 0pt; padding-left: 0pt;">$</td><td style="width: 141px; text-align: right; text-indent: 0pt; padding-left: 0pt;">(213,418</td><td style="width: 15px; text-align: left; text-indent: 0pt; padding-left: 0pt;">)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">Accounts payable &#8211; trade</td><td style="text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt;">178,542</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt;">204,810</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt;">(26,268</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">)</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">Accrued payroll</td><td style="text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt;">134,466</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt;">145,176</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt;">(10,710</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">Accrued clinical studies</td><td style="text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt;">68,428</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left:
 0pt;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt;">131,945</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt;">(63,517</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">)</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">Accrued professional fees</td><td style="text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt;">55,462</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt;">42,250</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt;">13,212</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">Accrued other</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">71,064</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">76,113</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(5,049</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">)</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;">&#160;&#160;&#160;Total</td><td style="text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">545,927</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">851,677</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">(305,750</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;">)</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140667120139056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><div><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 0.5in; padding-left: 0pt;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>17.</b></font></td><td style="padding-left: 0pt;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>SUBSEQUENT EVENTS</b></font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>&#160;</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">We have adopted the disclosure provisions of Codification Topic 855-10-50-1,&#160;<i>Subsequent Events</i>, which provides guidance to establish general standards of accounting for and disclosures of events that occur after the balance sheet date but before financial statements are issued. Codification Topic 855-10-50-1 requires additional disclosures only, and therefore did not have an impact on our financial condition, results of operations, earnings per share or cash flows. Entities are required to disclose the date through which subsequent events were evaluated as well as the rationale for why that date was selected. Public entities must evaluate subsequent events through the date that financial statements are issued. Accordingly, we have evaluated subsequent events through the time of filing on November 12, 2015, the date we have issued this Quarterly Report on Form 10-Q. This disclosure should alert all users of financial statements that an entity has not evaluated subsequent events after that date in the set of financial statements being presented.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">During the fourth quarter of 2015, we entered into a revised agreement with Plas-Pak Inc. of Norwich, Connecticut covering the supply of plastic syringes used to deliver&#160;<b>Mast Out<sup>&#174;</sup></b>, effective through the year ending December 31, 2020. On October 28, 2015, we filed a registration statement on Form S-3 with the SEC for the potential issuance of up to $10,000,000 in equity (subject to certain limitations). We filed Pre-Effective Amendment No. 1 on November 5, 2015, and our registration statement became effective on November 10, 2015. During the fourth quarter of 2015, our Board of Directors voted to exercise an option to acquire land nearby to our existing Portland facility for a potential site for a&#160;<b>Mast Out<sup>&#174;</sup></b>&#160;production facility for $238,000 (less the $23,800 option payment that was paid during the third quarter of 2015).</font></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140667120139056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Rights Plan (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_iccc_CommonStockRightsPlanTextualAbstract', window );"><strong>Common Stock Rights Plan [Textual]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockVotingRights', window );">Common stock, controlling the rights percentage</a></td>
<td class="text">Owner of more than 20% of our stock)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_CommonStockRightsPlanTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_CommonStockRightsPlanTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockVotingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of voting rights of common stock. Includes eligibility to vote and votes per share owned. Include also, if any, unusual voting rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockVotingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140666940452352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Assets (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Prepaid Expenses and Other Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Prepaid expenses and other assets</a></td>
<td class="nump">$ 234,628<span></span>
</td>
<td class="nump">$ 133,119<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDeposit', window );">Security deposits</a></td>
<td class="nump">40,931<span></span>
</td>
<td class="nump">15,280<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Current subtotal</a></td>
<td class="nump">275,559<span></span>
</td>
<td class="nump">148,399<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issue costs</a></td>
<td class="nump">59,248<span></span>
</td>
<td class="nump">26,489<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedAmortizationDeferredFinanceCosts', window );">Accumulated amortization of debt issue costs</a></td>
<td class="num">(18,553)<span></span>
</td>
<td class="num">(16,479)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositAssets', window );">Security deposits</a></td>
<td class="nump">8,920<span></span>
</td>
<td class="nump">8,920<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Long-term subtotal</a></td>
<td class="nump">49,615<span></span>
</td>
<td class="nump">18,930<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssets', window );">Total</a></td>
<td class="nump">325,174<span></span>
</td>
<td class="nump">$ 167,329<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Increase (Decrease) in Prepaid expenses and other assets</a></td>
<td class="nump">101,509<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInSecurityDeposits', window );">Increase (Decrease) in Security deposits</a></td>
<td class="nump">25,651<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets', window );">Increase (Decrease) in Current subtotal</a></td>
<td class="nump">127,160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_iccc_IncreaseDecreaseDebtIssueCosts', window );">Increase (Decrease) in Debt issue costs</a></td>
<td class="nump">32,759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_iccc_IncreaseDecreaseAccumulatedAmortizationOfDebtIssueCosts', window );">Increase (Decrease) in Accumulated amortization of debt issue costs</a></td>
<td class="num">(2,074)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherDeposits', window );">Increase (Decrease) in Security deposits</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Increase (Decrease) in Long-term subtotal</a></td>
<td class="nump">30,685<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_iccc_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssetsIncludingAmortization', window );">Increase (Decrease) in Prepaid expenses and other assets, Total</a></td>
<td class="nump">$ 157,845<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_IncreaseDecreaseAccumulatedAmortizationOfDebtIssueCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in accumulated amortization of debt issue costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_IncreaseDecreaseAccumulatedAmortizationOfDebtIssueCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_IncreaseDecreaseDebtIssueCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_IncreaseDecreaseDebtIssueCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssetsIncludingAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in prepaid deferred expense and other assets including amortization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssetsIncludingAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedAmortizationDeferredFinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, the accumulated amortization, as of the reporting date, representing the periodic charge to earnings of deferred costs which are associated with debt obligations existing as of the end of the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedAmortizationDeferredFinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, the carrying amount (net of accumulated amortization) as of the balance sheet date of capitalized costs associated with the issuance of debt instruments (for example, legal, accounting, underwriting, printing, and registration costs) that will be charged against earnings over the life of the debt instruments to which such costs pertain.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 835<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28555-108399<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of the asset transferred to a third party to serve as a deposit, which typically serves as security against failure by the transferor to perform under terms of an agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.8,17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other current operating assets not separately disclosed in the statement of cash flows.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net cash inflow or outflow in all other deposits that have not otherwise been stated in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3095-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other noncurrent operating assets not separately disclosed in the statement of cash flows.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInSecurityDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in security deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInSecurityDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (g)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6787-107765<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDeposit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.8,17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDeposit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140666866842080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Net Income (Loss) Per Common Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of shares outstanding</a></td>
<td class="nump">3,052,175<span></span>
</td>
<td class="nump">3,027,034<span></span>
</td>
<td class="nump">3,038,111<span></span>
</td>
<td class="nump">3,026,990<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_iccc_EffectOfDilutiveStockOptions', window );">Effect of dilutive stock options</a></td>
<td class="nump">136,174<span></span>
</td>
<td class="nump">78,798<span></span>
</td>
<td class="nump">124,509<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted number of shares outstanding</a></td>
<td class="nump">3,188,349<span></span>
</td>
<td class="nump">3,105,832<span></span>
</td>
<td class="nump">3,162,620<span></span>
</td>
<td class="nump">3,026,990<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Stock options outstanding as of September 30th not included in the calculation because the effect would be anti-dilutive</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">85,000<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="nump">251,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_EffectOfDilutiveStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of dilutive stock options included in calculation of net income(loss) per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_EffectOfDilutiveStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Antidilution<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Diluted Earnings Per Share<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Contingent Stock Agreement<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 16<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1505-109256<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 10<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1448-109256<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Weighted-Average Number of Common Shares Outstanding<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6528421<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140666933621008">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Segment and Significant Customer Information (Details 1)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=iccc_AnimalHealthInternationalIncMember', window );">Animal Health International, Inc. [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_iccc_AccountsReceivableDueFromSignificantCustomers', window );">Accounts receivable due from significant customers</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">37.00%<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=iccc_MwiVeterinarySupplyCompanyMember', window );">MWI Animal Health [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_iccc_AccountsReceivableDueFromSignificantCustomers', window );">Accounts receivable due from significant customers</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">26.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=iccc_AnimartLlcMember', window );">TCS Biosciences, Ltd. [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_iccc_AccountsReceivableDueFromSignificantCustomers', window );">Accounts receivable due from significant customers</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">13.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">During June 2015, Patterson Companies, Inc. (NASDAQ: PDCO) acquired Animal Health International, Inc.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">During March 2015, AmerisourceBergen Corporation (NYSE: ABC) acquired MWI Animal Health.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top">Amount is less than 10%.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_AccountsReceivableDueFromSignificantCustomers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage amounts represents to accounts receivable due from significant customers as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_AccountsReceivableDueFromSignificantCustomers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideRevenueMajorCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideRevenueMajorCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=iccc_AnimalHealthInternationalIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=iccc_AnimalHealthInternationalIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=iccc_MwiVeterinarySupplyCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=iccc_MwiVeterinarySupplyCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=iccc_AnimartLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=iccc_AnimartLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140666936863888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Expenses, Net (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Expenses, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeOther', window );">Interest income</a></td>
<td class="num">$ (4,461)<span></span>
</td>
<td class="num">$ (3,912)<span></span>
</td>
<td class="num">$ (10,634)<span></span>
</td>
<td class="num">$ (11,607)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseOther', window );">Interest expense</a></td>
<td class="nump">15,084<span></span>
</td>
<td class="nump">14,514<span></span>
</td>
<td class="nump">41,039<span></span>
</td>
<td class="nump">44,148<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingGainsLosses', window );">Other</a></td>
<td class="nump">4,488<span></span>
</td>
<td class="nump">644<span></span>
</td>
<td class="num">(3,346)<span></span>
</td>
<td class="nump">6,092<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other expenses, net</a></td>
<td class="nump">$ 15,111<span></span>
</td>
<td class="nump">$ 11,246<span></span>
</td>
<td class="nump">$ 27,059<span></span>
</td>
<td class="nump">$ 38,633<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest expense on all other items not previously classified. For example, includes dividends associated with redeemable preferred stock of a subsidiary that is treated as a liability in the parent's consolidated balance sheet.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4D<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=SL5624177-113959<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph -4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income earned from interest bearing assets not separately disclosed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.7)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other aggregate amounts of gains or losses resulting from nonoperating activities (for example, interest and dividend revenue, property, plant and equipment impairment loss, and so forth.) not otherwise defined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.7,9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140666939963952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Operations<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Business Operations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">BUSINESS OPERATIONS</a></td>
<td class="text"><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="padding-left: 0pt; text-indent: 0pt; width: 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>1.</b></font></td><td style="padding-left: 0pt; text-indent: 0pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>BUSINESS OPERATIONS</b></font></td></tr></table><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">ImmuCell Corporation (the Company) is a growing animal health company whose purpose is to create scientifically-proven and practical products that result in a measurable economic impact on animal health and productivity in the dairy and beef industries. The Company was originally incorporated in Maine in 1982 and reincorporated in Delaware in 1987, in conjunction with its initial public offering of common stock. We market products that provide immediate immunity to newborn dairy and beef cattle. We are developing product line extensions of our existing products and are in the late stages of developing a new product that addresses mastitis, the most significant cause of economic loss to the dairy industry. The Company is subject to certain risks associated with its stage of development including dependence on key individuals, competition from other larger companies, the successful sale of existing products and the development and acquisition of additional commercially viable products with appropriate regulatory approvals, where applicable. These and other risks to our company are further detailed under <b>PART II: OTHER INFORMATION, ITEM 1A &#8211; RISK FACTORS</b>.</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 275<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6003-108592<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 275<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2A<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=SL51803626-108592<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140666939799040">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MachineryAndEquipmentGross', window );">Laboratory and manufacturing equipment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3,602,690<span></span>
</td>
<td class="nump">$ 3,522,465<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BuildingsAndImprovementsGross', window );">Building and improvements</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,579,852<span></span>
</td>
<td class="nump">2,969,891<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FurnitureAndFixturesGross', window );">Office furniture and equipment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">569,567<span></span>
</td>
<td class="nump">470,607<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">738,282<span></span>
</td>
<td class="nump">1,270,672<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Land', window );">Land</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">72,807<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">9,563,198<span></span>
</td>
<td class="nump">8,283,635<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(4,607,584)<span></span>
</td>
<td class="num">(4,445,988)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,955,614<span></span>
</td>
<td class="nump">$ 3,837,647<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGrossPeriodIncreaseDecrease', window );">Property, plant and equipment, gross increase (decrease)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,279,563<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentPeriodIncreaseDecrease', window );">Less: accumulated depreciation increase (decrease)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(161,596)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_iccc_PropertyPlantAndEquipmentnetPeriodIncreaseDecrease', window );">Property, plant and equipment, net increase (decrease)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,117,967<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember', window );">Laboratory and manufacturing equipment [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGrossPeriodIncreaseDecrease', window );">Property, plant and equipment, gross increase (decrease)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">80,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingImprovementsMember', window );">Building and improvements [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGrossPeriodIncreaseDecrease', window );">Property, plant and equipment, gross increase (decrease)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,609,961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office furniture and equipment [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGrossPeriodIncreaseDecrease', window );">Property, plant and equipment, gross increase (decrease)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">98,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in Progress [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGrossPeriodIncreaseDecrease', window );">Property, plant and equipment, gross increase (decrease)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(532,390)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Land [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGrossPeriodIncreaseDecrease', window );">Property, plant and equipment, gross increase (decrease)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 22,807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">As of December 31, 2014, construction in progress consisted of a building addition that was completed during the first quarter of 2015. As of September 30, 2015, construction in progress consisted principally of partial payments towards new manufacturing equipment.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_PropertyPlantAndEquipmentnetPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_PropertyPlantAndEquipmentnetPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.14)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The change during the period, from the beginning balance of accumulated depreciation, depletion and amortization (relating to property, plant and equipment) to the ending balance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipmentPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BuildingsAndImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of building structures held for productive use including addition, improvement, or renovation to the structure, including, but not limited to, interior masonry, interior flooring, electrical, and plumbing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -Subparagraph (f)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6812-107765<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BuildingsAndImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FurnitureAndFixturesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FurnitureAndFixturesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Land">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -Subparagraph (e)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6812-107765<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Land</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MachineryAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -Subparagraph (f)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6812-107765<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MachineryAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGrossPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGrossPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 7<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ManufacturingFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140667131002384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><div><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: justify; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: center; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>As of</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>September&#160;30, 2015</b></font></p></td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: center; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>As of</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>December&#160;31, 2014</b></font></p></td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: center; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>Increase</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>(Decrease)</b></font></p></td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1003px; text-align: justify; text-indent: 0pt; padding-left: 0pt;">Raw materials</td><td style="width: 16px; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="width: 16px; text-align: left; text-indent: 0pt; padding-left: 0pt;">$</td><td style="width: 142px; text-align: right; text-indent: 0pt; padding-left: 0pt;">337,538</td><td style="width: 16px; text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="width: 16px; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="width: 16px; text-align: left; text-indent: 0pt; padding-left: 0pt;">$</td><td style="width: 141px; text-align: right; text-indent: 0pt; padding-left: 0pt;">306,444</td><td style="width: 15px; text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="width: 15px; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="width: 15px; text-align: left; text-indent: 0pt; padding-left: 0pt;">$</td><td style="width: 141px; text-align: right; text-indent: 0pt; padding-left: 0pt;">31,094</td><td style="width: 15px; text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: justify; text-indent: 0pt; padding-left: 0pt;">Work-in-process</td><td style="text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt;">468,059</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt;">355,745</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt;">112,314</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">Finished goods</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">58,847</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">283,566</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(224,719</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-indent: 0pt; padding-bottom: 4pt; padding-left: 10pt;">Total</td><td style="text-indent: 0pt; padding-bottom: 4pt;
 padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">864,444</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">945,755</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">(81,311</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;">)</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 2<br><br><br><br> -Paragraph 6<br><br><br><br> -Subparagraph a,b,c<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140666936819648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, Cash Equivalents, Short-Term Investments and Long-Term Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>Cash, Cash Equivalents, Short-Term Investments and Long-Term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Schedule of cash, cash equivalents and short-term investments and long-term investments</a></td>
<td class="text"><div><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="padding-left: 0pt;">&#160;</td><td style="padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: center; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>As of</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>September&#160;30, 2015</b></font></p></td><td style="padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: center; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>As of</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>December&#160;31, 2014</b></font></p></td><td style="padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: center; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>Increase</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>(Decrease)</b></font></p></td><td style="padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1003px; text-align: left; padding-left: 0pt;">Cash and cash equivalents</td><td style="width: 16px; padding-left: 0pt;">&#160;</td><td style="width: 16px; text-align: left; padding-left: 0pt;">$</td><td style="width: 142px; text-align: right; padding-left: 0pt;">2,469,087</td><td style="width: 16px; text-align: left; padding-left: 0pt;">&#160;</td><td style="width: 16px; padding-left: 0pt;">&#160;</td><td style="width: 16px; text-align: left; padding-left: 0pt;">$</td><td style="width: 141px; text-align: right; padding-left: 0pt;">850,028</td><td style="width: 15px; text-align: left; padding-left: 0pt;">&#160;</td><td style="width: 15px; padding-left: 0pt;">&#160;</td><td style="width: 15px; text-align: left; padding-left: 0pt;">$</td><td style="width: 141px; text-align: right; padding-left: 0pt;">1,619,059</td><td style="width: 15px; text-align: left; padding-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt;">Short-term investments</td><td style="padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">3,720,000</td><td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">2,489,000</td><td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">1,231,000</td><td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="padding-left: 0pt;">&#160;&#160;&#160;Subtotal</td><td style="padding-left: 0pt;">&#160;</td><td style="text-align: left; padding-left: 0pt;">&#160;</td><td style="text-align: right; padding-left: 0pt;">6,189,087</td><td style="text-align: left; padding-left: 0pt;">&#160;</td><td style="padding-left: 0pt;">&#160;</td><td style="text-align: left; padding-left: 0pt;">&#160;</td><td style="text-align: right; padding-left: 0pt;">3,339,028</td><td style="text-align: left; padding-left: 0pt;">&#160;</td><td style="padding-left: 0pt;">&#160;</td><td style="text-align: left; padding-left: 0pt;">&#160;</td><td style="text-align: right; padding-left: 0pt;">2,850,059</td><td style="text-align: left; padding-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt;">Long-term investments</td><td style="padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">487,000</td><td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">496,000</td><td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="padding-bottom: 1.5pt;
 padding-left: 0pt;">&#160;</td><td style="text-align: left; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(9,000</td><td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt;">)</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="padding-bottom: 4pt; padding-left: 0pt;">&#160;&#160;&#160;Total</td><td style="padding-bottom: 4pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">6,676,087</td><td style="text-align: left; padding-bottom: 4pt; padding-left: 0pt;">&#160;</td><td style="padding-bottom: 4pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">3,835,028</td><td style="text-align: left; padding-bottom: 4pt; padding-left: 0pt;">&#160;</td><td style="padding-bottom: 4pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">2,841,059</td><td style="text-align: left; padding-bottom: 4pt; padding-left: 0pt;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140667077914672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - Subsequent Event [Member] - Plas Pak Inc [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 28, 2015</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PurchaseOptionsLand', window );">Option to acquire land</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 238,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LandPurchaseOptionsDescription', window );">Land purchase options, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">During the fourth quarter of 2015, our Board of Directors voted to exercise an option to acquire land nearby to our existing Portland facility for a potential site for a Mast Out&#174; production facility for $238,000 (less the $23,800 option payment that was paid during the third quarter of 2015).<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Potential issuance</a></td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LandPurchaseOptionsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes contracts, agreements and arrangements that give the entity unilateral rights to purchase the land covered by the option for a specified period of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 970<br><br><br><br> -SubTopic 340<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51679414&amp;loc=d3e29293-110302<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LandPurchaseOptionsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PurchaseOptionsLand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of an option or options to acquire real property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PurchaseOptionsLand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=iccc_PlasPakIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=iccc_PlasPakIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140666866841584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract', window );"><strong>Accounts Payable and Accrued Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableOtherCurrent', window );">Accounts payable - capital</a></td>
<td class="nump">$ 37,965<span></span>
</td>
<td class="nump">$ 251,383<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrent', window );">Accounts payable - trade</a></td>
<td class="nump">178,542<span></span>
</td>
<td class="nump">204,810<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedPayrollTaxesCurrent', window );">Accrued payroll</a></td>
<td class="nump">134,466<span></span>
</td>
<td class="nump">145,176<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_iccc_AccruedClinicalStudies', window );">Accrued clinical studies</a></td>
<td class="nump">68,428<span></span>
</td>
<td class="nump">131,945<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">55,462<span></span>
</td>
<td class="nump">42,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccountsPayableAndAccruedLiabilities', window );">Accrued other</a></td>
<td class="nump">71,064<span></span>
</td>
<td class="nump">76,113<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">545,927<span></span>
</td>
<td class="nump">$ 851,677<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapital', window );">(Decrease) Increase in Accounts payable - capital</a></td>
<td class="num">(213,418)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">(Decrease) Increase in Accounts payable - trade</a></td>
<td class="num">(26,268)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedSalaries', window );">(Decrease) Increase in Accrued payroll</a></td>
<td class="num">(10,710)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_iccc_IncreaseDecreaseInAccruedClinicalStudies', window );">(Decrease) Increase in Accrued clinical studies</a></td>
<td class="num">(63,517)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_iccc_IncreaseDecreaseInAccruedProfessionalFees', window );">(Decrease) Increase in Accrued professional fees</a></td>
<td class="nump">13,212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities', window );">(Decrease) Increase in Accrued other</a></td>
<td class="num">(5,049)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_iccc_IncreaseDecreaseInAccountsPayableAndAccruedExpenses', window );">(Decrease) Increase in Accounts payable and accrued expenses</a></td>
<td class="num">$ (305,750)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_AccruedClinicalStudies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable arising from transactions not otherwise specified in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_AccruedClinicalStudies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_IncreaseDecreaseInAccountsPayableAndAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in accounts payable and accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_IncreaseDecreaseInAccountsPayableAndAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_IncreaseDecreaseInAccruedClinicalStudies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in accrued clinical studies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_IncreaseDecreaseInAccruedClinicalStudies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_IncreaseDecreaseInAccruedProfessionalFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in accrued professional fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_IncreaseDecreaseInAccruedProfessionalFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19,20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, which are not elsewhere specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Current Liabilities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Current Liabilities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedPayrollTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory payroll taxes incurred through that date and withheld from employees pertaining to services received from them, including entity's matching share of the employees FICA taxes and contributions to the state and federal unemployment insurance programs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Current Liabilities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedPayrollTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Current Liabilities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedSalaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in accrued salaries.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedSalaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period of all assets and liabilities used in operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in other obligations or expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, including trade payables, incurred through that date and due within one year (or in the operating cycle if longer) arising from transactions not otherwise specified in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140666939954576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Receivable (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Accounts Receivable[Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Schedule of accounts receivable</a></td>
<td class="text"><div><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: center; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"><b>As of</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"><b>September&#160;30, 2015</b></font></p></td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: center; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"><b>As of</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"><b>December&#160;31, 2014</b></font></p></td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: center; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"><b>(Decrease)</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"><b>Increase</b></font></p></td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1003px; text-align: left; text-indent: 0pt; padding-left: 0pt;">Trade accounts receivable, gross</td><td style="width: 16px; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="width: 16px; text-align: left; text-indent: 0pt; padding-left: 0pt;">$</td><td style="width: 142px; text-align: right; text-indent: 0pt; padding-left: 0pt;">783,547</td><td style="width: 16px; text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="width: 16px; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="width: 16px; text-align: left; text-indent: 0pt; padding-left: 0pt;">$</td><td style="width: 141px; text-align: right; text-indent: 0pt; padding-left: 0pt;">1,004,990</td><td style="width: 15px; text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="width: 15px; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="width: 15px; text-align: left; text-indent: 0pt; padding-left: 0pt;">$</td><td style="width: 141px; text-align: right; text-indent: 0pt; padding-left: 0pt;">(221,443</td><td style="width: 15px; text-align: left; text-indent: 0pt; padding-left: 0pt;">)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">Accumulated allowance for bad debt and product returns</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(16,958</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">)</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(16,194</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">)</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(764</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">)</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;&#160;&#160;&#160;&#160;Trade accounts receivable, net</td><td style="text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt;">766,589</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt;">988,796</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td
 style="text-align: right; text-indent: 0pt; padding-left: 0pt;">(222,207</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">Other receivables</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">22,625</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">16,496</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">6,129</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;">&#160;&#160;&#160;&#160;&#160;Accounts receivable, net</td><td style="text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">789,214</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">1,005,292</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">(216,078</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;">)</td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.3,4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140667078115392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Prepaid Expenses and Other Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Schedule of prepaid expenses and other assets</a></td>
<td class="text"><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: center; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: center; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"><b>As of</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"><b>September&#160;30, 2015</b></font></p></td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt; font-weight: bold;">&#160;</td><td style="text-align: center; text-indent: 0pt; padding-left: 0pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">As of<br />December&#160;31, 2014</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt; font-weight: bold;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: center; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"><b>Increase</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"><b>(Decrease)</b></font></p></td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1003px; text-align: left; text-indent: 0pt; padding-left: 0pt;">Prepaid expenses and other assets</td><td style="width: 16px; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="width: 16px; text-align: left; text-indent: 0pt; padding-left: 0pt;">$</td><td style="width: 142px; text-align: right; text-indent: 0pt; padding-left: 0pt;">234,628</td><td style="width: 16px; text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="width: 16px; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="width: 16px; text-align: left; text-indent: 0pt; padding-left: 0pt;">$</td><td style="width: 141px; text-align: right; text-indent: 0pt; padding-left: 0pt;">133,119</td><td style="width: 15px; text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="width: 15px; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="width: 15px; text-align: left; text-indent: 0pt; padding-left: 0pt;">$</td><td style="width: 141px; text-align: right; text-indent: 0pt; padding-left: 0pt;">101,509</td><td style="width: 15px; text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">Security deposits</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">40,931</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">15,280</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">25,651</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;&#160;&#160;&#160;&#160;Current subtotal</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">275,559</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">148,399</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black;
 border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">127,160</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">Debt issue costs</td><td style="text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt;">59,248</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt;">26,489</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt;">32,759</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">Accumulated amortization of debt issue costs</td><td style="text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt;">(18,553</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">)</td><td style="text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt;">(16,479</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">)</td><td style="text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt;">(2,074</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">)</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">Security deposits</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">8,920</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">8,920</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">0</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;&#160;&#160;&#160;&#160;Long-term subtotal</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">49,615</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">18,930</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">30,685</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-indent: 0pt; padding-left:
 0pt;">&#160;</td><td style="text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;">&#160;&#160;&#160;&#160;&#160;Total</td><td style="text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">325,174</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">167,329</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">157,845</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140666864833200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 924,432<span></span>
</td>
<td class="num">$ (297,786)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income (loss) to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">378,475<span></span>
</td>
<td class="nump">330,796<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization</a></td>
<td class="nump">2,074<span></span>
</td>
<td class="nump">2,158<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndTaxCredits', window );">Deferred income taxes</a></td>
<td class="nump">680,087<span></span>
</td>
<td class="num">(146,401)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">17,825<span></span>
</td>
<td class="nump">22,265<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets', window );">(Gain) loss on disposal of fixed assets</a></td>
<td class="num">(3,984)<span></span>
</td>
<td class="nump">4,519<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInReceivables', window );">Receivables</a></td>
<td class="nump">216,078<span></span>
</td>
<td class="nump">67,846<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="nump">81,311<span></span>
</td>
<td class="nump">167,062<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(127,160)<span></span>
</td>
<td class="num">(185,676)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="num">(92,332)<span></span>
</td>
<td class="nump">78,992<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="num">(6,690)<span></span>
</td>
<td class="nump">6,690<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">2,070,116<span></span>
</td>
<td class="nump">50,465<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property, plant and equipment</a></td>
<td class="num">(1,772,091)<span></span>
</td>
<td class="num">(520,142)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments', window );">Maturities of investments</a></td>
<td class="nump">2,489,000<span></span>
</td>
<td class="nump">2,489,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Purchases of investments</a></td>
<td class="num">(3,711,000)<span></span>
</td>
<td class="num">(2,985,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of fixed assets</a></td>
<td class="nump">66,215<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used for) investing activities</a></td>
<td class="num">(2,927,876)<span></span>
</td>
<td class="num">(1,016,142)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from debt issuance</a></td>
<td class="nump">2,500,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Debt principal repayments</a></td>
<td class="num">(136,339)<span></span>
</td>
<td class="num">(141,647)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Debt issuance costs</a></td>
<td class="num">(32,759)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">120,210<span></span>
</td>
<td class="nump">3,150<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense', window );">Tax benefits related to stock options</a></td>
<td class="nump">25,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used for) financing activities</a></td>
<td class="nump">2,476,819<span></span>
</td>
<td class="num">(138,497)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</a></td>
<td class="nump">1,619,059<span></span>
</td>
<td class="num">(1,104,174)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">BEGINNING CASH AND CASH EQUIVALENTS</a></td>
<td class="nump">850,028<span></span>
</td>
<td class="nump">2,270,385<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">ENDING CASH AND CASH EQUIVALENTS</a></td>
<td class="nump">2,469,087<span></span>
</td>
<td class="nump">1,166,211<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">INCOME TAXES PAID</a></td>
<td class="nump">3,600<span></span>
</td>
<td class="nump">1,752<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">INTEREST EXPENSE PAID</a></td>
<td class="nump">38,324<span></span>
</td>
<td class="nump">44,771<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>NON-CASH ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Change in capital expenditures included in accounts payable and accrued expenses</a></td>
<td class="num">(213,418)<span></span>
</td>
<td class="nump">84,031<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInFairValueOfInterestRateFairValueHedgingInstruments1', window );">Net change in fair value of interest rate swaps</a></td>
<td class="nump">$ 48,059<span></span>
</td>
<td class="num">$ (193)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentForAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4332-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4313-108586<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4304-108586<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3044-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 24<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 830<br><br><br><br> -SubTopic 230<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49171198&amp;loc=d3e33268-110906<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) and income tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 24<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=32706628&amp;loc=d3e11374-113907<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, excluding oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 205<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51717284&amp;loc=d3e1361-107760<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51719941&amp;loc=d3e2941-110230<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 25<br><br><br><br> -Subparagraph (f)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3536-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInFairValueOfInterestRateFairValueHedgingInstruments1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) related to the fair value of interest rate derivatives designated as fair value hedging instruments, as offset by the gain (loss) on the hedged item to the extent that the fair value hedge is determined to be effective.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4A<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=SL5618551-113959<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 815<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4C<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56946850&amp;loc=SL5624171-113959<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInFairValueOfInterestRateFairValueHedgingInstruments1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for interest during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4297-108586<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 25<br><br><br><br> -Subparagraph (e)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3536-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 24<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 26<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3574-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 24<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 26<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3574-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 24<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 25<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3536-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Net Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Other Comprehensive Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 9<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 15<br><br><br><br> -Subparagraph (e)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3291-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Investing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3213-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Investing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 13<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3213-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 12<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3179-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Investing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 12<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3179-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Investing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (j)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3255-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Financing Activities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options, after deduction of related income tax (expense) benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140667131002384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property, plant and equipment</a></td>
<td class="text"><div><br class="apple-interchange-newline" /><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: center; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>As of</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>September&#160;30, 2015</b></font></p></td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: center; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>As of</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>December&#160;31, 2014</b></font></p></td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: center; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>Increase</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>(Decrease)</b></font></p></td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1003px; text-align: left; text-indent: 0pt; padding-left: 0pt;">Laboratory and manufacturing equipment</td><td style="width: 16px; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="width: 16px; text-align: left; text-indent: 0pt; padding-left: 0pt;">$</td><td style="width: 142px; text-align: right; text-indent: 0pt; padding-left: 0pt;">3,602,690</td><td style="width: 16px; text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="width: 16px; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="width: 16px; text-align: left; text-indent: 0pt; padding-left: 0pt;">$</td><td style="width: 141px; text-align: right; text-indent: 0pt; padding-left: 0pt;">3,522,465</td><td style="width: 15px; text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="width: 15px; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="width: 15px; text-align: left; text-indent: 0pt; padding-left: 0pt;">$</td><td style="width: 141px; text-align: right; text-indent: 0pt; padding-left: 0pt;">80,225</td><td style="width: 15px; text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: justify; text-indent: 0pt; padding-left: 0pt;">Building and improvements</td><td style="text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt;">4,579,852</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt;">2,969,891</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt;">1,609,961</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">Office furniture and equipment</td><td style="text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt;">569,567</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt;">470,607</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt;">98,960</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Construction in progress<sup>(1)</sup></font></td><td style="text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt;">738,282</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left:
 0pt;">1,270,672</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt;">(532,390</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">)</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">Land</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">72,807</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">50,000</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">22,807</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;&#160;&#160;&#160;&#160;Property, plant and equipment, gross</td><td style="text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt;">9,563,198</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt;">8,283,635</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt;">1,279,563</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">Accumulated depreciation</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(4,607,584</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">)</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(4,445,988</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">)</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(161,596</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;">&#160;&#160;&#160;&#160;&#160;Property, plant and equipment, net</td><td style="text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">4,955,614</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">3,837,647</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">1,117,967</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch:
 normal;"><sup>&#160;</sup></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><sup>(1)</sup>As of December 31, 2014, construction in progress consisted of a building addition that was completed during the first quarter of 2015. As of September 30, 2015, construction in progress consisted principally of partial payments towards new manufacturing equipment.</font></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph b<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140666930862688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_iccc_ScheduleOfInventoryAbstract', window );"><strong>Schedule of Inventory</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 337,538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 306,444<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work-in-process</a></td>
<td class="nump">468,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">355,745<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">58,847<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">283,566<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total</a></td>
<td class="nump">864,444<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 945,755<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInRawMaterialsPackagingMaterialsAndSuppliesInventories', window );">Increase (Decrease) in Raw materials inventories</a></td>
<td class="nump">31,094<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_iccc_IncreaseDecreaseInWorkInProcessInventories', window );">Increase (Decrease) in Work-in-process inventories</a></td>
<td class="nump">112,314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_iccc_IncreaseDecreaseInFinishedGoodsInventories', window );">Increase (Decrease) in Finished goods inventories</a></td>
<td class="num">(224,719)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Increase (Decrease) in inventories</a></td>
<td class="num">$ (81,311)<span></span>
</td>
<td class="num">$ (167,062)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_IncreaseDecreaseInFinishedGoodsInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the book value of finished goods inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_IncreaseDecreaseInFinishedGoodsInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_IncreaseDecreaseInWorkInProcessInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the book value of work in process inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_IncreaseDecreaseInWorkInProcessInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_ScheduleOfInventoryAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_ScheduleOfInventoryAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInRawMaterialsPackagingMaterialsAndSuppliesInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the value of raw materials, packaging materials and supplies held in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInRawMaterialsPackagingMaterialsAndSuppliesInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.6(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.6(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 330<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 35<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655945&amp;loc=d3e3927-108312<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.6(a)(4))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.6(a)(3))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140666934126736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment and Significant Customer Information (Details Textual) - Sales Revenue, Net [Member]<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_iccc_SegmentAndSignificantCustomerInformationTextualAbstract', window );"><strong>Segment and Significant Customer Information (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">U.S. dairy and beef industries [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_iccc_SegmentAndSignificantCustomerInformationTextualAbstract', window );"><strong>Segment and Significant Customer Information (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">85.00%<span></span>
</td>
<td class="nump">84.00%<span></span>
</td>
<td class="nump">83.00%<span></span>
</td>
<td class="nump">82.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Foreign dairy and beef industries [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_iccc_SegmentAndSignificantCustomerInformationTextualAbstract', window );"><strong>Segment and Significant Customer Information (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_SegmentAndSignificantCustomerInformationTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_SegmentAndSignificantCustomerInformationTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 275<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 18<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6351-108592<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 20<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13531-108611<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 275<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 20<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6404-108592<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 21<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13537-108611<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersAxis=iccc_UnitedStatesDairyAndBeefIndustriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersAxis=iccc_UnitedStatesDairyAndBeefIndustriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersAxis=iccc_ForeignCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersAxis=iccc_ForeignCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140666866834736">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 2,469,087<span></span>
</td>
<td class="nump">$ 850,028<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">3,720,000<span></span>
</td>
<td class="nump">2,489,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">789,214<span></span>
</td>
<td class="nump">1,005,292<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">864,444<span></span>
</td>
<td class="nump">945,755<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other assets</a></td>
<td class="nump">275,559<span></span>
</td>
<td class="nump">148,399<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetCurrent', window );">Current portion of deferred tax asset</a></td>
<td class="nump">69,011<span></span>
</td>
<td class="nump">30,463<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">8,187,315<span></span>
</td>
<td class="nump">5,468,937<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">PROPERTY, PLANT AND EQUIPMENT, net</a></td>
<td class="nump">4,955,614<span></span>
</td>
<td class="nump">3,837,647<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">LONG-TERM INVESTMENTS</a></td>
<td class="nump">487,000<span></span>
</td>
<td class="nump">496,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetNoncurrent', window );">LONG-TERM PORTION OF DEFERRED TAX ASSET</a></td>
<td class="nump">543,602<span></span>
</td>
<td class="nump">1,230,340<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">OTHER ASSETS, net</a></td>
<td class="nump">49,615<span></span>
</td>
<td class="nump">18,930<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">14,223,146<span></span>
</td>
<td class="nump">11,051,854<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent', window );">Accounts payable and accrued expenses</a></td>
<td class="nump">545,927<span></span>
</td>
<td class="nump">851,677<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansPayableToBankCurrent', window );">Current portion of bank debt</a></td>
<td class="nump">133,959<span></span>
</td>
<td class="nump">150,382<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,690<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">679,886<span></span>
</td>
<td class="nump">1,008,749<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>LONG-TERM LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermLoansFromBank', window );">Long-term portion of bank debt</a></td>
<td class="nump">3,126,004<span></span>
</td>
<td class="nump">745,920<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_iccc_InterestRateSwap', window );">Interest rate swaps</a></td>
<td class="nump">118,773<span></span>
</td>
<td class="nump">38,817<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total long-term liabilities</a></td>
<td class="nump">3,244,777<span></span>
</td>
<td class="nump">784,737<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="nump">3,924,663<span></span>
</td>
<td class="nump">1,793,486<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS' EQUITY:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.10 par value per share, 8,000,000 shares authorized, 3,261,148 shares issued as of September 30, 2015 and December 31, 2014</a></td>
<td class="nump">326,115<span></span>
</td>
<td class="nump">326,115<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Capital in excess of par value</a></td>
<td class="nump">10,144,794<span></span>
</td>
<td class="nump">10,042,305<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated surplus (deficit)</a></td>
<td class="nump">349,865<span></span>
</td>
<td class="num">(574,567)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, at cost, 206,114 and 234,114 shares as of September 30, 2015 and December 31, 2014, respectively</a></td>
<td class="num">(450,901)<span></span>
</td>
<td class="num">(512,154)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(71,390)<span></span>
</td>
<td class="num">(23,331)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">10,298,483<span></span>
</td>
<td class="nump">9,258,368<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY</a></td>
<td class="nump">$ 14,223,146<span></span>
</td>
<td class="nump">$ 11,051,854<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_InterestRateSwap">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount as of the balance sheet date of interest rate swap due beyond one year or the operating cycle, whichever is longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_InterestRateSwap</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date, including liabilities incurred and payable to vendors for goods and services received, taxes, interest, rent and utilities, compensation costs, payroll taxes and fringe benefits (other than pension and postretirement obligations), contractual rights and obligations, and statutory obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-03.15(1),(5))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-03.15)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.3-4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph a(1)<br><br><br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 4<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 11<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e637-108580<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e681-108580<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 14A<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669686-108580<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.30(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 12<br><br><br><br> -Article 7<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3044-108585<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 605<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 13<br><br><br><br> -Section A<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards expected to be realized or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31917-109318<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31931-109318<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31928-109318<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 9<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31958-109318<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of noncurrent deferred tax asset attributable to deductible temporary differences and carryforwards. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31931-109318<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31928-109318<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 9<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31958-109318<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e31917-109318<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.6(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 330<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 35<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655945&amp;loc=d3e3927-108312<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19-26)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.32)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 7<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22-26)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 22, 23, 24, 25, 26, 27<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansPayableToBankCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of current portion of long-term loans payable to bank due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19, 20<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansPayableToBankCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.12)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermLoansFromBank">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of loans from a bank with maturities initially due after one year or beyond the operating cycle if longer, excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19, 22<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermLoansFromBank</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 7<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.31(a)(3))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments which are intended to be sold in the short term (usually less than one year or the normal operating cycle, whichever is longer) including trading securities, available-for-sale securities, held-to-maturity securities, and other short-term investments not otherwise listed in the existing taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph g<br><br><br><br> -Article 7<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140666934536960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Bank Debt (Details)<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2015 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">Three months ending December 31, 2015</a></td>
<td class="nump">$ 33,414<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo', window );">Year ending December 31, 2016</a></td>
<td class="nump">135,840<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree', window );">Year ending December 31, 2017</a></td>
<td class="nump">143,364<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour', window );">Year ending December 31, 2018</a></td>
<td class="nump">150,973<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive', window );">Year ending December 31, 2019</a></td>
<td class="nump">158,905<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFive', window );">After December 31, 2019</a></td>
<td class="nump">2,637,467<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_iccc_TotalLiabilitiesDebtCurrentPortionAndLongTermPortion', window );">Total</a></td>
<td class="nump">3,259,963<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=us-gaap_MortgagesMember', window );">$1,000,000 Mortgage Note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">Three months ending December 31, 2015</a></td>
<td class="nump">14,043<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo', window );">Year ending December 31, 2016</a></td>
<td class="nump">57,384<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree', window );">Year ending December 31, 2017</a></td>
<td class="nump">61,056<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour', window );">Year ending December 31, 2018</a></td>
<td class="nump">64,876<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive', window );">Year ending December 31, 2019</a></td>
<td class="nump">68,908<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFive', window );">After December 31, 2019</a></td>
<td class="nump">493,696<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_iccc_TotalLiabilitiesDebtCurrentPortionAndLongTermPortion', window );">Total</a></td>
<td class="nump">759,963<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=us-gaap_NotesPayableToBanksMember', window );">$ 2,500,000 Mortgage note [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">Three months ending December 31, 2015</a></td>
<td class="nump">19,371<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo', window );">Year ending December 31, 2016</a></td>
<td class="nump">78,456<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree', window );">Year ending December 31, 2017</a></td>
<td class="nump">82,308<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour', window );">Year ending December 31, 2018</a></td>
<td class="nump">86,097<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive', window );">Year ending December 31, 2019</a></td>
<td class="nump">89,997<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFive', window );">After December 31, 2019</a></td>
<td class="nump">2,143,771<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_iccc_TotalLiabilitiesDebtCurrentPortionAndLongTermPortion', window );">Total</a></td>
<td class="nump">$ 2,500,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_TotalLiabilitiesDebtCurrentPortionAndLongTermPortion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of total liabilities debt current portion and long-term portion, net of unamortized discount or premium, including current and noncurrent amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_TotalLiabilitiesDebtCurrentPortionAndLongTermPortion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing after the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph (SX 210.12-04.(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph (SX 210.12-04.(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the fourth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph (SX 210.12-04.(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the third rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph (SX 210.12-04.(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the second rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph (SX 210.12-04.(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInRollingYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph (SX 210.12-04.(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=us-gaap_MortgagesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=us-gaap_MortgagesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=us-gaap_NotesPayableToBanksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=us-gaap_NotesPayableToBanksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140666928008192">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Stockholders' Equity (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Capital in Excess of Par Value</div></th>
<th class="th"><div>Accumulated (Deficit) Surplus</div></th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th"><div>Accumulated Other Comprehensive (Loss)</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2013</a></td>
<td class="nump">$ 9,395,869<span></span>
</td>
<td class="nump">$ 326,115<span></span>
</td>
<td class="nump">$ 10,011,339<span></span>
</td>
<td class="num">$ (407,408)<span></span>
</td>
<td class="num">$ (514,341)<span></span>
</td>
<td class="num">$ (19,836)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2013</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,261,148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">235,114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(297,786)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(297,786)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of taxes</a></td>
<td class="nump">193<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">193<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">3,150<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">962<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 2,188<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">22,265<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">22,265<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2014</a></td>
<td class="nump">9,123,691<span></span>
</td>
<td class="nump">$ 326,115<span></span>
</td>
<td class="nump">10,034,566<span></span>
</td>
<td class="num">(705,194)<span></span>
</td>
<td class="num">$ (512,153)<span></span>
</td>
<td class="num">(19,643)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Sep. 30, 2014</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,261,148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">234,114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2014</a></td>
<td class="nump">9,258,368<span></span>
</td>
<td class="nump">$ 326,115<span></span>
</td>
<td class="nump">10,042,305<span></span>
</td>
<td class="num">(574,567)<span></span>
</td>
<td class="num">$ (512,154)<span></span>
</td>
<td class="num">(23,331)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2014</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,261,148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">234,114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">924,432<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">924,432<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of taxes</a></td>
<td class="num">(48,059)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(48,059)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">120,210<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">58,957<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 61,253<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options, Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense', window );">Tax benefits related to stock options</a></td>
<td class="nump">25,707<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">25,707<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">17,825<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">17,825<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Sep. 30, 2015</a></td>
<td class="nump">$ 10,298,483<span></span>
</td>
<td class="nump">$ 326,115<span></span>
</td>
<td class="nump">$ 10,144,794<span></span>
</td>
<td class="nump">$ 349,865<span></span>
</td>
<td class="num">$ (450,901)<span></span>
</td>
<td class="num">$ (71,390)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Sep. 30, 2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,261,148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">206,114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of recognized equity-based compensation during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized). Alternate captions include the words "stock-based compensation".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 35<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415241&amp;loc=d3e4534-113899<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 12<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=32706628&amp;loc=d3e11149-113907<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 13<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=32706628&amp;loc=d3e11178-113907<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Net Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Other Comprehensive Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 9<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1A<br><br><br><br> -Subparagraph (c)(3)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=SL4573702-111684<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 19<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51664549&amp;loc=SL4569616-111683<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 810<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 20<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51664549&amp;loc=SL4569643-111683<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)(iv)(2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28,29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options, after deduction of related income tax (expense) benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140667078116144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Expenses, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Expenses, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Schedule of other expenses, net</a></td>
<td class="text"><div><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: center; text-indent: 0pt; padding-left: 0px;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0px;">&#160;</td><td style="text-align: center; text-indent: 0pt; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6"><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>Three-Month Periods&#160;</b></font><br /><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>Ended September 30,</b></font></p></td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0px;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0px;">&#160;</td><td style="text-align: center; text-indent: 0pt; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6"><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>Nine-Month Periods&#160;</b></font><br /><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>Ended September 30,</b></font></p></td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0px;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-indent: 0pt; padding-left: 0px;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0px; font-weight: bold;">&#160;</td><td style="text-align: center; text-indent: 0pt; padding-left: 0px; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2015</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0px; font-weight: bold;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0px; font-weight: bold;">&#160;</td><td style="text-align: center; text-indent: 0pt; padding-left: 0px; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2014</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0px; font-weight: bold;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0px; font-weight: bold;">&#160;</td><td style="text-align: center; text-indent: 0pt; padding-left: 0px; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2015</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0px; font-weight: bold;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0px; font-weight: bold;">&#160;</td><td style="text-align: center; text-indent: 0pt; padding-left: 0px; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2014</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0px; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 815px; text-align: left; text-indent: 0pt; padding-left: 0px;">Interest income</td><td style="width: 16px; text-indent: 0pt; padding-left: 0px;">&#160;</td><td style="width: 16px; text-align: left; text-indent: 0pt; padding-left: 0px;">$</td><td style="width: 142px; text-align: right; text-indent: 0pt; padding-left: 0px;">(4,461</td><td style="width: 16px; text-align: left; text-indent: 0pt; padding-left: 0px;">)</td><td style="width: 16px; text-indent: 0pt; padding-left: 0px;">&#160;</td><td style="width: 16px; text-align: left; text-indent: 0pt; padding-left: 0px;">$</td><td style="width: 142px; text-align: right; text-indent: 0pt; padding-left: 0px;">(3,912</td><td style="width: 16px; text-align: left; text-indent: 0pt; padding-left: 0px;">)</td><td style="width: 15px; text-indent: 0pt; padding-left: 0px;">&#160;</td><td style="width: 15px; text-align: left; text-indent: 0pt; padding-left: 0px;">$</td><td style="width: 141px; text-align: right; text-indent: 0pt; padding-left: 0px;">(10,634</td><td style="width: 15px; text-align: left; text-indent: 0pt; padding-left: 0px;">)</td><td style="width: 15px; text-indent: 0pt; padding-left: 0px;">&#160;</td><td style="width: 15px; text-align: left; text-indent: 0pt; padding-left: 0px;">$</td><td style="width: 141px; text-align: right; text-indent: 0pt; padding-left: 0px;">(11,607</td><td style="width: 15px; text-align: left; text-indent: 0pt; padding-left: 0px;">)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: 0pt; padding-left: 0px;">Interest expense</td><td style="text-indent: 0pt; padding-left: 0px;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0px;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0px;">15,084</td><td style="text-align: left; text-indent: 0pt; padding-left: 0px;">&#160;</td><td style="text-indent: 0pt; padding-left: 0px;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0px;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0px;">14,514</td><td style="text-align: left; text-indent: 0pt; padding-left: 0px;">&#160;</td><td style="text-indent: 0pt; padding-left: 0px;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0px;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0px;">41,039</td><td style="text-align: left; text-indent: 0pt; padding-left: 0px;">&#160;</td><td style="text-indent: 0pt; padding-left: 0px;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0px;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0px;">44,148</td><td style="text-align: left; text-indent: 0pt; padding-left: 0px;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0px;">Other</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0px;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">4,488</td><td style="text-align: left; text-indent: 0pt;
 padding-bottom: 1.5pt; padding-left: 0px;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0px;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">644</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0px;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0px;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(3,346</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0px;">)</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0px;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">6,092</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0px;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: 0pt; padding-bottom: 4pt; padding-left: 10pt;">Other expenses, net</td><td style="text-indent: 0pt; padding-bottom: 4pt; padding-left: 0px;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; text-indent: 0pt; padding-left: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">15,111</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 4pt; padding-left: 0px;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 4pt; padding-left: 0px;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; text-indent: 0pt; padding-left: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">11,246</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 4pt; padding-left: 0px;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 4pt; padding-left: 0px;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; text-indent: 0pt; padding-left: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">27,059</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 4pt; padding-left: 0px;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 4pt; padding-left: 0px;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; text-indent: 0pt; padding-left: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">38,633</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 4pt; padding-left: 0px;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140667078763472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment and Significant Customer Information<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment and Significant Customer Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">SEGMENT AND SIGNIFICANT CUSTOMER INFORMATION</a></td>
<td class="text"><div><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 0.5in; text-indent: 0pt; padding-left: 0pt;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>14.</b></font></td><td style="text-indent: 0pt; padding-left: 0pt;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>SEGMENT AND SIGNIFICANT CUSTOMER INFORMATION</b></font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>&#160;</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">We principally operate in the business segment described in Note 1. Pursuant to Codification Topic 280,&#160;<i>Segment Reporting</i>, we operate in one reportable business segment, that being the development, acquisition, manufacture and sale of products that improve the health and productivity of cows for the dairy and beef industries. Almost all of our internally funded product development expenses are in support of such products. The significant accounting policies of this segment are described in Note 2.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Our primary customers for the majority of our product sales (85% and 84% for the three-month periods ended September 30, 2015 and 2014, and 83% and 82% for the nine-month periods ended September 30, 2015 and 2014, respectively) are in the U.S. dairy and beef industries. Product sales to international customers, who are also in the dairy and beef industries, aggregated 6% and 11% of our total product sales for the three-month periods ended September 30, 2015 and 2014, respectively, and 13% for both of the nine-month periods ended September 30, 2015 and 2014. Sales to significant customers that amounted to 10% or more of total product sales are detailed in the following table:</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-indent: 0pt; padding-right: 0pt; padding-bottom: 1.5pt; padding-left: 0pt; font-family: calibri, sans-serif;">&#160;</td><td style="text-indent: 0pt; padding-right: 0pt; padding-bottom: 1.5pt; padding-left: 0pt; font-weight: bold;">&#160;</td><td style="text-align: center; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6">Three-Month Periods&#160;<br />Ended September 30,</td><td style="text-indent: 0pt; padding-right: 0pt; padding-bottom: 1.5pt; padding-left: 0pt; font-weight: bold;">&#160;</td><td style="text-indent: 0pt; padding-right: 0pt; padding-bottom: 1.5pt; padding-left: 0pt; font-weight: bold;">&#160;</td><td style="text-align: center; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6">Nine-Month Periods&#160;<br />Ended September 30,</td><td style="text-indent: 0pt; padding-right: 0pt; padding-bottom: 1.5pt; padding-left: 0pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-indent: 0pt; padding-right: 0pt; padding-bottom: 1.5pt; padding-left: 0pt; font-family: calibri, sans-serif;">&#160;</td><td style="text-indent: 0pt; padding-right: 0pt; padding-bottom: 1.5pt; padding-left: 0pt; font-weight: bold;">&#160;</td><td style="text-align: center; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2015</td><td style="text-indent: 0pt; padding-right: 0pt; padding-bottom: 1.5pt; padding-left: 0pt; font-weight: bold;">&#160;</td><td style="text-indent: 0pt; padding-right: 0pt; padding-bottom: 1.5pt; padding-left: 0pt; font-weight: bold;">&#160;</td><td style="text-align: center; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2014</td><td style="text-indent: 0pt; padding-right: 0pt; padding-bottom: 1.5pt; padding-left: 0pt; font-weight: bold;">&#160;</td><td style="text-indent: 0pt; padding-right: 0pt; padding-bottom: 1.5pt; padding-left: 0pt; font-weight: bold;">&#160;</td><td style="text-align: center; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2015</td><td style="text-indent: 0pt; padding-right: 0pt; padding-bottom: 1.5pt; padding-left: 0pt; font-weight: bold;">&#160;</td><td style="text-indent: 0pt; padding-right: 0pt; padding-bottom: 1.5pt; padding-left: 0pt; font-weight: bold;">&#160;</td><td style="text-align: center; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt;
 border-bottom-style: solid;" colspan="2">2014</td><td style="text-indent: 0pt; padding-right: 0pt; padding-bottom: 1.5pt; padding-left: 0pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 815px; text-align: left; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt;"><font style="font: 10pt/normal 'times new roman', serif; font-stretch: normal;">Animal Health International, Inc.<sup>(1)</sup></font></td><td style="width: 16px; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt;">&#160;</td><td style="width: 16px; text-align: left; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt;">&#160;</td><td style="width: 142px; text-align: right; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt;">39</td><td style="width: 16px; text-align: left; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt;">%</td><td style="width: 16px; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt;">&#160;</td><td style="width: 16px; text-align: left; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt;">&#160;</td><td style="width: 142px; text-align: right; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt;">34</td><td style="width: 16px; text-align: left; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt;">%</td><td style="width: 15px; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt;">&#160;</td><td style="width: 15px; text-align: left; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt;">&#160;</td><td style="width: 141px; text-align: right; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt;">41</td><td style="width: 15px; text-align: left; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt;">%</td><td style="width: 15px; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt;">&#160;</td><td style="width: 15px; text-align: left; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt;">&#160;</td><td style="width: 141px; text-align: right; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt;">37</td><td style="width: 15px; text-align: left; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt;">%</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt;"><font style="font: 10pt/normal 'times new roman', serif; font-stretch: normal;">MWI Animal Health<sup>(2)</sup></font></td><td style="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt;">22</td><td style="text-align: left; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt;">%</td><td style="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt;">23</td><td style="text-align: left; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt;">%</td><td style="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt;">21</td><td style="text-align: left; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt;">%</td><td style="text-indent: 0pt; padding-right: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt;">22</td><td style="text-align: left; text-indent: 0pt; padding-right: 0pt; padding-left: 0pt;">%</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Accounts receivable due from significant customers amounted to the percentages of total trade accounts receivable as detailed in the following table:</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: center; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>As of</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>September&#160;30, 2015</b></font></p></td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt; font-weight: bold;">&#160;</td><td style="text-align: center; text-indent: 0pt; padding-left: 0pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">As of<br />December&#160;31, 2014</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt; font-weight:
 bold;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1191px; text-align: left; text-indent: 0pt; padding-left: 0pt;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Animal Health International, Inc.<sup>(1)</sup></font></td><td style="width: 16px; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="width: 16px; text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="width: 142px; text-align: right; text-indent: 0pt; padding-left: 0pt;">37</td><td style="width: 16px; text-align: left; text-indent: 0pt; padding-left: 0pt;">%</td><td style="width: 15px; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="width: 15px; text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="width: 141px; text-align: right; text-indent: 0pt; padding-left: 0pt;">45</td><td style="width: 15px; text-align: left; text-indent: 0pt; padding-left: 0pt;">%</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">MWI Animal Health<sup>(2)</sup></font></td><td style="text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt;">25</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">%</td><td style="text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt;">26</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">%</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">TCS Biosciences, Ltd.</td><td style="text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt;">13</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">%</td><td style="text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">*</font></td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>&#160;</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><sup>(1)</sup>During June 2015, Patterson Companies, Inc. (NASDAQ: PDCO) acquired Animal Health International, Inc.</font><font style="font-size: 10pt;"><br /><font style="font-family: 'times new roman', times, serif;"><sup>(2)</sup>During March 2015, AmerisourceBergen Corporation (NYSE: ABC) acquired MWI Animal Health.</font></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">*Amount is less than 10%.</font></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 280<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 34<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51669610&amp;loc=d3e8981-108599<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 280<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 41<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51669610&amp;loc=d3e9038-108599<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 280<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 33<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51669610&amp;loc=d3e8971-108599<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 280<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 12<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51669610&amp;loc=d3e8595-108599<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 280<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51669610&amp;loc=d3e8380-108599<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 280<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 32<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51669610&amp;loc=d3e8933-108599<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 280<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 26<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51669610&amp;loc=d3e8844-108599<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 280<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 35<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51669610&amp;loc=d3e8984-108599<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 280<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 40<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51669610&amp;loc=d3e9031-108599<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 280<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 42<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51669610&amp;loc=d3e9054-108599<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 280<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 10<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51669610&amp;loc=d3e8538-108599<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 280<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 29<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51669610&amp;loc=d3e8864-108599<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 280<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 31<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51669610&amp;loc=d3e8924-108599<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 280<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 30<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51669610&amp;loc=d3e8906-108599<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140666867105984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment and Significant Customer Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment and Significant Customer Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_iccc_ScheduleOfSalesToSignificantCustomersTableTextBlock', window );">Schedule of sales to significant customers</a></td>
<td class="text"><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="font-family: calibri, sans-serif; padding-left: 0pt; padding-bottom: 1.5pt; padding-right: 0pt; text-indent: 0pt;">&#160;</td><td style="font-weight: bold; padding-left: 0pt; padding-bottom: 1.5pt; padding-right: 0pt; text-indent: 0pt;">&#160;</td><td style="font-weight: bold; padding-left: 0pt; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; padding-right: 0pt; text-indent: 0pt;" colspan="6">Three-Month Periods&#160;<br />Ended September 30,</td><td style="font-weight: bold; padding-left: 0pt; padding-bottom: 1.5pt; padding-right: 0pt; text-indent: 0pt;">&#160;</td><td style="font-weight: bold; padding-left: 0pt; padding-bottom: 1.5pt; padding-right: 0pt; text-indent: 0pt;">&#160;</td><td style="font-weight: bold; padding-left: 0pt; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; padding-right: 0pt; text-indent: 0pt;" colspan="6">Nine-Month Periods&#160;<br />Ended September 30,</td><td style="font-weight: bold; padding-left: 0pt; padding-bottom: 1.5pt; padding-right: 0pt; text-indent: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="font-family: calibri, sans-serif; padding-left: 0pt; padding-bottom: 1.5pt; padding-right: 0pt; text-indent: 0pt;">&#160;</td><td style="font-weight: bold; padding-left: 0pt; padding-bottom: 1.5pt; padding-right: 0pt; text-indent: 0pt;">&#160;</td><td style="font-weight: bold; padding-left: 0pt; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; padding-right: 0pt; text-indent: 0pt;" colspan="2">2015</td><td style="font-weight: bold; padding-left: 0pt; padding-bottom: 1.5pt; padding-right: 0pt; text-indent: 0pt;">&#160;</td><td style="font-weight: bold; padding-left: 0pt; padding-bottom: 1.5pt; padding-right: 0pt; text-indent: 0pt;">&#160;</td><td style="font-weight: bold; padding-left: 0pt; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; padding-right: 0pt; text-indent: 0pt;" colspan="2">2014</td><td style="font-weight: bold; padding-left: 0pt; padding-bottom: 1.5pt; padding-right: 0pt; text-indent: 0pt;">&#160;</td><td style="font-weight: bold; padding-left: 0pt; padding-bottom: 1.5pt; padding-right: 0pt; text-indent: 0pt;">&#160;</td><td style="font-weight: bold; padding-left: 0pt; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; padding-right: 0pt; text-indent: 0pt;" colspan="2">2015</td><td style="font-weight: bold; padding-left: 0pt; padding-bottom: 1.5pt; padding-right: 0pt; text-indent: 0pt;">&#160;</td><td style="font-weight: bold; padding-left: 0pt; padding-bottom: 1.5pt; padding-right: 0pt; text-indent: 0pt;">&#160;</td><td style="font-weight: bold; padding-left: 0pt; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; padding-right: 0pt; text-indent: 0pt;" colspan="2">2014</td><td style="font-weight: bold; padding-left: 0pt; padding-bottom: 1.5pt; padding-right: 0pt; text-indent: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 815px; text-align: left; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', serif;">Animal Health International, Inc.<sup>(1)</sup></font></td><td style="width: 16px; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt;">&#160;</td><td style="width: 16px; text-align: left; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt;">&#160;</td><td style="width: 142px; text-align: right; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt;">39</td><td style="width: 16px; text-align: left; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt;">%</td><td style="width: 16px; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt;">&#160;</td><td style="width: 16px; text-align: left; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt;">&#160;</td><td style="width: 142px; text-align: right; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt;">34</td><td style="width: 16px; text-align: left; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt;">%</td><td style="width: 15px; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt;">&#160;</td><td style="width: 15px; text-align: left; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt;">&#160;</td><td style="width: 141px; text-align: right; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt;">41</td><td style="width: 15px; text-align: left; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt;">%</td><td style="width: 15px; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt;">&#160;</td><td style="width: 15px; text-align: left; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt;">&#160;</td><td style="width: 141px; text-align: right; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt;">37</td><td style="width: 15px; text-align: left; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt;">%</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', serif;">MWI Animal Health<sup>(2)</sup></font></td><td style="padding-left: 0pt; padding-right: 0pt; text-indent: 0pt;">&#160;</td><td style="text-align: left; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt;">&#160;</td><td style="text-align: right; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt;">22</td><td style="text-align: left; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt;">%</td><td style="padding-left: 0pt; padding-right: 0pt; text-indent: 0pt;">&#160;</td><td style="text-align: left; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt;">&#160;</td><td style="text-align: right; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt;">23</td><td style="text-align: left; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt;">%</td><td style="padding-left: 0pt; padding-right: 0pt; text-indent: 0pt;">&#160;</td><td style="text-align: left; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt;">&#160;</td><td style="text-align: right; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt;">21</td><td style="text-align: left; padding-left:
 0pt; padding-right: 0pt; text-indent: 0pt;">%</td><td style="padding-left: 0pt; padding-right: 0pt; text-indent: 0pt;">&#160;</td><td style="text-align: left; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt;">&#160;</td><td style="text-align: right; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt;">22</td><td style="text-align: left; padding-left: 0pt; padding-right: 0pt; text-indent: 0pt;">%</td></tr></table><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><br /></font><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><sup><font size="2">(1)</font></sup>During June 2015, Patterson Companies, Inc. (NASDAQ: PDCO) acquired Animal Health International, Inc.<font style="font: 10pt/normal 'times new roman', times, serif; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; -webkit-text-stroke-width: 0px;"><br /><font style="font-family: 'times new roman', times, serif;"><sup>(2)</sup>During March 2015, AmerisourceBergen Corporation (NYSE: ABC) acquired MWI Animal Health</font></font><br /></font></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_iccc_ScheduleOfAccountsReceivableDueFromSignificantCustomersTableTextBlock', window );">Schedule of accounts receivable due from significant customers</a></td>
<td class="text"><div><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1250.4px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: center; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>As of</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>September&#160;30, 2015</b></font></p></td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt; font-weight: bold;">&#160;</td><td style="text-align: center; text-indent: 0pt; padding-left: 0pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">As of<br />December&#160;31, 2014</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 950.4px; text-align: left; text-indent: 0pt; padding-left: 0pt;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Animal Health International, Inc.<sup>(1)</sup></font></td><td style="width: 12.8px; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="width: 12.8px; text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="width: 112.8px; text-align: right; text-indent: 0pt; padding-left: 0pt;">37</td><td style="width: 12.8px; text-align: left; text-indent: 0pt; padding-left: 0pt;">%</td><td style="width: 12.8px; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="width: 12px; text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="width: 112px; text-align: right; text-indent: 0pt; padding-left: 0pt;">45</td><td style="width: 12px; text-align: left; text-indent: 0pt; padding-left: 0pt;">%</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">MWI Animal Health<sup>(2)</sup></font></td><td style="text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt;">25</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">%</td><td style="text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt;">26</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">%</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">TCS Biosciences, Ltd.</td><td style="text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt;">13</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">%</td><td style="text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">*</font></td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>&#160;</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><sup>(1)</sup>During June 2015, Patterson Companies, Inc. (NASDAQ: PDCO) acquired Animal Health International, Inc.</font><font style="font-size: 10pt;"><br /><font style="font-family: 'times new roman', times, serif;"><sup>(2)</sup>During March 2015, AmerisourceBergen Corporation (NYSE: ABC) acquired MWI Animal Health.</font></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">*Amount is less than 10%.</font></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_ScheduleOfAccountsReceivableDueFromSignificantCustomersTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of accounts receivable due from significant customers that amounted to 10% or more of total trade accounts receivable as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_ScheduleOfAccountsReceivableDueFromSignificantCustomersTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_ScheduleOfSalesToSignificantCustomersTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of sales to significant customers that amounted to 10% or more of total product sales by the entity during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_ScheduleOfSalesToSignificantCustomersTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140666939987584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefits<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Employee Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">EMPLOYEE BENEFITS</a></td>
<td class="text"><div><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 0.5in; padding-left: 0pt;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>16.</b></font></td><td style="padding-left: 0pt;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>EMPLOYEE BENEFITS</b></font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">We have a 401(k) savings plan (the Plan) in which all employees completing one month of service with the Company are eligible to participate. Participants may contribute up to the maximum amount allowed by the Internal Revenue Service. Since August 2012 we have matched 100% of the first 3% of each employee&#8217;s salary that is contributed to the Plan and 50% of the next 2% of each employee&#8217;s salary that is contributed to the Plan. Under this matching plan, we paid $17,102 and $17,117 into the plan for the three-month periods ended September 30, 2015 and 2014, respectively, and $54,157 and $47,920 for the nine-month periods ended September 30, 2015 and 2014, respectively.</font></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140666940035200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Stockholders' Equity (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement Of Stockholders Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140666936906304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement Of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.10<span></span>
</td>
<td class="nump">$ 0.10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">8,000,000<span></span>
</td>
<td class="nump">8,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">3,261,148<span></span>
</td>
<td class="nump">3,261,148<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock, shares</a></td>
<td class="nump">206,114<span></span>
</td>
<td class="nump">234,114<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28,29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140666939949296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Bank Debt<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Bank Debt [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">BANK DEBT</a></td>
<td class="text"><div><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 0.5in; padding-right: 0pt; padding-left: 0pt;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>9.</b></font></td><td style="padding-right: 0pt; padding-left: 0pt;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>BANK DEBT</b></font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>&#160;</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">We have in place certain credit facilities with TD Bank, N.A. (a wholly owned subsidiary of TD Financial Group, which is a multinational bank with approximately $944 billion in assets and over 22 million clients worldwide) which are secured by substantially all of our assets. Proceeds from the $1,000,000 mortgage note were received during the third quarter of 2010. Based on a 15-year amortization schedule, a balloon principal payment of approximately $451,885 will be due during the third quarter of 2020. Proceeds from the $2,500,000 mortgage note were received during the third quarter of 2015. Based on a 20-year amortization schedule, a balloon principal payment of approximately $1,550,007 will be due during the third quarter of 2025. We hedged our interest rate exposure on these mortgage notes with interest rate swap agreements that effectively converted floating interest rates based on the one-month LIBOR plus a bank profit margin to the fixed rates of 6.04% and 4.38%, respectively. As of September 30, 2015, the variable rates on these two mortgage notes were 3.46% and 2.45%, respectively. All derivatives are recognized on the balance sheet at their fair value. At the time of the closings and thereafter, the agreements were determined to be highly effective in hedging the variability of the identified cash flows and have been designated as cash flow hedges of the variability in the hedged interest payments. Changes in the fair value of the interest rate swap agreements are recorded in other comprehensive income (loss), net of taxes. The original notional amounts of the interest rate swap agreements of $1,000,000 and $2,500,000 amortize in accordance with the amortization of the mortgage notes. The notional amount of the interest rate swaps was $3,259,963 as of September 30, 2015. Payments required by the interest rate swaps totaled $5,112 and $5,538 during the three-month periods ended September 30, 2015 and 2014, and $15,549 and $16,726 during the nine-month periods ended September 30, 2015 and 2014, respectively. As the result of our decision to hedge this interest rate risk, we recorded other comprehensive (loss) income, net of taxes, in the amount of ($49,147) and $5,017 during the three-month periods ended September 30, 2015 and 2014, and ($48,059) and $193 during the nine-month periods ended September 30, 2015 and 2014, respectively, which reflects the change in the fair value of the interest rate swap assets (liabilities), net of taxes. The fair values of the interest rate swaps have been determined using observable market-based inputs or unobservable inputs that are corroborated by market data. Accordingly, the interest rate swaps are classified as level 2 within the fair value hierarchy provided in Codification Topic 820,&#160;<i>Fair Value Measurements and Disclosures</i>. Proceeds from a $600,000 note bearing interest at 4.25% were received during the first quarter of 2011. This note was repaid during the third quarter of 2015. The $500,000 line of credit is available as needed and has been extended through May 31, 2016 and is renewable annually thereafter. The line of credit was unused as of September 30, 2015 and December 31, 2014. Interest on any borrowings against the line of credit would be variable at the higher of 4.25% per annum or the one-month LIBOR plus 3.5% per annum. These credit facilities are subject to certain financial covenants. We are in compliance with all applicable covenants as of September 30, 2015. Principal payments due under debt outstanding as of September 30, 2015 are reflected in the following table by the year that payments are due:</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: center; padding-left: 0pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">Period</td><td style="padding-bottom: 1.5pt; padding-left: 0pt; font-weight: bold;">&#160;</td><td style="text-align: center; padding-left: 0pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">$1,000,000 Mortgage Note</td><td style="padding-bottom: 1.5pt; padding-left: 0pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; padding-left: 0pt; font-weight: bold;">&#160;</td><td style="text-align: center; padding-left: 0pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">$2,500,000 Mortgage Note</td><td style="padding-bottom: 1.5pt; padding-left: 0pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; padding-left: 0pt; font-weight: bold;">&#160;</td><td style="text-align: center; padding-left: 0pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Total</td><td style="padding-bottom: 1.5pt; padding-left: 0pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1003px;
 text-align: justify; padding-left: 0pt;">Three months ending December 31, 2015</td><td style="width: 16px; padding-left: 0pt;">&#160;</td><td style="width: 16px; text-align: left; padding-left: 0pt;">$</td><td style="width: 142px; text-align: right; padding-left: 0pt;">14,043</td><td style="width: 16px; text-align: left; padding-left: 0pt;">&#160;</td><td style="width: 16px; padding-left: 0pt;">&#160;</td><td style="width: 16px; text-align: left; padding-left: 0pt;">$</td><td style="width: 141px; text-align: right; padding-left: 0pt;">19,371</td><td style="width: 15px; text-align: left; padding-left: 0pt;">&#160;</td><td style="width: 15px; padding-left: 0pt;">&#160;</td><td style="width: 15px; text-align: left; padding-left: 0pt;">$</td><td style="width: 141px; text-align: right; padding-left: 0pt;">33,414</td><td style="width: 15px; text-align: left; padding-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: justify; padding-left: 0pt;">Year ending December 31, 2016</td><td style="padding-left: 0pt;">&#160;</td><td style="text-align: left; padding-left: 0pt;">&#160;</td><td style="text-align: right; padding-left: 0pt;">57,384</td><td style="text-align: left; padding-left: 0pt;">&#160;</td><td style="padding-left: 0pt;">&#160;</td><td style="text-align: left; padding-left: 0pt;">&#160;</td><td style="text-align: right; padding-left: 0pt;">78,456</td><td style="text-align: left; padding-left: 0pt;">&#160;</td><td style="padding-left: 0pt;">&#160;</td><td style="text-align: left; padding-left: 0pt;">&#160;</td><td style="text-align: right; padding-left: 0pt;">135,840</td><td style="text-align: left; padding-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: justify; padding-left: 0pt;">Year ending December 31, 2017</td><td style="padding-left: 0pt;">&#160;</td><td style="text-align: left; padding-left: 0pt;">&#160;</td><td style="text-align: right; padding-left: 0pt;">61,056</td><td style="text-align: left; padding-left: 0pt;">&#160;</td><td style="padding-left: 0pt;">&#160;</td><td style="text-align: left; padding-left: 0pt;">&#160;</td><td style="text-align: right; padding-left: 0pt;">82,308</td><td style="text-align: left; padding-left: 0pt;">&#160;</td><td style="padding-left: 0pt;">&#160;</td><td style="text-align: left; padding-left: 0pt;">&#160;</td><td style="text-align: right; padding-left: 0pt;">143,364</td><td style="text-align: left; padding-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: justify; padding-left: 0pt;">Year ending December 31, 2018</td><td style="padding-left: 0pt;">&#160;</td><td style="text-align: left; padding-left: 0pt;">&#160;</td><td style="text-align: right; padding-left: 0pt;">64,876</td><td style="text-align: left; padding-left: 0pt;">&#160;</td><td style="padding-left: 0pt;">&#160;</td><td style="text-align: left; padding-left: 0pt;">&#160;</td><td style="text-align: right; padding-left: 0pt;">86,097</td><td style="text-align: left; padding-left: 0pt;">&#160;</td><td style="padding-left: 0pt;">&#160;</td><td style="text-align: left; padding-left: 0pt;">&#160;</td><td style="text-align: right; padding-left: 0pt;">150,973</td><td style="text-align: left; padding-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: justify; padding-left: 0pt;">Year ending December 31, 2019</td><td style="padding-left: 0pt;">&#160;</td><td style="text-align: left; padding-left: 0pt;">&#160;</td><td style="text-align: right; padding-left: 0pt;">68,908</td><td style="text-align: left; padding-left: 0pt;">&#160;</td><td style="padding-left: 0pt;">&#160;</td><td style="text-align: left; padding-left: 0pt;">&#160;</td><td style="text-align: right; padding-left: 0pt;">89,997</td><td style="text-align: left; padding-left: 0pt;">&#160;</td><td style="padding-left: 0pt;">&#160;</td><td style="text-align: left; padding-left: 0pt;">&#160;</td><td style="text-align: right; padding-left: 0pt;">158,905</td><td style="text-align: left; padding-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 0pt;">After December 31, 2019</td><td style="padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">493,696</td><td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">2,143,771</td><td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">2,637,467</td><td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-bottom: 4pt; padding-left: 10pt;">Total</td><td style="padding-bottom: 4pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">759,963</td><td style="text-align: left; padding-bottom: 4pt; padding-left: 0pt;">&#160;</td><td style="padding-bottom: 4pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">2,500,000</td><td style="text-align: left; padding-bottom: 4pt; padding-left: 0pt;">&#160;</td><td style="padding-bottom: 4pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt;
 border-bottom-style: double;">3,259,963</td><td style="text-align: left; padding-bottom: 4pt; padding-left: 0pt;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19,20,22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140666867510416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Nov. 09, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_iccc_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">IMMUCELL CORP /DE/<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000811641<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Smaller Reporting Company<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2015<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,055,034<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation 12B<br><br><br><br> -Number 240<br><br><br><br> -Section 12b<br><br><br><br> -Subsection 1<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation 12B<br><br><br><br> -Number 240<br><br><br><br> -Section 12b<br><br><br><br> -Subsection 1<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140666939975664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Expenses, Net<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Expenses, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock', window );">OTHER EXPENSES, NET</a></td>
<td class="text"><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 0.5in; text-align: justify; text-indent: 0pt; padding-left: 0pt;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>10.</b></font></td><td style="text-align: justify; text-indent: 0pt; padding-left: 0pt;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>OTHER EXPENSES, NET</b></font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Other expenses, net, consisted of the following:</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: center; text-indent: 0pt; padding-left: 0px;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0px;">&#160;</td><td style="text-align: center; text-indent: 0pt; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6"><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>Three-Month Periods&#160;</b></font><br /><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>Ended September 30,</b></font></p></td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0px;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0px;">&#160;</td><td style="text-align: center; text-indent: 0pt; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6"><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>Nine-Month Periods&#160;</b></font><br /><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>Ended September 30,</b></font></p></td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0px;">&#160;</td></tr><tr style="vertical-align: bottom;"><td style="text-indent: 0pt; padding-left: 0px;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0px; font-weight: bold;">&#160;</td><td style="text-align: center; text-indent: 0pt; padding-left: 0px; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2015</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0px; font-weight: bold;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0px; font-weight: bold;">&#160;</td><td style="text-align: center; text-indent: 0pt; padding-left: 0px; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2014</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0px; font-weight: bold;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0px; font-weight: bold;">&#160;</td><td style="text-align: center; text-indent: 0pt; padding-left: 0px; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2015</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0px; font-weight: bold;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0px; font-weight: bold;">&#160;</td><td style="text-align: center; text-indent: 0pt; padding-left: 0px; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2014</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0px; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 815px; text-align: left; text-indent: 0pt; padding-left: 0px;">Interest income</td><td style="width: 16px; text-indent: 0pt; padding-left: 0px;">&#160;</td><td style="width: 16px; text-align: left; text-indent: 0pt; padding-left: 0px;">$</td><td style="width: 142px; text-align: right; text-indent: 0pt; padding-left: 0px;">(4,461</td><td style="width: 16px; text-align: left; text-indent: 0pt; padding-left: 0px;">)</td><td style="width: 16px; text-indent: 0pt; padding-left: 0px;">&#160;</td><td style="width: 16px; text-align: left; text-indent: 0pt; padding-left: 0px;">$</td><td style="width: 142px; text-align: right; text-indent: 0pt; padding-left: 0px;">(3,912</td><td style="width: 16px; text-align: left; text-indent: 0pt; padding-left: 0px;">)</td><td style="width: 15px; text-indent: 0pt; padding-left: 0px;">&#160;</td><td style="width: 15px; text-align: left; text-indent: 0pt; padding-left: 0px;">$</td><td style="width: 141px; text-align: right; text-indent: 0pt; padding-left: 0px;">(10,634</td><td style="width: 15px; text-align: left; text-indent: 0pt; padding-left: 0px;">)</td><td style="width: 15px; text-indent: 0pt; padding-left: 0px;">&#160;</td><td style="width: 15px; text-align: left; text-indent: 0pt; padding-left: 0px;">$</td><td style="width: 141px; text-align: right; text-indent: 0pt; padding-left: 0px;">(11,607</td><td style="width: 15px; text-align: left; text-indent: 0pt; padding-left: 0px;">)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: 0pt; padding-left:
 0px;">Interest expense</td><td style="text-indent: 0pt; padding-left: 0px;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0px;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0px;">15,084</td><td style="text-align: left; text-indent: 0pt; padding-left: 0px;">&#160;</td><td style="text-indent: 0pt; padding-left: 0px;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0px;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0px;">14,514</td><td style="text-align: left; text-indent: 0pt; padding-left: 0px;">&#160;</td><td style="text-indent: 0pt; padding-left: 0px;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0px;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0px;">41,039</td><td style="text-align: left; text-indent: 0pt; padding-left: 0px;">&#160;</td><td style="text-indent: 0pt; padding-left: 0px;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0px;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0px;">44,148</td><td style="text-align: left; text-indent: 0pt; padding-left: 0px;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0px;">Other</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0px;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">4,488</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0px;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0px;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">644</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0px;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0px;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(3,346</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0px;">)</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0px;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0px; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">6,092</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0px;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: 0pt; padding-bottom: 4pt; padding-left: 10pt;">Other expenses, net</td><td style="text-indent: 0pt; padding-bottom: 4pt; padding-left: 0px;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; text-indent: 0pt; padding-left: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">15,111</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 4pt; padding-left: 0px;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 4pt; padding-left: 0px;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; text-indent: 0pt; padding-left: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">11,246</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 4pt; padding-left: 0px;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 4pt; padding-left: 0px;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; text-indent: 0pt; padding-left: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">27,059</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 4pt; padding-left: 0px;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 4pt; padding-left: 0px;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; text-indent: 0pt; padding-left: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">38,633</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 4pt; padding-left: 0px;">&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.3,6,7,9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140666866967216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueGoodsNet', window );">Product sales</a></td>
<td class="nump">$ 2,472,428<span></span>
</td>
<td class="nump">$ 1,770,129<span></span>
</td>
<td class="nump">$ 7,534,281<span></span>
</td>
<td class="nump">$ 5,391,599<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsSold', window );">Costs of goods sold</a></td>
<td class="nump">860,526<span></span>
</td>
<td class="nump">692,233<span></span>
</td>
<td class="nump">2,940,881<span></span>
</td>
<td class="nump">2,285,285<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross margin</a></td>
<td class="nump">1,611,902<span></span>
</td>
<td class="nump">1,077,896<span></span>
</td>
<td class="nump">4,593,400<span></span>
</td>
<td class="nump">3,106,314<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Sales and marketing expenses</a></td>
<td class="nump">381,740<span></span>
</td>
<td class="nump">373,595<span></span>
</td>
<td class="nump">1,086,928<span></span>
</td>
<td class="nump">921,588<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">Administrative expenses</a></td>
<td class="nump">301,566<span></span>
</td>
<td class="nump">302,216<span></span>
</td>
<td class="nump">941,417<span></span>
</td>
<td class="nump">873,866<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Product development expenses</a></td>
<td class="nump">301,746<span></span>
</td>
<td class="nump">361,232<span></span>
</td>
<td class="nump">904,170<span></span>
</td>
<td class="nump">1,716,114<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating expenses</a></td>
<td class="nump">985,052<span></span>
</td>
<td class="nump">1,037,043<span></span>
</td>
<td class="nump">2,932,515<span></span>
</td>
<td class="nump">3,511,568<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">NET OPERATING INCOME (LOSS)</a></td>
<td class="nump">626,850<span></span>
</td>
<td class="nump">40,853<span></span>
</td>
<td class="nump">1,660,885<span></span>
</td>
<td class="num">(405,254)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingExpense', window );">Other expenses, net</a></td>
<td class="nump">15,111<span></span>
</td>
<td class="nump">11,246<span></span>
</td>
<td class="nump">27,059<span></span>
</td>
<td class="nump">38,633<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">INCOME (LOSS) BEFORE INCOME TAXES</a></td>
<td class="nump">611,739<span></span>
</td>
<td class="nump">29,607<span></span>
</td>
<td class="nump">1,633,826<span></span>
</td>
<td class="num">(443,887)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="nump">260,447<span></span>
</td>
<td class="nump">19,277<span></span>
</td>
<td class="nump">709,394<span></span>
</td>
<td class="num">(146,101)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NET INCOME (LOSS)</a></td>
<td class="nump">$ 351,292<span></span>
</td>
<td class="nump">$ 10,330<span></span>
</td>
<td class="nump">$ 924,432<span></span>
</td>
<td class="num">$ (297,786)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted average common shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic</a></td>
<td class="nump">3,052,175<span></span>
</td>
<td class="nump">3,027,034<span></span>
</td>
<td class="nump">3,038,111<span></span>
</td>
<td class="nump">3,026,990<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted</a></td>
<td class="nump">3,188,349<span></span>
</td>
<td class="nump">3,105,832<span></span>
</td>
<td class="nump">3,162,620<span></span>
</td>
<td class="nump">3,026,990<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>NET INCOME (LOSS) PER SHARE:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic</a></td>
<td class="nump">$ 0.12<span></span>
</td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="nump">$ 0.30<span></span>
</td>
<td class="num">$ (0.10)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted</a></td>
<td class="nump">$ 0.11<span></span>
</td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="nump">$ 0.29<span></span>
</td>
<td class="num">$ (0.10)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs related to goods produced and sold during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.2(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 52<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=32703322&amp;loc=d3e4984-109258<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1252-109256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-04.23)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 18<br><br><br><br> -Article 7<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 21<br><br><br><br> -Article 9<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1252-109256<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 18<br><br><br><br> -Article 7<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 21<br><br><br><br> -Article 9<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.1,2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the income or loss from continuing operations attributable to the economic entity which may also be defined as revenue less expenses from ongoing operations, after income or loss from equity method investments, but before income taxes, extraordinary items, and noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 940<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 25<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51673353&amp;loc=d3e41242-110953<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 10<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 9<br><br><br><br> -Subparagraph (a),(b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(h))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Income Tax Expense (or Benefit)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6515339<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Net Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Other Comprehensive Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 9<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of other expense amounts, the components of which are not separately disclosed on the income statement, resulting from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business) also known as other nonoperating expense recognized during the period. Such amounts may include: (a) unusual costs, (b) loss on foreign exchange transactions, (c) losses on securities (net of profits), and (d) miscellaneous other expense items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 730<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 985<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueGoodsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.1(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueGoodsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 16<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1505-109256<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 10<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7655603&amp;loc=d3e1448-109256<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Weighted-Average Number of Common Shares Outstanding<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6528421<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140666939994752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORY</a></td>
<td class="text"><div><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 0.5in;"><font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"><b>4.</b></font></td><td><font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"><b>INVENTORY</b></font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"><b>&#160;</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;">Inventory consisted of the following:</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: justify; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: center; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"><b>As of</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"><b>September&#160;30, 2015</b></font></p></td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: center; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"><b>As of</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"><b>December&#160;31, 2014</b></font></p></td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: center; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"><b>Increase</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"><b>(Decrease)</b></font></p></td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1003px; text-align: justify; text-indent: 0pt; padding-left: 0pt;">Raw materials</td><td style="width: 16px; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="width: 16px; text-align: left; text-indent: 0pt; padding-left: 0pt;">$</td><td style="width: 142px; text-align: right; text-indent: 0pt; padding-left: 0pt;">337,538</td><td style="width: 16px; text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="width: 16px; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="width: 16px; text-align: left; text-indent: 0pt; padding-left: 0pt;">$</td><td style="width: 141px; text-align: right; text-indent: 0pt; padding-left: 0pt;">306,444</td><td style="width: 15px; text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="width: 15px; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="width: 15px; text-align: left; text-indent: 0pt; padding-left: 0pt;">$</td><td style="width: 141px; text-align: right; text-indent: 0pt; padding-left: 0pt;">31,094</td><td style="width: 15px; text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: justify; text-indent: 0pt; padding-left: 0pt;">Work-in-process</td><td style="text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt;">468,059</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt;">355,745</td><td style="text-align: left; text-indent: 0pt; padding-left:
 0pt;">&#160;</td><td style="text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt;">112,314</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">Finished goods</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">58,847</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">283,566</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(224,719</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-indent: 0pt; padding-bottom: 4pt; padding-left: 10pt;">Total</td><td style="text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">864,444</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">945,755</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">(81,311</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;">)</td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. This may include, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the major classes of inventory, and the nature of the cost elements included in inventory. If inventory is stated above cost, accrued net losses on firm purchase commitments for inventory and losses resulting from valuing inventory at the lower-of-cost-or-market may also be included. For LIFO inventory, may disclose the amount and basis for determining the excess of replacement or current cost over stated LIFO value and the effects of a LIFO quantities liquidation that impacts net income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.6)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 6<br><br><br><br> -Subparagraph a, b, c<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140666864811792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, Cash Equivalents, Short-Term Investments and Long-Term Investments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>Cash, Cash Equivalents, Short-Term Investments and Long-Term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock', window );">CASH, CASH EQUIVALENTS, SHORT-TERM INVESTMENTS AND LONG-TERM INVESTMENTS</a></td>
<td class="text"><div><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 0.5in; text-indent: 0pt; padding-left: 0pt;"><font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"><b>3.</b></font></td><td style="text-indent: 0pt; padding-left: 0pt;"><font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"><b>CASH, CASH EQUIVALENTS, SHORT-TERM INVESTMENTS AND LONG-TERM INVESTMENTS</b></font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"><b>&#160;</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;">Cash, cash equivalents, short-term investments and long-term investments consisted of the following:</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="padding-left: 0pt;">&#160;</td><td style="padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: center; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"><b>As of</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"><b>September&#160;30, 2015</b></font></p></td><td style="padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: center; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"><b>As of</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"><b>December&#160;31, 2014</b></font></p></td><td style="padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: center; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"><b>Increase</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"><b>(Decrease)</b></font></p></td><td style="padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1003px; text-align: left; padding-left: 0pt;">Cash and cash equivalents</td><td style="width: 16px; padding-left: 0pt;">&#160;</td><td style="width: 16px; text-align: left; padding-left: 0pt;">$</td><td style="width: 142px; text-align: right; padding-left: 0pt;">2,469,087</td><td style="width: 16px; text-align: left; padding-left: 0pt;">&#160;</td><td style="width: 16px; padding-left: 0pt;">&#160;</td><td style="width: 16px; text-align: left; padding-left: 0pt;">$</td><td style="width: 141px; text-align: right; padding-left: 0pt;">850,028</td><td style="width: 15px; text-align: left; padding-left: 0pt;">&#160;</td><td style="width: 15px; padding-left: 0pt;">&#160;</td><td style="width: 15px; text-align: left; padding-left: 0pt;">$</td><td style="width: 141px; text-align: right; padding-left: 0pt;">1,619,059</td><td style="width: 15px; text-align: left; padding-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt;">Short-term investments</td><td style="padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">3,720,000</td><td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style:
 solid;">2,489,000</td><td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">1,231,000</td><td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="padding-left: 0pt;">&#160;&#160;&#160;Subtotal</td><td style="padding-left: 0pt;">&#160;</td><td style="text-align: left; padding-left: 0pt;">&#160;</td><td style="text-align: right; padding-left: 0pt;">6,189,087</td><td style="text-align: left; padding-left: 0pt;">&#160;</td><td style="padding-left: 0pt;">&#160;</td><td style="text-align: left; padding-left: 0pt;">&#160;</td><td style="text-align: right; padding-left: 0pt;">3,339,028</td><td style="text-align: left; padding-left: 0pt;">&#160;</td><td style="padding-left: 0pt;">&#160;</td><td style="text-align: left; padding-left: 0pt;">&#160;</td><td style="text-align: right; padding-left: 0pt;">2,850,059</td><td style="text-align: left; padding-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt;">Long-term investments</td><td style="padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">487,000</td><td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">496,000</td><td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(9,000</td><td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt;">)</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="padding-bottom: 4pt; padding-left: 0pt;">&#160;&#160;&#160;Total</td><td style="padding-bottom: 4pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">6,676,087</td><td style="text-align: left; padding-bottom: 4pt; padding-left: 0pt;">&#160;</td><td style="padding-bottom: 4pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">3,835,028</td><td style="text-align: left; padding-bottom: 4pt; padding-left: 0pt;">&#160;</td><td style="padding-bottom: 4pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">2,841,059</td><td style="text-align: left; padding-bottom: 4pt; padding-left: 0pt;">&#160;</td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of the components of cash, cash equivalents, and short-term investments. Short-term investments may include current marketable securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140666939975664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">RELATED PARTY TRANSACTIONS</a></td>
<td class="text"><div><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 0.5in; padding-left: 0pt;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>15.</b></font></td><td style="padding-left: 0pt;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>RELATED PARTY TRANSACTIONS</b></font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>&#160;</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;">Dr. David S. Tomsche (Chair of our Board of Directors) is a controlling owner of Leedstone Inc. (formerly Stearns Veterinary Outlet, Inc.), a domestic distributor of ImmuCell products (<b>First Defense<sup>&#174;</sup></b>,&#160;<b>Wipe Out<sup>&#174;</sup></b>&#160;<b>Dairy Wipes</b>,<b>&#160;</b>and<b>&#160;CMT</b>) and of J-t Enterprises of Melrose, Inc., an exporter. His affiliated companies purchased $452,207 and $283,287 of products from ImmuCell during the nine-month periods ended September 30, 2015 and 2014, respectively, on terms consistent with those offered to other distributors of similar status. We made marketing-related payments of $3,222 and $6,355 to these affiliate companies during the nine-month periods ended September 30, 2015 and 2014, respectively. Our accounts receivable (subject to standard and customary payment terms) due from these affiliated companies aggregated $12,864 and $18,796 as of September 30, 2015 and December 31, 2014, respectively.</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 850<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 850<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39622-107864<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 850<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 850<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39678-107864<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 850<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(k))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph b<br><br><br><br> -Article 3A<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140666940002944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><div><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 0.5in; padding-left: 0pt;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>11.</b></font></td><td style="padding-left: 0pt;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>INCOME TAXES</b></font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Our income tax expense (benefit) aggregated $260,447 and $19,277 (amounting to 43% and 65% of our income (loss) before income taxes) for the three-month periods ended September 30, 2015 and 2014, respectively, and $709,394 and ($146,101) (amounting to 43% and 33% of our income (loss) before income taxes) for the nine-month periods ended September 30, 2015 and 2014, respectively. As of December 31, 2014, we have state net operating loss carryforwards of approximately $1,920,000 that expire in 2028 through 2031, if not utilized before then, and federal net operating loss carryforwards of approximately $1,750,000 that expire in 2029 through 2034, if not utilized before then. Additionally, we have general business tax credit carryforwards of approximately $220,000 that expire in 2027 through 2034, if not utilized before then, which effectively protects approximately $549,000 in taxable income (assuming a 40% tax rate) from taxes, which can be utilized only after all net operating loss carryforwards are utilized. The $965,000 licensing payment that we made during the fourth quarter of 2004 was treated as an intangible asset and is being amortized over 15 years, for tax return purposes only. Approximately $1,112,000 of our investment to produce the Drug Substance (our Active Pharmaceutical Ingredient, Nisin) for&#160;<b>Mast Out<sup>&#174;</sup></b>&#160;was expensed as incurred for our books. Included in this amount is approximately $820,000 that was capitalized and is being depreciated over statutory periods for tax return purposes only.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Deferred tax assets are recognized only when it is probable that sufficient taxable income will be available in future periods against which deductible temporary differences and credits may be utilized. However, the amount of the deferred tax asset could be reduced if projected income is not achieved due to various factors, such as unfavorable business conditions. If projected income is not expected to be achieved, we would decrease the deferred tax asset to the amount that we believe can be realized.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Net operating loss carryforwards, credits, and other tax attributes are subject to review and possible adjustment by the Internal Revenue Service. Section 382 of the Internal Revenue Code contains provisions that could place annual limitations on the future utilization of net operating loss carryforwards and credits in the event of a change in ownership of the Company, as defined.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">The Company files income tax returns in the U.S. federal jurisdiction and several state jurisdictions. With few exceptions, the Company is no longer subject to income tax examinations by tax authorities for years before 2011. We currently have no tax examinations in progress. We also have not paid additional taxes, interest or penalties as a result of tax examinations nor do we have any unrecognized tax benefits for any of the periods in the accompanying financial statements.</font></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(h))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 15<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32718-109319<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 9<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140666867362144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY, PLANT AND EQUIPMENT</a></td>
<td class="text"><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>&#160;</b></font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="text-align: justify; width: 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>7.</b></font></td><td style="text-align: justify;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>PROPERTY, PLANT AND EQUIPMENT</b></font></td></tr></table><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">Property, plant and equipment consisted of the following, at cost:</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify; text-indent: 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="padding-left: 0pt; text-indent: 0pt;">&#160;</td><td style="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; padding-left: 0pt; text-indent: 0pt;" colspan="2"><p style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin: 0px; text-align: center;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>As of</b></font></p><p style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin: 0px; text-align: center;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>September&#160;30, 2015</b></font></p></td><td style="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt;">&#160;</td><td style="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; padding-left: 0pt; text-indent: 0pt;" colspan="2"><p style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin: 0px; text-align: center;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>As of</b></font></p><p style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin: 0px; text-align: center;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>December&#160;31, 2014</b></font></p></td><td style="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt;">&#160;</td><td style="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; padding-left: 0pt; text-indent: 0pt;" colspan="2"><p style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin: 0px; text-align: center;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>Increase</b></font></p><p style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin: 0px; text-align: center;"><font style="font-style:
 normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>(Decrease)</b></font></p></td><td style="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1003px; text-align: left; padding-left: 0pt; text-indent: 0pt;">Laboratory and manufacturing equipment</td><td style="width: 16px; padding-left: 0pt; text-indent: 0pt;">&#160;</td><td style="width: 16px; text-align: left; padding-left: 0pt; text-indent: 0pt;">$</td><td style="width: 142px; text-align: right; padding-left: 0pt; text-indent: 0pt;">3,602,690</td><td style="width: 16px; text-align: left; padding-left: 0pt; text-indent: 0pt;">&#160;</td><td style="width: 16px; padding-left: 0pt; text-indent: 0pt;">&#160;</td><td style="width: 16px; text-align: left; padding-left: 0pt; text-indent: 0pt;">$</td><td style="width: 141px; text-align: right; padding-left: 0pt; text-indent: 0pt;">3,522,465</td><td style="width: 15px; text-align: left; padding-left: 0pt; text-indent: 0pt;">&#160;</td><td style="width: 15px; padding-left: 0pt; text-indent: 0pt;">&#160;</td><td style="width: 15px; text-align: left; padding-left: 0pt; text-indent: 0pt;">$</td><td style="width: 141px; text-align: right; padding-left: 0pt; text-indent: 0pt;">80,225</td><td style="width: 15px; text-align: left; padding-left: 0pt; text-indent: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: justify; padding-left: 0pt; text-indent: 0pt;">Building and improvements</td><td style="padding-left: 0pt; text-indent: 0pt;">&#160;</td><td style="text-align: left; padding-left: 0pt; text-indent: 0pt;">&#160;</td><td style="text-align: right; padding-left: 0pt; text-indent: 0pt;">4,579,852</td><td style="text-align: left; padding-left: 0pt; text-indent: 0pt;">&#160;</td><td style="padding-left: 0pt; text-indent: 0pt;">&#160;</td><td style="text-align: left; padding-left: 0pt; text-indent: 0pt;">&#160;</td><td style="text-align: right; padding-left: 0pt; text-indent: 0pt;">2,969,891</td><td style="text-align: left; padding-left: 0pt; text-indent: 0pt;">&#160;</td><td style="padding-left: 0pt; text-indent: 0pt;">&#160;</td><td style="text-align: left; padding-left: 0pt; text-indent: 0pt;">&#160;</td><td style="text-align: right; padding-left: 0pt; text-indent: 0pt;">1,609,961</td><td style="text-align: left; padding-left: 0pt; text-indent: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-left: 0pt; text-indent: 0pt;">Office furniture and equipment</td><td style="padding-left: 0pt; text-indent: 0pt;">&#160;</td><td style="text-align: left; padding-left: 0pt; text-indent: 0pt;">&#160;</td><td style="text-align: right; padding-left: 0pt; text-indent: 0pt;">569,567</td><td style="text-align: left; padding-left: 0pt; text-indent: 0pt;">&#160;</td><td style="padding-left: 0pt; text-indent: 0pt;">&#160;</td><td style="text-align: left; padding-left: 0pt; text-indent: 0pt;">&#160;</td><td style="text-align: right; padding-left: 0pt; text-indent: 0pt;">470,607</td><td style="text-align: left; padding-left: 0pt; text-indent: 0pt;">&#160;</td><td style="padding-left: 0pt; text-indent: 0pt;">&#160;</td><td style="text-align: left; padding-left: 0pt; text-indent: 0pt;">&#160;</td><td style="text-align: right; padding-left: 0pt; text-indent: 0pt;">98,960</td><td style="text-align: left; padding-left: 0pt; text-indent: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-left: 0pt; text-indent: 0pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">Construction in progress<sup>(1)</sup></font></td><td style="padding-left: 0pt; text-indent: 0pt;">&#160;</td><td style="text-align: left; padding-left: 0pt; text-indent: 0pt;">&#160;</td><td style="text-align: right; padding-left: 0pt; text-indent: 0pt;">738,282</td><td style="text-align: left; padding-left: 0pt; text-indent: 0pt;">&#160;</td><td style="padding-left: 0pt; text-indent: 0pt;">&#160;</td><td style="text-align: left; padding-left: 0pt; text-indent: 0pt;">&#160;</td><td style="text-align: right; padding-left: 0pt; text-indent: 0pt;">1,270,672</td><td style="text-align: left; padding-left: 0pt; text-indent: 0pt;">&#160;</td><td style="padding-left: 0pt; text-indent: 0pt;">&#160;</td><td style="text-align: left; padding-left: 0pt; text-indent: 0pt;">&#160;</td><td style="text-align: right; padding-left: 0pt; text-indent: 0pt;">(532,390</td><td style="text-align: left; padding-left: 0pt; text-indent: 0pt;">)</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt;">Land</td><td style="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left; padding-left: 0pt; text-indent: 0pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right; padding-left: 0pt; text-indent: 0pt;">72,807</td><td style="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt; text-indent: 0pt;">&#160;</td><td style="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left; padding-left: 0pt; text-indent: 0pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right; padding-left: 0pt; text-indent: 0pt;">50,000</td><td style="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt; text-indent: 0pt;">&#160;</td><td style="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left; padding-left: 0pt; text-indent: 0pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right; padding-left: 0pt; text-indent: 0pt;">22,807</td><td style="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt; text-indent: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-left: 0pt; text-indent: 0pt;">&#160;&#160;&#160;&#160;&#160;Property, plant and equipment, gross</td><td style="padding-left: 0pt; text-indent: 0pt;">&#160;</td><td style="text-align: left; padding-left: 0pt; text-indent: 0pt;">&#160;</td><td style="text-align: right; padding-left: 0pt; text-indent: 0pt;">9,563,198</td><td style="text-align:
 left; padding-left: 0pt; text-indent: 0pt;">&#160;</td><td style="padding-left: 0pt; text-indent: 0pt;">&#160;</td><td style="text-align: left; padding-left: 0pt; text-indent: 0pt;">&#160;</td><td style="text-align: right; padding-left: 0pt; text-indent: 0pt;">8,283,635</td><td style="text-align: left; padding-left: 0pt; text-indent: 0pt;">&#160;</td><td style="padding-left: 0pt; text-indent: 0pt;">&#160;</td><td style="text-align: left; padding-left: 0pt; text-indent: 0pt;">&#160;</td><td style="text-align: right; padding-left: 0pt; text-indent: 0pt;">1,279,563</td><td style="text-align: left; padding-left: 0pt; text-indent: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt;">Accumulated depreciation</td><td style="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left; padding-left: 0pt; text-indent: 0pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right; padding-left: 0pt; text-indent: 0pt;">(4,607,584</td><td style="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt; text-indent: 0pt;">)</td><td style="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left; padding-left: 0pt; text-indent: 0pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right; padding-left: 0pt; text-indent: 0pt;">(4,445,988</td><td style="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt; text-indent: 0pt;">)</td><td style="padding-bottom: 1.5pt; padding-left: 0pt; text-indent: 0pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left; padding-left: 0pt; text-indent: 0pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right; padding-left: 0pt; text-indent: 0pt;">(161,596</td><td style="padding-bottom: 1.5pt; text-align: left; padding-left: 0pt; text-indent: 0pt;">)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt;">&#160;&#160;&#160;&#160;&#160;Property, plant and equipment, net</td><td style="padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left; padding-left: 0pt; text-indent: 0pt;">$</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right; padding-left: 0pt; text-indent: 0pt;">4,955,614</td><td style="padding-bottom: 4pt; text-align: left; padding-left: 0pt; text-indent: 0pt;">&#160;</td><td style="padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left; padding-left: 0pt; text-indent: 0pt;">$</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right; padding-left: 0pt; text-indent: 0pt;">3,837,647</td><td style="padding-bottom: 4pt; text-align: left; padding-left: 0pt; text-indent: 0pt;">&#160;</td><td style="padding-bottom: 4pt; padding-left: 0pt; text-indent: 0pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left; padding-left: 0pt; text-indent: 0pt;">$</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right; padding-left: 0pt; text-indent: 0pt;">1,117,967</td><td style="padding-bottom: 4pt; text-align: left; padding-left: 0pt; text-indent: 0pt;">&#160;</td></tr></table><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><sup>&#160;</sup></font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><sup>(1)</sup>As of December 31, 2014, construction in progress consisted of a building addition that was completed during the first quarter of 2015. As of September 30, 2015, construction in progress consisted principally of partial payments towards new manufacturing equipment.</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13-14)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 205<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51717284&amp;loc=d3e1361-107760<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51719941&amp;loc=d3e2921-110230<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140667077938752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Receivable<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesAbstract', window );"><strong>Accounts Receivable[Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock', window );">ACCOUNTS RECEIVABLE</a></td>
<td class="text"><div><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 0.5in; text-align: justify;"><font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"><b>5.</b></font></td><td style="text-align: justify;"><font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"><b>ACCOUNTS RECEIVABLE</b></font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;">Accounts receivable consisted of the following:</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: center; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"><b>As of</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"><b>September&#160;30, 2015</b></font></p></td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: center; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"><b>As of</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"><b>December&#160;31, 2014</b></font></p></td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: center; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"><b>(Decrease)</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"><b>Increase</b></font></p></td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1003px; text-align: left; text-indent: 0pt; padding-left: 0pt;">Trade accounts receivable, gross</td><td style="width: 16px; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="width: 16px; text-align: left; text-indent: 0pt; padding-left: 0pt;">$</td><td style="width: 142px; text-align: right; text-indent: 0pt; padding-left: 0pt;">783,547</td><td style="width: 16px; text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="width: 16px; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="width: 16px; text-align: left; text-indent: 0pt; padding-left: 0pt;">$</td><td style="width: 141px; text-align: right; text-indent: 0pt; padding-left: 0pt;">1,004,990</td><td style="width: 15px; text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="width: 15px; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="width: 15px; text-align: left; text-indent: 0pt; padding-left: 0pt;">$</td><td style="width: 141px; text-align: right; text-indent: 0pt; padding-left: 0pt;">(221,443</td><td style="width: 15px; text-align: left; text-indent: 0pt; padding-left: 0pt;">)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">Accumulated allowance for bad debt and product returns</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style:
 solid;">(16,958</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">)</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(16,194</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">)</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(764</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">)</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;&#160;&#160;&#160;&#160;Trade accounts receivable, net</td><td style="text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt;">766,589</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt;">988,796</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt;">(222,207</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">Other receivables</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">22,625</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">16,496</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">6,129</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;">&#160;&#160;&#160;&#160;&#160;Accounts receivable, net</td><td style="text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">789,214</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">1,005,292</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">(216,078</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;">)</td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49124121&amp;loc=d3e5066-111524<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.3,4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 11<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49124121&amp;loc=d3e5162-111524<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(k))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49124121&amp;loc=d3e5074-111524<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 7<br><br><br><br> -Article 9<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansNotesTradeAndOtherReceivablesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140666939912512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Assets<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract', window );"><strong>Prepaid Expenses and Other Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_iccc_PrepaidExpensesAndOtherAssetsTextBlock', window );">PREPAID EXPENSES AND OTHER ASSETS</a></td>
<td class="text"><div><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 0.5in; text-align: justify;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>6.</b></font></td><td style="text-align: justify;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>PREPAID EXPENSES AND OTHER ASSETS</b></font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>&#160;</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Prepaid expenses and other assets consisted of the following:</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: center; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: center; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>As of</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>September&#160;30, 2015</b></font></p></td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt; font-weight: bold;">&#160;</td><td style="text-align: center; text-indent: 0pt; padding-left: 0pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">As of<br />December&#160;31, 2014</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt; font-weight: bold;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: center; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>Increase</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>(Decrease)</b></font></p></td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1003px; text-align: left; text-indent: 0pt; padding-left: 0pt;">Prepaid expenses and other assets</td><td style="width: 16px; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="width: 16px; text-align: left; text-indent: 0pt; padding-left: 0pt;">$</td><td style="width: 142px; text-align: right; text-indent: 0pt; padding-left: 0pt;">234,628</td><td style="width: 16px; text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="width: 16px; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="width: 16px; text-align: left; text-indent: 0pt; padding-left: 0pt;">$</td><td style="width: 141px; text-align: right; text-indent: 0pt; padding-left: 0pt;">133,119</td><td style="width: 15px; text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="width: 15px; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="width: 15px; text-align: left; text-indent: 0pt; padding-left: 0pt;">$</td><td style="width: 141px; text-align: right; text-indent: 0pt; padding-left: 0pt;">101,509</td><td style="width: 15px; text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">Security deposits</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">40,931</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">15,280</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style:
 solid;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">25,651</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;&#160;&#160;&#160;&#160;Current subtotal</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">275,559</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">148,399</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">127,160</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">Debt issue costs</td><td style="text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt;">59,248</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt;">26,489</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt;">32,759</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">Accumulated amortization of debt issue costs</td><td style="text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt;">(18,553</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">)</td><td style="text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt;">(16,479</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">)</td><td style="text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt;">(2,074</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">)</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">Security deposits</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">8,920</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">8,920</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">0</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left:
 0pt;">&#160;&#160;&#160;&#160;&#160;Long-term subtotal</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">49,615</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">18,930</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">30,685</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;">&#160;&#160;&#160;&#160;&#160;Total</td><td style="text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">325,174</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">167,329</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">157,845</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_PrepaidExpensesAndOtherAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of prepaid expenses and other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_PrepaidExpensesAndOtherAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140666940031456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract', window );"><strong>Accounts Payable and Accrued Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">ACCOUNTS PAYABLE AND ACCRUED EXPENSES</a></td>
<td class="text"><div><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 0.5in; text-align: justify; text-indent: 0pt; padding-left: 0pt;"><font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"><b>8.</b></font></td><td style="text-align: justify; text-indent: 0pt; padding-left: 0pt;"><font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"><b>ACCOUNTS PAYABLE AND ACCRUED EXPENSES</b></font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;">Accounts payable and accrued expenses consisted of the following:</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: center; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"><b>As of</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"><b>September&#160;30, 2015</b></font></p></td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: center; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"><b>As of</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"><b>December&#160;31, 2014</b></font></p></td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: center; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2"><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"><b>(Decrease)</b></font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-size-adjust: none; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-size-adjust: none; font-stretch: normal;"><b>Increase</b></font></p></td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1003px; text-align: left; text-indent: 0pt; padding-left: 0pt;">Accounts payable &#8211; capital</td><td style="width: 16px; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="width: 16px; text-align: left; text-indent: 0pt; padding-left: 0pt;">$</td><td style="width: 142px; text-align: right; text-indent: 0pt; padding-left: 0pt;">37,965</td><td style="width: 16px; text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="width: 16px; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="width: 16px; text-align: left; text-indent: 0pt; padding-left: 0pt;">$</td><td style="width: 141px; text-align: right; text-indent: 0pt; padding-left: 0pt;">251,383</td><td style="width: 15px; text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="width: 15px; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="width: 15px; text-align: left; text-indent: 0pt; padding-left: 0pt;">$</td><td style="width: 141px; text-align: right; text-indent: 0pt; padding-left: 0pt;">(213,418</td><td style="width: 15px; text-align: left; text-indent: 0pt; padding-left: 0pt;">)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">Accounts payable &#8211; trade</td><td style="text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt;">178,542</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-left:
 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt;">204,810</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt;">(26,268</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">)</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">Accrued payroll</td><td style="text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt;">134,466</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt;">145,176</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt;">(10,710</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">)</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">Accrued clinical studies</td><td style="text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt;">68,428</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt;">131,945</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt;">(63,517</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">)</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">Accrued professional fees</td><td style="text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt;">55,462</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt;">42,250</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt;">13,212</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">Accrued other</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">71,064</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">76,113</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">(5,049</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 1.5pt; padding-left: 0pt;">)</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;">&#160;&#160;&#160;Total</td><td style="text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">545,927</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">851,677</td><td style="text-align: left; text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;">&#160;</td><td style="text-indent: 0pt; padding-bottom: 4pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">$</td><td style="text-align: right; text-indent: 0pt; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">(305,750</td><td style="text-align: left; text-indent: 0pt;
 padding-bottom: 4pt; padding-left: 0pt;">)</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;"></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a),20,24)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140667132371008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Bank Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Bank Debt [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of principal payments due under debt outstanding</a></td>
<td class="text"><div><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; border-collapse: collapse; font-size-adjust: none; font-stretch: normal;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td style="text-align: center; padding-left: 0pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">Period</td><td style="padding-bottom: 1.5pt; padding-left: 0pt; font-weight: bold;">&#160;</td><td style="text-align: center; padding-left: 0pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">$1,000,000 Mortgage Note</td><td style="padding-bottom: 1.5pt; padding-left: 0pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; padding-left: 0pt; font-weight: bold;">&#160;</td><td style="text-align: center; padding-left: 0pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">$2,500,000 Mortgage Note</td><td style="padding-bottom: 1.5pt; padding-left: 0pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; padding-left: 0pt; font-weight: bold;">&#160;</td><td style="text-align: center; padding-left: 0pt; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">Total</td><td style="padding-bottom: 1.5pt; padding-left: 0pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 1003px; text-align: justify; padding-left: 0pt;">Three months ending December 31, 2015</td><td style="width: 16px; padding-left: 0pt;">&#160;</td><td style="width: 16px; text-align: left; padding-left: 0pt;">$</td><td style="width: 142px; text-align: right; padding-left: 0pt;">14,043</td><td style="width: 16px; text-align: left; padding-left: 0pt;">&#160;</td><td style="width: 16px; padding-left: 0pt;">&#160;</td><td style="width: 16px; text-align: left; padding-left: 0pt;">$</td><td style="width: 141px; text-align: right; padding-left: 0pt;">19,371</td><td style="width: 15px; text-align: left; padding-left: 0pt;">&#160;</td><td style="width: 15px; padding-left: 0pt;">&#160;</td><td style="width: 15px; text-align: left; padding-left: 0pt;">$</td><td style="width: 141px; text-align: right; padding-left: 0pt;">33,414</td><td style="width: 15px; text-align: left; padding-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: justify; padding-left: 0pt;">Year ending December 31, 2016</td><td style="padding-left: 0pt;">&#160;</td><td style="text-align: left; padding-left: 0pt;">&#160;</td><td style="text-align: right; padding-left: 0pt;">57,384</td><td style="text-align: left; padding-left: 0pt;">&#160;</td><td style="padding-left: 0pt;">&#160;</td><td style="text-align: left; padding-left: 0pt;">&#160;</td><td style="text-align: right; padding-left: 0pt;">78,456</td><td style="text-align: left; padding-left: 0pt;">&#160;</td><td style="padding-left: 0pt;">&#160;</td><td style="text-align: left; padding-left: 0pt;">&#160;</td><td style="text-align: right; padding-left: 0pt;">135,840</td><td style="text-align: left; padding-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: justify; padding-left: 0pt;">Year ending December 31, 2017</td><td style="padding-left: 0pt;">&#160;</td><td style="text-align: left; padding-left: 0pt;">&#160;</td><td style="text-align: right; padding-left: 0pt;">61,056</td><td style="text-align: left; padding-left: 0pt;">&#160;</td><td style="padding-left: 0pt;">&#160;</td><td style="text-align: left; padding-left: 0pt;">&#160;</td><td style="text-align: right; padding-left: 0pt;">82,308</td><td style="text-align: left; padding-left: 0pt;">&#160;</td><td style="padding-left: 0pt;">&#160;</td><td style="text-align: left; padding-left: 0pt;">&#160;</td><td style="text-align: right; padding-left: 0pt;">143,364</td><td style="text-align: left; padding-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: justify; padding-left: 0pt;">Year ending December 31, 2018</td><td style="padding-left: 0pt;">&#160;</td><td style="text-align: left; padding-left: 0pt;">&#160;</td><td style="text-align: right; padding-left: 0pt;">64,876</td><td style="text-align: left; padding-left: 0pt;">&#160;</td><td style="padding-left: 0pt;">&#160;</td><td style="text-align: left; padding-left: 0pt;">&#160;</td><td style="text-align: right; padding-left: 0pt;">86,097</td><td style="text-align: left; padding-left: 0pt;">&#160;</td><td style="padding-left: 0pt;">&#160;</td><td style="text-align: left; padding-left: 0pt;">&#160;</td><td style="text-align: right; padding-left: 0pt;">150,973</td><td style="text-align: left; padding-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="text-align: justify; padding-left: 0pt;">Year ending December 31, 2019</td><td style="padding-left: 0pt;">&#160;</td><td style="text-align: left; padding-left: 0pt;">&#160;</td><td style="text-align: right; padding-left: 0pt;">68,908</td><td style="text-align: left; padding-left: 0pt;">&#160;</td><td style="padding-left: 0pt;">&#160;</td><td style="text-align: left; padding-left: 0pt;">&#160;</td><td style="text-align: right; padding-left: 0pt;">89,997</td><td style="text-align: left; padding-left: 0pt;">&#160;</td><td style="padding-left: 0pt;">&#160;</td><td style="text-align: left; padding-left: 0pt;">&#160;</td><td style="text-align: right; padding-left: 0pt;">158,905</td><td style="text-align: left; padding-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: justify; padding-bottom: 1.5pt; padding-left: 0pt;">After December 31, 2019</td><td style="padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">493,696</td><td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">2,143,771</td><td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td><td style="text-align: left; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style:
 solid;">&#160;</td><td style="text-align: right; padding-left: 0pt; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">2,637,467</td><td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="font: 13px/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; padding-bottom: 4pt; padding-left: 10pt; word-spacing: 0px; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">Total</td><td style="font: 13px/normal 'times new roman', times, serif; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; padding-bottom: 4pt; padding-left: 0pt; word-spacing: 0px; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</td><td style="font: 13px/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; padding-left: 0pt; word-spacing: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">$</td><td style="font: 13px/normal 'times new roman', times, serif; text-align: right; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; padding-left: 0pt; word-spacing: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">759,963</td><td style="font: 13px/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; padding-bottom: 4pt; padding-left: 0pt; word-spacing: 0px; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</td><td style="font: 13px/normal 'times new roman', times, serif; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; padding-bottom: 4pt; padding-left: 0pt; word-spacing: 0px; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</td><td style="font: 13px/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; padding-left: 0pt; word-spacing: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">$</td><td style="font: 13px/normal 'times new roman', times, serif; text-align: right; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; padding-left: 0pt; word-spacing: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">2,500,000</td><td style="font: 13px/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; padding-bottom: 4pt; padding-left: 0pt; word-spacing: 0px; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</td><td style="font: 13px/normal 'times new roman', times, serif; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; padding-bottom: 4pt; padding-left: 0pt; word-spacing: 0px; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">&#160;</td><td style="font: 13px/normal 'times new roman', times, serif; text-align: left; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; padding-left: 0pt; word-spacing: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">$</td><td style="font: 13px/normal 'times new roman', times, serif; text-align: right; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; padding-left: 0pt; word-spacing: 0px; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; white-space: normal; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;">3,259,963</td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 470<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6479336&amp;loc=d3e64711-112823<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.4-08.(e),(f))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 835<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=34725769&amp;loc=d3e28878-108400<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21538-112644<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 835<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1A<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28541-108399<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 835<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28551-108399<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 7<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21521-112644<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140666940325216">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Segment and Significant Customer Information (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=iccc_AnimalHealthInternationalIncMember', window );">Animal Health International, Inc. [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">39.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">41.00%<span></span>
</td>
<td class="nump">37.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=iccc_MwiVeterinarySupplyCompanyMember', window );">MWI Animal Health [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideRevenueMajorCustomerLineItems', window );"><strong>Revenue, Major Customer [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">22.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">22.00%<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">During June 2015, Patterson Companies, Inc. (NASDAQ: PDCO) acquired Animal Health International, Inc.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">During March 2015, AmerisourceBergen Corporation (NYSE: ABC) acquired MWI Animal Health.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 275<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 18<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6351-108592<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 20<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13531-108611<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 275<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 20<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6404-108592<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 21<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13537-108611<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideRevenueMajorCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideRevenueMajorCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=iccc_AnimalHealthInternationalIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=iccc_AnimalHealthInternationalIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=iccc_MwiVeterinarySupplyCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=iccc_MwiVeterinarySupplyCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140666934462768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock Rights Plan<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_iccc_CommonStockRightsPlanAbstract', window );"><strong>Common Stock Rights Plan [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_iccc_CommonStockRightsPlanTextBlock', window );">COMMON STOCK RIGHTS PLAN</a></td>
<td class="text"><div><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 0.5in; text-indent: 0pt; padding-left: 0pt;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>13.</b></font></td><td style="text-indent: 0pt; padding-left: 0pt;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>COMMON STOCK RIGHTS PLAN</b></font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">During the second quarter of 2015, we amended our Common Stock Rights Plan by removing a provision that prevented a new group of directors elected following the emergence of an Acquiring Person (an owner of more than 20% of our stock) from controlling the Rights Plan by maintaining exclusive authority over the Rights Plan with pre-existing directors. We did this because such provisions have come to be viewed with disfavor by Delaware courts.</font></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_CommonStockRightsPlanAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_CommonStockRightsPlanAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_CommonStockRightsPlanTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_CommonStockRightsPlanTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140666934466864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text"><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="text-align: justify; padding-left: 0pt; text-indent: 0pt; width: 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>(a)</b></font></td><td style="text-align: justify; padding-left: 0pt; text-indent: 0pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>Basis of presentation</b></font></td></tr></table><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>&#160;</b></font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">We have prepared the accompanying unaudited financial statements reflecting all adjustments, all of which are of a normal recurring nature, that are, in our opinion, necessary in order to ensure that the financial statements are not misleading. We follow accounting standards set by the Financial Accounting Standards Board (FASB). The FASB sets generally accepted accounting principles (GAAP) that we follow to ensure we consistently report our financial condition, results of operations, earnings per share and cash flows. References to GAAP in these footnotes are to the FASB<i>&#160;Accounting Standards Codification</i>&#8482; (Codification). Certain prior year accounts have been reclassified to conform with the 2015 financial statement presentation. Certain information and footnote disclosures normally included in the annual financial statements have been condensed or omitted. Accordingly, we believe that although the disclosures are adequate to ensure that the information presented is not misleading, these financial statements should be read in conjunction with the financial statements for the year ended December 31, 2014 and the notes thereto, contained in our Annual Report on Form 10-K as filed with the Securities and Exchange Commission (SEC).</font></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash, Cash Equivalents, Short-Term Investments and Long-Term Investments</a></td>
<td class="text"><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="padding-left: 0pt; text-indent: 0pt; width: 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>(b)</b></font></td><td style="padding-left: 0pt; text-indent: 0pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>Cash, Cash Equivalents, Short-Term Investments and Long-Term Investments</b></font></td></tr></table><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">We consider all highly liquid investment instruments that mature within three months of their purchase dates to be cash equivalents. Cash equivalents are principally invested in securities backed by the U.S. government. Certain cash balances in excess of Federal Deposit Insurance Corporation (FDIC) limits of $250,000 per financial institution per depositor are maintained in money market accounts at financial institutions that are secured, in part, by the Securities Investor Protection Corporation. Amounts in excess of these FDIC limits per bank that are not invested in securities backed by the U.S. government aggregated $1,968,787 and $566,637 as of September 30, 2015 and December 31, 2014, respectively. Short-term investments are classified as held to maturity and are comprised principally of certificates of deposit that mature in more than three months from their purchase dates and not more than twelve months from the balance sheet date. Long-term investments are classified as held to maturity and are comprised principally of certificates of deposit that mature in more than twelve months from the balance sheet date. Short-term and long-term investments are held at different financial institutions that are insured by the FDIC, within the FDIC limits per financial institution. See Note 3.</font></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory</a></td>
<td class="text"><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="text-align: justify; padding-left: 0pt; text-indent: 0pt; width: 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>(c)</b></font></td><td style="text-align: justify; padding-left: 0pt; text-indent: 0pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>Inventory</b></font></td></tr></table><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">Inventory includes raw materials, work-in-process and finished goods and is recorded at the lower of cost, on the first-in, first-out method, or market (net realizable value). Work-in-process and finished goods inventories include materials, labor and manufacturing overhead. See Note 4.</font></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TradeAndOtherAccountsReceivablePolicy', window );">Trade Receivables</a></td>
<td class="text"><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="padding-left: 0pt; text-indent: 0pt; width: 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>(d)</b></font></td><td style="padding-left: 0pt; text-indent: 0pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>Trade Receivables</b></font></td></tr></table><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>&#160;</b></font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">Trade receivables are carried at the original invoice amount less an estimate made for doubtful collection. Management determines the allowance for doubtful accounts on a monthly basis by identifying troubled accounts and by using historical experience applied to an aging of accounts. Trade receivables are written off when deemed uncollectible. Recoveries of trade receivables previously written off are recorded as income when received. A trade receivable is considered to be past due if any portion of the receivable balance is outstanding for more than 30 days. Interest is charged on past due trade receivables. See Note 5.</font></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text"><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="padding-left: 0pt; text-indent: 0pt; width: 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>(e)</b></font></td><td style="padding-left: 0pt; text-indent: 0pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>Property, Plant and Equipment</b></font></td></tr></table><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">We depreciate property, plant and equipment on the straight-line method by charges to operations in amounts estimated to expense the cost of the assets from the date they are first put into service to the end of the estimated useful lives of the assets. The cost of our building (which was acquired in 1993) and the 2001 and 2007 additions thereto are being depreciated through 2023. We are depreciating the building addition that was completed during the first quarter of 2015 over twenty-five years. Related building improvements are depreciated over ten year periods. Large and durable fixed assets are depreciated over their useful lives that are generally estimated to be five to ten years. Other fixed assets and computer equipment are depreciated over their useful lives that are generally estimated to be five and three years, respectively. See Note 7.</font></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsFiniteLivedPolicy', window );">Intangible Assets</a></td>
<td class="text"><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="padding-left: 0pt; text-indent: 0pt; width: 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>(f)</b></font></td><td style="padding-left: 0pt; text-indent: 0pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>Intangible Assets</b></font></td></tr></table><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">We amortize intangible assets on the straight-line method by charges to operations in amounts estimated to expense the cost of the assets from the date they are first put into service to the end of the estimated useful lives of the assets. In connection with certain credit facilities entered into during the third quarters of 2010 and 2015, we incurred debt issue costs of $26,489 and $32,759, respectively, which costs are being amortized to other expenses, net over the terms of the credit facilities. See Notes 6 and 9.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">We continually assess the realizability of these assets in accordance with the impairment provisions of Codification Topic 360,&#160;<i>Accounting for the Impairment or Disposal of Long-Lived Assets</i>. If an impairment review is triggered, we evaluate the carrying value of long-lived assets by determining if impairment exists based on estimated undiscounted future cash flows over the remaining useful life of the assets and comparing that value to the carrying value of the assets. If the carrying value of the asset is greater than the estimated future cash flows, the asset is written down to its estimated fair value. The cash flow estimates that are used contain our best estimates, using appropriate and customary assumptions and projections at the time. We also review the estimated useful life of intangible assets at the end of each reporting period, making any necessary adjustments.</font></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Disclosure of Fair Value of Financial Instruments and Concentration of Risk</a></td>
<td class="text"><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="padding-left: 0pt; text-indent: 0pt; width: 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>(g)</b></font></td><td style="padding-left: 0pt; text-indent: 0pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>Disclosure of Fair Value of Financial Instruments and Concentration of Risk</b></font></td></tr></table><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">Financial instruments consist mainly of cash, cash equivalents, short-term investments, long-term investments, accounts receivable, accounts payable, bank debt and interest rate swaps. Financial instruments that potentially subject the Company to concentrations of credit risk are principally cash, cash equivalents, short-term investments, long-term investments and accounts receivable. We make short-term and long-term investments in financial instruments that are insured by the FDIC. We account for fair value measurements in accordance with Codification Topic 820,&#160;<i>Fair Value Measurements and Disclosures</i>, which defines fair value, establishes a framework for measuring fair value and requires additional disclosures about fair value measurements. The estimated fair value of cash, cash equivalents, short-term investments, long-term investments, accounts receivable and accounts payable approximate their carrying value due to their short maturities. The estimated fair value of bank debt approximates its carrying value because the interest rates are variable. Interest rate swaps are carried at fair value. See Note 9.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">Concentration of credit risk with respect to accounts receivable is principally limited to certain customers to whom we make substantial sales. To reduce risk, we routinely assess the financial strength of our customers and, as a consequence, believe that our accounts receivable credit risk exposure is limited. We maintain an allowance for potential credit losses, but historically we have not experienced significant credit losses related to an individual customer or groups of customers in any particular industry or geographic area.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">We believe that supplies and raw materials for the production of our products are available from more than one vendor or farm. Our policy is to maintain more than one source of supply for the components used in our products. However, there is a risk that we could have difficulty in efficiently acquiring essential supplies.</font></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_iccc_InterestRateSwapAgreementPolicyTextBlock', window );">Interest Rate Swap Agreements</a></td>
<td class="text"><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="padding-left: 0pt; text-indent: 0pt; width: 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>(h)</b></font></td><td style="padding-left: 0pt; text-indent: 0pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>Interest Rate Swap Agreements</b></font></td></tr></table><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>&#160;</b></font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">All derivatives are recognized on the balance sheet at their fair value. We entered into interest rate swap agreements in 2010 and 2015. On the dates the agreements were entered into, we designated the derivatives as hedges of the variability of cash flows to be paid related to our long-term debt. The agreements have been determined to be highly effective in hedging the variability of identified cash flows, so changes in the fair market value of the interest rate swap agreements are recorded as comprehensive income (loss), until earnings are affected by the variability of cash flows (e.g. when periodic settlements on a variable-rate asset or liability are recorded in earnings). We formally documented the relationship between the interest rate swap agreements and the related hedged items. We also formally assess, both at the interest rate swap agreements&#8217; inception and on an ongoing basis, whether the agreements are highly effective in offsetting changes in cash flow of hedged items. See Note 9.</font></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="padding-left: 0pt; text-indent: 0pt; width: 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>(i)</b></font></td><td style="padding-left: 0pt; text-indent: 0pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>Revenue Recognition</b></font></td></tr></table><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">We recognize revenue in accordance with Staff Accounting Bulletin (SAB) No. 104, &#8220;Revenue Recognition&#8221;. SAB No. 104 requires that four criteria are met before revenue is recognized. These include i) persuasive evidence that an arrangement exists, ii) delivery has occurred or services have been rendered, iii) the seller&#8217;s price is fixed and determinable and iv) collectability is reasonably assured. We recognize revenue at the time of shipment (including to distributors) for substantially all products, as title and risk of loss pass to the customer on delivery to the common carrier after concluding that collectability is reasonably assured. We recognize service revenue at the time the service is performed.</font></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_iccc_ExpenseRecognitionPolicyTextBlock', window );">Expense Recognition</a></td>
<td class="text"><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 0.5in; padding-left: 0pt; text-indent: 0pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>(j)</b></font></td><td style="padding-left: 0pt; text-indent: 0pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>Expense Recognition</b></font></td></tr></table><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">Advertising costs are expensed when incurred, which is generally during the month in which the advertisement is published. Advertising expenses amounted to $27,545 and $15,844 during the three-month periods ended September 30, 2015 and 2014, respectively, and $72,539 and $42,915 during the nine-month periods ended September 30, 2015 and 2014, respectively. All product development expenses are expensed as incurred, as are all related patent costs.</font></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 0.5in; padding-left: 0pt; text-indent: 0pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>(k)</b></font></td><td style="padding-left: 0pt; text-indent: 0pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>Income Taxes</b></font></td></tr></table><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">We account for income taxes in accordance with Codification Topic 740,&#160;<i>Income Taxes</i>,<i>&#160;</i>which requires that we recognize a current tax liability or asset for current taxes payable or refundable and a deferred tax liability or asset for the estimated future tax effects of temporary differences and carryforwards to the extent they are realizable. We believe it is more likely than not that the deferred tax assets will be realized through future taxable income and future tax effects of temporary differences between book income and taxable income. Accordingly, we have not established a valuation allowance for the deferred tax assets. Codification Topic 740-10 clarifies the accounting for income taxes by prescribing a minimum recognition threshold that a tax position must meet before being recognized in the financial statements. In the ordinary course of business, there are transactions and calculations where the ultimate tax outcome is uncertain. In addition, we are subject to periodic audits and examinations by the Internal Revenue Service and other taxing authorities. We have evaluated the positions taken on our filed tax returns. We have concluded that no uncertain tax positions exist as of September 30, 2015. Although we believe that our estimates are reasonable, actual results could differ from these estimates. See Note 11.</font></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 0.5in; padding-left: 0pt; text-indent: 0pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>(l)</b></font></td><td style="padding-left: 0pt; text-indent: 0pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>Stock-Based Compensation</b></font></td></tr></table><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">We account for stock-based compensation in accordance with Codification Topic 718,&#160;<i>Compensation-Stock Compensation</i>, which generally requires us to recognize non-cash compensation expense for stock-based payments using the fair-value-based method. The fair value of each stock option grant has been estimated on the date of grant using the Black-Scholes option pricing model. Accordingly, we recorded compensation expense pertaining to stock-based compensation of $6,342 and $4,974 during the three-month periods ended September 30, 2015 and 2014, respectively, and $17,825 and $22,265 during the nine-month periods ended September 30, 2015 and 2014, respectively, which resulted in a decrease to income before income taxes of less than $0.01 per share during each of the periods reported. Codification Topic 718 requires us to reflect gross tax savings resulting from tax deductions in excess of expense reflected in our financial statements as a financing cash flow.</font></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Income (Loss) Per Common Share</a></td>
<td class="text"><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 0.5in; padding-left: 0pt; text-indent: 0pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>(m)</b></font></td><td style="padding-left: 0pt; text-indent: 0pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>Net Income (Loss) Per Common Share</b></font></td></tr></table><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">Net Income (Loss) per common share has been computed in accordance with Codification Topic 260-10,&#160;<i>Earnings Per Share.</i>&#160;The basic Net Income per share has been computed by dividing Net Income by the weighted average number of common shares outstanding during this period. Diluted Net Income per share has been computed by dividing Net Income by the weighted average number of shares outstanding during the period plus all outstanding stock options with an exercise price that is less than the average market price of the common stock during the period less the number of shares that could have been repurchased at this average market price with the proceeds from the hypothetical stock option exercises.<i>&#160;</i>The Net (Loss) per common share in 2014 has been computed by dividing the Net (Loss) by the weighted average number of common shares outstanding during the period, without giving consideration to outstanding stock options because the impact would be anti-dilutive.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6"><p style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin: 0px; text-align: center;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>Three-Month Period&#160;</b></font><br /><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>Ended September 30,</b></font></p></td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6"><p style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin: 0px; text-align: center;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>Nine-Month Period&#160;</b></font><br /><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>Ended September 30,</b></font></p></td><td style="padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt;">&#160;</td><td style="font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2015</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt;">&#160;</td><td style="font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2014</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt;">&#160;</td><td style="font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2015</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt;">&#160;</td><td style="font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2014</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td></tr><tr
 style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 814.078px; padding-left: 0.7pt;">Weighted average number of shares outstanding</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 142px; text-align: right;">3,052,175</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 142px; text-align: right;">3,027,034</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">&#160;</td><td style="width: 141px; text-align: right;">3,038,111</td><td style="width: 15px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">&#160;</td><td style="width: 141px; text-align: right;">3,026,990</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.7pt;">Effect of dilutive stock options</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;">136,174</td><td style="padding-bottom: 1.5pt; text-align: left;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;">78,798</td><td style="padding-bottom: 1.5pt; text-align: left;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;">124,509</td><td style="padding-bottom: 1.5pt; text-align: left;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;">0</td><td style="padding-bottom: 1.5pt; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="padding-bottom: 4pt; padding-left: 0.7pt;">Diluted number of shares outstanding</td><td style="padding-bottom: 4pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;">3,188,349</td><td style="padding-bottom: 4pt; text-align: left;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;">3,105,832</td><td style="padding-bottom: 4pt; text-align: left;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;">3,162,620</td><td style="padding-bottom: 4pt; text-align: left;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;">3,026,990</td><td style="padding-bottom: 4pt; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-left: 0.7pt;">Stock options outstanding as of September 30th not included in the calculation because the effect would be anti-dilutive</td><td style="padding-bottom: 4pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;">0</td><td style="padding-bottom: 4pt; text-align: left;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;">85,000</td><td style="padding-bottom: 4pt; text-align: left;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;">3,000</td><td style="padding-bottom: 4pt; text-align: left;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;">251,000</td><td style="padding-bottom: 4pt; text-align: left;">&#160;</td></tr></table><div>&#160;</div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 0.5in; padding-left: 0pt; text-indent: 0pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>(n)</b></font></td><td style="padding-left: 0pt; text-indent: 0pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>Use of Estimates</b></font></td></tr></table><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual amounts could differ from those estimates.</font></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncement</a></td>
<td class="text"><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 0.5in; padding-left: 0pt; text-indent: 0pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>(o)</b></font></td><td style="padding-left: 0pt; text-indent: 0pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>New Accounting Pronouncement</b></font></td></tr></table><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>&#160;</b></font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">In May 2014, the FASB issued Accounting Standards Update No. 2014-09,&#160;<i>Revenue from Contracts with Customers&#160;</i>(ASU 2014-09), which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. ASU 2014-09 will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. ASU 2014-09 was initially effective for the Company on January 1, 2017. Early application was not permitted. In July 2015, the FASB approved a one-year deferral in the effective date to January 1, 2018, with the option of applying the standard on the original effective date. ASU 2014-09 permits the use of either the retrospective or cumulative effect transition method. We have evaluated the effect that ASU 2014-09 would have on our financial statements and related disclosures. We expect that ASU 2014-09 will have no significant effect on our ongoing financial reporting, but we continue to evaluate this pending accounting standard.</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_ExpenseRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entire disclosure of accounting policy for expense recognition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_ExpenseRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_InterestRateSwapAgreementPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the interest rate swap agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_InterestRateSwapAgreementPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 305<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 05<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Financial Reporting Release (FRR)<br><br><br><br> -Number 203<br><br><br><br> -Paragraph 02-03<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (c)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49121117&amp;loc=d3e13279-108611<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 820<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 60<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 19<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32840-109319<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 05<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6423966&amp;loc=d3e40913-109327<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 954<br><br><br><br> -SubTopic 740<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 17<br><br><br><br> -Subparagraph (b)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32809-109319<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 25<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32247-109318<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 740<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=37586315&amp;loc=d3e32280-109318<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsFiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for finite-lived intangible assets. This accounting policy also might address: (1) the amortization method used; (2) the useful lives of such assets; and (3) how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 350<br><br><br><br> -SubTopic 30<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26713463&amp;loc=d3e16323-109275<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsFiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for major classes of inventories, bases of stating inventories (for example, lower of cost or market), methods by which amounts are added and removed from inventory classes (for example, FIFO, LIFO, or average cost), loss recognition on impairment of inventories, and situations in which inventories are stated above cost. If inventory is carried at cost, this disclosure includes the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 330<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28360613&amp;loc=d3e4492-108314<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.6(b))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 330<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28360613&amp;loc=d3e4556-108314<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Financial Reporting Release (FRR)<br><br><br><br> -Number 206<br><br><br><br> -Paragraph b<br><br><br><br> -Subparagraph i, ii<br><br><br><br> -Chapter 2<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 6<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18823-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18726-107790<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 605<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SAB TOPIC 13.B.Q1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012821&amp;loc=d3e214044-122780<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 13<br><br><br><br> -Section B<br><br><br><br> -Paragraph Question 1<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (b),(f)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TradeAndOtherAccountsReceivablePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for trade and other accounts receivables. This disclosure may include the basis at which such receivables are carried in the entity's statements of financial position (for example, net realizable value), how the entity determines the level of its allowance for doubtful accounts, when impairments, charge-offs or recoveries are recognized, and the entity's income recognition policies for such receivables, including its treatment of related fees and costs, its treatment of premiums, discounts or unearned income, when accrual of interest is discontinued, how the entity records payments received on nonaccrual receivables and its policy for resuming accrual of interest on such receivables.  If the enterprise holds a large number of similar loans, disclosure may include the accounting policy for the anticipation of prepayments and significant assumptions underlying prepayment estimates for amortization of premiums, discounts, and nonrefundable fees and costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6378556&amp;loc=d3e10133-111534<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 15<br><br><br><br> -Subparagraph (d)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49124121&amp;loc=d3e5212-111524<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49124121&amp;loc=d3e5093-111524<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 3, 4<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TradeAndOtherAccountsReceivablePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 275<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6061-108592<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 275<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 9<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6143-108592<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 275<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51801978&amp;loc=d3e6132-108592<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140666939828512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingent Liabilities (Details)<br></strong></div></th>
<th class="th">
<div>Sep. 30, 2015 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_iccc_CommitmentsAndContingenciesLiabilitiesTextualAbstract', window );"><strong>Commitments and Contingencies Liabilities [Textual]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_iccc_CapitalExpenditures', window );">Capital expenditure</a></td>
<td class="nump">$ 728,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_iccc_OtherObligations', window );">Other obligations</a></td>
<td class="nump">261,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_iccc_InventoryProduction', window );">Production of inventory</a></td>
<td class="nump">$ 576,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_CapitalExpenditures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Capital expenditure</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_CapitalExpenditures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_CommitmentsAndContingenciesLiabilitiesTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_CommitmentsAndContingenciesLiabilitiesTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_InventoryProduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Production of inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_InventoryProduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_OtherObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_OtherObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140666867535472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Receivable (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_iccc_ScheduleOfAccountsNotesLoansAndFinancingReceivableAbstract', window );"><strong>Schedule of accounts receivable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableGrossCurrent', window );">Trade accounts receivable, gross</a></td>
<td class="nump">$ 783,547<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,004,990<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Accumulated allowance for bad debt and product returns</a></td>
<td class="num">(16,958)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16,194)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Trade accounts receivable, net</a></td>
<td class="nump">766,589<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">988,796<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivables', window );">Other receivables</a></td>
<td class="nump">22,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,496<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">789,214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,005,292<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_iccc_IncreaseDecreaseInAccountsReceivableGross', window );">(Decrease) in Trade accounts receivable, gross</a></td>
<td class="num">(221,443)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease', window );">(Decrease) in Accumulated allowance for bad debt and product returns</a></td>
<td class="num">(764)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">(Decrease) in Trade accounts receivable, net</a></td>
<td class="num">(222,207)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables', window );">(Decrease) in Other receivables</a></td>
<td class="nump">6,129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInReceivables', window );">(Decrease) in Accounts receivable, net</a></td>
<td class="num">$ (216,078)<span></span>
</td>
<td class="num">$ (67,846)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_IncreaseDecreaseInAccountsReceivableGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents net increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_IncreaseDecreaseInAccountsReceivableGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_ScheduleOfAccountsNotesLoansAndFinancingReceivableAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_ScheduleOfAccountsNotesLoansAndFinancingReceivableAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableGrossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer) for goods or services (including trade receivables) that have been delivered or sold in the normal course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.3)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph a, b<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableGrossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, the amount due from customers or clients for goods or services that have been delivered or sold in the normal course of business, reduced to their estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 942<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.9-03.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 210<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-03.5)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 3<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.3-4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 3<br><br><br><br> -Subparagraph a(1)<br><br><br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 4<br><br><br><br> -Article 5<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A valuation allowance for trade and other receivables due to an Entity within one year (or the normal operating cycle, whichever is longer) that are expected to be uncollectible.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=49124121&amp;loc=d3e5074-111524<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the allowance for doubtful accounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due from customers for the credit sale of goods and services; includes accounts receivable and other types of receivables.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsAndOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amounts due as of the balance sheet date from parties or arising from transactions not otherwise specified in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.8)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140666936931680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Comprehensive Income (Loss) (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Other Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 351,292<span></span>
</td>
<td class="nump">$ 10,330<span></span>
</td>
<td class="nump">$ 924,432<span></span>
</td>
<td class="num">$ (297,786)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive (loss) income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_iccc_InterestRateSwapBeforeTaxes', window );">Interest rate swaps, before taxes</a></td>
<td class="num">(81,767)<span></span>
</td>
<td class="nump">8,347<span></span>
</td>
<td class="num">(79,956)<span></span>
</td>
<td class="nump">322<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_iccc_IncomeTaxApplicableToInterestRateSwap', window );">Income tax applicable to interest rate swaps</a></td>
<td class="nump">32,620<span></span>
</td>
<td class="num">(3,330)<span></span>
</td>
<td class="nump">31,897<span></span>
</td>
<td class="num">(129)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive (loss) income, net of taxes</a></td>
<td class="num">(49,147)<span></span>
</td>
<td class="nump">5,017<span></span>
</td>
<td class="num">(48,059)<span></span>
</td>
<td class="nump">193<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive income (loss)</a></td>
<td class="nump">$ 302,145<span></span>
</td>
<td class="nump">$ 15,347<span></span>
</td>
<td class="nump">$ 876,373<span></span>
</td>
<td class="num">$ (297,593)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_IncomeTaxApplicableToInterestRateSwap">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This amount Represents income tax applicable to interest rate swap.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_IncomeTaxApplicableToInterestRateSwap</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_InterestRateSwapBeforeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Comprehensive income, before taxes, from forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_InterestRateSwapBeforeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Other Comprehensive Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Comprehensive Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51831223<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=d3e557-108580<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Net Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Net Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51831255<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.19)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 225<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SX 210.5-03.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 944<br><br><br><br> -SubTopic 225<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.7-04.22)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Other Comprehensive Income<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51831270<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 19<br><br><br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 9<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1A<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669619-108580<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1B<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=36458714&amp;loc=SL7669625-108580<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 220<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 55<br><br><br><br> -Paragraph 15<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51821188&amp;loc=d3e1436-108581<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140666939963952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="padding-left: 0pt; text-indent: 0pt; width: 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>2.</b></font></td><td style="padding-left: 0pt; text-indent: 0pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</b></font></td></tr></table><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="text-align: justify; padding-left: 0pt; text-indent: 0pt; width: 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>(a)</b></font></td><td style="text-align: justify; padding-left: 0pt; text-indent: 0pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>Basis of presentation</b></font></td></tr></table><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>&#160;</b></font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">We have prepared the accompanying unaudited financial statements reflecting all adjustments, all of which are of a normal recurring nature, that are, in our opinion, necessary in order to ensure that the financial statements are not misleading. We follow accounting standards set by the Financial Accounting Standards Board (FASB). The FASB sets generally accepted accounting principles (GAAP) that we follow to ensure we consistently report our financial condition, results of operations, earnings per share and cash flows. References to GAAP in these footnotes are to the FASB<i>&#160;Accounting Standards Codification</i>&#8482; (Codification). Certain prior year accounts have been reclassified to conform with the 2015 financial statement presentation. Certain information and footnote disclosures normally included in the annual financial statements have been condensed or omitted. Accordingly, we believe that although the disclosures are adequate to ensure that the information presented is not misleading, these financial statements should be read in conjunction with the financial statements for the year ended December 31, 2014 and the notes thereto, contained in our Annual Report on Form 10-K as filed with the Securities and Exchange Commission (SEC).</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="padding-left: 0pt; text-indent: 0pt; width: 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>(b)</b></font></td><td style="padding-left: 0pt; text-indent: 0pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>Cash, Cash Equivalents, Short-Term Investments and Long-Term Investments</b></font></td></tr></table><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color:
 #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">We consider all highly liquid investment instruments that mature within three months of their purchase dates to be cash equivalents. Cash equivalents are principally invested in securities backed by the U.S. government. Certain cash balances in excess of Federal Deposit Insurance Corporation (FDIC) limits of $250,000 per financial institution per depositor are maintained in money market accounts at financial institutions that are secured, in part, by the Securities Investor Protection Corporation. Amounts in excess of these FDIC limits per bank that are not invested in securities backed by the U.S. government aggregated $1,968,787 and $566,637 as of September 30, 2015 and December 31, 2014, respectively. Short-term investments are classified as held to maturity and are comprised principally of certificates of deposit that mature in more than three months from their purchase dates and not more than twelve months from the balance sheet date. Long-term investments are classified as held to maturity and are comprised principally of certificates of deposit that mature in more than twelve months from the balance sheet date. Short-term and long-term investments are held at different financial institutions that are insured by the FDIC, within the FDIC limits per financial institution. See Note 3.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>&#160;</b></font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="text-align: justify; padding-left: 0pt; text-indent: 0pt; width: 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>(c)</b></font></td><td style="text-align: justify; padding-left: 0pt; text-indent: 0pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>Inventory</b></font></td></tr></table><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">Inventory includes raw materials, work-in-process and finished goods and is recorded at the lower of cost, on the first-in, first-out method, or market (net realizable value). Work-in-process and finished goods inventories include materials, labor and manufacturing overhead. See Note 4.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="padding-left: 0pt; text-indent: 0pt; width: 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>(d)</b></font></td><td style="padding-left: 0pt; text-indent: 0pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>Trade Receivables</b></font></td></tr></table><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>&#160;</b></font></p><p style="color: #000000; font-family: 'times new roman', times, serif;
 font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">Trade receivables are carried at the original invoice amount less an estimate made for doubtful collection. Management determines the allowance for doubtful accounts on a monthly basis by identifying troubled accounts and by using historical experience applied to an aging of accounts. Trade receivables are written off when deemed uncollectible. Recoveries of trade receivables previously written off are recorded as income when received. A trade receivable is considered to be past due if any portion of the receivable balance is outstanding for more than 30 days. Interest is charged on past due trade receivables. See Note 5.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;">&#160;</p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="padding-left: 0pt; text-indent: 0pt; width: 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>(e)</b></font></td><td style="padding-left: 0pt; text-indent: 0pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>Property, Plant and Equipment</b></font></td></tr></table><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">We depreciate property, plant and equipment on the straight-line method by charges to operations in amounts estimated to expense the cost of the assets from the date they are first put into service to the end of the estimated useful lives of the assets. The cost of our building (which was acquired in 1993) and the 2001 and 2007 additions thereto are being depreciated through 2023. We are depreciating the building addition that was completed during the first quarter of 2015 over twenty-five years. Related building improvements are depreciated over ten year periods. Large and durable fixed assets are depreciated over their useful lives that are generally estimated to be five to ten years. Other fixed assets and computer equipment are depreciated over their useful lives that are generally estimated to be five and three years, respectively. See Note 7.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="padding-left: 0pt; text-indent: 0pt; width: 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>(f)</b></font></td><td style="padding-left: 0pt; text-indent: 0pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>Intangible Assets</b></font></td></tr></table><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal;
 font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">We amortize intangible assets on the straight-line method by charges to operations in amounts estimated to expense the cost of the assets from the date they are first put into service to the end of the estimated useful lives of the assets. In connection with certain credit facilities entered into during the third quarters of 2010 and 2015, we incurred debt issue costs of $26,489 and $32,759, respectively, which costs are being amortized to other expenses, net over the terms of the credit facilities. See Notes 6 and 9.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">We continually assess the realizability of these assets in accordance with the impairment provisions of Codification Topic 360,&#160;<i>Accounting for the Impairment or Disposal of Long-Lived Assets</i>. If an impairment review is triggered, we evaluate the carrying value of long-lived assets by determining if impairment exists based on estimated undiscounted future cash flows over the remaining useful life of the assets and comparing that value to the carrying value of the assets. If the carrying value of the asset is greater than the estimated future cash flows, the asset is written down to its estimated fair value. The cash flow estimates that are used contain our best estimates, using appropriate and customary assumptions and projections at the time. We also review the estimated useful life of intangible assets at the end of each reporting period, making any necessary adjustments.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="padding-left: 0pt; text-indent: 0pt; width: 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>(g)</b></font></td><td style="padding-left: 0pt; text-indent: 0pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>Disclosure of Fair Value of Financial Instruments and Concentration of Risk</b></font></td></tr></table><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">Financial instruments consist mainly of cash, cash equivalents, short-term investments, long-term investments, accounts receivable, accounts payable, bank debt and interest rate swaps. Financial instruments that potentially subject the Company to concentrations of credit risk are principally cash, cash equivalents, short-term investments, long-term investments and accounts receivable. We make short-term and long-term investments in financial instruments that are insured by the FDIC. We account for fair value measurements in accordance with Codification Topic 820,&#160;<i>Fair Value Measurements and Disclosures</i>, which defines fair value, establishes a framework for measuring fair value and requires additional disclosures about fair value measurements. The estimated fair value of cash, cash equivalents, short-term investments, long-term investments, accounts receivable and accounts payable approximate their carrying value due to their short maturities. The estimated fair value of bank debt approximates its carrying value because the interest rates are variable. Interest rate swaps are carried at fair value. See Note 9.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"><font style="font-style: normal; font-variant:
 normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">Concentration of credit risk with respect to accounts receivable is principally limited to certain customers to whom we make substantial sales. To reduce risk, we routinely assess the financial strength of our customers and, as a consequence, believe that our accounts receivable credit risk exposure is limited. We maintain an allowance for potential credit losses, but historically we have not experienced significant credit losses related to an individual customer or groups of customers in any particular industry or geographic area.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">We believe that supplies and raw materials for the production of our products are available from more than one vendor or farm. Our policy is to maintain more than one source of supply for the components used in our products. However, there is a risk that we could have difficulty in efficiently acquiring essential supplies.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>&#160;</b></font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="padding-left: 0pt; text-indent: 0pt; width: 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>(h)</b></font></td><td style="padding-left: 0pt; text-indent: 0pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>Interest Rate Swap Agreements</b></font></td></tr></table><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>&#160;</b></font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">All derivatives are recognized on the balance sheet at their fair value. We entered into interest rate swap agreements in 2010 and 2015. On the dates the agreements were entered into, we designated the derivatives as hedges of the variability of cash flows to be paid related to our long-term debt. The agreements have been determined to be highly effective in hedging the variability of identified cash flows, so changes in the fair market value of the interest rate swap agreements are recorded as comprehensive income (loss), until earnings are affected by the variability of cash flows (e.g. when periodic settlements on a variable-rate asset or liability are recorded in earnings). We formally documented the relationship between the interest rate swap agreements and the related hedged items. We also formally assess, both at the interest rate swap agreements&#8217; inception and on an ongoing basis, whether the agreements are highly effective in offsetting changes in cash flow of hedged items. See Note 9.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal;
 font-family: 'times new roman', times, serif;"><b>&#160;</b></font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="padding-left: 0pt; text-indent: 0pt; width: 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>(i)</b></font></td><td style="padding-left: 0pt; text-indent: 0pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>Revenue Recognition</b></font></td></tr></table><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">We recognize revenue in accordance with Staff Accounting Bulletin (SAB) No. 104, &#8220;Revenue Recognition&#8221;. SAB No. 104 requires that four criteria are met before revenue is recognized. These include i) persuasive evidence that an arrangement exists, ii) delivery has occurred or services have been rendered, iii) the seller&#8217;s price is fixed and determinable and iv) collectability is reasonably assured. We recognize revenue at the time of shipment (including to distributors) for substantially all products, as title and risk of loss pass to the customer on delivery to the common carrier after concluding that collectability is reasonably assured. We recognize service revenue at the time the service is performed.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 0.5in; padding-left: 0pt; text-indent: 0pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>(j)</b></font></td><td style="padding-left: 0pt; text-indent: 0pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>Expense Recognition</b></font></td></tr></table><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">Advertising costs are expensed when incurred, which is generally during the month in which the advertisement is published. Advertising expenses amounted to $27,545 and $15,844 during the three-month periods ended September 30, 2015 and 2014, respectively, and $72,539 and $42,915 during the nine-month periods ended September 30, 2015 and 2014, respectively. All product development expenses are expensed as incurred, as are all related patent costs.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>&#160;</b></font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 0.5in; padding-left: 0pt; text-indent: 0pt;"><font style="font-style: normal; font-variant: normal;
 font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>(k)</b></font></td><td style="padding-left: 0pt; text-indent: 0pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>Income Taxes</b></font></td></tr></table><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">We account for income taxes in accordance with Codification Topic 740,&#160;<i>Income Taxes</i>,<i>&#160;</i>which requires that we recognize a current tax liability or asset for current taxes payable or refundable and a deferred tax liability or asset for the estimated future tax effects of temporary differences and carryforwards to the extent they are realizable. We believe it is more likely than not that the deferred tax assets will be realized through future taxable income and future tax effects of temporary differences between book income and taxable income. Accordingly, we have not established a valuation allowance for the deferred tax assets. Codification Topic 740-10 clarifies the accounting for income taxes by prescribing a minimum recognition threshold that a tax position must meet before being recognized in the financial statements. In the ordinary course of business, there are transactions and calculations where the ultimate tax outcome is uncertain. In addition, we are subject to periodic audits and examinations by the Internal Revenue Service and other taxing authorities. We have evaluated the positions taken on our filed tax returns. We have concluded that no uncertain tax positions exist as of September 30, 2015. Although we believe that our estimates are reasonable, actual results could differ from these estimates. See Note 11.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>&#160;</b></font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 0.5in; padding-left: 0pt; text-indent: 0pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>(l)</b></font></td><td style="padding-left: 0pt; text-indent: 0pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>Stock-Based Compensation</b></font></td></tr></table><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">We account for stock-based compensation in accordance with Codification Topic 718,&#160;<i>Compensation-Stock Compensation</i>, which generally requires us to recognize non-cash compensation expense for stock-based payments using the fair-value-based method. The fair value of each stock option grant has been estimated on the date of grant using the Black-Scholes option pricing model. Accordingly, we recorded compensation expense pertaining to stock-based compensation of $6,342 and $4,974 during the three-month periods ended September 30, 2015 and 2014, respectively, and $17,825 and $22,265 during the nine-month periods ended September 30, 2015 and 2014, respectively, which resulted in a decrease to income before income taxes of less than $0.01 per share during each of the periods reported. Codification Topic 718 requires us to reflect gross tax savings resulting from tax deductions in excess of expense reflected in our financial statements as a financing cash flow.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin:
 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>&#160;</b></font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 0.5in; padding-left: 0pt; text-indent: 0pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>(m)</b></font></td><td style="padding-left: 0pt; text-indent: 0pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>Net Income (Loss) Per Common Share</b></font></td></tr></table><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">Net Income (Loss) per common share has been computed in accordance with Codification Topic 260-10,&#160;<i>Earnings Per Share.</i>&#160;The basic Net Income per share has been computed by dividing Net Income by the weighted average number of common shares outstanding during this period. Diluted Net Income per share has been computed by dividing Net Income by the weighted average number of shares outstanding during the period plus all outstanding stock options with an exercise price that is less than the average market price of the common stock during the period less the number of shares that could have been repurchased at this average market price with the proceeds from the hypothetical stock option exercises.<i>&#160;</i>The Net (Loss) per common share in 2014 has been computed by dividing the Net (Loss) by the weighted average number of common shares outstanding during the period, without giving consideration to outstanding stock options because the impact would be anti-dilutive.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font>&#160;</p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6"><p style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin: 0px; text-align: center;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>Three-Month Period&#160;</b></font><br /><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>Ended September 30,</b></font></p></td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6"><p style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif; margin: 0px; text-align: center;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>Nine-Month Period&#160;</b></font><br /><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>Ended September 30,</b></font></p></td><td style="padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt;">&#160;</td><td style="font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2015</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt;">&#160;</td><td style="font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2014</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt;">&#160;</td><td style="font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2015</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt;">&#160;</td><td
 style="font-weight: bold; text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2014</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 814.078px; padding-left: 0.7pt;">Weighted average number of shares outstanding</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 142px; text-align: right;">3,052,175</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 142px; text-align: right;">3,027,034</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">&#160;</td><td style="width: 141px; text-align: right;">3,038,111</td><td style="width: 15px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">&#160;</td><td style="width: 141px; text-align: right;">3,026,990</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.7pt;">Effect of dilutive stock options</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;">136,174</td><td style="padding-bottom: 1.5pt; text-align: left;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;">78,798</td><td style="padding-bottom: 1.5pt; text-align: left;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;">124,509</td><td style="padding-bottom: 1.5pt; text-align: left;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: left;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid; text-align: right;">0</td><td style="padding-bottom: 1.5pt; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="padding-bottom: 4pt; padding-left: 0.7pt;">Diluted number of shares outstanding</td><td style="padding-bottom: 4pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;">3,188,349</td><td style="padding-bottom: 4pt; text-align: left;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;">3,105,832</td><td style="padding-bottom: 4pt; text-align: left;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;">3,162,620</td><td style="padding-bottom: 4pt; text-align: left;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;">3,026,990</td><td style="padding-bottom: 4pt; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-left: 0.7pt;">Stock options outstanding as of September 30th not included in the calculation because the effect would be anti-dilutive</td><td style="padding-bottom: 4pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;">0</td><td style="padding-bottom: 4pt; text-align: left;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;">85,000</td><td style="padding-bottom: 4pt; text-align: left;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;">3,000</td><td style="padding-bottom: 4pt; text-align: left;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: left;">&#160;</td><td style="border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double; text-align: right;">251,000</td><td style="padding-bottom: 4pt; text-align: left;">&#160;</td></tr></table><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-align: justify;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align:
 top;"><td style="width: 0.5in; padding-left: 0pt; text-indent: 0pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>(n)</b></font></td><td style="padding-left: 0pt; text-indent: 0pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>Use of Estimates</b></font></td></tr></table><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">&#160;</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual amounts could differ from those estimates.</font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>&#160;</b></font></p><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 0.5in; padding-left: 0pt; text-indent: 0pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>(o)</b></font></td><td style="padding-left: 0pt; text-indent: 0pt;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>New Accounting Pronouncement</b></font></td></tr></table><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-indent: 0px; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;"><b>&#160;</b></font></p><p style="color: #000000; font-family: 'times new roman', times, serif; font-size: 10pt; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: start; text-transform: none; white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; font-stretch: normal; margin: 0px; text-indent: 0.5in;"><font style="font-style: normal; font-variant: normal; font-weight: normal; font-stretch: normal; font-size: 10pt; line-height: normal; font-family: 'times new roman', times, serif;">In May 2014, the FASB issued Accounting Standards Update No. 2014-09,&#160;<i>Revenue from Contracts with Customers&#160;</i>(ASU 2014-09), which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. ASU 2014-09 will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. ASU 2014-09 was initially effective for the Company on January 1, 2017. Early application was not permitted. In July 2015, the FASB approved a one-year deferral in the effective date to January 1, 2018, with the option of applying the standard on the original effective date. ASU 2014-09 permits the use of either the retrospective or cumulative effect transition method. We have evaluated the effect that ASU 2014-09 would have on our financial statements and related disclosures. We expect that ASU 2014-09 will have no significant effect on our ongoing financial reporting, but we continue to evaluate this pending accounting standard.</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18861-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18780-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18726-107790<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18743-107790<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 235<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 5<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51655414&amp;loc=d3e18854-107790<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140666933236416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock', window );">Schedule of net income (loss) per common share</a></td>
<td class="text"><div><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; border-collapse: collapse; widows: 1; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" cellspacing="0" cellpadding="0"><tr style="vertical-align: bottom;"><td>&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6"><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>Three-Month Period&#160;</b></font><br /><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>Ended September 30,</b></font></p></td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: center; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="6"><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: center; font-stretch: normal;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>Nine-Month Period&#160;</b></font><br /><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>Ended September 30,</b></font></p></td><td style="padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom;"><td>&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2015</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2014</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2015</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td><td style="text-align: center; font-weight: bold; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;" colspan="2">2014</td><td style="padding-bottom: 1.5pt; font-weight: bold;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="width: 814.07px; padding-left: 0.7pt;">Weighted average number of shares outstanding</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 142px; text-align: right;">3,052,175</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 16px;">&#160;</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 142px; text-align: right;">3,027,034</td><td style="width: 16px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">&#160;</td><td style="width: 141px; text-align: right;">3,038,111</td><td style="width: 15px; text-align: left;">&#160;</td><td style="width: 15px;">&#160;</td><td style="width: 15px; text-align: left;">&#160;</td><td style="width: 141px; text-align: right;">3,026,990</td><td style="width: 15px; text-align: left;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: white;"><td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0.7pt;">Effect of dilutive stock options</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">136,174</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">78,798</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">124,509</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td><td style="padding-bottom: 1.5pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 1.5pt; border-bottom-style: solid;">0</td><td style="text-align: left; padding-bottom: 1.5pt;">&#160;</td></tr><tr style="vertical-align: bottom; background-color: #cceeff;"><td style="padding-bottom: 4pt; padding-left: 0.7pt;">Diluted number of shares outstanding</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">3,188,349</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">3,105,832</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">3,162,620</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">3,026,990</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr><tr style="vertical-align: bottom;
 background-color: white;"><td style="text-align: left; padding-left: 0.7pt;">Stock options outstanding as of September 30th not included in the calculation because the effect would be anti-dilutive</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">0</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">85,000</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">3,000</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td><td style="padding-bottom: 4pt;">&#160;</td><td style="text-align: left; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">&#160;</td><td style="text-align: right; border-bottom-color: black; border-bottom-width: 4pt; border-bottom-style: double;">251,000</td><td style="text-align: left; padding-bottom: 4pt;">&#160;</td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; text-align: justify; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; widows: 1; font-stretch: normal; -webkit-text-stroke-width: 0px;"></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 260<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>69
<FILENAME>0001213900-15-008486-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-15-008486-xbrl.zip
M4$L#!!0````(`!2!;$<`5_^U^JT``"^,"0`1`!P`:6-C8RTR,#$U,#DS,"YX
M;6Q55`D``]?_1%;7_T16=7@+``$$)0X```0Y`0``[%UM<Z,XMOZ^5?,?O/GN
M&/%.MKNW\MJ;V:2333)S9^K>6RD"BL,V!@_@=#);=7_[E<".A0V8%R&#K:FI
M3AD0/.?HT3G2D73TZ>]O$W?P"H/0\;W/!^!0.!A`S_)MQQM_/OCEX6*H'PS^
M_N6GOWSZZW`X^`H]&)@1M`>S$#TP./]S^-O)W=6B_$`[E`Z%0W7PWP",@#@2
M!:`,!/U(`D>"-KB]_M_!<+AXU8D9HM>@,O$+Q$.0W$-WWYX"USG"_PX0-B\\
M<BS+^GSP$D73H]'HQX\?A\YD,K.@ZQY:_B3^B&!(PL%/?YD_[SK>]]3S^%V'
M?C!&SPK2"-]^0E\_&`P^BN`G;.>C$%E`'24W4X^O?>*'%#\/#,,8Q7=3CX=.
MUL/HY6#TV_75O?4")^;0\<+(]"R$*P7+*1!E6619Q@E]601:4:GD";*0YWO>
M;))=QHZ"4?0^A2/TT!`]!0/'2I7=7'"]4*S3*%/A2J+PB'S<\F=>%+RGGP^A
M=3CV7T?SFY@)TE``0PFDBLZ"`#$ZK^S\+BXLKQ>VH9-=#MW(*0+?K)?L,OA.
M3-?U0H[W"L,HNUAR+T<ZSW2L,+M<?`L7`^O%0L?*+H1NY!6)ID%.&70GI]`L
M'(Y-<_I1[MD,G^)ZGM_(40>ZBXD39I:+[^04?',+>/_;U4J[G$5![N/&"-W%
M31$;+-R@C\*XF=[!YT'<P(_,P`I\%Q:;@=$T\*<PB!P$>6EXDA=@03X?A,YD
MZGY<>PG@\^<#;/&&"\-V^!;:!X/1PG">^EX$WZ+!/;0B;'/G-C6QFM;\IF-_
M/I@_^"A=GS\*X/'&BAZ17/*#(#PF_S_</$K@\0Q:*]<O3"?XU71G\.3].`QA
M=.J:87C\YH2/EYX-GQW/B:#KO$+[TD/69^P\N3!^+KR&DR<8'"SA0"]RHO?E
M;\?&5YX=&`QB;::5M^#3Z>4_#[X(Z#\=`%4&GT:KA9<O#.%X@JXN+MCHDV]3
MU[&<*,$RL!UT/_%M<\H=Y8IW\&7Q2"DY/XTR/XFQC-;0C;(5@JCA^#8A3V0&
MT1GRL.@2KI0A$!#)B3<2]S]T;*<*B*A)D!]<W%U<67YRE.),*1+]/',168"0
M)I'P>`^G*]?/X%-TB=Q3,,,JB-ES[0?1V!S#\,:#_:#*NA`'7W#;/%H7I7TV
M8"IH5=B`"QA#2:#/!@.Q86DZC(UL8%//]=J8L=IDMJ;5X_#QYCF[-55H9<A8
MP0!U&.X0I/L?YK2_+6UIC;,D:J/!)?WI**>>EW>[4,_<FG:R<A>.TO1P%8+5
MWM:U&:2O=]@T)AWZ*@X'/2VUTOV8-YD,_?5"KRGJK2F)LEU9^&4@97?UB>O=
M59*TZI6WIZ3'^PA1&!N;\S]F2()3?S+U/?0S&1.AGQ/?NX]\ZWL_S'"A.$NO
MNR97ZS:Y/W5^;-L.'GR;[JWIH.'AJ3EU(M/=J?HOE)%SX8,+=S`R'0_:YV;@
M.=ZX)T&0DB3(%H[7_D?M/P30#&?!^^[9_PS)>+TO/8!ES28S%\^%W40O,,"W
M`_B"=?T*+SW+G_1D4%;6&Y25M[\<28<XY9Q!N=S-SO/*R$VN&BJ4VPIJ5=4J
MZD][%I(V,''GX\X)OY^\GT#/>IF8P?>XZ=V;+@SOX"OT9O`;G/,+#0#_[0>G
MLS!"3`R2-GKA!]`9>Q\7^]$@-\F_;).9BBAH?Z4AK.MR'JC)UBB#T'>/^?QA
M8$_PF@D8AO>),A*.7O]P?H410N*9R-7.IE,W-L&F]]X/MA9*MPCO;9"1\Z<^
M?XX]9V*Z_X"F&[W$<7+/3`9MR"?O#H,V2\DYQ,:G_H(GQ>VXSL(STPG>CSW[
M!,+G2\]&SP4.Y%ZVL9<MJ^.]XKR1FE?I?>^\VKQ*9[3*8^$LF]YNDH0'SSEY
M:I.'1]LY72K0A8?G.5%X/+]K\?S=(14/5G=W&+W-8'5?^<R#U=T(5N\F?WBP
MFG.(!ZMWR\MV*UC=$<ZO[O#H6;@ZM=YF34EM;8/AT>?.K,3N3YWS8#+G`H\-
M\]KGH=Y]K7<>N=W62NS6.'+Q>\&0\6.M?D<[S\T')2VE\*BJU<>$3`_FV_$L
M>O$#)'4R_,8\1:.\*]\RW9]G@1/:3IR*IA_-+%LJ8@A=+%XWQ[$=I\P9NAA&
MCG6:9.K:#:)D"L7IL9D>'XX.-S'<LN9Y2W":,WRY3TZ[0"(R@4F6:'M%E=4-
M>#USZBO]'D:[%$NT*!X18]77[4N=\X@8YP*/B/':YQ&Q?:UW'A';7D2L@QSA
M2[D8+N7J*1WXRJP]I`2/[S**[_:-`3Q<NY.U7<(%!-&5NVL&GY"IO]6=3OF@
MY$R:*]V,GJY$I96J2044-HDT-FNU,`]W/YI-4:+U%5$83%#TF`I\ZU=W%Z5O
M;>M7C_G,XP4=V/JUL_SA`0;.(98^E6_]VJNM7SWF?-&0XN&'WP^:;C[:YT.4
MO6)#>O-K[X?MU1:3=4:K?)44RZ:WFR3ARZHX>6J3AZ_#XG2I0!>^<(L3A:_T
MZMI*K]TA%9^ZZ&Y099M3%WWE,Y^ZZ,;4Q6[RAT]=<`[QJ8O=\K+=FKKH*^<S
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M0"<_2',>3C"0XWA=9VK6]2[/PP&`FC3]]CQ/FYC9F)>'&?#&O,>-N=JD.J-S
M;#E3]YRIJ^:QR?$??QT.!WAG^N`>QIMN!H/A<'']I[]<_A_XGXM?;_\!W^"9
MHFKZ[W?P#^?+Y<MW^'K^W0G>?FB?+%F6+451K(?_O'SY^EE6+K7/7P'ZJP#]
MY\LC\%DW-/#U7/O;Y='EWRYTY=/\`PF2&?XT)GOX8@80*7%^?1+'C>&7N8KB
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M$A1%D.2422G`A27X6)MCAB_'GHW_X&F[5].-@[#1J1D$[^C97TUWEDVWU0ZI
ME-,AE;($P6Z9D`+K7=0$"74,1I60417E@P]R#D_D<J(@^ZZ*`&Q3E`JG\Q6*
MHBN"(.J=J)02C;>07[)J"+K60)3[%^2?'F`PN?1>81C%LQ4LZD"4=0-U&Y;(
MLX`T`4I+Q9(F"I6`'EL6/A,SO(,61!7PY.*M3O.>"`O-`D%01$-<`BX"1`,X
M+4UKNB$"N3IN7`\>ZOR_H]LL%&S(BJ80-IW\?AU<M/2GJVB\*F_&=1O`J>G8
MYV]3-.;'9_<2NSA9\E36)<-8PBT!BZ(4U"PPHH)27XHS^`S111L?M!L_P]96
M2(*L2DOP!6@H@*:E<N3RR'Y(2=#,^:W(JFY(A&_.)0%STNI`UR2@E("6N]^,
MD:V5=$E398UL7_F`:`"GI6+94!25]&9E@5_YWG@+_3'94%.]G`P8#5!2TZJN
M54&991J^^9[%T,F)$AK#"L76:@F)#GA:VE9D217$.M@)I\=8W\CD$MK.Q-$(
M*#W[H)(&>"/0Y!X3%0)!`;HBKWJ':FAHZ0G(HB@!62U$,Q\HS!=<(>.*K@0S
M:%\YYA-.%.K`A6]#]]@24E>`JFGK@YJJ6-N6EY[-4`R1LKQ7ONFE5].Q'*8H
M@J2+I,O)`=,8,;4F(TD&.20IA7AAV^?961@J6$7]^74?D\;1#"DMQ5:"N<YO
M1L$?79/)RE^#41\DM0&<9NBZ6AKCO(\7T_@B\">8P2QTJ6%3EM'93`%IA)1:
MC!*(J/<NEX`:+^18W;/.9B"G`^06,K]?"Q@U:XG&PII4@"R#I6R[$)HN:V0<
M(1-((Z34>"C*LJ;5A,K$/&J&).>8GAJPJ.G-$&65#,3EP"+F/YE-EDFB"LB1
MRBJ&NOCH<:X\OIP]^T011CY:%B6!#+]MQ$5/"FIV$\DK:X9<5XK5K?/$#EK4
MN<++"5G4Q5!!7EXE+-9F6/2$H-8$9$-7E;HRI#:R,S,K"A`!&6-81U$?([48
MC2(8`BB+L<06\"L_Q#&SF^<'\XT)NT5)DD!J,%X%8DO2T:J>H08D<NC80+JX
M1E]\UX9!F&ST9[$ZR$#C=%TE!FOK,)B`K)S!J8H_[J9,Q1F*-GAO@",L79<P
M)^].88.2!4T6]*Y+EI53IMC'`UF20=?%*I\RI5!88.B2VHZLM)82&D"45*.E
M"JD`LC=VCYY,C>R>A+K*VZ=6"W9/$Q1`CF2Z*5D-NX?ZV%+7Q:)F]U2Y)5FI
M+1P4%62;V_:OFT'VQN[1DZF1W5N)UG13PCIV;S7XT4W)ZMF]ELPY14K2L7LK
M0_Q6;'SC4*%HZ++>MB=J(57QUCM\+:?BK1;@[::$-0S?:L"TFX)5MGNK\<IN
MBD7)[JT$_XIE)>;3CCU[.[V_]75UFU#1DJ"]M7A5)""LZZT9W`0Q2^PXC'X+
M@W@_9RO50.0V(,01#[X(AX`@4`EX%*6I726M2Y-LK#V>12]^X/P);?IUDK/?
M5Q>$]$:[`E`4L->K@;:Q7X;AC*'.XSZ,K!?@3@`UQ$Q5UW4PIUQI\A`S'8N2
M#$#>3&>"I0%4JJH5!;4*5/(XOZ^^;X=Y>VOFZ<A^GKD4HL=`TP0@DO,O&3!J
MP4SG56@(4Y$,H!AMP$QKL_$.<DV4R<WP+6FSZ=Y@14(H07F8IWX8W3S'=^Y1
MCZ1]6JH&ZAQ)I%5*`:B*C2H715%7Q%0:BF;@J#)05P5%5%M27-/68<B"3M*N
M`-S7P`_#V\!_SEGT0]<("IJF&X36B*]7`4659A(05(GT'S5!4:470"[-('>Q
M4=%4XY5%AB23_<4<4/?0=?&)[IY];0;?(4XD-=]9WC[%)$U2##)(DHNE`6*J
M_#-$H.AZRXBIDE/2@4;N#F6@X\:Q7!UYNLI*_@H]&)@NWOYE3QPO3E`7.:^0
M'9L%402DO2P&U!0[55[KFJ2K[+#393AZDB%VJEPW9"`#K1;V.QA",[!P+J8S
MU$EU_7BK/SNVJT"4")]7"*<9;JI,!QI(CT!;!$Z;YAH9&&6F\*84%Q##A1JX
M;Z8XE^O2V&<'*2CW>25-(-=XK&&H#I!N_U<!R-CI5`%29:FA*VBLU:("&P^W
M)%%)I44H!7"YMKM]$J+QH))%P26&.A"ITG`HHTHFYYDH@:1*1554$1E;5F3C
MH:.*1O]9=,P!B:<SO_F>O\):!J81B*3WR0-2&RQ=,ZFK9*",.EBZX0-DTP$S
MS39.1B>0B1_*@%TR&6\3QZ@<;X8>G5/=]\(3^.P'\XGY!_,-AN=OJ-_K!W9\
MIN%E!"?QWEY4,O#CH>!B$W7[M!<-52#ZYRW*LDV5478.LJ3KNZ\TNLX*`(W<
M\;.C.J/L/"5))^/Z3)6&BL^-W0D:M+,)R1NBMM:NUG#4A4K7"`!9!>1*,<I@
MZ<Y0JH(LLU)LTVE*P9`,N1+6;S!B.7Y!@V@R05[JZ]5@T66D:&@:F9B#(3"J
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M-QN'%6UT$QDHF")>J8E^YZ3O#H7G@.IBW@Z-&X)NC\J`D:(I8B;W7A5@SDRH
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ML4G@NL46UG(B4.851B\E7K<JC)Y<]2IL)0E1H6!E^G"W?H`7<QQ'4>`\S:)D
M['-KYAZ*MMW>?P':K@G>UD*@_5(3E<5&^Z6R&@N:]E97#=9+[9>BZ*S)ZJ^]
MWT)TI4>R<U_7F86U^Z6R/?)UVUP;O%^*HI2#O3V3']=@DL?W;!8@WM_"P/&3
M!-;QO9MIO&7T_`T&EA.VLM9D;3J-S%=1&>#VI6O+A>V>*NJ[*4,5=UDQS9S1
M[NFCJL,1@;YZ_-=.Z8/ZOI;.J:AI5@11$$&_Y=L;-[+%T8ZB&\KJN6P[I9H=
M<R3,1RXJ$-=.]MPIA?3"DR134YWLL>=,KFU62(%,W==(K0G'(4@=W=-!O6QC
M@GG'-5*/*:+>/E7R+=(BAC+/(L0NK:"B"4UZ(]FXNZJ*SO1O=TIM]?O"G'W;
MZS?OE.X:S`[LM^*VWQ??K,YC^]^S,,(BA`]^CK&)_?*3B=Z')4!OB--.WD$D
M<^A$\!X&KXX%$RQWT/+'7OR6&!:+0[I$\DSBM@7JG?+:\LM<T:PF1SC#MSCY
MPK7-;-T<5_669XWVK`*:SDEINKB_9GE[`0&N:%8A!,[P+08=N+:9A2FXJK<<
MV&!9`6<08;6<N#2#U8^2H)'G39-?;X"JZ6Y]39?)E*1YJ);U<N$'QQ.\!O5/
M1HK#9Q)G$60%2'VT5=,?/)[!I^C2"Z-@AC\1-X1K](VQ.89E3+NH"$)J%JP%
MF>A.7PF:7!'M&7R&00!MXBR:8\]&?T_112=B<2`&D%69/*)E$R3*\)N>F*0+
M`GG*5!7TB[R(:0/)X&A'0UO==KR&HB;.-@/%5('2/39+DD4F"J4[`-X,]"OJ
M#N--#3?>F1-._3!VT#?/QV$(F=@&60'$MHM"-#1A-W76AB[70(U,!NX1PS.8
M_+U$?24+.J]XZP@+9:NHCY$^QBP?#DW<3?=CBD`5-)T*\$OO%?E+/W"8*!RH
MFD!NHRC$0Q-X\[R8$@!4<-\&<(K&#`NO.9_O1!XS'J:PLC-`5U2MD/IE<#*1
MM/&R?`VUEG8E18--?X8&AK?F.VYRJ"BZ$LR@?>683XZ+[!^+UJ7IAE'8MLK`
M9")HT]9HB)+4LJ0+-MQ!U*Y9K!%05:.0I2N`:*-O6B4-X'^#T:D9OMP&_JMC
M0_OD_9<0CR8^3N0^MB+GE5$;4@29[("7A]::0,U'R`(`:E.14$-:A+ZL/V9.
M`%%Y5")ZOW5-+T+M"P?AIA-:^3R*ZP@_2C3_\MA:DZCQ*$43!0,T%BGP+0CM
M^!#>:S.:!7$UQNXM>1TJ>&JZ;HA/N_&#*(+!!/=;YF%-!L-;63=2\:6&B-D*
MW[0EMBG\*E_B`@_,Z]?0E;2(97"U(4CCX#,`#04A*O?>=.'-\Q8M9@[I-N!J
M3YRFP2=5!$ICD7(<85*?C+L=0R``->74RJ-K3:;&40I#U'1M<]=C@TQD]>*%
MQ:9GH2K&,QU;:SAI&-3`-M[+LS)[4P[RW8>_8:55(`.5S'B^BJ`ANJ:=,4F5
M)*,<NMO4G86.3_V0A;?-<$\9..C!;7SHAD9F%"H+F33N7<@.M!$0;?24TU)4
MPI]CL2^<_V_O79L;1W)TX>\=T?^!;V_-'M<)VBU2U*U[9R)<+E>/9ZO*GK)[
M^O2G#DI,69RB2#4O=GE^_0L@DS>)U)6B*#DW=F9<$I5$`LA,``D\<$%8M9^1
M[;XQZ*T\3@J(V]N4=G8)>MU^]KYGNRGA3\A7""9HZ3R!#82Q+THSF8_$U"$G
MK65HV?O63>C;X[QV74A=;9##1-MV6IF+<LP>JN&\[77RT=+LZW>C;-<SH=MJ
MK4D9[V=4#\,,H]?+W?:D+]^!J%UYU6_KQFJB1"H:W6)8=AC!,\#7"&.O[Z+P
MLQ?^SFKB8M]HM;7L<EF/L#U-9O<[U[:A]7>;SF)8_(-I^Y3^=SO.MNQ*/OX[
MLQYAWT]SN@*MCAT\BW1<"=&'X,*.$I]#P*R<#9\QY`>_%9%W,,&JF=/?_ML)
M?R;T324(7QSVUQ_&,-1/BM::A3^ZG@\35/Y/:$_!P''9LP)FH.G^'U6A3U0E
M@.-K_+/R;%OA!'[3Z?9FWWY6D)+ST#?=8`P#_*2XGLO$I[9K,1R^A<\Y#*.4
MY\',1&L%G\/7P7">;Z6?TJ/P!N\Y@%?\K"!]YX']'W9N4@9?/#[_//19.)JD
M8YT_L^%7&\C!M\.WWE=V+LC%@7]0AO`RYJ,,E1%S'/':Y-\ST[+$O__[,?R9
MN.7'K'IB?FB/3.?<=.Q']R<E]&8_IX]9\6-BC'.'C6GJX0(SPH2'K8N.[::#
MX*2R@CFGO]/IT6=/IF^;;CCWZ3/USI[[<($_"3>YR$$HMLO.)T6_'9M3VWGY
M::4Z),0/\0_M`O_\<1A_^"..E?PCM+9CUPDQZ-VO]S>?K^_OE=N[ZR^7#S>W
MG^_7X]B/H9_^B2LX_M<L9LC(<SS_)^6_*-+3VI#*Q9GOR-^RY5[(4,^?36`#
M^4DQH]`3"B!661":_J).E.X[SQ,[9/36#-F9_:1@MUFQ:91HRM3T80<7^\KQ
MZZ<YG?W\7UJW5:"#LU>H:<W0JSFM/Y'#XF8ZC:[@L%6N0!@>MV^4LW#"%$R\
M-=V7MXH=**;RZ'O/V+/*=-'P4B;,=,()V$'T#`C$`\]^%L$0\+_P@]!3T/H*
MP;09V<`P>XR'M?-R/O.])^;",)8R\\T1G>'PEV=%HQ!^-C%#!>RSR`D5&YY2
MIE2'1382`Z/+F]HCQ89WCD+%<^>(X6/22!A[><$1<"(6V'DO].V0L3%\:H'I
M@OE_%\I#.D_EV0Q`(6V0-Q(*CXT$1YB%(WW"\CO\0QOT=1K-9_//O&>.^6SZ
M\6,]%?\`LO\=N2-B[+,-=&+ROXT%13CS:.C`E+SQF"$&"_R!/)W"HP&&_"Z4
MWQ@JX5<6SC%IQB-/P(PILVQD-/R%1O(+\AYD#L:5.S_UD1F&#J-!D4J+/3''
MF^%[Q>"D50KH.99?H:$+]'B1#Y_8=/&3$H%CBIDBCQT2=8CE*_B;S,@F*6`\
M/M$.1@;(.(!'IR8,&]J@DCC(U`M@$<'R)VW!"THS`G6"\1+9.UY`RI7*58CS
M)2],4,$@&OZ;X2M!%<%8!/$IOAU\!=*#P,/Z))!9(@\B/4,YW8^">)V(.K59
M#)U'YHX8JMU71J\%);,B<$)46@8LI.QI90QK3?$P(1&8XC_"__!%8C,QRR`:
MC6#VX\A1`M/ATRMD+\TQ0PZQ?,1+U/!-\$,S*6\CM<'`,"GODTU+)AF.YFG.
MX-\SGY3%9X]8<^>A=N#'3S2/9Z":X0>B/37Q%"2`;^93XAP$EJ)6Q*L?]6`<
M^?2`A76J#K`V`G[Y2F)JW5U^>5!N;GY2;A_^?OU%N?G\X?;+)S*Y5.7FX?J3
MHETJ_-SKZQILX5]N[O]7^7!Y]7#[)6.3790<B)G`[(*SEJMN2)5+9!XB\)$'
MTP7Q/(#>OW-@U4GW3KIWS3VQDR6E2_=N.8/N?_WTZ?++[\KM!^7^YI?/-Q]N
MKBX_/RB75U>WOWY^N/G\BW)W^_'FZN9:>GW%MGA37;R<IX`[E3U^.07%7<?O
MDR?*7D^4(LU27O4Q<V:^W?2<V9J))\2V=V9@DR\T`U\')DC&J#QGY#G3(!V=
M.W!*%%.&'&7(L4KU^XTI$_,)HQ-L9OJ,!SK,D8@F8!@D<LW(LC%`,^8)56#8
M!#&*4*#X;.RP$05,3,=1S!3P1Z4/8-,%<8TF%)C`*(D@%GZ(]_[X.Y?"!*J(
M1^%?MDLQ#0Q:P4:MPAPP2F-2A$DANP/#'LP-X'?\9TAV(7WX6M<+E:D=.,S$
M0X]";F//<;QGFBD//.!O7,OTK0#8$RK#%QKR0S)D&J)0[I,GWWGP/\K9A\O[
M=V]YS`O_5*A&]Y&YS*<`$+R$S9"!F;?-8.8C>X:5[V>_7%[>O>73>$XH2^?W
M3&E:<("%,"$8#B3E^2$Q*)TQ/,&C3ZH(V?)P81)X414FP,H4^$RA?@X42AJ9
MP409PQN#"^4+EAMB8(VB2DB6""D&2)87`A\9YZB(^N%L4?WM_`96R*LKSZ)H
M3W+T9G[4-_KZS\I9]A'@YY6(%`*O/%]Y@0G$'`RXT@X9<U&/'#,(X(>HO1YR
M`O<*'F9#(C$25*0;.6,@?9M-/^>Q=V10/''%LH.1XZ%(`J'#/#+M1!:/.-/2
M<=T(7E*HBBG-*"TLE[9`F15O:L.>:5V0BOFHH<Z+BE(?,L=F3T+!,:KN18]\
M2EE22)`6^S/"4&+!JLC.1\P8R0WF5H4:R[F(\@!>[6#<&KAM6H6!]-(%"&^G
M+TE^&+BUE/>PG!%626EK*HK'2$*L7,,P>,E"3Z78'R'MQ3O")6?O%[$$7.4#
MBEIKG?^O8L*K*-B9D'./.PQ/2L7QK[^-X+1YI+@TS#N@RY7[ZZNW98',4SYF
MI94GHPFO+)KPN@,'PXT#!Z\L1H`9Z:J"_ZUD$M-5A6I6S[%H5<E6T^*)\M$#
M]LQ_(\,*,FGIX$J]1=+2]]^=LJXU0[-.-H9`#BJZY>CR3V!`<(T<&[91M-SC
MK1'^3)*ZN7\R)<^?+';RGWR&B2=N."'O%6QXV\=$)K#;`TPQ";EC"FX(>:TL
MW:8O^,:=^83\(N%E"T\-Z>"N1)!Z!D-S]!4^%/[^KQ?W%\JC!Q:%BV2F7B&]
M<&@Z)GG'\`'[AB$))/,#L]#1!Z^&4/O@+,`L*4Q/R:5Q?7A_<_46F#*UN6_^
M1N^T5%AMY(^GGA/RR`XC[JY1#@>-"DX43F@*M*0>$;"*O<0I28EK#'PM'"Y(
M`BQ\_LRB0,L,%HD:SS_C,O$C#=Y[YX-3QCV]S(3`79WR]^68P9U(G&L\59S$
MT'2_IF]'QW,;:2CFXZ//'BE9Z(VF#KI]M=?OT4G\IM/MJMUV#[U`H.(>XRW<
MPVRI/`"`3RWXG10LF>'DGICS<B'.>H0,R:@M5Z5,D`'>,6$.!1NF'('D)4G!
MPL"93S6J6=W#3#(T4BFX$6=E<6W)K@,2*??=YU8#)3(5K@=\,7GRZ0^?F?.T
M\,M8><&79Z`M^.,+;L`T9+KK4YV1$M+AE$Z"R(;W6?:8`ENK%X9-P9-$`5&/
MU71[6E3LPO&`0I#<9XP9M65LH6FG[^G%%K:\09+A!IF\4&\,8B23%[9@6PR2
M^R(C"_*X:8!>RH(H&5FHJR`JWOKB>]9`\<UG]!_@&5XEX?E?8=I8RD0N*-W8
MVJX-_H(%KJ-G\8]L3%3`VU5&#@%5R7C/8,!3C4\`#K#GBBM,/T`^JN(O+P)W
MA843#YQE\(6%KWWF,BR-`FWX#QE13UBY_O9"^6TU-78&@5U,*CL?QQRBJP^_
M`YY$8W,41KP6":R."3.MC&]AO$;?0H:1F[;52S="WEKNS6.PY*WE<@X]^"8<
M()G&)=))D.=&8[3S(#G-WW]W%.K7#&4[3;^![XI^IKT475:8OF^G#D",+X`F
MN6>/F&+2A18(FRQW!>&5T3('?EF8_^HKEA<-0ZP5!_UT^)78A?+)=,U'GE!J
M,;R&@"D$/!<4$WGI]B+WX^2BSB-0!;SP<%Z4(96H#,'3L0BB@7*O0:+1T$DS
MA[E'`0]%`7X]L?&"CE`;V+<93)^*XJEDG.?"PBS,1P%E$`]QH11SY]G'-%2L
M9,>,;?C#8C`KK!V/9TM%Z-B!]8F1^X+7?0M#S7SV9'M1`%/*CHAO2#TP<GV\
M*>,OXC^G#-B%`=%SBR^7^9R&3)F9`3`[@B]A8/=%P610482/?,_\.KX^PNJ?
M**04;V0'RB.]>FJW%,M\`<;$@&3TT@D"!E@HI.1U"[/->&,=Z8T=P:F:/X^D
M#R-]F/W[,$SZ,,LY%#>>4!5J/<&3]>/F$]*?.8V=]Z@U55YY2->EOF1*BX$1
M3:!8"!HEML99LC6RI&>0N+,`VDQ\[3D!AO';"G02N`G+$:)2N%R$<A.9>[&'
M0W8UXQT\:42\$HFM:9.W'$TRLBRJ,YLP`36%MR3*+,*,/A@$)O*$KI2H#V2(
M5<6'2=\5!0S=(`=,_B#_$EY"&;\<Z[V&D>V0Q7[&BT@1%\[DO:0L#NPV:+]-
MJL?T5DNC?\`?O02/*ZDG(X*'3&"("1;C+WTJK--;>CL#QR8>(#<,$]%B2N)A
M1<&F&5`2'"PS&,KBES7)19+R9P2KAE\S418BNDZ8ZN:&+^=C8`!5Q5'EI4.T
M)&^QIP3.E^:R92GFHX#G1#5U,\+.AT$^HKAI_I:`Z1O;W\C=(@D6CT(YA3F1
M),EP:05K3E&&..X3E[&@`5Y.;5_G7HCEI<";"#F0:FW5='#I8[(DD;*0TQE[
M:#WIH4D[X?!V@O0UI:^Y-U]S+'W-5<ETH>D^8BA3X3W*I7\ISXV#:Z?T+U^O
M?YE<5];H88(#"(?I?[#>)=D.A=%^>C[E#:&5N"P#5A)C4(_`C;1#90R*X_`"
M-$970!9_<\:="R>V;\7N7"#\N99P-K4.X;78HI,1>#=#O$,*(CYK4>[758W^
M@%>KM76UUQGD/155X"3Q7Z2N:BPK8B@'?A9L#1`8*4S\)P4O'Y/9+TPM]80"
MI4MD#*1#)`\V>;#)@^TDG"!>A1[:"!"%H&O8TR`0^0`\41LWPI>T2%D<0GAV
M$?`6)0HDX%'8V,+V!4Z8]V0G+1BR(&7*@S>S1TJ[VU+SJD[89AD8M!@$ZR8=
M%3YY;P<S+S`))(]*<3]B&D36,:%QX`C#/(<L29AD`=S`YAZ^_?C(J)@;CB"&
MF>CB,*5\%THCH?1T?`F5RCKT$C%[.-+CK!4*.XZS;Z%6"%B4'?!$B,QYZR($
M&<X.<0$C*N=-D>32(\EG6+%.,(+Q"3UF<U9`'"8TQ6%KAH)@<>`O3B-WNH]7
M/81<>J3^)WY<69TU'1:H5_,_C;-88$VZ2)*=,W+&P"O^3A&\CH=)GLD$,J.X
M=[$IX,R&F&R2/*B*M)YL;PAB3A2$H/8^*74TY9V'XPXK_^9V31!G->'"X%%L
M)_!B/2DQEK@H%FU`,92PM)@)5@D''23D0@HWJ["C?.4]:%XR\(P9^$=I7$CC
MXO#&A8RVRFCKWJ*MCS+:NIQ#[Q.<4@+*P;/R7_'YG$+K9GJ]TJEVY8$EYH8"
M.`<>_6('7V6<5IXX!]=KZ<Y*=[8F7?N00Q:*MT<!!$XX8`)HB6`KY_'05(1L
M+H"R4HO1DM2TP"#-;L]\.#-?^"<$Y$7A3:JJCO/E?>HX^&S.P"$K)ISW2?00
MPIQWQ4LZ`F8:!7+T[G3O)W];!#*QV=T"IELEDQ>]_!;F+_H]?F79X<H!I\"E
M&Y=/O01<BGMJ_-T4)$C]2=%NDR6CST<I"@(1?;TP$)$Y>#]E!R5,M!1*/(TX
MQ+%HBXVIFB6E2D4_$KB#)>W8BG3LFU.&1?A$/2>9`A[I/'A[3LK9"K)-$G,@
MYD,LM"^9//>LBWSN_2Z`O&*(-<"]\V^\,HAG+<W%'JPD=&'[G(H8-RUI<UHV
ME\SR2M\24,AA[B5#QOMQ<H3WS#+D5P>THY$.WRRNT?EBJ&P,(\F6DI<#IWG&
M??]=DTXY:5&=MK8U2=<6W,JL94$GJKB.I<K)@N/`#G+&!\%`BIXC\7TR16KQ
M@A@^?)YX4XS)<Q,B&F+U(?69QD[#>!!@>-:*X#A'"BA\[\,I")/-7U]DNVKX
MS'T$0D5V=/HZ.*E4+*LTR4*$<Q`K0=5\!Q'\1=&TLFQ@WV;<78>YBOD),XCC
MSE)%::ZL-;'IXG&P*S1R?@@'>EJ@BN6@HM40HI6FY:I6OLET=@P@THDS"?#Z
M(^GRG$P<+U$>@6DS;BDF["!"7PC:UAY%CNDGG:GI%\Q[],T96#AX$IKRH)-;
MCSSFI*Z=B*[]-M<X*H@(#X![>SGTM.166K2F%\<BGA-)LWKJ+O5DV@ZO)\&$
MK;1P'D2G/#'7\F@C'IO^]$*YQ5]C$_<7NIWVTJ,C_[L`7C,BIX<(?$F(P:M@
M>``/*;HO%5>E,447RM^]9YB<K_*R'GR+R0^ON(/:B)I5T5F#R,]X`H34.8[A
M/VS>18U7$:%#!>>L.,%B5LD300:2Z[D@D9#-\C:S(:IX-I&WF2MK1W@H[0N&
MTNZ?S9ER^>@S)ML^R6.E69HJ>TE+SZ-^];MT'`6.:/O)#*D.(\;\>G2I?$%4
MEN0[NO!40]O/74+\QO)U&(OWC(J9;+QHV.=J,<`'<9.J$H'$EC[]C#Y#=G0*
MO%D,HU`"#H#E9X'M;ZS'M*Z$WZTDR<29M-<8G<RVLJ$K]%[22R>\W>&70!FB
MTL[`"81<7.(NFFF!Z\(+17"Z2$]<F#)'C4"/PYN=;$9KX"F\^6T0-RHF?@LX
MZUS.[')FS^.X40,@-F%NP&DC5+<SC-^]515,?G;2QM/D2](\TDO0<F:>L8O'
M"PX0QU-.[1$VU@X=00FAY\7W7.=$+,_9!3_22<;,T8LNH"#FK>@"CKH.[+6\
M$=W6"OF3]/`">F+/0`CA,XIF#>:XF9_#4*0W\-J038,T)S=Y*8_QJF#9AA,E
MZ=:\Y`6B6;:N]7Y&5K-9TJ2:_@?^^]%#O2`L0;S#950N-+<"J#-2@59YXS'R
M%P?(Z$J:T`SBR4](WA5*RV:;HR6N>)0NLW29#ZZ,.[G,MG29EW/H"WMB;D0`
MY6@&XGDE'65YG!Q</^5]G/2*Z[N/2YQ@K,>C_;`@G?,^!-](R=2,OHL<D#4\
M>79_^>XM6-H70)BA*K$7H+<*M]?X6^UGL-`OW\6_2U,PZ9IL3/DCODU7@;RU
M,+A.0S;V_`R50<9_)Z<U8$G3(OLM^F5!9)+GQY[0\QR).T?,$O%]]"$R=:2J
M8L-O+(;UI_X+^+S@PXT$8@+X;`+F(>L,^\RU>&FKC3\E7`JP6YB?<80H)X<C
M?`OP.<2_$UYTDL5I/[V-0=MCSY`F9P8>/L0K*WV1[+(HKDQM)=U83@24W1EG
M!OGB'B:TAKX]A)7F!V_I/C.3]8/O<)SD&I.R=4([%/31_245Z`:8:1H$2?%K
MDNGBIJR+O_.F4\\5F9P^N-98X8H)U#%)*(HM9AT#;A3-GLN`?V]3#US<-F`(
MN9'*(_O@1[9T]O;J[.7\N-?6AO7LW]+96\ZA:X'V))T]>7(T23^ELR>=O;JN
M0"TZ2@G&)05R$WAM%K_-BF'BXB([A*=)$*XSD'/4&0H]1?X8W>*(X;E;A?9W
MQ$OQL'=2YM4Q0)Q`Y>.7B6_TGMHQ.AR!3NNH?</((]SYC)WSEPI(<42`@=_>
MLUG(ID-P+MHME>.8B[M68Q["CL;NZ6JG+9#N#%T=P/.9][C(Z9U>`W--/2GP
MBN`S;R8<S7C>6:[S=E."YZ:XAX01XFNZF8DE#%Q>TH^1IU$]UI*\QWK-KDU\
M!]H093S[*IV;5<F?E-KR8'Z3/7;E.=(`Q91>C?1J:D0,SV"4B"R_$+?"-8%)
M>D8A,,G"ILK11Y+OYY2</N/>4/XVZSE[?6$J9.L#L4!A)A40*.<)@CB'S",L
MQ?:`+WPVCEPKA?]`#!1&=U1+1BM$%,7G>8(=3QUETYGG(T@F%J4Q'V_+!/@I
M0GO`,,^F;R47/Z!'1%\,BAZ#V`I<FKC$SR8WD$KK'/LK5HY3A1W66!-G>#9K
M9@8"XO/9!@=H&`^;Z8*5$L]KWKF$D,Q-IA7G3`X][VMVC/RP%W3=Z:,90?CG
MV0+Q!&7&HC1/1+6E9,=<\7G)["Y*5/!<:RDC!Q;8V(X3@_,0O3G-'KY@,^-@
MY-M#`CI5$"-W&DUC51--P."1B>=8XN*3J)AY`?]V&B%6$TMO5CFD>R8I.L[&
MS=3X@PX)V)L;5S2J!@XAAX%6/^!`,8@42\FCO`@2-81V0'.4HL."U8O%[_R#
M9WH.AXN<4*#7`*E>%-*408DB5\`8T(MCH!X2"PZ?`#9Y:3ZN&5FVR'MEWTR\
M<.4O$\F]5#"#4#_Q/?6]N#FDE%6>FVI^(^9&X<2+$7)^$WH0@QGSI-J8J2`X
M\RMVE>9UH6/;$;*'S3#RW<SOQ54H$[)QO72*.3$%_((:0P/`VL4P!,8;@#Q<
M'<]L$5,A!?H5ZY3?KA)^5HAH!:`AP/-`U*7R99+T/@C2G2.;4JMI,A(A+4@9
MB9"1B%?E99\Y,@ZQG$/WH3?Z>OZ.(/D1-Y'!F2]O6N6)T@@EE3$)&9,X3$PB
MH&V1=RH99;;%=>,36K\H/I'=8,]IYUW<<W.`J>E%;A*@B,BE3\,3H`GG5%27
M(S/NE#8_EYGY,A58./$%*E9NGE/)IGB&=V?C1:5Y/%%JW4'#*1XO%GST$68-
M<V\IPS8-6GAIS2S^DC^7OO2=8P)-]R-P=;$2E@^&F;?XP-2SF+/HS"=UEX4S
MG7%/3.3.ELH/6Z=UU;:AB_MD==#;T[6UUE/[NK@>UW55[U9\;1WK"'<'N>^/
MX:41NHP$&2O"#R)6D`M&8&XP!P0T7>5-ZZ*E(1E*,*%NVIQ,DK:HXHUIY'U;
M,#^@6.L7]72,Z<*(JH=O`R\Y,)^H>I>339$2<EWA*XL)V"@*`[)OV`6&U$Z(
M6`R6@C@5A3DX;*'X!M,FXH)3Z0`WU5SY_KM3,5BD"RQ=X(:IXME4NL#+.?29
MA8JX.3K[B$@3RAT<A5>\&N8>3T3I#!_QZ7(J9XMTAJ4S7).N+>Z(,RH%I!V1
M^PB)RX?>512['ZL]8[V+UZ9%SO%UC.N#NR]MNQ>I0YP^_T"83P$,E:$R]5T6
MZ<*6I`CTC<Y`YB?B3I$S&F^%P9@P'\$QB\CY0O"@S'P#O-G$VDL:)O'C>,FB
MC=[R>]NAU^V;JF7DQ'Z:,G/`_<*<Y.QC6<<]X`(RT<UB_L@.F*A[I6M(1&M/
MO$.ZUQ9D"(`G_FC<&5RPB49?),6)<><7IB#J21-P75&C.XO\T80<=\HW0#S>
MHK<GG75GOC=BS,JT?Y^\S/`VF$S#?+@BGBS/RR[-"4$=0Z&4*3^'"#-6B#7,
MCU*)PK&D7RK.'YO</-I/O#K`#6PPI/E:(YBP,LGG>KU,84,,86]$*0SQ)CVT
MSRU49?N)28]9VC0'L6GR'Q^1F\R=V7,LDC=G`;`K_FN?'O3.;O/0"T-OFO6<
M"Z2PS%'D`\#<+CJ):[CZU]GU-B((Q82!?,!SL;<,,5@\_UTL3'KEW'="_P//
ML2UDD(?\<?_Z0_>'A>WK6-9+@=699]T)[`:Q0_Y`,?A/%!R_H^-NK7C:T%=^
M/!TF7"_>!JP52]S#0I7+7"[S?<3=<#RYR@^[RC-!RST8"#E6#SW'2L/OVVTF
M!0/6O[_H1"U>S6XH"F61_!TF?DJ<-"0G7[%.?O]=,WFY=ZW<9/=5AC`][$[H
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MS4+;!ZI?9#/33]")"C%M;"PQ=%$(B!5-I8^_7%[>I6@[\`)3=$<-/?C75Y;%
MD47@Z2"(IB+4Q*&%>8@(HT4QJ(]H[T/!)X'KC#^-0:IM,91E!R/'PTZ?O&B1
M\([QS66_"7-04&7XQ!S0N80<T3LTQ@86;7D6RB(1-(HP<N.?%F'D>CF,7+G(
MY7%2BZTC,8$.X9I(QZ3(,?&D8[(*$^@YVSO]SO=<#]'>\:223HH\51JCJ!N>
M*J](^9JA:J?IM]RXRB?S18"2HOG]X?+^G6*#CP%F>V;?O,<;;6I#\^N,[/_/
MW@7]ZKPU*,(`BAM[D*5^!63YYB@46#578%=X4^8'18@M9Y?WO\8#OTV1485W
MA#`W0!"X3CGH7$*V(4<AXV+@(Z*1*F\`B@3`9T/&Q\#V('&O&*YB//-M!B3;
MB%KSZ"%0*N+N\NXD].M13#QX*"FEO&T.^#L.Z*0R]8*0MPZQJ:D+)R?;'>8Q
MLCFZ$OB#OU[<7W`GD'>!Q9XP""$4B,M_Q&_)OXOZEL)`A"></)1,!I&(3?<%
MD7O_8;H1-HC1"("V=Z%<FS[\QIS-G!C-"4?#C`3PN\`G)4184(I_1`YI12>C
M%?`KWWNBOCNP#,]?F.F+)CM@QHH\AI0:TA)@6)Z$OIKB_0@H'_11@9Z7V`$,
MA*K%R,.>;\,BA%?DQ\[SA%//\8DB'HMD-F\D0XXHK/@8<%>A+D]3RK9X2C(L
M2`-$<QX!FUS<;B9^'EWOG%12_"-O&:@MN+UQ?]G4_^;-:;B2%@R-RB4Z("D!
M[(^$Q85M;47Y`W^?YSYZ!,.;O)<[X/"9J@PCZH;%G7R^..)YQ?!7(F4E7?2Q
M),I<Z__Y,0K.'TUS]M-]2E2Z:=QYH&0V"QY@XWSG>*.O?_O^N_^)?W%E!A/\
MSS6L;*`#>7/I6O<3H/<!9'GC/H%G3RQ+?D[$PS^^L/%??[CB?_\Q^'3]1TO[
M`[3L#U37AU;K#_[_#[=_M%M_W+-9_O,?_H;T6_:3=,\.X)XM>!H%#EOIH;JA
M8#;B5=X6:U]LZE4=R<2N+N__KBKXW\KU/W^]^=?EQ^O/#_>J<O_WVR\/YP_7
M7SXI-Y__=7W_\`D_5RX_OU<^WG[^9>&;JCRG+6:?L\GFC=]]K+X5QF:U2_+P
M*K*M'W((4?)-10IS7IAXL*H<,)^EYRL,B,<KD.M/P5Y+#E@>YP?K8?$;`B,,
MJ`V$B/=[V&<1&=I4G9#+NW!YGT82S:G`\I4'8W>KYRNU.K9#]RJ(%=<!V%'I
M'E(TK^V.Q\.=R9=X=5KO<7P*;$OJ+E+UCUOQK,7,>A:>7,FO2"7E2MZ*;>_9
M:'XA\WBB(1>R7,B'T,@;E[=GDVMY4\Z=O1>=[9:F+M2R=O>.VJ:U6NU"P*4R
M4M%S)W]\WGDO944.YFO[O68Y6EC9P&]6CE<&8E8VHJX:W8':ZO<JIG13%C20
MDR4`8&4C]CLMM:67XP`M1P2K@`&=:OBX&7W5\U%3NQIH9*<<K*-B3C8-;BTI
M<R^,'A[&'"KC[%Z,H2WH*U6IO1'85GMZ:VFQYZ[R/[0)+&6.!"+$;DHB')?]
M@93ZR4L]2Z"FZNWE9=U[D_G^\<K**2GXZSX:AEYH.BLU<S\J6*FZT&!=5>LO
MMWZKI.O8N--6V^W!4IOV-7-'5\GB7V*GGJYI^K'H]EJ>5\TXKXQ^3UHHKTOB
M@ZZ4^*N2^-E^G9"WM=NA.42DK8S3A[4LTPW?4Z]VKL2=6A%RVY-.KD=65^WV
MNEO:TA5)10IYWV2UU7Z[LZ5+((5\)$(&S\;0MO1L=I)*:0+[CZ*`)*V`V:*>
M)5L.@]^[H>>_O$]J@F3=R\G4O33@UMU8NZ3E\+1BH<GGA]LOOZ]'LBPS.:(\
M=$>6F9R,,)-#2]:)G(I(99U((^M$BI!]-RBF7=/K*!QKK]FLZTQ!YK?*1/6C
M8=M>2D[J6IQR_4M%ENM_)[;MHU!%+G^Y_&5YR[%PKHKREKTMQX,4O&SNL'PQ
MGQ4$=?9MTUFS\J5*9VA%!<?:K]JA.F;M=[3;/;737EWEL>M<MF+;\<FCK#9D
M?7FTNJIAE+=(7U$KL@^V=?8ECUWG4(L\-+4U.*`XZLB8W'R#_<WSO\*#YS/?
M&[&@?(NM/,2T-V7?14>,;G_#V^5Z0F^GQ.-VIZ/VC$YUE'__G>3R8JVBIJMM
MK7R[:^`.M\2FW(3:]0SC#[9K!Y,8V[<I[O#ZDFA8@NE!2>[TU;ZQ27+?Z<51
MI.)L0[+>;ZN=;E=JCM2<3;/<==U0>UHUEN)!,M^7^Q-+Z2S(H-02,I<GNV\U
M>!-5>P]IM(<DM-\UE@8KME'G*B0I5:5QJC(PP'_K5.._254Y:54YZVO@A&JU
MJ<J2(W)5UOZRM/ML>OY'SW2#SU[(@@??M-BE:]UB<Y$O;,3L)WQ%(//V3S!O
MO_`:JP%WC)WM^E,T;R*75U>WOV*GB2_75]<W_[I\]_%ZO9GM/^>_,,`N$XUK
M331NGC!E*4"Q.$77IP"[G(DC\=!%`7(!'WX!-]]8.<E*`5D4(+,"95)P8]@F
MBP+D^C\)19;K7Q8%R.7_:O5XP]1VR;L,[S8JJ'@%10$;9I]1V#WN39V-,J@*
M4+,D@_44DM)W+A+H8<;+DEPI622PD3QV3DI']&Y#'0S*`1-EF4"]$CG3=4TU
MC/;>)U-K/D^EF4B7HU$TC1P3`[HF!G)-=X0Q71_(LA2+#4-J7#3S/2L:A;!%
MAY'ORAS;HTMXRS>8.-.ZZJ"S";QBU1EO4F4:KS+S"J,MJ;B2"B,5)J\PO>XA
MM:49Y2OEBK?F7TL<))>%6ZR04RJ+ZG6[:J<O"_SVR>-!OZ_V!M5454@>EWHI
MNJJWJBEZ.AG'A%(Q,SN>]#F.VAX`%>_JU2::']M5B%2<;4@&Q\.HZ`"2BO.:
M%`<<5KW.FKXC*:7?OO5-T5\%&:+;NB:RO.>0A/;Z`U6O"&-"5H*=M*K@/5='
MU0>Z5!:I+"O+!G4PX%J]:J\:]E0WN%4](!84VJ/1Z*<[G\U,V[K^-F-NP(+X
MUY=!P#+M@63YH"P?7)F+M#3GJ-O`,L&E!-]]N;Z[O'FO7/^_N^O/]]?WRN7G
M]\KMP]^OORB7]_?7#_?KS>>U%P<>M(:HD5U_*I/7GNK_&B<Q<40I3)Q1E-KA
M4:#5I&/J9*K[7HM$9;U><^OUMLB`;V@`\K4F\>\UX?QX:G(.QX976&/'V?+,
MT'7'+<;9+@*_T9)=?&4MJSA1\J&O_(@?K"BI:ABGY?Y[NAM/TSJE'(X3LO/)
MCK4!*YVN4K:=0E7-SE5.>MM0N[ILA=*4FAJMW5:U)6"YLL:I9GFT-+73.J`\
MCB>E\)Z-(M\.7Q2+S;S`7K+SR@2?(TCP,5KJH%TM(*G,#'L-BJ-U5+U?7J4K
M%:>F*L0C5!V]HW8[C=ASFI55N/8DUOSK*O)]AJYM-`QW;$)P"NOFV%=-KZ-V
M*FK%)G?<UZ0YFM%7VP.I.5)S-M8<O:<"P4W0G/J[^\A2RR83?SR42C9+-C?4
M\YBC]CTB%=E!$"%"?;!5:*\9W*U&-3H#53>J2;J7JZ_D8JJK&A)]8J\L;NMJ
MK^8.WDVXS9BC-0?1-O6`E/^8H>VYF*)KR6TO._R9UE<[G7*\OQTHWP:/ZK18
M"_M=;R^+\=6S5E=;O;VT=V\F+):\K7V%\9B^.M`;$8V1>B/U1NK-R>M-(W2F
M"=[$LBE\_UWA)-;\ZZ,'XX3,G\IKVI-8,L9`[6H2HTTJSL9W;7!(MQNQX4K%
M.2K%:;?4;K\1.\Z>/6,9]FW^O99DLV3SZ;"Y_J23=="Y-G<R'G;T*R3LVR$(
M;>L=5:LHIEVE)*6J-$Y5M&Y/;5>,U"M5Y315I=-3^T:U_L)6DI18=-OA8&5P
M`A+TS0W`,Q%K,P;KO/.]&5@S+W>.Z8;P_/6?D3V;PIP+,#HK!-U,!#PO"V+,
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MW?X5V?42HR_NX>)[/9I7(FX>P^)<B6YY`EN/LQMB\S%,]#6)<2^(TS5L7G)_
ME`NK8;.3^^,)BG$%1+O<'N7V*-?5%NMJ>\#Y8YCKSI+\_KM&SR\ORRH@\_>V
M81T0,G]MXC^:L`&:H>>_4,`1&!Z-S5$8^?#K-/Q8RKL<G'J56_P*G/:U7[4#
M;O[:[VBKW9:N=@?E91E5S693QAVI1,J0VC>02$?75:-;GK^T`JM]'XSK[$LB
MN\ZA#HGT6ZJN'U`<=92')I'_M<E]%]D./DE[KSV=^=X3P_VV'(!A7V9T]6J_
MB[88:J<W4/N=3?J>[\.'.6TNZ^J@"UP>;`*R+;F\*9<UL`X&P.EZN5PG_,S:
MU-Z.Q_:(*>/(=VTP,5G^CON5ZTD'UF*GVY-K<9_G2J\%JU'R>)\\'O1AL]ND
M0OW@F]T&V!_KTWK,H;(KSX5W12."/K1=!>S21Y\%9)4&$453SC0><1'_7(RY
MO-X%T&OW5;TO3=?]&E4Z;N4]R>5]<OFLT];5]I*XU@ZDUX>7N&M\]R-8J?4'
MC]-7[.-F:[\ZMV^*-]Z1=;6_Q.HKD6$].XA4G`8K3J>EMEKEVY]4'*DX):&U
MQNPX3?2--D8F65H;H2I`<O#:0^88/&JKVF"M3A3??R=MXFTOLL"W:ZO=]B;0
M")++V_AWI-''%$?:*FB^[3&>;55AL9G/1C:UJI!V0Y,HWMCC-C`^K7;ZY7A.
MU=L.Y4TAI,X<A\X81D<=],N/?JDS4F?R.J-U-;4SZ!Y08^IW3%;@4-7EK;AL
M]57WSJ16IH@KX<+VDWFV9SHW3T@:=#IJ5UO_6#;JCP1)96F&LK35?KNG=HWU
MXS]265ZMLFBJIO74P9+$G]J4Y=4A*DDDOMJK=N)\D;P.EF:1G#R`C1!R$)K^
MXH)MEE:>E`+.Y2]1R;025]PJ<:&M2KA+1:E0>4`F4QDFF?RP"]/#X<0,E6<3
MGYS.0$\P3L?+J@B^R?:#4/DS`K'#^V`(A#VX4#@="3*"$@,BK$7(#$8?V3/3
M<5YPE!F,;9L._.\+U10HH?=L^A9G4DFAUT7)$OR?'[<!@\V"R%Z.1N"^A<&=
M^8)'"_P2/O$C9GVTS:'M`,]8L%\\60&#2X=KXP&*CAK;,P?C67B8+9HFI<#0
M!1O.AM+:B('Y^M)^)<"=QS+;RZNKVU\_/]PK=Y>_7[[[>$VPG/#AEU^OWRO7
M_^_N^O/]]?UZ#'GML-U5+=?#*<5&X)>-$2;?<J0XY\49'[]H#=#AAT%)DY_`
M"A-8\$M0)M<"EVR,%L@EO?62;KYI=&K8C>L;!XUKQ1B#[ZPSA;UT-EP)OE/5
M=A3/=#OKZH`FW7988*^=;7O!)JQK<<KU+Q59KO^=V+8/[#VY_.7RKUN/-\1'
MD[S+\&XCG,!ZE^,!D>76]E86(@Y\-GU=`^]L9,[L9<UF%\'&*G*05J"8K?VJ
M'7#EUGY'&_,"5F-F[3J5K;AV?.(H@S!;^QUZ1U/;_?**A!489OM@6V=?\MAU
M#G7(XTS7VJJAE6<]5S69PV6N5K/9AKYIL2T.J=V,P^JU?A=ET7I]M6-L`A=1
M3UB.QOK^NQ/ALMXRU+ZV"5Y$C5P^$1Z?Z5U5[ZY5YGG@C6ZC>KA-MCJZM(*=
MSO><<A/R=6B#UC94HUM>QR%77`4\-CJJUI,\WNNNIK74WGY.CN,PWVA/&SFV
MBU3`D)%ELW),@]>A%-V^:NA[.>GDNDO.#TT=&)N`&4@>;[RW==MJ1]L$=?1$
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M9&EDR:DHL7AI`O%@8_"`QDWAW>7G_U7>7[][6&\FKZSJOP'UOTNE-V=7U);]
M?[C"_89*Y#>F3,PG1K@]8-,PV`']T(1_C7QFV:$RAHGQ(POV^7"B/+Q7WIGN
M5U7Y?'%YH9R9,%F/4'V>70:;130,;,LV?8+Y@6<_V*[ICA#KYQ=PP&<J\F8T
M4>Q`,95IY(3P=<AOW88P*G^%.9OYWC=[:H8,!GXS,`P%CDU'H`N90<#"@$`"
M/-B,%5U7IN+;D6,3FA"(Q+&`B^RM>)WIP_G&1G"46LKPA:@,31<AB.`%\%](
MK!?Y8NP+Y<[W1HQ9@3(&=A+:P!L-VZW@?Y2IYX>/YB,#-H9,>68PML]&S'[*
MPRB%$]NWYF"46A?`O`"#[C`/.##/7Y@);\41[?\0(Y1@-&%6Y#`5D9N`-,]S
M4_0D10`F$;!3GDL&>![]?@<X"-,9,J"$K:!&;Q5.5%<[NT^TDYNHWJIPHIK:
MH=XWO4VF"O2@HC/K$6D"2=M8^,."4/%A6$29($-+(7`L%K#\W(7JYW\3/)LS
MQ7ST&1,05@BJQ<9C-@J!0T`IV&IH+,`+QXX'<P;R<B,$,&W!(B0;-I[S*2S3
MB?+QYMWM%UB-44"L@66!U].P%OE.!B:'P.GZ!K_F(\$LNQ<MXR^T+(R+=O\O
M*L@JF,7$+(/OPK$($@VM0#%<S(;PV5M@!>I!^\+H\I?I%T9G\64@&+"P["<3
M/PEH_8'J>(\NV'#)C$'JL#<`)R>,A0IP#SZT?=AQX+^>3"=B,%#(10J;68S[
M@38Q\)+O`'AWQ<PQ<)7/(R,/HM-B\-74QJT)N`:Z,@'S!623R`EW%%2+6'DX
M(W#'>XE?:.,Q8(]M3((R@PE*\YF_G3;.(6,NO">`<Y\Z'B"L6OP8U[@@'BD[
MN,UY(%0R48P8$>U"N9J8+OY6/)AR):%KJ3K&+`=+%X?GUWP$^.:S"7,#/G?X
M-U/.@*/!6T)_IK'-;PS>_X`Z"=:>C9LSB)[OTK"$*9E_+1K@H<R^B1S+["YB
M,R`)F",DE)2!5AJ),KM9B-?E59'3.$=:.64!0=Z]::MZ!YM>MU%2A4L"ML48
ME\Y'^#EQ:I2-&F)0%QYYTU$U3>?3[*B==C^_*0%7Q/J>P<KP8,]E+LIF\?U\
M71'&'PT&B[1C#,3?7;6G=[,CN[:[Q<`+FP,.!1_"D1P?AA8;V0'!!7I<37%G
M#>98X-L!V`+/&5TK4C2N84+?\HJFQ@J>BN_LC3%0-:/W-N9E2^M5Q$L8NJ^V
M.@,QM#9H5\O*V+[QV=B!SSA;1[22-UO(W,@Y<]*(0>$"30=;LB2#W$:5;(@1
M;J.*-P03\8GV?CA>OK+PG)]*MCN+<`G[2N1FGA$?TV&'6PP(W??`GZ:M#Q8)
M'T.QS-`$M:)E#6]!QI311J,X,&&^Q<*B=!BP4M%I*UADVL1FONF/)B]X*C[9
M8GN[\BSX_8CO%@_>S!XI?;VEYMT,&PW>#SC4OVBH3\S$4U]LF"#0-.3"$\#H
M!_-6DJF\Z8H]C`RC(9@VN<,=6&-<Z)V_E)M,11";&DH4UA<WMDS<>V:FO8ZE
MA8KP)MY6$8\4OQ+F.QK:3Z;M<&`M=!$8<HR?7@'7"7`]N)K#PO*BQXGRR7R)
M<4:[]*B-U(!W(>"YW(@,Y_3PY33,O1KG$+E1P(5:N--RIL]#FUXH-S$KT7QT
M7S!@XQ/6%\SF$9R3@)L%\R_T(L?"0SZQ9KA-08<^9QB7"RQNFL44U;O4]FI?
M9!^E*8)%M.@6D7,1#?\-ZQVWRMA_&B>>SPC\%/@;#W4P0O%Q=*\0>M5.CSST
M0L#2=4"'D?+D-\M.J7EK.2!3.`)9XNX]!/;!6@5'!Y?@$AF0DM)^Q==2#EU-
MX=%!<?Z1&4^+/WDE_AQ>^_I0V'9PZ//!C],`.#LR5+,Y!(B">Y\<*O30<ZS]
MI5/<D;6Q,O:ZNF_1(LW;W.(=GBGSZ"D9-^)3[`-\AH/RH"R38LFX<U(LS1'+
M\C2C_?&G+NR7[[\KM@1*[J,>T%]4R+XCAPZMFGFC<TTLD[W!B52/Y5):,:JV
MC-5((9N1N>G\&\C&,LR/,C8.U'9/6SEL";Y'12@H>P-3J8V-;81)*<]<KYB-
M=11GK-J,?D</JF036MWSL(KLK$IK<<KJQWIJ>TFCV"J).C;6]/JJT=FD8O_U
ML$9K=]2^L4E&7,T[P)I%J+OL`:N;K1V+-+O@LTE%+QRLKZOMUB;H`:^'-9K1
M5ML;%;.=FA6PNE?VL<BR:ZC]C<!I7H^:][MJ:[!)G<#K88W6::F#WB95B:=G
M!927UAV;-+M]=2"/NN(]8*`.Y!Y0L@>@VFR"_7,45L":R`QXI;[%EK#'^NC&
M5T/72*`Q:*O=P39F364"DA*OE4!=1:^DMR3>*V5^>C+OMGNJT=WF?&YL"X75
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MDRON2`77C!6W]SK._O:-K\7YG""$<$RA4K9MV!Y^_=-_Y_;PWU9=4:VL\%S[
M'6?8B'5UL>*N4YF'EY92R$NAK0Z6=*.J3PJ=?4EAUT6]0WWI^E+06FJWO77)
MJ11#56+0U&ZK/+EJ7V)H0G\V(O'[[PH.,W&3L841L%M(:$.F[JMAT;<X^5MM
M;50\7(]7?U(L-M3.*F-3LG@G%AN:VFI7TR)+LKB$Q8:J&=4VX:XR_EAUW['E
M(=/;_?3QW+>>-"S#_*`D@YO6KT:=C_5N2NK--B1WC5J:OTJM.2FM.6NK;6.3
M,K9=I5KN$DM].0)]0<2":IJIUW@'O.\>ZTOKI0K2$W=8`H7Y_LU;``=IT[@_
M0C7LZK!)X6<]@I2:TCQ-T52]XO-4:LI):HK>PQXD4E.DIJRL$^RKW?8F18)[
M$F1A:5%:*KA1'6"V@)#_YL'\)IO=GDSIX&%K`K6M.]L>A-Z;SU>WGZZ5A\O_
M=WV_'N'-K/)[[15,LL9O;S5^U*V3&A6&YK?8FU;.ALQE8SM\JYB/CSY[I`9D
M;_1N2S6,7MS=3=5[/>6,=Y:SL9>1IQAMWK>RV_E+W.@NUP91&3)@-,N\DL&'
M8]$H:LO6<_D6<41<KS50VP-#=*73C*ZJM;2W)<2VV]L06U%G0'CQ0HLN:OE'
M7>6"$%NY46<Z>`EO<XJT*2/3]U^`E&?3MX+"/JX#G;<.X9U3O\ULWAE+;^G]
MI!69WL)7VF-LBZ9$H>U0`U$Q;9BDR]DY9G#&89_*;>CH=<KH&&3I,);2`:R"
M8X2WHJ0^@((_CZ"F2-D0V^TQH`>56#016T6:7LJ@WOJ$Q2T)LZUIX2TAM2><
M>V''&-`+L0F8^4TT_./Z9@9!-$6FFHK1^@O-`IOXO16=@WDK1_ZFD>EB%[:$
M&,_%+LL$:H==SE;*"#N*Q3\6W>T&W8[H;C?"EI+PN[A!,/'F&9L76KDNP&-8
M+*#XN69Y+8.:TL$N$W=J-;&E=&BZCS;OCQ=@(UK>\&[(:+:B2ZEH-@TK!5N@
MP51ID2$36!CYKC*+_)D74.M<6C;S.J9I.DT@6<5/+`CY!#P4AQ6-2%S*>S]Z
M5.YY@VKXZ`R?ON2M:N\F)FR+(Q:13:;<N(^H1C"&JGRV@2FT\O.G%5D3G\P@
M5&XCBCT&T2QSIO4,?HS%GZ8&2#(*,DSLN<0QT(?(QXZHR``D;NAY7P-LV3=R
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M<KG)W>ZUL?_S"EM2C7<7[B;PWN2TP,+0MX=1N-B_UV=/-E""CX,I$7##D`)Q
M9*Z)1KB4LHU=Y[_`4G1A%[EG_A,8IQ?PQXB:4+?[>KQ;+3Q\Y5F,PINX6?(^
MUMAI7?35YCO9S`$!B&;+8/=.P42B/0=[(I.!RS=>OEWROM?PNM7&=6;'%;U^
MD2C:6<U,JW+O&?R68&+/XDE<>=.9Z:+[&N!>A2W$Y98CMYQ7Q_Z'="TH8]MA
M038ZQ=V09&7]>G%_D<0F_@W.:6#9?'?`91B@=0-?\!!*]FOL%(Y-P<=`'_LV
M8C/Z4,VN0VYEP`J']>IG]Z]<K,P$EUUL&[AQX<87A1//YYW+T7DB=S:.%_`V
M]+_!WH0^GAN"G4A!#'C1PG@P1=BXP`4-1%]S)_#BI[$]N`W.7!(1B0,$=M+8
MW0>3$;[@'=3A_S'N%#G<P)M_%;!?L;PDI(*SC]R,08L_$.%`/BE\0FQ;L6$J
M)&*.1IQ_N#VF+=I)!-3/?-F>MHB1N>S^*GO/!4*##9Q><.E:>)D%[P<3&&8O
M;[Y.YN9K]4UQO7=A^G;XF,V9P=7MIT\W#Y^N/S_<*Y>?WRM7MY\?;C[_`O]6
M/MY<OKOY>/-P(^_-&GI02COEX/=FPQ?'?`[(9#>G=/>#1["X"N!^AR7"/EG3
M@@(]R*6I:X_!T@CQ<F(,WHW/_0?+AL,7`R5QA&)J?K.GT11.[1!="3ASX;3#
MT`<8'>\9T(`^%OP/AHD3JT#E8?NO<":!=^.8?OS*$(]WV+E#\RNPGE["3(PF
MB=<F=Q\F<&%FXC5$0BWLV=R^`L.$#G28#!A2-,7X]_Q.(:9Y\2+AA8=5_HQL
MGT=OB$@BB0>&,@Z;C3X;`]N)3@L'*2=?+0UEV]/$C82A+!8B<UQ&-M/4M,D'
M3#G*%TU?UWH_<X]5\#W[N6.;0W#Z@$W@/48^WA/$5R](?"Q6G]G38>0'++YF
MR(H8K20Q\X#?G82>BE:9AT&EB>F,X=5JF=AG,&QDIJ/.<S]ET(7"[V_SWWM#
M.%6%<?<,!J'R"+.PQB:ZY\`YSFJRWE).@ST';G,ZQH,WLT>*T26D?!LU7E5^
MB4`;P%QB`>TR].F%<@DVGX^'6/9>#LU''^\KT(A.&(IL(1%G*33IY8N7IN#K
MVWA'$U_+^AC@3#2;WC(QZ07>:&3B+!)E(@-^GFFQ(GJQ_8H#)Q)`&S@10&SD
M8OC0<QOKA\O339YN^V'_9<F:%$O/`HY-Q1DT=_W8T_O\^M&++Q[Y_28<2N"#
MP;O?='K=^`FQ!]$M!@^PX<VM2U>0N"6:;M;)?:-CSV/^2QYJS&PC<I'*1?K*
M%BE8.`2[AF$?+S7)@M@FLWT+3CV?8D`B/D,'-=X2CCPT77#%)?=NW"S@A@ZL
M<K0IQ?KB9EIJL=(1GA^?TE1HR8H;ROC.S[>#K]R^P6@Y"[AU2(D'>#,'UAIM
M-31D;*#B@$](I9@(4UR3HO$BZ)1,E0S>*9[48`!0A@SCL?R<V9S>;7K+C245
MF(&09TJ`(3X:$@;R`I:S5X0%6V*7DN&9Q.F2=`[<'GT[W@P#+A'+#D834O''
M3$PM6#3X<C0B+X=F0#?--",3-L>7P`YB]N29Q04`^ZKGQ->C\15GXIF,3=L'
MCCM1\JO89D-1S#QT.VR:)TB5\H,2&S)@6<T#(L#ZAL/`V<`NC&.EZUN&3=UN
MY%XO]_K]78M8L&8=;S:EE#3X>83Y%#PE#_<$8.!71O>2>-=(BU"9,-,),670
M3PPMS%(%I]@1V7GH$@+-N$OP_2#UUD:.:4^#-"\%MF^?+#ZQQ4?\9F+,F).X
M]V*1H]M$\7`'::9E7.!6XZD21#/PZT+NC/&;U176W.(UP6;A?[PXL$>C$?W,
M<^]#^.P+UB(%=X[IREL">4M0Z2U!^Q1N"6X_*_</MU?_JWRY^>7O#_?*W<?+
MS_)>H)$GA3RH#YL@FN;(!PQ3&?,Y\B*$(JX+Z-3CQY!"YY#"#R(%3R*,[OML
MZCWQLH`D5LO/6O"@,%*"QS'1B2`<E$R41C&9PQ,DDP9=/!UIRGP\'!DW$\!,
MQT@\?GO'?#BVE3-3I"?A`U->YV!B6412)!,@J:(T`4])'UX0#S\W@3@$CU^S
M;R,'G$U,,1!9$B\\[WS^=^3VP03/V3<[((LFF119')9M\23X(1N94<`6K@W(
M"N%Y&I0<BBEGP`@:%YPN2CK-79Z@.[QN<L(:MD,V-^&>/:)E\H6AF0-SD0D)
MTM38DZEA'+NI<7_]"V8C4#+"_<TOGV\^W%Q=PK^O?@7KX]/U%^7F\X?;+Y\N
M'VYNI?G1S/,OD>5:/9BD15)+F'@&Y_O(GE$$CSO9+(X()^'?@)]3BL6"D6\/
M>:G99P^>U"Z4N\R-=,$UL=YOJ7EYT]VP./J4Y.Q+KXW)"LJ0`D(!8P<?RQ>#
M"*I4;O3PNK5P/A9BH@D3B*R'-##">!JHZ9"IDX0_:"1[BN8"+PT101)*21>7
M44]DFXQ!F9Z#I.#7,FUQ+S5D#*^J+#BS?!MCVI?.U`M"JK],PLP\*1TX/H[(
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MAK71+O1)?=YB;1.PVU#,<&Q.;><%&`*O'_HVR`3X?LX%LSN*WPZ$U=!ZKXBZ
MI634TI9X9;/KN#]O6>?<(Q!1<R@Y<F59U>+Y&'5E;[V6Y39Y$IJ_4[M9N=T=
MN="W:54KA7[D0I<K_02$_OUWI[/6F]BJ>KD@MX\5K"Z*X3F5?^?7!3?9D)F*
M`'T45Q=8?V<:;\>3A?Y;>1N[9A_G=1BPQ][.U;Y^B\;/:Q"PI#/D/N?]%RG:
M_8MV=7/IPXAV1</I:GF[EUUS`]%NWJ%Z#0*,\D9`^YRW%.W^1=O>0R_R+43;
MA-YF![-?/OUVH^1LF*R]HF]AK^Q;)>M?!%6KO5Y-1[^=-C$II952JJ8%D)32
M?J5439M`*:43W?&:F>K;A+2)AF20R/2^5ZZ'>V/_)4^&#1!>@-E/E*>#V/-4
MH52<OI7-W!)`IAA#-A]%'BUE;P%/+1:GVN9&)Y3FXTSD>NW+4*9Q'3B-:TLC
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MU/^MHRIW)K(`D=9XMQ`JG$=?4CG[?'G__O*?/REW[Z]NWW)8$P2/7LL+S4E\
M?J(4,N:SS2B0"$,4_B"N!%O%E(7IZT73_V3ZHXF8_^44?AAXD3]B[PB*#OB0
M]/8`'OQ^?_V3<OGN*L.`!4NY`,)$*GR="O]_+Y/^\P[B]!!$H-;ZRV;`O6M@
MXV6A]+XP!Z$E[DP_?'E`UIN\G:.$U$MUR+:\YP!>4?E54>WH>H>PH9)S-0:9
M+SE0BPRK@]+[Y?KCY</U>^7N\LO#[\K#E\O/]Y=7")/WZMOW+:R(QNVE1VG,
M59-/4HEPWOL7RGOSR;:4^POEP9L&HPE3SJXFV-1"0`^]\TP?N[TI[V,@V;=X
M=)DY^-H$]/8C8U80(B0=-\N0"\QW7I3[D)G8?_A?V&:.-U*YC4)@`C?#WJHP
MHN4!GV&W0Z!9W@3=HT%OIM/H"C;*%(CN+!'\!]L/0N4]&R,87,:8$@K1,WY>
M"`;2[^9`]^BSW^P90ZHV&*9@E/>$\81C!=G7+=-4T[4*OK_Z])`^\E8TW5/^
M<1XJUVC'SL`4Y!DWGYCC>P'CG$0L)P3'\Q`Y^4+Y.\IJ/+8=FZ"E1K'=C)WR
M1A/JA?+&Z.BJWNK1&][H_;:J]WLYW#]*!DJD8*4XS;N#;ZG4-9YZV8!"!2!X
MEK9&I/XQXS$3W0YYYZJ,<O#^-Z)'(W9*%GT5J&U@TM3AW.?&CY*T%81?O8%9
MZCJ?<E=M=SHBFPF;LL3LRG"KTCGSUH-%N5%GF7;9,!_7PK6'@_#L*UPU23,^
MY-G;-%=KCO:LJ#/08F\T7>UW#3YOK:_V!MW27C'T4'S1JL3WJW-3666G;F!X
MSK6E1GA'<FPN7>MZ.G.\%P9>#_721L3HX-4;K-)*W<5*[1Z7E7K]Z>[C[>_7
MU\J[Z\_7'VX>7KUQVE2+5*8S'QBQF3H8F(K1TLZ^OE4"$YM`@+F#W1'.\/S&
MP^,M9A[S?GT(/,S$\1+0H>F(5E!@Q/)C'HT,YC_9(Y:VU8O;%2,N)8--+VZC
M3%W]$#`Z9!?*7?P/WLOXA=O,:+LP)9K-]Z@6S?9,S(7F':KQ6Q&S=)0OV+4"
M3OM[3DK<X_<R>H2]'X]F/>DB-36!,3"$UN*=)RC'F@SE-OV;FE;'D\XT<`X0
M;!.-#`[T'&3H3;*]J<T$6@:==&P7Q*WHE0Q]H?SJ\OYXV!`/YX&R0.D1[O7,
MM-%PZ:E:2QAO^+?6XXT<*1L=Z:L<&_5-QU"UCC"1C9XZT%L5(M!NW+-K;=LH
MUTXC&@;LSPAV@6OL?R(-*&E`[6)`]8[+@+K_]=W]]3]_Q1X9U_^"_Y8&5#-/
M\%<<TFNH1!*;RO)F=%HCD'GBOF>;1\'Y7]#BHM_IG&NM\T[K7"ML=9$<2PH_
METBN<:L+LM'H%1:0_QC95MS^D@6X'NU@HCS"R>?#'..("1&2Z?*`!S4>O"G1
M]`1U`1-HY-YHA"&9<2AZ:@W!6,'W!!/&0L7"8!`V.!ZR,6*4CVT7OK7Y*T/1
MP)=`Y(,@PD;&R[D`9S_=S@;9%NTYXMS8[L"(%W\G=N["OLA<%"ZVX3!'8=S(
M.*4(&Z>)?AXP5.3P<%?:'U15,!#+;6*8;#"A;M4^]FR>*&,P/8,+C"_RWL+X
MG2"6K#1!)!-@]B%96%[T.!&""E)9"NX^,S20L4$RQ9],_`0L;C/@'9;%73PC
M&3U/A'E((S^;V(Z#-V+#-BH@ZQ$V8.643='HC<<M>&],5X90&'BEX`H[+Z?D
M+W\/+BAD-H;@R(%0/GM/W`#4=%7<X2<$Q:/S5W.#]Y^\X9WS(AJ_X!@?8"G"
M4C[_)W8R@6<R2R^8>)$#3'7`>B!')@H8#XH63I3C[KN<B2_P]H`T:MGTXA41
M"T44;`8L+'T+[S0S`^7#PA)+MDR108A7=F!F&EF.L3OBI+"1)95=40TT;*PF
M;+-PBE*+:-$2GL<:P)T+SN_,K_P^#7[_V?.?8:M5X8QQ770@1W`NC;`99/Q.
M[(3D4$<6\(7I/BUXP2]A-E$@]G'F@./I%]Q>?8)?;'@'!B?*>,Q=V=QV^`('
M#7K"2-?<-8+>NE!N7>5V%'KXH=Y74[Z,J3(<&?*(-SW\#$WVEV1'O#]OI]&8
M^^NKQ!V?>7B%A)L2[JRF:-?)PRUOM)8*.HK_P:T,3S;8"+.W+B/82DWXRK&G
M=LA/S+>\5S>1=>>S\^MDMI?8BY2H^NQ=*%INQ^_$4Z)[.SBB2^:#C3CAV$A9
MF#LV1-S@0EE#IXIO:Y4G3X18V#?FC^R`K`>PY*@?JA=GBBD.TNF"R##NY-%@
M20_1.SB*Z/LQ+$EJ1$XF58;5`:Q._F$U.I6.$O<5`VIS;W^CM_LDQS.11<7P
M([4/GXC))3=EU&`=#CL*'F5N\N#(]1>:S+[=,`^K+*B2C;R\,P,[N!U?)B;I
M'?8=>^'_O8\P3/-C+T>=;95-!$>*[?%+8=GH8GIX+H!3>A+%U;"Y<^[)]&W3
M#><^C6MQEQ^)\XFLL+VY['Q2]-N-LU=IO9Z9;S>-!FW-Q!-B&VT,/-6"S&4Z
M'*H*3,W;91O1N3CW'3E<MC<4LM3S9Q/8;7["=M=>T4Y3O".M2I0JV(=6;"<E
MBE$*AQ`K\@GIZ+9QN!-3/R%@,-S\L('ZE_>LCE_]XJ`C;(PSTQ=11XSIT;4K
M6G"1:T:6C;9M81C"9V.,'>&3&!GAI@5]I<;-9L4%,&\Z:`IB,1TK\LE&=$UL
MA2L:Z)KXE\VC;=[,=BG"!@X8&)]XK8G?^'1Q"8:V2]$9^AF_>BV).F'T96H'
M#C/QT.-N!D%A9:.7:503HR[B5OA#,F1J5"KWR9/<#3C[<'G_[BUO@(M_X@!!
M'"T%#Q%>PBBBF^V(R_L=4_?.7RXO[]X*\SFA+)W?,\ND[,%PO@A9[1Z.I(RW
M3#P2+&)PE;'"%%^/9(E`5(!D>2'P400KQ24PSC8),*<;6"&OLK':-/0LKJZ-
MOOZS<I9]!/AY)7Q$X!4X(N3F)LE\I+1#QES4(W"_`_@A=[^`$[A7I$XK70@7
MZ$;.&$C?9M//N?M(OIB8>"YRS'7807T<.9&50JR9KAO!2PI5,:49I86)M!9&
MA#WP@,.BH.B0.39[$@J.-45II#5#"@G2`M^(HJ^+JR([GR1:B)D!^56AQG(N
MHEP$0(<8I39IKC"#?T<N]Q<33A?^-HX7Q&$*5I#L&,?@%:YA%(T//94\-9`)
M9R\J_"5G[V+4]G\QU,UC!VFT`G<8$6"'\:^_C>"T>:2<$IAW0+5<]]=7I9YH
MZGVNYUCF$BMA65VZ%O[/-3C^3Z:#S)">Z)%ZHJ_;Z1QN['2^,O\2E[FJX'\K
MF=6N*O<3V*;.'QCL43?N$Q.&$>U&'SU@S_PWTB5=UR=HJI=Z`DJ]T:76Z6M:
M,_3J9+U/<FW0H4-G<0(#@E'MV+")HLT7;XSP)]`49:[7I^0SDJU'EK?/1!9Q
M())E;3\IO:(K=7)IP(`E?X>EF_0%W[8SGY!%+?PS8>,C'=P(#5*;$L%_TOSA
M7R_N+Y1'O!]TD<S4GZ`7BCR7@&[#OJ$SBV1^8!8EU+P'<S:P0S@)P'2GF[0<
MWL"']S=7;_E-&:^ITCO\:@T]N=3F1A[98<0-?2S@XJ/B99&/N<IVQI8&5K$7
M4;J5.E6YS(W,<$'BFO/Y,XM<=,S!5N/Y9XQM?J#!>^]\,.>YCY"9$#@Z4_Z^
M'#.X^X%SC:>*DQB:[M?T[>BR;".-?&F6.NCVU5Y?9!EWNEVUV^[M5IXE3GHL
M%LNH+5>EC'L*[Y@PA]Q44F"\9,/AZ3%O2J6&5D[W@"2\*N5N,<^G$G+-K0,2
M*??ZYE9#7+2VN![H(A)]P/2'S\QY6OAE09+6!3=?&C+=]:G.2`GI<$HG061C
M,HY-99'NZH5AD]N=*"#JL9IN3XN*73@>4`B2^XS1AO9JKW0M'S/KE.+"=&%A
MRAO18_5#Y8WH@G,ZDC>B6[`MV0JDRREO01N@E]+IE$YG3;J6;'WQY4V@^.8S
MFI;PC.G`P\#,KS#M\YGOD7="UT"V:P=8[/GH8>4A?F03I@0>^F0KHI6'):64
MXC;R@I!C;L0UH3"@*O[R(K!D63CQP(\"-TFX86<N_)?/0!O^0T84IHLS3(I<
M38TMIF23ATF3RL[',8>B-`-X$HW-4<B3\]`_FC#3RIB=QFJSL\R*S%J:#]B6
M"&S36[S*B7L??4D`./@OI=EY+&;GZ[8P+7G]L9Q#M-J5='G+>PQYC]$<[92)
M==+*K%_]^)Z88HZ)X*CI^W9J+H+%!FR@&."3A[@G`IO$X78>UM[::,=QI#7,
MI+&\:!B.(X<:[O'8^H7RR73-1Y[39"'NWQ2FP$LU".2$PJ"Y'R<1?\QQXI%3
MYT494I;T$.QB%`4XEE3`X<./G#1YC=N?\%`4X-<3&R/]:$(@&!Y,']/'%',V
M<T0Z%J*8/)*QF=0*!Q=*,7>>?<R$<A&+#E01_K"P1,M2(C>>+3R*:6J\#DOT
MP5P8:H8U7EX4P)2R(_(BV]A>)T/9FS+^(OYS2L):&%"@J-`M%9_3$`%2@I!`
MX6P8V'U1"!X8BX0Y4DOFUW$<&A/0HY"R#.-BZ32&W6XIEOD"C"$8&A`[O70"
MJP1SQ-ST=0NSS=CNG=6V^UIV>=:0O_,QAS!\0;B3$%%0_HSL&6J:#"%+6_YH
M-N/4EF?2EE_.H7C!JP03%?+,R7C12[M>VO4'UU09*I9&?'WY218#<W)$,,6S
M9&N<)5LCB[?&.-:+I>?XVG,D041YT5SFQAQE(:55&9C(8(IDF-C6%S7D"#W'
M\5\PE!S;E69`M25)DH.`7&$<()%C#\ZBD(,=Q&"*HEB#<6!K^C-Y5Q0P=`@0
MIB#(OX37L\0OQ^3[860[9+N>\8H>K/5.&J#`3+3!H/TV2>776RU-X/`AYK5`
MX$F2^XE@CF&2LMA*@`WTEMZF0AU\+'D@KBA/*(F'38O/!;(DRU6@<\;,5:!3
M^!NS1]SPY7R,D`!8HD!E,!S'.GF+/45DI$Q!499B/@KX$%3@()`)+Y2/*&X.
MAQ3Y9-&.[6_D>)`$BT>A-)V<2)+\DK2<**<H0QSWB<M8T``O)_-^[H4NAZJ.
MD`.IUE9-!Y<^YA\1*0MI4K&OTEOMJZSK>N0S7,"_(I#02YKV!]N%S?`CNG;R
MSD'Z*4T_;U(_92S]E%4)+/%*5_A2E[Z)]$T.KIW2-Y&^27V^";@.<)3^!Y./
MD\U0F'NGYXW<4-&QRS(UQS&(V`@<$#N,<:OP7B`'^E8&114(3Z`5PX5S8#3;
M16`"="#8,.2PD31K47O158W^@)<.M'6UUQG,XYASYXC_(G5R8EEE.NP(M@:(
M;Q`FEK?HTB-FOS"UU(8.E"Z1,5@+^O'T-QMYK,EC31YKQZYKO"0PM!'G`;%3
M8/<7L(-Q:B3')DPJQL0AA&<7X6?096N"`8'PS;8OX#Y6`&BWNZTBX.S+/,(U
M-0M)1X5/WMO!S`M,PKJANBB*-V3=$AH'CK!QC"@M?HP7U<`-&R;HVX^/C"KK
MGE,D9'X$F+Y/5_&4$(HOH;HEAUXB9@]'>GSS3P&K<?8MA"^)%7(!OTS.G+<N
M(HG@[!#>)Z+:JA00)CV2?(;E@X0&%)_08S9G!<0!)E,<MF8H"!8'_N(T<J?[
M>-5#R*5'T`$!E.S.F0X+U*OYG\:9`+`F"8_3SADY8^S$2.\48<]XF.293`B,
MT%T%-`D/C.*%??*@*E(CS!D&C'T*'>=[RP%1T73&;2[\!I[[-[=K@C@S!!<&
MCW\Z@1?K28FQQ$6Q:`.*H82E11UC_+B/L0A4JK"C?"5BW9<,RE(&Q6F=?.`5
M,;=L@.X#,/I?R.?;<8*M=),6]\H@G0S2-?V$2H-TCS)(MYQ#:?=)*G?'3?9?
M\<:>0JMEUC]MA[#B1_`/4?X.CWZQ@Z\RO"?]H(/KM?2#I!]4DZY]R.$#Q-NC
M`((D-`\!ET#04_.H)BI"]A4`4JC%F`=J49?DS(<S\X5_0G`<%!>C`K@X6=6G
MYC#/Y@PL^6+"R7A.<.R!]*070*;)(T=O3/=^<M1$!,R',V`!F:62R7-(BL7Y
MBQ;77UEVN'+8"/`%QN53+X&(X"8^?S=YEZDCHDR9B<\GH\^[MT7-C_1"#S9S
M\'[*#DK()BF49.JJQD%,BXTIE3RE2DW[06'2MC+VS2G#>DF>T$RCDZ><S@/?
MLJH3DSG$FLB2R7.7K,A9V^\"R"N&6`/<K?O&T_)YHL2<TVHE/J_M<RIB]!,*
MWRZ;2V9YI6\)R%>=>PFVLXA$2#ZW#'G,F78TTN&;Q34Z7XF0=7Z3!`T9599G
MG+2GI*Z=BJXM.)59NX+.4W&+QYOU+!X&=I`S/0C*22!.Q]>0%.##>T7X\'GB
M33&4RPV(:(B%/[R%CTE5.P\8U;,B.,R1`HKZ^G`&PF3S4>\LIK+/W$?>)QNC
MCNGKX)Q2L:+))/N0VN2,T%C+XD?C+XJFE64#^S;CSCK,5<Q/&$$<.XZ*N7(5
M96EG(C$.'.ATHXE='-/:,*S$$D#SU`DOJ12SE`!6`9DQH%>Y,8!()[Z`QJBY
M:]E/MH7HS_'$,?;^"$R;<3LQ80<1^B):A$>.Z>./X5O_A7[!O$??G(%]@^>@
M*8\YN?7(8T[JVHGHVF]S;0.H26&,@)^#N4DN,S.=W\3)(CX1O06>3-OA">R8
MYY/6K(+HE"?F6AYMQ&/3GUXHM_AK?H=C!QSW41P=^=\%\!K>,%!T48R)P1M$
M>``/*;IF$S=L,447RM^]9YB<K_(Z`GR+R0^ON'_&B%H5T%F#Z(UX`H34-X3A
M/VS>0X.7+:`[!>=LW%M/L&KUC==:EUAXZV6/1J.?8@_L"W#^'OROR[CSI"RA
ME;=>1[.QI+=>$WGKM3(UG8=<<,4KN.259,W+-'5YC]4<3970.-)&K5_]+AU'
M@2/:?C)#2O2.@5D>7<J/%JGK>?QNGLMD^[E@]6]SW;T7[Z/2-M\4%L@E>U-K
M[#AM7<#EI$\_HW69'9U"-!;#>(6H5&7Y62#8N?68)J[S&'R2K9C)JXLA9&PK
M&^1`.S>]G,!;`'Y9D"$J[2"6X/S$U9>B=4+:WQJFB_3$F>]SU`B('[P!R*;,
M!9["FV0%<4,SXK=`J,PEY2UG]CS8#L&]LPES`TX;0>^<8:3GK:I@=J63-J@C
MKX/FD5Z6E3/SC%T\7G`4'Y[3AHW884=P!"4$<13?AYP3L3PI$#P.)QDS1R\Z
M"X(8T92<=!W8:WDCLO&%_$EZ>%$YL6<@A/`91;,&<]S,SV$HTAMX;<BF09KT
ME[R41P-5L&S#B9)T=5OR`M%43]=Z/R.KV2QI9D?_`__]Z*%>$.`3WO4QJD>8
M6P&$@U^@5=YXC/S%`3*ZDF9,@GCR$UI]I_0_/V[D*643"K^`-^A&[`O?/W"B
MTJV2;M71G(6I6V5+MVHYA\1*5S)+73I3TIDZN'[*Z+[TG.J+[B>.$A:%T'Y8
MD!IV'X+]G&U9_2YR0-8V-KR]?/<6K+$+(,Q0E=A2U%N%VVO\K?8S6'&7[^+?
MI>E<%'0?TVVT;]/%`F\VAAVTV=CS,U0&&1^/')N`)5CU]ENTW8/().^`/:%W
M,HH;'\/T?!_MS$PQDZK8\!N+81&4_P)^$=CY(U&V"W:]J#7.MXEV+5Y?9>-/
MJ3@:[!;F9XQENN'G4)T".P?A>X2GE62$V4]O8_35V'N@R9F!AP_Q\AY?7)TO
MBBM3X$/W'Q.!Q'/&F4'^FH?)<:%O#V&E^<%;NAW)Y!#@.\"'CB]%Z.X_M$-!
M']V&4)58@%EK09!48"7WYF[*NO@[;SKU7)$5YH/[A656F(P9DX2BV&+6<=5W
MT>RY#/CW-G7%PFT#AEAY`;/2Z$\N7ZYYC;5T#X[?/<A9_J^M7]/9OZ5[L)Q#
M8J5+]T"Z!XW23^D>2/>@KHL5BXY2JCY/\6<$S(S%8^0QNDU<XH%5]0FD8P8I
MAYH"H&_!'Z/8L!B>&^)HL46\$`1A\S.OCG%M!)@0OZ)XH_?4CL&[Z;[1.FK?
M,/+`/#YCY_RE`D,3"]?AMR4=>1>;\*I\[)ZN=MH"H,?0U0$\GWF/BYS>Z34P
MU]3V!CL:/O-FPC6)YYWE.N\T('ANBML-&"$._L],3*'E\EH1'U]IS.:A,/&.
MY<'\)@U>:?`>S1:6&KQ?I<&[*LV(+E%AA<N&6]+2;8!B2DM76KHU@E]FJJ9%
M/DF(6^&:I=(]H[!4>F%3Y?70R?=S2DZ?<0LY'Q-_S@9!387L/R`6*,PDG6!3
M5DI%P3ED'F%IM3%\X;-QY%II03)693.*="\9K1`<"Y_GJ1P\28E-9YZ/>$^8
M*,]\C+D+'"\L-H9AGDW?2L+'H$=$7XSOF;:JI9AO7'9@DVM`Z?Z._16KV2CK
M'^N^B#,\;RHS`X%6]6R#43R,A\VT`DB)YW5X7$+4!7>#:<79.4//^YH=(S_L
M!5V:^&A&$)1GMF@MJ7NW**$(`=HHK297$%<RNXL2%3S76LK(@04VMN,4M#S:
M7$ZSAR_8VRP8^?:0,+L4A'N;1M-8U40G!'ADXCF6N#XA*F9>P+^=1H@>P=+[
M&8Y.FDF_B_.^,G6'H$.B$/_&%7WK@$/(8:#5#WCI.H*>49H2+\Q`#:$=T!RE
M0&=@\V)!'O_@F9[#X2(G%/7T0*H7A31E4*+(%:65].(8.H#$@L,G$!)>FOEE
M1I8M,JS8-Q.O;?C+1!H991@A^$!\VW4O[A\H.8IG09G?B+E1./'BFOW?A![$
MN'P\?2MF*@C._(I-YGBMRMAVA.QA,XQ\-_-[<:'"A&Q<+YUB3DP!O^9"=Q%8
MN^B:H@\*Y.'J>&:+=9XI9IU8I_R.AA`]0JR@!`T!G@>B5H8ODP3&-TAWCFSR
MEJ:M`P57['-F_=+["1#U#K$($?8#_%F2T"WEJ%VZU@V5Z8*GC6T?)!Z<=%D;
M;XND+JLC7=;E'+H/83,XI\6O9%>_=%^E^WIP)97NJW1?#^.^!K0M<GSF469;
M7->5U?I%KFQV@SVGG7=QS\VA?:7W0(DO&Y'WEWJRH`GGE.F?(S/N#S$_%W!B
MIZ*4.^G$9MK^.=61B&=X3PI>Z9('PR+`8AI.\7@%PZ./*"&8[$4I7:E_ZZ6%
M//A+_ESZTG>."33=C\`KPO(</ABF>N$#4\]BSJ+?EQ2#%,YTQHUVD:Q5*C]L
M&-%5VX8NKJ/406]/MUY:3^WKXG9-UU6]6_&M5ZPCW'/@;B)&(D;H71#>F?!4
MA5N9\ULQ&8WCV9BN\J9UT=*0#"684/<Y3B9)6Y06Q31RM&J\7BS6^D4]'6-^
M&H+"X-O`H0K,)RHIXF234TU>#GQE,8%Z0!$C]@VQKTGMA(C%8"D&09%'S%%W
MQ#=XZQI7P:SVE;;P@[)NU+4H4+IC/HTD;_FDRW0TYU_J,DVER[2<0Y]9J(B@
M]-E'+)=48,7C08[INK3RI?,DG:>#JZMTGJ3S5).N+>Z(,ZI5H!V1VY2)BR`Z
M'EMK>E)Z%V]DBIRIV-RBW9>VW8O4@4J??R#@@@"&RE"9VKJ+=&'C'L0U1.,Q
M\Q-Q7<$9C1=.8$R8CV#(1V2L8P5\9KX!7II@<0@-D]C]O*;"1N_JO>W0Z_9-
MU3)R8KM>F3E@KF,*7/:QK*,7<`&9:)8S?V0'3!3FT`T'@E,FW@1=F0DR!$H!
M?S3NGR?81*,ODN+$,)L+4Q`%+PF6F"@BFD7^:$*.'EUE(OQ8T=N3_E,SWQLQ
M9F6:)$Y>9GC11*9AWKV-)\O3`$NOFU''4"AERL]Q+HP58@WSHU2B<"SI*H3S
M1T3O1_N))Z.Z@6V)/I,<ZZ),\CE@ZRELB"'LC2B%(5[2A?:YA:H,?I$$[I0V
MS>%MFN8[Q]R%/<?:/7,6`)/BO_;I-^_L+`^],/2F67^Y0"3+W$,^`,SMHI,X
MA*M_G5UE(T+_21C(!SP7.\H00XKSW\7"I%?.?2>T/O`<VT(&><@?]Z\_=']8
MV+2.9944V)IYUIW`'A"[X0\4J?U$(=0[.N36PDX;^LJ/I\.$Z\68\;+@0[))
M[F&ARF4NE_D^HFTXGESEAUWEF5#E'@R$'*N'GF.E0??M-I."`>O?7W2B%F]O
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MSES3^GVU;:R__(U*%[^4T!H2:G74?EN7$FJNA+JZVM77WZ*EA.J6T"JGM`H)
MU>^<+IR>][E<K&R6UB(403A1$!?#CB$-!'!$!N,AE\S%$3I*DKFDKE:FJW(7
M::ID^AVUU9+B::IXVE(Z#9:.WM'V+I_2&BG+?BKXH?@T+>E<49.9+=_\-6"W
MX^L$IT=6:\IJS>9G!IVYLEIS.8=^Y6!HR<)>CUVR-E/6,>Q1.65MIJS-K$G7
M'JCDC<U,/P%`*83-P(:QGHM"0.12JI;[Y?+R+@7T@!>8HN-7Z,&_OK(LJB'"
MH`9!-!5Q"@YTR>,+O*\NQPT1#0@H<B%01O&G,62J+8:R[&#D>-B]BM>Y$?HF
MOKGL-V$.;:8,+3/3YG>1'-$/*T:J%(T#%BKI$)>&$!OCGQ8A-GHYQ,:219Y:
MJ7G3,VN4?F;/:<^X.]]S/82GI,EP4U:"C$BS]6CVHM1L]:39N@IDY#G;+3*W
M]*4)*TW8QBCJ6N4XTJJ55FVEZG?C*I_,%X&*A\;9A\O[=XH-%B@8=9E]\QXO
MRP@R_]<968?8+Q=_==X:%(&*Q"#D9,>A_>2;HU"`7UR)9JU!$03$V>7]K_'`
M;U-H/F$[(VX&$!2^Y+$;"2J#S,B,`8J/B$9@O($5$@"?#1D?`Z',8UQ[KF(\
MJ68&)-L(@_'H(5)?MN<N_#KN-!N`_9I2RB'^P1IV0">5J1>(;KX<@)Z3DT6R
M?XQL#M<"WL*O%_<7W$7@7<P0OQXQ20)QKXB`$/EW4=\M6[3+31Y*)H.@>Z;[
M@M"18*I&"&:O$0)B[T*Y-GUL:#N;.3$\#(Z&EYTS;`4<$B0A*,4_(H>THI/1
M"OB5[SU1CP!8AN<OS/1%0P`P8\45:4H-:0DP+$]"7TT!1`0V"'HP0,]+[!X$
M0M5BZ$O/MV$1PBOR8^=YPJGG@"<1CU0QFX/>DYL"*SY&?%2H(\64+G*?DLM;
MT@#12$#@=A9#X\?/HV.6DTH*J.(M0U7$-L:B/UKJG7$@?:ZD!4.C<HEN#4H`
M^R.!^V!;-I%9S=_GN8\>X4`F[^7N&7RF*L.(.G=P%Y`OCGA>,9Z.N`U/%WTL
MB=6.UZ;N50XU?S1A5N2`YQ:7QESRRIC/E.=V.Z8+A^`!3:]]^&?Q#<A1N&H2
M\N(8:^$W5*-55>G%<BPU1C9\^_+!ASP65CED1/5$'KS86ZIQP]6X>DB$$]3B
M_4(65%XE7:IG^4+GTRL//W%.U@A9<.*<E#IY-#JYO\JC'&"!Q"N0>`5),8#$
M*Y!X!:DV2+R"VO`*%@G?QS&V!3%<)?9&S2J\@G4%6K\S_IJDM`*O0`JI"4):
MA5<@I=0$*96?I]7(Y]7C%52@6"N+>>K4J_6(68U7L%J]-N&RE-`6$EJ!5R`E
M='`)K<`KD!(ZM(16.:552&B3(_3[[R1B@=368F+D/M)4R:Q`+)#B.?@V+Z73
M6.FL0BRH^`@N*;NH,B4%L^3L\<O/RGPZ_3[*K5:DKV^7I9<P*TT!64!QV"K5
MLCA7\\H,)OB?ZS\C^\ET,-/STK7N)YX?/C!_>N,^L2"D!%"9N'E*B9OE960[
M)@5L/V!14D!!E5L=20%[VY^:DC)WB9X'26+M`J539$/B>J7JV6Y1@4-G+>;4
MLS#D2CMB%9,KC>;]GHWF%QJO)#+D0I,+K0H-NW%'/C,#)M?:&2PV8L524(%:
MUM;>,Q^U5JM=F+541BHZ.U2]-\(_6.KVE+(BERNW_5ZP/.6N;.`W*\<KRP0L
M&U%7C>Y`;?5[%5.Z*0L:R,F2++JR$?N=EMK2RY-IEJ?55<"`3C5\W(R^ZOFH
MJ5T--+)3?N-=,2>;EK.8W!1AV.4<SI"I8J>!E\.8*V6<;5AR3XT$MM6>WMHQ
M7MIL$U7*?)Y`."S[`RGS5R5S3=7;N]Z+-,Y<7DU)P5_WT3#T0M-9J9G[4<%*
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M!`.^@?O;$HMR$VK7,XL_V*X=3.(^>DUQ5M>71,-21@Y*<J>O]HU-KNM/+\HA
M%6>K.HA^6^UTNU)SI.9LFK>FZX;:TZJQ$P^2R[;<FUA*9T%.A):0N3Q];;W!
M*TZXW(^F["$UYI"$]KO&TF#%-@I=14K3WE\@56530@<&^&^=:OPWJ2HGK2IG
M?0W<T/)6156KRI)#LD&9>!<=VSVZ7+SEV7/%&7>B[7;PV0M9\-$#IERZU@?>
M`=Q]_,)&S'Z227BGFH0G\^V.*6%@3;6J]OI\TY<V+__G>-@F\_GD^C\)19;K
M?RNVR7Q!N?Q/08\WS*J3O,OP;J/<S%>0C[CAU?>#;UI,,857J_B)`ZLJ0,V2
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MXH#+JM=94'`D=7S;(^D6_759G7,B,XL/26BO/U#UB@I<91+Z2:L*WG-U5'V@
M2V61RK*R8D$'`Z[5J_:RH9*2A67)^1LGVF?S]=^S,?-]9EUY01A<F3,[A.G]
MAUEW/IN9M@4CD6][&00L#-[;P<CQ@LC?2]*^S-0_)%SN)KEO#74]9/I>TU/0
M9/:NS-Y?[Q6<+<\,C0+<PISM?/N-MH3%5]:R2R2+8N@K/^('*Y*U&\9IN;_+
MC<II*/SK\7!.PL7NF-4H'!:%?9LQ-P`Q82:@1_=R)CDOI6P[A7S@G?.S];:A
M=I>T1)+YV1O)8_?\['9;U99@#,GL[)KET=+43NN`\CB>9(A[-HI\.WQ1+#;S
M`GO)SBNO)H_@:M)HJ8-VM2@N\D[[-2B.UE'U_B;]7:7B2,4A6[2C=CN-V'&:
ME0VQ]B36_$N`.2E!-`QW1&Z4J^;PJZ;743L5H=?+_?8U:8YF]-7V0&K.[F+X
M_KM7ISMZ3P6"FZ`[]8,BGV*92!5%(LT@_G@HE6R6;&ZH[S%'[7O$6+"#(&+*
M"#/&7KEJ=`:J;E23+BA77\G%5%<U9.7L?GMRZ6JOYK9G3;C-F*,U!RXS]8"4
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MGY$]F\)\DJ?WTYYZZ"LCQPR"O_Y@SF8.`R:&S!]-3/>1G;OLV;%=]@-'!2$9
M2(@LV<Q:PJ4L!_W8*[C'\<!;'8X-KQ"N2J[/8U!,N3YIWK(9M%R>3=3+IJ&'
M'8X3$@UL1QB=CR:L+#/T_!?"`0,Q1&-S%$8^/*NPV+<KY=TI0%#M#`G65KLM
M7>VNT2)8@H+5`T+55CNZKAK=\M",A`6K5R+]EJHOZ11U$JA@&*"QQR\;D/LN
MLAW\G/9>>SKSO2>&^^UKKYLQU$YOH/8[U32CD#?!Q</KZJ`+7!Y4@R`DN5P\
MO`;6P0`X72^7FU%9,T?M[7AL8Q_ZR'=M,#$9;7NKC<S7H2<=6(N=[E[ZA<JU
M&)\KO1:L1LGC??)XT(?-KIKTVR89=YO2NL_PQY7GPN?1B*JN;5<!N_'19P%9
MC4%$T8XSC4=$Q#\78R*O5T%[[;ZJ]Z5I63V/L]G#FJKC9MN3?-YKJ7:GK:OM
M)9&G'4BON5A[APCL1[`CZP_ORM*+ZDCNZ6J_(KOL6*_1I.)L0W*GI;9:LMA+
M*L[&*,"-V7&:Z+UL7!81IX6JR@P30_.1'54!DH/7'M3&\$Y;U082!F^?7$;?
MKJUVV]5D94LNEP6U]1[I\S'%>6J%B\JBY%ELYK.132AYTFHX9JOAS,#XL=KI
M5UM*MERRV^#129UIDLX81D<=]*LY^*7.O`:=T;J:VAET#Z@Q37!+]E/"O<)7
M<=DV5]&R$O.0A!KJH--1NZL:?\NR7:DLF!W:;_?4KE%M]$<JRTDJBZ9J6D\=
M5)284WV5-_YK+R4>239K[#VWZ/_V4@Q-Q@)]QC+/S9=!;UKN'+.GRCR,[[];
M*$2)4RSR8BM-O*B^,$<*:%F=4'%"#%4X*G&!GQ+7]:D(7E"86T-?V`&&<^"'
MIC),4K=A$=/#X<0,E6<3GYS.@+<8^.%U-.&$*6/;#T+ES\CT@><X!%;Y7BB<
MCJ006(GK?]<B9`:CC^R9Z3@O.,H,QK:!83/SA9+(E=![-GV+LZZDLN=BB8+^
M*.`74B")U>`/6:B(^]&$69'#;L>7HQ'X!F%P9[[@O@6_A$_\B%D?;7-H.\`_
M%CS@-\DX%8)(2"P(B04ABUE7E'"NJ5;5;MF;OG28[-PDRU75GI)M&;9)K`FY
M_D]"D>7ZWXIM$LM"+O]3T.,-$1\D[S*\VP@W1&)E%*1TD!>+#C;YE'PV?5T#
M[VS$815+.7<*N`R[(V5@)'4U"H"$R:@'E$'O:&J[7Y[#)4$RZI7'F:ZU54,K
MSQ.I:C)-O.O?9+,-?=-B6QQ2)Y6"V>NK'4.6U^T5(:-EJ'VMWF+FU\;C,[VK
MZMV]),4WL]WLXD:'-R&XS_F>LTUKB5/2!JUMJ$:WFKPWN>)*>&Q@,PS)X[WN
M:EI+[>WGY#@.XXWVM)%CNT@%#!E9-GOM%6#=OFKHK[+\:YN^<EN?()HZJ*@I
MQY%QN;[=K=M6.]I><)2.RV;SO3$+`MMS88\;LU>_P74Z8+Q)EW2O$&:ZJG>D
M1[K?$T35M7JUN`DVW-IUK;3U>=@Q:@M%D45FC2DRZVEJJUMG(6OS[ONEXFRE
M.%U5TZHI_9>*\YH4YZRCMHQJ6VO66M2Z$X;=]D6LLN?P,5:.=;#H7V]`W9A4
ME::K2K^CJ=V>5!6I*BL)/6NW.FJOH@C`.J)<<H06]1K>I>BKN'CL/1N&-U0+
M1U5MR=/[Z3-<<;78DM*NS1(Y]UZO-9?;6J#11-@SPS6`HSG6_@S%.V"F5X[I
MN[816$#S+FGAAV/*?%[X&PUQ3_$_RB?/#Q_-1Z9\]L+RI*@Z6";%\D97.U(L
MC1/+<@=J?_PY2%9[`MQ0<J`_3'S&E"E,91(HS,5'%@KAU\S1WEN:=/4YZJ6Y
M,&K+6)T!O1F9F\Z_@6PLRV4N8^-`;??*.URMR%NN*+M[;TGBM;&QC>G?Y1'Y
MBME8:T_$$N)^9Z9?M@F59ZA5Z756>L=8=B_>4]L;089N3]2QL:;75XW.)KF(
MKX<U6KNC]HU-//V:=X`UDVMVV0/*8V+')LTN>&Q2T0L'Z^MJN[5)7N3K88UF
MM-7V1I?TIV8%E.O%L<FR:ZC]C=+N7X^:][MJ:[#)_<?K88W6::F#WB;9%J=G
M!92G#!R;-+M]=2"/NN(]8*`.Y!Y0L@>@VFQ2TW`45L":&:=C1,S<?$O88]Y7
MX[.\:B30&+35[D:="BH7D)1XK03J*GHEO27Q7BGS-5CZ_7=')O5NNZ<:&P&A
M5R2D_1FH(L&C/?NV=H+'XBRKQM]>(SM'(U&O"]1=+7(P<G'YA>H67#T`#P_,
MPC46?*.U<SD3J\]^JTLNY;=Z.XI#;-E2'IO)H]<!OW!)H\E&+Y+7MOU(/AZ;
MAI[JMB&W\6;)(TF,/,YE\MHV(,G'8]/04]TXY$;>+'FT5;W0(B_M3K?81FIU
M;4]Q)=`M8DY\]EQL0F6&P,P;=^1-V?6W&7,#MK<&4ONK#MI5US;K)75D#:3F
MJ@E6%]VMOY&OKH@KB51N^(HMIK#G>HANPNT:.B/LM0/"TDX'5.-P_@EK'!1>
M2Q;,R6R8;$_9]@=#7_FQ/BJO016L?/._);3MJS6#7#9RV0B%_&R[<M54H]*;
MW%F5G8"'/^TJK@A<:R4?J$9P:=7;`5DH!;=:<"ORHZ7@FBHXN>*.5'#-6'%[
MKZ_N;]]J1YS/-RA.%H2*3;&*4K9MV)!J_=-_YX94*^-P%?0'$^\XP^8/J\N(
M=YW*/*2-E$)>"FUUL`3_MCXIK-D,;',I[+JH]]H,+):"UE*[[:V+P:48JA*#
MIG9;Y4F/^Q)#$Q"ARXXRQ@/N6Y@`NP6$-J1W7P"IW^*B#+6U45%_/3[]2;'8
M4#NK3$W)XIU8;&AJJUT-)*]D<0F+#54SJFW[4V7TL6J<X^4!T]O]]`W8MYXT
MK-KGH"2#D];?29V__^[H[Z:DYFQ#<M>HI=V$U)J3TIJSMMHVJFE7N9Y4RUUB
MJ2]'H"^()5)-^Z8:[X#WW=6IK(@P-<IBMSY0%9>%.RR!PMS>YBV`@P##[X]0
MK:-JVB8EV?4(4FI*\S1%4_6*SU.I*2>I*7I/;76J[=<D->4D-:7=5[OM:EO"
M;27(K:H0-JDKP,H$>S0:97Y^;SHL>/#N87;V&$P[-[R*`I@"\X.]U20<=2$"
MO-Q[#N#MQU230!2-S:GMO,!<X/&A;P,[@67G@J<%E3\K'`F?9[K0HPL+8I.J
MM+DDH$93DMT+XFRG/;B":TYM/L=[9>5`G.Q<EH9\"B)J#B7-5I95^?+'J"L[
M)J[+;?+$-7^-W-UC8W5S*&F\T,OO;XZ-U<VAI/%"ERO]%0J]N2O]<%G_2Z:Y
MQGR<Q>K(6%@YN(8GT[=--YS[-&9X'MEAWD-._.D8(])!$W52]-O82"N(%7!+
MC:B^=&T,*/R=F0Y8N90"ZIJA[;FFH\(_1Q<XK2"B*LLSC=^<BG_2W[E:S)7I
MY+LQ>`_]TO;S^@VZU&U`P)(TOGW.^R]2M/L7[>HZ@,.(MJ3QWGYXNY==>0/1
MKM_-;P,"C`K;)DK1-DJT[:W+1BH5;7UI**_0/OKTVXV2LY&R]I"^A3VT;Y6O
M?Y%5O:ST39*[]K1)2BFME-)N+:NDE.J1TC9-/.A-WW\GY?0:]KS2C(H$"6L>
M07/5Z5F$^)0YD7<\]\M2%`H/>L^?34PW^$DQH]#+&V)!:/HQDQ8R(PJQ-C-I
M#07Y$"MR%TKLE47(L$1@%QW;/3K+*2?[A/@L@%C.0CKJ667,/CX/>$T<8(U#
M93ES4/S@?>2#VBC_B%RF8/1=5>Y,U.G`<Y4K;SHS71O?AL$WY>SSY?W[RW_^
MI-R]O[I]JYBC/R/;9Y:R5MAN1ZRVJI%SU\5^SJRSM8"=G>4(=5L+=LZ\%V+[
M9/JCB9#;Y11^&'B1/V+OF/_(4'[^S/-)$B"[W^^O?U(NWUUE!%?H3^35I`QZ
MKP#W[G]^W#97K2#/[7(T`K\P#+ZP$;.?\.GW$?L`K*HU\RV#QEL9%N,VFDS;
M;Y6ZO`-T>2)OL@PJ2@W4.ZT+0R8'5@37N*'IN$TYTG;6Z?J`8PLWC?M!%ZMT
M91?-]-`HJY>!XHU)-L,E6_?)LR%)ATL5MMVBWJZ=M9AST,6SW2MJQP@L?&4M
MJSA1\MA"B1OX9J3-._GN`4IP"T[O/:E@D#M.-ZPP61(BKVQAUG;3KU_TUT,4
MV_P>)SOTEBQ>_V5%;UN[%&?]*Z+=Y[3ZKF^?(JE3(+N*PRA/=:MJ/H>[G6O&
M-E/YA5GEMO?>]'07S=170"57O3.\$JY64P:]WR6^"HUK.R(?KNZ5=[87C&SF
MCG#E?@RMBU>N#EHU%:QRD=5WG/S?#0Z)BKFS^F;L$'')BB/LNT4E]Q]%6*M!
MS1XB*E(TRT13[";6=K&UX@XQO>X[A0NBQ1E+W3^4[O_?RRE>D2EV`),-`B6<
MF"Z,_9<"&:4>3H),4=U]6W)[=ST>LU%X.WYO.U%H/['[$+Z]G:%Z!867<FUQ
M*1<Y>/EFE%S*I9__H$2NS8<()J;/@A\4BXU0/8.__G#S^<,/?^OU>X.^F-PR
M<K:G.7^16`7-K;W2F^?Q&A>?*^G5VEVM9]3(Y$J(UHU.:[`FT3%JRZ4;VE;\
M#!O!EAK"H7'];>1$%K-P=>!)$H6T@]Z.KTW?A5TEN&/^/5(AUF<]FM_OP/:8
M`LY40GH]O*A^1>D=[5B94?UR/4X^5+\#M/>C$OP<Q<_>F0&S\%?,#>AG[]G(
M9_`A6(KB?SG6TT<O"-XQ,%\8__>#^>T]"T:^33M0-6OD;Q\3D^!-ZZ*EQ0=^
MA80>:O;K)._4,_M$F2P*L`6@(0+'J^I-_]?[]UF%AAEJG;YA9/1Y@80M"-QA
M)UXDT-`'6J=B`G?8'1<)U'L=HVH"=]BV%@GLZ9WV8%T"K\Q@\N']S=6-&T3@
MNBW96B^#/V['A=1LQT8T/#([:R$A64K?LV%X$P21Z8[8E1>$Y29@6_L#%B?0
MTAJ4T-A:D\:NT<]P<H&"[<BK3-!M4,5UR?OU_A</],"=@JN;'ER7X97I^R^@
M&O\RG:A8-X7<8Y[.K^^"SY<2W>EVN^U>2O5:A%4ZDZHT6!MT^^`X[C"5.Q_A
M',.7.P?<Y$O7NOXSLF?XZU\#-HZ<C_:XFNWBC](7O7MY>)FQRV]V\,>[R'8P
MMGPSG?DP#?PV^$3I,#_\[4YK_9[.<PVR&S_+2\NR\3Q.9JAW3F2&W`!E?O)=
M,L7VB<R0L%`O@X!E%/14I%?Z#$T:'Q-S_N.+Z3[RWWRR77L:324OD!?FMQPO
M=MFXT"3!_^!C3Z:#&R+\Z'[B^>$#\Z<W[A,+0MHGZS@XV^WVH*7W\Q;3>N15
M/ZFJSM"NUA^TLF?H9I,B]PP?AV?F?I7\!+[ZZ+F/AY!8O]TAB6U/YOXF69D$
MN[TN2;""2<:N=.I:KZV7E1K6FM[FD<`-J%HRB6*F;++J*IV=CC'?SJ!T=AN1
MNV3:ZRIDI9,['RP3W&;*MYXRA_7+S]`VE]\*LK-'!'[LAI[_\L5\_F3"@S:\
MNI8-L]4ULM&I0D)VHK2J7:_=[G7:_6TH_<WSO]ZX8(F,,-98!U,[G5XV8%5,
MR6ZT5L56H]MO94,:&]#Z`8S@8,*L7SS/JH6O.ISNW6X!K3E*=J.U*KYV^GVC
MMQFI\[M*5K'OS-%7\Q&\Z.03/!VBV<RQ61`/#G_6$`+36H/<AE$%V4N.A)P>
MUCI3#8T2HW33+R-LR5QRPJ]U+N>Z;O2T\A.LC+)<9'TA\^07WPN"J\CWV?((
M=E4;`)B(QF"0O1Q<2E(UQ%>U(_1@]\IN"1O0[CC>,\:8/WC^>R\:AN`Y+_ZZ
M1CF<:UTMNPEL1.!>9E:5D&!F@TZ_BIDM//29U2*;0;_?&W27J1D0LA.EE2V(
M;K>3O>Q922D%H=)O:[$YM*Z1Y>8\"=N25]F=GM[5.\O)*]GQ2[:?6HXBS3#:
MI4=1"6&;;QN\^<K\"VJ88*^[\=Y83.MR^W!QE%J$I^NMWC+[;Y&L]:8!EN%:
M*ZC2^70U?;#.9`J(6UCZ=SZ;F;8EKOSK-(O:;4T;S.T"A=3L3G-E&U?;Z&9#
MZ^O1+.YX7]ZSF1?8]3"WH_<S%N<<!5L25YGWWAJTM;6(>\_&#-AI@:&?9"O4
M9)$LY'044K(CL97Y[0/=Z&]$+&P1T31RP,'%%!H_M/\CDM46?UF3P=++&U7K
M4K>'2566^-'O=-H[3THL"WZ/78<L^@.]E=6ES.NWHJLJ=JY)5WX[CH_`^MBG
M=7OM[/&\C)XJZ*XL5*UWJ.YB4[H7S8_\+VL(><&3K:4&49ZBY=3/'4>U^!:=
M;D=;1O\\3<MG0((2=L@2_:GX*K2G=5O+YK!(5:F?%V<HUI4@>2XR)-<@II3F
MDMW]=ESW9,#1*0O_KDGC&MI5W^)8K5,;+(K/GCNJ=UVT6]U^9^44YNE:$@$1
M6UEL-11NS_`K)Z+LQ8R4:]@#.KT^WB!637E6L)_,T<1VF?^23<LJCP%5?D>J
MZT8W(\]R<G8GNK*#O=O2N]G[A_6(CC-@,8J0S?6MC=GZH#OH#S+GXE***B&]
M,@^WTQOT._H6I'^(?!@V\G%=?+"_X5_U<=SHM;K9,%DI,3M37)GCVQUTNIM2
M#+0$H1^-<&^AN]!'>*HV+BNV]=<?;D(V_4,CLZG5[64490EM%4RA(K:G4VC_
M\+=>NZ_W-Y_!1].U:JDCR9</X6LW(:.R:R.]GUU9\V249AS7MO9!B.UNNY/U
M_Y:15`WQ57$7-H&V-NAO0WS&)@9#TH=1151FYC#\`WZ<M45*!Z[E!MLPC,Z@
MWR^,*>U$?=T<J>SFVX`#J],W]LN1Y=ITJ!L[.#M0[]=5^M67=0>;YEI5'I],
M-QJ;HY"0ASZ8(]NQPQ=1O[%T8VOI^MK;VK$S:4EQWO*896LPZ&JOA4NWX[$]
M8O.%;\OS4P;9Z-9ILZ?8@EO-I=0L-&!G[K3U]N#5\`P-NC7T2,^;@;ORI*K#
M[F!))UI7Z\SE?>UQ0DE8K?1W+CL8+S1-ZPVZ<8'4YA069<?=F2^8]9$-O=<2
MN>EH[7[^YK.,G`JHKBQ.!NSO[$KT@V]:=6;1Z"VCKQ7D%A>04P'5E=V,]_H=
M0]^&:C]B%CSE>X[S8'YCM>9Q&QVME]^K2JC9G>;*&-TVC.[:--/.(QZY<FP7
M,;WOP\@J2_:O/"-,&R3W!\5D[$!E986L?2.IU2TG<I[AOC<&&XJP73^P6M76
M`/>GM:@!Q0150WIET=V.T=6W(9W?*.4W%30=^``?;7.(WF--:MWK:EKF,%R;
MMLHG5%DL4VME<X6WFM`ZS]>X2/H=K=LK*'-9@[P]S*JR]6-T!OKNLRJXM`;;
M%`QP]_'*G-FAZ=20U0`GF98KI%U%TWKYVUF+HXY,GZ[>73J+(KI6S@1%>&\Z
M9DU5>5JKES4Y5Y*TO)YCW6.\VCETVV#,+:OF6&9\E/Y@_FBJP6MLZYJ^:A[S
M9*V1*;/U65.MF#HM8VEBWT9GSXK2G86?BPR56A+06IU>IQR/8B6)N2M-`5Z!
M25V?S%#`RWUA,_.%XL&WXSO?=D?VS'2^L*F)L/;^[?B#'8"F_\Y,OQY<!$/+
MF!"[DMS`Z?]!.7442,77\BL,SP\?S4>V5DC>:!GM5\>ASU[(DK//>V>Z7]?B
MU:#=TP[.JQOW"_C48(#@&`_/7CW^?:=OM+::^CRYS9KUKLNGTVOWM]M@CH\O
MVRT:S-7L-H=#$Y_5@\9JM-O=*C0#"6[:S'==-5VM58E.'`MOMELY?;W=ZC>(
M2Q^\J!:C#:ML>MO9)`OT-FS>.R\<H]^K8.$<"6>V7#9=4)\&\<A^JN?`Z?0'
MK4X%\P9Z&S;OG5<-@KJ^&LYLN6H&@TI6304\NAR'S*]SZ>C==L_H[CC['-5-
M9,&NJ\@8M+N#'0^?HV32=@M*!P^@MV6XH)Q?%+A[\$+3R00=<41QGW*'24N4
MOQ2_3GQ24VGW8-"-P8NVH;()4]QUG?1.E0E;K@.JC&GMR(\4CB%+EEA&+^_-
MD%7=?:N(`Q]ME]V.KWQFV4D;BX<)4][`'%68I`)KEBG>6!G1(]C3U'PR;8?@
MITSLC\HL9BE8"S2!?PX9<Q6@C;GX:3CQO>AQHGPR7Y2VIF*[VRX]"J,`?]@S
M'\5U(]-Q7A2\D6`F[@\7<SUW5K&GG)_(]#4Z5K5*F-=:;PW=NBSMAY!M#K%(
MS,ZD[KC<'YZ]M"-+:VU2"?>460$VX(M;(-V.LP=`G5Q>`1J:+UQ;37KE$ZU,
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M$[L9@[-!>40;=`#=DTXO,9I64%W5Q/8DR&4._.J)%=E160]QZ8[,G;"-5E]!
M6'>)19>EI-R)R#A%M^-_@7;BX\BO=V9@5Y./M:X;^=].^+-E/_WW8_AS+#@%
M/%G3?5&&GN][SXCJHIB/I@UCT7$SYVL^>Y%CX:GT).:AF/RYB?TXX>>1<:%W
M_J+,X!_H14X5SZ<'/)>=3V%Z$^7CS;O;+\K,B0*E?9%]]`+)^U'05^8%+>=F
M$M5(E2J85U%Q`*YSFN_8UKE#[7+6I6=GVBMM2:UU>WJW1N(K;5?=T9(\TOH9
MO_,56\<8;$9\<B)FEGP,*E!]OWA3>9YX&!SRGEUPG()H&-B6;?HON/H?WBL<
M^]4V'>47WXMF*CQNCR84IE*FD1/"UWR;5X:F^U5YMF%/,&<SW_L&3`@9#/QF
M8!C*$.Q?)-J&_8GCVV&8"GL-*[JN3,6W(\<FL3Q[OF,]VQ;+V`?+N9'/&^;,
MY<WK*0]W_[O#>7N@90J""FC8AL1*-X%S3>OFH>8KH;'2M7YN&%UMSVS<O<B@
MVS8VIE'D0]>ECE@26D!DEHJMJ*Q6(PU#,_I[H+):G=0ZK?[^>;GSRM%:[<'Z
M5,;HGEY<G/0+VHD?O:"LK*!2_>P:\V5Z):3L1'*ERMIM#?0::*Y4=0VC/]\3
M8O]\WKGBI&W,=PA:@^CL(WPK7H;R7:DR@WV:I;B4DNW)K521V_UNN[U7<BO5
M80WL?ZU&[NZ:&=3+]?]<B]SK\9B-T#'@3SR8W]`Q0/)L-X(?B@)2SZU\9YZ/
MS.D8F<MBC:Q/6H43VD'="R>45?>#3&B'!5$X(>/0$]IAR>QI0C%X-SS.`;N3
MJFL\*ZY,WW\9>_ZSZ5O!/=Z@4-+(J*1`?/,:_C\28B^C<.)A#@4%[G+O^D?D
MVX%E$WS96L5C>CY<N>T<M^33>YA0$-JC/;,H?LT5QHG]=8`3M5YG:\;$;\OR
M!'[&(PO9)U?%6C[\OF23*D)Y^!OL_+;/,`:BM_1>DKVCM[+NY"I::J=[6\W.
M3[>?G:YVA-,MUM+\)`<5R/2C/:)F;:4M.<19<CL*@?!6R82RGW\P;?]?IA.Q
M=R^T.*X<,PC$?8_%QC:L,^9@4@&XC*;[:&,9-RVB==`GNYT\B'6&^AP4.[WE
M8]%;>*'K7&,%?K^M513DS.>,;4E+IDX?;[IX`BX&3=^9#F8"):FX2Z[I-MXS
MEA=[9;(DUR/J$',0"XJV"WPA[A>4M<DU,*:#/[7.Y@_NUC;S+CTK"E=G\`MS
MX0AQWD6![;*:VDJL.N[7HC3GR9<>@[@A<#'$_51K@;PW!KD9;D+?:NOU"X,I
MX-4`_3!A5E`>@=MA/1:;L:U59NQ2&I/E*8""R%6TJ&M$/?!9>C]=604T)/01
MM;=#QWY<XB-47G*CI<3-$Y#;V-S0\U_N?,_B0,&UX%GUNOD]:8Z&?(>,Z=1S
M[T-O]/5?'BK_%_MQ4M5EY-]P%Z2K>SC!,,',1,OD+_@!5EX&^-:WV988A;3,
M-?3`;!SN<GVQ@Z]I>D[Q^;QI..*/A3>\>WG'W-%D:OI?N:EI.ECV`ER-L(<Y
M/R3^^&3^V_.O(IC2E/G<H/D`<[8?W>3#E9E(M&JSX:5ELZV7*\F!&6_L]^R1
MSCF>9/AL_XN%8)FXIO]R'\UFS@O(<F:ZB_[3XIQ3..P.SE]O']_\+UV<S=^9
MZ803NNJ([Z%AM]V(`ST*$!E-Y$!UZ^)7M'@MXFCP'MP![*_UCK$Q.`#P'"*A
MK;=2^G7P:=/HW^'WCSK6S\9<J67_&-#^H1_?_"O;/[06;2"])K*@@1M(':JR
M<1+_H3>05K>)7*EE`]&TVG:0BAE0W0["[Z@&361!`W>03NT[[1'L(`<P01JS
M@[1I!ZG#AZN8`=7M(%108S22!0W<01JY5K;CT\I]H;7^7..^$83GRPM-L1SC
M?<2P/.8>-B5[;(],-TS$4M7%<#W[!(]U=-,&&>M/M,GLJ6X7Z=(NTCE)!OGA
M1V=#=E!D*`GJ'I@=FU3VU;.<N.O?$&VICCV5+2<]"0R<((/674["--V.`_'!
M)0X]?/0+HPY\=T#`>C#_.^;*ZOVVWL_$=DI)J8K>71.^.[K>VI3>1<'DGZVS
MDUF_-]=T<1W**IY,9?B:>K]K[#29S`,O#[[I!B;=)L:]%5"LF8^#W^QPDOU)
M#441[4XGJVT[D5OOS'=&KLL&K2J8.>V1U].9X[TP=F\^8?4V]MBLON;SUF4*
M56^+C7GY2^=R9VQ,LF$N_!'B@W'VR8T[]ORI62&5E]$C'`:(::8KSTR9F$]`
MM1F.)LQ2M!:_TL9:]+'MPV-M^C<S1Q.%B>G\GT`)L,\/`I^9A*R&A/GV,`H1
M.\VC7^,<J!:UDX[H`L&*OL.`.7BU-3BVG,7BS^#.M(N1C:HM9NEI6F\9_5ER
M=B2\TJW(Z`WT5DV$5UO@TM-:^D$XOFO2BZ%UME*5N\@?3<R`W=(&$V"'ZK6,
MBTZ)<9&U7:-AP/Z,X!R]QB2<I`OVW.<BRO21/9K.M1O&2;Y`-!#[M<C4+[`-
MV_T\F,CBK'*)O?#ON4=6;>VY5-\#S/YO[U.HJK$7^>$DCU6E=53**GKGF;Z%
M'[VW?38*/7!%GCRQ)[)OS!_9`<)0*AZ?*GQJCOZ,,&_:0=&[S/2'+_@Q#L:`
M%,Q$4A#+D[X?BWI_H,%73&4&0P/1IJ,$=LC$AY],.`1NH_"_S>GLY__2>L;/
MRBS-`,N-\`8$1]";9PXF=N+DX",5A!D3*/!U^3;_;`;P`:RGY;A=6N=M9MM?
M+NRL6E#N%:(),HMSFZ<;4\+V9_9,WQ0[#MQ7^D/O%BN(WB_XO,;E(2"/,@MD
MK:FNC7`5P\74!&2V%"RQ&.`J5\>Z\5SVSX@]("`6,T(WU@4\*V$$L.+_.S]7
M/GA>Z,+J5^X97]?GY\@EQW:__C06WWV$?RC?Z*,0M/NO/S"!EON#^-3W'/AT
M$H:SGW[\\?GY^>+;T'<N//_Q1[W5:O^(7_^(#_Z0#.UXH]R(#F:P>WX\X,3'
MF?\7CXK%'SKFD#GPJ#G\0WSQXP*IEWY^7-,?Q3^'/U?0*9[X$;:V\#P>,?[Y
M&/R-W,OC]WA__2%FXA_Z#XKG6\S_ZP_:12M#W@;3;9=-MWW(Z;;W-5VC;+K&
M(:=K[&NZG;+I=@XYW4[A=+N[3[=7-MW>(:?;*YQN?_?I#LJF.SCD=`?[DJ[6
M*MV:6P?=FUO[$K!6?A@=]C0J/HZJD+%>.F/]H#/6]R;CTA-8.^@1K!6?P57(
MN/00U@YZ"FO%QW`5,BX]A[6#'L3:WDYBK5LZX^Y!9]S=FXQ+C0_MH-:'5FQ^
M:%5,N=0`T0YJ@6A[,T'T4A-$/Z@)HF]F@L2CY8@#9]V+P)F?FV'6'5G?_<[0
M.W5@*/<1W'CW_-?['_YV&5"<D8TH\A!WO3%4#'A@F(+'!6P7HW^/OBC<#NP`
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MVOPG'^$?]"F^S_X)_QO^^?\#4$L#!!0````(`!2!;$<X]$Q`\`X``"4!`0`5
M`!P`:6-C8RTR,#$U,#DS,%]C86PN>&UL550)``/7_T16U_]$5G5X"P`!!"4.
M```$.0$``.U=;5/<.!+^?E7W'RCV,YF0W-YM4IO;&B"DJ")``;F]^[0E;`WH
M\-BSD@W,_?J3/#:,;;W:'JL]\"G)1"WWTX_4:KVU?OWM:1[M/&#*2!)_V=U_
M]WYW!\=!$I+X]LONC^OCO5]V=W[[YU__\FM$XOL;Q/`.%XC9E]V[-%U\GDP>
M'Q_?/=W0Z%U";R<?WK__."D+[JY*?GYBI%+Z\6-9=G_R[^^G5\$=GJ,]$K,4
MQ<&+E*A&)K?_Z=.G2?Z_O"@CGUDN?YH$*,TA&/7:4980_]HKB^V)G_;V/^Q]
MW'_WQ,)=80.:1/@2SW;RSW].EPO\99>1^2(2:N>_W5$\^[)+@B#@\OL_O__T
M\;V0_ND`10+=U1W&*=O=$17]N#RI:$OF\RS`4?0N2.8346!2%9H(#0(4!5F4
M0SWEWZMH@I]2'(<X+'41=3A](:<Y"2J51L*P":WB*^K,K3=#["8W8<;V;A%:
M3`3N"8Y25OZ26V+O_7YAR9^*G_^8,L:_>IA1BN.T_$"$;G"4?_8/1;G)P&H>
M(G8WC4/QQ]<_,_*`(JX&FZ:'B-(E[R;_0E&&->I;RM?IG=(J0D2#\B/\KPUN
MJRVY*#%AV7R>U[9'4CPOY6<TF6M-7'PW:04DH2&FW)5P3Y(QKF2R$`J@:'?G
M$9/;NY3_U^[0'%[=)32]QG1^$C]@ELZ%XAK*Y,7A,R37NR#D`R1"ID&09%R[
M2QQ@WI)N(GR&4PM7H!6#3Y!>_X*HCY"($BTIYG4ON:(:8JK%X!-1U;<P_-\@
M&?Z"X@4BX=>G!8X9YG[W/+W#U';,M)*&3Y,5C(*]GR&Q=X1GF*L77J.GE;96
M[DTK!9\MK?H%2W\WLC2IQ;C;&?8:X]WA`]TN\;C?=JD<;J6.`E1D>D&3!:;I
M\H*WR)0[.!%9+T3@IA]O]6*`*=$K#C%4/4WB6_NI@[0T8#ZD^D(,1&6#RUD2
M!ZT&U75!P.285(<8MZY%:%;T*,H#9D6AL748NNT!SBE!-R0B*<$6P82LL*_%
MB`NT%%-R/BKQ7VB&PZ9R_/^L6G7[*KTV?#5UJI4,=X`0H[#3!,4EE.OD`,7W
M%BU7+3,2#C4((`9BY6AXB1]PG&'[Z71=8"3TJ-2WCLY>T4!CY905Y7U-*/+N
M=\P;B.AY%E.*6GDHK;AI>M4<HP:@WX&@N><J?OGC)$XQY3.;2Y3BJT>TD-A9
M40Z^?16*6_ON5^0?[+R"!U_02ZP,H)4J^[Y$9Y`18(]CR3CHD,3D;R[C*DV"
M^[LDXN9@8FDR7>J."4@*#WXZ)9G/DSC7Q'@0I5'4:VM5F[IQ\*2A.$0/,@U#
MLM+B`I'P)#Y$"Y*B:$UYW7J!A?!(V+*!`G%Z>8E31&(<?D4T)O$MFP9!-A>F
MQB&?B9&`Z(8#&^&1\&<#!>(&P37%B&5T:>4+985'PH],=?-&P)Z7,UYEP\F7
MS+D'6%!\AV-&'O!)S`=\?)HPL:=Q/KM&3_K55+>:1D*E,ZZW/89F'#N-0Z>H
MS2SJ<>[A-$\%,,_0&E\S^8`9PO43_8^-%EG)3A/"]M<DKE+N"_-#".>S\P6F
M>;7L1XPR'E,*[V1W<<)4S2:N4IB^.7!3_D;YP'%!DYDV;*V4&KRWH0BS8G/C
M6Y*$3'_D25[<:X^3&+G1N:1:0W1^APGC84:NXQ5W!MJ%A%I)Z"0T%#:[M[WA
M`BE@GJ-0(;XM3EWK8A))V<&]"+<E5X"/>-\1O<=KRNA\B4;(:V-6&K_A5S0(
M('J7;SCFR")Q3B2<DYBP5.!\P&:NC)+C(,P(`^::&,/<(N+:WQ$?PZ(D/ZIK
MYLP@-P[&#"`@'<.`.H2\K&'8#"+KI0?W3RWC9>^MN&GBAN=95QKBV-!'Q#$"
M'B2JO\6ANINGI4'%D:'#).:FR[CU7E0[P+.$%NNDU^@)LZ]/?%#E-B4QHLL3
M#B;?Y.:2'%^4<[0Z*Z-I7QO]JK>.U=$/^^I<`S0!92==-P)(IRDV##BVI.95
M=`0K15X=RTI+O'ED=9,[PZF5(ZF5&SYEP78.'+[ZIY3V9D*%#<*'Z'^?@12N
MXX#/[_63!Z7$6-B5J-[-7?:S4:38->^T:V2L<]-;2$8%?(0;[4]P.!S;L`)E
M>=I_Y7-R;R-1SBSB=VKI8'+ME8`*I(%N713^8KI81"1873"SOXIA)3Q6;JS`
M03J0#=DM2?2Q\$9:*2\3N4$\JZ_.8D&2=()F>QP.5%S899(T(H)JZ@,X+R3R
M4AY'R6/'P*]9R\9#O>8GAV^S0HD+FCP0CN-@^8/A\"1^7@N;!BEY,)U/=*GD
MK5-:3<P<2;'KHZ"\Y1'FCB<@N3TTO%2+C9R6*AB(V_[3\+_9*AG4<4*G\X2F
MY'\FBC0R(^=+@PSB/9@R;<3:2MLT%BFD#OF/1)N\S"PZ<BK-`"&FU+JZ0Q0?
M(`Y6!&H\2C/U197`R-E3P8*8`/8;(K$8=L_C(\(6"<NO1)[/C,D_#7(C9]"`
MSIPCUL,U-NXKQ(T[?(17?Y[$+]F[=4P:Y$;.I`%=P>0_@#-9I@'7SVP,<EO'
M9`5=P>0OP)DL,H67`[PT8[@3Q785;AWW=K"+1O$)>*.P25+HU"CL*MRZ1F$'
M^WE]`5(<U@132ZOGQ']#=NNH;B`L634O&PV]%05UV7252KOCLJFTDL&3TZ-E
M;NSK9!K\F1&*E=G;-0!=*H'8G31T-I+;.T`UK\9Z&$*YO@'&87Z&ZSM*,YK#
MS6."%;+\_:\HXMTO?VLJM<Z+W[GFL3>-KO@AKA,WVKOC.VN6\F.GW@ZE>2W9
MLT,05]G/9ZV&`)=:QLZV"U;KU>:WV&I%Q#&)41QTC*VDE?CL62>,92*7TOGL
M"-_8=J2Z$,1^HZ%+UV_JT"#N7%\^C]Q&UII%1\Y5$Y#].7`/X<E*R;)1B60@
M-D&)5&KDQ&FQP0]`1**J\UPK]O4)TX`PK,M38R$[=C[-"$%N:`M51>O#X1&?
M"<6W%YB2),R364IAE*<1BWLG%@E>^OK"R!M(;W8P[[%[NA?I/U25OXN^,G1]
M@55W*-VI&@\G*#T<$?5V(+H%I9+3E]9@(0:X?E:WMY!Q*5B(RWE^YMQ;R+@4
M;*=\41VN2`AST.7Y[(K<QF1&`K$(M=K/%>%`$I&`JW<DDKY'S/K&A%.E&[E`
MX:3!P!WI]YQ0'$X?N*^_Q6?9_`93/N<B4<9_S8\QLO,L92F*0ZZMIC<YUS2T
MSU`HV-#L`#$2N`-5U>/5<[2DM^X\'"$/<G'WZVR&@[3`0AXJ<P0)>Q8R8V;*
M`IZGBV]BU*F-7+)=)3Z^21[X=G3VO7QK$V-`+XIYF"S6=!;)VMWV35TJ&3R-
MM#2LFO(XB=(E[V/&5ZKLY+V'CFXD-C)2VZ&$."]T;*L`M_2[TZ?=P0>1M&%8
MWZB()N2M_%D/^<=584;+RGSXO^$=_-!=J3N],H]H"QFB6[1KR=K26\*DM.B;
M;VRF2*H=O5;$!-;.HY]J8<2+0^R>>.EI/=%N%T^JX`^5`ZR&M%L[AC;Z]<RD
M$^HW;]K2F]:'-/,!]GZKWT"O`C1L@.Z'EM0;^J.C63QY6H=IE:7P:^&W_^"U
M_2)O>0][Z;A@VY#;Q.)KXR.#7^PLOJ]_-;!:;/C;I\77+]'C=\1;)$&1_L:Q
MM+SG]/Q-0S?OD4KUACA/?U;U]X3>B_ON28"U.>%4`N,AI:8XQ*,GS[H>BZ?1
M[G"8/]9HPTI-8#RLU!2'])R8?]^^N40M7F&LN\<+%-RC6Q+?/O\BHLA,I(7&
MK"W>=A_P_?R+F6R+]$.MD'N*SRL>6<^U<PWC(=,96K\CES5;%4_=BBUU#:-G
M2PW-TX''(H-1^<@>JJ0N<IQ)6=6UB=F5U8<'OXJUKE,U)=1A1JGI#KB%M)?<
M^U7-S$AT0EZ[LP-!TGS["DP09W%7.!`I-'B`FF>1U)T_J9<<*T4-()`V`2#Z
MJS4-Q,-B=OVZ6=Y7_N;5)8+5Y5S]&I=2PO\3.2KSJQ(S-R!`=#[3(,CFPJ0X
M7$\'+L.@8<VIEO$PZ00+9-J`PL$:<X;6RHV'HIKBD%:>((XCNC&[9<#K(]W,
M,,$[Q,!*U0^L4$$<@/J,;,9$F`+'6R#LN@Z]>EYM9;\6N;%EXOX7UZNF=P)4
M%P6V*J>FRSJA=SV1!RA_)CGV5IWLNC7/IO`6\=D$!^K)^A'YOY<AI*T+;-;@
MO^?DBK7J-C5)B'U&19FYV]3`]9Q]V7(K23$W?LG&IEPTZ%;=&*GLAKCGA05+
M?MO1N+5L*4BQ2#`XNH'*>B_9YGT5+A5E(A^!X>G%_C\!9/C:P,P$R-'ESO1;
MCG0U$XPCZ-]L5/;*6D#3"IY.L=<>#T+/CP>5KM?Q3(9U?9LXEV']\>&WI(PO
M-)F7>9UJ\;#KMJ[<NINSAU25\AIIM:!,LM>F!@?1Y]<4OJ8HM#APHY7:,@ZK
MX"`>U2\0<GVYJ:+\#64K"I5"6\"@$EN_#X0K9AF%`H>\).%VO$IY[*`^G:HJ
M/58:M*`@9C\OVPM-9IBQ7)UC[-*)5()C9=`6'\1WOE=1>[=W1AWJ&#O%#E#-
MCX$/MUC4?]AOO6"D-%;Y:?N%(8NJ@"P"]/YP+_0NUI5\RT4!QX=\A[UFHW#_
M3NU;7L&H*74%Z^F2E%L0:B^_Q=RIHM6>9@N;\M"%]E<H0L[W4QNRHZ;7`2?$
MB8C1`OEBA"N_D@JVEV0)6(BS%$DX4#Y#<X@6)!7:N413#>$M9;@)U#PKT>UA
MM]]%.4#QO=A/=]PLJ8MM8D^D_HVNL<5UPBV]%I"*NHMIY878#N.MZR677/&+
M*LYH5Y>OW+%"NY?'P==?V;R@)`[(`D67>(X()XB>SXX)XTS^!R.JZ;S=J_;7
MM;LT!%52VO9V@+B?XH#J)+Y,(J[`K4!S_9CTTV::M;ZZYM(T`<1=F]:`N!*Z
M$+!CO:^\M:R,`'':UQ;2<9+U-!Q)JGW=K65E`X@3R=:(R,,F?,NJVE?>6'(;
M0)R+MD$TG:68;JC%U.I^O<VF9HA.^V_M)[KY/D4Y4S_#KA->E?@F)KZJ;PW<
MH<Z2."G7*4YBKATV7X'4R`R_-L6;'6;I2HW<IMK%*$EIK[OB1O,WEYDD$"#.
M+DM%"SRVU%2+CY.;*@:0:4K*4][/`+\A$K/3A,G/!-B)C8LM/99.>4TFXH,W
MB&'^C_\#4$L#!!0````(`!2!;$?R#Q[CX1,``*\Y`0`5`!P`:6-C8RTR,#$U
M,#DS,%]D968N>&UL550)``/7_T16U_]$5G5X"P`!!"4.```$.0$``.U=6W/C
MMA5^[TS_@\=Y]FIE[R;9G6PSDB^I.K+EL;UI^\2!2$A"E@(5@+2M_OH"O,BB
MA!M%4H`V>FD=+0YX/GRXG0N`7WY]G8<GSY!0%.$OI]UW[T]/(/:C`.'IE].O
M3S=G/Y^>_/J/O__MEQ#A;V-`X0D3P/3+Z2R.%Y\[G9>7EW>O8Q*^B\BT<_[^
M_46G*'B:E?S\2E&I],M%4;;;^<_M\-&?P3DX0YC&`/MO4KP:D5SWTZ=/G?1?
M65&*/M-4?ACY($XA:/4ZD9;@_W56%#OC/YUUS\\NNN]>:;#2BY4)XM5GUBOX
MV,G^\?2$MQ<@/HE"^``G)_F?7Q\&VW((QYT`S3MYF0X(0_8IKL3G>+F`7TXI
MFB]"6/PV(W`BQ5@HP%7_R)7^@=?6J:$-^QMBWC7.`C@!21@WJ-MVW0UI&LT!
MPNTHFE5=2\^TBK,YG(\A:5+)4KUU-)PQ98B?C.'9"GB#>HIJKZ,MCN)>HT,F
MKS#5J5!(5SGR?9_5T/WX_M/%^[26QQC$D.&+Z6CR&$?^MUD4!FR6O?XS0?'R
M*P9)@&+(9I5-H%Q!-)\G/@S#=WXT[Z0H3:NKJW4RGP.R9-]`4XPFR`<X[OE^
ME."8K0?W48A\!.D5C`$*Z1-\C1,0&D/8I>Z:>.Y)Q'I;O+P/^<=PP)MKP9LQ
M_XRI[MIZ:NK9!_C;%1Q756M3K%DM*O(KD:ZITX#M1>;P";RNNH:I/@+)NJ,#
M3CGGC/^U+GR9T)A]APSP)"+S=`]24=&JU>X71;<E&-T]XZ@Z6^U6>^WY=TSA
MGPG[\/4SG^RK]B2)>*H5VV0AC+C.0Z9"23FF/,0!7XVR7WEE#2U(J>40^:7/
MA7RO'A'A^IRNS1-`Q^D"G="S*0"+#F^D#@QC6OR2-MO9^VZ^.?\A_]E;J<4P
MP@'[DQ9?"<$8ANFW/7EACUD_'5LJ/X'Q6P]1J9L6]+JYJF^\]DA9:;9%*JK+
M=TN5S(\)B>8F#99_,M)I&Q'60;Z<,HF$,DVB!=>9C\B3;`OVV8]PS+KB=9C*
ML3&3C<'3U;^'$87!E].8)-`B3UD7OXSFBPCS`=![14:]3"3GG;?"HF(+KV!U
MQ92&41D0.<'[YFI#PZN212C@2%C>NVB%&YFAJB!&UN!BGJ1@OCM^O*O"*=$N
M3V771]M$O:&2$K9OOIB.\PBGZ_QMR7$AX&JKK/>A'7Y$CI1M;J2C0<R)4'MW
M!DXO"%#V\7N`@@&^!`L4@U!+BE+.^WA`!&F1Y&1U'6#K@>^_,0RN`<$(3ZF6
M)K&`]^,!\2.'D!-S[@`Q3P0"FI"EV8PF*.W]=$"42/3/^;AP@(^>[R?S)&2K
M:#"*9Y!P:`3.^/K[##-'CGZ*,ZW#^_F`N*N$*F?T@P.,;OL$E";29F'ODTV.
MJMFY(MT=6H0>9X!`.DIB'E_E85T5$9MEO>[[@R%"J+M#B\X=C+,!.XRHRF%0
M*N=UV_'SM$#`MMX.K3"RR9/KRA0?39[`ZWU$TN:-8X+&2<R](4_1/>M5.%;0
M5;-FK]N."Z@%@IM`ZMH2-:`T@<%50G@,$A(4!;^#,('IOXU2W>CU*R0^HF_N
M<=D*5J4NK]N2=ZFE%:XRMISHC^X2G2T8#3&MJ,SK6G6`-$"U#ES.]8_N<BWO
MK,7$U8>8L1-?OR[8U*8.PS3R!:]KU>O2Z@2@0)QWE9\<Z"J]X(^$QFD,\RF2
MN)72GL^S`0.^[C$4:=#W`;*-/D4Q?(3D&?DP:X\'Z$?3C,BT:93NN'8_[76M
MNHRJ=*Z]-$7>ZWZ6];I..3C>0KA\E^0GX_&PG4C`?_&4WQHJ`N05I*M%S&6*
M&K6.+#Y>M8I]1LXKMF1YB.P"[,"#[-)$N_[RB7U;$VHWD+89<-^%3_&D:0C4
MG;B55&&NKC;\:R!M/5AO2$E%/LL`_U)\NA+<;Y_81@/^DB6VGZ"0.T6+'98T
MG*(H;3>0;SA&!$NH'(T[`ZK0<3!?D.@YRZS4AKSD0G9#^CM190;*H<"*%&7J
M)^50]0P:UV$W!Z`6H94P.A2OX;9F$D.RTM<D]4DD83=9H!9W"D2N!7=ZE$*#
M.7.KK-UT@%KL"+$X%&%Y`'BJL]E695H*^>_9,BO!<6BQ2O72YY^]E6HM\F]L
M496:4M'::_JZLY_;I;U=L7@J-[R#&<NWK.GFR5S+0*F<Y62+S=XL;OIMC=WI
M];?@U:S5U\M9SH`P;/4MC1N9W.LYQ+,X06],8P)\48[*[I59RD_8F[]<@+95
M0GD$J[\9P;J"/D_-Y6DT^?^_)=3TX20B<'6(^0I2GZ!4(RG/#7[#4LY"309%
MW:'I1G%GLA5#TV5W;@E82D1HE&H#A`[MQ7O!,S/Y$&40]>DFVX4M!?=;(4R"
MSB4O$*"SFZO!Y0#3A,"@-^=853X@47FO:\4%U`IE<H`.>83X120\8XG?*'89
MT5CE@=@JZW6MN(1:84L,SB$?T=?'WR(V!V#N\WJ$?D)8<T/:BR\!(4L&69=*
M923O=:V<)VF%47/`#J7@2MV<7RF<).$0350<&TA[YU8.JK3"L"E<7=IMZUEM
MVFNQ7.EE0X/;8/3"5FZ'\6<P2$(XFL@C!;I[8PRKL'&CC%FC2S;[%7`=T^+<
M38O;A<^*$^<Q+>Z8%O>=\.E*D.C`TN*:BF_@9,(V;^DIF!O@HQ#%2X-HAU3J
M`%/J#%&Y,RB/J74'EUHWFC`K"IHG7@G+'W#*G!2/2X[1"#-+-O&Y`@/,X$X)
MI/J!I1([Z$0Y-2R'?*-#@`,M36^%#C@_K@S"(:?G+?!GS,`ERW5$OQ'UO2!R
M(;NWY=2QX=68'%J1BJ63,D77ET\=:4HYR[?KU"%.C\NAI>HF(:QQ$P*9LC?H
ME?^E)4XJ8SE)K`YI:DP.+5'BU51'F4+*<HY9'=)TJ!Q:UOAZJ]E36+[WI@X1
M*_4/(:ZF&RMJ0<M7UM1AR0"80]?5K%WO>`47!/HHST];A#!M=,P3+$B,_I?^
M+@6G2B!JZ!.6+ZRITR<:;0*';K"1*GH'53U")6;YYIA61GX!2W<+C`O,I;-4
M=I--D9Q:)*ON/)N+J[.4D];^'*^`F_>`3P[T@*;FI,I]I=T/6\J=<VF54#3,
MRJ'1QAD#J4(8FO>2'6NRE&!7A_8Z2`L>I9ZIUE.O-I_^LY%?F]JEINE5$@D;
M.55E573I4X+2-C*E%.TGGLXD>A]X)E09E2;Q:;NP"WE.$F),6'0O@ZFLWQV8
MZ]-<9"+6<Y7$;6W"2QG$=\J.*YE'S=#D8G81VUQ.P=3@VJ"-DG:SB%1#01+U
MVU;?G3%S%\60WH-E=G4]WV?I^9#*V$T6JLZ,$HA#X=AAA*=/D,PYPEL0YX=@
M'N`"+-,P),\A1MA'"Q`^0`Z9:3Z:W"#J@_"_$"@S'VI6;3?MJ/(VL0FXA]DQ
M!O@A"ID"4P[CZ25JID]LUFHWIZG-[B!"ZE#0?V<D3`F5/5BK7KO)5/OK#056
MAW(*=L5R$R4-+1=;U=K-V]I;;RB@NI2IL"L4]-S&W,"KM9P,MK_>4&!U*(UB
M%RR]20Q)2WVB5+?EA+.]=(QMP(TD:4@B)4]1#,(A`F-^9B5]=V,<7R:$/U)6
MO%^&@P)&_HLL5K)+79:ST8P9K0=0ERBQ[QA)Y6=5CJ&28ZCD&"HYADI<=,8?
M0R4NLW,,E;3,UH!-O`32^`'$\/$%++0>>K'`H05.Y"C<&4B[1[$.+%8B4+_-
M*V17GQMA^<7BDI(NQ2143:M0OQ'/LJYIGUXBPZ9=E73)OV_>M"7U&W'22IJ6
M!Q3S>**Z9;<*NN0JUS:L4'N7_)W,"!I-+@D,D/XVA>W"+CFJ3:9F,8+&'8X4
M^N^FT7,G@(A3\8'_P1GXL,8`^\D;PBD(KW&,XJ7$#!.4:LL?W+P!)E.^\;"P
M:7MG>DCW[YM%6G.P:LTI6<MMM^^6ODUO^-IK6]O&T,Z-O(]W&9\"[J6\`^K%
ML5S*DOM8V`U%#N-M9=VQ3LH36AZ>6%XQ>TK]PD(E><N'G&OZ/U6@',KTV5B:
M()F;>Z998<M'G.OZJ`L$#B7<W)/(AS"@-PQL<>7X:+(>#500I!>V?/ZX,F&&
MB!S*D"FLPV$$,#.^'R!;,FG,9H'L)!3R[[,(+M>?]D$81A$N?HKZ\`'Z$#U#
MU0T0#7W!\B'EREVA2=@.&9658#75*RP?6VZ7^_5#RJ[EQ3!]?:8G@]*'(+WS
M$[W"8-TC;9@$HZ_(\B'B6ADOAN@<NH-$J?WO['^YU=\$SZ*Z+!\<;I9J*<#&
M[PPIK'6$G]EW.-<7^=^<Y8LUEK-?&5""GD',EI&[*/NV]"4CC82EES:J)R\9
MP'#K1I#5=G']%([AGGE=Q#L_K(1!)0Z'KNPH`ULSC4>38N3S$=\'M$*JC;H:
M[_PP,@5WQM;JC1AO8Y]N1L[S79>()U-1[_PPO#R5\&AOMMCC>$N?M^</.1(X
MXT[>9_CV2N<=C$>3)_"J&&<FXM[Y87F!C#$5/+K@&%J/QA4/!9AY6S62WOEA
MN81,X!3$N>`0Z@5_)#3FX&XBLG[WD8(RJ8QW?EA.&S60@B:I'Z;U[/;5"\4\
M)=_*)4"C!22`/W''9Y_T^<%)1%X`"=X>Z59-SWII&QGO<K5TV>\:21N9\(9M
M+%EK]'@./$-^-81Z23R+B#P]0RW@0J:\`5EBEN60W`G:;NNHS<V6B5C/G)>W
MMRD_+F;/-\J0[821YJER,(/^D<<@TI-[/@C_E1!$`Y3>,:]-#]1(VLVI5PT7
M,6L&<-P99PP,L]R1?\E=F$3_])RPO-U$^^H,24$XE(V2H4K[4FI?\"_Q=C79
M3PBE6DK9W^>F0HK+?=X,5R^)7%MG`BIN,J3M7XFT-TCN3(,ML>;6QJ-9^AS<
M@@S2"!U7-M/=X!"?2,#N01'MJ)&Q)8/BSBB[`8C\#L($]I<]2F%\&0)*-2N:
M5*:E(R3[6<^4J!Q*P5SIF6I);R&@"8$!3SOR$\)3%-+(VU<<C2DDSUFNPB*)
MV3]'F/NCT[Z[#E([I;;UR=:N0S)>1)6D:_I)&XWAX,3P770S5U9]M_J;D_N%
MG!L8\G38`8X!GB*&J4"OW3X8R%N^;:O5&42V%3%MEB9F($FJQLHK<(4H#PHP
MT/E]3;TQC0GPA9EJ9I*6K]O:*0A3!9ISYC33^/IUP>8]V(>8-;GJX(=$PM(1
MJBK-KG$""_"XLX)?3R;0CU?I(TQ=G@UT&6'63Q/65?,^&V'57M^\$DN'K>JS
M61&B0R-1K'EYF2BYOM?R"2IS;E:MI1-<;?6""J`=,A'9M@X2MJ/@#OAT?9<O
M3R5(RH36W:JT=(RK?G^H!=BA`W\5<!0QF&:Z05&;I<-<>^T!):P.G=YCJF>9
MB.O:FJ5EZD0MG=^J3ZL1,)?.YR&?[S$O(RK,9!<5LW3@JCXW6R`<.D)WDYK/
M0Y'YG#V:PJ^X7G\[-#W[V550MF.-E@YGU6>W#MY&3M=)_1)%G(:.7C`,^B#D
M!_E7-YC+3]&92ULZK[4[:56Q.73,;FOA%D[Y]#=FM1,0]A.*,*3JTUR[5&CI
M7%<+&Q]SN`Z=Y)/OUKCO-0NVAV'TPCOT3AG?V]58.BU6G_'*()LYTK<_+\BJ
M!]/T=%5-Y\=&;98.F.W'YR'":O]I[,?LC`$SNA_1%*,)\@&.+Q,:,QAD@%GO
MG></NULY-9-=H?9O%+#&?(8X@;?@CX@4^@T-3LX8UF#C],RC/X-!$L+19$O)
M_K*D)NTO'^"";^CP-&=,>\*F@=IMG,*IP)=X+#:$^\!/ZZQRK(I=10%0DY*D
ME'/A[$Y#]$KZC@Z].T&I7#-M+DBIG/4#/=H&EO"R">+@>7`ECZ890O9Q^6L/
MHSD(_PE!&,_26QDPR.IF>R[UA;!Z2;O'<+9ZM\"!8(:AQ9R3VQ?T.V3?11B0
MY6.R6(1+?K4"P/)S-49R=L_7F#2]"0*'8MF7S.9@D+)(^P.BW]YNWE+Y4%5B
M=E_$J+TCU$'3D>>:$=8]6F%'*^QHA1VML*,59GNQ/5IA!\W#T0H[6F%'*^QH
MA9EV?!(/0Y-NOE;.KNUDW*DW-&[S`<&>[_-D!YK=U,^W`E<)Y-?9"HP?Z96C
ME2JQ^^S@SGOIW8`>FC5KZ:7YHTU[M&F/-FT3_L7^L@^Q/V-KR#>-6:L3_>XM
M6Y,&<,>HVM:VT%5K9^E$K9O`)DR8<K@-[2_"H2OF<YMD.GBT_Q&$D.9STAW4
M/U$L+&_7V#891))%6`;&G3%77B4T:^)VX99L<7=603%DAT*H_-7LT:2DIG:V
ME,JTY0`P7NK$S2VF1HG"G1'6,$&NK&,-,;4//_!7?@(I2/W6]`H@LF3F?A_"
MR0`'3!N"H/R&F4KR=ETWRN$@<-940=6BE_@F(A!-\:HGJ:D0E[9[46#5AI=C
M:-,G;.KI,KR<9\?J6KHL<"_>S1J0'=HOM)%RU=:-?@9'86J08FAE;0+5S(7M
MNZR3,85_)DREZV>^@;5TVF5##1,GM$S$BM>YK(O6C2PH;L,OK&I"B0TJT?S`
M/;N;L-CW='E*8@DG_+@2CLP870/BCM4C4%*?\"*3L>Z!532Y,4<N>EP;9LD5
MV[1)NESTJ9:UU?M41>4M)S"IQH<11^TY4XLGN`.(."<?^!^<B@]K5+"?O"&<
M@C`S*21+CZ"4$PY3H^5&HGSCIHQI<V=J2*>GS2+67)F2=MMNW$UM;?7CR@UK
M>YK?L87WX6J\#P&]!]^T"::;Y>RX#D6]4.#X$"GKSA[F/B'^#%`X2E6@0X`#
MQ5HH*&W7>UC=HI-`<,C'Q%7:T-+P66BEH%WG876B]&@<NC[V,8[\;P-*$QA<
M)?PZ^NPBMO3*^COXDOZ+^AB0@;PE3V$-[XDQ*MWMKP*_8(=_<LPZ!_N/_P-0
M2P,$%`````@`%(%L1R(EI8P#70``(UH%`!4`'`!I8V-C+3(P,34P.3,P7VQA
M8BYX;6Q55`D``]?_1%;7_T16=7@+``$$)0X```0Y`0``Y;U]<^0VDB?\_Q-Q
MWP'AVR?.CJAN=]L>GSVQ.Q<EJ=2N&;5**U5[QN&X<%`D2L(UBZPA65)K/OWA
MA62QB@`(@"\)[?VQ.^T2,LD?F&](`)G__K^^;&/TA+.<I,E_?/7^[;NO$$["
M-"+)PW]\]6E]^>:GK]#_^LM_^__^/2;)Y_L@QX@2)/E_?/58%+L_?_OM\_/S
MVR_W6?PVS1Z^_>[=N^^_K09^)4;^^4M.CD8_?U^-??_M/SY>W86/>!N\(4E>
M!$EXH&)L9'3O?_[YYV_Y7^G0G/PYY_17:1@4'$+G>R'E"/9?;ZIA;]A/;]Y_
M]^;[]V^_Y-%7;`ZR-,:W>(/XX_]<O.SP?WR5D^TN9J_-?WO,\$;^#G&6?<OH
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MV`J^^`K'KQ;<__'77][]</7]U0_+]S_]R>;5J&>C;)ACQ<F;3W=?_:4B0T$2
M(4&(&I3H]XKV?_^[>)D:VSP[_B!!%E8O2O_9`:X<\6V84H>[*]X<X=QDZ;;?
M%RC?*^TU6=\:BUT)DT/,<?CV(7WZ-L*$0GW_`_L'$\D?WKQ[7SKR_TY_^D,\
M]Q8_$/:XI+@.ME@F@S_\Z<>__O0#^Y\??_[;7]__\/.[G_Y0TT\A>C_^SY^N
MWOW(_N>G]Q^OOO_Q_7?O-&_4DKA2R`[C$!L((EUV<WLB5%;3,(4LG5.!SH)X
M24WLE[_AERZ#IB&<VH#I,"C$IQR(^$A$AX*;I\X/(35':JIQ1>9\GV7T@9<D
M#X/X-QQD-!Z^H!&&C0E2\X`T0QIDI[)4#D5B+&*#J0^,$!ONE4'J^EJ=1DG)
M8`K#=$EBG)W3ISVDF859.B&#,TJG[Z\P27P8JL9Y9(^D\]]AC8YIQI62*AI;
M4[8V]N>8#M+FG"!0!MGL[UX9%MG4=QJ3(Z)Q16-.GQ.Q9UW&P8.)Z3@A@#`:
MI^]\*@WUWQ$;X(6=D$ZSTD(<CY[&-M1).]L@1<'`!VMQBDEI-L1`/T,3[0<R
M-B7'U-.(E`B&Q),OZ6^YB7W1$$/8&AT6I3B5X6XI57RX%U:H\\,H+9*:<DI1
M8G&U4I"Z]*?%P@<+U<;5)51\#04G4M:S;&FG3NDGR>NDVVV:W!5I^/GN,:#?
M?[4OV$XEVR"U2/)HN0!F?/3H5.D?3H4XV0P)0M2@],*>F7^^KM20CH6;"&Z"
M_)XCW.=O'H)@Q^3P3]_BN,BK7_@^2D,@RY__N"NHBV:ZL-I<DB1(0D(M;IJ3
MKLT4F6K:\82RB);(3T6V)D.K#:H)444)O<72_[L8V%`KAE-+]#S/<9&;;@2J
MJ*8VH<JW;ZTW^0"-F/5^WR><W:?UCO90KWUWMUC?@1MRO9!(#;>"!$:LR\RO
MJV56,($VQ2IL<MF?H2K3#Z@$0\`Y_W1[N[A>(Z$;?_;.7VA%SLA!R#E,K3KG
M0?XX3R+V/XM_[LE3$-.WR>?%>9!E+S3H^C6(]](LE,QR&#*#\A^F6%NR2`GX
MJ1'^CP;I#`4%JJ@1)_?"X_0&&K)_X`/IX*AVK3."XR([6WQ87E\OKS^@\_G=
M+VA^?2'^L?C/3\M?YU?4TK3\[T`8#V<WQT6XN+ZP@@<67EA9'&W48<9I\E7C
M8YH5:YQME\D3S@NV!#!.D^EY0(<B"F2M52`;]H:-0XV!7D4A5D@*AH2HD8#'
M(CJ),UNKRAA,'L2'8;JG#[[%(::Z?!_C:UR4X9'Q2E7+`VS=JD?6BN3+X>@P
M?H8H11W;>Q%CN(+*&J`2W,("M^HU$#_]&EC'8&IE8HJ<4-XO]!ULG<\Q+;33
M.4%R*E>D^K-7_J7CI9>CO731N,,RZ"OS*R[>>3Z9F!MYO"/"J97S)L.[@$2+
M+SN<Y)A&L*OB$6='^0!3AV?$"LKOF>$\E;22"I5D?#W*"=%)BLL+-]@/(Q9D
M.0>9<I`!)YW8,`R'K$H_YOO[`LQD.&N*@9LWX3.U0;G`&TR?'*V#+^)%])&S
MSJ)J64''`GJ<K0,;Y6A$A]>V`S2.'@Y;I68[NG!C.ZOI!D45W(+"Y5;$.W=M
M(*=&WEO'!W3OR6Y'%=Q!=QGSL1VNO5/J>F,>IJ*PU`ZY+P7>6+5:4X*ZE9LL
MW>&L>+FA4\POD/YS3W8L.>2PJ-3S@G8L'4C;X9L8/D.<0-PHKDBXCQE>51H7
MZ2?"MJNQX0,V2<H&U&W:HKM=W2QNU[_1+W<U9]O+UQ=\D^3FX^)Z#9>0<M<<
M"Z^I932U;;E*DP>#31*9&9620KE0.8Y3L6.CQ#Y"8]P,29,J(YN*(4!H-D-`
M%N&&[[^Z_O!FO;C]B);7OR[NUA^]VA;5*(0V1)#1^;#^O*9S,-P2M,D-.ECH
M1&N^$#V0>>54K1$>5.MF=;M>KJ[1ZA)=+"X7M[>+"[2>_T.<X_+.MYH)KO.:
MM,%J:I5L9*7TFBBS10IB*!^KPG(JA<=98D#=Z@5B_<OBMCSV.$ZX;;_J-GWW
M0X3@7?I7JP]:!RNGA$DSV;K2B@K:9=9O+\\P>;0-JGS3]6H]OT*`1_5-OK.%
MORI))E_WD>">Q*0@.*=+4'[1ZS&-([ID8<O1XL7V;HHY/[`5HCGBECT]D-8Y
MIN+%M_LM?0`NYV?+J^5ZN;CCJ9B[]>K\;[^LKBX6MW?_@R=FUK]YXT)L15>_
M;#-E!JB@/2_4Z#A!.R0M2HT:>G^_Q@I8=<FFH8;^W;3I%D@C?Z=A`W72]29X
M8<<$J?[37[(]CB3OF$3VRS=W_M`G9!UF1'G0M.3%'6?)#378>9!V'0/UKH$Z
M*%%7IXR\B!8&!`UW)G%8K3/9"'9E/OV^3I!4;[E.SX+DL^-!)`TC\.!!@[&=
M$J%C:UNT3A$;[N<))!M8DO-']Y0`1?C>OQW43IDT"R"47*"V6V[Q$T[VV/+L
MD8H:RO<KT2BW4<J1?AT$MH>1B9'>.#"]6&G=DX(4?NW:?\WJ@;N1H3)9HWJ4
M5C7"<'QX+U;'ZO`>12EHCFM12%4Y1(L]DJ\R)AYD7*78M+ISH/`XSVH&J]Z4
M!\_O.`B/70Y5P@'J1!N/$R\I=A8BVJ]ZI$S`79`"F^%JQ]-C+N:HJFWM5[+<
MT0BBX5)'QL%<H13-J98)G42<%[=!@>^>@UV7FU$0@32=DKQ[^U:O&(+8&,0&
M@;H-Z]?.V&OG=-#PB<*H+"K+VTX-]>+K1XS"JOA2L&7Y,13D3#<+^I?[(&8M
M+E'^B'&!(H:-_H6TP*)H3P?CEY3=P$PP>F%E?=.,\V#GI>DK4_;A2\@*%CP_
MDO"1KG$R1'(44RW!V5MPAZK5+75GL!:%%R%HCP6;3V=$5=@,0T\_5V[=R7BN
M$\)5OI+EF^-I3SD'0`UR6+)YL4#3ZX0'9Q_U[RI.A3765^#>0",;IHLI@$+;
M-L?`]&6<80^`Z2M"6YR,:@ZNSGW-BR(C]_NB6ES=!-!IBN'@2@Y^^7<4Q>+,
ME^/,3%[^]5!OWZ[2:XL.K*AK&T%KL_*HA0(?-4/+/-_CR(O$GCF$7$#XMW=O
MW[]#.[I0>6+C$5VFT'4.M08S]-/LW;MW[/_$#SD*]L5CFI%_X6B&OI]]]^/[
MV?L??JK^2/@DE*NF.ZH6>'M/>7W_;H:8P/!3)!<X+']]SW_]P1L7IQ)>?='0
M4Z+)3W]%$6\"$,0W`8F6R7FP(S0H:;R7K=,SX0CM_(Q0MTXUU42(4:%E@DJZ
MV5%?%*_\GA/2<A`B"<)?0IQSA:P5W#M':"[#9G<1NME-K:6WN`A(@J-%D"4D
M><CG8;C?[N.@P-$%WI"0&&^2F7""<IY&*$]EM2)"%17ZND&'2L)OO'"M3@";
M:/)]MHOW%&*D@`7F_<PE5.L/#=A,K7OK#`=TWE_T8:G./LDX0'M`*:I6/J$<
M=!2L#J=)/XOW3_`#^[Y.[LT.1AFP!@4*T[Q@\>./L_?O?^"!Y7??_\#_706J
M5D'H#%&:'0X+\H1CF!;4M@)HX1`EY`"7%"H[P&_`4F>\R_`C3G(ZX\LD3+?X
M*LW9+??59AU\,?6&UFP!KR18XM>Y$7$U_8@'$DS0UXS--[P@!&N;1GEYX3F'
MQ2]JFX9'^&-*[HTW=13WKD/[5CSATZ[]TZWP?E:*RCV]ZM%6G!$RL0^7-X;^
M#UZ_K1B^V+A)$Y_>>,[$/CY`=YZQ7AT\.%'KO6/ZVKLJ`@Z[H0H^'FR1JA":
M50OP:PO5%$MK7_7UEP>PW865,P'<(*+^<)7QMK817Y+<X(SW:+8-&HQ80D<1
M9KCU.TV4$*TR)$C%4AY18M'$VZ,*L;VPEBM\9:X:-!<_*#+T-4E0E,9Q0&/&
M>LL-)B'86[\L_+T)/T"S)/K$S^MM3H<M[#8+#W:S);CTYD80H`.%%WD$)T2E
MZK6VL+UQ]@;R9[H+W:('UR5Q-**'6S]FXY$K/\%GHD]@)T4&A72L4$2*R"?'
M)1-$6V=UQ`-T#TN\B:ECDI)".20YCJYM*S'0"_]C">!(4;QQ-QIITKH9&=WT
MK2A9HIL'C=L>U>24;*#=BQI?^Z85W_"IAVI.[H+;XHZO9MAD4<YC\GV.(,9Y
M69KB0YI&N:)_C4SSY+10UEB!I+6[P88=RJ3PD>.TI7&QR(8@;K(TVH<%RMEP
M;RRQ3I:TIEA*.'VHGQ>K#7_\71H[A/@GY-"VMXVG'?_F?%N=CT%LD&>!O`D`
M?C+F@2/()0C`G85"K`P#]F/:J57B0Y;F.;4U&_,3G4<D4*[@^+U/I8;_%8D_
M>U#ITN1EMT'V0!(/MJO<7Q;,*TF$6.N,FN,GC\9P3'D^S)/H8Y!]QNQZ?=E,
MU_KTB883M&?2HFS%:V(PW[6MAU<-L+WR5W:P>!C*0&UK4*I:M.`^K%LLS0Y'
MJ-E,[MEP@K,@9K5BHRU)"%M]L>.R&FV3VI8N-F`>L!-?RW8+"E$2^H@&3-F&
M`78"!E3)G&3(Q&=U\)C^AE".Z9P\TA>ZH,NZ..6]-!U=60<S:&_6A;5]14B,
M+\_NUQ1>^C1;<%5B(FK@\M:M&4FID6?3<YJ\OUU5FJE\`>/=%0DA6%\["896
M.[BZ!-5BK"K^#OW@K%[<.V^DE!U]'[@6%9C,'^X.V/H9*0MH[R+'I1:HHXLS
M'IVC,\/![OD<"LN1$DL\#A;GNP:&6!9KQ!JJS]?+ZP]H>7V^^KB@WV5U=^??
ML3B-]ACY/QD]2%?7ZS1)3VR1L?-3TH/V=I4CDK=W;8X=+9RTSW!:XZB\XL`]
M7@UO^(X/`<Z[=^A(=[-7&3',J0EF9%C]W?,TH2^SI^]36J$TR<_P)LW*:X3K
MX`O.%U_HBCC-(I($V<NRP%M>FI!2TJF,N=T2!3_=3EZ,]"K0L<>X\ZPX`2(B
M%\2>B`Z/1(=G(O'0*M+ACYVAHP<C_F11-/3P;%0]W*-08N(I;@8AZ&QQN;I=
M5)')>OX/H`J-8/IE$>",^1XPYI.^8VF_SW""+79XE>1089(:C\+$T*%5=(2^
M+D?[49+'&DI!H>`*ROU84'9I3E@Z^==1(8G;V>0`K`940?0@O6,)QXO@=1RI
M`@MB.^R7-H95T4YM@Z]QX9ZH.B&&#A-/L<B2.L?!W5$UB6*\:A+.V2H32.-F
MI_ILVL"_O7M`W/GNB[7GN32I:AL%F<>44YNDOV/R\$A=RYR*7O"`K_>LIMAJ
M(VY&K/9%7@1)Q(YO6#9"L^<+%4@ZS,"I>%8L4,D#"2:\>INX7];@,T,7)-ZS
MT9YU4QMR(H)R(L+RLIV8A?3`Q)^N:ZX:H(TXK)GZJO=G04Y"VU#%DCET*&,[
M%SW5G[/Q*.P9#'ZE]$D-OZWW7H5,?9%+OR1X*.*DVD:ABAUG3TQ:Z6U;+]DS
MDE&S]2R0T>`?)H[Q8*^Q/_0J)O/*=HT*U8.T&LQG\RW2[#)0+H&FDN?41KDJ
MHE[517*][*[F`QT]:A">2FO='J"N>>9KJRH+4*W<#+I9W**[7^:W"__Z576)
MHU$8I&0"K5S*Q9K,&BF(H:(7%99N'8)94?7!P']O%,_3U,X#B3&L<'CC7K7:
MH'6B<DIH;2Y]>%]/6;/QS5$>\)GH.,QB8Q@\593JA\8/BLE[#W^B14X.ON(Q
M?3N"LE#0:B.VB.9))&F98+LW8\T6K+B/-?YV5X.JLA1=&FI:C@#7G1KD*QDX
M.EN>(*?Y.YJ"W/`V!?1W5LD-7V#QOZ[KRB&>".U8!YDU^8%VP_X\OBYC1YR9
MX\X]XD1%>;["OV7O<'IE=C&H_^/,+0\)PY#;DW<_?_^.6Q/VRQ_50=M;:O'N
MGH.=.*G+S^AV^<EN^JD=H@&B]J$^,1JQX8B-1^41>DX!NL[L`R=C<'(Z/I^A
M>P&H&`50E(9[YBKY0>\1$!V;5F$YCB'-$%-O1']X#K((W5/]B!`_2TXU)&>=
M<9\?2?B(BN>4U>07;4X>,LQ/U[$I0J*E#PGIGU\8EAP5CT&!6.)Q0[ZP+=N"
M_H)YMASS&(G]%R>MGH.>2?&(GH*,\'-[-2/Q-FF"@K*6#7V?YB>B:YT(?^'_
M_@:E5#KH0-:>D&P(I1,O]A8\V#(U%=*HJI-X`"-6'ER=[W8Q"=D76*>G3S0-
M>6PX0H4T5J@U!_T/E*QO6=L6>A&E#`&6'=H.#F"IXI.VI9S>-@X.=_U(J'';
MIGNZE+O%U'#FW`H1\UF`,39]%=$@ZK)@Y^-ZSC1KX7=S5,>.H*^O"VHOH*$D
MYBG73OS*-(]`1@#J4-!E.)A':\,F3)\*P`S5X=7+MJZ2]]%9GXZ.'&I6T(D@
M/4[]`D1B=5)N=6:37=QQOCYBAUO<.-28(F\"!0OY-6T%H^0#N+?1;NK88T=#
MQ\R#?0PM5O7N!0T`9`V:_=ZVZ/ZNIIL5&DY@<KMFYM#6?9Q20WN,%AJU"/[.
MA_C7ET7^00S[-A^1@HF2$&EFG=.$+6OG7XAQ]<8.)N`F3X&M=>1#&+3#.&K;
MZ$@/[9KN8YG9,RF'R4\;';_$1;H-2"N5TWG80LX$VJJIL'4)'?I=#/7/R&F_
MEMF9%BD'P,Z:'S$[JFYJYB2$'G2DK3'H^F:BW\6PX;?&[4^HVKZ[-^97*3BF
M365+JJD%?AY%A"7)@_@F(-$R.0]VA"X_U<*OLP(=S*#-;A?6=HW^:CQB!&](
M@DH2*)49$ET%A:):?`EQSEM6W029:'OOG8<Q$E0C3Z/G-'U3@H(Z.AQ59SKM
MW(Z*&LKW*-&T^PV(@:@^2^V1%S)&,0_#_78?!_SP]`7>D)#5!;O;9[MX[T_R
M7"]B6@>E(`7MS>SFFZ0LH#V2')>^5[-WEEGS<8SLL8Q^\C#HH,BJ'2([PVS!
M$,I6VV#6&3[9'C';I?'`D(\)4=[,`,S(6TNPUNZ;<P-+2EY1O\0+V#KGN!L<
MH!V!%)4FU\V&B7K2_N6"U%_(+NE]()]<QEQKL7A4;<6D.H48,VM631F^2B\_
M24L_:E98F6Z3]S\+Z'^&_"QO65=CA"K#_/T7B5UQVX'>'FXWP:G8!WPY#Z.;
M'6G&EO_-4R/K5)P9L74EO1\'[7?ZSU>O$X,S5#(_/L.S]K#X[E@S97CD$.!&
MS/];LQ'A#4EX7O##GD3,,/L\)QX<TQS5+EK$BWV?-?T")@T_+_-\CZ.+?4:=
MI+AIR+/N_&^K'6_=L?B"LY#D\@(;\A,`UHSA3E_8ST%[-<3V+@43)+@@P68F
MMC!FY?9FR0O5S#Q(3`PQ`=7?>%4YCC051%Z<PQ\"H1C"CO0&X3_W),.(_AFF
MI,=`"F<21%MS]<2"B>C?V(3I4PCV3X`.I9UF1;HB?R/NKC*?1AU:(.+C+*/C
M1/;G_@4UQ]V(*Z]HSF[ASBIS-ZOM';^)*U[&HWAZD.E2FL!961#6JZ#YM4$V
M;.XS&>2\A1D\=S*T$;/*DUJS]\11J%U9%:^7#9`L>^4.]KA7$Q8KYTL7+'>%
MQ\W+5:CDC+XN>?M1`'*\B6*8R]YB.<JPV/YCY2K&";![]$_S;`Y>3Q2N-S+#
MQN:*9TU_RO/_[/."%T99IXKS;]QQ\(BR&7C>8KKPRDF![W#V1$(L`-_B,'T0
MV3*.W?Z@Z-CO`[T:F&#&V\=5ZT>R#/K)Z56TK$^OEI'BF[/6,F.&ZJ>C\O'E
MR@$U7L"KH!I@HKFFOZG*'1T8>A>!3J7VAL=N1WX9P!O"YT'^>!FGSWF/B\$2
M'N"7X^3(M->`&0'B%)[?_E5^,]-+OVT&`/U:V4O<9.D3B7!T]O*):LXR*=M_
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MYZ/^I50`O<EI,8#WT&U,+9?0^+,'YX%<7YUMT[#_?&#=4.,TF%ZMQ_P0'OA3
MA788.L53ZND]VP9G&?.W9?5=ZF63B/[O.?V1%-97I[KYP7O`3L1M[R)(JNB:
M$Z$@B?@&:$GGF;MT!WFH2.WAN6%3>37TKQW,0*Z5G9UFMXU3Q0IJT`MF,C2F
M9]J\<%7F*'S:]+&1#Y.DMIQT:OWX$)"$K1A7R07)=VG.]W96FWF>8WM7U<$,
MVD]U83T5/S:^ROO0L*]!Q,OV9"P_4;R@&TI4\.JK.Q9_L$.@8;QG5_'0BL3<
MJ7T(\L-X[N4([TU>_>:5I[.=)C:6S4_$1P<QFYRRDPPG\>IPI"VXKQG!-RBV
MQ`CNU8WTVLBEZSE-;:].FX,ULEKE?K9MQMR&(Y3?MT(MZ0K#B5BU)/&O;]C!
ME$.NNBZPYE>BNA?H\T=V=)\=P_<G8VPON]H(PH(=O);>XA"3)W8)T#JJZ&`&
M'55T83511QIG-(AFB+<C\"HHL$5Y#&X>AJQ+$SO96A'QV[1>A0:V$!M_]<[]
M&RF@D?O7<X(W+,ODB0;=:4:Z>W@:,O''R1]C,S0DY$#D0<\DGT'UN`A@#TO\
MM;72\R@8D6B29?S1Y`!O&6XRO`M(5*4DRWL`\T145W/+<+@^Q;\@Q7!V#/6S
MY(9*-CS'(2IIS`?.`?1N##785!PMI\I9:4P%%FS$KD;*YT+D"@8/[T:)?1PG
MI1/]*PB5;`R'8PQE]`AX$UK%[3?!"XOWZ/O17[(]%3(2W).8'R%RC[K,N/L3
MCAG.AJ')K-=$)3NN*25#U.#HP4F)P::BQKQK8`Y*S)7)\#3YU/OK1\VO'^AF
M(E9_?8_B11OC8!E(&K&&-X^5^;[%-.ZUOY%IP-"_N+&-V=#>U:<A2DK/TUO=
M.&M`F1R0AY&-0F`=@YA3;OY>Q3*-46PX0L4E5J@'N&+E01*I-V2CJP7>N%I[
MN=:Z5PMVGF@PRR/EHUZFU#X!VNDZS8JEIM?,)KJIY%ZT;)#9.+U*N;S^=7'W
M6J]2&JA'GZN4.O93&XBRSAZK7B"J458GIOBA*[HNJ(]=F;IX&XY0+MX*=2L#
M5Q+S>B1E"<^*?B8.J\WX:K-FXL6.2C_,]`T?`U&@;U=CW?&#>0PJ5D$%\_'V
M@JWU\1;L)E?A+`TQCO)+.B$?@V*?<8O"$Z#BG>G;G0=QG*\V=X]I5E!/L14F
MB/_5UN'W?ART]^\_7^V<O."(&$MTX#E##:Y<3SA?5E&$<WZSIJQ1@[=72_;A
MY^G`A=D1HL8-'A@,I%-&44+?9X&'#/RMUMU6Q<A,RYEY$R@HL)K$"&.K_)"Q
M@2G,,BSP0I][B)=+`"#E!.G[[X(8KS96\;NI">QD[9-/[YX'I?]FTH08??/^
MR=@Q_<"NNB_\O(3O]>T+![FW]L5=?/W-Y?7,QDLY>I:-EZ,>($?G;S;>'#+/
MQG^]9S`W:?9-Z9E?5S)>(]8NR7@9.T\4^)(D01*.F8S7/@':=3O-BJ6BU\P\
M*1LV^GR<IN,OE]?SZ_-7FHXW4)`^Z7@=>\AXGI5D9RW[5IL+?&^>?M=P`%M%
MZU#IH]%J.(M(&8$'A_5ZH(GH($1*&F\\<+?0Z5?&:O*IU>>VSIFIE49G@-KT
MT-Y1@JA]3:Y.,:^&5I(!3KX;(&`_HUU&J!7>!3$Z9#Z]\U`J`3/R/RUBJ,RM
M>'REJ^=I;I^OE;*`SM+*<2ESLZ5+.?@83N&#A['"<]%T*B@<%L,`2>7!4(!G
MD35Z8Y0[EM&#9HR':&MIP!#:B9I@[L@)>]%T=UR,V)O6NUY\2_!8PUA3[3/;
M7C12-%^.]\QG2SEZEL^6HQX@S>5O/ML<<NMT>2.WO:DQOY[<MD;$77+;,G93
M*S-[+WY.)7]D.V1/0<P"'M'4ZO1BBVV$8<<;.MBPG(E6YI;)NC@J1O_1X#"K
MFM9)KG]Y%(?TA*^XVQ96L\+_@0^,O8I-7CMV]YH//9%?+]9H>7U^NYC?+2CZ
MA?C7-_0WQ'<RYM<7XA^+__RT_'5^M;A>WWD7K[F80*/0S8HQP*7=JA`UZWIH
M&JJUR`"K$)R\OT0M#Q74V1A?[L]WO??U^>KC`JWG_UC<H9OY\L*+K-``[PUY
M15\FZUUW[X]HIM=/ZLMQ7JB44W^_N4D+'5B=(&FKJ?@SC(KV>?'K]>)V<;=&
MBW_<+*ZI`P31U;$!@+MGF2(8WLMO$$Z>)*&(J=\_'%]*HGJYMRSPUKI_H05#
ML!2)!>96)"EH&T?[6.1\2(QP>M\*,?<"O+I^(V)DX(,]/87-)/UAS&WZ[`<O
M!\VKC$6DV%/!H7Y_SVIWG.V+Z[3X#3LY8'.^T,[98@;:&0]1';U)BRIB1*D1
M)4>4?AS/WB?5X8Z95T\7JWN!'C?1DX0UN."-C?2%K(8OZ35`N``S+]X%'+9&
MP3`78,@4OGC794"R7X-XCU>;*H2ZI3)5__P+CAZ8Y4ZHT=[S_?'W%MF#(1[F
M3^5#M[DR;$3!N"#.AAT0J]=)[`'-OY7/0(V'>!$=C35;?&>IMC<;-A%/?"+X
M7<9RDC(V2?ESL//C3(T?<^%-?#FHT;$LH>CRI*F-\BI[")*R3^=YFN1I3"+^
M'S1TOJ%O3-\J$-V&RD`ZB._H+UA<.W>\A#+00Z$CVJ'F[E35SO8Y27">5[7@
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MH/VF'J>RJZ3/'L[@TQF><U+S\4`<K9V3G@?<WI\6F5H"#^/]<RBVH*CQOUZO
M;G_SQO2;R%O'_I"&P?1E4.H&TJY&7,H"VGC+<2E[X!V&>VR]-=_*L*A(FWYJ
M>;M*@R2_3@N<K[,@JKML-EZMAQEW9`YEWUWGXE2*.9\9XIQFB/-J-/UML)O,
M,=@GXH::BS(!=X=N%^<+NM`XNUIXXSEZR;[6I;AQGEKWJQYUO)I)>3J-_`M'
M90/>XXZ[_1<7O1\'[</ZSY>J(_2BV1&ZV1O<Y\7+0.)CY"K[/LM<M4@8AEQA
MWOW\_3NN+NR7/\H'51_J^('&CM&*U=1NT`YGIRC/6Z+LR]*G)]#;!;LD5=V8
M$MFQU?J7Q2V:W]TMVDFQWMBB-.2GT/BA@''!K1\QHD]B/2^B0VS".T=U]*Y_
M"^[6'?14ZL1M^`"4`).7M'=UR@8,H=VN"69)V:AF`XCC_@\^.U7C#VQ:.:J#
MFS<"W&.9:<<3L)*R#7([B?8YP]@7^"T[XK?^C0*_XD<ZJ+MEFU8W;`<*W.GT
MD>NNTLSF#('.">8WXOX6?;VYN-5V18)[$O,Z5N?L9A-_=7;YL_R/?J<)>SP/
MVHD-,&/*9.E-XW9AR?40AGOLZX:2(INCB^X/\U''>CA-9_90_M-]/JP4I\'-
MX_3L@)-1)6AOYK^Q["SWK_3'VT^+PQK7&S?;4RFT'M>5]_1IV_MBB&RLG`NT
MHU2B:]T`"9+/H@B\QRY._ZT,4Y]2%K!29^UNE.10[D2-1UK>WN<%ECF4L_GU
MW]#%XLR?=5.'6&D-MHIV\JNZ+#,HBL6QA5J5,G2]@]O!#=I`=Z(]%3JQ"5`-
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M\),ZD`7+1P?GC?<T%TRMJS1@,X[ZV)T@[V(!<G*\$Y>YQOBR9G+$13W2ZAK=
MK5?G?T.WRP^_L,WUJ_DUN`^R$#_UP>@.^LG+@.$'YOEN\2[->&,!QW62F@_T
MDDB#L%4$2PP5!4T:A;_.]WE!U[LL?[U)LRV_1^#S&JCKHQHM=Y1,H$6TQW+&
MB!58C3HCG"J9K<F\SIXY8EQ\8`L4OCYI5J<[_T2=Q,?%+5I>7ZYN/_(RIN!>
MPD%L];7I#/A,7V4A9O7;;X*L>%EG09*S!L1ITJ/D0A<_:"]B@/A4:DL2Q&E0
MD\AGWV'Z:0TK-'0P\T5P>_@4*Y90OL4.MX4D^^QL>H)>7,W7BPMT,[]=_X;6
MM_/K.]9GS*="V0[2K'4U-OPFCP(?@PR?!3F[P[YEYPE$77S7Y4H'-VAWTXGV
M5%H7VUV<OF",SG""-\3OR@=FW])LE:)G!;`+<WB))*J^2OE1V%+?H=*H%4_`
M'1@;Y))D5DTN[F:>"#1/;7E7;[LGZL7'FZO5;XL%.EM<+RZ7(]0^<*J1V@\4
M3]R].9O?+=ANTD=V[,VOE9F+DG;M()DSG-QQ[N]S_,\]74(NGOJ4"E?S`7>6
M:H3M;A354"3&^K:]-`"F&;K`>9B1'1-'_WQ_ASB:>7T5$VCELL](JAF`Y2$U
MF`STR;=5H!6<3V=WB__\Q'*-BU^]*M#=*6CZ'**2>FJ%H:$ZR5>;DRX;+^+_
M:[5'9U1,N4)[*F/T[<N:E)#5D3J0SD03FA?T>_F_<)'QN)!WC<9WWKDS.WDV
M<FZ&+"%Z:;#S4<?5_`T45]5OP(`99+\,$ZRR#AGB^&"K288WRCHTWB&ZZ'CC
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M<C8=0?5$3[JUV&JQ^EJB,:?I3^P_X62/;W&8/M#XA\I*SP6\`4/H6,,$<_N,
M/J=!#:)7$E<,A-:[V,!8<@VOTG1QZQT3E'7Z[%2M99,,N(!$`2;H6N=SR_*4
M#2(_O?Y`X#QP\DY(9!W7Y$Z^[+^&L@-_3WRYL?:IG7@W"[#JAKWWFU5\H'VU
M!J&ZPJ%7^UV#HP/:Y7*3'ZM=9P43/^["K7;E_8,ESYR0)\QO'MAEQ9U8@YU4
M=IJ'UJ%?QN7-/6.#FGQF2'#BZ:B:5WD/R9O(>L1Y835JWIRUY@7<70Z@!OK3
MT@Y\IS8!BR!CB8K\!F?\=7OZUTYVT&ZV&V\K*"PI$"5!G.;5>%U[L*PG1.F`
MO[Y*\_P;CKJJ$,9X>.>2#278R#-W\9I:.S_E>+59Y`79!@7.37WO*1646VV]
M_:FTT0%LA54/\2C1-`@>;SR<7(ZTSNN$9&K)O\;/C8L+69K0?X:XL775TU'9
M\X?V7`XSTK;NSXV+/^B8B4?*!S@-WKDW5T4P\G?6S"=?H8:/.-K'U!3]';,J
MESB:TX`H>,#7^^T]SE8;[J;S-3L@:G]GUHTYV"K5<2Y:Z[&2#W-5%2=4LD*"
M%_N3X(9^Y_R\R5*/.1D)#7Y)&?S&//C=T:D(1?";@P6_`XJNR:+5B3.<76`7
MHTXN1]&U-;\XQFZ'-2Z'=1L);;V!`9X('4(,,FM*#5IMD/P>GZB#*[_*YX%Y
M@9LQ:G-"/F/L_R-\,F,YGS%VEH1:I>/+CS&[_'CZ%^]"E^&4U*R81__'P9FQ
M^B;:N6AWWS>BZ>(''\1T(M89FL:5RY+<!TLR%N"T`=C#$,1,=@VCC@YF<!I:
MW4B[3@N<7Z5!PFQ*>;0V>3C<4QL@PG!XE#^AA<L\Z22_XC=#G.,,<9[<#=9<
M&S<CI[`#[MF+\:8IJ&[#9C6IQP&!LS)91@+VSYG:P%S@#::&+CI/\R(_#W:D
M"&+R+QS=9'@7D*B^#\NO[O0H+]W_.5`APP`SU#K&7;)$G"=;L=1<9ZCD.VM>
M->>\CXM4>QEMC#!732.S$VRJTV_""J=\B@*_KLX-I5;:J*7W0[RYS#[\-7:/
M8A,CU%9WMWU0_\$1'RMZA7Y7H\>O[^;ZP'?6?5J&W`0O3`3IZ]%?LCV.&GUU
M^R8/7)X!GU!PFAF3E0<J.7(M*'D>MS&&7G),/#'U6F/7F)B@G)@J-O`F%!A"
M=PR3%PX/@+,D%_B^:-P('B!OH>8('0(8H=:)_%6=<6<,CFZ9@VO_J,!W&:%K
MY5T0,V47@*,]1OLDPNRJ*YV+=%_D!;4`=$'M51#4#_IJ0Q>"%?2;"OK%WF3I
M!QX0F2NY93Y%R0[.C/$EUG6:L)@M8.=8Q/G5\@Y3WU#(CCM\$&0Y&SKQ%ZF/
M)J_Z:'#)[AL?UD'3S`>UA"+/484W,W9<Q,,8QT4=#*,;*]:];Q$?GGL7Q#1L
M2AN==*M&NHYG.MSY0\4Q/69$I^*<#UJGTB[%]`_EAHIG68XQ)H/J=\XGHTA1
MWIB,L&(U_97FD:'3`?LXR$YN.^LG`16/08&"+5ODT*4>'?;^W?^/T@QM4T%>
MI`6+%+,TVH=%R>S^A9=!87>=BA<:/&95811J1D@:P5R;'M8L&,12SLP'-*3M
MHJHTGKVDD^)F6EM7SP=Z$DA9AZ%F26=N)16+^8J",??7!$\_5?+M;+[N9"KL
MBX&>;&+DIMI^B@S-=R$*;4O8![R1"K/=]P%]PQ"C_!'C`D5!@3TI?S&HM5.7
MR!CF,="W?5F+F-"UD5\',^B47Q=6DWN^G&;,UG[NB3U;>/\%;O9*I=7I7N\Q
MI_X%KS8;'!:KS06)]^Q"/Z]X(.[Y=U[:-6``4^9*CZFE/7PX"W(J`L0IRMH7
MPWMG\PVQ'G"HLXLJ.#F'DXX$QZ'`E1VBP\4N.2)V\RG>1S0L(`D*@SBD$4=5
M,O=P,:IQ+XI?B/+$Z9LHH*;<E8YZ:A<]I\ODZ@O=X9"NEMFFX>*+^#@LKF#%
M1/9"4%:;4\LVY\&=K2L?Z*'0+G^HN3O5G29?=&",*LXBY&[PYE4`)/&$>()'
M4<18,W9W9%H:.X3E$N*.JC?F!NG[=\4C2M+BR/ZP%4;3!MWC,-CG6.21A&E^
M3O=Q1/^`:'A-WE08AI]:MB+R:FI7C<D\MN"CS2)X)#BH432*&(=Y8O_<W7Z[
M#;*7U::QF#QIZ%D=*3'+T-GP@\G#62%N]Y'FU'QOHY$!:59[*#F46Y<P>_?]
MODMG;L*"F3<GD,]>UO39\R]$NF)R.OW99`D=FICAMNR?Q2C1[XS6OR,H%A^Z
MWZ'<!C]OA)F]T46Z#4AK*:?:P#=B!76\Q`RGD_`*:G@K[/!)M:<F3/CTC@[.
M]B1F<>`\BGB5YH\\I+8Z!:%B`7K008FKU=N]'(BJD>AW,7;X3*W[=KT]FJ!"
ML^5#/=LAUTM=]R:X@GYJXUV]QG*[R](G4?1*K4`R6Z'C`&6JM:B4`M<</9X*
MN9SD<\/#7`TQP03F9[JE3^M>-.3>!$'\N"!S=QJU<HH@VXR]C>XE<V`9)HE3
MN)P%K!0/]*F&"/E;7*>6>9'[P5G]1G:.0TD.Y374>$ZEM1K9O`OKFVWM^#I:
MPZJBG5K"&A?'W:RGA`&TE91A:F6WF_461HM$W#=,S#%<DB^LKJ8>";CE5LJ9
MD85N4T_>UH].O#)K*#,.#0(H:]M\YU9#.O8WR)Q>QYP9F-##:!!A<#.71Z30
MAO(8AT)$(#-GQC-I84N:=%,+SD>2D.U^:Q?%G1!!69/3=S\5E_+O_H5ITDG7
M6I9CBLF%)/BB%Q*=5IP00UN84RPMH1%_]S=ND7X,(SMS3-E_AUZWQWI%$KPL
M\-;L%*@I*YA]>5.<K2WYKGUX1HPX-;QM<OBDFGUX,SY3'1+!7XI]$-N>]N_S
M!-C;LHZSTN-(2<G,KPL#HTQ&VCT97Y?<OO'&=_17%H,;GD[L^YL`::O!"QQF
MF/ZX3*K_%3=`V/V/,[Q),URW(KW`>9B1G6QS4VXC!WT@C$<;=LZD[4!1N^TE
MJIZ`JD?0?U17<]A3D'A,]1-]$&H\"?HBQ<BS5D_.UZ1D]0T[RGK<EN5>3%#Y
M8\$Z!:.H9.M%\_&1)VE9H`SO*!2^M\DO8B#1=S9L"EI4/N]X*I?-BQRMF:SG
MT9^&YF/8-DW0-N33)K\\$CWAK"`Y=35E51;;=:J,`_1B58JJ=4?C,`B5HSP(
MOIPA8#D$\'6W6L+,CM6WR2??NPWRQ\N+Y?DR81?I(_6%*>G6HIP8;-]6@:6U
M:\N[#+&1J!PZUE4DES,^IB@N<80SNKR*\"[-";OK0L?S*@1AFNW23'B]F&R)
M1X7(M>*FWXJ64D[?G^"^6.;YGLTSKW-NZU$D#*`=B@Q3.Q!E93[+0;Q/@$?N
MQ!@`H8.8>N0>M@=32I:1)VE33]Z<^^Y#2LU=PI8&ARMB\^(\R+(7ZN!^#>)]
MYZTL2V9@K;P-L;8Z8M^A`V'CZNP,!06JB!&G]J!DMC/*MW=OT<,!9_#PD.&'
M@-78":1N%LP;6<FLOC^X$2=O#J-^RO%F'U^1C?6*R(@EM$<SPVUY]%30(D;L
M1=W'H<!*6EK,T%Z`C25@P3VEA53W.UC;X#=@V4%).TY9+T[Z(JS*^O&ONNTJ
M3>VO81X)7(APH'GK:MC;ZM?+&\^B5JM>^AQ>!O_T+W#;78!SEU;-CD];]\Y>
M1]_>T76G,\\Z[/,@LDAF+89MXPT;SM!AA]4LR)-2I\9GIND6[E%UEU[([_;W
M_,G>!1KV4FT4;UBP[1UVL.=0YBJ#(K4B9L>S'#F#!!&NLR#34>[X3]54:*@(
M!52!P=3Z.MHLK&7*"K"M/.A7+2M%Y2CDC;;#%Y0FZ)%W\LK1,XYC]K\1WK)?
MRHP[_9T4C^@^2#[GK&SP1C32#6*6BB](L>=UJ-ZB)5U=Q7EZ>(1HG?&9)%%^
M5+F8UR-^#)Y$3:H'G/#\?O@8,)^.,T*9AISB]#UX=2M*RTM<E<5UT39XJ?<&
MJBOTE-UFSQ[+"A\G+Z@@6]&N3!3`(D\X?N&$#%F4!<^2X>Q/Z;Y@K9`HZ"2E
M+X49_!VF[(N7MT(YCF)`S`M%L=P686?\4!@'>4XV!//9W0;99USPBLIY(R56
M3E<S@#P*&F?HD3P\TO>-"7U6=!2<B\K.[!P`G6N4X2`B="#U!7R_C3VI2-'G
M)'U.RI04G]:0NV#V$/JU$AQD;$()F\F"O=5+/<DOJ#QN@+;L##:=5?IQ/G,6
MC^S</O\B3RSE4U<9._X;22@"^K8H"PI,1>2#^-8Q78ZG"7W39J3,A2S-R`-A
MGZ]\%W:DC->>SC!&VS0I'KD(QCC/T3_W`5VWOY1-J?@[1Y@*)Y>`MVAUPHI^
M<,Q:B)\^XH7-4:-5P6,J;I.SGP[OY\FIB%Y^3AV6N['M[;6K<Q6'<Q9]0FDK
MEJ"'5(UQMXX`56?'&J?)FCYY3"_LW+.E/]JO*U)^E$F^TO:H](LSX#4W.17H
MJ`;=Z)Z244^7\2.WHH]*/2'H=$(\JQ]CI^O=1VX-^8U@H^3&TB(/T++JO9\!
MLMKH/S-&YHV'68%L,5*G#+Q;@HPX-<>V,*PFYS0A*<([J6'P8$DS_/PXFDZ7
M^?,D%!S(,*F#PKX/&,'T&B9Q+)P06/+&PK&9+>^EQG.:!,V`H:$EUF-KR-;,
M'IB[P>$Z&C?I='@?%IHL8'O.\&1!X>D*NA@Q..Q\EM=!8O=,F0>+IIGKUQHU
M]I@KT^BQ$?E4R4@/#.N$,S9X/&DRHZ\LLC2T;OTCS*X'#7AJB;%-*-F+VXUY
M'1]/NDC+$.H."]7C?;S@[H8J;:#R*QPR$$2;?L-M)E.?F*G?X#9X_ABPW;T@
M-J[:IB"&.@ZOPM(NU?6,ZK][<=?*YLVWJC<'.[ZNE2'M<74Y)9@._#W-/B^3
MFRP-<6Y]0DS%!?HTF!+=J7"QO[]9)F_*$5YD(=Q`D.3-3@X"_"R77M:,SFTI
M6(!IS25)2$X]VH<TC>Q=QPDUN.\X1=.Z[EK^'?$!?GD/XW=_D+T[O/^02I*9
M`SDFG5X73A=*38=V$X2?@P>Z$*U_82GY_6X7$YQ7".@_[3W.,$^%]U`#S9YA
M6N4H_INA^@&''\769?D,U'B(9TYQ^GFKHT^>%U',B@=>=DA]-/3*@SQRA-3W
M49C086X,<DUJ=IXDL#5X301]F2#&@?UOR0/4`(P/F`C`C:A9I]M>9)$M$#LF
MBMGO]VGZN3P^FV[0,Q,*^I?3.7KQ-BO<I?@VB5\EKQ$,UE$LYQ`?6;/U[#R!
M!K^A`3M>I'@7P(R#FS1P\P4.K!D;!_A@YFPCGRH@:S:(&KL?0E#R''#GJJPW
MFU^G!<ZOTB!A(>"EN*N3/-SB$),G=OG$\6Z]/7O@>_0.\Z';!JO8(<X/<8;\
M)$'-$AUX>GDY?L@):5[GRFI*/P*5_BIA<G_=FO?D54'+%SR\RH<LS?-S?N_/
M>%O;E!MTCJ<3;:OL9B6^!XH9XC0S5%)Y$<LX`UQG081E6CI##XS2&S]L)[!F
M!4?UK"97Q3A.GUG)NLLTNTCW]\5F'[=?4:.9LJRV)5.HC0];["T]K>C1)LU0
MQ0%)U7<LO;6O*=<;=4BC_WTLBLD=S<!]P"Y$WXM*5KLLC?8AJPM>[+-DP$7(
MSP)X(NK9O4+H8)M-3KJNW8.RXP@?9ESC`:(+SL2_H$)@,XHEZ-`9&J>&Q+!Q
MA!R3)GQ(,$QI2P<)ZA4S,`X@'8`/KV!\WJ%-!^7P)0CDK7(;8[PXYF#\XIGZ
MQ<'<CDINM)ZE131"LET1BO?,M2NY>I9J5Z,WNLXB<2QBC>J%2^F-^3BY;KM@
M]2K%;@[Z]M##ASI2EV2[*.5#1XDB1?27-,'HA17R^9J&R>P_[O<Y2=@N8O@2
MQI0CLQYUR:2<1].\B%*&(U*@/!`I/9&JYS>?<?9$0NS_;<$.\^*2K%>Q]#-K
M<,/%XA3%L$D$U3/\SBDH9Z9/BD$P19+]02]BF(%GYMA`_S^Q,M?KTP`+=<4#
MX(^4ME^U_X%1&4_H5;TA<L,C`1(KX45PUA.M<6CF8S+`1K8=#U]*&/JCP?,D
M<LTC6#*%NTYAA]U6F9D?\S-+T1?Y,6!_$QI.TMUQE\.&(TCB[X8N]P(2E4T2
M';?J=9R@?:\6I3S;5HZNVGOZN3MOA:M"5';[%-9&%$L.\AQ[V+2M6SB-W*B&
MS=3J5C:O>KD0E:--W6.+#,H!MM^_=5:K'('*(5YX+XO7KJI^>^.1%"*C]3FG
M--/W\=Q@JF#EP331,M%A?U;)!MJ?J/&U&V.*D>5Y3='<,^?;M%YY$AM$WK?Z
MU`J?8<-/.0^`8PY5[FN^91GY?Y4=XMNO9YQ[M6$)EFJUPJT[R],DGR&Y.GKA
MHX:#'#3(13\+O<:ZP^US7@L,+EPFV%Z9]8E?"W[31P`\\ICSA86]WS\BAO?V
MQUC:'E&T@9E+5U'`;EW_ZGZ$O1:R8.7#FY33-P=NKC>K5(]:'V0&0\\#RC=W
M(%.E'<KQC1SG2/IB?VS:$9%Q(J4_)..*KHZ0I`=&P1REB>YH/:.6`?R&R?'K
M]=_N/.4'[3`-$&OV!^I-$I*@Z55MV$W/3MR*':'7EZLUE7+'C<\39O`Z?))B
MZ['3V>;DS_:F!*6A!)_F@?U89#LA5-BFSM@99%T]RC?T+BENKH^6>[,M-O"6
MAL<NY8:5VWK:C*=_48,4N:'LBB5&23S:4L.YI?>P8"N8N:^]OFVDVC%"D#`<
M_%X)V_M8LLRB4<;=B(47U>5:N+JOB?!M($[C00Z])ZAC9>K:X.J-C+MU\O1?
M$5K_*GB=T!Q+1=6[`GS;AZ-OW3*9-&";],/Z4;M/;C[-Z_6=T`]NWA4;*JM-
MM]TWOCMD_`ROKA2:STRWYU#MSK)R5^!>9<H9:1@O=KVN.@2\"U[XC4N6\J$_
M9GLZ3S$)[DG,&]-[?!_1?4X<C7I@L0T\O;6?5);45Z9\W!X?WEP:K!UZ/<"3
M/$#_=.,)&W]RC:?XK!;ZPV<9!\W!.6)[30DXJ7A:9M^.>7BB<M=T>D;(OK79
M>IJ`D^"W4LT#_:M)P[E#9GTBW_`&FZ\M%Z<2\S[IN!;/$2J]E#N#U:DWZ9X_
MI8KW$8T=FR[>*7W7ZWE>Y/KZS9A1_9AJ][H^;5N=_9F?G/U!]6..5H+^=40>
M9<HLM_S'*NLV1.>*(>?'<2VX*^<OJH0.-PZ<->>1,2^%KKDV\K;?16\#9],0
MP_UADU^EJVMBWV0I%8/BY8:*44%?E;5PWC&)7KM4DS#G"QVO6<Q`^PBC()@A
M3L)UI"9"OW.R5@UY\,C%]I,;A2[&3*<6\(]!LM\$8<'-WF40LOS?RT>\O<=9
M5^ABQ`)JY:_'=2JI1Z-1-1S]+@B&[W/@<JK(#A%EG68!;VW.U&Y[!!`?E%"!
M$&S);R"/VN6^CG[RL@>;#0EQK>!JK=)>3Y<S@78+*FRM.@=\7-/L0^G4@&@V
M^RPA5,1$V.>)-CD(D84#DW.86J/.TR0OLGW(8D'>4>V!2DINYZ[T/*#\50>R
M4T%L#A?K.D'@GT$W^61:BZYE,+4`7E&%=[/C34IHXWV$HATY4)OFK25K?P`C
M\]4@F_Z.GB+@OR()7A9X:W%3KYL3W'T]`Y26"T1&BCBM/^;,_&MVW!WK9#/]
M2C!\I`_/7IJO8U7/W(03M.G3HFPO"\O!QY(Y\ZA.N1,NL\6A=[:_6T*-?(&&
MS=0Z=[8G,<MQLBI]R^TN2Y\P>YE<J78RD]3!!,HC=&$[%<IZ/)?))@64O@V)
MBH,B#0)O/)J1#&J=F9[#U#IU62W.><_*+^Q?:GW2F1L-(V@OIL-X*H&71\F*
M:K2//LP&E3X3XYWKZA1*(\^EYN)'(L;*;6E9^)6&40FA*@LSEG)%F'4>9T_[
ML"<1NV,R#:Y=.=X;GV4@?@XY)1A58JD)EV02O!<JWUR60/+*KUB\)[BC:$J#
M<6;+GYR6E0?HXN)=+DME+[5Y+)]6+SV0[6ID^(`,KMFVBSSUR<L!M<DZW!NY
M8*W50E(67]S%F/V#OF'S>)3R[6W]RW#/A?91`\Z@KCQHDS<K`%MRY_IR7!SV
MQ%;,CHW%Q'7J/)BYJ,';.V\\M/Z9-NL=YJ%^107]FOFY\?8S@C!N46<25WC?
MMF_PN5!'(K(3W:\D.NG1FL^)\6N-9,RMR!1V'=+N3.%"S-N,#A$+G=HWCPR;
M5Y-]A?/\ST=E"9I!E#=&$%(!`<*MWH96<1E1^<`$6UC#UA4@%[8@5PN=\*NB
MA]+0S)N&YAH7+5-3L8(O.#8H?$7PI.C5[L$EP$'0ST5/^70CO?%'?X[9?>J8
M/.&(3M#C2T["(*[N\>USS&_^L1N!29IMZ5^HX>--H"EEW8N>S6B2LFDL<!)1
M$M8ZFLY1$..W:/$EV%)K4ET*Q#-*1S]"ACE)3+:$&?$BG2'ZWA'[:[FA/D/;
MHR-(C6^6B@W0QB_'>Z&;>J.7_5>8;G?[`F>'\9[<1'2W;NH+APX\`<)A7H?I
M1I1A:I:5=(AEU:P\"$0U."51I*A.50Z?B7O<X[7%[)4=<P%6E=UZ@\)@1WPL
MW&`@F:9AE9(/L+;QCM\:;5.T55*S`&Q@IL'5K5V<`$J[!@1TT*J"48![-@NY
MZ^J]I:0'T"%6))"^"IV.>!U\P;F[PU)R\L!?J5%*Y(_732Q'(S[<4V=ECVHG
M1OOHH#H$T=0_J=CT7K*7O,_I2+:4N"OV$<&=QR*TI"!+;R4.E<Q4(U$Y%-"E
MN`$(*P#Y2`#LE\#&&,Z#+'MA1\V?@GA/%X$Y6Z"R9>M]$/-ZU/DCI@O]*"@P
M^TMZ'Y,'_AI\7;KGY6R*QRS=/SS2_PW*D6SU6!>+S4C.'L`TE;G:)`]"P8"M
M8WGYFV="5]?Y#H=D0PX+YR+XDB;I]L631:=>/]4+2P4=E"O.T@W.<SK_07R)
M>[MC%3=?7+(2K=(M-R@0(_'9-5NCVS71;7#;5'GCJ/5B:N6L%:PF+^S!RU0=
M!^=LFT"\Y=6AC+;IZM*"(=1:TP9SZ[*&J,9WLOX4&X*E.%^-6'O<?AW:!VR%
MB+M#<'_G+++:A:DY-^!4C_2EADFTZEE[X#4MYJ$K5:12U1$]JG.UW7[(X7K4
M#B9Z[DE:+5\/"F7O<!:P@ISG(G=NZEU-.'E4H;Z-TK02=D6)SN6;"P">U`F?
MHA>F^2Z*.]!A"_)/`-6GXOP*_;2MSW_*!M[RR!+QMN&#*5?HR,$8O7F;&-FV
MDT=K<&?$YLH+MR\UA$A:1!2&++U0:1;HW`5QD%FLU`T8^1-*M#&:ZRP/]2M*
M+P.);G1J_03?X7*4+2>'>LIEA/X8YCM>QDVYU$R]:EJHP6ZB;,N#.`)OGHV!
MN$,!X7?;Q@!MT%KBJ+F@="I@=LH&4$Z#6,&.XWC6ZG0[P6B#WH*;)YUXU&@M
M#51K0PUZ>[\/UJ[8H&M[#>`D0!^X3D:I-0D>-K.>\IO[TJRGPW[9M.)1L8)?
MH/7:9'5H3>?/]JM##SS'O4IM2T5/]VNGFYT.<R'=X!W=(/H-W\.4EOO.]UA3
M/4Y$*W]NV5NM1VS;Q=>?*+=S!HSZ2K;,WKQA]BIF_C6/=,%OFK]FAK^*"?%8
M,S!0/.PN!%507$;`W5/@R6G6'M;`,E+L8#IUS'B![XLE+^3IW(=1R@(ZQI/C
M.I7;JJ4@.\M]:`C-:-&!./>VS:+FXQDY8!D]K`#.OQ#C;209)=2^D13%J;2=
MR!7ZG8WSHS&BT?M?L5XR5%/.,QRIWAYLXT<M1]J='@D9K`9<!UM\D6X#(FU[
M;FX-FGS\,L9'"#MT9(;8:/2[&.^[!6Y_.P<SW&`R>?NB-"L>@@=LV0VP10;6
ML+;U_JUN1-6(\7IHVF_+=[_VO[V?O7OWCOT?J@:CZ[3`GG77'6#ZX9KFRF5?
MWRCWA&9J?64B4)\)2L^"Y+-&<W5F3,,(VG?H,)Z*%Q];YQR*%/'A4*H^%*I_
M0]_-_G2J_8E.^\'=8J=@&OE%-1?8$.W*MNFDDMR/Y<J5IKUD:\URY6%#R8[/
M8[$`N`)K'<G2#VN<;=G[?`Q8'T&6Y[[%N^"%)R%6FYN,)"'9!?$M9M%AA+/5
MYI+D81#_A@/[7KJ]GP?M&0:8L=8*]R@'-$,'MC-T8,S6P#5K]H>2.?M=L$>,
MOT?N9H2I6E/AQVB;)L5CCG#"^_-=X)#;9_3]^QEB<NZ=8QI*R\S:RO1]F,<V
M:)G<IC%]@0?VHNOGU-05]GH$E+OL-R\#&!FVG5+RY:8%4<Y>+/F&G1D.36%+
M?O0FVAA`2[0121_^K\9B,.\Q8L@B>]@KBE>D<S6*'6&\O:H$/_0LZ6S*_WS-
M\8E:GX8.3B1/>BUVYI+*[MBAB7C&:XM-RID9PZ@PUJ\Z.E',C<Z4_/3JPY.F
MJHP2G_`'O!K#09XFBT_$LUYK>%+.U"B&A++^+Q&<*.9(9U!^_B\3FS15:=30
MA#_H-1B8^88JAL[*#&773Q[TFF*4TSD:V+X$C/V(5L;^%,`8D\3_WFU:7DUP
MUH5W01X>BY.D]'S_L,^+$OMW[UYUG"8U'(,':\=/Z7W3@I>#:]S=8*]2%D2[
M83W!>'NPZCW+7TQ#KQX/`*V`X#@GTDI[S7MDXNQRR0F5A/S@/6.&&+?J5R\"
MJ^$G(]T7>1%PU?>@H.+@^#PJ[S`0K+KD>E"W&./SC.*&6$=,K,-2K'<-L8[K
M,*#\571BHTSV22!:#K+>CB0/!?,,[3*\)?OMK&PDQIY<,18-R)+Z/_D+#7EA
MNYIS^CIQFN\S_&%/(E97WDM]@2V7T<=M=)?.<.(^_85N*MDX+VZ#`M\]!SN[
M8[DJ:KC:6@HT[=MD8B!B(Q$;ZM]Q4?VGZ2@N)27M'6?5IU%7";8[!JHD!XV1
MI'C4)XK?CW?.T]U'6F*@HVH4GE4O4DM7M[&5T`XG[>OGU,PN*LE`;E]+WU\M
M&724'X?]75[^.T#5[/ON8H@GUY350J^^A2RAZ:U\[&1V>3#;P=-(J$$=C0R-
M[&I!?;/`HPL%Q@#^[<?R"H'VY@"@J[3]"I[Y1Z5*=+O'-NGDFQ@DP:L-N]=+
M"KM%AHP2;)M!AD)WB9D4?OA4>P"K3@!P>6VE+.D3U6TR-RW(<?CV(7WZ-L*$
M*<`/[!],[G]HR#W]Z8\K_!#$BZ0@Q8NJZH!,V:6D4.Y+CJ,E,6P$$D,@K^T;
M3Z>!X931C2LOXD'JJ_E-76B/G]HF2MZXM5E6"@3DW7K]I&G,1FMP_VVJB-TP
MO`X<`MI34MBMI5,<K;SO!;\7BZ[G_ET@U7P)@YSN,1WL)=%RL_7E(BCP!<[#
MC.Q4&YO=5QJ5S/RX0*K&VEG>HR)%C':&&M1>1&2]<)(&SFV%,^(X(S5.3V[1
M=LBOQ9U:%2?@4F<XVYH:>1T'Z&.;4E2=:L?&>9"]L`=QT"E42#"`'Y)4"YE+
M139&/K6:W&1IB'&47U+`RSS?L^WIU:9YCLC4AYEP@G)@1BA/);`B0HP*561L
M,<Y/(ZZKTXA>N*Y^"'E[>E(A3#>-@Q:1!"&8TS*75JW',F`#58SK*@V2?)7<
M8KK6S0OJ0V]XCP$2WH@C?.P%\[,@CM,TJ7Y*S_`M#C%YPI&MCQOLL=".<;CY
M4VT.(<X:I0EBS)'@/D,5?U1RX\XVGZ'R&?7/18KN,:J>XY$W'F_FJBG8U4>R
MRW.HWOGQ@;7/R/D/]4RO+95I\&#)%+KDH"GV#ENR,K(E7L07@R&/*RN:,>28
M\R@;Z5#@N\I:RH"#5PNT$GFC6H)F'"%O.=$7"MD.[P,^PP'K?'1)ON"H>:K-
M-N:PY0X=6EC/AO3R4KU<X&I>,D$E%\39H(K/T1#&U(O3^\/.1[VXF#'MK\#>
ME_.QX?-!ZOEH#,DD\P$>0+AIC/7]2`/67MF*7^G_9P<=NLQ%UXTI0\8^W'@T
MG8.N&XX2(U%Q\LA.C#\;2A/Q5,V&7U9B(%$V.4-AS;7?ECE)GB@C9AF^+__-
M;,+W#9L@?OWC@L8P3T%!5R?7:<$;Y,WYW1KC7=8N-F`[KIWXVEGL:N@,58.1
M&.U!"J`/'G:R4,`)I'#@-I7-A%"_P=S!`S)+WZR3[)*;/Z;W(2-_@DB?AS^J
M^NV%OW.!PA/N"8>RDT/Q(L<NDS7CS/H1,>SV;V,C>K6I7"-SB6=!;GX8T(TW
M]/+5<B8Z-Y,;'-A>6!V4\NM[G(M7J]4QX:=&\,$7IRZZX+!_W<&X]Y&]@S?.
M3R]5EMDRLYZ=1GQ`;HF9(53'9#F27*:M*.'OD?6'5RWU^/(.Y0S>;BQX]G?-
MW/#=XAT=B<O6F3S[G>%_[DF&(W3_POO,2V"WNM![<F?-0DG5E]A,F$!>FKD,
M0E9(X*7CI*<V8=C%#CILZ,;;<=>F(H(]YCD.Q%!`W-00H4]X]A(UFV1T!R^H
MFAG+)$RWF#<4-UT32TFAJV4<XU"6RA##9F@EZR@/L@BV!$#X,'"792!&1L4]
MFG10*E`VE5;J@,Y$R'E`NR`%,J50E>,&5XN?!88$/]`@)')R-;90RH;IWOD2
MG;`9.1`I@ZE5AC_U.DU2&CK3,#-Y^!"0)+]*\T:C]R[WH><!Y4<ZD)W*&Q^.
MFN,1)T!?"Y)OO/`M+J"\<2TFLJ;U,5H&T_<@/;R'<'JE(MMZ'`TC:+>CP]@N
M4=%0'3$8?5T.'UYY["M2NF`21J'T0#FOL.B='^J40\.6HRHNDWNDZC687O,:
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MG`J/7`]'U7B_(T'M9[0(!^5\/!%-E\!0R00V.E1CLQ!(/^/$CL]F$"RJ.$PO
MANQL.'L1\5YN@:**"[Q=5*!K2V`UL,I[@A57'1J/MT&M7O0,#;J4Q=1*=!F0
M[-<@WN.SEWF>X^(\#O)<%63(K(J&`90-UV%JM>IC`Q`?`1E"6,ZL@:U64X.)
M&'^/_",.6`NFB%VV9RV?2/+`SR5_2M+['&=/XK+<;E_0/]-9(S'A3J8)0QUI
MZ)1VO/>`]A4CSK!67R`C')@O;6'@1WN)Z>.L"&](0@H<LSHWRZ2@`D'HZU;`
M[+IC&3&#"__-L+:#EHKN#2=$!THD2/TJ>>^.LX85<$O@7=['2EH[5CLFG/S9
MH+XB"5[2E9EU?LB();2/,\-MMWG-*!$G]<^'67QG(W=DPJ_WS;!Z-^FB;K6Y
MQE^*?1#/[_,B"\+.(J;&;$#NA1GAT^PB'LA024<7'26E!_W%^L+[O1P-[PTL
MI5%]`\J`Q]0>8+'9X)#=R:K?C=W).D\3JMU[JN"EIJ>)M2.PX0SM#ZQFH=6#
MHR)&#>GE-S6/H^^ZKH\'-4(&`5["+2C<K*SW1^$%Q8-_)]SMQ=S(#UJP]4.Q
MCR7R:`N\'F=^6K[?,Z"693UGQEW]3\]<',:S`[DPQF&""?KT]NXMVN"(JD*,
MPC3;I=Q:5&;#BR7LP)#%ER:U?2P/7+-+IM5$?'V/$[HB++X!O14TO%8;K(5[
M/6#ZDC,;G&4X8J?:^%)=O?8Y>F?;<,G].=#!4X\9:E>%$*S$>2#.;(9TR^Z6
M4?4HMAIP7@1(;D'JR8C99(0-+E[MT$*#!X\X^]H-PU(]C@_QV(I6)^:,CSZZ
ML(;KN>8R#P.8R8J;!^'E,'-P6<91OAE%[Q`#]J)SUOF.SG3V?*>V=_3=1#F5
MYNOT*"S4S0\Z"C1`W&IB2JU765:H231N:2'W>,X185E5*#Q"Z'-E(5/9-8I0
M.IE-7_$K9*OM\S3O+BPHIP&K1W_\YNTJ5OS/B/_=`S=O^+KA**_K5.'>[(53
M425T@_'7[P<L!F!8CF:L%X>KHB_11WV!_";!Y,</^1&.*]D1CEO,#E31*&2^
M3;."_(NGL43CG_?6IPM='P,=!;C/3RO:%0>@KN0'H&:H9H>:_,IF6UZE0D::
M$W)R>HK.25;/2="<DYUT3L#CC)ZZ9'9NTO$9`QQ>J4[DYZOG!$=G0<SZD=Y4
M31/5O3,D)P_,6`$=8C'$J;Z9D2-.B4I25-..U5+#X2A+;Y`>%#)V1G&99H@T
M/M?S(PD?49!A],]]D!1D0T11XT-'4-$\9"8*&8M?J9FZ+S_P(XXC%-`E49SF
MO/"J5[6.[317=]C'B`]X)E:Z0LL_X(0EF\[V.4EP[M!,P>TIT/&+\^P8I6@5
M"0_ZEY(AJCAZE/88;$HJC/?E$'X"0)(=\;'50A^=<=O),7N$/P?&V>T4<8L\
MCM-G9NE,LRMV//VK=29%;G-V?(9J%JCFX4$&IR?DP\$HJNAE3S^OZD.["+-C
ML3<)0Q\/!-9&)W<J..WT"&B7[S8O[J<`#T%`6=)ZO*-_?;(60T]+D.?[+;-_
MY/C4L'?.OH>>]#@SK.??.QUQGFZW1"Q&YDDD#B@_8/I`G%^1X)YU?*#_=+E>
MX\@9)%GA.@NG4MW@@R@C=,0)-5A-<3''W*^/-@>!=@X\N\C32Q74RWTWMOT5
M.]B1(HAYA6-J+_:9_/2^M*6JDAZL$Z\:44O\Q"C4'.:%_W3`@`_#ID\3CH\!
MS*-W*8B^6;"*N+?*<I>^NH_)@_IB7<MJM8E`/*CDW>6%YAMCX//WQF^=COC6
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M-4]4,?6N7=6`LJ3=Y1SB.2`-8=CSJY,3U>NXM$#H8`;MV[JPGFI!-:PAV7ZV
M/S#ZB.:]7Y2<)A=.\7"[E@<G1&"&^>3=6R96_-V_!@;22=?;O2.*WDO<>4*V
M0?P+#N+BD?=/3G@2@E<[L>L^8,P.-'EEA+=5(9H3(4&%CLAF[*3%>(5P[0],
MCH?R[7@PW1-@XR#UQNE8ZFAWGLR`5V^;\O&9_(HI:Y($V<O=?K>+7^A*9Q<D
MANW$#)F`I,L,L)U*&R5!!QHDB%!)Y4<-;6=H?U^B8V6",Q%#X5%^*D\VM4RU
M2YWKZ^0P^:'0TQ7<T?KMRK4(N#%;Z+62.?Y3@2W'STZR!7[7`;?\W&;G&0UY
M3I_"3E@&4]1?O27YYYLZI2F]CRU;).AY0*VY.I"U\[V-X8B-KT\<2]*[$^X1
M#8(GH^.AL]7VHF.PW-0R&&;UF157L?-:\X@8?F5YC$6Z[LB*&:*#_&II9XI@
M?7Z'SDB:AP13N<@IDB)2KPL]6#9)A,MPD=2D["_H8<CNV>:W.,2$-T:ZV.-+
M"N*./"1D0\(@*>I\M='ZR)(CR&+)%G5+7TIZ=&"`*`?$6*`&C\,N"?19@\$0
M9P?$$47,Y!WE#<3A:(CM%UI]0:\?<<-WEM?VV13LZ/OSK8`B18'US*`@9UMJ
M;#NYNO.?/V)<H"@HL">+.2>[H%[9V;$#CX7/7LZH&WFDMO:SRPY8-S_HA9T!
MXNXX&=4DOFZ)F7Y8PT,1'<S@Q;9Z';N]LFX^WBSEV@CMQ-2W;3;33VBW%#IE
M,OF.;1#CO$QW7./"K5FX@@FTY51A:^WLLG&H3H-=0_=O=)AJFQ,#4@Y3R]WQ
MZ1J;SMHR2BBC)T71,G-U0M6O1MKJ3Z`U81*RJ87G.MCBU>;H1=QZ7VL801LO
M'4:UA/G:>KKSBQF9+C67WLF53ZRZ8L1/4^47`<E>YDETAO%FF43T21G!A@V=
M+9F!I%0LL+8Z8'%2T:HF1YR8UPU@Y.A`[]&.=!^PK-U7Q#&RN@#W#".9`*-]
M]J3_%\W%%U6B]2378:NFZC2',:?>IN4RS3!Y2&J7Z;!-H6(!NEFAQ"6INLD&
M'C*LWIUULX9B;Q5@]S'T,MB]FZ&@[ZT;Y4E4JGN2[.(RV:395I01<K@PZ<P;
MQ"F[SX3JH#+SR[(-#M3@YN%5R^$G(C"9B*]+?O#]!(90#+7?<V7<6]5O<<SZ
M0=P$6?&RSH(D#_@-:Y-274JS9LP3U%&:(V\?S>*4B).B)NT4BNM\"&`4P+`*
MVE\$35VM*<.IDRYERI#M!#9>D9CWV-8P@,K?Z3`ICDF*S>*FG!*`>ET#@<D%
MFJ*I9\^D>$19B6_'I!#<(QJ+H#9QJ::>6I7:6^S'+W2^SS(L[ZFA2[(9LX7.
M;9KC-SC-,SM5QADJZ;UPB`-BSAJ8FPHJ,4#@"5]+$3=*_YKRG-XS2CTVK[67
MXYP9G*8C_SLUL$T2<__9\S%P7K;O_!B'B3-4<16>;=WR;$>D'AP9'V]RN.]N
M^O:9J&V9OSZW/XA^=00'_9[1>WF\V.[B]`7C,YS@#2EZ+8L[>8$NA[N1MFJO
MEQ2H(O%Z]3L$/D\7NX9"VKW([6(TF#K=!4\D>>"5R#J:5K=2<%TL0-+$G;B4
MLE52B/IS8_:EMMZB=<>4EYAV#).F$S7`EJPUJ,9?V9%S7&$,4_HOS`LVY3A[
M(B%&^R3"60F>8_=D=]9,Z=2YZ0YZ@`9SA+6[$S:*O4W5M:J1)[==I!LRA5ZB
MFV*7=(LCO`6F(.36IM$5KD'LA<,>"NY]"9<I8XX>2K1$C19\@6XEW*:-WPPX
MPBMQ%7/<!"0R77MW<8%:6G>B,]'/V2'N9%1>)+.=@34UL?H/&B!(<(&M9\U$
M4KM<[6`Q^2V"_7V._[FG`=*"E=!65O/4GFR7\H#V@PIDK:,&]3#$QX&6U+2?
M90LK+V4`+6_T>397")3D8+4'E7@Z!8V-]>UF0<?GT=<F5-!Z(&)N=PPTC'PS
M;DV,AH+GZX6#SL_G9.P.7(#%T>PR0@>Q)]9.?2^OY51AC@U/@L$78VUP?EY/
MV3MU2Z-9&L5^=BL>VR8&W>N08&DUUJ%#Z+KK\[A%8-VKHYI"V%$(A$+8\E&>
ME3]5R53W3D6+$MCR7^DJ&1KH]]6T)0L-[,:5IC9AVWQ>`1<EM)MB>RMZ!59F
M\(9^],<@QRN>;<^O@D2:'M-%75(6T%&N'%?+AI6C4#ELAMA`KY+49D#$7T6Y
MHW_N2891+`$"'J!KI,TH-)?13ZTQ[*$G[V&QR6S*!<I,=Z([E3Q&@-IZY,M>
M<S]<NPI76N'2[#>#>2(SB=3ZHPX6T_>[2<//RSS?X^ABGY'DX09G)(U^#6)6
MON29_\6A[XT14VC/98J]%37Q?H."$`E*)$AGB!.S(C?/8L#4Y0['P'N3%C1R
M(FS'E0YA5?J\<W=68FS8^<>$(Q=A,1DTLOS\%_IO^C_W5+?I'_XO4$L#!!0`
M```(`!2!;$<593>G)3(``'&)`P`5`!P`:6-C8RTR,#$U,#DS,%]P<F4N>&UL
M550)``/7_T16U_]$5G5X"P`!!"4.```$.0$``.U]6W/D-K+F^T;L?W#T>;;;
MI?9<>N+XG-#51[MJ22')GITG!D2B2IAFD65>U"K_^@5XJ>(%5Q)DDK0>9MQ=
MC03SRTP`B40B\9___;;UOWO%44S"X.</JQ]^_/`=#MS0(\'FYP^_/EU]__</
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MSI#/I/_X@G$2ZS)4)[+)P3V**-`7G!`7^9W8J??0D[?'!"68B3Z^6]_M<)2)
M//XU0*E'$NSI,JCJQB*7Y^%V%^$7',3D%5_3`;W%-V'<CV5EGQ;Y?TQ"]^M+
MZ'MT9KK\/:7&WHMU67?C<-W)HCOU;=.*4/QRY8??>MI-NY>^<T4:DP#'\7$0
M:<\1;<J^\DJW6Q3MJ8+()B!KJ@(Z0[MNF-(I.MC<ASYQ"=;F3[.WGCPSC;#_
M,3MZ13Y3T^-+&"5/.-I>!Z\X3C+5T87F)@PVC5]UH?3[2$^$K*L@":.]+K='
M@IY?+K05/V`74]S/C$*/!0YE3U[N([Q#Q+M\V]%)&S-1W]%I(CJ-8X-57MY)
M;PY#.A*3_;V/<L>&&LN.68`^=Z(.+.GQ'NV9*FC7])<HQ0=!F*I5W%%OSRGX
M>H&?M45V:-_SNYD9E"!NL?;W6W2]QSIS19[0F[Y.JB1]Y])PNR6'J>P\S"9J
M^K<;@IZ)3Q*#R5^G*PO<AD'F2SR0S0NU2CIN3/AK$_==/_&FV-14EKSS-$ZH
M@J(.NR3M_GKR_8!]E/M>R?XI0D&,7"-/1$C?DZ]+VBC<8WR&`[PF^M-\BZZW
M7_0<X]]3JHK+5Q.WH44WBG\VC)]FRU\KOA;*O_;$EA=3!'I]0OJ;9K!L?,J6
M[VG&>9/,NA]JQHZ0WJY/BFKNI!F+.ET-Y9^:<BKOQJZOBEHN9C?5J[JSY+>:
M,=>@LNS#FO$BH![)(S*<[\UZ'675O<`)(K[E1;?L=$P$3_@M20WB>EWZAER#
M#15EY5NV5F%#WEMTUM=A0X;$'0RY$ALRJ=774&NQ,:^*?H9>C3L:@+(_2^NQ
M(7M-,KM<&,ZL`FK+7H*AA$3D]N)>QG-<B])>%`P)0E>F:XA^CT/$Q#IP*^QC
M)'_0U)LR['9<%*N!8*Q&QF'J&7;K?:!8IJ%%J;JQ'-DTY$Y$;CG.:;RGX9,;
M<<7+:/*C*/]"@#=,*RR?Z3/+9UK]->.[^/D&/6.!=5:3HS[7^LJ)/O[7=V-P
M>(\C$GJ703=6&]2C\OR8T)'0@^L*_4A\/X4)\CMQ7*$<B5?J2'7B]$`WEDQQ
M%.-N,CU26N0U:?-I+,BC!.DLM8MP3*>N;%VZH6S4&*0+%`X\ECB4_\HZZ)/G
MF*6BAF[M&SY+_@PCU4S-?G%DG9\^QTE$UZRR(Y^!S+IWM&F='S]\]U&;R4(.
MF8QC[/ZP"5\_>IA06:]^8G]@`'[Z_L=5D83Z'_0G)__T`]X0]L4@N45;S.%8
MU-19%0Q6U78:U9E%D5MV2?_8TED];;9H\7&7I:%][[X0_Z#N=11N.TBPX"54
M0PDC#T<_?Z`T:4R9#'>L*^9OC:&$<PHE0OXU-?"W_XOW4BTTVCHG,U8#!TNA
MA]78BCA/(P;WBL0N\O^%4427^@LZ>0IT(6KN?)JE.F1P"HV<P`R-*^+CZ)RR
MLLF2\"0#H];2^6F6>A`@*53P:6P5E$">:+<"V5>;.'^9I=";$`II_S2VM$\I
M$QYCY,I'&X&X:VV<O\Y2WBT,A<#_`F7>A[V=9,+GMG7^-DL%"+$4BO@KE"+R
M]2=GZXK^%BN4T6KO_'W6"N'B*93R-UBE,*=`7R6'UL[G!2BDAJ90Q]^!=@K'
M\X''%RJ!^"Y-V(5'=L]2OFV0$#JK'V>I)4UDA<8^"S3VL1EW:`K"1BRB?L6Q
MDZ&L4?R<"3B-O]\@M&/6\I>/V$_B\I<L3%$QF^)GYW")ZFY]10+*!Z&33!@3
M1:S"A+Q[N*([K#PI0`-`O2%4X,)4G'5[%V,11BXHOC6F^[H\9"WA/V/^%4?/
MX2'`"*/+8ANJK=)&>ZA8B%@W,AURF%^$*EG"%KMV4L_;.DW.413MZ9S\&_)3
MGI=M1`\59U&JD*]Q;4R+L`!>CIYL?>$TAXK?=-2O"((XFCDG?;8S!V]Q4LA&
M-D=+R*!"11WUJX(BCI'.2<^'E-7L$J90K]5F4"&HCGILLBX.K,Y);_6DV?K%
M:O4PU:"&BG-UU+(F(G&<=T[*ORA8?4)O.4*MN5E"!15#ZZAL!1)Q;'E.2M8=
MRW4;!XJ]=5UCF[R+H]%FJDLJR4CC3\V".P+R)59&!A:M,]WF*D$LPSOFEK81
M:I;3VED!1Z1T%2KB?1G>+V\AN0T#M]-:>B1T5C.)2FG`6(:[7/$&M?3+;>^L
M)A&!4JM5S/TR_-^R")7")W)6DX@HZ0:',W9M^:Z0#E#EFA6[C-(J/J@1Z]?M
MPED!!Y7ZG>P8P5R(ZW2$K'_T(R9R5L#1*",5*JV`AVX1YP/"2G8<\(&GM49W
M[=)9`8>V%/J6AZ,[H;5D0DGE.LKX6RX4E."?0G976QT:$=(X*^"`5R<3D,-9
MQO)0[D@>\"L.4JP?U:P3."O@0%@G!4NP+&._W9:*T:+OG`"'P;H-6SX.6QOK
MB7CZQQ7'S)]KTSDGP+$QNRZ=`.`RINLR/)@M35=4DFQ5T@B%UMH[)\#A,K6V
MY,'1-AI@GUUP@?4ZH!X<CI,'NF=]_(9V'$5QVSDGP($O4P6)42QDV/'D83K?
M.B?`X;'.PTZ(QI:7-)$U54^CS@EP#,R"'C,,2_"(.D4[)2[&R?S#6PITR]C9
M5&ZD*).=&TV=$^!XE$)!?*UR42PC5.EY).?['A'O.CA'.T(GE`I@65!22>R<
M`,>>.JE;$]<RW*L'5D@KP-XEB@(2;.)3UTVW:5:@[`*OB4MDD[F:V#D!#DYU
ML@!-7,N8SI\BC.(TVFM-Z.W&SB?@0%4G#0MP]';+>`7@(`Z@2G/-TB,$+Q+>
MXN1N_83>Y.=.)CTYG\`O'W:9[SN`7$9R25M<1IZ[\PDXF-5)W0(<?X9LE!Y9
M*,XGX+A8)UUKH1HL$7O\J_?U)T[?[^%;WNY2\=Y%&9]>YC/<XRBKR:"W`Q91
MS_O&OB;`16R76[4X3M/D)8S('\<1*S>!)A7TE7YKJN<!6\8&N07R.HY3,WWG
M%-!W^BWK^@AJ@=O@'*+N/CAO#7VGOY]^!8`&O!(QBG=4?6#]^)CY\87UT:^@
ML]WD@2D-KTA``>$(/2(?QT6^UB]AZ,7R2WZ\YM"NCD2:@LVB`,1"W)F83A89
MK,?0ER]IM9;0;HNQ&CG\+\,[^24*X_@^"M?2.'VE%;078JRZ!N]+2'MXI$L4
M"3:G@?<%15\Q>[&I*.8@FTZ%1-".A_FD*H6RC%N8O^"`>AL^N[O@;4F0E>-/
MR"M6*UI!"5U:R'P`J_$L(YK^0/5!9<DJH5U0C\$/LVH`:H5+Z:`K$!FK6XEF
M&25+BLW$8>:2;19;;:$+#ADKE8M@"05,#L".YWPZBCRVABXGU%V5=0SB,MPS
M4B8[O;T-@[!AK3*-"DB@BPN9JU4"1%S3>SYW(H_6RBX?Y.^<IA3F,:ASAM=A
MA"MOMEZ^49E1["1`T?Z:"C)+V:64%(R?#8`\:5X9?1GDJ^!UCHQ-;&AAB`N9
MSV<*.F`OAE_QBJ;2Q%H4X%63.IH''\@AV#)OI^\6)UI^0JT=>(4D8TVVV2_U
MUSM:!CDV_XG9D]/8.Z5&A#;X-MT^X^ANW7I502,J;]H5>#DE8QOHA+`TDYD?
M!>IB/T,Q<2U82=8/>`6G3AKO9SQ'X(LX3Q'`OB!^2G_5>="F8T_@I:&&MQTI
M]&6<Y92W#<JT*8UU2$0"7BK*>+V1(BGU._,S@29&U?K!;0]>TDFJ*3WE'H$L
M8MYOPBOF*@/-%A3@M9HLZ+8*9<!Y>?3L(<&M$+!4HDJZ5\X->X"GS:-9XK5.
M3Q"I1QTWWI-)R-.5J]9^?"&SILY=J_RM4/H[RT[$%SC_KX9-]^\<.L?)FO78
M$06TBZU9YB>/0&>Q9XYUJ$B@DZ/LJ*IN!CJ8IUK"J0@HG^YV/G'S4I#Z=9TT
MB*$SIP;4MR9ZZ&$]WE+2<[&`3KL:PE1,\2\A]Y(#4\-")%30"5I#&H8"]F!%
MK$;?W+5O!D]A7]>QP)8&/<CUD9*Q)[8<Z2#(&DYH%R>7)W\(M<%8<K9\J)(1
M!9Y<`&R&"`,VB$[?B/057!G=9/9:!R4IE"D",6_=-E!=A%M$`ED4D]<>>@^E
MU)$@C"G",F^55J[M?L'L)$WNY-3;0F^/A#H1>BMM_A?P'(2@'IU2GU(ZZ/V,
MH6Z56&QM9"$5W2P[I]0PGP!Z1V*H6C$(:_M-0)W6[M4K%<II#7U7Q%";`@2V
MMHI`RZA&B3CU=*S;!_25$M.IV027K9M^D$/ZX&'>T&DK2VK7V?<<&D-?+3'>
M[-0XM[7.@FU?^U4\A+ZTP5>*2(%<]BUYQ+LLIDCYB1*H<6B04,G)&YQ*7$E'
MDUSN;0U%>$W.\UZ%B0:%5RIF[=QJG3V$4::7)(G(<YKD1Y%YG<J^^1OBGL'O
M6YC8A@VLUHYB0/TJNE[E9>4NTHC.<OFQ559*,ONWNPQ4?/F&(Y?$T@1+X[[`
MKU\8K^S&Z);A>W.1YPND)2.1=`9^T<*"E:C@62N$/3TS$0^0<IXM+JUJE&.R
M\P7PBQJ#3CL2S+:*AT"_G_/O-$ZR)(*G4!"CSL;;,Z+B8&L\%4"FX@=,=V0Q
M2?`CCEZ)BW-1/F`WW`19+ZJ7.(;^-/@]$Q/+'$48MDJDS/O-!^@K*GTC(,<@
M9.]Z*/G&^3*`>N>E9P!D*G'(;@&08RRR=\$0KAZGE(,VE6<=EI60]F=ZV*%+
MZMJX+SNTM@OCW_!#\<N5'WZ;Q)V^`S-F(ZQ%!G1;C_%Q'X6OA*KC;/\K=;JN
M@T/EN5,W(:_YHSQJ<.:=36C8<=4AC!!WP+F(FX#=PO_`T?]N^M(Y';"71SJA
MS3';404N\7$-ZU-H;Z(8XG/0R:PVC6PH^2SC"MD%IMRZ)%.PQ,BJS:#38X=2
M*-]\FL@7-D5=A='IEAVR_:$R`2$-=$KMN/8@%<-2YH2<U4I!T]/`H_\]IS^2
M1.:JJ$BA<W3'GCO4TEC&*V)E>:-ZD%D5EVL10"?]CFL>8ADLY"T01`(FLKO@
M@L2[XDFVN_5I'&/I)"*E@\X2'M=$E*+HG=PPB9?;FU>T*](J3K'TGHS3[`0Z
M%7E<&S*3RS*>*6ECIF+&Y)4ED,FF'BD=>!:TF29UK:&)L.\.9Z(SRG7P2D4<
M1L30`"ITX,G3PQA`$V'O7<Q$+>`^PCM$O-(K+])RJ$>>9:(JW9)N'8*G:P]C
M,]K0>^]O)FI,IZX;IG0!OT=[-G6R9]Y<-THIAP0]$S];FXV,2:=#\/SN88Q)
M&_H2TKW;\,M!5+RW:V0U#5KP=.YA#(2'<AF/)^J?=%@Y*P9/Y+9\?&@">PEE
MW`20F0<7VTHQD'0VG;1M&SD&*J!+J*U!E]0R/=C]/241ID*@XR/9W_LH2.A*
MR[*BLJ=*)8:BWPEX]G1'5?/MQA#W(C;.%**+L9>]=?<%)6F4"2MS]W-AL'K,
MR/=9YN9+&"74N+>Y=+-_E5E1OY[!,[#MFI8%82SCM+$UR#*\3_IFI4,/GO4]
M[+PDA+R,W7=UL#PB']^M.ZUB^KTX)\"1WL'F&AW@RSA]U!>A%1?9.0&.#5LU
M&4/<UJY83V]K=44"%+B6ME:2SIR3J93UL+&U4@%=1M9+=6)E]X,I9#JY7N!G
MW66H3N2<3#/M5J5,]:K#P;F``J4/!V==J?1F4^<$.$YK5=5<=,LX1;RO`2OM
M^#R,M?8D'"KG9)H1V(Z#7`%T@?L/PV(K2EKG!#BF.MBL+X:[A'.\^=1:.9EF
M3+:;@=D4RJ*/$#GBM;)A<4ZF&8?M9DZ&N*T5B8)\"HKBS:++\0N+^[PBGZW@
M_+>2)!9CTHUS,I6B&T:;6V.(@[T,!6X>IW281-&>C@A5@28M>N?35`H*6S`(
M'C9;2PM\D=J1[&&6Q0OTL=E:.*!K+U6NLK$J8_)<M6I+Y],LXYL\%,NHX5<^
MBZI4X[&9\VDJY84-==B`L(R*=K=AX%(A',]D`N_@MF9UQ73.*73[<#Y-I4ZP
MV?&$$3Y;!?)@[:+(L\TVNAY)4JHO.HNEC/NS-+D-DW]AU:#7[<+Y!!W,--*O
M:!$W`+N`8XMV>O45(E'FJMRMJX]E'W[^'^QMF$`#*LLTB_>NY`M___Z=3]!1
M40N694\2`Z9ZC5)O[BR-28#CN,C-#H-X[!IS=]$&!46ICG/Z_=`G7FY3@7=?
M07NW+M2,_&.1/(V5U$K_(%7K6/8AM<>*:B3^0JLQ=-4Y:W(7.!!<P/.N_9AN
MMRC:WZT?R28@:^*R'+#\!A8+IU,!NBQ6//Y3<PT.=&J?"8E`7OJ6R?.):NJ,
M?ORK[,!'JP/H$2<7NN#41AO9K(<6VYDT@D&\U%PZ-=V$P::9XPP0V&M&K@*/
MRZ]Z))IW!E+Z6)M+G>':H3?HL=M-3>+@9P?XPQ70&V6(E\42]F,/U\.'+TCL
M^F%,W1*MHCA"*H@!R&%'9Z3)R*"'E$+"HIVA'-#,!TEYH?]86F;LT5(I:J,Q
M2CBM(4;'38B"^#9,J$L4(>]03:/"G=FPZ=0?]'@2Z((_CCHCG+6;611?*5*9
MXD8%&Z!JH5G29Q%+)7]@KV"RSIS1VM6S9[,13%S7S2#^^/G3CQE`]HLC%;5L
M#!I00X\X"W*NCTY#[#-?[,1W$<=/4^8SHC'6E+00ZZ&0*;-ET*0;Z+&HI0?^
M6F@*<^;#3E@TJIQQ@"*8TBI6Y^Q8,=,..U\J_J(=Y^S<-<3@U>'9;!QW[!%Z
M2-M0'G_$]Q#(K/W?,Q1\S2[<C>[J/B>&'BR/`&(TUCG1&6T""NC1)!8I?XQ(
M8,Q\`<S<Z7*QN\6CCX;L^WE^)/,V2C]?XZA<2@@Q.NH<505K-F:,^H$>26HU
M\$>4,<B9C[-*"O#X,?_BTX8Q?R$53,R_Q8Y>S%],!CUT%!(6Q?SE@&8^3-BS
MJ>1POGT>9D?\F#US?*R'//9Q+Y\EM^86ZQQNF_0#]:2ODD&M(VVCCJ"'H;%>
M!`?9QJ!GO7NJO&_\0#8O=/OHHT!_:`H"Y=Q>)6-+360E?L_]@C)N+Z>",GL]
MD7%"\6HX,U]['O%FFX=/*HEFYVF<T`67NJKK,-KF#Y*-G1&8\_6`=^R=P&"C
M\ZBU@`0DH;'!B]E:HD$-O8#(A,U?*S1!S7P\/6"?E=NY1U&R?XI0$%.90"3M
MB_C02NF0DT*,)Q%/9N/*H!?H\:6C!/XX,P0Y\_%VN=WYX1[CHD;-Z..,_Q*E
MSFHE)03:"AWY"+R&9)GCHY?;:]`-]"A3*T&X[S'"..M=SV/Z'./?4]KEY2M$
MMGWS^SJ#2T`"X@HV>-%R`$4TX`-&(EB!VR>#,O/%1^\^V/N]L,X0Z-1,XKMU
M@ZE]_O\Z`TFO`^A1U>5>F#ZR!5R\%Y03TS8#+7H'N,Q.%RO0!K:$%YD.5S_T
M%2\B<8#+\731M0R+M1?:`-5;NX?0O@>3HY;H6HO>`2[&TT7QVL"6\?R(,!M7
M?]CK=N$`%^'I8@TFV*R]+@(ZZR<HV!"6I9E=@+@B`4GP#7G%GG)*4-(ZP+5R
MNJT#&J"LE=L%U'REY,^A`DFEOH]2^UKT#G")[RX6H`W,5KW%;E8@.%BNEF]Z
M_(9VIYL(8[WYW8C>`:ZV;:)98V#+*,18O$I-?9EP0R<QBD!_C5?2.L"5L[N,
M;"U0MHHM6AW512*KD2KU")T5<,5KXX&L!ZE0X^=Y#^%#;J;)IIQ/XJQF&(>3
M@CE$7>:M8_XQ6?Y<"-V!4!%0X5+_,SOX4KIE'7IS5C.,S77%61K-K&-UER@*
MJ+38DP^9'/1G!P6ELYIAZ$X'4ZGVF;_L^&M,=R67<4*VU(N5%<2L-W16,PS,
M<2"46ISU`UVW^%M%'%$8T#^ZN+*WU!_-IETYJQF&Y#J!+"W%?G!NS+/O4'[V
M_915$GH_^39WN=P7[*7LQ?%_8I9XCKU3.J^C#;Y-M\\XNEMGZT@N7ZV,DB[]
MS?%<O#/0F>>B]"J@"C-,_X1E5(_6:5`#U'R,=^T<>L#;++)J1QHSGQ4..0,P
M(WP1E5>/AG1@K"@ZTV%DRKN`'G^=*K*:@)OY<&HG7\",JUG6:#W:22G&K/QH
M5HBT^D9,1;A&0\NX5^C19E2OM2?.6=]`:!3$1/6"F"`C<"&U6T&%H5=+JU_7
MT&/<>H58FX*9^6HLS(2#F1+^/$5D>Z5@3F9H#E$P=DG#JU$C$[7*Q((&=]^+
MQ8K\0AGW'7:LYMU"#^SARL;VE<JLO?"R=BR4PSW;"K)'JV$\51)US0:BB!AZ
MN)G6E=5#-.NATBPP"S-D%E1F]F@S&6]TS@[S9T79B[^,SX+)#NN;28?00ZUK
MX=GN:&?NP^J6-X,9H&!%S@0YW$<S>414'$\A1VAJ%[)K5]"#2[^D61^$PPTH
M.YIO'W%<I/B*"LN&+?3H'/IV?F?KZ(EY[N_7Z]5(N<`)(OY[HEC_1&M6%\35
M0"&E@YZ*;>18MP`MH`Z*-*7M+DWB!`4>%4*&7:)\HWZ@9UZE8OGV8(P1U#Y$
MM^K6:^PF=*=,_)3=%<DJ$>=72'BY]4H:Z+HGAKK4PK.$TC8"8\T@8Z]EL^9#
M6]03=#T4NX-;AM):B9PP03Z0F9S2-=$KAP%VTRB+,U^^N7Y*O3+F5+*K9FFN
MQ;MU4[BG6[:JREP;&_U#%U7I:%+6L-NJP@-ZKT//7V<[E90B^S.Y[:(=M);<
MLOV=<)^LW\6<'/0NV"SY8O[$*EB=[9_HMT_?B.QBI`8UE$O>196&&11UD`NU
M`P;Q(MPB$G3*H#E00[OSFEHT3:*IX8,R`<$\?Y92B;#XG^=EE3V^8.9ZBJ9T
M?FMHIUM3\IQI7(QGWB.UQ'6]W47A:WYU5ZA9-1&T"]Q)P7JP;.VVIS8E9P>C
M3#QJO6OW`5U=L)<9&*&TM;D&LHI\9X>C`T:E#0@HH*L)]M*X!).M/2V0?BNI
M\$K-MMI"UQ'LI5,NFB64A7U`P4:UDSJT@2H%:&^_5(,R\S4XPZ(<AY56X!4`
M:]*7**C"[KS]X2\D(-MTJU12K1UX_;ZF#OB::O,\<UVA-SU=5=N!5]33U%6+
M9["Y3Q3WE4WJ-R3`UPG>"L]J]:C!:M[U7[],48)M)/J%]?-S$-6CS9TZ`ZN,
M9ZJZ[E%_#N`I)F/P"WI>8#?"],?KH/QOGE)]$\;Q&5Z'$3Z4B+W`L1N1#(K0
M1"Q^`ZR67D_=\PS)ME@6D`S&EXDL=YQ+X*R`HE16K40#XX"9M&.>?7OT^PF)
MJ72*2QNR,^]68V<%%*$:1-L"?$MX#8L5++NZN#Z_#MBM.D^9NL-M[ZR`8E>#
M:%L,<1D/7V77(>,X18&+L[(>$G6WVCJK&<2XM%7-A[>$N.6OC[^$U,P"%L`]
MIIF=)N<HBO945MF[/A+%:]$[)T`!LT&,01_R$EZ]$H;[?XWQ.O5OR%IF'AK4
MS@E0F&X0X]`%;.LIK%G6]P6Z7C6K`K_*FY%]-*",#%G]"G1VJ(TRO@.)90'[
M?OZ;S_H>A!8];(:I=;6+-Q1:D@"^M&TK7M06G#1:U&X.E6\ZJE6(@"\C?J0_
M-UM9BZ%274>?1_3%L82+:!P?4V(NG-90&;*CVH4`]V`7Q/KXN?RU\"`,_KY"
MY,YVZ@PJ6W84D^@G%FN!+\`I@P_^'D<D],H#O/)`S]A[Y7<#E8T[`2=6+!!;
M,3++%8B:K%X'FCZ)`354)N]X,XR^'`:,A]DU`\$F3=MGM=$M;/XPC.$8"\C6
MD_3=%BEM>S)P8[2(P9*3(8U#)`=;3],#S2I-5RRQ.[LHN@?+GY[>-*,CJ<+6
M/EN?;\9]F0WH;`;X:3;E:<OA2_I')RT2Z',0H^?4=,`LX/3B@.L!??N"*"<$
M^;+8$;?]1$XGN#KB[]*$,!9QM'!`]\\P^GH=W$>ABV,MK=8()G*\T$6M+1S+
M."TXX+LB`8FI@'X)0T]+L36"B9P"=%%L"X>M\/U$%'N+M=9[VFPB(?LN2BRX
MMQ9X!PRCMCWHZHIRC]RO:$."S>$7MF%/=SN?X+@4!_VC5.4V/C"18+Z1L=C"
M;2M:/_@FN+9HR:W#L(>)1-XUU-\!V&PBZ+6UJY-^13U,))+>7;\R8-"A\:$6
MBJ[S?U4\TPB$]YK6&W`&"UL#O4@.%$\:^4ER[7=,5*]DZX>73'N$CCYI/2]N
M`>,"@E+M4?1+%,;E(Y$2.Y833B1,U46I_,E4#7<1X:Q3WP^_L:MG5V%T$:;/
MR3KUV]`UK,.DGXD$ORP:BRGZ)3SDT`8H#[!PVT\D7#;DO%&@7$8P+2NR5UEN
M)?IN-IU(4,V>JGD`EW$]FVO$75R$(]E$HF0##_0*V-F$Q@2>CG[D1-#!1`)C
M_35N#ALZ;#:F;VB<UMRGVXD$X\;V',7"6&H`KRT#HSA>FWPBX3Q[EJ,+VE;0
M;ZH60N5GX)0:]3.5?-<QC$8$'SK-=;"CY([F4I//-))8AS2/)EQ;F:A0M47N
M([Q#Q"M*J,6HL/J\;#S0><)%(;BL^M,YVI$$^>0/[!6\GM9Y-,EA[=DSQ"//
M&4-U+:DWGF(BZ),)"QJ0!!^$D!<1FRX*8.TO\"Z,B4S_C9;0SS@/IG0.SF4D
M7]8-N2X@]?#7H(9^/FXPD]#$OH1*#*4,<]<F+Y8H/W(04$`_2C>8,4CP+B8P
MG6Y3'R593=0H(7\4U;';N.5Q:MU>H)^W&\Q4#&70.YK].3>?`&_8)\%FD&S=
MS*4EG3<J[:"?MAMPMFB@7$;8NB*-VS!P]38/S?;0K]L-NV_@H;4528;T$&3.
M4$?_$?I)/!#'L7*R`%3C8*BP7QVU4>2O3@IUGC"X7>@`7VI0N+&_-HL,-XG!
MG_(;T42XV'O'BB?A,[;!9E(K]M;*M46''/PUP1$M18#^$,::=$F=\JT&X0Y3
M@PK\.4+KRM8%7>JX>ZRRYX2@J67!UOANW4W]FMV!O7PXKEV82*,TF.Y1RRFO
M()V<C!HEV'N)4.M&#7AI'=U#FE.VCN/FO*N+T>P![(U$*&OA"J"T&J`"L]I9
MN8502IEQM^F4RD\]$FRJ,ZE^WF[G3X"]HSCN4M570J6I]7^C">2^K?"Y(:`T
M&2$_&HDP2EJ(5)=C!I>0O2=%YJMN%]!I,%KR%^0\&$"<]^OV0GQG^R?Z[=,W
M(@]B*ZFA\V),5"D*6FN!7*@=,(@7X181V=/'&M30R3":6C0T@3J^>9O`%Q2D
M:SHMIA%U+*Z02WR2[+_@[3..)*J74$&GO&AJC:]R!:Y%)#N>I51^%-[U=A>%
MKSBK_:M4N)@(.F^EE[[EL):1\7BW7A,7'\2B5#6W/71J2B\M"Q$MXZ;\>1A0
MUS9U&>]9>;4-U9%Z2,O(H)-2>JE;!<Q6@B+0BGV#`D^IW&,CZ+227JJLP[!U
MT7UJWO8-"?!U@K>=-ET'8N@\D0'W7#6,ME9E,(>;RC'`T;X*4%0'04T$GONA
MIS21NRV%M2AWFUV5K+J9*I5+Z<#S./IH78UL&8[W51H%)&&G`>R2[!O[DU+K
M0AKP9(X^&I>C6K(7KM*WA`H\3:./QE6X;/G@'EX3:EJ4]I>4>.PB"8Q#KG#%
MP?,G^NCR``"ZT-3`;KAJK,H)P9,>^JA8`]HRKNQ4DL(N,&7<)<5EM)V/,WT%
MM60QH5PD9F+K$^"Y#WT,RJH0K%T8`JQA*D0HOU<L(W-64XW2]9EQ2F#6;@5-
M4>G9M&I<SZY+=\YJJO&_WLN2!/`RK@W9FD3-"R<.^F%G!1RIG,+")A'-@)6O
M^F2."J$$6-_".O;DG,PPRMD'J[5;2E#ES\I2<?=HSX+^=`M)?XG20VHK5`FT
M!E^G![YN"'IFZ1X$E]5LZ+]5$KO5J9]]NX;(#&WP7+TSIX^T2@6=_VE#"<*9
M7P9Z02^V%`B?(N3I/,@AIH).`QW-&)J@%_+J!A,514A9\9_0&]9[NT=`!)T*
M.J@M2#!;JX?6R10$OES!\CEM25SD/R:I)WG"D-\:.M'3OD(58*V]=#N!01V%
M:QS'&?M7V&1@\PFADT"'']QBW+9.12#-(K]EIB%$6=ZH;A_0N:3#&8N1"&P=
MJ$S(8Y2)TL[&"3HQ=32/4B6$)111X]RFWN&(JC38%%=M)4:C)H;.?!W.5O2P
M]SY!F6C5`M[>R\A0>!U`9\^.:2PB_+9.32!7)"Y:)L='Y"/C5[H;M.#)MB-;
M20N[K:,)JYM9(>N:VUM=>O"DVX%VO$;X[95/&\4$FOLV8QMH=@">ASNV$7`%
MT+_`VB27"AO;X!Z]@F?\CNJQ&DFE?X&VT:8=/J#RV--H`I)W!9Y4/.94I"&*
M_F7:0*L@G:'@*RM-"/8V&/VTV9-?/`*(0^RLH&-VWT"GDA&G-?2AM5B4_-E4
M`&'>E4CJH!0UB-J-H<^:!3K14>`RB@G5,=VBK;J"D(@$^JR8KQX=5=8QS%NA
M7\(HV:`-5I>2:+2$/AF6J82O1`Z`!>3S9,^TED&^D/D7:E4*::"/>,V5*H6R
MA`R=NDAN-*I(""B@3V1[K)TU##,O#7$3!ILG'&T9PB^(%2%C.Z@'O$/[[((\
MJZQ!`I?LD/^`F>U3M'?K*^HX(O]?&$GKP?3L&OK<5:)TOI78`+R`)<!`#-?!
M0^A3!C8,_M.WT(XU-7N%/I0=TI!X6)=1RJ*S$"@3LKUXKWZACVS',Z42[3(J
M9705PU686EKB6MV"'^R.9DL'M,MXIK>S&,CK$/,2ZQ;\F'@\6RK1+J,P2!<Q
MG*ZI=S>00=7Z!C]W'L6JVI!ALV0%YWY/V0'1\9"+02P.NN[9W=_L&G")O_A%
M=/#7I2_P@V)M8^@'<;`D5X@#O2?:14IY?S_7>S_7>S_7>S_7FZ?^WL_U9G^N
M=QU09PC'R0-*\.,WM%.>"?$)YG?*)\8Q;X5V/ZB=W9D>!P!TA%6P1SAP>A=@
MH5X$+:=U'B?3BP2`K6"E\:!2*>3I6ZBID$/+:1U_Z2ND!@`ZXB?0"SNF+T[I
MY6II-9S669)2*US^9_ZF!=OZWZW/*9=$_;)0N_&TCG!T%B`^ABD5QXVQ^\,F
M?/WH8<+T^!/[`U/?3Q7UT9^<&[Q!_F60D&0OV)1Q6DWLH$2P'1,Q+G85AA5U
MSH9PV]1L`G:"());6[HM=H4>=/]@J\<":;=(OCC46X%%R[FRX85$V^S.>P]B
M+Q=M6K'MCLEH*XN5GR:AT>($9W]!]\X7.'8CLA.<:AC1@]]ADBE01^4R7(MX
MOZ@Q''"TU8_!T\;@SR+T5?`!Q!(RAN^CT,78BZ^HF*[C.&4/IMRMJR>U$N6J
MB<&?+#!7MB:H961>E7&!FQ`%\5WP@*FG%U,EX;P2,7'O\[-Y!CT^0[X?AD'Y
M4WB&'["+R>OQ#%028.SY!?"G#<P-R2;R)50:-)*'+8L"?^U@8+NI/FZPH&PK
M"M5ERMK@,XRRI]?)&_:JQS6:J57JCL`?'S"WD`X`IQ2/&LA$?J/_S_9F-JR$
MUQ?XDP.6#46(T5:2E<W8)0E>*8O,4CX5?V8V\JEB(_FO5$@1>:6:><6W8<[V
MZ9:5BN"%B>04SLD$DH7T]*V#9"'/)QU\\^IE3LT]2I7$.9E4&I'ISJ0%91D/
M'-6%4@F?W*W+Z8I-4V<H-D@:DW?CG$PJO&@>C]"`-]$'A([S5=S,Q"E\7&%U
M)`U2YV0VD40C2$.^!#3B4,^?2PFWE.<7',04]G7@AENZ[8GC6YS<K9_0FV2(
MZY`[)[,+-6K#LE9P#]BCKYR>7R&7W0?8ZYTF*"B=D]E%'G4062M[!_R0H??O
M-$Z88*["J/H\GD3A0AKG9':Q03D6>W7KFK[Z*-=<LCFL+,1')RV@^G49&_GL
MR9[9*_C1N.\B)X2X]U+Z`SE3&7\:V=F5UM#W7M0BY8\3`91%G*.6V`IIZ&JU
MVASZ*DQ?M3:Q]#Y1G<0#!1F<VS`(RR<8?D$DB)D'IWXN1T`&?4^FJZ)5F)9Q
MBEH%F`NID)!$VT(:Z%LT754M!63M_!+DWFX.)WO'#\B7.7!@='%70@7AQ1R>
MI&'C_QQ%T7X=1M]0Y,6JF[P*2FCO1B%GP=2HQC3O!-"#5$[3Y"6,Q%GE<@)P
M'T>M)Y&3(X*S-+TJK_^*2*#=&K&*=%6ZE"O`CRS!)"NZX2+__Z01B3WB,@3*
M.SP*2FAW1J8ROI(U`,U;UU0`=.]%W'-V-ASME1KFMH>^*6RN5R&,F1>)S261
M66T6?F1?8KK066RY5-"7C7NNN$),R]2SYN(KH(.^QZQ0F9&>CXCF/3]?9]D\
M#%D.5*,<!X\`^C*T4DLBY8K`+"+J>X5(]!OR4WRV/XUCG)S[*(X5<[60!OJV
M=.>96HIHYM?D#M@R9/$7C%A`P&.9W.RY*RJM+#'GUR!\CG'TFJ=@[M*$_G,8
ML%/?3(M5P2BG^*$^"7ZY6VHG"M,:0A9S7U@\O"8!2;#/;I9<4WT&&\+>3RM$
MI5QG-.C!J]T.:@"B-4M7,(M8P\33_HW&-6\-:O#:MIT7-EUPM@Y$;-5"XH2P
MB_*DDG,&34KP"_RZ2JFKU`3=(H;U`6MQ<'>&`SJK:1TPU2G`[O";J$P1X>4@
M6H22+]=K[":'O%**E"49GX<!'1\I'2+%6`D#V12NWPG8;?_^IF`(<@G5`/B0
MZXY1+3Q>.1DW-A>];L$J"`QE0`:P;6V$89^DRQEED?K,&18OQC59R,XC.G8)
M5D.@ORGU@KR$X@$&`BC/>>Q84-D;6"&!48VGAM9660%(NZ&8\PL559AZ%TQ4
MI&"%`_I;A!8TV(=6;%TO<ID7?Q[&W*N$O&9@U_S[J[4%P]IS*8`JO,KB:C>\
MN%K^3B=[):AR@R:ODK*2:+MCCV#U`/H;1A_$MNH&6+X[?#PFC.^^!=@[0SZK
MU'5X04I<]4&?&JQ&0'>-FZ);2MF`AH?#7>#B7W!`'1__+(U)@&-Y`8$N'8*5
M$AC`1]0';*NX`.0B(_:(V4E2KD;?#[^Q8=3I:*/=#5AY@O[&8@S36LF"J0?'
M#J,F5EWGZ]`;6#F#<4)A/+1#5CD8Y>K0>;C=DGPI1H&7!X\WV27QRN.'(%>*
M*IR=5CAS&4<FEXR,^C&[=B1P_21?K(A5\_BR4V?0%XZ,9<YQ$CL#MW0,9O7]
MU7.T(PGRLT,[.H-0],+*09RF4%>,^NF!IU,^-N"#2X'.LEG^[MDG&^%Y([<=
MU*4AZ]KB`9OHVV5L1QG0QOO[*/125Q`Y%36%N@-D76,";`/>8A_-26%'D:'[
M]8%L7I+XWD>!L5LB6:U;G>NLRD(B:TY$ZPL&/H.*%LI%T!.?P!_0`06Z_-MS
M?0NHOX5L.L@!*YQ<#@6XXZ"C,/Z.3()H.'=AE-GL$6^RQWP#[Y%L`K(F+@J2
M\S1.Z,8SN@[68;3-+Z+`[+L*]A[PCL7;@XW&%DM$`E'$X=%]P5[JX[OU9?:J
MU3^)1_?Q=%ED.?I?T+_#J!1U?+8_<%P@4!9ZL-`[]-Y,IBS^4+0$>MYW$P[W
MQ,K8<HE/<3=*2@==.\*29@5FHT(^<X/(T2CO/M7:01>44.I$H,HF!BC5"9SE
MTX!LD?\_&/G)2U:[+4`Y0]>!*W^%44T)72"B)7N.;ZR'8HJ!L2_?R&^8]D@"
M%.T?T]W.W[/JPB@0EWW0HH,N_Z"C-1T,T/$62T=3S=6EMK;<:%S*TNP!NC3$
MH`NJ@0QF7DKB/`S86S#Y]84'$G\]/@XC2YR2D4$7DC!0GFA#+`<WU.P^Q3WQ
MZGU3_+XI?M\4@\_3[YOB]TWQ^Z;X?5,\R>W5^Z;X?5,\:A)"9G!1<N/K#*]*
M._!-J^Y@:O"\C.+XX\4F@'>@DXA-_`TP-B$:MJ[+KIO$^8/F#.9%BMD;EIRM
MJ#`)S*@3Z,J'!LKB306F4/],D8DBO^$]/O$>GWB/3X!O1ULQT[/]&0[<%^K*
M?%6$*%2DBXY2Z(!?FF64^)2Q"Q4I=#A#1WFZ:F\CF[?:'Y&/XV*8W.)$_7@$
MKSUT\$-'38)%001GWEJM3W>*B;W=&#PL,N14SH<[\_/A6[2ETJI!4T[;0AKH
M\`M?0WQM2D%,+/[\*ZOIX67!]?@"D6A/]U!G&*^O`X^R'A$L+NAL1`\=5Y'J
MA+-_-L$US9MQ5V&$Z6;X8+-R/?);0\=`3+4F1K&(PIJC!4&!7X281!`4\@T)
MP9#6#7-IWD#KV!WX>PX&&N3,$7U0+^+:FOVL/:C'&GKK4W.'W<0ZZUCY`_;9
ML^;W*$KV3Q$*8I1=08:J(")B1R,XKB*U<L57]!'-.5:3'#ITK2-*SEQJ@&X1
M=>^+]8:=HU6@$VG=<B$-Z+U?`\WQ)TDIK$4HNWV$6@=ZGD9,S!+5:_8`6HND
MMR$8@(1."1ITQ2K>^HC9B*@*\I\D>:F2F"]HNCV#5DBQ,*'T!C_84P>C.&:7
MVYT?[G'Y6@R40_;X0I5]AF+LL90^*OO<C#1R%:2$5IRQIH@TG3`%&;3SI18<
MQ_72P#3-N&3)^"-Z)<&FJ!(D*Z6O007J2FEH0J(_,:!%.%$7[$E#[!6R82C+
M\K^5K;ED4M&B!W6@C-5O#&T9;E,;;BFQ>T0\(Q.H$H(Z/19UW\0T]W)PC^ES
MC']/:9>7K-P=F#?38$/'CQ&0@.1<UGE1)E%RFH-[-Q)Q"A)@!"CFG?_21$6_
MI[J`R:<`3VH4J$=/F140B].G^D:EB`8Z'5&B)6VU+B;]L`Y-G7[(:P^=?BC5
MCY9*)W+[LJK3&+L_;,+7CQXF3)T_L3\P+?Y4T2+]R;G!&^3GI\2"*9;3"CS!
M4&M:%3`NWB(,*^F<"^&\UVP"E<4GD%I;M$UFA:;?.PQ"?7[JZW]57O-NMH-*
MI.-)AQ/6X+&[J.7@1B/-2D0"G4[7RW.KH0#+C+*CT_LT<E]0C.\RMN,;%,@"
M$)S6X!ER$MWPM2D`L8@@(P/3P*?W.JN<$#S1S5S+&H"6$4W,:HY?QW&*O8LT
M(L$F?VV2/1V&;_&W[%_DQ8TTZ,$2V[H;@#ZN<0]+/S)NGZE5TK_\?U!+`P04
M````"``4@6Q'OZ9FX_$-```/G@``$0`<`&EC8V,M,C`Q-3`Y,S`N>'-D550)
M``/7_T16U_]$5G5X"P`!!"4.```$.0$``.U=6W/;MA)^STS^`T<O)YV)K"A.
MTMH3I^-+W'K&B3V6<T[?.A`)R9CPHA*@;9U??Q;@G5A0D.2TU*$?FLK$[@+[
M+;#`+D#PXZ^/@>_<TYBS*#P:C/?>#!P:NI''POG1X-OM^?"7@?/KIY<O/G+W
MC@;$$22>4_&5!)0OB$N/!G="+`Y'HX>'AST6!(E+?7_/C8+1VS?C]V\.]J4\
MGP8T%.=1')S1&4E\<33X*R$^FS'J#9R7+Z`)(3]DKNO:B'OYPE$,-=J'_;TH
MG@/5F_'HCR^7$]78@5,0'_HL_%[C>)S&?LZS/Y+%4\)IE452>*)@JC*\'Z6%
M-7*_1?X?EU!!4SAK86`A%R1TZPW2E,C4'A\<'(Q4:0G/84CG1%#/6,?!*(Y\
M.LK(JO4D?#@G9%%PS@B?*JZL0!EC^&8\W!\C;$,BA)D5"F,V303E558W2D(1
M+^M8<^KNS:/[458H:]W7:W63.(8>:^+-2B7S.YW9HPSG@P(#"WUT[W`>66*`
MAH7WE`N<+2TS:!<2YG*<3Q5)MK'.QIF+,T&!@04,))8+RE'3J1*#;EPL8D-E
M4&*H+:8S8\?\,(+2NI46,757=&82NZH_SX@KAO1QX9.0B"A>GL/?-42C,$P"
M7)`GXI%4=01$0Z"B,7-KO*L9*TS2:Y(PC`01X%P_?22+!0MGD7PLA^JA;.XM
M,#GRQ[>;"[/S4XJ=16XB_>AQZ'T.!1/+"Q`6!TKXP&&`32M%4:U'9RQDJDG@
M+9VAD[-5?X(()Y7A5(1\'#4EY$(33KVK\)/Z#<;B($-Q2+>7<64D&$<IT([>
M);Z;^.8*1C5\-P7\A/C2`T_N*!4\1;C^"(?T+>`X`>UIAFG&XZ1,/8;PFH`K
M%G=4,*@<P;->CH.[WPJN\ZHFXZ=^@5W@PJ]F5PL:J_KXMY`D'E,SO$1\%1$.
M^[L&[*44)YHYI1SG52&IQ^"?1@&H=4=#SN[I!:RF`WH9\39+K.3`S?*^U2PU
MH4XJU7DEY?[T;">)^D1$[O>[R/<@_/G\5P*378N)VHAQZWQHM4Y5WK^<5.*S
M658@C4PA&W'B!OMY*X,]3SZ%-R/\[MR/'EH]GDZ#&^67=A\'8APEI[]CYR3A
M+*2<E]-PMKC2G^,0'\B5/^.N'_$DIG)5E7%69O9^03I)@H#$2_`H;!ZR&8QG
MB*I<E8A@X?PZ\IG+:`:S)2T*_?A-$_I,FG(XI3RG%.CD$OME$3G0Y7_2[]X3
M7X[_R5T4BUL:!Q<J@Z)\`L2MEU$X;SQ-#;6="-Q^XZ;]9`6O4[=4J>>UHVH:
M2J%.1:I#(,Z6M6DE_;*N5#R4V9K44N6?..IOFZ@7#/V"+?,*_(:Z%+K:U*<I
M?LAS',C])I`YIU.R]@O2ZY@N"/,^/RX@;J+2&5S!BBX^YKQ(`K63X$"_:P*=
M"7%R*<H3*#E.*JAOL$>PU!#+:Y^D^4OPG0OI"'/(3<4XW.]UN%,!KQTE0J%=
M".D7U/D0OR9+.;P!37@2)[3HT'4?8B;#H?]@="F9)(5])JOH_OTRP0D)OY_1
MJ<B3H-E?.*`_:ZMSH'<D0[]`4\XQ[R]?:0:>]A0'\9<FB*FKS1E?.\#:+SC3
M?.`M><P'?/4!#J(6)V8Y1<73+_1.HR!@1;QP&JG0#/ZZ9&3*?&ANCJH-(8KV
M6RTTK(A2/K04YE2D]<\.4:A2<S=L?@?3%4SO)?)Z$8ZU'L8IYC3GYZ3L:N70
M+W0G=)[M)U=R$:<)%S#J8VW[V9H:MX$6U&7R5%^OYD)RD?W=F;ZA/DESVF)Y
M&Y.0$[>2]S.6XKAK,6#&[R@!3E5"OU#^'"S\:$GI"0VA?7GTISW%4=4"OIS/
MR1G[!>8DF7+Z5P*J?+XO4W+:4QQ,+9PK^9R4L6]@VJ2<-TE3MZ>KWVK!G7VZ
MVGF5_^K9]DP&4=0._*T,C>NFLN/`#:4%C>L8*I7<,S-MM3M0M=Y3",*-J@6Q
M3[79T%.3%[L&5?,U'^*F0$+AC*VG6.I;#E50C:4HNOM:Z(ML2_04Y\;F`ZEM
M/E0AMR'$T=>"X95[%;VUA6%7HFZ'=B+<!EHPW+J!T5/\&UL41-NBP%S0*F+<
M'N:-TK9=C9[:)=_0J,+?>(:CK`7-Q59'3Y%L[FY4$364X<AJ$32R_]%3C&W3
MEK4(;3T>W"9Z,+U&PK.OQK+*8IQ109B_5N(C9\%-M54XG8E^MI09]EOZ*)+B
M1/<FG+C=M(AY`[LY614]L]]6:8S:`'P22;A]M3#\Z3(B_1RU11JC9D'M*6J-
M=UK87DF*]!-./>]1P]5<C`.L1>9H7J2?4+?F.VJH6U'B!D#"\I6ID;Z:PY#V
M:)AB!15N!BT:7Y$=Z:<)5F8\4%^TDAHWB1:Z6R9(^FF:/!M2LT#S(0ZT%LE7
M<B3/8#9C"4,9#JT6D.O0]C08:.:::OW65(B#K(72:":JGSVY<@2WL?[6GN/@
M:O%N]81N7U&MG)LEAB.X]7C5GAZW@AZ56IW<[;-]M(.ZFD6,%*@-WJ.GI[$3
MO7U%W3:%7<^EKLF$VT8+8]=+?#_;RP+Z\48&&QLLMM79['+Q-'ZV61OZ]2SX
M9KRX_;2`>3/[]7/Q:SI/7_.,JXAPNVA1L_GL?5_]7O.\?0UU4R&.MA8Z:V?R
M^PIR\QQ^8P,5+\1!1HZ(-\[J_]^`+/^1EP;?T)FC;M\]E'>`'@TX@WY%!]FS
M.W77J;S=>)A?8OPGJ+3W&/@YB93<<A>P,E$3A:SB7$1V_6G[[<`@1.5)(=@8
MY8T?C)Y`'P!\77WJ-NJ4-CZ9KJL-L%"_<XI`OUY7D<90>%IU1OD5N/"KO!@7
M"D"3*!9.B%XK;KH8.[V1_#)RE9@6%OG7,.<;RD?#\=OA_GCOD7MIP]:HO]!H
MS?ISOO7JQR\=MZPY9Y!5OK>HK/6>;T.=JCZ4<41]P?,GPU*4K=8M]V.WM05A
MRWX/2Q'KM@&[@MRF$56^_(]MFH'=9F[5CBIC\=>P%+-N2[2[SFU:43"I7UMT
M"?WJ<YOJ2Z[TY[`4L&X#FM>HVU2?\\@?VU3=O%3=JNZ<2?U:K_95WPVP<49^
M'->XI$<ZD$YP_&&;%EBZPDKM8MN:VZ^9MVU-5<KG4LAZC6O]8(%-K\AYY(_U
M?,&*R^]M8&AR;6$8_-K^]1H1A5\W:4?[1Q(VGS.5+-1#9E]346UIO_+_>,I%
MK+JEC.+DRO!/._)T>:F^4'((SU@XOQ`TD*'/P"$9U=%`Q(E<?"HJ6.ZQR+M5
M?%X29Y="A,SWY=9_3LLA$H1*$UGZ6QPEB[P2!N('SNB3H^EW$0H*@8^X`:\Q
M>2"+BBYZ4;7=002#G<1+K.4SXG.TZ>D:4>1%T_1R^:.!&U./B1^BT`D%`U2O
MX4%UJU%MK69IH1^I9[9E>;Q8^,Q5K_Q%K=:THM\)W5LO")0YU!,_<K]7E+=E
M2+5/OV!R*/+G&^K_!(JB^W*(VUE!UR%_@[84,]DJPJZ9JCF4CN<Q5>7JO/L2
M4]&>I6O*9@/IAKK1/,TQF;6TH.V:>O+K9E[BTZO9A/B4WT;(#E'Z.B.F\$;<
MW84`.4.=T/,X"C8$92MY78/I\VQ&77$U.V,^L-U3Y:^N%FI#J3H&6LEJ[OF.
M@$OX!^UN]6[0;7D5<FK==;C^YMG($X=WP!F[R91>&/4^29@OO\EX['G*1WVA
MP93&%15-!+4>Z44!8>$_-KFVHG_)0J5_M5_:,G1H`6'9U=*-=&2IM"%_EQ"0
M+N*$<.K)#Q#!W)H=4X`%-CR$=7[V__(S1VET4T0`9Y2[,5ND#2J!>5*Q=GC]
MW7/9-F_*87WIB05WJ)-)9>1]J@:=VCX#D2[?-^/_81D&CTZ?+O!6(Z$<&9BE
MZY&W%<./"[U_I/*XH>6IJG5165/2;L+5/FHLZ7=3=3N7(+;N,2LE[@)\Y=12
MO./;.@$A5!V:3733_2>*OU^$UW'D4L[SQC/:;F\STTZD+76%SEG(.)CPMRCR
MK%$P,^T$"GHFX&LD(-J(2"B=/6@'54)G+?,#K1U_?2&='A=Z=@1$\?8.8>39
MB?[0U$>^#GC!>4)/(][J_YN$N^#6FSJ`Z9(@44>2CP.8MMA_50NN9M8H6$O8
M17BDLU<[-V=T1N.X>%>ZOH$#7'ZB<C,5`%I'S!92=V),&5_[A_9>J[8T,:EM
MEJW/O`N=*WLW_M2'^=,E_D2`=6M3K8E@-[:]D5FA75U[EEVPKE$;Z,XS6"Z"
M).*?4SL$=)Z=A<#F4V0KUA4MW+L`RVTDB%][MW@J3M4)37$M/7L45K)1V9,*
M+INQ[X+/^`*-G9,YY5<AU?8[L,(N[744[;M]B,R-KQ1VJ?$R6,E&E=9VI*Q+
M3;_UY*4=7XG6[F9!EQI]!H+OB=QYY<U#%P!U,]%D1;T+GJ_<FBG>%S-OC-D0
M=RIT+C)Z5P\AA<ZGX+N&1KEL`8T.Y-Q5T\^.81<,:_CH7;IK6\Q49EMOR-\A
M\Y^2!8-Y6:U$8#Z$SEK??4)*=V!O286?5U.?S4GS"(E>M`M+C"(M#2MJ+W&U
MP!PIW0$S&<\FFD?;:O(.#:[CD`7$_YT27]RI&3!4LHD/<X0V[]L0=VDM\.6!
M_9M",UD('6N2+!;^4AYX(.%27T:N).V28LH0L;CT#3:J%76JX>N<"*SG:];A
MRU0&?>5I,*A^,Z_R!`I_"Z',FPA85/(SPN(E3,(GE,XN0B^10Y]RS8+V+%VR
M['D44[!%801-+1-!EY2P_A:!^<S9IA(Z-">8[E\Q:VW-T2$MF_>=F+5;2=E!
MK2;D'IJ17>Z&G0%<1=BE4WW0.'Y-OF-+$KWHG_4GH_0]Q4\O7_P/4$L!`AX#
M%`````@`%(%L1P!7_[7ZK0``+XP)`!$`&````````0```*2!`````&EC8V,M
M,C`Q-3`Y,S`N>&UL550%``/7_T16=7@+``$$)0X```0Y`0``4$L!`AX#%```
M``@`%(%L1SCT3$#P#@``)0$!`!4`&````````0```*2!1:X``&EC8V,M,C`Q
M-3`Y,S!?8V%L+GAM;%54!0`#U_]$5G5X"P`!!"4.```$.0$``%!+`0(>`Q0`
M```(`!2!;$?R#Q[CX1,``*\Y`0`5`!@```````$```"D@82]``!I8V-C+3(P
M,34P.3,P7V1E9BYX;6Q55`4``]?_1%9U>`L``00E#@``!#D!``!02P$"'@,4
M````"``4@6Q'(B6EC`-=```C6@4`%0`8```````!````I(&TT0``:6-C8RTR
M,#$U,#DS,%]L86(N>&UL550%``/7_T16=7@+``$$)0X```0Y`0``4$L!`AX#
M%`````@`%(%L1Q5E-Z<E,@``<8D#`!4`&````````0```*2!!B\!`&EC8V,M
M,C`Q-3`Y,S!?<')E+GAM;%54!0`#U_]$5G5X"P`!!"4.```$.0$``%!+`0(>
M`Q0````(`!2!;$>_IF;C\0T```^>```1`!@```````$```"D@7IA`0!I8V-C
M+3(P,34P.3,P+GAS9%54!0`#U_]$5G5X"P`!!"4.```$.0$``%!+!08`````
..!@`&`!H"``"V;P$`````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.3.0.814</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>95</ContextCount>
  <ElementCount>250</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>34</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="iccc-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>001 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immucell.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="iccc-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>002 - Statement - Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immucell.com/role/BalanceSheets</Role>
      <ShortName>Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="iccc-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>003 - Statement - Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immucell.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="iccc-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>004 - Statement - Statements of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immucell.com/role/StatementsOfOperationsUnaudited</Role>
      <ShortName>Statements of Operations (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="iccc-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>005 - Statement - Statements of Comprehensive Income (Loss) (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immucell.com/role/StatementsOfComprehensiveIncomeLossUnaudited</Role>
      <ShortName>Statements of Comprehensive Income (Loss) (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="iccc-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>006 - Statement - Statements of Stockholders' Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immucell.com/role/StatementsOfStockholdersEquityUnaudited</Role>
      <ShortName>Statements of Stockholders' Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="iccc-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>007 - Statement - Statements of Stockholders' Equity (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immucell.com/role/StatementsOfStockholdersEquityUnauditedParenthetical</Role>
      <ShortName>Statements of Stockholders' Equity (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="iccc-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>008 - Statement - Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immucell.com/role/StatementsOfCashFlowsUnaudited</Role>
      <ShortName>Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="iccc-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>009 - Disclosure - Business Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immucell.com/role/BusinessOperations</Role>
      <ShortName>Business Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="iccc-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>010 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immucell.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="iccc-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>011 - Disclosure - Cash, Cash Equivalents, Short-Term Investments and Long-Term Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immucell.com/role/CashCashEquivalentsShortTermInvestmentsAndLongTermInvestments</Role>
      <ShortName>Cash, Cash Equivalents, Short-Term Investments and Long-Term Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="iccc-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>012 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immucell.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="iccc-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>013 - Disclosure - Accounts Receivable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immucell.com/role/AccountsReceivable</Role>
      <ShortName>Accounts Receivable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="iccc-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>014 - Disclosure - Prepaid Expenses and Other Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immucell.com/role/PrepaidExpensesAndOtherAssets</Role>
      <ShortName>Prepaid Expenses and Other Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="iccc-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>015 - Disclosure - Property, Plant and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immucell.com/role/PropertyPlantAndEquipment</Role>
      <ShortName>Property, Plant and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="iccc-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>016 - Disclosure - Accounts Payable and Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immucell.com/role/AccountsPayableAndAccruedExpenses</Role>
      <ShortName>Accounts Payable and Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="iccc-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>017 - Disclosure - Bank Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immucell.com/role/BankDebt</Role>
      <ShortName>Bank Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="iccc-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>018 - Disclosure - Other Expenses, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immucell.com/role/OtherExpensesNet</Role>
      <ShortName>Other Expenses, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="iccc-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>019 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immucell.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="iccc-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>020 - Disclosure - Commitments and Contingent Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immucell.com/role/CommitmentsAndContingentLiabilities</Role>
      <ShortName>Commitments and Contingent Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="iccc-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>021 - Disclosure - Common Stock Rights Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immucell.com/role/CommonStockRightsPlan</Role>
      <ShortName>Common Stock Rights Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="iccc-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>022 - Disclosure - Segment and Significant Customer Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immucell.com/role/SegmentAndSignificantCustomerInformation</Role>
      <ShortName>Segment and Significant Customer Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="iccc-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>023 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immucell.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="iccc-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>024 - Disclosure - Employee Benefits</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immucell.com/role/EmployeeBenefits</Role>
      <ShortName>Employee Benefits</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="iccc-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>025 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immucell.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="iccc-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>026 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immucell.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.immucell.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="iccc-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>027 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immucell.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.immucell.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="iccc-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>028 - Disclosure - Cash, Cash Equivalents, Short-Term Investments and Long-Term Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immucell.com/role/CashCashEquivalentsShortTermInvestmentsAndLongTermInvestmentsTables</Role>
      <ShortName>Cash, Cash Equivalents, Short-Term Investments and Long-Term Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.immucell.com/role/CashCashEquivalentsShortTermInvestmentsAndLongTermInvestments</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="iccc-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>029 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immucell.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.immucell.com/role/Inventory</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="iccc-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>030 - Disclosure - Accounts Receivable (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immucell.com/role/AccountsReceivableTables</Role>
      <ShortName>Accounts Receivable (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.immucell.com/role/AccountsReceivable</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="iccc-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>031 - Disclosure - Prepaid Expenses and Other Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immucell.com/role/PrepaidExpensesandOtherAssetsTables</Role>
      <ShortName>Prepaid Expenses and Other Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.immucell.com/role/PrepaidExpensesAndOtherAssets</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="iccc-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>032 - Disclosure - Property, Plant and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immucell.com/role/PropertyPlantAndEquipmentTables</Role>
      <ShortName>Property, Plant and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.immucell.com/role/PropertyPlantAndEquipment</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="iccc-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>033 - Disclosure - Accounts Payable and Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immucell.com/role/AccountsPayableandAccruedExpensesTables</Role>
      <ShortName>Accounts Payable and Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.immucell.com/role/AccountsPayableAndAccruedExpenses</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="iccc-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>034 - Disclosure - Bank Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immucell.com/role/BankDebtTables</Role>
      <ShortName>Bank Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.immucell.com/role/BankDebt</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="iccc-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>035 - Disclosure - Other Expenses, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immucell.com/role/OtherExpensesNetTables</Role>
      <ShortName>Other Expenses, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.immucell.com/role/OtherExpensesNet</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="iccc-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>036 - Disclosure - Segment and Significant Customer Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immucell.com/role/SegmentAndSignificantCustomerInformationTables</Role>
      <ShortName>Segment and Significant Customer Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.immucell.com/role/SegmentAndSignificantCustomerInformation</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="iccc-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>037 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immucell.com/role/SummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.immucell.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="iccc-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>038 - Disclosure - Summary of Significant Accounting Policies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immucell.com/role/SummaryOfSignificantAccountingPoliciesDetailsTextual</Role>
      <ShortName>Summary of Significant Accounting Policies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.immucell.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="iccc-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>039 - Disclosure - Cash, Cash Equivalents, Short-Term Investments and Long-Term Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immucell.com/role/CashCashEquivalentsShortTermInvestmentsAndLongTermInvestmentsDetails</Role>
      <ShortName>Cash, Cash Equivalents, Short-Term Investments and Long-Term Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.immucell.com/role/CashCashEquivalentsShortTermInvestmentsAndLongTermInvestmentsTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="iccc-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>040 - Disclosure - Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immucell.com/role/InventoryDetails</Role>
      <ShortName>Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.immucell.com/role/InventoryTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="iccc-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>041 - Disclosure - Accounts Receivable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immucell.com/role/AccountsReceivableDetails</Role>
      <ShortName>Accounts Receivable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.immucell.com/role/AccountsReceivableTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="iccc-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>042 - Disclosure - Prepaid Expenses and Other Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immucell.com/role/PrepaidExpensesandOtherAssetsDetails</Role>
      <ShortName>Prepaid Expenses and Other Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.immucell.com/role/PrepaidExpensesandOtherAssetsTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="iccc-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>043 - Disclosure - Property, Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immucell.com/role/PropertyPlantAndEquipmentDetails</Role>
      <ShortName>Property, Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.immucell.com/role/PropertyPlantAndEquipmentTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="iccc-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>044 - Disclosure - Accounts Payable and Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immucell.com/role/AccountsPayableandAccruedExpensesDetails</Role>
      <ShortName>Accounts Payable and Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.immucell.com/role/AccountsPayableandAccruedExpensesTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="iccc-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>045 - Disclosure - Bank Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immucell.com/role/BankDebtDetails</Role>
      <ShortName>Bank Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.immucell.com/role/BankDebtTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="iccc-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>046 - Disclosure - Bank Debt (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immucell.com/role/BankDebtDetailsTextual</Role>
      <ShortName>Bank Debt (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.immucell.com/role/BankDebtTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="iccc-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>047 - Disclosure - Other Expenses, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immucell.com/role/OtherExpensesNetDetails</Role>
      <ShortName>Other Expenses, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.immucell.com/role/OtherExpensesNetTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="iccc-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>048 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immucell.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.immucell.com/role/IncomeTaxes</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="iccc-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>049 - Disclosure - Commitments and Contingent Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immucell.com/role/CommitmentsandContingentLiabilitiesDetails</Role>
      <ShortName>Commitments and Contingent Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.immucell.com/role/CommitmentsAndContingentLiabilities</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="iccc-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>050 - Disclosure - Common Stock Rights Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immucell.com/role/CommonStockRightsPlanDetails</Role>
      <ShortName>Common Stock Rights Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.immucell.com/role/CommonStockRightsPlan</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="iccc-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>051 - Disclosure - Segment and Significant Customer Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immucell.com/role/SegmentAndSignificantCustomerInformationDetails</Role>
      <ShortName>Segment and Significant Customer Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.immucell.com/role/SegmentAndSignificantCustomerInformationTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="iccc-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>052 - Disclosure - Segment and Significant Customer Information (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immucell.com/role/SegmentAndSignificantCustomerInformationDetails1</Role>
      <ShortName>Segment and Significant Customer Information (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.immucell.com/role/SegmentAndSignificantCustomerInformationTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="iccc-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>053 - Disclosure - Segment and Significant Customer Information (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immucell.com/role/SegmentAndSignificantCustomerInformationDetailsTextual</Role>
      <ShortName>Segment and Significant Customer Information (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.immucell.com/role/SegmentAndSignificantCustomerInformationTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="iccc-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>054 - Disclosure - Related Party Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immucell.com/role/RelatedPartyTransactionsDetails</Role>
      <ShortName>Related Party Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.immucell.com/role/RelatedPartyTransactions</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="iccc-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>055 - Disclosure - Employee Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immucell.com/role/EmployeeBenefitsDetails</Role>
      <ShortName>Employee Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.immucell.com/role/EmployeeBenefits</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="iccc-20150930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>056 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.immucell.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.immucell.com/role/SubsequentEvents</ParentRole>
      <Position>56</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">In ''Balance Sheets'', column(s) 3, 4 are contained in other reports, so were removed by flow through suppression.</Log>
    <Log type="Info">In ''Statements of Cash Flows (Unaudited)'', column(s) 1, 2 are contained in other reports, so were removed by flow through suppression.</Log>
  </Logs>
  <InputFiles>
    <File>iccc-20150930.xml</File>
    <File>iccc-20150930_cal.xml</File>
    <File>iccc-20150930_def.xml</File>
    <File>iccc-20150930_lab.xml</File>
    <File>iccc-20150930_pre.xml</File>
    <File>iccc-20150930.xsd</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies/>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>

</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140666864754864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Sep. 30, 2014</div></th>
<th class="th"><div>Sep. 30, 2010</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_iccc_SummaryOfSignificantAccountingPoliciesTextualAbstract', window );"><strong>Summary of Significant Accounting Policies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_iccc_ShareBasedCompensationDecreaseIncreaseInIncomeLossBeforeIncomeTaxDescription', window );">Decrease (increase) in income (loss) before income taxes descripton</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Less than $0.01<span></span>
</td>
<td class="text">Less than $0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">$ 6,342<span></span>
</td>
<td class="nump">$ 4,974<span></span>
</td>
<td class="nump">$ 17,825<span></span>
</td>
<td class="nump">$ 22,265<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising expense</a></td>
<td class="nump">27,545<span></span>
</td>
<td class="nump">$ 15,844<span></span>
</td>
<td class="nump">72,539<span></span>
</td>
<td class="nump">$ 42,915<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Federal deposit insurance corporation limits</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtIssuanceCosts', window );">Debt issue costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_USGovernmentSecuritiesAtCarryingValue', window );">U.S. government aggregated amount</a></td>
<td class="nump">$ 1,968,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,968,787<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 566,637<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=iccc_BuildingAdditionMember', window );">Building Addition [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_iccc_SummaryOfSignificantAccountingPoliciesTextualAbstract', window );"><strong>Summary of Significant Accounting Policies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">25 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingImprovementsMember', window );">Building Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_iccc_SummaryOfSignificantAccountingPoliciesTextualAbstract', window );"><strong>Summary of Significant Accounting Policies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentOtherTypesMember', window );">Property, Plant and Equipment, Other Types [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_iccc_SummaryOfSignificantAccountingPoliciesTextualAbstract', window );"><strong>Summary of Significant Accounting Policies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentOtherTypesMember', window );">Property, Plant and Equipment, Other Types [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_iccc_SummaryOfSignificantAccountingPoliciesTextualAbstract', window );"><strong>Summary of Significant Accounting Policies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_iccc_SummaryOfSignificantAccountingPoliciesTextualAbstract', window );"><strong>Summary of Significant Accounting Policies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OtherAssetsMember', window );">Other Fixed Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_iccc_SummaryOfSignificantAccountingPoliciesTextualAbstract', window );"><strong>Summary of Significant Accounting Policies (Textual)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_ShareBasedCompensationDecreaseIncreaseInIncomeLossBeforeIncomeTaxDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>It represents share based compensation decrease(increase) in Income(loss) before income tax description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_ShareBasedCompensationDecreaseIncreaseInIncomeLossBeforeIncomeTaxDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_iccc_SummaryOfSignificantAccountingPoliciesTextualAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">iccc_SummaryOfSignificantAccountingPoliciesTextualAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>iccc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 720<br><br><br><br> -SubTopic 35<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of debt issuance costs (for example, but not limited to, legal, accounting, broker, and regulatory fees).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 28<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=56944662&amp;loc=d3e3602-108585<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_USGovernmentSecuritiesAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt (bills, notes or bonds) that are issued by the government of the United States which are short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_USGovernmentSecuritiesAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=iccc_BuildingAdditionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=iccc_BuildingAdditionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentOtherTypesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentOtherTypesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OtherAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OtherAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.3.0.814</span><table class="report" border="0" cellspacing="2" id="idm140666940020784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingent Liabilities<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2015</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingent Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENT LIABILITIES</a></td>
<td class="text"><div><table style="font: 10pt/normal 'times new roman', times, serif; width: 1567px; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px;" border="0" cellspacing="0" cellpadding="0"><tr style="vertical-align: top;"><td style="width: 0.5in; text-indent: 0pt; padding-left: 0pt;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>12.</b></font></td><td style="text-indent: 0pt; padding-left: 0pt;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;"><b>COMMITMENTS AND CONTINGENT LIABILITIES</b></font></td></tr></table><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">Our bylaws, as amended, in effect provide that the Company will indemnify its officers and directors to the maximum extent permitted by Delaware law. In addition, we make similar indemnity undertakings to each director through a separate indemnification agreement with that director. The maximum payment that we may be required to make under such provisions is theoretically unlimited and is impossible to determine. We maintain directors&#8217; and officers&#8217; liability insurance, which may provide reimbursement to the Company for payments made to, or on behalf of, officers and directors pursuant to the indemnification provisions. Our indemnification obligations were grandfathered under the provisions of Codification Topic 460<i>, Guarantees</i>. Accordingly, we have recorded no liability for such obligations as of September 30, 2015. Since our incorporation, we have had no occasion to make any indemnification payment to any of our officers or directors for any reason.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">As of September 30, 2015, we had committed approximately $728,000 to capital expenditures, $576,000 to the production of inventory and an additional $261,000 to other obligations.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">We enter into agreements with third parties in the ordinary course of business under which we are obligated to indemnify such third parties from and against various risks and losses. The precise terms of such indemnities vary with the nature of the agreement. In many cases, we limit the maximum amount of our indemnification obligations, but in some cases those obligations may be theoretically unlimited. We have not incurred material expenses in discharging any of these indemnification obligations, and based on our analysis of the nature of the risks involved, we believe that the fair value of the liabilities potentially arising under these agreements is minimal. Accordingly, we have recorded no liabilities for such obligations as of September 30, 2015.</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0px; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">&#160;</font></p><p style="font: 10pt/normal 'times new roman', times, serif; margin: 0px; color: #000000; text-transform: none; text-indent: 0.5in; letter-spacing: normal; word-spacing: 0px; white-space: normal; font-stretch: normal; -webkit-text-stroke-width: 0px;"><font style="font: 10pt/normal 'times new roman', times, serif; font-stretch: normal;">The development, manufacturing and marketing of animal health care products entails an inherent risk that liability claims will be asserted against us. We feel that we have reasonable levels of liability insurance to support our operations.</font></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 825<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6449706&amp;loc=d3e16207-108621<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 460<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=51674963&amp;loc=d3e12565-110249<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 450<br><br><br><br> -SubTopic 20<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=25496072&amp;loc=d3e14435-108349<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.25)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 440<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6394976&amp;loc=d3e25287-109308<br><br><br><br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
